
<html lang="en"     class="pb-page"  data-request-id="bbaf32b9-58d4-44bb-b92e-cc6c108ab3e9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.8b01520;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)" /></meta><meta name="dc.Creator" content="Huihui  Ti" /></meta><meta name="dc.Creator" content="Yang  Zhou" /></meta><meta name="dc.Creator" content="Xue  Liang" /></meta><meta name="dc.Creator" content="Runfeng  Li" /></meta><meta name="dc.Creator" content="Ke  Ding" /></meta><meta name="dc.Creator" content="Xin  Zhao" /></meta><meta name="dc.Description" content="Chronic obstructive pulmonary disease (COPD) is a very common and frequently fatal airway disease. Current therapies for COPD depend mainly on long-acting bronchodilators, which cannot target the p..." /></meta><meta name="Description" content="Chronic obstructive pulmonary disease (COPD) is a very common and frequently fatal airway disease. Current therapies for COPD depend mainly on long-acting bronchodilators, which cannot target the p..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 25, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01520" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01520" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01520" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01520" /></link>
        
    
    

<title>Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01520" /></meta><meta property="og:title" content="Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0001.jpeg" /></meta><meta property="og:description" content="Chronic obstructive pulmonary disease (COPD) is a very common and frequently fatal airway disease. Current therapies for COPD depend mainly on long-acting bronchodilators, which cannot target the pathogenic mechanisms of chronic inflammation in COPD. New pharmaceutical therapies for the inflammatory processes of COPD are urgently needed. Several anti-inflammatory targets have been identified based on increased understanding of the pathogenesis of COPD, which raises new hopes for targeted treatment of this fatal respiratory disease. In this review, we discuss the recent advances in bioactive low-molecular-weight drugs (LMWDs) for the treatment of COPD and, in addition to the first-line drug bronchodilators, focus particularly on low-molecular-weight anti-inflammatory agents, including modulators of inflammatory mediators, inflammasome inhibitors, protease inhibitors, antioxidants, PDE4 inhibitors, kinase inhibitors, and other agents. We also provide new insights into targeted COPD treatments using LMWDs, particularly small-molecule agents." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01520"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01520">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-8/abseba.2021.7.issue-8/20210809/abseba.2021.7.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-15/accacs.2021.11.issue-15/20210806/accacs.2021.11.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-31/ascecg.2021.9.issue-31/20210809/ascecg.2021.9.issue-31.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-8/bomaf6.2021.22.issue-8/20210809/bomaf6.2021.22.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-29/cgeabj.2021.99.issue-29/20210809-01/cgeabj.2021.99.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-15/enfuem.2021.35.issue-15/20210805/enfuem.2021.35.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-15/joceah.2021.86.issue-15/20210806/joceah.2021.86.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-30/jpcafh.2021.125.issue-30/20210805/jpcafh.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-30/jpcbfk.2021.125.issue-30/20210805/jpcbfk.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-30/jpccck.2021.125.issue-30/20210805/jpccck.2021.125.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-30/jpclcd.2021.12.issue-30/20210805/jpclcd.2021.12.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-8/jprobs.2021.20.issue-8/20210806/jprobs.2021.20.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-15/orlef7.2021.23.issue-15/20210806/orlef7.2021.23.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-15/orgnd7.2021.40.issue-15/20210809/orgnd7.2021.40.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01520&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01520&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01520&amp;href=/doi/10.1021/acs.jmedchem.8b01520" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5944-5978</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01439" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.8b01651" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Huihui Ti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huihui Ti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huihui++Ti">Huihui Ti</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yang Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yang Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, P. R. China</div><div class="loa-info-affiliations-info">Division of Theoretical Chemistry and Biology, School of Biotechnology, Royal Institute of Technology (KTH), AlbaNova University Center, Stockholm SE-100 44, Sweden</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Zhou">Yang Zhou</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xue Liang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xue Liang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xue++Liang">Xue Liang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Runfeng Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Runfeng Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Runfeng++Li">Runfeng Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ke Ding</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ke Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou 510632, P. R. China</div><div class="loa-info-affiliations-info">State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 510120, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>For K.D.: phone, +86-20-85223764; fax, +86-20-85224766; E-mail, <a href="/cdn-cgi/l/email-protection#27434e49404c42674d495209424352094449"><span class="__cf_email__" data-cfemail="37535e59505c52775d594219525342195459">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ke++Ding">Ke Ding</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Xin Zhao</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Key Laboratory of Molecular Target & Clinical Pharmacology, State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences & The Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, P. R. China</div><div class="loa-info-affiliations-info">School of Life Sciences, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR 999077, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>For X.Z.: E-mail, <a href="/cdn-cgi/l/email-protection#4c36242d233425227e7c7d7b0c2a2334212d2520622f2321"><span class="__cf_email__" data-cfemail="e19b89808e99888fd3d1d0d6a1878e998c80888dcf828e8c">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Zhao">Xin Zhao</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6659-3748" title="Orcid link">http://orcid.org/0000-0002-6659-3748</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01520&amp;href=/doi/10.1021%2Facs.jmedchem.8b01520" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5944–5978</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 25, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 September 2018</li><li><span class="item_label"><b>Published</b> online</span>25 January 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01520" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01520</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5944%26pageCount%3D35%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHuihui%2BTi%252C%2BYang%2BZhou%252C%2BXue%2BLiang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D13%26contentID%3Dacs.jmedchem.8b01520%26title%3DTargeted%2BTreatments%2Bfor%2BChronic%2BObstructive%2BPulmonary%2BDisease%2B%2528COPD%2529%2BUsing%2BLow-Molecular-Weight%2BDrugs%2B%2528LMWDs%2529%26numPages%3D35%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5978%26publicationDate%3DJuly%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01520"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3111</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01520" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Huihui&quot;,&quot;last_name&quot;:&quot;Ti&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Xue&quot;,&quot;last_name&quot;:&quot;Liang&quot;},{&quot;first_name&quot;:&quot;Runfeng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Ke&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Zhao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;5944-5978&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01520&quot;},&quot;abstract&quot;:&quot;Chronic obstructive pulmonary disease (COPD) is a very common and frequently fatal airway disease. Current therapies for COPD depend mainly on long-acting bronchodilators, which cannot target the pathogenic mechanisms of chronic inflammation in COPD. New pharmaceutical therapies for the inflammatory processes of COPD are urgently needed. Several anti-inflammatory targets have been identified based on increased understanding of the pathogenesis of COPD, which raises new hopes for targeted treatment of this fatal respiratory disease. In this review, we discuss the recent advances in bioactive low-molecular-weight drugs (LMWDs) for the treatment of COPD and, in addition to the first-line drug bronchodilators, focus particularly on low-molecular-weight anti-inflammatory agents, including modulators of inflammatory mediators, inflammasome inhibitors, protease inhibitors, antioxidants, PDE4 inhibitors, kinase inhibitors, and other agents. We also provide new insights into targeted COPD treatments using LMWDs, parti&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01520&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01520" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01520&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01520" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01520&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01520" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01520&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01520&amp;href=/doi/10.1021/acs.jmedchem.8b01520" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01520" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01520" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01520%26sid%3Dliteratum%253Aachs%26pmid%3D30682248%26genre%3Darticle%26aulast%3DTi%26date%3D2019%26atitle%3DTargeted%2BTreatments%2Bfor%2BChronic%2BObstructive%2BPulmonary%2BDisease%2B%2528COPD%2529%2BUsing%2BLow-Molecular-Weight%2BDrugs%2B%2528LMWDs%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D13%26spage%3D5944%26epage%3D5978%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291161" title="Inflammation">Inflammation</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/jmcmar.2019.62.issue-13/20190711/jmcmar.2019.62.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Chronic obstructive pulmonary disease (COPD) is a very common and frequently fatal airway disease. Current therapies for COPD depend mainly on long-acting bronchodilators, which cannot target the pathogenic mechanisms of chronic inflammation in COPD. New pharmaceutical therapies for the inflammatory processes of COPD are urgently needed. Several anti-inflammatory targets have been identified based on increased understanding of the pathogenesis of COPD, which raises new hopes for targeted treatment of this fatal respiratory disease. In this review, we discuss the recent advances in bioactive low-molecular-weight drugs (LMWDs) for the treatment of COPD and, in addition to the first-line drug bronchodilators, focus particularly on low-molecular-weight anti-inflammatory agents, including modulators of inflammatory mediators, inflammasome inhibitors, protease inhibitors, antioxidants, PDE4 inhibitors, kinase inhibitors, and other agents. We also provide new insights into targeted COPD treatments using LMWDs, particularly small-molecule agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72738" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72738" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec1_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">1.1.  What is COPD?</h3><div class="NLM_p">Chronic obstructive pulmonary disease (COPD) is a highly prevalent disease<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> that is associated with enhanced chronic inflammation of the respiratory tract.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> It is becoming a major global health problem with high morbidity and mortality.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> The Global Burden of Disease study 2015 (GBD 2015) reported that from 1990 to 2015, the prevalence of COPD increased by 44.2%. In 2015, 3.2 million people died from COPD worldwide,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and the disease became the third-ranked cause of death and the fifth-ranked disease in terms of disease burden.<a onclick="showRef(event, 'ref1 ref8'); return false;" href="javascript:void(0);" class="ref ref1 ref8">(1,8)</a> This disease is increasing in importance and has been designated a high-profile respiratory disease.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> However, it is difficult to define COPD, and the term is used to describe patients who suffer from airflow limitation (AL) accompanying small airway obstruction and have a low forced expiratory volume (FEV).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> AL, which is defined by a forced expiratory volume in 1 s (FEV<sub>1</sub>) to forced vital capacity (FVC) ratio <0.7,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> is a sensitive indicator of the level of airway obstruction, and patients with AL can be categorized into 4 stages (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD).<a onclick="showRef(event, 'ref1 ref12'); return false;" href="javascript:void(0);" class="ref ref1 ref12">(1,12)</a> In COPD, AL is attributed to irreversible physiological changes in the lungs, and chronic bronchitis and emphysema are two common symptoms of these changes (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Figure S1</a>).<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> In some patients, COPD can coexist with asthma, which also features chronic bronchitis and emphysema (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and the term asthma–COPD overlap syndrome is used to describe the symptoms of patients who have features of both.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> In addition, COPD is closely associated with progressive abnormal decline in lung function,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> which results in chronic respiratory failure. Therefore, COPD is a leading cause of death worldwide.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Stages of Airflow Limitation</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">stage</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">mild (GOLD1)</th><th class="colsep0 rowsep0" align="center">moderate (GOLD2)</th><th class="colsep0 rowsep0" align="center">severe (GOLD3)</th><th class="colsep0 rowsep0" align="center">very severe (GOLD4)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">value (%)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">>80</td><td class="colsep0 rowsep0" align="center">79–50</td><td class="colsep0 rowsep0" align="center">49–30</td><td class="colsep0 rowsep0" align="center"><30</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The ratio of actual FEV<sub>1</sub> to predicted normal FEV<sub>1</sub>.</p></div></div></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0026.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Relationships between airflow limitation, chronic bronchitis, emphysema, asthma, and COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">1.2.  Epidemiology of Risk Factors for COPD</h3><div class="NLM_p">Cigarette smoking is generally recognized as the culprit for COPD development.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> However, an increasing number of reports have indicated that many nonsmokers have developed COPD.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In fact, environmental triggers, including exposure to tobacco smoke (passive smoking),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> indoor and outdoor air pollution, such as the burning of fuel, wood, grass, charcoal, crop stems, and animals stools, PM2.5,<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> and occupational inorganic and organic dusts, such as grains, metals, and vehicle exhaust, as well as toxic gases,<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a> also play an important role in COPD development. Gender and age are additional factors: generally, males may be susceptible to COPD due to smoking; however, the prevalence of COPD in females is higher than that predicted based on their low smoking rates, and this disease affects men and women almost equally.<a onclick="showRef(event, 'ref1 ref28'); return false;" href="javascript:void(0);" class="ref ref1 ref28">(1,28)</a> Furthermore, deaths owing to COPD are associated with the aging of the population, and the elderly are particularly susceptible to COPD.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> From the childhood to the adulthood of an individual, COPD may originate during development in the mother’s uterus if the mother smokes or is affected by environmental factors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> presents a cartoon depiction of the risk factors for COPD during the different stages of life.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Bronchial hyperresponsiveness and asthma can lead to a decline in lung function<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and are deemed risk factors for COPD.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Several other risk factors, such as genetics, socioeconomic status and poverty, body mass index, and respiratory system infections, have been identified.<a onclick="showRef(event, 'ref1 ref31 ref34'); return false;" href="javascript:void(0);" class="ref ref1 ref31 ref34">(1,31,34)</a> The epidemiology of risk factors for COPD is summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Knowledge of the risk factors for COPD is helpful for COPD prevention and screening.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0027.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Risk factors for COPD during different stages of life.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Risk Factors for COPD</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>Risk Factors</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="6" valign="middle"><b>External Causes</b></td><td class="colsep0 rowsep0" align="center">smoking</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">passive smoking</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">indoor and outdoor air pollution</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">occupational dust</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">respiratory system infections</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">socioeconomic status and poverty</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" valign="middle"> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="5" valign="middle"><b>Internal Causes</b></td><td class="colsep0 rowsep0" align="center">gender and age</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">in utero and early childhood</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">genetic factors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">bronchial hyperresponsiveness</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">body mass index</td></tr></tbody></table></div></div></div><div id="sec1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7">1.3.  Pathogenesis of COPD</h3><div class="NLM_p">The phenotypes of COPD are mainly considered to be emphysema, airway fibrosis, and chronic bronchitis. These features can result in a chronic inflammatory process, which is an innate immune response of inflammatory cells in the respiratory tract to external triggers, and these cells, whose amounts increase with disease progression, include macrophages, neutrophils, lymphocytes, dendritic cells, and epithelial cells.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Increased inflammatory effects in turn exacerbate COPD.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Oxidative stress, which is relevant to inflammation, is another crucial driving force of COPD, and its influences and pathogenic mechanisms in COPD have been highlighted.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Moreover, an imbalance between proteases and antiproteases also contributes to COPD. In COPD, increased elastase activity and/or decreased antiprotease activity result in emphysema and neutrophilic inflammation.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p last">COPD is a complex and troublesome respiratory disease; however, it is easily neglected by the public because of poor knowledge and awareness about this disease. The pathogenesis, pathophysiology, diagnosis, and pharmacotherapy of COPD have been summarized in several review studies from a clinical viewpoint,<a onclick="showRef(event, 'ref1 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref1 ref40 ref41">(1,40,41)</a> but there is a lack of panoramic descriptions and classification of LMWDs for COPD treatment in medicinal chemistry. In this review, we aim to discuss the status of drug development and recent advances in bioactive LMWDs for COPD and provide an outlook on potential targets and targeted treatments using LMWDs for COPD.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">2.  Molecular Targets for the Treatment of COPD</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Current pharmacotherapy for COPD mainly depends on bronchodilators, which perform pharmacological modulation of the airway smooth muscle cells. Two targets are available for this modulation, muscarinic acetylcholine receptors (mAChR) and β<sub>2</sub>-adrenergic receptors (which are connected to airway smooth muscle contraction and relaxation, respectively).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">COPD is characterized by a complex chronic inflammation of the airways; hence, the most direct therapy targets inflammation. When the respiratory tract is infected by external irritants, an innate immune response is initiated by the activation of airway immunocytes, including epithelial cells, macrophages, and neutrophils. In this process, oxidative stress is an important medium for activating these inflammatory cells.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> In addition, chemotactic factors, particularly chemokines, are released in the same process. Neutrophils and lymphocytes are attracted by chemokines, and adaptive immunity is also activated, resulting in further enhancement of neutrophilic inflammation.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> All activated cells, including epithelial cells, macrophages, neutrophils, and lymphocytes, promote the release of inflammatory mediators. Some specific inflammatory mediators, such as cytokines, chemokine receptors, lipid mediators, and inflammasomes,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> as well as oxidative stress, can serve as targets in the treatment of inflammation. These cells also release proteases, such as neutrophil elastase (NE), proteinase 3, cathepsin, and matrix metalloproteinases (MMPs), that may be directly responsible for lung damage such as emphysema and mucus hypersecretion.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45,46)</a> Therapeutic approaches that target proteases are also available.</div><div class="NLM_p">Inflammation in the lungs is the source of COPD, and anti-inflammatory strategies have been investigated for the treatment of COPD. Phosphodiesterases (PDEs) are involved in the regulation of cyclic 3′,5′-adenosine monophosphate (cAMP) signaling, which functions in the release of inflammatory mediators. In particular, PDE4 is expressed in neutrophils, T cells, and macrophages, and PDE4 inhibitors can reduce the activity of inflammatory cells.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Therefore, PDE4 is a predominant target for the development of broad-spectrum anti-inflammatory drugs. In addition, inflammatory genes can be regulated by many kinases or epigenetic mechanisms, and kinase inhibition or epigenetic modulation may be used to suppress inflammation. Moreover, phosphoinositide 3-kinase δ (PI3Kδ) and epigenetic modulators may be used to reverse the resistance of corticosteroids to inflammation.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In the lungs of COPD patients, the levels of adenosine are increased. Adenosine signaling plays a pathophysiological role in the chronic inflammation of the airway, and adenosine receptors are expressed on the surface of inflammatory cells. Targeting these adenosine receptors may be an effective therapeutic approach for COPD.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a></div><div class="NLM_p">Small airway fibrosis is usually associated with chronic inflammation and chronic obstructive bronchiolitis, and preventing fibrosis is necessary for suppressing inflammation.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Small airway fibrosis results from the activation of fibroblasts, which is mediated by fibrogenic mediators such as transforming growth factor-β (TGFβ) and peroxisome proliferator-activated receptor-γ (PPARγ), which are released from epithelial cells and macrophages.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> These mediators are potential targets for novel COPD therapies.</div><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> summarizes the possible molecular targets for COPD treatments using LMWDs. The reported effective small molecules for each target and the related mechanisms are discussed later in this review.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0028.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inflammatory pathways and potential molecular targets for COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">3.  LMWDs for the Treatment of Copd</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35644" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35644" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.1.  Bronchodilators</h3><div class="NLM_p">For stable COPD, bronchodilators are the first-line drugs for pharmacological treatment.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> There are two types of bronchodilators, mAChR antagonists and β<sub>2</sub>-adrenoreceptor agonists. M<sub>3</sub> subtypes expressed on airway smooth muscle cells are the most dominant target for the mAChR agonists. The postganglionic cholinergic nerve activates M<sub>3</sub> receptors via the release of acetylcholine (ACh), and the activation of M<sub>3</sub> leads to airway smooth muscle contraction.<a onclick="showRef(event, 'ref1 ref52'); return false;" href="javascript:void(0);" class="ref ref1 ref52">(1,52)</a> The blockade of M<sub>3</sub> receptors can relax the airway smooth muscle by reducing cholinergic tone and results in a reduction in air trapping and exertional dyspnea. In another approach, the activation of β<sub>2</sub>-adrenergic receptors on airway smooth muscle cells leads to airway smooth muscle relaxation.<a onclick="showRef(event, 'ref1 ref52'); return false;" href="javascript:void(0);" class="ref ref1 ref52">(1,52)</a> Similar to M<sub>3</sub> antagonists, β<sub>2</sub>-adrenoceptor agonists can antagonize cholinergic tone and result in bronchodilation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0029.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mode of action of bronchodilators in COPD. ACh, acetylcholine; mAChRs, muscarinic acetylcholine receptors; SAMA, short-acting muscarinic antagonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β<sub>2</sub>-adrenoreceptor agonist; LABA, long-acting β<sub>2</sub>-adrenoreceptor agonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Short-acting and long-acting drugs are available for both targets, and several drugs are approved for use in clinical therapy or clinical trials for COPD, including short-acting muscarinic antagonists (SAMAs), such as ipratropium bromide (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S1</a>), long-acting muscarinic antagonists (LAMAs), such as tiotropium bromide, short-acting β<sub>2</sub>-adrenoreceptor agonists (SABAs), such as salbutamol (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S1</a>), long-acting β<sub>2</sub>-adrenoreceptor agonists (LABAs), such as salmeterol, and dual muscarinic antagonist-β<sub>2</sub>-agonist (MABA) compounds such as batefenterol.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> To date, LAMAs and LABAs have been the mainstays of pharmacological treatment for COPD. Another effective pharmacological strategy is dual bronchodilator therapy, in which the LAMAs and LABAs are administered together, and these LAMA/LABA fixed-dose combinations (FDCs) (such as indacaterol/glycopyrronium bromide) show additive benefits. The details of bronchodilating drugs have been well reviewed in this journal.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Herein, we attempt to address only new progress in bronchodilators. Some well-known LAMAs such as tiotropium bromide and aclidinium bromide, and LABAs such as salmeterol, vilanterol, and abediterol are listed in <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a> for comparison.</div><figure id="cht1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Chemical Structures of Some LAMAs and LABAs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Revefenacin (TD-4208) (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) is a novel LAMA that differs from other LAMAs in its chemical structure. It has a high affinity for the human M3 receptor with a <i>K</i><sub>i</sub> value of 0.18 nM.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> A 28-day, randomized, double-blind, placebo-controlled, parallel group phase II study of nebulized revefenacin (88, 175, or 350 μg) in 355 patients with COPD demonstrated that revefenacin significantly improved D28 through FEV<sub>1</sub> at a dose ≥88 μg, and in the first 4 h post dose, an increase in FEV<sub>1</sub> of at least 100 mL from baseline was observed in more than 80% of patients; further, the bronchodilation was sustained for 24 h. The 350 μg dose did not give additional efficacy compared with the 175 μg dose, which indicates that 88 and 175 μg doses are appropriate. In addition, patients were tolerant to a high dose (350 μg) of revefenacin, and no safety issues were found.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> These data were supported by two replicate pivotal phase III efficacy studies and one 12-month phase III safety study sponsored by Theravance Biopharma (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifiers NCT02512510 and NCT02459080). Supported by these positive results, revefenacin was approved in November 2018 in the USA by the Food and Drug Administration (FDA) for the treatment of patients with COPD.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Bencycloquidium bromide (BCQB) (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) is a novel SAMA that is similar to other LAMAs in chemical structure. BCQB binds to M3 receptors with high affinity (p<i>K</i><sub>i</sub> = 8.21) and selectivity over M2 receptors. Conversely, the SAMA ipratropium and the LAMA tiotropium do not exhibit selectivity for muscarinic receptor subtypes. The onset of action of BCQB is faster than that of tiotropium, while the offset is slower. However, the duration of action (DOA) of BCQB is markedly shorter than that of tiotropium,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> which indicates that the DOA of muscarinic antagonists is attributable not only to the rate of dissociation from the muscarinic receptors but also to other factors such as their pharmacokinetic properties in vivo. Additionally, BCQB has shown almost no adverse events<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and can be administered more than once a day as a novel SAMA to treat COPD. BCQB has been submitted as an NDA in China. Trantinterol<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) is a novel LABA designed from the SAMA salbutamol (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S1</a>), with a DOA that is longer than that of salbutamol. Common chemical features of LAMAs are a saligenin head, characterized by an <i>ortho</i>-hydroxymethyl phenol (OHP) scaffold or a similar group, and a long hydrophobic phenylalkoxy alkyl chain (e.g., salmeterol, vilanterol, and abediterol in <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>). The lipophilic properties of this large building block may contribute to its long DOA.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Salbutamol and trantinterol are both peculiar small molecules. Salbutamol contains only the saligenin head, and the OHP group may be degraded easily by catechol-<i>O</i>-methyltransferase (COMT). The headgroup of trantinterol is replaced with a nonhydroxybenzene group, which is insensitive to COMT. This replacement may lead to the long DOA of trantinterol.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Trantinterol represents a novel low-molecular-weight LABA and is currently in phase IV clinical development for the treatment of asthma in China.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> MABA Compounds</h4><div class="NLM_p">MABA is a type of bronchodilator with the pharmacological effects of mAcChR antagonism and β2-adrenoreceptor agonism. It represents a new kind of single-molecule, bifunctional LMWD with a dual mode of action. The first-in-class MABA is batefenterol (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>). In a phase IIb study, batefenterol significantly improved the FEV<sub>1</sub> of patients with moderate to severe COPD at all doses tested compared to the placebo and positive control salmeterol (50 μg twice daily) and was well tolerated at each dose, and the optimal dose was 400 μg once daily or 200 μg twice daily.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> AZD8871 (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>) is a long-acting MABA that is also in phase II clinical development. A 400 μg or 1800 μg dose of AZD8871 gives a 36 h duration of bronchodilation in patients with COPD. In another study of the efficacy, pharmacokinetics, safety, and tolerability of inhaled AZD8871 in patients with moderate to severe COPD, AZD8871 significantly increased the FEV<sub>1</sub> at both the 100 μg and 600 μg doses (380 and 420 mL, respectively, compared with placebo) after 2 weeks, and on both day 1 and day 14, the DOA of AZD8871 was sustained over 24 h. Common adverse events were headache and worsening of COPD-related symptoms without dose dependence, and there were no severe adverse events.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> LAS190792 (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>), whose structure has features of both batefenterol and AZD8871, is a novel MABA with potent M<sub>3</sub> receptor antagonism (pIC<sub>50</sub> = 8.8) and β<sub>2</sub>-adrenoreceptor agonism (pEC<sub>50</sub> = 9.6). Inhaled LAS19072 induced sustained bronchodilation (13.3 h) in dogs, and minimal cardiac effects were observed. Its sustained DOA is longer than that of batefenterol in isolated lung tissue.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> LAS19072 is a promising next-generation, long-acting MABA with few side effects that has been developed in a phase I study. Although many bronchodilators have been approved for clinical use in recent years, many mAChR antagonists (such as ASM-024 in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S2</a>), β<sub>2</sub>-adrenoceptor agonists (such as TD-5471 in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S2</a>), and MABAs are also in preclinical or clinical development (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). It is noteworthy that the development of new bronchodilators has focused on LAMA/LABA FDCs or a combination of a bronchodilator and an inhaled corticosteroid (ICS) due to their beneficial additive effects, and several drugs have been approved recently (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Tables <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).</div><figure id="cht2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Chemical Structures of Some MABAs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Clinical Studies of Bronchodilators and Bronchodilator/ICS FDCs for COPD<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug type</th><th class="colsep0 rowsep0" align="center">bronchodilator</th><th class="colsep0 rowsep0" align="center">clinical stage</th><th class="colsep0 rowsep0" align="center">ClinicalTrials.gov identifier</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LAMA</td><td class="colsep0 rowsep0" align="center">ASM-024</td><td class="colsep0 rowsep0" align="center">phase II</td><td class="colsep0 rowsep0" align="center">NCT01855230</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MABA</td><td class="colsep0 rowsep0" align="center">batefenterol</td><td class="colsep0 rowsep0" align="center">phaseII</td><td class="colsep0 rowsep0" align="center">NCT02570165</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">AZD-8871</td><td class="colsep0 rowsep0" align="center">phase II</td><td class="colsep0 rowsep0" align="center">NCT02971293</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">AZD-2115 (<a class="ref internalNav" href="#cht2" aria-label="Chart 2">Chart 2</a>)</td><td class="colsep0 rowsep0" align="center">phase II</td><td class="colsep0 rowsep0" align="center">NCT02109406</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">CHF-6366</td><td class="colsep0 rowsep0" align="center">phase II</td><td class="colsep0 rowsep0" align="center">NCT03378648</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">LAS190792</td><td class="colsep0 rowsep0" align="center">phase I</td><td class="colsep0 rowsep0" align="center">NCT02059434</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LAMA/LABA/ICS</td><td class="colsep0 rowsep0" align="center">budesonide/formoterol fumarate/glycopyrronium bromide</td><td class="colsep0 rowsep0" align="center">phase III</td><td class="colsep0 rowsep0" align="center">NCT03197818</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MABA/ICS</td><td class="colsep0 rowsep0" align="center">batefenterol/fluticasone furoate</td><td class="colsep0 rowsep0" align="center">phase II</td><td class="colsep0 rowsep0" align="center">NCT02573870</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Information was collected from <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Newly Approved LAMA/LABA FDCs and Bronchodilators/ICS FDCs for COPD</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">drug name</th><th class="colsep0 rowsep0" align="center">drug type</th><th class="colsep0 rowsep0" align="center">active ingredients</th><th class="colsep0 rowsep0" align="center">year</th><th class="colsep0 rowsep0" align="center">approval agency</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Trelegy Ellipta</td><td class="colsep0 rowsep0" align="center">LAMA/LABA/ICS</td><td class="colsep0 rowsep0" align="center">fluticasone furoate/umeclidinium bromide/vilanterol trifenatate</td><td class="colsep0 rowsep0" align="center">2017</td><td class="colsep0 rowsep0" align="center">FDA<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Trimbow</td><td class="colsep0 rowsep0" align="center">LAMA/LABA/ICS</td><td class="colsep0 rowsep0" align="center">beclometasone dipropionate/formoterol fumarate dihydrate/glycopyrronium</td><td class="colsep0 rowsep0" align="center">2017</td><td class="colsep0 rowsep0" align="center">EMA<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bevespi Aerosphere</td><td class="colsep0 rowsep0" align="center">LAMA/LABA</td><td class="colsep0 rowsep0" align="center">formoterol fumarate/glycopyrrolate</td><td class="colsep0 rowsep0" align="center">2016</td><td class="colsep0 rowsep0" align="center">FDA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Spiolto Respimat</td><td class="colsep0 rowsep0" align="center">LAMA/LABA</td><td class="colsep0 rowsep0" align="center">olodaterol hydrochloride/tiotropium bromide hydrate</td><td class="colsep0 rowsep0" align="center">2015</td><td class="colsep0 rowsep0" align="center">EMA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Brimica Genuair</td><td class="colsep0 rowsep0" align="center">LAMA/LABA</td><td class="colsep0 rowsep0" align="center">aclidinium bromide/formoterol fumarate dihydrate</td><td class="colsep0 rowsep0" align="center">2014</td><td class="colsep0 rowsep0" align="center">EMA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Anoro Ellipta</td><td class="colsep0 rowsep0" align="center">LAMA/LABA</td><td class="colsep0 rowsep0" align="center">umeclidinium bromide/vilanterol trifenatate</td><td class="colsep0 rowsep0" align="center">2014</td><td class="colsep0 rowsep0" align="center">FDA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Breo Ellipta</td><td class="colsep0 rowsep0" align="center">LABA/ICS</td><td class="colsep0 rowsep0" align="center">fluticasone furoate/vilanterol trifenatate</td><td class="colsep0 rowsep0" align="center">2013</td><td class="colsep0 rowsep0" align="center">FDA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ultibro Breezhaler</td><td class="colsep0 rowsep0" align="center">LABA/LAMA</td><td class="colsep0 rowsep0" align="center">indacaterol maleate/glycopyrronium bromide</td><td class="colsep0 rowsep0" align="center">2013</td><td class="colsep0 rowsep0" align="center">EMA</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">US Food and Drug Administration.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">European Medicine Agency.</p></div></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16">3.2.  LMWDs Targeting Inflammatory Mediators</h3><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">3.2.1.  Cytokine Inhibitors and Chemokine Receptor Antagonists</h4><div class="NLM_p">There are three major types of innate and adaptive cell-mediated effector immunity, denoted as type 1, type 2, and type 3 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Figure S2</a>). Type 1 immunity uses CD4<sup>+</sup> T helper 1 (T<sub>H</sub>1) cells, CD<sub>8</sub><sup>+</sup> cytotoxic T (T<sub>C</sub>1) cells, group 1 innate lymphoid cells (ILC 1s), natural killer (NK) cells, and the transcription factor T-bet, which regulates the production of IFNγ. Type 1 immunity protects against intracellular microbes, including bacteria, protozoa, and viruses, via the activation of mononuclear phagocytes. Type 2 immunity uses CD4<sup>+</sup> T<sub>H</sub>2 cells, CD<sub>8</sub><sup>+</sup> T<sub>C</sub>2 cells, ILC 2s, and the transcription factor GATA3<sup>+</sup>, which regulates the production of IL-4, IL-5, IL-9, and IL-13. Type 2 immunity protects against parasitic infections. Type 3 immunity uses CD4<sup>+</sup> T<sub>H</sub>17 cells, CD<sub>8</sub><sup>+</sup> T<sub>C</sub>17 cells, and ILC 3s, which express the transcription factor RORγt<sup>+</sup> and secrete IL-17 and IL-22. Type 3 immunity protects against extracellular bacteria and fungi.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">Although some cases of COPD are also driven by type 2 immune responses (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Figure S3</a>),<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> the inflammation patterns of COPD are predominantly type 1 and type 3, which involve macrophages and neutrophils (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). External irritants such as cigarette smoke and reactive oxygen species (ROS) stimulate airway epithelial cells to release CXC-chemokine ligand 1 (CXCL1), CXCL5, CXCL8, and proinflammatory mediators such as tumor necrosis factor (TNF). CXCL1, CXCL5, and CXCL8 attract neutrophils and monocytes via acting on CXC-chemokine receptor 2 (CXCR2). Meanwhile, macrophages release CCL2 and recruit monocytes via acting on CCR2. Epithelial cells and macrophages also produce CXCL9, CXCL10, and CXCL11 to attract T<sub>H</sub>1 cells, T<sub>C</sub>1 cells, and ILC 1s by binding to CXCR3.<a onclick="showRef(event, 'ref35 ref64'); return false;" href="javascript:void(0);" class="ref ref35 ref64">(35,64)</a></div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0030.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Primary inflammatory pathways of nontype 2 immunities in airway diseases. CXCL, CXC-chemokine ligand; CXCR, CXC-chemokine receptor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The important role of cytokines and chemokines in innate and adaptive immunity makes them highly important as therapeutic targets for the treatment of inflammatory airway diseases. However, unfortunately, low-molecular-weight cytokine inhibitors are rare.</div><div id="sec3_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18"> CXCR2 Antagonists</h5><div class="NLM_p">Small-molecule CXCR2 antagonists, including squaramide (navarixin), pyrimidines (AZD-5122, AZD-5069), diarylurea (danirixin), and thiazole pyrimidine (AZD-8309), can be categorized into several classes according to their structural characteristics. Several small-molecule antagonists of CXCR2 have been developed in clinical trials for the treatment of COPD (<a class="ref internalNav" href="#cht3" aria-label="Chart 3">Chart 3</a>). Navarixin (SCH527123) is a potent CXCR2 antagonist that weakly improves FEV<sub>1</sub> in COPD patients over 12 weeks of oral treatment.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> SB-656933, a diarylurea compound, has been reported to affect ozone-induced airway inflammation,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> and the diarylurea analogue danirixin has also advanced in phase II trials.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> A bicyclic thiazolopyrimidine-based compound, AZD-8309, reduced lipopolysaccharide (LPS)-induced neutrophil recruitment in healthy individuals.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> AZD-5069 is a phase II, pyrimidine-derived, orally bioavailable candidate with high efficiency and CXCR2 selectivity.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Compound <b>1</b> is a newly reported diarylurea-based CXCR2 antagonist that reduces neutrophil infiltration in rat and mouse models during oral administration and might be a promising candidate for inflammatory diseases.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> SX-517, a boronic acid-containing compound, was identified as a dual CXCR2/1 antagonist that moderately prefers CXCR2. It suppresses inflammation significantly in vitro in humanized polymorphonuclear cells and in vivo in murine models. It represents a novel dual CXCR1/2 antagonist for the treatment of neutrophil inflammation.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Additional series of CXCR2 antagonists are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S3</a>.</div><figure id="cht3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 3. Chemical Structures of Representative Chemokine Receptor Antagonists</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20"> Other Chemokines</h5><div class="NLM_p">AZD-4818 (<a class="ref internalNav" href="#cht3" aria-label="Chart 3">Chart 3</a>) is a CCR1 antagonist that is clinically ineffective in moderate to severe COPD patients.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Other chemokine blockers, such as antagonists of CCR2, CXCR3, and CCR5, which are implicated in COPD,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> have not been studied in COPD or were not effective. Small-molecule CXCR3 antagonists have been discussed intensively,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> and some newly reported small-molecule inhibitors of other chemokines are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S3</a>.</div><div class="NLM_p">Overall, although some small molecular chemokine receptor antagonists have been studied in clinical trials for COPD (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), no candidates have been approved.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Small-Molecule Chemokine Receptor Antagonists in Clinical Trials for COPD<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">chemokine receptor</th><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">clinical stage</th><th class="colsep0 rowsep0" align="center">ClinicalTrials.gov identifier</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CXCR2</b></td><td class="colsep0 rowsep0" align="center">AZD-5122</td><td class="colsep0 rowsep0" align="center">phase I</td><td class="colsep0 rowsep0" align="center">NCT00984477</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">SB-656933</td><td class="colsep0 rowsep0" align="center">phase I</td><td class="colsep0 rowsep0" align="center">NCT00615576</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">NCT00551811</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">NCT00504439</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">AZD-4721</td><td class="colsep0 rowsep0" align="center">phase I</td><td class="colsep0 rowsep0" align="center">NCT01962935</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">AZD-8309</td><td class="colsep0 rowsep0" align="center">not applicable</td><td class="colsep0 rowsep0" align="center">NCT00860821</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">AZD-5069</td><td class="colsep0 rowsep0" align="center">phase I</td><td class="colsep0 rowsep0" align="center">NCT01083238</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">navarixin</td><td class="colsep0 rowsep0" align="center">phase II</td><td class="colsep0 rowsep0" align="center">NCT01006616</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">(terminated)</td><td class="colsep0 rowsep0" align="center">NCT00441701</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">danirixin</td><td class="colsep0 rowsep0" align="center">phase II</td><td class="colsep0 rowsep0" align="center">NCT02130193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CCR1</b></td><td class="colsep0 rowsep0" align="center">AZD-4818</td><td class="colsep0 rowsep0" align="center">phase II</td><td class="colsep0 rowsep0" align="center">NCT00629239</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Information was collected from <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>.</p></div></div></div></div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22">3.2.2.  The NOD-, LRR- and Pyrin Domain-Containing 3 (NLRP3) Inflammasome Inhibitors</h4><div class="NLM_p">The NLRP3 inflammasome, which is a multiprotein complex comprising the pattern recognition receptor (PRR) NLRP3, procaspase-1, and an adaptor protein, ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain), is a component of the innate immune system.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> The NLRP3 inflammasome is the best-characterized inflammasome, and its activation is associated with inflammatory diseases. The activation of the NLRP3 inflammasome is proposed to have two stages, priming and activation (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The priming stage initiates the activation of PRRs such as TLR (Toll-like receptor) by pathogen-associated molecular patterns (PAMPs), leading to the activation of nuclear factor-κB (NF-κB), which upregulates the expression of pro-IL-1β, pro-IL-18, and NLRP3. In the second stage, the inflammasome is activated by extracellular ATP via the P2X7 receptor<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> as well as by ROS, uric acid, and bacterial toxins.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Then, ASC and procaspase-1 are recruited, causing the oligomerization of NLRP3, ASC, and procaspase-1 to form the full NLRP3 inflammasome. The full NLRP3 inflammasome induces the cleavage of procaspase-1 to release caspase-1. Activated caspase-1 subsequently cleaves pro-IL-1β and pro-IL-18 to generate their mature forms, IL-1β and IL-18, respectively, which are secreted from cells and execute their proinflammatory functions.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> In COPD, IL-1β levels in the lungs are increased and are associated with macrophage activation and neutrophilic inflammation. IL-18 is also increased, leading to a decline in lung function.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Antibodies specific for IL-1β or IL-18 may be suitable drugs, but IL-1β antibodies were found to be ineffective against COPD, and IL-18 antibodies have not been tested in clinical trials.<a onclick="showRef(event, 'ref48 ref78'); return false;" href="javascript:void(0);" class="ref ref48 ref78">(48,78)</a> Considering the importance of IL-1β in inflammatory diseases and its original activator, the NLRP3 inflammasome, targeting the NLRP3 inflammasome has become an advanced therapeutic strategy for the treatment of inflammation.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0031.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Priming and activation of the NLRP3 inflammasome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Theoretically, pharmacological inhibition of the NLRP3 inflammasome by blocking NLRP3 priming and activation can provide anti-inflammatory targets for COPD therapy. Several targets are involved in NLPR3 activation and regulation, and small-molecule inhibitors of these targets have been reviewed;<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> however, studies of these inhibitors in COPD are limited, and we focus herein on several that are related to COPD.</div><div id="sec3_2_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> MCC950</h5><div class="NLM_p">MCC950 (also known as CP-456,773, <a class="ref internalNav" href="#cht4" aria-label="Chart 4">Chart 4</a>)<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> is a potent NLRP3 inflammasome inhibitor that inhibits the release of IL-1β in lipopolysaccharide (LPS)-induced mouse bone marrow-derived macrophages (BMDMs), human monocyte-derived macrophages (HMDMs), and human peripheral blood mononuclear cells (PBMCs) with high potency (IC<sub>50</sub> < 10 nM in BMDMs and HMDMs). Studies of its pharmacokinetics and druggability indicated that MCC950 is a promising candidate for further development, with a wide selectivity window (hERG IC<sub>50</sub> > 30 μM), moderate metabolic stability (half-life 3.27 h), and acceptable oral bioavailability (68%). A preliminary mechanism of action study indicated that MCC950 can specifically inhibit the activation of NLRP3 but not TLR signaling or NLRP3 priming and that it does not inhibit K<sup>+</sup> efflux, Ca<sup>2+</sup> influx, or NLRP3-ASC interactions. In the NLRP3 inflammasome activation process, NLRP3-dependent ASC oligomerization is a key step. In the LPS- and nigericin-induced BMDMs model, ASC l complex formation was blocked by MCC950. In ATP-stimulated ASC-cerulean cells, ASC speck formation also decreased in response to MCC950. These data suggest that MCC950 inhibits NLRP3 inflammasome activation by blocking NLRP3-induced ASC oligomerization. The intensive mechanism of action of MCC950 has not yet been fully explored. The molecular targets of MCC950 may be involved in the posttranslational modification of NLRP3.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> In mouse models, ASC specks can recruit neutrophils and monocytes, and ASC specks are abundant in bronchoalveolar lavage from COPD patients and cigarette smoke-induced murine models of COPD.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> This abundance indicates that NLRP3 inflammasome activation and subsequent ASC speck formation are important to the inflammatory progress of COPD. Furthermore, IL-1β response correlates with increased neutrophilic inflammatory response, which is the pathogenic characteristic of COPD.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Thus, NLRP3 inflammation activation and IL-1β responses may lead to the development of COPD, and MCC950 may have potent effects in COPD.</div><figure id="cht4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 4. Chemical Structures of Selected NLRP3 Inflammasome Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Other NLRP3 Inflammasome Inhibitors (<a class="ref internalNav" href="#cht4" aria-label="Chart 4">Chart 4</a>)</h5><div class="NLM_p">In addition to IL-1β, the proinflammatory cytokine TNF-α shows increased levels in the sputum of COPD patients and amplifies airway inflammation. Auranofin,<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> a drug for rheumatoid arthritis, targets inhibitors of kappa B kinase (IKK) and suppresses the expression of IL-6 and TNF-α.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Fc11a-2 is a benzimidazole derivative with in vivo activity in the mouse dextran sulfate sodium (DSS)-induced colitis model, in which the expression levels of TNF, IL-1β, and IL-18 are low.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> TAK-242 (TLR4 antagonist) and bromoxone are also effective NLRP3 inflammasome inhibitors that can suppress the expression and processing of TNF-α<a onclick="showRef(event, 'ref86 ref87'); return false;" href="javascript:void(0);" class="ref ref86 ref87">(86,87)</a> and may have the potential to treat COPD.</div><div class="NLM_p last">The above compounds were selected from many reported NLRP3 inflammasome inhibitors because of their ability to inhibit the proinflammatory cytokines TNF and IL-1β, but this ability is not an absolute standard. The anti-TNF-α monoclonal antibody infliximab has been studied in clinical trials in COPD patients, but unfortunately, no positive results have been obtained.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Furthermore, there were no LMWDs available for cytokine blocking, and the effects of low-molecular-weight NLRP3 inflammasome inhibitors are unknown because they have not been applied to COPD research.</div></div></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26">3.2.3.  Leukotriene B<sub>4</sub> (LTB<sub>4</sub>) Receptor Antagonists and LTB<sub>4</sub> Synthetic Modulators</h4><div class="NLM_p">LTB<sub>4</sub> is a proinflammatory mediator that is generated by the activation of 5-lipoxygenase (5-LO) and leukotriene A<sub>4</sub> (LTA<sub>4</sub>) hydrolase and is an activator of neutrophils and macrophages.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> LTB<sub>4</sub> plays an important role in the recruitment of several types of inflammatory cells via binding to its receptors BLT1 and BLT2; therefore, several inflammatory diseases, including COPD, are associated with elevated levels of LTB<sub>4</sub>.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The modulation of the biosynthetic routes of LTB<sub>4</sub> via inhibiting 5-LO, 5-LO activating protein (FLAP), and LTA<sub>4</sub> hydrolase or via antagonism of the LTB4 receptor are potential pharmacological strategies for COPD.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Alternatively, the product of 15-lipoxygenase (15-LO) pathways, 15(<i>S</i>)-hydroxyeicosatetraenoic acid (15(<i>S</i>)-HETE), modulates LTB<sub>4</sub> levels and stimulates inflammation and mucus secretion (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Figure S4</a>).<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> This key role of 15-LO makes it a drug target for the treatment of inflammatory diseases.</div><div class="NLM_p last">Theoretically, LTB<sub>4</sub> receptor inhibitors (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S4</a>), 5-LO inhibitors (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S5</a>), FLAP inhibitors (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S6</a>), LTA<sub>4</sub> hydrolase inhibitors, and 15-LO inhibitors that can target the LTB<sub>4</sub> pathway are available for the treatment of COPD.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> However, these inhibitors either lack studies in COPD or showed negative results in clinical development.</div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27">3.3.  LMWDs Targeting Proteases</h3><div class="NLM_p">An imbalance between proteases and antiproteases occurs in COPD and contributes to emphysema, mucus hypersecretion,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> and neutrophilic inflammation (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a><b>)</b>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Connective tissue components in the lung parenchyma, such as elastin, are important for maintaining lung function. Elastin can be digested by proteases, and the loss of elasticity in the lung parenchyma causes emphysema.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> In contrast, endogenous antiproteases, including α<sub>1</sub>-antitrypsin, secretory leukoprotease inhibitor (SLPI), elafin, and tissue inhibitors of MMP (TIMP), can limit this degradation.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Ideally, the inhibition of such proteases and/or increasing the antiprotease levels would prevent lung destruction and slow the progress of inflammation. Antiproteases are protein drugs and must be applied through gene therapy. In contrast, treatment using low-molecular-weight elastase inhibitors is more convenient and feasible.</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0032.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Imbalance between proteases and antiproteases in COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Neutrophil Elastase Inhibitors</h4><div class="NLM_p">Human neutrophil elastase (HNE), together with proteinase 3 (PR3) and cathepsin G, belongs to the neutrophil serine proteases. HNE is a worthwhile therapeutic target for the treatment of inflammatory diseases.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p">Sivelestat (ONO-5046, <a class="ref internalNav" href="#cht5" aria-label="Chart 5">Chart 5</a>) is the only marketed low-molecular-weight HNE inhibitor, and it has been used to treat acute lung injury and acute respiratory distress.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Some HNE inhibitors, including ONO-6818 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S7</a>), AZD9668 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S7</a>), and AZD6553 have been investigated in clinical trials; unfortunately, these developments have been discontinued. BAY-85-8501 (<a class="ref internalNav" href="#cht5" aria-label="Chart 5">Chart 5</a>) is a new, highly potent, and selective HNE inhibitor. BAY-85-8501 inhibits the activity of HNE at picomolar concentrations (65 pM) in vitro. BAY-85-8501 binds to HNE with higher affinity (<i>K</i><sub>i</sub> = 80 pM) than to rat or mouse NEs and cannot inhibit 21 other serine proteases. These data show the high potency and selectivity of BAY-85-8501. In addition, BAY-85-8501 has good pharmacokinetic properties, with a half-life of 8.5 h and 63% oral bioavailability, and it showed in vivo efficacy in an HNE-induced acute lung injury mouse model at a dose as low as 0.01 mg/kg.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> BAY-85-8501 has been developed in a phase II trial for safety and efficacy evaluation in patients with noncystic fibrosis bronchodilation (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT01818544). Compound <b>2</b> (<a class="ref internalNav" href="#cht5" aria-label="Chart 5">Chart 5</a>) represents a series of novel HNE inhibitors with an <i>N</i>-benzoylindazole scaffold and can specifically inhibit HNE with an IC<sub>50</sub> value of 7 nM.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Testing of a silanediol peptide analogue (compound <b>3</b>, <a class="ref internalNav" href="#cht5" aria-label="Chart 5">Chart 5</a>) indicated that the incorporation of a silanediol isostere in the structure improved the selectivity for HNE over other serine proteases, including trypsin, chymotrypsin, cathepsin G, plasmin, thrombin, and porcine pancreatic elastase.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The O<sub>3</sub>-pivaloyl derivative <b>4</b> (<a class="ref internalNav" href="#cht5" aria-label="Chart 5">Chart 5</a>) was identified as a potent HNE inhibitor with excellent selectivity and cytotoxicity profiles. In addition, its stability against hydrolytic enzymes from plasma and microsomes was tolerable, and its stability against microsomes was higher than that of sivelestat.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><figure id="cht5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 5. Chemical Structures of HNE Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">These compounds provide promising leads or show therapeutic potential for the development of new HNE inhibitors for the treatment of COPD. Additional evidence of their effects in treating COPD must be provided by further studies. Other reported HNE inhibitors that represent different structural types are presented in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S7</a>.</div></div><div id="sec3_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Matrix Metalloproteinase (MMP) Inhibitors</h4><div class="NLM_p">MMPs are a family of structurally related and zinc-dependent metalloenzymes that mediate the breakdown of connective tissue, and they are targets for anti-inflammatory therapies.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> MMP-12, also known as macrophage metalloelastase, is involved in the pathological condition of emphysema. It was proposed that MMP-12 also mediates the release of TNF-α from macrophages and leads to smoke-induced inflammation.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> Moreover, MMP-12 plays a pivotal role in COPD because blocking MMP-12 can markedly impair macrophage and neutrophil recruitment and protect against emphysema in a cigarette smoke-induced mouse model;<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> therefore, MMP-12 can serve as a target for the treatment of COPD.</div><div class="NLM_p">Marimastat (<a class="ref internalNav" href="#cht6" aria-label="Chart 6">Chart 6</a>) is a nonselective MMP inhibitor that significantly inhibits MMP-12-induced early inflammatory responses, including neutrophil influx and cytokine and MMP-9 release, and inhibits late responses by decreasing macrophage recruitment.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> Marimastat underwent a clinical trial for cancer therapy, but it exhibited major side effects, such as arthralgia and musculoskeletal pain,<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107,108)</a> which limited its development.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> A dual MMP-9/12 inhibitor, AZ11557272, ameliorates morphological emphysema and prevents small airway remodeling in a guinea pig model.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Another dual MMP-9/12 inhibitor, AZD1236 (<a class="ref internalNav" href="#cht6" aria-label="Chart 6">Chart 6</a>), has been used in phase IIa studies against COPD. Although oral doses of AZD1236 were well tolerated in short-term treatment in moderate to severe COPD patients, no clinical efficacy of AZD1236 was shown.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><figure id="cht6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 6. Chemical Structures of the Nonselective MMP Inhibitors Marimastat and AZD1236</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Because of the highly homologous structures of the MMP family, nonselective MMP inhibitors may interact with other MMPs and thus cause side effects. Therefore, the design of MMP-12 inhibitors with high selectivity and specificity has attracted the attention of researchers, and increased efforts have been made to identify specific MMP-12 inhibitors. The common features of the active site of MMPs consist of three parts: the Zn(II) ion, the backbone of the enzyme, and the S1′ pocket. The specificity of the S1′ pocket is responsible for the enzyme’s selectivity and is determined by the depth of the pocket.<a onclick="showRef(event, 'ref103 ref111'); return false;" href="javascript:void(0);" class="ref ref103 ref111">(103,111)</a> The rational design of specific MMP-12 inhibitors based on the structure and specificity of MMP-12 includes adding a functional group termed the zinc-binding group (ZBG) to chelate the active site Zn(II) ion, a H-bond receptor or donor for interacting with the amino acid backbone through hydrogen bonding, and a hydrophobic scaffold to fit into the S1′ pocket via hydrophobic interactions (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). The structure of marimastat is a hydroximic acid ZBG linked to an amino acid backbone. AS111793 (<a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>) was designed by attaching a 5-(2-thiophenyl)-1,2,4-oxadiazolyl moiety to the backbone of marimastat, which may occupy the large S1′ pocket of MMP-12 to increase selectivity. This selective MMP-12 inhibitor, AS111793, not only significantly reduced the number of neutrophils and macrophages but also decreased the activity of inflammatory cytokines such as TNF, IL-6, and pro-MMP-9 in bronchoalveolar lavage fluids of mice exposed to cigarette smoke. This study indicated that AS111793 suppresses the lung inflammation induced by cigarette smoke via the inhibition of MMP-12 and demonstrated that the use of MMP-12 inhibitors may be a therapeutic approach for the treatment of inflammation associated with COPD.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> Compound <b>5</b> (<a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>) is a substituted γ-keto carboxylic acid compound with carboxyl serving as a ZBG and the 4-position on the phenyl substituted by alkynyl groups, which fit into the bottom of the S1′ pocket. Structure–activity relationship (SAR) studies revealed that the groups at the end of the alkynyl are important for the interaction between inhibitors and the S1′ pocket. The IC<sub>50</sub> value for the inhibition of MMP-12 by compound <b>5</b> is 0.2 μM, and <b>5</b> provides protection against emphysema in vivo. This compound may have the potential to be further developed for COPD therapy.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> The phenoxybenzenesulfonyl compound <b>6</b> (<a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>) was identified as a selective and potent MMP-12 inhibitor; its phenoxybenzenesulfonyl scaffold may occupy the S1′ pocket well, its hydroxamic acid group can serve as a ZBG, and the sulfonyl interacts with the backbone of the enzyme via H-bonds. Compound <b>6</b> had an IC<sub>50</sub> value of 0.2 nM, with good selectivity for MMP-12 over MMP-1 and MMP-14. This compound also showed subnanomolar activity for MMP-9, which is another MMP related to COPD.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> The selectivity and activity of MMP408, MMP118, and compound <b>7</b> (<a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>) revealed that substituted dibenzofuran groups were another core suitable for occupying the S1′ pocket of MMP-12. This series of compounds showed good oral efficacy in a lung inflammation mouse model. MMP408 has a half-life of 3 h and a bioavailability of 27% in C57BL/6 mice.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> MMP118 was generated by optimizing MMP408 through replacement of the amide group by a five-membered heterocycle in the dibenzofuran core. MMP118 maintained the potency, selectivity, and half-life of MMP408 but had improved bioavailability (63%).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Compound <b>7</b> represents the most potent MMP-12 inhibitor reported in the literature and has high metabolic stability. Moreover, <b>7</b> and two of its analogues were selected for the synthesis of their fluorine-18-labeled analogues, and the radiolabeled compounds were evaluated in vivo by imaging MMP-12 with positron-emission tomography (PET). This in vivo biodistribution approach provides a tool for the diagnosis of MMP-associated diseases.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> Compound <b>8</b> (<a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>) was designed to represent novel MMP-12 inhibitors with a <i>N</i>-1-hydroxypiperidine-2,6-dione group as a new ZBG. The in vitro inhibition of MMP-12 by <b>8</b> showed that <b>8</b> had an IC<sub>50</sub> = 33 nM and exhibited 1200-, 176-, and 20-fold selectivity for MMP-12 over MMP-14, MMP-9, and MMP-2, respectively.<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> Compound <b>8</b> is a promising hit among MMP-12 inhibitors with a new ZBG for further optimization and evaluation against COPD. Compound <b>9</b> (<a class="ref internalNav" href="#cht7" aria-label="Chart 7">Chart 7</a>) was described as a thiophene-based MMP-12 inhibitor with nanomolar affinity. The X-ray structure of <b>9</b> complexed with the MMP-12 catalytic domain showed that its biaryl moiety fitted into the S1′-pocket well but that no groups interacted with the Zn(II) site; that is, <b>9</b> represents a series of new leads of MMP-12 inhibitors without a ZBG.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> The thiophene and its bioisosteric derivatives, a class of compounds with a β-hydroxy carboxylic acid template, and the newly reported radioiodinated probes of MMP-12 inhibitors are listed in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S8</a>.</div><figure id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0033.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Rational design of MMP-12 inhibitors. (A) Structural features of specific MMP-12 inhibitors. (B) Active site of MMP-12 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JK3">1JK3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="cht7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Chart 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 7. Chemical Structures of Selected MMP-12 Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The above cases indicated that the active site of MMP-12 may have a large and extended S1′ pocket, and the design of novel, highly selective MMP-12 inhibitors may focus on this specificity pocket to reduce side effects.</div></div><div id="sec3_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Proteinase 3 (PR3) Inhibitors</h4><div class="NLM_p">PR3 is another neutrophil serine protease that is also considered a target for the treatment of COPD. PR3 and HNE are homologous proteases that share up to 50% sequence and structural similarity.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> The ketomethylene-based short peptide PR3 inhibitor <b>10</b> (<a class="ref internalNav" href="#cht8" aria-label="Chart 8">Chart 8</a>) showed a low micromolar IC<sub>50</sub> of 1.9 μM, with selectivity for PR3 over HNE, and exhibited competitive and reversible inhibition of PR3.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Another peptide-based phosphonate inhibitor, <b>11</b> (<a class="ref internalNav" href="#cht8" aria-label="Chart 8">Chart 8</a>), inhibits human PR3 as well as macaque PR3 and has no effect on HNE. In addition, molecular probes were designed using biotinylated valine residues to provide a tool for exploring the function of PR3 both in vitro and in vivo.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Compound <b>12</b> (<a class="ref internalNav" href="#cht8" aria-label="Chart 8">Chart 8</a>) is a reported hit among selective PR3 inhibitors based on the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> PR3 has specific functions in regulating the inflammatory response that are different from those of HNE; however, research of PR3 inhibitors is still in the initial stage.</div><figure id="cht8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Chart 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 8. Chemical Structures of Reported PR3 Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35">3.4.  Antioxidants</h3><div class="NLM_p">Oxidative stress is an imbalance between oxidant and antioxidant levels and is involved in many chronic diseases, including inflammation, cancer, and diabetes. ROS are chemical species in the oxidative stress response that contain oxygen and contribute to the pathophysiology of oxidative stress.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> When the levels of ROS exceed the levels of antioxidants, oxidative stress occurs. In COPD, particularly during exacerbations, the increased production of ROS is primarily stimulated by exposure to cigarette smoke, but they are also released from the activation of inflammatory cells, including macrophages, neutrophils, and epithelial cells, in the lungs.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Oxidative stress contributes to the pathogenesis of COPD in several ways and plays a key role in the development of therapeutic approaches for COPD (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). In the airway, ROS lead to the activation of proinflammatory/inflammatory cytokine and chemokine genes by activating NF-κB and p38 mitogen-activated protein kinase (p38 MAPK); ROS contribute to increased elastolysis and accelerate lung damage by destroying the balance of endogenous proteases/antiproteases. ROS also activate TGFβ, which causes lung fibrosis. Additionally, the expression of histone deacetylase 2 (HDAC2) is reduced by oxidative stress, leading to corticosteroid resistance in vitro and in vivo.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Therefore, antioxidant therapy is a promising area for COPD intervention.</div><figure id="fig9" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0034.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Oxidative stress in COPD and potential therapeutic targets for antioxidants. Nrf2, nuclear factor erythroid 2-derived factor 2; NOX, NADPH oxidase; MPO, myeloperoxidase; SOD, superoxide dismutase; iNOS, inducible nitric oxide synthase; NO, nitric oxide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Mucolytic Drugs</h4><div class="NLM_p"><i>N</i>-Acetylcysteine (NAC), erdosteine, and carbocisteine (<a class="ref internalNav" href="#cht9" aria-label="Chart 9">Chart 9</a>) are mucolytic agents with antioxidant and anti-inflammatory properties. They have been used to reduce the mucus thickness in patients with COPD in the clinic. Recently, in China, the efficacy and safety of high-dose NAC (1200 mg daily) for the long-term treatment of patients with moderate to severe COPD was evaluated in a designed PANTHEON study, which is a prospective, ICS-stratified, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. This study found that high-dose long-term (1 year) NAC treatment can prevent COPD exacerbations.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> In a prospective randomized, double-blind, placebo-controlled study of erdosteine, enrolling patients aged 40–80 years with the Global Initiative for COPD stage II/III study (RESTORE study), the exacerbation rate was assessed as the primary outcome after long-term (1 year) treatment with a 300 mg twice-daily dose. This study demonstrated that erdosteine can decrease both the rate and duration of exacerbation, and the occurrence of adverse events in the treatment group was similar to that in the placebo group.<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a></div><figure id="cht9" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Chart 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 9. Chemical Structures of NAC, Erdosteine, and Carbocisteine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Nuclear Factor Erythroid 2-Derived Factor 2 (Nrf2) Activator</h4><div class="NLM_p">Nrf2 is a basic leucine zipper transcription factor that regulates the genes that express multiple antioxidant proteins.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Nrf2 becomes functionally defective because of reduced stability due to reduced HDAC2 activity in COPD patients,<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> and Nrf2 activators can protect against this functional defect. The Nrf2 activators sulforaphane and bardoxolone methyl (CDDO-Me) (<a class="ref internalNav" href="#cht10" aria-label="Chart 10">Chart 10</a>) were developed in clinical trials. Two dose levels of sulforaphane were administered orally in patients with COPD in a phase II trial, but sulforaphane affected neither the Nrf2 pathways nor the levels of antioxidants or inflammation.<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> An analogue of CDDO-Me and another synthetic triterpenoid, CDDO-imidazolide (<a class="ref internalNav" href="#cht10" aria-label="Chart 10">Chart 10</a>), was administered to a cigarette smoke-induced mouse model and delayed or prevented the progression of COPD.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a> A novel chalcone, <b>13</b> (<a class="ref internalNav" href="#cht10" aria-label="Chart 10">Chart 10</a>), was reported as an Nrf2 activator in mice and human lung epithelial cells, and this study provides a promising lead for the treatment of COPD.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></div><figure id="cht10" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Chart 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 10. Chemical Structures of Some Known Nrf2 Activators</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Considering that the side effects and toxicity arise from the lack of specificity demonstrated by these Nrf2 activators, an alternative strategy for targeting selective Nrf2 activation mechanisms is focused on Kelch-like ECH-associated protein 1 (Keap-1)-Nrf2 protein–protein interaction (PPI) inhibition.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Keap1 is selectively responsible for Nrf2 recognition as a substrate receptor. The PPI between Keap1 and Nrf2 is the first step of Nrf2 ubiquitination, and inhibition of this PPI results in the activation of Nrf2.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> Compound <b>16</b> (<a class="ref internalNav" href="#cht10" aria-label="Chart 10">Chart 10</a>) is a promising lead compound that tightly and selectively binds to Keap1 and disrupts the PPI between Keap1 and Nrf2 with nanomolar activity. Compound <b>14</b> upregulates Nrf2-dependent gene expression in bronchial epithelial cells from COPD patients and restores the ozone-induced depletion of reduced glutathione (GSH) levels in the lungs in vivo.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Compound <b>15</b> (<a class="ref internalNav" href="#cht10" aria-label="Chart 10">Chart 10</a>) represents another series of Keap1-Nrf2 PPI inhibitors. Cell-based experiments showed that <b>15</b> activates Nrf2 and induces its downstream protein expression. In the LPS-challenged mouse model, <b>15</b> significantly reduces the levels of several proinflammatory cytokines and relieves the inflammatory response.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> These studies provide a selective and effective way to explore Nrf2-targeted antioxidant therapies.</div></div><div id="sec3_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> NADPH Oxidase (NOX) Inhibitors</h4><div class="NLM_p">NOXs are a family of enzymes that catalyze the transfer of electrons from NADPH to molecular oxygen and are a major source of ROS. There are seven isoforms of NOXs, including NOX1–5, Duox1, and Duox2;<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> NOX4 is the predominant isoform and plays critical roles in pulmonary fibrosis.<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> The identification of specific NOX4 inhibitors may provide a new opportunity for antioxidant therapies to treat pulmonary fibrosis and COPD. Although a large number of natural or synthetic NOX inhibitors have been reported, only a few selective NOX4 inhibitors are known. The known NOX2 and NOX4 inhibitor VAS2870 (<a class="ref internalNav" href="#cht11" aria-label="Chart 11">Chart 11</a>)<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> inhibits oxidized low-density lipoprotein-induced ROS formation in human endothelial cells,<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> and a later study indicated that VAS2870 may interfere with the protein and signaling pathways related to NOX enzymes and is an indirect NOX inhibitor.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> GKT136901 (<a class="ref internalNav" href="#cht11" aria-label="Chart 11">Chart 11</a>) is a first-in-class NOX4 inhibitor that showed double-digit nanomolar potency toward NOX4 with dual activity toward NOX1 and exhibited an excellent in vitro pharmacokinetic profile and high selectivity for NOX4 over the NOX2 isoform. This highly potent, orally bioavailable NOX4 inhibitor can serve as a lead compound for the development of novel antioxidants.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Sulfonylurea compound <b>16</b> (<a class="ref internalNav" href="#cht11" aria-label="Chart 11">Chart 11</a>), which was newly designed using a pharmacophore modeling strategy, can inhibit NOX4-dependent signaling in a cell-based assay with submicromolar activity. Nevertheless, more studies are needed to directly evaluate NOX4 activity and determine the selectivity of this novel compound.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a></div><figure id="cht11" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Chart 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 11. Chemical Structures of VAS2870, GKT136901, and Compound <b>16</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Myeloperoxidase (MPO)</h4><div class="NLM_p">MPO is released by neutrophils and macrophages and catalyzes the formation of potent oxidants, thereby further amplifying oxidative damage and the inflammation of lung tissue. The 2-thioxanthine MPO inhibitor AZD5904 can attenuate the oxidative stress promoted by MPO in vivo.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> In a 6-month cigarette smoke-induced COPD guinea pig model, AZD5904 retarded the progression of emphysema and small airway remodeling, which occur at both the early and late stages of smoke exposure.<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> Some novel MPO inhibitors have been reported in the literature, including PF-06282999, whose human pharmacokinetics, safety/tolerability, and MPO inhibition have been in clinical trials:<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> aromatic hydroxamates (<b>17</b>),<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> 3-alkylindole derivatives (<b>18</b>),<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> and compounds with virtual screening-directed new patterns (<b>19</b> and <b>20</b>).<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> The structures of the above-mentioned compounds are presented in <a class="ref internalNav" href="#cht12" aria-label="Chart 12">Chart 12</a>. These chemical entities exhibited highly potent MPO inhibition at nanomolar levels, and additional studies are needed to evaluate their effects on COPD.</div><figure id="cht12" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Chart 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 12. Chemical Structures of Some MPO Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Other Antioxidants</h4><div class="NLM_p">Superoxide dismutase (SOD) is an enzymatic antioxidant that can protect the lungs and blood by neutralizing ROS.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> Therefore, SOD mimetics with SOD activity can be used as antioxidants. AEOL 10113<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> and Tempol<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> are known SOD mimetics that efficiently neutralize ROS. Spin trap compounds such as NXY-059 are another type of antioxidant that can scavenge free radicals; however, there is no evidence of their efficacy in COPD.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Inducible nitric oxide synthase (iNOS) is implicated in many chronic inflammatory diseases. A study of smoke-exposed mice treated with the iNOS inhibitor L-NIL indicated that L-NIL protects against smoke-induced emphysema and pulmonary hypertension. This study demonstrated that iNOS inhibition may be a therapeutic option for COPD.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Moderate levels of nitric oxide (NO) reduce neutrophil activation and suppress iNOS overexpression, and compounds with NO-releasing capacity therefore have the potential to treat COPD. Compound <b>21</b>, which contains NO donors, exhibited potent inhibitory activity against COPD-like inflammation in cigarette smoke- and LPS-induced mouse models,<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a> and this study proposes using NO-donor derivatives as antioxidants to mitigate COPD. The structures of the above-mentioned compounds are presented in <a class="ref internalNav" href="#cht13" aria-label="Chart 13">Chart 13</a>.</div><figure id="cht13" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Chart 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 13. Chemical Structures of AEOL 10113, Tempol, NXY-059, L-NIL, and Compound <b>21</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46">3.5.  Kinase Inhibitors</h3><div class="NLM_p">More than 500 kinase genes have been identified in humans, and kinases play essential roles in regulating cell proliferation, apoptosis, and inflammation. Several kinases have been implicated in orchestrating chronic inflammation by modulating inflammatory gene expression.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> In COPD, multiple inflammatory mediators and proteins are regulated by kinase signaling pathways. Therefore, these kinases may be targets for the development of kinase inhibitors for COPD treatment. To date, over 30 kinase inhibitors have been approved by the FDA, but few of these inhibitors have been applied to inflammatory diseases; however, kinase inhibitors are still a powerful tool for treating inflammatory diseases and full of possibility for use in future studies. Numerous kinase inhibitors have been reported in the literature; herein, we discuss only the kinases and their inhibitors related to COPD.</div><div id="sec3_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> IKKβ Inhibitors</h4><div class="NLM_p">NF-κB is a proinflammatory transcription factor that is activated in epithelial cells and macrophages, induces multiple inflammatory genes in patients with COPD, and is involved in the activation of inflammasome and oxidative stress. IKKβ is an essential component in the NF-κB pathway, which is activated by the overexpression of inflammatory mediators in COPD. IMD-3054 (<a class="ref internalNav" href="#cht14" aria-label="Chart 14">Chart 14</a>) is a selective IKKβ inhibitor that inhibits TNF-α-induced NF-κB transcription activity with an IC<sub>50</sub> of 1.2 μM<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> and counteracts allergic airway inflammation and hyperresponsiveness in a mouse model.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Its prodrug, IMD-1041 (structure not disclosed), advanced to a phase II trial in patients with COPD for testing for anti-inflammation potency, but the study was halted due to side effects.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div><figure id="cht14" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Chart 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 14. Chemical Structures of Some IKKβ Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Other IKKβ inhibitors, including BAY65-1942, TPCA-1, PS-1145 (<a class="ref internalNav" href="#cht14" aria-label="Chart 14">Chart 14</a>), and ainsliadimer-A, have been studied in lung inflammation-related models for their anti-inflammatory effects in vitro or in vivo. These studies were introduced elsewhere<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> and provide evidence for the potential of IKKβ inhibitors as anti-inflammatory agents against COPD.</div></div><div id="sec3_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> p38 MAPK Inhibitors</h4><div class="NLM_p">The p38 MAPKs represent a family of serine threonine kinases and comprise four isoforms, α, β, γ, and δ. Among these isoforms, p38α and p38β are highly homologous and widely expressed. p38 MAPK regulates the expression of multiple inflammatory genes, such as the cytokines TNF-α, IL-6, and IL-1β, and the chemokine IL-8, which is involved in COPD.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> p38 MAPKs have been investigated for COPD. Indeed, several p38 inhibitors have advanced in clinical trials in patients with COPD, and p38 inhibitors are the kinase inhibitors most extensively studied for COPD treatment.</div><div class="NLM_p">Acumapimod (BCT-197), PH-797804, losmapimod, and dilmapimod are oral p38 inhibitors that have been studied in phase II trials for COPD (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Although oral p38 inhibitors are efficient, high doses of oral administration may produce side effects. Directly delivering the agents to the lungs of COPD patients may avoid common adverse events. Therefore, discovering an inhaled p38 inhibitor is an alternative strategy for improving the therapeutic window.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Several inhaled p38 MAPK inhibitors have also been evaluated clinically for use in COPD treatment (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Detailed information about the p38 inhibitors in clinical trials for COPD treatment has previously been presented in the review literature.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Talmapimod (<a class="ref internalNav" href="#cht15" aria-label="Chart 15">Chart 15</a>) has been investigated in a phase II trial for the treatment of rheumatoid arthritis. It is also effective in a corticoid-resistant cigarette smoke-induced mouse model.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> Another compound, SB-239063 (<a class="ref internalNav" href="#cht15" aria-label="Chart 15">Chart 15</a>), can reduce LPS-induced TNF-α production in vivo.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> A newly reported compound, <b>22</b> (<a class="ref internalNav" href="#cht15" aria-label="Chart 15">Chart 15</a>), suppresses the production of cytokines TNF-α and CXCL8 induced by LPS and inhibits both p38 and hematopoietic kinases in a nanomolar range. Compound <b>22</b> is also highly effective against cigarette smoke-induced pulmonary inflammation in mice and is active for a long time in vivo.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Oral p38 MAPK Inhibitors in Clinical Trials for COPD<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0043.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Information was collected from <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Inhaled p38 MAPK Inhibitors in Clinical Trials for COPD<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0044.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Information was collected from <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Structure not disclosed.</p></div></div><div></div></div><figure id="cht15" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Chart 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 15. Chemical Structures of Talmapimod, SB-239063, and Compound <b>22</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of their structural features and their interaction with p38 MAPK, p38 inhibitors can be categorized into three types: teardrop binders, linear binders, and extended binders. Both the first two types interact competitively with the ATP-binding site, while the third undergoes allosteric binding with the kinase. The active sites of all p38 isoforms in which the p38 inhibitor and ATP competitively interact with have distinct features that include (1) a ligand-rejecting pocket and a special residue, Thr106, named the “gatekeeper pocket” and the “gatekeeper residue,” respectively, (2) a hydrophobic floor, and (3) a linker residue, Met109. All three types of ligands have aromatic ring or heterocyclic groups that fit into the gatekeeper pocket and hydrophobic floor and a hydrogen bond receptor for interacting with Met109 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> For instance, SB-239063 is a teardrop binder, dilmapimod is a linear binder, and PF-03715455 is an extended binder. These characteristics can guide the structure-based design of novel p38 MAPK inhibitors for COPD treatment.</div><figure id="fig10" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0035.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. 2D model of the interactions between selected p38 inhibitors and p38α kinase. (A) Representative compound of the teardrop binders (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1A9U">1A9U</a>). (B) Representative compound of the linear binders (PDB entry). (C) Representative compound of the extended binders (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Phosphoinositide-3-kinase (PI3K) Inhibitors</h4><div class="NLM_p">PI3Ks generate lipid second messengers and play an integral role in the immune system. PI3Ks are divided into three classes and have several isoforms, including PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ. Specifically, PI3Kδ and PI3Kγ were proven to be the main players in chemoattractant-stimulated neutrophil and macrophage migration, which are implicated in COPD.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Therefore, PI3Kδ and PI3Kγ can be targeted pharmacologically for the treatment of COPD.</div><div class="NLM_p">GSK2269557 (<a class="ref internalNav" href="#cht16" aria-label="Chart 16">Chart 16</a>)<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> is an inhaled selective PI3Kδ inhibitor that was evaluated in a phase II trial (NCT02294734). The inhalation of GSK2269557 suppressed airway inflammation, as reflected by decreased IL-8 and IL-6 levels in the sputum of patients with COPD.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> The PI3Kδ/γ inhibitor TG100-115<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> (<a class="ref internalNav" href="#cht16" aria-label="Chart 16">Chart 16</a>) reduces the lung inflammatory response and pulmonary neutrophilia after aerosolization in the treatment of BALB/c mice induced by LPS or cigarette smoke exposure. Considering the favorable biological activity, pharmacokinetic, and safety profiles of this compound, it is suitable for development as a candidate for COPD therapy. The study also indicated that PI3Kδ and PI3Kγ are reasonable molecular targets for the treatment of COPD. Compound <b>23</b> (<a class="ref internalNav" href="#cht16" aria-label="Chart 16">Chart 16</a>) is a newly reported orally bioavailable PI3Kδ inhibitor<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> derived from the inhaled clinical candidate GSK229276 (<a class="ref internalNav" href="#cht16" aria-label="Chart 16">Chart 16</a>), which is indicated for respiratory treatment. Replacement of the indazole core of GSK2292767 with a dihydroisobenzofuran and optimization at the 6-position of the dihydroisobenzofuran scaffold led to <b>23</b>, which was identified and found to show a marked increase in oral bioavailability compared to GSK2269557 (54% vs <2%) while maintaining activity. In an acute rat ovalbumin model of lung inflammation, the in vivo pharmacodynamic assay showed that in bronchoalveolar lavage, protection against eosinophil recruitment was achieved by <b>23</b> at 3 mg/kg after oral delivery, and the blood concentration of <b>23</b> (at 1 h, after dosing, and with a 30 min ovalbumin challenge) was 0.19 and 1.27 μM at 3 and 9 mg/kg, respectively. Future studies of this compound will focus on enhancing the activity and selectivity. LAS191954 is another selective and orally available PI3Kδ inhibitor, which inhibits PI3Kδ with an IC<sub>50</sub> of 2.6 nM, exhibits selectivity for PI3Kδ over PI3Kα, γ, and β, and shows no hERG channel activity at 10 μM. LAS191954 blocks IL2 production with an ID<sub>50</sub> of 0.13 mg/kg in a concanavalin A-induced IL2 production rat model. In a 6 h postovalbumin challenge rat model, LAS191954 administered twice daily was observed to reduce the number of eosinophils in the bronchoalveolar lavage with an ID<sub>50</sub> of 0.16 mg/kg. In addition, LAS191954 has a good PK profile, with half-lives of 3.1 and 10.2 h, high oral bioavailability (101% and 98%), and low clearance (9.6 and 1.4 mL/min/kg) in rats and dogs, respectively. These results indicate that LAS191954 can serve as a long-acting, orally available candidate for preclinical development.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></div><figure id="cht16" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Chart 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 16. Chemical Structures of Some Reported PI3K Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Janus Kinase (JAK) Inhibitors</h4><div class="NLM_p">JAK regulates the expression of multiple inflammatory genes by phosphorylating the signal transducers and activator of transcription (STAT) protein. The JAK isoforms JAK1 and 2 are activated by cytokines IL-6, IL-12, and INF-γ through the phosphorylation of STAT3. STAT4 is activated by IL-12 and IL23 and is increased in the airways of COPD patients.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> JAK-STAT signaling is also involved in COPD by releasing regulating chemokines that bind to CXCR3, including CXCL9, CXCL10, and CXCL11. Inhalation of the pan-JAK inhibitor PF1367550 (<a class="ref internalNav" href="#cht17" aria-label="Chart 17">Chart 17</a>) reduces the release of CXCL9, CXCL10, and CXCL11 in both BEAS-2B cells and airway epithelial cells, indicating that pan-JAK inhibitors are beneficial in inflammatory diseases, particularly COPD.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div><figure id="cht17" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Chart 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 17. Chemical Structures of pan-JAK Inhibitor PF1367550 and EGFR Inhibitor AG-1478</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht17"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Epidermal Growth Factor Receptor (EGFR) Inhibitors</h4><div class="NLM_p">Mucus hypersecretion and neutrophil infiltration, which can lead to chronic bronchitis, are typical characteristics of airway inflammation. EGFR tyrosine kinase mediates mucus hypersecretion and the expression of IL-8 in airway epithelial cells. The EGFR inhibitor AG-1478 (<a class="ref internalNav" href="#cht17" aria-label="Chart 17">Chart 17</a>) was explored for its ability to suppress the secretion of MUC5AC mucin and IL-8, which were markedly induced by both LPS and TNF-α in vitro.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> In addition, in an LPS-treated rat model, intranasal instillation of AG-1478 inhibited mucus generation and neutrophil infiltration in the nasal epithelium of rats.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> In another study, in which mucin synthesis and MUC5AC mRNA expression were induced by cigarette smoke exposure, AG-1478 also inhibited the synthesis of mucin both in vivo and in vitro.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> Another EGFR inhibitor, BIBW 2948 (structure not disclosed), has been studied in a phase II trial to evaluate its safety and efficacy in patients with COPD and chronic bronchitis. However, BIBW 2948 did not show inhibition of epithelial mucin and tolerance in patients with COPD, and ex vivo analyses proposed that high doses may be effective but that adverse events should not be neglected.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a></div><div class="NLM_p last">Other kinases, such as spleen tyrosine kinase, Jun N-terminal kinase, and Bruton’s tyrosine kinase, may also play roles in the pathophysiology of COPD.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Nevertheless, the application of inhibitors of these kinases to COPD has been reported in only a few studies.</div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58">3.6.  Phosphodiesterase-4 (PDE4) Inhibitors</h3><div class="NLM_p">Phosphodiesterases (PDEs) are encoded by 21 genes to produce over 100 different isoforms and can be divided into 11 isozyme families (PDE1–11) based on their substrate specificity, sequence homogeneity, and pharmacological properties.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> PDE4, one of the PDE families and commonly located in neutrophils, eosinophils, T cells, and airway macrophages, specifically catalyzes the degradation of cyclic 3′,5′-adenosine monophosphate (cAMP) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> cAMP has multiple functions in inflammatory cell pathways, as elevated intracellular levels of cAMP lead to the inhibition of T-cell activation, the downregulation of macrophages and neutrophils, and bronchodilation. Increased intracellular cAMP levels also inhibit fibrosis, the release of inflammatory cytokines and chemokines, proteases, the production of ROS, and arachidonic acid metabolites. Therefore, PDE4 inhibitors are of great interest for treating COPD due to their broad-spectrum anti-inflammation function that acts via inhibiting the degradation of cAMP, which results in increased intracellular cAMP (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></div><figure id="fig11" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0036.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Synthesis and degradation of cAMP. cAMP is synthesized from ATP by adenylate cyclase (AC) and hydrolyzed by cAMP-specific PDEs such as PDE4 to produce 5′AMP. ATP, adenosine triphosphate; M<sup>2+</sup>, divalent metal ion; 5′AMP, adenosine 5′-monophosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig12" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0037.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Roles of PDE4 inhibitors and cAMP in COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">PDE4 has been categorized into four isoforms, PDE4A–D, according to the characterization of genes and their corresponding protein products, and considering the mRNA splice variants of each isoform results in over 18 subtypes (e.g., PDE4D1–5).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> The N-terminal region of PDE4 comprises a targeting domain, upstream conserved regions 1 and 2 (UCR1 and 2), and linker regions 1 and 2, which link UCR1 to UCR2 and UCR2 to the catalytic domain, respectively. Additionally, PDE4 isoforms can be classified into four groups, including long, short, super short, and dead-short, based on the presence and size of UCR1 and 2 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Although the PDE4 family contains several isoforms or subtypes, they share a highly conserved catalytic domain that represents an active site for cAMP metabolization, and the catalytic domain has been extensively investigated for the design of specific inhibitors.</div><figure id="fig13" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0038.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Four groups of PDE4 isoforms and subtypes. UCR, upstream conserved region; LR, linker region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Oral PDE4 Inhibitors</h4><div class="NLM_p">The PDE4 inhibitor roflumilast (<a class="ref internalNav" href="#cht18" aria-label="Chart 18">Chart 18</a>) is the sole approved anti-inflammatory drug for treating COPD. Roflumilast is an orally administered drug, dosed once daily at 500 μg, and is the first PDE4 inhibitor approved for maintenance treatment of severe COPD. Clinical trials demonstrated that roflumilast reduces exacerbation frequency in COPD and improves lung function. Mode of action studies indicated that it targets the inflammatory process in patients with COPD.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> A multicenter, double-blind, phase III study was conducted to evaluate the tolerability and pharmacokinetics of roflumilast (250 μg and 500 μg) using an uptitration regimen. In the PK/PD model, dosing 250 μg of roflumilast once daily for 4 weeks reduced discontinuations and improved tolerability. However, this low dose was ineffective for long-term maintenance therapy, supporting the dose of 500 μg that has been used in the clinic as a maintenance dose.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Before the development of roflumilast, cilomilast (<a class="ref internalNav" href="#cht18" aria-label="Chart 18">Chart 18</a>) was the first candidate among the second-generation oral PDE4 inhibitors. In phase I and II studies, cilomilast significantly improved lung function; however, phase III research on the efficacy, safety evaluation, and mechanism of action of cilomilast gave disappointing results due to its low therapeutic ratio.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> Tetomilast (<a class="ref internalNav" href="#cht18" aria-label="Chart 18">Chart 18</a>), another oral PDE4 inhibitor, is currently being studied in a phase II trial for efficacy in COPD. The pharmacological profile of tetomilast revealed an IC<sub>50</sub> value of 380 nM, which is weaker than those of roflumilast and cilomilast. Moreover, it has a long half-life (approximately 24 h) and high bioavailability (nearly 100%), which are better than those of roflumilast and cilomilast.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> These data support tetomilast as a suitable once-daily orally administered candidate.</div><figure id="cht18" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Chart 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 18. Chemical Structures of Selected Oral PDE4 Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Selectivity of PDE4 Inhibitors</h4><div class="NLM_p">Over the past few decades, oral PDE4 inhibitors developed in clinical trials have been found to have severe side effects, such as nausea and emesis, although they also have demonstrated therapeutic benefits. PDE4 inhibitor-induced emesis may be mediated through a noradrenergic pathway,<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> and the cAMP concentration may exceed normal physiological levels due to full PDE4 inhibition. This dysfunction of the tight temporal and spatial aspects of cAMP signaling within cells can also lead to these side effects.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> Traditional PDE4 inhibitors can compete with cAMP for binding to the active catalytic site of PDE4 and inhibit the activity of PDE4. An isoform selectivity theory proposed that isoform PDE4B has anti-inflammatory relevance,<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> whereas the side effects result from PDE4D inhibition.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Therefore, research on the development of active site-directed PDE4 inhibitors has focused on the design of small molecules that selectively inhibit PDE4B. Because of the high homology between PDE4 isoforms, inhibitors with high isoform selectivity are still lacking, and it is difficult to attribute emesis to the inhibition of a particular PDE4 isoform. Rolipram is the representative first-generation PDE4 inhibitor (<a class="ref internalNav" href="#cht19" aria-label="Chart 19">Chart 19</a>) and binds to the high-affinity allosteric binding site (HARBS) in the UCR2 of PDE4. This binding negatively regulates cAMP hydrolysis without direct inhibition of the PDE4 active site.<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> The cocrystal structure of compound RS25344 (<a class="ref internalNav" href="#cht19" aria-label="Chart 19">Chart 19</a>) with PDE4<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> reveals that the UCR2 region can interact with the catalytic domain of PDE4. The PDE4 enzyme exists in multiple conformations, including an “open” and a “closed” conformation for accessing the active site, and the enzymatic activity can be regulated by the phosphorylation of PDE4 or the partner proteins.<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> PDE4 allosteric modulators such as rolipram and RS25344 can bind to the allosteric site of the enzyme and keep UCR2 in the “closed” conformation to inhibit the enzyme’s activity. Both compounds lead to emesis by fully inhibiting cAMP hydrolysis even though they are not traditional active site-directed inhibitors; however, it is possible to design selective allosteric modulators with only partial inhibition of function.</div><figure id="cht19" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Chart 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 19. Chemical Structures of the PDE4 Allosteric Modulators Rolipram, RS25344, and D159404</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A shows the interaction of UCR2 with the helix (blue) and active site (cyan) of PDE4D. The cavity between Phe196 in UCR2 and Phe538 and Gln535 in the active site can accommodate a designed low-molecular-weight modulator to lock in the “closed” conformation (such as D159404 in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B). A similar cavity exists in PDE4B, although there is a Phe196/Tyr274 sequence variation between PDE4D and 4B (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Figure S5</a>). For PDE4 allosteric modulators, a planar aromatic ring scaffold interacts with Gln535 via a hydrogen bond, and two aromatic substituents serve as pliers to clamp Phe196 through a π–π interaction, thereby locking in the closed conformation. These components are linked by a CH<sub>2</sub> linker (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>C).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> D159404 (<a class="ref internalNav" href="#cht19" aria-label="Chart 19">Chart 19</a>) was selected from an SAR study<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> of a series of PDE4 allosteric modulators and was shown to inhibit LTB<sub>4</sub> production in human whole blood cells but was less effective in the HEK293 cAMP assay. This result indicates that D159404 completely inhibits the biological response of PDE4 with partial enzyme inhibition, which can be explained by the formation of an asymmetric PDE4 dimer (with only one UCR2 in the closed conformation).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> D159404 represents a series of PDE4 allosteric modulators that can selectively interact with a particular conformation of the enzyme. These compounds can maintain spatial and temporal features but inhibit biological cAMP signaling, thereby decreasing side effects. Additionally, the selectivity of these allosteric modulators for PDE4D over PDE4B may be due to the Phe196/Tyr274 sequence variance between isoforms.</div><figure id="fig14" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0039.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) The interaction of the UCR2 helix (blue) and active site (cyan) of PDE4D. (B) The “closed” conformation was locked in by D159404. (C) Design of PDE4 allosteric modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The allosteric modulation theory provides new insight for the design of selective PDE4 inhibitors with decreased side effects; however, there are currently no PDE4 allosteric modulator candidates in clinical development.</div></div><div id="sec3_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Inhalation by Design</h4><div class="NLM_p">The emetic side effects of PDE4 inhibitors may be due to mediation of the noradrenergic pathway.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> These effects can be decreased by limiting the distribution or the drug to the brain. When used for treating COPD, a respiratory disease, PDE4 inhibitors can be delivered directly to the lung by inhalation, and designing inhaled PDE4 inhibitors is an alternative strategy to minimize side effects and maximize the therapeutic window by reducing systemic exposure. The design of inhaled drugs involves compound structure modification following “inhalation by design” principles, which have been used to describe the design strategy focusing on lung-delivered drugs. The desired attributes of this objective include the following: (1) a low dose of a high-potency chemical, (2) a long DOA for a therapeutically relevant period, (3) low oral bioavailability and absorption and rapid clearance, (4) multiple clearance routes leading to minimal drug–drug interactions, (5) an appropriate physical form for inhalation, such as high crystallinity, low hygroscopicity, and suitable particle morphology, and (6) good cell and tissue penetrability for anti-inflammatory targets.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> “Lipinski’s rule of 5” describes a drug candidate with good oral absorption. The requirements of inhalation by design suggest that designing compounds that do not satisfy the rule of 5 may result in drugs suitable for inhalation. For the design of inhaled PDE4 inhibitors, the compound structures can be optimized in multiple ways, for instance, (1) adding hydrophobic groups or enlarging the hydrophobic scaffold to reduce aqueous solubility, (2) adding groups with poor metabolic stability to increase clearance, thus reducing systemic exposure, (3) increasing the number of rotatable and hydrogen bonds to increase the protein binding of compounds, and (4) using compatible excipients for adaptation to a dry powder inhaler.</div><div class="NLM_p last">Both the SAR and the pharmacokinetic profile need to be considered for an inhaled drug in a coordinated effort. Some examples of the design and development of inhaled PDE4 inhibitors are introduced in a later section.</div></div><div id="sec3_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Inhaled PDE4 Inhibitors</h4><div class="NLM_p">Many inhaled PDE4 inhibitors were developed in clinical trials (representative compounds are shown in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>); however, none of them have been approved. UK-500,001 has been discontinued due to negative results in clinical studies, and phase II studies of oglemilast and tofimilast have not been updated. GSK-256066 is the most potent PDE4 inhibitor (IC<sub>50</sub> = 0.015 nM) and was well tolerated in a phase II trial in patients with moderate COPD, but a favorable safety profile and clinical efficacy must be demonstrated in further studies.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> CHF6001 is another potent inhaled PDE4 inhibitor (IC<sub>50</sub> = 0.04 nM), with activity at subnanomolar concentrations. Compared with cilomilast, roflumilast, GSK256066, and UK-500,001, it preferentially inhibits the low-affinity rolipram binding sites (LARBS) over the high-affinity site. CHF6001 has the best ratio of HARBS inhibition to LARBS inhibition at 40.6, while those of cilomilast, roflumilast, GSK256066, and UK-500,001 are 2.1, 4.4, 11.0, and 2.2, respectively.<a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a> In addition to administration by inhalation, this finding also explained why CHF6001 has less severe side effects and a wider therapeutic window, as confirmed in clinical studies.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Inhaled PDE4 Inhibitors in Clinical Trials for COPD<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0045.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Information was collected from <a href="http://www.clinicaltrials.gov" class="extLink">www.clinicaltrials.gov</a>.</p></div></div><div></div></div></div><div id="sec3_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Discovery of Next-Generation PDE4 Inhibitors</h4><div class="NLM_p">The PDE4 catalytic binding domain includes a hydrophobic pocket, a metal-binding zone (Zn<sup>2+</sup> and Mg<sup>2+</sup> bind in this pocket and participate in catalytic activity), and a solvent-exposed pocket. The design of new PDE4 inhibitors aims to generate LMWDs that extend to fill these three pockets in the catalytic binding domain. For instance, CHF6001 was designed by replacing the amide linker of roflumilast with a substituted benzoic acid ester to interact with the solvent-exposed pocket, bearing a catechol group to interact with the hydrophobic pocket and dichloropyridinyl groups to interact with the metal-binding zone (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). In addition, the candidate was selected based on suitable absorption, distribution, metabolism, and excretion (ADME) properties, including lipophilicity, metabolic stability, plasma protein binding, and Caco-2 permeability, for administration by inhalation.<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a> Compounds <b>24</b> and <b>25</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>A) were developed to fill the solvent-exposed pocket by modifying the benzoic acid ester group of CHF6001, which was found by exploring the chemical space. These two heterocycloalkyl ester compounds with optimal in vitro and in vivo activities and ADME properties are potential candidates for treating respiratory inflammatory diseases such as COPD.<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Compound <b>26</b> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>B) is a newly reported inhaled PDE4 inhibitor with highly potent activity (PDE4B IC<sub>50</sub> = 45 pM). Compound <b>26</b> was optimized via the modulation of solubility and metal-binding pocket interactions from a novel naphthyridinone scaffold, which was obtained by hybridizing the scaffold of a pyridazinone compound<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a> and GSK256066. Unfortunately, the low solubility of <b>26</b> could lead to negative in vivo results, and the physicochemical properties of <b>26</b> restricted its potential. For these reasons, the naphthyridinone series was abandoned.<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> This lesson indicates that a low-solubility strategy is not always suitable and that the balance between the in vivo potency and solubility of molecules should be considered.</div><figure id="fig15" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0040.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Overlay of CHF6001 (in magenta) with the crystal structure of the catalytic domain of human PDE4B in complex with roflumilast (in yellow; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig16" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0041.jpeg" id="gr40" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Design of compounds <b>24</b> and <b>25</b>. (B) Design of compound <b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The PDE4 enzyme has been proven to be an effectively druggable target, and numerous studies of low-molecular-weight inhibitors have focused on this target for developing novel broad-spectrum anti-inflammatory agents to treat inflammatory diseases such as COPD. Some more recently reported PDE4 inhibitors are listed in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S9</a>.</div></div><div id="sec3_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> Dual PDE3/4 Inhibitors</h4><div class="NLM_p">PDE3 is abundant in smooth muscle cells, and its inhibition causes airway smooth muscle relaxation and enhances bronchodilation. The combinative inhibition of PDE3 and PDE4 may offer additive anti-inflammatory and bronchodilatory effects, and dual PDE3/4 inhibitors are beneficial to airway inflammatory diseases.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> RPL554 (<a class="ref internalNav" href="#cht20" aria-label="Chart 20">Chart 20</a>) is an inhaled dual PDE3/4 inhibitor with IC<sub>50</sub> values of 0.4 and 1479 nM for PDE3 and PDE4, respectively. RPL554 inhibits LPS-stimulated TNF-α in vitro and increases intracellular cAMP in vivo.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Clinical studies have demonstrated that RPL554 is well tolerated with mild adverse events, produces bronchodilation in COPD patients, and significantly reduces neutrophil counts.<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> RPL554 is in phase II trials to treat patients with moderate to severe COPD (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> identifier: NCT03443414). Although four other dual PDE3/4 inhibitors (zardaverine, benzafentrine, pumafentrine, and tolafentrine, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S10</a>) have been evaluated in clinical trials for asthma or bronchodilation, they have been discontinued for various reasons such as their unclear DOA.<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a></div><figure id="cht20" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Chart 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 20. Chemical Structure of RPL554</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69">3.7.  Others</h3><div id="sec3_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70">3.7.1.  Modulators of Adenosine Receptors</h4><div class="NLM_p">Elevated levels of extracellular adenosine in the bronchoalveolar lavage fluid of patients with asthma and COPD render adenosine signaling an attractive target for these airway inflammatory diseases. Adenosine exerts its functions via engaging cell surface adenosine receptors, which belong to the G-protein-coupled receptor (GPCR) family and include four subtypes, A<sub>1</sub>, A<sub>2A</sub>, A<sub>2B</sub>, and A<sub>3</sub>. These adenosine receptors (ARs) are widely expressed on inflammatory and stromal cells to bind adenosine and are involved in the physiological processes of asthma and COPD (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). A<sub>1</sub>AR and A<sub>3</sub>AR downregulate cAMP via coupling to G<sub>i</sub> proteins and inhibit AC, while A<sub>2A</sub>AR and A<sub>2B</sub>AR activate AC through G<sub>s</sub> proteins, which is followed by increased levels of cAMP.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The action of adenosine on A<sub>1</sub>AR leads to inflammation, mucin secretion, and bronchoconstriction,<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> and the activation of A<sub>2A</sub>AR regulates the activity of neutrophils, macrophages, and T lymphocytes, resulting in anti-inflammatory effects as well as bronchodilation.<a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a> In contrast, A<sub>2B</sub>AR activates proinflammatory cytokines and chemokines in the lung and mediates fibrosis and airway destruction, although it may upregulate cAMP.<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a> Although A<sub>3</sub>AR has been implicated in complex pro- and anti-inflammatory responses, in an environment with elevated adenosine, the inactivation of A<sub>3</sub>AR prevents airway eosinophilia and mucus production.<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> Therefore, A<sub>1</sub>AR, A<sub>2B</sub>AR, and A<sub>3</sub>AR antagonists or A<sub>2A</sub>AR agonists will effectively contribute to the treatment of COPD as well as asthma.</div><figure id="fig17" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0042.jpeg" id="gr41" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Role of adenosine and its modulators in COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">L-97-1 (<a class="ref internalNav" href="#cht21" aria-label="Chart 21">Chart 21</a>) is an A<sub>1</sub>AR antagonist that markedly reduces adenosine-induced hyperresponsiveness and allergic airway responses in a rabbit model of allergic asthma. L-97-1 does not inhibit PDE2–5 isoforms at 100 μM and shows much greater selectivity than theophylline.<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> All these data suggest that L-97-1 may also be beneficial for COPD. UK-432,097 (<a class="ref internalNav" href="#cht21" aria-label="Chart 21">Chart 21</a>) is an A<sub>2A</sub>AR agonist whose safety and efficacy against COPD were evaluated in a phase II clinical trial (NCT00430300), but its development was terminated. Another A<sub>2A</sub>AR agonist, GW-328267X (<a class="ref internalNav" href="#cht21" aria-label="Chart 21">Chart 21</a>), was assessed for safety, tolerability, pharmacokinetics, and pharmacodynamics in a phase I study (NCT01640990). Examples of A<sub>2B</sub>AR and A<sub>3</sub>AR antagonists in COPD treatment are lacking, especially in clinical trials. However, several novel A<sub>2B</sub>AR and A<sub>3</sub>AR antagonists have been published in recent years,<a onclick="showRef(event, 'ref201 ref202'); return false;" href="javascript:void(0);" class="ref ref201 ref202">(201,202)</a> and their application in COPD-related studies is expected.</div><figure id="cht21" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Chart 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 21. Chemical Structures of UK-432,097, L-97-1, and GW-328267X</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72">3.7.2.  Theophylline and Its Derivatives</h4><div id="sec3_7_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> Theophylline</h5><div class="NLM_p">For nearly 100 years, theophylline (<a class="ref internalNav" href="#cht22" aria-label="Chart 22">Chart 22</a>) has been used to treat airway diseases because of its bronchodilatory effects. It has been proven in recent years that theophylline has a multiple mechanism of action in inflammation that attenuates COPD. Theophylline not only antagonizes A<sub>1</sub>AR and A<sub>2</sub>AR but also inhibits PDE isoforms without selectivity, and at high concentrations, PDE inhibition leads to upregulation of IL-10. Moreover, in the alveolar macrophages of patients with COPD, a low dose of theophylline can increase the expression and activity of HDAC2, thus reversing corticosteroid resistance.<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a></div><figure id="cht22" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Chart 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0023.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 22. Chemical Structures of Theophylline and Doxofylline</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> Doxofylline</h5><div class="NLM_p">Doxofylline (<a class="ref internalNav" href="#cht22" aria-label="Chart 22">Chart 22</a>), also known as doxophylline, is a theophylline analogue derived from the addition of a dioxolane group at the 7-position of theophylline. The anti-inflammatory and bronchodilation efficacy of doxofylline is comparable to that of theophylline. Doxofylline was more effective in improving pulmonary function in COPD treatment than theophylline, with a reduced incidence of adverse effects.<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> More importantly, the mechanism of action of doxofylline differs from that of other xanthines, which leads to a distinct pharmacological profile for doxofylline, including no significant drug–drug interactions, fewer effects on known PDE isoforms, no significant interactions with β<sub>2</sub>-adrenoceptors, a lack of adenosine receptor antagonism, and no activity toward HDAC2. Therefore, it may exhibit a better safety profile and therapeutic window, because, for instance, doxofylline treatment did not result in an increase in myocardial oxygen demand, which is beneficial for the treatment of COPD patients who may suffer from cardiovascular comorbidities.<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> Doxofylline is thus a special xanthine for the treatment of respiratory inflammation diseases such as COPD.</div><div class="NLM_p last">In addition to theophylline and doxofylline, there are more than 300 kinds of theophylline combinations or derivatives, such as aminophylline and dyphylline (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S11</a>). Many of them target ARs and PDEs without selectivity, and PDE inhibition may cause the side effects of these types of compounds. In the future, the design and synthesis of novel theophylline derivatives to avoid PDE inhibition may supply new opportunities for COPD pharmaceutical therapies.</div></div></div><div id="sec3_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76">3.7.3.  Chemoattractant Receptor-Homologous Molecule Expressed on T<sub>H</sub>2 Cell (CRTH2) Antagonist</h4><div class="NLM_p">Prostaglandin D2 (PGD<sub>2</sub>) is a major prostanoid implicated in responses to allergens. It is released by stimulated mast cells and plays a crucial role in the pathogenesis of allergic inflammatory processes. CRTH2, also known as DP2, is one of the receptors to which PDG<sub>2</sub> binds. CRTH2 is expressed by cells involved in allergic diseases, including eosinophils, basophils, T<sub>H</sub>2 cells, and innate lymphoid cells.<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> Signaling through CRTH2 attenuates AC, thereby decreasing the intracellular levels of cAMP, which causes chemotaxis of T cells, eosinophils, basophils, and monocytes and stimulates T<sub>H</sub>2 cell cytokine production. This relationship suggests that in allergic diseases, the recruitment of these inflammatory cells is mediated by the CRTH2 receptor, and the activation of CRTH2 also leads to enhanced eosinophilia, tissue remodeling, and airway hypersensitivity.<a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a></div><div class="NLM_p">Arachidonic acid metabolism goes through two independent pathways: the 5-LO-mediated leukotriene pathway (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Figure S4</a>) and the cyclooxygenase (COX)-mediated prostaglandin pathway. In the latter, PGD<sub>2</sub> is generated from arachidonic acid via the catalysis of COX in lung mast cells. COX inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) block the synthesis of PGD<sub>2</sub>, but excessive inhibition of COX may lead to overproduction of 5-LO and activation of the leukotriene pathway, which results in diseases such as aspirin-exacerbated respiratory disease, bronchoconstriction, mucus secretion, and severe asthma.<a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a> Thus, targeting CRTH2 is an alternative way to block the prostaglandin pathway. CRTH2 receptor antagonists can be used to inhibit the PGD<sub>2</sub>/CRTH2 signaling pathway to intervene in allergic inflammation. Allergic inflammatory diseases such as asthma involve high CRTH2 expression levels in mast cells, T<sub>H</sub>2 cells, and eosinophils. These diseases thus might be treatable with CRTH2 receptor antagonists. Although COPD is associated with macrophages and neutrophils, increased levels of PGD<sub>2</sub> were observed in a smoke-induced mouse model of COPD, demonstrating that CRTH2 receptor antagonism may be beneficial in COPD treatment.<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> Some known LMWDs targeting the CRTH2 receptor are suitable to treat asthma, and many of them have been used as a therapeutic approach for COPD. Ramatroban (<a class="ref internalNav" href="#cht23" aria-label="Chart 23">Chart 23</a>) was the first LMWD to exhibit CRTH2 antagonism. Optimization from ramatroban led to the discovery of AZD-1981 (<a class="ref internalNav" href="#cht23" aria-label="Chart 23">Chart 23</a>). In a completed phase II study (NCT00690482), the efficacy and safety of AZD01981 was assessed in patients with moderate to severe COPD. AZD-1981 was dosed at 1000 mg twice daily for one month, and the results showed no safety concerns but no beneficial clinical effect;<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> however, it gave a good indication for long-term studies in further research. AM-211 (<a class="ref internalNav" href="#cht23" aria-label="Chart 23">Chart 23</a>) is a novel nonindole-scaffold CRTH2 receptor antagonist with high potency against the CRTH2 receptors of humans (4.9 nM), mice (7.8 nM), and guinea pigs (4.9 nM) in vitro as well as in allergic inflammatory animal models.<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> In addition, AM-211 has good PK/PD properties and tolerance.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> AM-211 and its analogue, AM-461 (<a class="ref internalNav" href="#cht23" aria-label="Chart 23">Chart 23</a>), have completed phase I trials for COPD treatment, but no follow-up studies have been published.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> Another two CRTH2 receptor antagonists, AZD5985 and AZD8075 (structures not disclosed), entered into phase I clinical studies, but unfortunately, both were discontinued (because of safety issues for AZD5985 and adverse events of urine turbidity for AZD8075).<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a></div><figure id="cht23" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Chart 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0024.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 23. Chemical Structures of Ramatroban, AZD-1981, AM-211, and AM-461</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht23"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78">3.7.4.  Adhesion Molecule Inhibitors</h4><div class="NLM_p last">An adhesion molecule is a kind of protein that is located on the cell surface. The recruitment and activation of inflammatory cells, including neutrophils, monocytes, and T cells, in the lung depends on the adhesion molecules present. The accumulation of these inflammatory cells is attributed to chronic inflammatory diseases such as COPD. The adhesion molecules that are expressed on activated endothelial cells, including P-selectin, E-selectin, and ICAM1, can interact with sialyl Lewis<sup>x</sup> (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S12</a>) on leukocytes or neutrophils, thereby enhancing their adherence.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Targeting the interaction between selectins and sialyl Lewis<sup>x</sup> with low-molecular-weight inhibitors may be beneficial for COPD treatment. Oligosaccharides and glycosylated peptides have been reported to inhibit granulocyte adhesion. However, these compounds have some drawbacks as pharmaceutical agents due to their high cost and poor pharmacokinetic properties.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> TBC1269 (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Chart S12</a>) is a low-molecular-weight mimic of sialyl Lewis<sup>x</sup> without the oligosaccharide group and has been proven to be effective in asthma.<a onclick="showRef(event, 'ref215'); return false;" href="javascript:void(0);" class="ref ref215">(215)</a> However, the reports of adhesion molecule inhibitors in the treatment of COPD are limited.</div></div><div id="sec3_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79">3.7.5.  Combination Therapy and Multitarget Agents</h4><div class="NLM_p">Bronchodilators are still the first-line therapies for COPD, and LAMA/LABA combination therapy has been discussed in a previous section of this review. The combination of bronchodilation and anti-inflammation therapy may be a more effective approach than combination therapy with multiple bronchodilators. COPD monotherapy with an ICS can improve lung function and reduce the risk of exacerbations. However, ICSs have been linked to an increased risk of pneumonia in COPD patients. This risk may come from alteration of the pulmonary microbiome and impaired macrophage function, which is controlled by ICS use.<a onclick="showRef(event, 'ref216'); return false;" href="javascript:void(0);" class="ref ref216">(216)</a> Using a combination of a LABA and an ICS may give the dual effects of bronchodilation and anti-inflammation and reduce the risk of pneumonia. However, in a phase III study, LABA/ICS FDCs (salmeterol/fluticasone) showed lower levels of FEV<sub>1</sub> improvement in patients with COPD than did QVA149 (indacaterol/glycopyrronium, LABA/LAMA FDCs) when compared to the control groups.<a onclick="showRef(event, 'ref217'); return false;" href="javascript:void(0);" class="ref ref217">(217)</a> Therefore, a triple inhaled therapy of LABA plus LAMA plus ICS may be beneficial for improving lung function and preventing exacerbations.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> An anti-inflammation study of combinations of roflumilast and a LABA (salmeterol or formoterol) or a glucocorticosteroid (dexamethasone) reported increased inhibition of LPS-induced inflammatory cytokine production in PBMCs, therefore indicating additive anti-inflammatory effects for PDE4Is/LABA or PDE4Is/glucocorticosteroid combinations.<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a></div><div class="NLM_p">The development of single LMWDs with dual modes of action is a new strategy for combination therapy. The above-mentioned MABA is representative of a kind of bifunctional molecule that acts on several different targets and may have additive effects. PDE7 is similar to PDE4 in terms of its enzymatic profile, and the inhibition of PDE7 also reduces inflammatory responses. A dual PDE4/PDE7 antisense oligonucleotide, TPI 1100, showed anti-inflammatory effects against smoke-induced lung inflammation that were more potent and broader than those of roflumilast in mice, but its clinical study was terminated in phase I (the reason was not disclosed).<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> GS-5759 (<a class="ref internalNav" href="#cht24" aria-label="Chart 24">Chart 24</a>) is a novel bifunctional compound that contains a LABA pharmacophore linked to a PDE4 inhibitor pharmacophore, with an IC<sub>50</sub> of 5 nM against the enzyme PDE4B2 and an IC<sub>50</sub> of 11 nM for binding the β<sub>2</sub>-adrenoceptor. GS-5759 exhibits bronchiectatic and anti-inflammatory activities and inhibits profibrotic and proinflammatory mediators released from human lung fibroblasts. This finding indicates the potential of GS-5759 as a therapeutant for COPD.<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> Several other bifunctional agents designed by the hybridization of pharmacophores from bronchodilators and PDE4 inhibitors have been reported (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">Supporting Information, Chart S13</a>). A dual p38α MAPK/PDE4 inhibitor, CBS-3595 (<a class="ref internalNav" href="#cht24" aria-label="Chart 24">Chart 24</a>), inhibits p38α MAPK and PDE4 with IC<sub>50</sub> values of 0.5 and 0.2 μM, respectively, and suppresses TNF-α release in LPS-stimulated human whole blood and in vivo. Moreover, CBS-3595 has excellent kinetic properties and low plasma protein binding, which support it as a candidate drug for the treatment of TNF-α-related inflammatory diseases such as COPD.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a></div><figure id="cht24" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Chart 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0025.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 24. Chemical Structures of GS-5759 and CBS-3595</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i81">4.  Conclusions and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13400" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13400" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">COPD is a constant, severe threat to human health and a prevalent global issue due to its complicated disease progression, clinical features, mechanism, pathogenesis, early diagnosis, and management. All of these factors are not fully understood. Currently, pharmacological treatment is the major means for the management of COPD, and as in other diseases, the use of LMWDs is a common therapeutic strategy. Generally, diverse LMWDs can cover a larger chemical space, which makes them easily recognized by various molecular targets. The chemical properties of LMWDs determine their pharmacokinetic properties and druggability; therefore, it is more convenient to optimize chemical structures than to optimize biomacromolecules. In addition, LMWDs can be obtained by efficient synthetic methods, which lowers the cost of drug discovery. All of these characteristics and advantages of LMWDs have caused their development to become a major field of drug discovery. Studies focused on LMWDs are always popular aspects of targeted therapies for human diseases. In the clinal treatment of patients with stable COPD, the mainstay drugs are long-acting bronchodilators. LABAs or LAMAs can decrease breathlessness and improve lung function, thereby relieving symptoms and reducing the risk of exacerbations. In the event of exacerbation, oral antibiotics are used to decrease sputum purulence or volume, and oral corticosteroids may reduce the blood eosinophils of patients. LAMAs can reduce exacerbation frequency, and LABA-ICS combinations have similar effects.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Although other types of drugs, including macrolide antibiotics<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> and mucolytic drugs, also lower exacerbation frequency and slow the exacerbation process, long-term treatment with ICS and antibiotics may lead to drug resistance. Moreover, the use of ICS may increase the risk of pneumonia and osteoporosis, and the adverse cardiovascular events caused by macrolides also need to be addressed.<a onclick="showRef(event, 'ref1 ref216'); return false;" href="javascript:void(0);" class="ref ref1 ref216">(1,216)</a> The PDE4 inhibitor roflumilast is the only drug for suppressing inflammation in the small airways; however, this drug is not sufficient to substantially alter the course of COPD. Additionally, side effects such as emesis are prevalent in treated patients. Small airway fibrosis is accompanied by chronic inflammation, and the prevention of pulmonary fibrosis by blocking the activation of fibroblasts may mitigate COPD, but there are no efficient antifibrotic LMWDs available for application in COPD therapy.</div><div class="NLM_p">In fact, current therapeutics using LMWDs relieve only the symptoms and do not control the progression of this disease, and drug resistance and side effects are disadvantages of long-term treatment. Therefore, there is still a large unmet pharmaceutical requirement, especially for LMWDs, for targeted intervention in the cause of chronic airway inflammatory in COPD, and therapies aimed at the pathogenesis of COPD as well as the radical abolishment of COPD and its comorbidities are urgently needed.</div><div class="NLM_p">COPD and asthma are both characterized by chronic inflammation of the respiratory tract and progressive destruction of the lung parenchyma. Asthma and COPD feature different types of inflammation: asthma features type 2 immunity, which involves the activation of mast cells, eosinophils, and T<sub>H</sub>2 cells, while the inflammatory pattern of COPD predominantly indicates type 1 and 3 immunities, which relate to macrophages, neutrophils, and T<sub>H</sub>1 cells. Although COPD differs from asthma in its causal mechanisms, in some cases, manifestations usually found in asthma patients, including pulmonary infiltration of eosinophils, reversible airway obstruction, airway hyperresponsiveness, and a good response to corticosteroids, are emerging in patients with COPD. This behavior indicates that some therapies for asthma can be used to treat eosinophilic inflammation-associated COPD. Many FLAP inhibitors, A<sub>1</sub>AR antagonists, A<sub>2A</sub>AR agonists, A<sub>2B</sub>AR and A<sub>3</sub>AR antagonists, and their analogues have been reported to be effective in COPD despite a preference for asthma in their clinical studies. The activation of CRTH2, which accompanies eosinophilia and airway hyperresponsiveness, is an obvious characteristic of allergic diseases. CRTH2 receptor antagonism is also appropriate for treating some cases of COPD. Therefore, in addition to asthma therapies, therapeutic approaches based on these targets can also be selected for the treatment of some specific cases of COPD.</div><div class="NLM_p">Cytokine inhibition is a potential strategy for treating COPD, but only antibodies are exhibiting progress in the pipelines of cytokine inhibitor discovery. Unfortunately, antibody therapies have not been successful in COPD patients. Furthermore, antibody therapies have certain drawbacks; for instance, antibodies must be administered via injection, which is not convenient, and antibody therapies are costly. The targeting of chemokines may be more beneficial than cytokine inhibition. First, because chemokines are involved in the recruitment of inflammatory cells in the lungs through binding to their receptors, it is feasible for LMWDs designed for these targets to block the chemokine receptors. Second, different chemokines can bind to the same receptors, and antagonists of each receptor may inhibit multiple inflammatory pathways. Thus, chemokine receptors are promising targets for LMWD intervention in COPD.</div><div class="NLM_p">The NLRP3 inflammasome is also of great importance in the progression of inflammation and is associated with many diseases, including gout, diabetes, and Alzheimer’s diseases. The modulation of its activation by LMWDs makes the NLRP3 inflammasome a high-profile pharmaceutical target and provides new hope for novel anti-inflammatory drug discovery. There are currently few inflammasome inhibitors for use against COPD, but considering the broad role of inflammasome antagonism in the intervention of inflammatory pathologies, further cutting-edge research targeting the NLRP3 inflammasome will be inspired for the treatment of COPD.</div><div class="NLM_p">Oxidative stress is a major driving force of COPD because it is not only the causal factor of inflammation but also involved in several pathological pathways of COPD through a range of mechanisms, including increasing protease levels, activating TGFβ, and reducing HDAC2 expression. Pathogenic ROS are mainly endogenous, and low-molecular-weight antioxidants with superior ADME/T properties and cell permeability are particularly preferred in the antioxidant therapy of COPD, which may be an area of focus for future research.</div><div class="NLM_p">The common issues associated with elastase inhibitors and kinase inhibitors are selectivity and drug resistance. For elastase inhibitors, an optimized approach is the design of small molecules based on increasing the specificity of binding to targets, such as designing nonpeptidic-scaffold MMP-12 inhibitors to improve their selectivity and safety. Kinase inhibitors are widely used in cancer therapy, but no kinase inhibitors have been approved for treating COPD. The lessons from cancer therapy indicate that a specific and highly conserved site on kinase may be suitable for structure-based drug design.</div><div class="NLM_p">Another potential target is epigenetic modulation. Epigenetic modifications, such as histone acetylation and methylation, can modulate the transcription of inflammatory genes.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Several epigenetic modulators have relevant anti-inflammatory activities,<a onclick="showRef(event, 'ref224 ref225'); return false;" href="javascript:void(0);" class="ref ref224 ref225">(224,225)</a> and their future application in COPD treatment is anticipated. For the cases of COPD that showed a good response to corticosteroids, epigenetic modulators as well as antioxidants, macrolides, and PI3Kδ inhibitors can contribute to increased HDAC2 expression, and corticosteroid resistance can be reversed; thus, this reversal of corticosteroid resistance can serve as a therapeutic target for COPD.</div><div class="NLM_p">In addition to targeting a single mechanism with LMWDs, known LABA/LAMA FDCs, LABA/ICS FDCs, or bronchodilator/PDE4 inhibitor combinations, combination therapy affecting multiple pathogenic pathways of COPD using diverse compounds based on different targets is another promising strategy. For instance, the side effects of oral PDE4 inhibitors, such as nausea and emesis, may be mitigated by coadministering 5-HT<sub>3</sub> receptor antagonists. In addition, we anticipate anti-inflammatory “cocktail therapy” combining two or more anti-inflammatory agents with different mechanisms will be applied to COPD. In recent years, an increasing number of drug combinations have been approved, and this mode of therapy has become more widespread because of the support of evidence-based medicine and the acceptable clinical effects of combination therapy; therefore, this strategy may also provide valuable therapeutic approaches for treating COPD. However, it should be noted that adverse events resulting from combination therapy due to the incompatible pharmacokinetic properties of different chemical entities need to be considered.</div><div class="NLM_p last">Overall, the targeted treatment of COPD using LMWDs is a challenging but attractive research area, and the discovery of novel LMWDs may face many barriers. Because the inflammatory response is involved in several diseases, the phenotypes of COPD are difficult to define, and this difficulty results in dubious in vitro screening models. Moreover, the development of animal models for COPD depends on exposing animals to cigarette smoke for a long period of time, and the animal models that have been developed cannot completely simulate the persistence of disease progression in COPD patients when cigarette smoke exposure is halted. These problems of in vivo and in vitro models are major barriers to the identification of novel LMWDs for use against COPD. On the other hand, the lack of biomarkers makes COPD difficult to diagnose and makes the efficacy of drugs difficult to evaluate in clinical therapy. The clinical value of blood and sputum biomarkers, such as pulmonary surfactant-associated protein D, fibrinogen, club cell 16 protein, and CCL-18, may predict the features of COPD, but the therapy response is not yet clear.<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> Although blood eosinophil levels and FeNO are suitable biomarkers for therapeutic responses of patients with type 2 immunity-associated airway diseases, biomarkers for nontype 2 immunity diseases such as COPD are less useful due to the poor response of blood neutrophils in neutrophilic lung disease,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> and thus, the development of new biomarker patterns for detecting COPD therapeutic responses is urgently needed. Another aspect that should not be neglected is the drug delivery route: the focal zone of COPD is the lung and airway, and the direct delivery of drugs to the lungs by inhalation may avoid the systemic side effects caused by the oral route. At present, research on COPD drugs focuses more on developing novel inhaled PDE4 inhibitors and kinase inhibitors than on orally delivered drugs. LMWDs with suitable physicochemical properties for delivery by inhalation can be rationally designed, and the soft drug strategy can be used to decrease the side effects in long-term treatment. The inhalation by design approach can also be applied to the design of bronchodilators, PDE4 inhibitors, and kinase inhibitors. In addition to molecular structure, delivery by inhalation depends on specific devices and appropriate drug formulations, which are less convenient than the oral route; therefore, oral drugs are always preferred by patients and doctors in the clinic. However, to date, the most effective drugs for COPD have been inhaled, and the discovery of excellent oral drugs for COPD remains a challenge.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01520" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01520" class="ext-link">10.1021/acs.jmedchem.8b01520</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Supplementary figures, charts and references (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf">jm8b01520_si_001.pdf (1.12 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01520" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46067" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46067" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ke Ding</span> - <span class="hlFld-Affiliation affiliation">International
Cooperative Laboratory of Traditional Chinese Medicine Modernization
and Innovative Drug Development of Chinese Ministry of Education (MOE),
Guangzhou City Key Laboratory of Precision Chemical Drug Development,
School of Pharmacy, Jinan University, Guangzhou 510632, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Disease, National Clinical Research
Center for Respiratory Disease, Guangzhou Institute of Respiratory
Health, The First Affiliated Hospital, Guangzhou
Medical University, Guangzhou 510120, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9016-812X" title="Orcid link">http://orcid.org/0000-0001-9016-812X</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#99fdf0f7fef2fcd9f3f7ecb7fcfdecb7faf7"><span class="__cf_email__" data-cfemail="8befe2e5ece0eecbe1e5fea5eeeffea5e8e5">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Zhao</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Molecular Target & Clinical Pharmacology, State
Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences
& The Fifth Affiliated Hospital, Guangzhou
Medical University, Guangzhou 511436, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Life Sciences, The Chinese University
of Hong Kong, Shatin, N.T., Hong Kong SAR 999077, P. R. China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6659-3748" title="Orcid link">http://orcid.org/0000-0002-6659-3748</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#19637178766170772b29282e597f766174787075377a7674"><span class="__cf_email__" data-cfemail="443e2c252b3c2d2a7674757304222b3c29252d286a272b29">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huihui Ti</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Molecular Target & Clinical Pharmacology, State
Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences
& The Fifth Affiliated Hospital, Guangzhou
Medical University, Guangzhou 511436, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Zhou</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Molecular Target & Clinical Pharmacology, State
Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences
& The Fifth Affiliated Hospital, Guangzhou
Medical University, Guangzhou 511436, P. R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Division
of Theoretical Chemistry and Biology, School of Biotechnology, Royal Institute of Technology (KTH), AlbaNova University Center, Stockholm SE-100 44, Sweden</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xue Liang</span> - <span class="hlFld-Affiliation affiliation">Key
Laboratory of Molecular Target & Clinical Pharmacology, State
Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences
& The Fifth Affiliated Hospital, Guangzhou
Medical University, Guangzhou 511436, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Runfeng Li</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Respiratory Disease, National Clinical Research
Center for Respiratory Disease, Guangzhou Institute of Respiratory
Health, The First Affiliated Hospital, Guangzhou
Medical University, Guangzhou 510120, P. R. China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>H.T. and Y.Z. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83638" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83638" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="42" class="article__inlineFigure"><h2 class="fig-label">Huihui Ti</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=BIO-d7e3223-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Huihui Ti</b> is currently an Associate Professor in the School of Pharmaceutical Sciences at Guangzhou Medical University. She received her Ph.D. degree at the South China Botanical Garden, Chinese Academy of Sciences, in 2012 and served as a postdoctoral researcher at HKU-Pasteur Research Pole, The University of Hong Kong, in 2016. Her research focused on pharmacochemical biology based on natural products and anti-inflammatory drugs.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="43" class="article__inlineFigure"><h2 class="fig-label">Yang Zhou</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=BIO-d7e3228-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yang Zhou</b> received his Master’s degree from Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, and is currently a Ph.D. student in the Department of Theoretical Chemistry and Biology, KTH Royal Institute of Technology. His research is focused on developing computational methods for complex molecular systems and understanding the properties and mechanisms of protein–ligand binding/unbinding.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="44" class="article__inlineFigure"><h2 class="fig-label">Xue Liang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=BIO-d7e3233-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xue Liang</b> received her Ph.D. in Medicine from Guangzhou Medicinal University in 2016 and then become a research assistant at the Fifth Affiliated Hospital of Guangzhou Medicinal University. She is mainly engaged in exploiting natural drug resources, evaluating the pharmacodynamics of natural products in inflammation and innate immunity, exploring the pathogenesis of COPD, and screening potential drugs for its treatment.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="45" class="article__inlineFigure"><h2 class="fig-label">Runfeng Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=BIO-d7e3238-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Runfeng Li</b> received his Master’s degree at South China Agricultural University in 2011, and he worked as a research assistant in the State Key Laboratory of Respiratory Disease with research interests in small-molecule compounds that target different proteins of influenza virus and in establishing a tree shrew model of influenza virus infection and a mouse model of COPD.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="46" class="article__inlineFigure"><h2 class="fig-label">Ke Ding</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=BIO-d7e3243-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Ke Ding</b> received a Ph.D. degree from Fudan University in 2001. After postdoctoral training in the University of Michigan, he was appointed as a research investigator in 2005. Dr. Ding was appointed as a research Professor and the Director of the Chemical Biology Institute in the Guangzhou Institutes of Biomedicine and Health in 2008, and he moved to Jinan University in June, 2016, to serve as the Dean of School of Pharmacy. His research focuses on the design and synthesis of bioactive lead compounds for novel drug discovery. Dr. Ding has published approximately 150 peer-reviewed papers and coinvented over 60 international patents, and he is currently serving as an Associate Editor of the <i>Journal of Medicinal Chemistry</i> and an Advisory Editorial Board Member for <i>ACS Medicinal Chemistry Letters</i>.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="47" class="article__inlineFigure"><h2 class="fig-label">Xin Zhao</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=BIO-d7e3254-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xin Zhao</b> received his Ph.D. in Medicinal Chemistry from the Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences, in 2012, subsequently becoming a research assistant at the GIBH. In 2016, he was invited to work on the development of new antivirals at the University of Arizona, USA, as a visiting scholar supported by the State Scholarship Fund of China Scholarship Council, and he was subsequently a visiting scientist at The Chinese University of Hong Kong in 2017. Dr. Zhao is currently an Associate Professor in the School of Pharmaceutical Sciences at Guangzhou Medical University and started his independent research in 2018. His research interests are focused on small-molecule targeted interventions for respiratory diseases, including respiratory virus infection, COPD, and lung cancer.</p></figure></div><div class="ack" id="ACK-d7e3259-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74675" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74675" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful for the support of this work by National Natural Science Foundation of China (grant 81873071 to H.T., grant 81872765 to R.L., grant 81803817 to X.L.), the Pearl River S&T Nova Program of Guangzhou (grant 201806010115 to X.Z.), State Scholarship Fund of China Scholarship Council (grant 201600160013 to Y.Z.), National Key R&D Program of China (2017YFC1309300), and start-up grant from the Guangzhou Medical University (to H.T.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">COPD</td><td class="NLM_def"><p class="first last">chronic obstructive pulmonary disease</p></td></tr><tr><td class="NLM_term">LMWDs</td><td class="NLM_def"><p class="first last">low-molecular-weight drugs</p></td></tr><tr><td class="NLM_term">AL</td><td class="NLM_def"><p class="first last">airflow limitation</p></td></tr><tr><td class="NLM_term">FEV</td><td class="NLM_def"><p class="first last">forced expiratory volume</p></td></tr><tr><td class="NLM_term">FEV<sub>1</sub></td><td class="NLM_def"><p class="first last">forced expiratory volume in 1 s</p></td></tr><tr><td class="NLM_term">FVC</td><td class="NLM_def"><p class="first last">forced vital capacity</p></td></tr><tr><td class="NLM_term">GOLD</td><td class="NLM_def"><p class="first last">Global Initiative for Chronic Obstructive Lung Disease</p></td></tr><tr><td class="NLM_term">mAChRs</td><td class="NLM_def"><p class="first last">muscarinic acethylcholine receptors</p></td></tr><tr><td class="NLM_term">NE</td><td class="NLM_def"><p class="first last">neutrophil elastase</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinases</p></td></tr><tr><td class="NLM_term">PDE</td><td class="NLM_def"><p class="first last">phosphodiesterase</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">TGFβ</td><td class="NLM_def"><p class="first last">transforming growth factor-β</p></td></tr><tr><td class="NLM_term">PPARγ</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptor-γ</p></td></tr><tr><td class="NLM_term">ACh</td><td class="NLM_def"><p class="first last">acetylcholine</p></td></tr><tr><td class="NLM_term">SAMA</td><td class="NLM_def"><p class="first last">short-acting muscarinic antagonists</p></td></tr><tr><td class="NLM_term">LAMA</td><td class="NLM_def"><p class="first last">long-acting muscarinic antagonists</p></td></tr><tr><td class="NLM_term">SABA</td><td class="NLM_def"><p class="first last">short-acting β<sub>2</sub>-adrenoreceptor agonists</p></td></tr><tr><td class="NLM_term">LABA</td><td class="NLM_def"><p class="first last">long-acting β<sub>2</sub>-adrenoreceptor agonists</p></td></tr><tr><td class="NLM_term">MABA</td><td class="NLM_def"><p class="first last">muscarinic antagonist-β<sub>2</sub>-agonist</p></td></tr><tr><td class="NLM_term">FDCs</td><td class="NLM_def"><p class="first last">fixed dose combinations</p></td></tr><tr><td class="NLM_term">BCQB</td><td class="NLM_def"><p class="first last">bencycloquidium bromide</p></td></tr><tr><td class="NLM_term">DOA</td><td class="NLM_def"><p class="first last">duration of action</p></td></tr><tr><td class="NLM_term">OHP</td><td class="NLM_def"><p class="first last"><i>ortho</i>-hydroxymethyl phenol</p></td></tr><tr><td class="NLM_term">COMT</td><td class="NLM_def"><p class="first last">catechol-<i>O</i>-methyltransferase</p></td></tr><tr><td class="NLM_term">ICS</td><td class="NLM_def"><p class="first last">inhaled corticosteroid</p></td></tr><tr><td class="NLM_term">LTB<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene B<sub>4</sub></p></td></tr><tr><td class="NLM_term">5-LO</td><td class="NLM_def"><p class="first last">5-lipoxygenase</p></td></tr><tr><td class="NLM_term">LTA<sub>4</sub></td><td class="NLM_def"><p class="first last">leukotriene A<sub>4</sub></p></td></tr><tr><td class="NLM_term">15-LO</td><td class="NLM_def"><p class="first last">15-lipoxygenase</p></td></tr><tr><td class="NLM_term">FLAP</td><td class="NLM_def"><p class="first last">5-lipoxygenase activating protein</p></td></tr><tr><td class="NLM_term">5-HPETE</td><td class="NLM_def"><p class="first last">hydroperoxyeicosatetraenoic acid</p></td></tr><tr><td class="NLM_term">15(S)-HETE</td><td class="NLM_def"><p class="first last">15(<i>S</i>)-hydroxyeicosatetraenoic acid</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-à-go-go-related gene</p></td></tr><tr><td class="NLM_term">IL</td><td class="NLM_def"><p class="first last">interleukin</p></td></tr><tr><td class="NLM_term">T<sub>H</sub>1</td><td class="NLM_def"><p class="first last">T helper 1 cells</p></td></tr><tr><td class="NLM_term">T<sub>C</sub>1</td><td class="NLM_def"><p class="first last">cytotoxic T cells</p></td></tr><tr><td class="NLM_term">ILC 1s</td><td class="NLM_def"><p class="first last">group 1 innate lymphoid cells</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">natural killer</p></td></tr><tr><td class="NLM_term">DCs</td><td class="NLM_def"><p class="first last">dendritic cells</p></td></tr><tr><td class="NLM_term">CCL</td><td class="NLM_def"><p class="first last">CC-chemokine ligand</p></td></tr><tr><td class="NLM_term">CCR</td><td class="NLM_def"><p class="first last">CC-chemokine receptor</p></td></tr><tr><td class="NLM_term">CXCL</td><td class="NLM_def"><p class="first last">CXC-chemokine ligand</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">CXCR</td><td class="NLM_def"><p class="first last">CXC-chemokine receptor</p></td></tr><tr><td class="NLM_term">NLRP3</td><td class="NLM_def"><p class="first last">NOD-, LRR-,, and pyrin domain-containing 3</p></td></tr><tr><td class="NLM_term">PRR</td><td class="NLM_def"><p class="first last">pattern recognition receptor</p></td></tr><tr><td class="NLM_term">ASC</td><td class="NLM_def"><p class="first last">apoptosis-associated speck-like protein containing a caspase recruitment domain</p></td></tr><tr><td class="NLM_term">PAMP</td><td class="NLM_def"><p class="first last">pathogen associated molecular patterns</p></td></tr><tr><td class="NLM_term">TLR</td><td class="NLM_def"><p class="first last">Toll-like receptor</p></td></tr><tr><td class="NLM_term">NF-κB</td><td class="NLM_def"><p class="first last">nuclear factor-κB</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">BMDMs</td><td class="NLM_def"><p class="first last">bone marrow-derived macrophages</p></td></tr><tr><td class="NLM_term">HMDMs</td><td class="NLM_def"><p class="first last">human monocyte-derived macrophages</p></td></tr><tr><td class="NLM_term">PBMCs</td><td class="NLM_def"><p class="first last">human peripheral blood mononuclear cells</p></td></tr><tr><td class="NLM_term">IKKβ</td><td class="NLM_def"><p class="first last">inhibitor of NF-kappa B kinase β</p></td></tr><tr><td class="NLM_term">DSS</td><td class="NLM_def"><p class="first last">dextran sulfate sodium</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SLPI</td><td class="NLM_def"><p class="first last">secretory leukoprotease inhibitor</p></td></tr><tr><td class="NLM_term">TIMP</td><td class="NLM_def"><p class="first last">tissue inhibitors of MMP</p></td></tr><tr><td class="NLM_term">HNE</td><td class="NLM_def"><p class="first last">human neutrophil elastase</p></td></tr><tr><td class="NLM_term">MMPs</td><td class="NLM_def"><p class="first last">matrix metalloproteinases</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc binding group</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron-emission tomography</p></td></tr><tr><td class="NLM_term">PR3</td><td class="NLM_def"><p class="first last">proteinase 3</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">HDAC2</td><td class="NLM_def"><p class="first last">histone deacetylase 2</p></td></tr><tr><td class="NLM_term">NAC</td><td class="NLM_def"><p class="first last"><i>N</i>-acetylcysteine</p></td></tr><tr><td class="NLM_term">Nrf2</td><td class="NLM_def"><p class="first last">nuclear factor erythroid 2-derived factor 2</p></td></tr><tr><td class="NLM_term">Keap-1</td><td class="NLM_def"><p class="first last">Kelch-like ECH-associated protein 1</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">protein–protein interaction</p></td></tr><tr><td class="NLM_term">NOX</td><td class="NLM_def"><p class="first last">NADPH oxidases</p></td></tr><tr><td class="NLM_term">MPO</td><td class="NLM_def"><p class="first last">myeloperoxidase</p></td></tr><tr><td class="NLM_term">SOD</td><td class="NLM_def"><p class="first last">superoxide dismutase</p></td></tr><tr><td class="NLM_term">iNOS</td><td class="NLM_def"><p class="first last">inducible nitric oxide synthase</p></td></tr><tr><td class="NLM_term">NO</td><td class="NLM_def"><p class="first last">nitric oxide</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide-3-kinase</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducers and activator of transcription</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic 3′,5′-adenosine monophosphate</p></td></tr><tr><td class="NLM_term">AC</td><td class="NLM_def"><p class="first last">adenylate cyclase</p></td></tr><tr><td class="NLM_term">UCR</td><td class="NLM_def"><p class="first last">upstream conserved regions</p></td></tr><tr><td class="NLM_term">LR</td><td class="NLM_def"><p class="first last">linker region</p></td></tr><tr><td class="NLM_term">HARBS</td><td class="NLM_def"><p class="first last">high-affinity rolipram binding site</p></td></tr><tr><td class="NLM_term">LARBS</td><td class="NLM_def"><p class="first last">low-affinity rolipram binding site</p></td></tr><tr><td class="NLM_term">GPCRs</td><td class="NLM_def"><p class="first last">G-protein-coupled receptors</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">adenosine receptor</p></td></tr><tr><td class="NLM_term">CRTH2</td><td class="NLM_def"><p class="first last">chemoattractant receptor-homologous molecule expressed on T<sub>H</sub>2 cells</p></td></tr><tr><td class="NLM_term">PDG<sub>2</sub></td><td class="NLM_def"><p class="first last">prostaglandin D2</p></td></tr><tr><td class="NLM_term">COX</td><td class="NLM_def"><p class="first last">cyclooxygenase</p></td></tr><tr><td class="NLM_term">NSAIDs</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drugs</p></td></tr><tr><td class="NLM_term">PDE4Is</td><td class="NLM_def"><p class="first last">PDE4 inhibitors.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54488" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54488" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 226 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burney, P. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celli, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedzicha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, E. F. M.</span></span> <span> </span><span class="NLM_article-title">Chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Primers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15076</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2015.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrdp.2015.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=27189863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1eisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15076&author=P.+J.+Barnesauthor=P.+G.+J.+Burneyauthor=E.+K.+Silvermanauthor=B.+R.+Celliauthor=J.+Vestboauthor=J.+A.+Wedzichaauthor=E.+F.+M.+Wouters&title=Chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnrdp.2015.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes Peter J; Wedzicha Jadwiga A; Burney Peter G J; Silverman Edwin K; Celli Bartolome R; Vestbo Jorgen; Wouters Emiel F M</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15076</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a common disease with high global morbidity and mortality.  COPD is characterized by poorly reversible airway obstruction, which is confirmed by spirometry, and includes obstruction of the small airways (chronic obstructive bronchiolitis) and emphysema, which lead to air trapping and shortness of breath in response to physical exertion.  The most common risk factor for the development of COPD is cigarette smoking, but other environmental factors, such as exposure to indoor air pollutants - especially in developing countries - might influence COPD risk.  Not all smokers develop COPD and the reasons for disease susceptibility in these individuals have not been fully elucidated.  Although the mechanisms underlying COPD remain poorly understood, the disease is associated with chronic inflammation that is usually corticosteroid resistant.  In addition, COPD involves accelerated ageing of the lungs and an abnormal repair mechanism that might be driven by oxidative stress.  Acute exacerbations, which are mainly triggered by viral or bacterial infections, are important as they are linked to a poor prognosis.  The mainstay of the management of stable disease is the use of inhaled long-acting bronchodilators, whereas corticosteroids are beneficial primarily in patients who have coexisting features of asthma, such as eosinophilic inflammation and more reversibility of airway obstruction.  Apart from smoking cessation, no treatments reduce disease progression.  More research is needed to better understand disease mechanisms and to develop new treatments that reduce disease activity and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcrna7Vp9c5EewzGPswiWOfW6udTcc2eaAAdqzsCHepLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1eisA%253D%253D&md5=278360c87e28cdb595b55776f4ce6554</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2015.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2015.76%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DBurney%26aufirst%3DP.%2BG.%2BJ.%26aulast%3DSilverman%26aufirst%3DE.%2BK.%26aulast%3DCelli%26aufirst%3DB.%2BR.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DWouters%26aufirst%3DE.%2BF.%2BM.%26atitle%3DChronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Primers%26date%3D2015%26volume%3D1%26spage%3D15076%26doi%3D10.1038%2Fnrdp.2015.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P.</span></span> <span> </span><span class="NLM_article-title">Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1164/rccm.200612-1749OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200612-1749OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17575095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srptFCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2007&pages=753-760&author=N.+Zhongauthor=C.+Wangauthor=W.+Yaoauthor=P.+Chenauthor=J.+Kangauthor=S.+Huangauthor=B.+Chenauthor=C.+Wangauthor=D.+Niauthor=Y.+Zhouauthor=S.+Liuauthor=X.+Wangauthor=D.+Wangauthor=J.+Luauthor=J.+Zhengauthor=P.+Ran&title=Prevalence+of+chronic+obstructive+pulmonary+disease+in+China%3A+a+large%2C+population-based+survey&doi=10.1164%2Frccm.200612-1749OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey</span></div><div class="casAuthors">Zhong Nanshan; Wang Chen; Yao Wanzhen; Chen Ping; Kang Jian; Huang Shaoguang; Chen Baoyuan; Wang Changzheng; Ni Diantao; Zhou Yumin; Liu Shengming; Wang Xiaoping; Wang Dali; Lu Jiachun; Zheng Jingping; Ran Pixin</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">753-60</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">RATIONALE:  The prevalence of chronic obstructive pulmonary disease (COPD) in China is largely unknown.  OBJECTIVES:  To obtain the COPD prevalence in China through a large-population, spirometry-based, cross-sectional survey of COPD.  METHODS:  Urban and rural population-based cluster samples were randomly selected from seven provinces/cities.  All residents 40 years of age or older in the selected clusters were interviewed with a standardized questionnaire revised from the international BOLD (Burden of Obstructive Lung Diseases) study.  Spirometry was performed on all eligible participants.  Patients with airflow limitation (FEV(1)/FVC < 0.70) were further examined by post-bronchodilator spirometry, chest radiograph, and electrocardiogram.  Post-bronchodilator FEV(1)/FVC of less than 70% was defined as the diagnostic criterion of COPD.  MEASUREMENTS AND MAIN RESULTS:  Among 25,627 sampling subjects, 20,245 participants completed the questionnaire and spirometry (response rate, 79.0%).  The overall prevalence of COPD was 8.2% (men, 12.4%; women, 5.1%).  The prevalence of COPD was significantly higher in rural residents, elderly patients, smokers, in those with lower body mass index, less education, and poor ventilation in the kitchen, in those who were exposed to occupational dusts or biomass fuels, and in those with pulmonary problems in childhood and family history of pulmonary diseases.  Among the patients who had COPD, 35.3% were asymptomatic; only 35.1% reported lifetime diagnosis of bronchitis, emphysema, or other COPD; and only 6.5% have been tested with spirometry.  CONCLUSIONS:  COPD is prevalent in individuals 40 years of age or older in China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTroqdm9wT0W90Q2ypr7jHkfW6udTcc2eaAAdqzsCHepLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srptFCgsA%253D%253D&md5=121c7caef419af320f3d5cc1649f82be</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1164%2Frccm.200612-1749OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200612-1749OC%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DNi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DRan%26aufirst%3DP.%26atitle%3DPrevalence%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520China%253A%2520a%2520large%252C%2520population-based%2520survey%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D176%26spage%3D753%26epage%3D760%26doi%3D10.1164%2Frccm.200612-1749OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buist, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBurnie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmer, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannino, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulsvik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizankowska-Mogilnicka, E.</span></span>; <span class="NLM_contrib-group">BOLD Collaborative Research Group</span> <span> </span><span class="NLM_article-title">International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(07)61377-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2807%2961377-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17765523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srhs1Sisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=741-750&author=A.+S.+Buistauthor=M.+A.+McBurnieauthor=W.+M.+Vollmerauthor=S.+Gillespieauthor=P.+Burneyauthor=D.+M.+Manninoauthor=A.+M.+Menezesauthor=S.+D.+Sullivanauthor=T.+A.+Leeauthor=K.+B.+Weissauthor=R.+L.+Jensenauthor=G.+B.+Marksauthor=A.+Gulsvikauthor=E.+Nizankowska-Mogilnickaauthor=BOLD+Collaborative+Research+Group&title=International+variation+in+the+prevalence+of+COPD+%28the+BOLD+Study%29%3A+a+population-based+prevalence+study&doi=10.1016%2FS0140-6736%2807%2961377-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study</span></div><div class="casAuthors">Buist A Sonia; McBurnie Mary Ann; Vollmer William M; Gillespie Suzanne; Burney Peter; Mannino David M; Menezes Ana M B; Sullivan Sean D; Lee Todd A; Weiss Kevin B; Jensen Robert L; Marks Guy B; Gulsvik Amund; Nizankowska-Mogilnicka Ewa</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">9589</span>),
    <span class="NLM_cas:pages">741-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) is a growing cause of morbidity and mortality worldwide, and accurate estimates of the prevalence of this disease are needed to anticipate the future burden of COPD, target key risk factors, and plan for providing COPD-related health services.  We aimed to measure the prevalence of COPD and its risk factors and investigate variation across countries by age, sex, and smoking status.  METHODS:  Participants from 12 sites (n=9425) completed postbronchodilator spirometry testing plus questionnaires about respiratory symptoms, health status, and exposure to COPD risk factors.  COPD prevalence estimates based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were adjusted for the target population.  Logistic regression was used to estimate adjusted odds ratios (ORs) for COPD associated with 10-year age increments and 10-pack-year (defined as the number of cigarettes smoked per day divided by 20 and multiplied by the number of years that the participant smoked) increments.  Meta-analyses provided pooled estimates for these risk factors.  FINDINGS:  The prevalence of stage II or higher COPD was 10.1% (SE 4.8) overall, 11.8% (7.9) for men, and 8.5% (5.8) for women.  The ORs for 10-year age increments were much the same across sites and for women and men.  The overall pooled estimate was 1.94 (95% CI 1.80-2.10) per 10-year increment.  Site-specific pack-year ORs varied significantly in women (pooled OR=1.28, 95% CI 1.15-1.42, p=0.012), but not in men (1.16, 1.12-1.21, p=0.743).  INTERPRETATION:  This worldwide study showed higher levels and more advanced staging of spirometrically confirmed COPD than have typically been reported.  However, although age and smoking are strong contributors to COPD, they do not fully explain variations in disease prevalence-other factors also seem to be important.  Although smoking cessation is becoming an increasingly urgent objective for an ageing worldwide population, a better understanding of other factors that contribute to COPD is crucial to assist local public-health officials in developing the best possible primary and secondary prevention policies for their regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTAJAVB43A0lUIs6wFK5xJfW6udTcc2eZnfaqpwSnVKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srhs1Sisg%253D%253D&md5=5f6b58f94a5407c1bd75f5ac62245ac6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2807%2961377-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252807%252961377-4%26sid%3Dliteratum%253Aachs%26aulast%3DBuist%26aufirst%3DA.%2BS.%26aulast%3DMcBurnie%26aufirst%3DM.%2BA.%26aulast%3DVollmer%26aufirst%3DW.%2BM.%26aulast%3DGillespie%26aufirst%3DS.%26aulast%3DBurney%26aufirst%3DP.%26aulast%3DMannino%26aufirst%3DD.%2BM.%26aulast%3DMenezes%26aufirst%3DA.%2BM.%26aulast%3DSullivan%26aufirst%3DS.%2BD.%26aulast%3DLee%26aufirst%3DT.%2BA.%26aulast%3DWeiss%26aufirst%3DK.%2BB.%26aulast%3DJensen%26aufirst%3DR.%2BL.%26aulast%3DMarks%26aufirst%3DG.%2BB.%26aulast%3DGulsvik%26aufirst%3DA.%26aulast%3DNizankowska-Mogilnicka%26aufirst%3DE.%26aulast%3D%26atitle%3DInternational%2520variation%2520in%2520the%2520prevalence%2520of%2520COPD%2520%2528the%2520BOLD%2520Study%2529%253A%2520a%2520population-based%2520prevalence%2520study%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D741%26epage%3D750%26doi%3D10.1016%2FS0140-6736%2807%2961377-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agustí, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzueto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Roisin, R.</span></span> <span> </span><span class="NLM_article-title">Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1164/rccm.201204-0596PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.201204-0596PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22878278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVGhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2013&pages=347-365&author=J.+Vestboauthor=S.+S.+Hurdauthor=A.+G.+Agust%C3%ADauthor=P.+W.+Jonesauthor=C.+Vogelmeierauthor=A.+Anzuetoauthor=P.+J.+Barnesauthor=L.+M.+Fabbriauthor=F.+J.+Martinezauthor=M.+Nishimuraauthor=R.+A.+Stockleyauthor=D.+D.+Sinauthor=R.+Rodriguez-Roisin&title=Global+strategy+for+the+diagnosis%2C+management+and+prevention+of+chronic+obstructive+pulmonary+disease%2C+GOLD+executive+summary&doi=10.1164%2Frccm.201204-0596PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</span></div><div class="casAuthors">Vestbo, Jorgen; Hurd, Suzanne S.; Agusti, Alvar G.; Jones, Paul W.; Vogelmeier, Claus; Anzueto, Antonio; Barnes, Peter J.; Fabbri, Leonardo M.; Martinez, Fernando J.; Nishimura, Masaharu; Stockley, Robert A.; Sin, Don D.; Rodriguez-Roisin, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">347-365</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy document for the diagnosis and management of COPD.  This executive summary presents the main contents of the second 5-yr revision of the GOLD document that has implemented some of the vast knowledge about COPD accumulated over the last years.  Today, GOLD recommends that spirometry is required for the clin. diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.  The document highlights that the assessment of the patient with COPD should always include assessment of (1) symptoms, (2) severity of airflow limitation, (3) history of exacerbations, and (4) comorbidities.  The first three points can be used to evaluate level of symptoms and risk of future exacerbations, and this is done in a way that splits patients with COPD into four categories-A, B, C, and D.  Nonpharmacol. and pharmacol. management of COPD match this assessment in an evidence-based attempt to relieve symptoms and reduce risk of exacerbations.  Identification and treatment of comorbidities must have high priority, and a sep. section in the document addresses management of comorbidities as well as COPD in the presence of comorbidities.  The revised document also contains a new section on exacerbations of COPD.  The GOLD initiative will continue to bring COPD to the attention of all relevant shareholders and will hopefully inspire future national and local guidelines on the management of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXROvO3tH2OLVg90H21EOLACvtfcHk0lhNinO_ytiTgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVGhs7Y%253D&md5=c2b519b14e69420564a575d40a449e5d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1164%2Frccm.201204-0596PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201204-0596PP%26sid%3Dliteratum%253Aachs%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DHurd%26aufirst%3DS.%2BS.%26aulast%3DAgust%25C3%25AD%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DStockley%26aufirst%3DR.%2BA.%26aulast%3DSin%26aufirst%3DD.%2BD.%26aulast%3DRodriguez-Roisin%26aufirst%3DR.%26atitle%3DGlobal%2520strategy%2520for%2520the%2520diagnosis%252C%2520management%2520and%2520prevention%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%252C%2520GOLD%2520executive%2520summary%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2013%26volume%3D187%26spage%3D347%26epage%3D365%26doi%3D10.1164%2Frccm.201204-0596PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Chronic obstructive pulmonary disease: a growing but neglected epidemic</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e112</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0040112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1371%2Fjournal.pmed.0040112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17503959" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=e112&author=P.+J.+Barnes&title=Chronic+obstructive+pulmonary+disease%3A+a+growing+but+neglected+epidemic&doi=10.1371%2Fjournal.pmed.0040112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0040112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0040112%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DChronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520growing%2520but%2520neglected%2520epidemic%26jtitle%3DPLoS%2520Med.%26date%3D2007%26volume%3D4%26spage%3De112%26doi%3D10.1371%2Fjournal.pmed.0040112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span> <i>Chronic Obstructive Pulmonary Disease (COPD)</i>; <span class="NLM_publisher-name">Centers for Disease Control and Prevention</span>: <span class="NLM_publisher-loc">Atlanta</span>, <span class="NLM_year">2018</span>; <a href="https://www.cdc.gov/copd/index.html" class="extLink">https://www.cdc.gov/copd/index.html</a> (accessed Aug. 4, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chronic+Obstructive+Pulmonary+Disease+%28COPD%29%3B+Centers+for+Disease+Control+and+Prevention%3A+Atlanta%2C+2018%3B+https%3A%2F%2Fwww.cdc.gov%2Fcopd%2Findex.html+%28accessed+Aug.+4%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DChronic%2520Obstructive%2520Pulmonary%2520Disease%2520%2528COPD%2529%26pub%3DCenters%2520for%2520Disease%2520Control%2520and%2520Prevention%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">GBD
2015 Chronic Respiratory Disease Collaborators</span> <span> </span><span class="NLM_article-title">Global, regional, and national deaths,
prevalence, disability-adjusted life years, and years lived with disability
for chronic obstructive pulmonary disease and asthma, 1990–2015:
a systematic analysis for the global burden of disease study 2015. <i>Lancet</i></span>. <i>Respir Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(17)30293-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS2213-2600%2817%2930293-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=691-706&author=GBD%0A2015+Chronic+Respiratory+Disease+Collaborators&title=Global%2C+regional%2C+and+national+deaths%2C%0Aprevalence%2C+disability-adjusted+life+years%2C+and+years+lived+with+disability%0Afor+chronic+obstructive+pulmonary+disease+and+asthma%2C+1990%E2%80%932015%3A%0Aa+systematic+analysis+for+the+global+burden+of+disease+study+2015.+Lancet&doi=10.1016%2FS2213-2600%2817%2930293-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2817%2930293-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252817%252930293-X%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520deaths%252C%250Aprevalence%252C%2520disability-adjusted%2520life%2520years%252C%2520and%2520years%2520lived%2520with%2520disability%250Afor%2520chronic%2520obstructive%2520pulmonary%2520disease%2520and%2520asthma%252C%25201990%25E2%2580%25932015%253A%250Aa%2520systematic%2520analysis%2520for%2520the%2520global%2520burden%2520of%2520disease%2520study%25202015.%2520Lancet%26jtitle%3DRespir%2520Med.%26date%3D2017%26volume%3D5%26spage%3D691%26epage%3D706%26doi%3D10.1016%2FS2213-2600%2817%2930293-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teo, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abisheganaden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, B. H.</span></span> <span> </span><span class="NLM_article-title">Economic burden of chronic obstructive pulmonary disease</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1843.2011.02073.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1440-1843.2011.02073.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21954985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FptVOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=120-126&author=W.+S.+Teoauthor=W.+S.+Tanauthor=W.+F.+Chongauthor=J.+Abisheganadenauthor=Y.+J.+Lewauthor=T.+K.+Limauthor=B.+H.+Heng&title=Economic+burden+of+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1440-1843.2011.02073.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Economic burden of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Teo W-S Kelvin; Tan Woan-Shin; Chong Wai-Fung; Abisheganaden John; Lew Yii-Jen; Lim Tow-Keang; Heng Bee-Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND OBJECTIVE:  The aim of this study was to estimate the direct medical costs of COPD in two public health clusters in Singapore from 2005 to 2009.  METHODS:  Patients aged 40 years and over, who had been diagnosed with COPD, were identified in a Chronic Disease Management Data-mart.  Annual utilization of health services in inpatient, specialist outpatient, emergency department and primary care settings was extracted from the Chronic Disease Management Data-mart.  Trends in attributable costs, proportions of costs and health-care utilization were analyzed across each level of care.  A weighted attribution approach was used to allocate costs to each health-care utilization episode, depending on the relevance of co-morbidities.  RESULTS:  The mean total cost was approximately $9.9 million per year.  Inpatient admissions were the major cost driver, contributing an average of $7.2 million per year.  The proportion of hospitalization costs declined from 75% in 2005 to 68% in 2009.  Based on the 5-year average, attendances at primary care clinics, emergency department and specialist clinics contributed 3%, 5% and 17%, respectively, of overall COPD costs.  On average, 42% of the total cost burden was incurred for the medical management of COPD.  The share of cost incurred for the treatment of conditions related and unrelated to COPD were 29% and 26%, respectively, of the total average costs.  CONCLUSIONS:  COPD is likely to represent a significant burden to the public health system in most countries.  The findings are particularly relevant to understanding the allocation of health-care resources and informing appropriate cost containment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROsHOCQUWjJSCEBeYuoi7AfW6udTcc2eZHM_YZXh4bDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FptVOqtQ%253D%253D&md5=9366bb24664acaa1af55a3ce9167fe63</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1843.2011.02073.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1843.2011.02073.x%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DW.%2BS.%26aulast%3DTan%26aufirst%3DW.%2BS.%26aulast%3DChong%26aufirst%3DW.%2BF.%26aulast%3DAbisheganaden%26aufirst%3DJ.%26aulast%3DLew%26aufirst%3DY.%2BJ.%26aulast%3DLim%26aufirst%3DT.%2BK.%26aulast%3DHeng%26aufirst%3DB.%2BH.%26atitle%3DEconomic%2520burden%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespirology%26date%3D2012%26volume%3D17%26spage%3D120%26epage%3D126%26doi%3D10.1111%2Fj.1440-1843.2011.02073.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burney, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naghavi, M.</span></span> <span> </span><span class="NLM_article-title">Global and regional trends in COPD mortality, 1990–2010</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1247</span>, <span class="refDoi"> DOI: 10.1183/09031936.00142414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1183%2F09031936.00142414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25837037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2MjgsFCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=1239-1247&author=P.+G.+Burneyauthor=J.+Patelauthor=R.+Newsonauthor=C.+Minelliauthor=M.+Naghavi&title=Global+and+regional+trends+in+COPD+mortality%2C+1990%E2%80%932010&doi=10.1183%2F09031936.00142414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Global and regional trends in COPD mortality, 1990-2010</span></div><div class="casAuthors">Burney Peter G J; Patel Jaymini; Newson Roger; Minelli Cosetta; Naghavi Mohsen</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1239-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Between 1990 and 2010, chronic obstructive pulmonary disease (COPD) moved from the fourth to third most common cause of death worldwide.  Using data from the Global Burden of Disease programme we quantified regional changes in the number of COPD deaths and COPD mortality rates between 1990 and 2010.  We estimated the proportion of the change that was attributable to gross national income per capita and an index of cumulative smoking exposure, and quantified the difference in mortality rates attributable to demographic changes.  Despite a substantial decrease in COPD mortality rates, COPD deaths fell only slightly, from three million in 1990 to 2.8 million in 2010, because the mean age of the population increased.  The number of COPD deaths in 2010 would have risen to 5.2 million if the age- and sex-specific mortality rates had remained constant.  Changes in smoking led to only a small increase in age- and sex-specific mortality rates, which were strongly associated with changes in gross national income.  The increased burden of COPD mortality was mainly driven by changes in age distribution, but age- and sex-specific rates fell as incomes rose.  The rapid response to increasing affluence suggests that changes in COPD mortality are not entirely explained by changes in early life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_uq_pzhUCkVZoq0fPSOTvfW6udTcc2eb4CxNl_orqurntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjgsFCmuw%253D%253D&md5=ac0b863a4349debb4d01467223ca7e19</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1183%2F09031936.00142414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00142414%26sid%3Dliteratum%253Aachs%26aulast%3DBurney%26aufirst%3DP.%2BG.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DNewson%26aufirst%3DR.%26aulast%3DMinelli%26aufirst%3DC.%26aulast%3DNaghavi%26aufirst%3DM.%26atitle%3DGlobal%2520and%2520regional%2520trends%2520in%2520COPD%2520mortality%252C%25201990%25E2%2580%25932010%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D45%26spage%3D1239%26epage%3D1247%26doi%3D10.1183%2F09031936.00142414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span> <i>Chronic Obstructive Pulmonary Disease (COPD)</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>; <a href="http://www.who.int/respiratory/copd/en/" class="extLink">http://www.who.int/respiratory/copd/en/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chronic+Obstructive+Pulmonary+Disease+%28COPD%29%3B+World+Health+Organization%3A+Geneva%2C+2018%3B+http%3A%2F%2Fwww.who.int%2Frespiratory%2Fcopd%2Fen%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DChronic%2520Obstructive%2520Pulmonary%2520Disease%2520%2528COPD%2529%26pub%3DWorld%2520Health%2520Organization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonough, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seyednejad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gefter, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxson, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paré, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWilliams, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span> <span> </span><span class="NLM_article-title">Small-airway obstruction and emphysema in chronic obstructive pulmonary disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1106955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJMoa1106955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22029978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSrsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1567-1575&author=J.+E.+McDonoughauthor=R.+Yuanauthor=M.+Suzukiauthor=N.+Seyednejadauthor=W.+M.+Elliottauthor=P.+G.+Sanchezauthor=A.+C.+Wrightauthor=W.+B.+Gefterauthor=L.+Litzkyauthor=H.+O.+Coxsonauthor=P.+D.+Par%C3%A9author=D.+D.+Sinauthor=R.+A.+Pierceauthor=J.+C.+Woodsauthor=A.+M.+McWilliamsauthor=J.+R.+Mayoauthor=S.+C.+Lamauthor=J.+D.+Cooperauthor=J.+C.+Hogg&title=Small-airway+obstruction+and+emphysema+in+chronic+obstructive+pulmonary+disease&doi=10.1056%2FNEJMoa1106955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Small-airway obstruction and emphysema in chronic obstructive pulmonary disease</span></div><div class="casAuthors">McDonough, John E.; Yuan, Ren; Suzuki, Masaru; Seyednejad, Nazgol; Elliott, W. Mark; Sanchez, Pablo G.; Wright, Alexander C.; Gefter, Warren B.; Litzky, Leslie; Coxson, Harvey O.; Pare, Peter D.; Sin, Don D.; Pierce, Richard A.; Woods, Jason C.; McWilliams, Annette M.; Mayo, John R.; Lam, Stephen C.; Cooper, Joel D.; Hogg, James C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1567-1575</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The major sites of obstruction in chronic obstructive pulmonary disease (COPD) are small airways (<2 mm in diam.).  We wanted to det. whether there was a relationship between small-airway obstruction and emphysematous destruction in COPD.  METHODS We used multidetector computed tomog. (CT) to compare the no. of airways measuring 2.0 to 2.5 mm in 78 patients who had various stages of COPD, as judged by scoring on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) scale, in isolated lungs removed from patients with COPD who underwent lung transplantation, and in donor (control) lungs.  MicroCT was used to measure the extent of emphysema (mean linear intercept), the no. of terminal bronchioles per mL of lung vol., and the min. diams. and cross-sectional areas of terminal bronchioles.  RESULTS On multidetector CT, in samples from patients with COPD, as compared with control samples, the no. of airways measuring 2.0 to 2.5 mm in diam. was reduced in patients with GOLD stage 1 disease (P = 0.001), GOLD stage 2 disease (P = 0.02), and GOLD stage 3 or 4 disease (P < 0.001).  MicroCT of isolated samples of lungs removed from patients with GOLD stage 4 disease showed a redn. of 81 to 99.7% in the total cross-sectional area of terminal bronchioles and a redn. of 72 to 89% in the no. of terminal bronchioles (P < 0.001).  A comparison of the no. of terminal bronchioles and dimensions at different levels of emphysematous destruction (i.e., an increasing value for the mean linear intercept) showed that the narrowing and loss of terminal bronchioles preceded emphysematous destruction in COPD (P < 0.001).  CONCLUSIONS These results show that narrowing and disappearance of small conducting airways before the onset of emphysematous destruction can explain the increased peripheral airway resistance reported in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUaZj-JIivxbVg90H21EOLACvtfcHk0lillWdue6SKwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSrsrbM&md5=7c79a7a19ed50dc69016eff9972db616</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1106955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1106955%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonough%26aufirst%3DJ.%2BE.%26aulast%3DYuan%26aufirst%3DR.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DSeyednejad%26aufirst%3DN.%26aulast%3DElliott%26aufirst%3DW.%2BM.%26aulast%3DSanchez%26aufirst%3DP.%2BG.%26aulast%3DWright%26aufirst%3DA.%2BC.%26aulast%3DGefter%26aufirst%3DW.%2BB.%26aulast%3DLitzky%26aufirst%3DL.%26aulast%3DCoxson%26aufirst%3DH.%2BO.%26aulast%3DPar%25C3%25A9%26aufirst%3DP.%2BD.%26aulast%3DSin%26aufirst%3DD.%2BD.%26aulast%3DPierce%26aufirst%3DR.%2BA.%26aulast%3DWoods%26aufirst%3DJ.%2BC.%26aulast%3DMcWilliams%26aufirst%3DA.%2BM.%26aulast%3DMayo%26aufirst%3DJ.%2BR.%26aulast%3DLam%26aufirst%3DS.%2BC.%26aulast%3DCooper%26aufirst%3DJ.%2BD.%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26atitle%3DSmall-airway%2520obstruction%2520and%2520emphysema%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1567%26epage%3D1575%26doi%3D10.1056%2FNEJMoa1106955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mapel, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalal, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchette, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, G. T.</span></span> <span> </span><span class="NLM_article-title">Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.2147/COPD.S16975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2147%2FCOPD.S16975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22135490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FktlChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=573-581&author=D.+W.+Mapelauthor=A.+A.+Dalalauthor=C.+M.+Blanchetteauthor=H.+Petersenauthor=G.+T.+Ferguson&title=Severity+of+COPD+at+initial+spirometry-confirmed+diagnosis%3A+data+from+medical+charts+and+administrative+claims&doi=10.2147%2FCOPD.S16975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims</span></div><div class="casAuthors">Mapel Douglas W; Dalal Anand A; Blanchette Christopher M; Petersen Hans; Ferguson Gary T</div><div class="citationInfo"><span class="NLM_cas:title">International journal of chronic obstructive pulmonary disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">573-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  This study was conducted to determine COPD severity at the time of diagnosis as confirmed by spirometry in patients treated in a US managed care setting.  PATIENTS AND METHODS:  All patients with one or more inpatient stays, one or more emergency department visits, or two or more outpatient visits with diagnosis codes for COPD during 1994-2006 were identified from the Lovelace Patient Database.  From this group, a subset of continuously enrolled patients with evidence in claims of a first available pulmonary function test or pulmonary clinic visit and a confirmatory claim for a COPD diagnosis was selected.  Medical chart abstraction was undertaken for this subset to gather information for diagnosis and severity staging of each patient based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for COPD.  RESULTS:  Of the 12,491 patients with a primary or secondary COPD diagnosis between 1994 and 2006, there were 1520 continuously enrolled patients who comprised the study cohort.  Among the 648 eligible records from patients with evidence of a pulmonary function test, 366 were identified by spirometry as having COPD of GOLD stage I or higher (average percentage of predicted forced expiratory volume in 1 second: 60%): 19% were diagnosed at the stage of mild disease (GOLD stage I); 50% at moderate disease (GOLD stage II); and 31% at severe or very severe disease (GOLD stage III or IV, respectively).  The majority of patients in these groups were not receiving maintenance treatment.  CONCLUSION:  The results demonstrate a very low incidence of early-stage diagnosis, confirmed by a pulmonary function test, of COPD in a large US sample and support calls for increased screening for COPD and treatment upon diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtz4ddVfs_c2K_SFaaT9INfW6udTcc2ebdaUcrodFJv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FktlChsQ%253D%253D&md5=42511d3257e465c1dc44996ebf8837bd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S16975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S16975%26sid%3Dliteratum%253Aachs%26aulast%3DMapel%26aufirst%3DD.%2BW.%26aulast%3DDalal%26aufirst%3DA.%2BA.%26aulast%3DBlanchette%26aufirst%3DC.%2BM.%26aulast%3DPetersen%26aufirst%3DH.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26atitle%3DSeverity%2520of%2520COPD%2520at%2520initial%2520spirometry-confirmed%2520diagnosis%253A%2520data%2520from%2520medical%2520charts%2520and%2520administrative%2520claims%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2011%26volume%3D6%26spage%3D573%26epage%3D581%26doi%3D10.2147%2FCOPD.S16975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span> <span> </span><span class="NLM_article-title">Pathophysiology of airflow limitation in chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)16900-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2804%2916900-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15325838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2cvhvFKntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=709-721&author=J.+C.+Hogg&title=Pathophysiology+of+airflow+limitation+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2804%2916900-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pathophysiology of airflow limitation in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hogg James C</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">9435</span>),
    <span class="NLM_cas:pages">709-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The airflow limitation that defines chronic obstructive pulmonary disease (COPD) is the result of a prolonged time constant for lung emptying, caused by increased resistance of the small conducting airways and increased compliance of the lung as a result of emphysematous destruction.  These lesions are associated with a chronic innate and adaptive inflammatory immune response of the host to a lifetime exposure to inhaled toxic gases and particles.  Processes contributing to obstruction in the small conducting airways include disruption of the epithelial barrier, interference with mucociliary clearance apparatus that results in accumulation of inflammatory mucous exudates in the small airway lumen, infiltration of the airway walls by inflammatory cells, and deposition of connective tissue in the airway wall.  This remodelling and repair thickens the airway walls, reduces lumen calibre, and restricts the normal increase in calibre produced by lung inflation.  Emphysematous lung destruction is associated with an infiltration of the same type of inflammatory cells found in the airways.  The centrilobular pattern of emphysematous destruction is most closely associated with cigarette smoking, and although it is initially focused on respiratory bronchioles, separate lesions coalesce to destroy large volumes of lung tissue.  The panacinar pattern of emphysema is characterised by a more even involvement of the acinus and is associated with alpha1 antitrypsin deficiency.  The technology needed to diagnose and quantitate the individual small airway and emphysema phenotypes present in people with COPD is being developed, and should prove helpful in the assessment of therapeutic interventions designed to modify the progress of either phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTicL3IkZ1Ezq91pGlMMoT5fW6udTcc2ebdaUcrodFJv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvhvFKntw%253D%253D&md5=020c93595544690ab6519a8d88cfb9ee</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2916900-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252916900-6%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26atitle%3DPathophysiology%2520of%2520airflow%2520limitation%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D709%26epage%3D721%26doi%3D10.1016%2FS0140-6736%2804%2916900-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, C. K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. F.</span></span> <span> </span><span class="NLM_article-title">Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD</span>. <i>Expert Rev. Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1586/ers.10.91</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1586%2Fers.10.91" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21348581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVemtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=9-16&author=C.+K.+M.+Huiauthor=K.+F.+Chung&title=Indacaterol%3A+pharmacologic+profile%2C+efficacy+and+safety+in+the+treatment+of+adults+with+COPD&doi=10.1586%2Fers.10.91"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD</span></div><div class="casAuthors">Hui, Christopher K. M.; Chung, Kian F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-16</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Indacaterol is a novel once-daily long-acting β2-agonist (LABA) for the treatment of chronic obstructive pulmonary disease (COPD) that is currently completing Phase II and Phase III trials.  It represents the first of a group of drugs now referred to as theultra-LABAs''.  It has recently gained approval in Europe, and is pending regulatory review in the USA.  Indacaterol produces a rapid and sustained bronchodilation that lasts for at least 24 h in patients with COPD.  To date, 1-yr studies with indacaterol indicate that it can be taken once daily with good overall safety and tolerability profiles.  The therapeutic potential for indacaterol is supported by data on patient-reported outcomes with an improvement in symptoms such as dyspnea, exercise capacity and quality of life, and a redn. in exacerbations.  It is likely that indacaterol could be used in conjunction with other agents such as inhaled corticosteroids and anticholinergics for the treatment of COPD as a single once-daily combination treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5viZJwdQIsrVg90H21EOLACvtfcHk0lhkNzAfsXV04A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVemtrg%253D&md5=cd1765d5b63fb8aaddd4cc60009447d5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1586%2Fers.10.91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fers.10.91%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DC.%2BK.%2BM.%26aulast%3DChung%26aufirst%3DK.%2BF.%26atitle%3DIndacaterol%253A%2520pharmacologic%2520profile%252C%2520efficacy%2520and%2520safety%2520in%2520the%2520treatment%2520of%2520adults%2520with%2520COPD%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2011%26volume%3D5%26spage%3D9%26epage%3D16%26doi%3D10.1586%2Fers.10.91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postma, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabe, K. F.</span></span> <span> </span><span class="NLM_article-title">The asthma-COPD overlap syndrome</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">1241</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1411863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJMra1411863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26398072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XkslCitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1241-1249&author=D.+S.+Postmaauthor=K.+F.+Rabe&title=The+asthma-COPD+overlap+syndrome&doi=10.1056%2FNEJMra1411863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">the asthma-COPD overlap syndrome</span></div><div class="casAuthors">Postma, Dirkje S.; Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1241-1249</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This article describes about asthma-chronic obstructive pulmonary disease overlap syndrome a condition in which a person has clin. features of both asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9FzMKOH3BmLVg90H21EOLACvtfcHk0lhkNzAfsXV04A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkslCitA%253D%253D&md5=172afa6a356861b696efe8fa3af1e9cc</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1411863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1411863%26sid%3Dliteratum%253Aachs%26aulast%3DPostma%26aufirst%3DD.%2BS.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DThe%2520asthma-COPD%2520overlap%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1241%26epage%3D1249%26doi%3D10.1056%2FNEJMra1411863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Asthma-COPD overlap</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.chest.2015.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.chest.2015.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26757281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28rpslGnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2016&pages=7-8&author=P.+J.+Barnes&title=Asthma-COPD+overlap&doi=10.1016%2Fj.chest.2015.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Asthma-COPD Overlap</span></div><div class="casAuthors">Barnes Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKuc2YiC6XWgxyojvcjibhfW6udTcc2eaFU8fEemY6Nbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rpslGnsw%253D%253D&md5=f3f6da66140e57913074411b9721f02e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.chest.2015.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chest.2015.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DAsthma-COPD%2520overlap%26jtitle%3DChest%26date%3D2016%26volume%3D149%26spage%3D7%26epage%3D8%26doi%3D10.1016%2Fj.chest.2015.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agustí, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marott, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Camblor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto-Plata, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesfaigzi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span> <span> </span><span class="NLM_article-title">Lung-function trajectories leading to chronic obstructive pulmonary disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJMoa1411532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26154786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12qurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=111-122&author=P.+Langeauthor=B.+Celliauthor=A.+Agust%C3%ADauthor=G.+B.+Jensenauthor=M.+Divoauthor=R.+Fanerauthor=S.+Guerraauthor=J.+L.+Marottauthor=F.+D.+Martinezauthor=P.+Martinez-Camblorauthor=P.+Meekauthor=C.+Owenauthor=H.+Petersenauthor=V.+Pinto-Plataauthor=P.+Schnohrauthor=A.+Soodauthor=J.+B.+Sorianoauthor=Y.+Tesfaigziauthor=J.+Vestbo&title=Lung-function+trajectories+leading+to+chronic+obstructive+pulmonary+disease&doi=10.1056%2FNEJMoa1411532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Lung-function trajectories leading to chronic obstructive pulmonary disease</span></div><div class="casAuthors">Lange, Peter; Celli, Bartolome; Agusti, Alvar; Jensen, Gorm Boje; Divo, Miguel; Faner, Rosa; Guerra, Stefano; Marott, Jacob Louis; Martinez, Fernando D.; Martinez-Camblor, Pablo; Meek, Paula; Owen, Caroline A.; Petersen, Hans; Pinto-Plata, Victor; Schnohr, Peter; Sood, Akshay; Soriano, Joan B.; Tesfaigzi, Yohannes; Vestbo, Joergen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Chronic obstructive pulmonary disease (COPD) is thought to result from an accelerated decline in forced expiratory vol. in 1 s (FEV1) over time.  Yet it is possible that a normal decline in FEV1 could also lead to COPD in persons whose maximally attained FEV1 is less than population norms. methods We stratified participants in three independent cohorts (the Framingham Offspring Cohort, the Copenhagen City Heart Study, and the Lovelace Smokers Cohort) according to lung function (FEV1 ≥80% or <80% of the predicted value) at cohort inception (mean age of patients, approx. 40 years) and the presence or absence of COPD at the last study visit.  We then detd. the rate of decline in FEV1 over time among the participants according to their FEV1 at cohort inception and COPD status at study end. results Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation (P<0.001).  Approx. half the 332 persons with COPD at the end of the observation period had had a normal FEV1 before 40 years of age and had a rapid decline in FEV1 thereafter, with a mean (±SD) decline of 53 ± 21 mL per yr.  The remaining half had had a low FEV1 in early adulthood and a subsequent mean decline in FEV1 of 27 ± 18 mL per yr (P<0.001), despite similar smoking exposure. conclusions Our study suggests that low FEV1 in early adulthood is important in the genesis of COPD and that accelerated decline in FEV1 is not an obligate feature of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2S2XiqyOZAbVg90H21EOLACvtfcHk0lh96gEV9JKbcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12qurfN&md5=7aaffaf1e9dc958f362b5dd3aea4aea0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411532%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DP.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DAgust%25C3%25AD%26aufirst%3DA.%26aulast%3DJensen%26aufirst%3DG.%2BB.%26aulast%3DDivo%26aufirst%3DM.%26aulast%3DFaner%26aufirst%3DR.%26aulast%3DGuerra%26aufirst%3DS.%26aulast%3DMarott%26aufirst%3DJ.%2BL.%26aulast%3DMartinez%26aufirst%3DF.%2BD.%26aulast%3DMartinez-Camblor%26aufirst%3DP.%26aulast%3DMeek%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DH.%26aulast%3DPinto-Plata%26aufirst%3DV.%26aulast%3DSchnohr%26aufirst%3DP.%26aulast%3DSood%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DJ.%2BB.%26aulast%3DTesfaigzi%26aufirst%3DY.%26aulast%3DVestbo%26aufirst%3DJ.%26atitle%3DLung-function%2520trajectories%2520leading%2520to%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D111%26epage%3D122%26doi%3D10.1056%2FNEJMoa1411532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, B. G.</span></span> <span> </span><span class="NLM_article-title">Role of tobacco smoking in the causation of chronic respiratory disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1056/NEJM196210182671601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJM196210182671601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=14012834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADyaF383gsVOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1962&pages=787-794&author=D.+O.+Andersonauthor=B.+G.+Ferris&title=Role+of+tobacco+smoking+in+the+causation+of+chronic+respiratory+disease&doi=10.1056%2FNEJM196210182671601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Role of tobacco smoking in the causation of chronic respiratory disease</span></div><div class="casAuthors">ANDERSON D O; FERRIS B G Jr</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">787-94</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTtiJI_FX8GiA3UY9EwTNrfW6udTcc2earMVFbR4vnD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF383gsVOksg%253D%253D&md5=035917f73dd54de8f0c5a87bfe5de82c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJM196210182671601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM196210182671601%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BO.%26aulast%3DFerris%26aufirst%3DB.%2BG.%26atitle%3DRole%2520of%2520tobacco%2520smoking%2520in%2520the%2520causation%2520of%2520chronic%2520respiratory%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1962%26volume%3D267%26spage%3D787%26epage%3D794%26doi%3D10.1056%2FNEJM196210182671601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Chronic obstructive pulmonary disease in non-smokers</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">743</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(09)61303-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2809%2961303-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19716966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1MrovFymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=733-743&author=S.+S.+Salviauthor=P.+J.+Barnes&title=Chronic+obstructive+pulmonary+disease+in+non-smokers&doi=10.1016%2FS0140-6736%2809%2961303-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic obstructive pulmonary disease in non-smokers</span></div><div class="casAuthors">Salvi Sundeep S; Barnes Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">9691</span>),
    <span class="NLM_cas:pages">733-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide.  Tobacco smoking is established as a major risk factor, but emerging evidence suggests that other risk factors are important, especially in developing countries.  An estimated 25-45% of patients with COPD have never smoked; the burden of non-smoking COPD is therefore much higher than previously believed.  About 3 billion people, half the worldwide population, are exposed to smoke from biomass fuel compared with 1.01 billion people who smoke tobacco, which suggests that exposure to biomass smoke might be the biggest risk factor for COPD globally.  We review the evidence for the association of COPD with biomass fuel, occupational exposure to dusts and gases, history of pulmonary tuberculosis, chronic asthma, respiratory-tract infections during childhood, outdoor air pollution, and poor socioeconomic status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqLnV-F6XH0eIHSmpohpd0fW6udTcc2earMVFbR4vnD7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrovFymuw%253D%253D&md5=7293ed37beeda2a3119a8312bb423810</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2961303-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252961303-9%26sid%3Dliteratum%253Aachs%26aulast%3DSalvi%26aufirst%3DS.%2BS.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DChronic%2520obstructive%2520pulmonary%2520disease%2520in%2520non-smokers%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26spage%3D733%26epage%3D743%26doi%3D10.1016%2FS0140-6736%2809%2961303-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adab, P.</span></span> <span> </span><span class="NLM_article-title">Passive smoking exposure and risk of COPD among adults in China: the Guangzhou biobank cohort study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(07)61378-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2807%2961378-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17765524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srhs1Sisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=751-757&author=P.+Yinauthor=C.+Q.+Jiangauthor=K.+K.+Chengauthor=T.+H.+Lamauthor=K.+H.+Lamauthor=M.+R.+Millerauthor=W.+S.+Zhangauthor=G.+N.+Thomasauthor=P.+Adab&title=Passive+smoking+exposure+and+risk+of+COPD+among+adults+in+China%3A+the+Guangzhou+biobank+cohort+study&doi=10.1016%2FS0140-6736%2807%2961378-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study</span></div><div class="casAuthors">Yin P; Jiang C Q; Cheng K K; Lam T H; Lam K H; Miller M R; Zhang W S; Thomas G N; Adab P</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">9589</span>),
    <span class="NLM_cas:pages">751-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in China, where the population is also exposed to high levels of passive smoking, yet little information exists on the effects of such exposure on COPD.  We examined the relation between passive smoking and COPD and respiratory symptoms in an adult Chinese population.  METHODS:  We used baseline data from the Guangzhou Biobank Cohort Study.  Of 20 430 men and women over the age of 50 recruited in 2003-06, 15,379 never smokers (6497 with valid spirometry) were included in this cross-sectional analysis.  We measured passive smoking exposure at home and work by two self-reported measures (density and duration of exposure).  Diagnosis of COPD was based on spirometry and defined according to the GOLD guidelines.  FINDINGS:  There was an association between risk of COPD and self-reported exposure to passive smoking at home and work (adjusted odds ratio 1.48, 95% CI 1.18-1.85 for high level exposure; equivalent to 40 h a week for more than 5 years).  There were significant associations between reported respiratory symptoms and increasing passive smoking exposure (1.16, 1.07-1.25 for any symptom).  INTERPRETATION:  Exposure to passive smoking is associated with an increased prevalence of COPD and respiratory symptoms.  If this association is causal, we estimate that 1.9 million excess deaths from COPD among never smokers could be attributable to passive smoking in the current population in China.  Our findings provide strong evidence for urgent measures against passive smoking in China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTAJAVB43A0sK3uFsUIZtkfW6udTcc2eb17RvmJUjo5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srhs1Sisw%253D%253D&md5=d8d2dfceafd085479ec868505e2b63be</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2807%2961378-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252807%252961378-6%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DC.%2BQ.%26aulast%3DCheng%26aufirst%3DK.%2BK.%26aulast%3DLam%26aufirst%3DT.%2BH.%26aulast%3DLam%26aufirst%3DK.%2BH.%26aulast%3DMiller%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DW.%2BS.%26aulast%3DThomas%26aufirst%3DG.%2BN.%26aulast%3DAdab%26aufirst%3DP.%26atitle%3DPassive%2520smoking%2520exposure%2520and%2520risk%2520of%2520COPD%2520among%2520adults%2520in%2520China%253A%2520the%2520Guangzhou%2520biobank%2520cohort%2520study%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D751%26epage%3D757%26doi%3D10.1016%2FS0140-6736%2807%2961378-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. B.</span></span> <span> </span><span class="NLM_article-title">Indoor air pollution from biomass fuel smoke is a major health concern in the developing world</span>. <i>Trans. R. Soc. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1016/j.trstmh.2008.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.trstmh.2008.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18639310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1cvpvFWmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=843-851&author=D.+G.+Fullertonauthor=N.+Bruceauthor=S.+B.+Gordon&title=Indoor+air+pollution+from+biomass+fuel+smoke+is+a+major+health+concern+in+the+developing+world&doi=10.1016%2Fj.trstmh.2008.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Indoor air pollution from biomass fuel smoke is a major health concern in the developing world</span></div><div class="casAuthors">Fullerton Duncan G; Bruce Nigel; Gordon Stephen B</div><div class="citationInfo"><span class="NLM_cas:title">Transactions of the Royal Society of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">843-51</span>
        ISSN:<span class="NLM_cas:issn">0035-9203</span>.
    </div><div class="casAbstract">One-third of the world's population burn organic material such as wood, dung or charcoal (biomass fuel) for cooking, heating and lighting.  This form of energy usage is associated with high levels of indoor air pollution and an increase in the incidence of respiratory infections, including pneumonia, tuberculosis and chronic obstructive pulmonary disease, low birthweight, cataracts, cardiovascular events and all-cause mortality both in adults and children.  The mechanisms behind these associations are not fully understood.  This review summarises the available information on biomass fuel use and health, highlighting the current gaps in knowledge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeQ5PhyrCF7UH3Rlp_k91zfW6udTcc2eb17RvmJUjo5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvpvFWmtg%253D%253D&md5=9ac0accfb7c2975b286361f055d62142</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.trstmh.2008.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trstmh.2008.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DFullerton%26aufirst%3DD.%2BG.%26aulast%3DBruce%26aufirst%3DN.%26aulast%3DGordon%26aufirst%3DS.%2BB.%26atitle%3DIndoor%2520air%2520pollution%2520from%2520biomass%2520fuel%2520smoke%2520is%2520a%2520major%2520health%2520concern%2520in%2520the%2520developing%2520world%26jtitle%3DTrans.%2520R.%2520Soc.%2520Trop.%2520Med.%2520Hyg.%26date%3D2008%26volume%3D102%26spage%3D843%26epage%3D851%26doi%3D10.1016%2Fj.trstmh.2008.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P.</span></span> <span> </span><span class="NLM_article-title">Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural south China</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1136/thx.2006.061457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1136%2Fthx.2006.061457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17483137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srosVChsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=889-897&author=S.+Liuauthor=Y.+Zhouauthor=X.+Wangauthor=D.+Wangauthor=J.+Luauthor=J.+Zhengauthor=N.+Zhongauthor=P.+Ran&title=Biomass+fuels+are+the+probable+risk+factor+for+chronic+obstructive+pulmonary+disease+in+rural+south+China&doi=10.1136%2Fthx.2006.061457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China</span></div><div class="casAuthors">Liu Shengming; Zhou Yumin; Wang Xiaoping; Wang Dali; Lu Jiachun; Zheng Jingping; Zhong Nanshan; Ran Pixin</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">889-97</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  There is increasing evidence for a possible association between chronic obstructive pulmonary disease (COPD) and the use of biomass fuels for cooking and heating in developing countries.  Data on the prevalence of COPD and objective measurements of indoor pollution from biomass fuel have not been widely available from China.  A study was undertaken to investigate the prevalence of COPD in two study communities in Guangdong province in China and to measure the association between COPD and indoor biomass fuel air pollution.  METHODS:  A cluster disproportional random sampling survey was performed in populations aged over 40 years in urban (Liwang) and rural (Yunyan) areas in Guangdong, China.  Spirometry was performed in all subjects and a post-bronchodilator ratio of the forced expiratory volume in 1 s to forced vital capacity of <0.70 was defined as COPD.  Measurements of indoor and outdoor air pollutants were also performed in a random sample of households.  RESULTS:  The overall prevalence of COPD in the two areas (Liwang and Yunyan) was 9.4%.  The prevalence of COPD in both the whole population and a subpopulation of non-smoking women in rural Yunyan was significantly higher than in urban Liwang (12.0% vs 7.4%, and 7.2% vs 2.5%, respectively).  The use of biomass fuel was higher in rural Yunyan than in urban Liwang (88.1% vs 0.7%).  Univariate analysis showed a significant association between COPD and exposure to biomass fuel for cooking.  Multivariate analysis showed a positive association between COPD and urban/rural area (surrogate for fuel type and local exhaust ventilation in kitchen) after adjustment for sex, age group, body mass index, education, occupational exposure, respiratory disease in family, smoking status, life quality and cough in childhood; similar results were found in non-smoking women.  Pollutants measurements showed that concentrations of carbon monoxide, particulate matter with an aerodynamic diameter <or=10 microm, sulphur dioxide and nitrogen dioxide in the kitchen during biomass fuel combustion were significantly higher than those during LPG combustion.  CONCLUSIONS:  Indoor pollutants from biomass fuels may be an important risk factor for COPD in rural South China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsG4DBTFKwYOQ4Pl9hzjQhfW6udTcc2eb17RvmJUjo5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srosVChsg%253D%253D&md5=0e13d942464b8a36b5f5ba3d7a927cca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1136%2Fthx.2006.061457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2006.061457%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DRan%26aufirst%3DP.%26atitle%3DBiomass%2520fuels%2520are%2520the%2520probable%2520risk%2520factor%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520rural%2520south%2520China%26jtitle%3DThorax%26date%3D2007%26volume%3D62%26spage%3D889%26epage%3D897%26doi%3D10.1136%2Fthx.2006.061457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippmann, M.</span></span> <span> </span><span class="NLM_article-title">Factors affecting personal exposure to thoracic and fine particles and their components</span>. <i>J. Exposure Sci. Environ. Epidemiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1038/jes.2012.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fjes.2012.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22760443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GjtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=439-447&author=S.+I.+Hsuauthor=K.+Itoauthor=M.+Kendallauthor=M.+Lippmann&title=Factors+affecting+personal+exposure+to+thoracic+and+fine+particles+and+their+components&doi=10.1038%2Fjes.2012.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Factors affecting personal exposure to thoracic and fine particles and their components</span></div><div class="casAuthors">Hsu, Shao-I.; Ito, Kazuhiko; Kendall, Michaela; Lippmann, Morton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Exposure Science & Environmental Epidemiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">439-447</span>CODEN:
                <span class="NLM_cas:coden">JESEBS</span>;
        ISSN:<span class="NLM_cas:issn">1559-0631</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Central monitoring site (CMS) concns. have been used to represent population-based personal exposures to particulate matter (PM) of ambient origin.  The authors investigated the assocns. of the concns. of PM2.5 and PM10 and their elemental components for elderly clinic patients with chronic obstructive pulmonary disease in two cities with different PM compns., i.e., New York City (NYC) and Seattle.  Daily measurements of CMS, outdoor residential, and indoor PM10 and PM2.5 concns., as well as personal PM10, were made concurrently for 12-consecutive winter days at 9 NYC and 15 Seattle residences, as well for 9 NYC residences in summer.  Filters were analyzed for elemental components using X-ray fluorescence (XRF), and for black carbon (BC) by light reflectance, and outdoor-indoor-personal relationships of PM components were examd. using mixed-effect models.  Using sulfur (S) as a tracer of PM of ambient origin, the mean contributions of outdoor PM2.5 was 55.2% of the indoor concns. in NYC, and 80.0% in Seattle, and outdoor PM2.5 in NYC and Seattle were 19.7 and 18.5% of personal PM2.5 concn.  S was distributed homogeneously in both cities (R2=0.65), whereas nickel (R2=0.23) was much more spatially heterogeneous.  Thus, CMS measurements can adequately reflect personal exposures for spatially uniform components, such as sulfate, but they are not adequate for components from more local sources.  Journal of Exposure Science and Environmental Epidemiol. (2012) 22, 439-447; doi:10.1038/jes.2012.23; published online 4 July 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBaUY8iaMvYLVg90H21EOLACvtfcHk0lgGTfLZ_wOuYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GjtrjP&md5=4b29d33f5724b63c5bbbeed406038049</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fjes.2012.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjes.2012.23%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DS.%2BI.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DKendall%26aufirst%3DM.%26aulast%3DLippmann%26aufirst%3DM.%26atitle%3DFactors%2520affecting%2520personal%2520exposure%2520to%2520thoracic%2520and%2520fine%2520particles%2520and%2520their%2520components%26jtitle%3DJ.%2520Exposure%2520Sci.%2520Environ.%2520Epidemiol.%26date%3D2012%26volume%3D22%26spage%3D439%26epage%3D447%26doi%3D10.1038%2Fjes.2012.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chester, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, F. D.</span></span> <span> </span><span class="NLM_article-title">The prevalence of chronic obstructive pulmonary disease in chlorine gas workers</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=5765628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADyaF1M7hsVWntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1969&pages=365-373&author=E.+H.+Chesterauthor=D.+G.+Gillespieauthor=F.+D.+Krause&title=The+prevalence+of+chronic+obstructive+pulmonary+disease+in+chlorine+gas+workers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The prevalence of chronic obstructive pulmonary disease in chlorine gas workers</span></div><div class="casAuthors">Chester E H; Gillespie D G; Krause F D</div><div class="citationInfo"><span class="NLM_cas:title">The American review of respiratory disease</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-73</span>
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUQZJZoYVNdczK395ZObgVfW6udTcc2eaBU64Grpi5Brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF1M7hsVWntA%253D%253D&md5=16817892f35808d4987cb34aa1463088</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChester%26aufirst%3DE.%2BH.%26aulast%3DGillespie%26aufirst%3DD.%2BG.%26aulast%3DKrause%26aufirst%3DF.%2BD.%26atitle%3DThe%2520prevalence%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520chlorine%2520gas%2520workers%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1969%26volume%3D99%26spage%3D365%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eduard, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douwes, J.</span></span> <span> </span><span class="NLM_article-title">Chronic bronchitis, COPD, and lung function in farmers: the role of biological agents</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1378/chest.08-2192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1378%2Fchest.08-2192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19318669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1MngsVyrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=716-725&author=W.+Eduardauthor=N.+Pearceauthor=J.+Douwes&title=Chronic+bronchitis%2C+COPD%2C+and+lung+function+in+farmers%3A+the+role+of+biological+agents&doi=10.1378%2Fchest.08-2192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic bronchitis, COPD, and lung function in farmers: the role of biological agents</span></div><div class="casAuthors">Eduard Wijnand; Pearce Neil; Douwes Jeroen</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">716-725</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Farmers have an increased risk of respiratory morbidity and mortality.  The causal agents have not been fully established.  METHODS:  In a cross-sectional study of 4,735 Norwegian farmers, we assessed respiratory symptoms and lung function.  Atopy was assessed in a subsample (n = 1,213).  Personal exposures to dust, fungal spores, actinomycete spores, endotoxins, bacteria, storage mites, (1-->3)-ss-D-glucans, fungal antigens, organic dust, inorganic dust, silica, ammonia, and hydrogen sulfide were measured for 127 randomly selected farms.  RESULTS:  Compared to crop farmers, livestock farmers were more likely to have chronic bronchitis (odds ratio [OR], 1.9; 95% confidence interval [CI], 1.4 to 2.6) and COPD (OR, 1.4; 95% CI, 1.1 to 1.7).  FEV(1) (-41 mL; 95% CI, -75 to -7) was significantly reduced, but FVC (-15 mL; 95% CI, -54 to 24) was not.  Exposure to most agents were predictors of respiratory morbidity, except FVC.  Ammonia, hydrogen sulfide, and inorganic dust were most strongly associated in multiple regression models adjusted for coexposures, but the effects of specific biological agents could not be assessed in multiple regression models because they were too highly correlated.  Farmers with atopy had a significantly lower FEV(1) (OR, -87 mL; 95% CI, -170 to -7), but atopy was not directly associated with chronic bronchitis, COPD, and FVC.  However, the effects of farming and specific exposures on COPD were substantially greater in farmers with atopy.  CONCLUSIONS:  Livestock farmers have an increased risk of chronic bronchitis, COPD, and reduced FEV(1).  Ammonia, hydrogen sulfide, inorganic dust, and organic dust may be causally involved, but a role for specific biological agents cannot be excluded.  Farmers with atopy appear more susceptible to develop farming-related COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQa3PQttJFn2_3jf77P2BG3fW6udTcc2eaBU64Grpi5Brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MngsVyrug%253D%253D&md5=e13c54c1d92a1ad6d0824002e0f2aa27</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1378%2Fchest.08-2192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.08-2192%26sid%3Dliteratum%253Aachs%26aulast%3DEduard%26aufirst%3DW.%26aulast%3DPearce%26aufirst%3DN.%26aulast%3DDouwes%26aufirst%3DJ.%26atitle%3DChronic%2520bronchitis%252C%2520COPD%252C%2520and%2520lung%2520function%2520in%2520farmers%253A%2520the%2520role%2520of%2520biological%2520agents%26jtitle%3DChest%26date%3D2009%26volume%3D136%26spage%3D716%26epage%3D725%26doi%3D10.1378%2Fchest.08-2192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Husman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskenvuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaprio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terho, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vohlonen, I.</span></span> <span> </span><span class="NLM_article-title">Role of environment in the development of chronic bronchitis</span>. <i>Eur. J. Respir. Dis. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=3499347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADyaL1c%252FivFyhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1987&pages=57-63&author=K.+Husmanauthor=M.+Koskenvuoauthor=J.+Kaprioauthor=E.+O.+Terhoauthor=I.+Vohlonen&title=Role+of+environment+in+the+development+of+chronic+bronchitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Role of environment in the development of chronic bronchitis</span></div><div class="casAuthors">Husman K; Koskenvuo M; Kaprio J; Terho E O; Vohlonen I</div><div class="citationInfo"><span class="NLM_cas:title">European journal of respiratory diseases. Supplement</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-63</span>
        ISSN:<span class="NLM_cas:issn">0106-4347</span>.
    </div><div class="casAbstract">Based on data in the Finnish Twin Registry, which was obtained by postal questionnaire, the prevalence of chronic bronchitis among non-smoking farmers was 3.6% and among a corresponding group of non-farmers (reference subjects) 3.4%.  The six-year incidences of chronic bronchitis for these 2 groups were 2.7% and 0.7%, respectively.  The difference in incidence between these groups was significant (p less than 0.001).  The fact that the incidence among farming subjects was three times the incidence among non-farming subjects indicates that chronic bronchitis is a work-related disease among farmers.  This is analogous to previous findings that symptoms compatible with chronic bronchitis occur more often among grain elevator workers than among urban dwellers.  The occurrence of chronic bronchitis among both farmers and grain elevator workers probably is associated with exposure to grain dusts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT__Tb7vkptBxLDWw4HIq2sfW6udTcc2eaBU64Grpi5Brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c%252FivFyhsQ%253D%253D&md5=4d0685d142920315337ceb01924c706c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHusman%26aufirst%3DK.%26aulast%3DKoskenvuo%26aufirst%3DM.%26aulast%3DKaprio%26aufirst%3DJ.%26aulast%3DTerho%26aufirst%3DE.%2BO.%26aulast%3DVohlonen%26aufirst%3DI.%26atitle%3DRole%2520of%2520environment%2520in%2520the%2520development%2520of%2520chronic%2520bronchitis%26jtitle%3DEur.%2520J.%2520Respir.%2520Dis.%2520Suppl.%26date%3D1987%26volume%3D152%26spage%3D57%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmer, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hnizdo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villnave, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBurnie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buist, A. S.</span></span> <span> </span><span class="NLM_article-title">COPD and occupational exposures: a case-control study</span>. <i>J. Occup. Environ. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1097/JOM.0b013e3181651556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1097%2FJOM.0b013e3181651556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18469625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltl2hsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2008&pages=561-569&author=S.+Weinmannauthor=W.+M.+Vollmerauthor=V.+Breenauthor=M.+Heumannauthor=E.+Hnizdoauthor=J.+Villnaveauthor=B.+Doneyauthor=M.+Grazianiauthor=M.+A.+McBurnieauthor=A.+S.+Buist&title=COPD+and+occupational+exposures%3A+a+case-control+study&doi=10.1097%2FJOM.0b013e3181651556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">COPD and occupational exposures: A case-control study</span></div><div class="casAuthors">Weinmann, Sheila; Vollmer, William M.; Breen, Victor; Heumann, Michael; Hnizdo, Eva; Villnave, Jacqueline; Doney, Brent; Graziani, Monica; McBurnie, Mary Ann; Buist, A. Sonia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Occupational and Environmental Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-569</span>CODEN:
                <span class="NLM_cas:coden">JOEMFM</span>;
        ISSN:<span class="NLM_cas:issn">1076-2752</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Evidence demonstrates that occupational exposures are causally linked with chronic obstructive pulmonary disease (COPD).  This case-control study evaluated the assocn. between occupational exposures and prevalent COPD based on lifetime occupational history.  Cases (n = 388) aged 45 years and older with COPD were compared with controls (n = 356), frequency matched on age, sex, and cigarette smoking history.  Odds ratios for exposure to each of eight occupational hazard categories and three composite measures of exposure were computed using logistic regression.  Occupational exposures most strongly assocd. with COPD were diesel exhaust, irritant gases and vapors, mineral dust, and metal dust.  The composite measures describing aggregate exposure to gases, vapors, solvents, or sensitizers (GVSS) and aggregate exposure to dust, GVSS, or diesel exhaust were also assocd. with COPD.  In the small group of never-smokers, a similar pattern was evident.  These population-based findings add to the literature linking occupational exposures to COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfK17DueBkxLVg90H21EOLACvtfcHk0lhyUPkTw5PfOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltl2hsbc%253D&md5=da0c0b203e23bcc37d243ae494ff26b6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2FJOM.0b013e3181651556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJOM.0b013e3181651556%26sid%3Dliteratum%253Aachs%26aulast%3DWeinmann%26aufirst%3DS.%26aulast%3DVollmer%26aufirst%3DW.%2BM.%26aulast%3DBreen%26aufirst%3DV.%26aulast%3DHeumann%26aufirst%3DM.%26aulast%3DHnizdo%26aufirst%3DE.%26aulast%3DVillnave%26aufirst%3DJ.%26aulast%3DDoney%26aufirst%3DB.%26aulast%3DGraziani%26aufirst%3DM.%26aulast%3DMcBurnie%26aufirst%3DM.%2BA.%26aulast%3DBuist%26aufirst%3DA.%2BS.%26atitle%3DCOPD%2520and%2520occupational%2520exposures%253A%2520a%2520case-control%2520study%26jtitle%3DJ.%2520Occup.%2520Environ.%2520Med.%26date%3D2008%26volume%3D50%26spage%3D561%26epage%3D569%26doi%3D10.1097%2FJOM.0b013e3181651556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gershon, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascagnette, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victor, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, T.</span></span> <span> </span><span class="NLM_article-title">Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60990-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2811%2960990-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21907862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3Mfislykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=991-996&author=A.+S.+Gershonauthor=L.+Warnerauthor=P.+Cascagnetteauthor=J.+C.+Victorauthor=T.+To&title=Lifetime+risk+of+developing+chronic+obstructive+pulmonary+disease%3A+a+longitudinal+population+study&doi=10.1016%2FS0140-6736%2811%2960990-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study</span></div><div class="casAuthors">Gershon Andrea S; Warner Laura; Cascagnette Paul; Victor J Charles; To Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9795</span>),
    <span class="NLM_cas:pages">991-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Although chronic obstructive pulmonary disease (COPD) is one of the most deadly, prevalent, and costly chronic diseases, no comprehensive estimates of the risk of developing COPD in the general population have been published.  We aimed to quantify the lifetime risk of developing physician-diagnosed COPD in a large, multicultural North American population.  METHODS:  We did a retrospective longitudinal cohort study using population-based health administrative data from Ontario, Canada (total population roughly 13 million).  All individuals free of COPD in 1996 were monitored for up to 14 years for three possible outcomes; diagnosis of COPD by a physician, reached 80 years of age, or death.  COPD was identified with a previously validated case definition based on COPD health services claims.  The cumulative incidence of physician-diagnosed COPD over a lifetime adjusted for the competing risk of death was calculated by a modified survival analysis technique.  Results were stratified by sex, socioeconomic status, and whether individuals lived in a rural or urban setting.  FINDINGS:  A total of 579,466 individuals were diagnosed with COPD by a physician over the study period.  The overall lifetime risk of physician-diagnosed COPD at age 80 years was 27·6%.  Lifetime risk was higher in men than in women (29·7%vs 25·6%), individuals of lower socioeconomic status than in those of higher socioeconomic status (32·1%vs 23·0%), and individuals who lived in a rural setting than in those who lived in an urban setting (32·4%vs 26·7%).  INTERPRETATION:  About one in four individuals are likely to be diagnosed and receive medical attention for COPD during their lifetime.  Clinical evidence-based approaches, public health action, and more research are needed to identify effective strategies to prevent COPD and ensure that those with the disease have the highest quality of life possible.  FUNDING:  Government of Ontario, Canada.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRf9_DAJUZjPrqxQ2mb9Pu8fW6udTcc2eZYb8jKYRkAE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mfislykuw%253D%253D&md5=f9ab88b566a86e8045f4a91fb1b26863</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960990-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960990-2%26sid%3Dliteratum%253Aachs%26aulast%3DGershon%26aufirst%3DA.%2BS.%26aulast%3DWarner%26aufirst%3DL.%26aulast%3DCascagnette%26aufirst%3DP.%26aulast%3DVictor%26aufirst%3DJ.%2BC.%26aulast%3DTo%26aufirst%3DT.%26atitle%3DLifetime%2520risk%2520of%2520developing%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520longitudinal%2520population%2520study%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D991%26epage%3D996%26doi%3D10.1016%2FS0140-6736%2811%2960990-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesario, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span> <span> </span><span class="NLM_article-title">New treatments for COPD in the elderly</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5968</span>– <span class="NLM_lpage">5982</span>, <span class="refDoi"> DOI: 10.2174/1381612820666140314154331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2174%2F1381612820666140314154331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24641227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Gmtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5968-5982&author=M.+G.+Materaauthor=L.+Calzettaauthor=P.+Roglianiauthor=A.+Cesarioauthor=M.+Cazzola&title=New+treatments+for+COPD+in+the+elderly&doi=10.2174%2F1381612820666140314154331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">New Treatments for COPD in the Elderly</span></div><div class="casAuthors">Matera, Maria Gabriella; Calzetta, Luigino; Rogliani, Paola; Cesario, Alfredo; Cazzola, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">5968-5982</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In elderly people the respiratory function is affected by anatomical and physiol. modifications caused by aging.  Elderly COPD patients are characterized by a complexity due to an increasing prevalence of comorbidities related to the age that suggest peculiar care in prescribing the therapy in those patients, also considering other disabilities that are not related with respiratory disorders as phys. and mental limitations.  Nowadays a therapy that allows modifying the long-term decline in lung function of patients suffering from COPD does not yet exist and, therefore, the treatment of this disease is mainly focused on the administration of bronchodilators and the use of inhaled glucocorticoids.  As for younger subjects, also in elderly patients the main classes of bronchodilators used in the treatment of COPD include β 2-agonists, anticholinergics and methylxanthines.  The inflammatory response suppression represents another mechanistic approach for treating COPD in the elderly, although the use of inhaled corticosteroids is limited to specific indications.  Indeed, nowadays there is a strong medical need for novel treatments of COPD in the elderly.  These are mainly represented by agents that reduce the spillover of inflammatory mediators from the lung and by compds. that inhibit the chronic systemic inflammatory syndrome.  The therapeutic approach of COPD in elderly patients remains a topic of increasing interest, however the development of novel compds. for preventing the COPD progression in the elderly, other than bronchodilators and corticosteroids, remains a challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE51_hCOsNYLVg90H21EOLACvtfcHk0lhyUPkTw5PfOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Gmtr%252FJ&md5=42405593a73f52de86628c394d0df02e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F1381612820666140314154331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612820666140314154331%26sid%3Dliteratum%253Aachs%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DCesario%26aufirst%3DA.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DNew%2520treatments%2520for%2520COPD%2520in%2520the%2520elderly%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2014%26volume%3D20%26spage%3D5968%26epage%3D5982%26doi%3D10.2174%2F1381612820666140314154331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitfessel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillissen, A.</span></span> <span> </span><span class="NLM_article-title">Maternal smoking promotes chronic obstructive lung disease in the offspring as adults</span>. <i>Eur. J. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1186/2047-783X-14-S4-27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2F2047-783X-14-S4-27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20156720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3cnmsValsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=27-31&author=D.+Beyerauthor=H.+Mitfesselauthor=A.+Gillissen&title=Maternal+smoking+promotes+chronic+obstructive+lung+disease+in+the+offspring+as+adults&doi=10.1186%2F2047-783X-14-S4-27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Maternal smoking promotes chronic obstructive lung disease in the offspring as adults</span></div><div class="casAuthors">Beyer D; Mitfessel H; Gillissen A</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medical research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14 Suppl 4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-31</span>
        ISSN:<span class="NLM_cas:issn">0949-2321</span>.
    </div><div class="casAbstract">INTRODUCTION:  In utero and/or childhood environmental tobacco smoke exposure is well known to adversely affect lung function and to depreciate child's health in many ways.  Fewer studies have assessed the long-term effects on COPD development and disease severity in later adulthood.  METHODS:  COPD patients were interviewed using a structured questionnaire regarding their personal as well as the smoking habits of their parents.  Data were compared with the disease history, e.g.  COPD exacerbation rate, and their lung function data.  RESULTS:  Between 2003 and 2004 COPD patients were recruited a) in a private practice specialized in pulmonary medicine (n = 133) and b) in a hospital (n = 158). 75% of their fathers and only 15.4 of all mothers smoked regularly.  COPD patients from smoking mothers had lower FEV1 predicted than those raised in household without maternal smoking exposure: 39.4 +/- 9.5% vs. 51.9 +/- 6.0% (P = 0.037).  Fathers had no effect on FEV1 regardless if they are smokers or non-smokers.  Rate of severe exacerbations requiring hospitalization remained unaffected by parental second hand smoke exposure.  CONCLUSION:  Maternal smoking negatively affects lung function of their offspring even in late adulthood when they develop COPD.  It even aggravates the cumulative effect of active cigarette consumption.  Clinical course of the COPD remained unaffected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSS1i4bhTL7ilWTCLT8lX9SfW6udTcc2eZRCa2CnIYMarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnmsValsw%253D%253D&md5=a9518771d9fe45dd47fb05f071c0355e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2F2047-783X-14-S4-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2047-783X-14-S4-27%26sid%3Dliteratum%253Aachs%26aulast%3DBeyer%26aufirst%3DD.%26aulast%3DMitfessel%26aufirst%3DH.%26aulast%3DGillissen%26aufirst%3DA.%26atitle%3DMaternal%2520smoking%2520promotes%2520chronic%2520obstructive%2520lung%2520disease%2520in%2520the%2520offspring%2520as%2520adults%26jtitle%3DEur.%2520J.%2520Med.%2520Res.%26date%3D2009%26volume%3D14%26spage%3D27%26epage%3D31%26doi%3D10.1186%2F2047-783X-14-S4-27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postma, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berge, M.</span></span> <span> </span><span class="NLM_article-title">Risk factors and early origins of chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">899</span>– <span class="NLM_lpage">909</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)60446-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2814%2960446-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25123778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhslWkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=899-909&author=D.+S.+Postmaauthor=A.+Bushauthor=M.+van+den+Berge&title=Risk+factors+and+early+origins+of+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2814%2960446-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors and early origins of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Postma Dirkje S; Bush Andrew; van den Berge Maarten</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9971</span>),
    <span class="NLM_cas:pages">899-909</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease is mainly a smoking-related disorder and affects millions of people worldwide, with a large effect on individual patients and society as a whole.  Although the disease becomes clinically apparent around the age of 40-50 years, its origins can begin very early in life.  Different risk factors in very early life--ie, in utero and during early childhood--drive the development of clinically apparent chronic obstructive pulmonary disease in later life.  In discussions of which risk factors drive chronic obstructive pulmonary disease, it is important to realise that the disease is very heterogeneous and at present is largely diagnosed by lung function only.  In this Review, we will discuss the evidence for risk factors for the various phenotypes of chronic obstructive pulmonary disease during different stages of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvZ_LAXZIzn3RxY89Cm6SyfW6udTcc2eZRCa2CnIYMarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhslWkug%253D%253D&md5=f8ab6f1e12fcf7733aaf6fbd79dad09a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960446-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960446-3%26sid%3Dliteratum%253Aachs%26aulast%3DPostma%26aufirst%3DD.%2BS.%26aulast%3DBush%26aufirst%3DA.%26aulast%3Dvan%2Bden%2BBerge%26aufirst%3DM.%26atitle%3DRisk%2520factors%2520and%2520early%2520origins%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D899%26epage%3D909%26doi%3D10.1016%2FS0140-6736%2814%2960446-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grol, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koëter, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rijcken, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postma, D. S.</span></span> <span> </span><span class="NLM_article-title">Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 30-year follow-up study</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">1830</span>– <span class="NLM_lpage">1837</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.160.6.9812100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Fajrccm.160.6.9812100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10588593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fls1eiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1999&pages=1830-1837&author=M.+H.+Grolauthor=J.+Gerritsenauthor=J.+M.+Vonkauthor=J.+P.+Schoutenauthor=G.+H.+Ko%C3%ABterauthor=B.+Rijckenauthor=D.+S.+Postma&title=Risk+factors+for+growth+and+decline+of+lung+function+in+asthmatic+individuals+up+to+age+42+years.+A+30-year+follow-up+study&doi=10.1164%2Fajrccm.160.6.9812100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 30-year follow-up study</span></div><div class="casAuthors">Grol M H; Gerritsen J; Vonk J M; Schouten J P; Koeter G H; Rijcken B; Postma D S</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1830-7</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Little is known about factors determining the outcome of childhood asthma.  The purpose of this longitudinal study was to assess the factors in childhood that determine the level of FEV(1) in early adulthood in asthmatic individuals, and to examine factors associated with decline in FEV(1) during adulthood.  Between 1966 and 1969, 119 allergic asthmatic subjects aged 5 to 14 yr were studied (Visit 1).  Of these subjects, 101 (85%) were reinvestigated at ages 22 to 32 yr (Visit 2) and 32 to 42 yr (Visit 3).  At the first survey and during follow-up, a standardized questionnaire was used, serum total IgE and peripheral blood eosinophils were measured, and physical examination, skin tests, lung function tests, and histamine challenge (provocative concentration causing a 10% decline in FEV(1); PC(10)) tests were performed according to the same protocol.  Multiple linear regression analyses were performed with FEV(1) at Visit 2 and with the change of FEV(1) from Visit 2 to Visit 3 as outcome variables.  A low FEV(1)% predicted at Visit 1 and PC(10) </= 16 mg/ml at Visit 1 were significantly associated with a lower level of FEV(1) at Visit 2.  Subjects who quit smoking and subjects who continued to use inhaled corticosteroids had a significantly smaller annual decline in FEV(1) from Visit 2 to Visit 3, adjusted for attained level of FEV(1) at Visit 2.  In conclusion, bronchial hyperresponsiveness and a low level of lung function in childhood are independent risk factors for a low level of FEV(1) in early adulthood.  A smaller decline in FEV(1) after ages 22 to 32 yr occurs in asthmatics who quit smoking and who continue to use inhaled corticosteroids.  Our data stress the importance of studying intervention strategies for asthma in young childhood and early adulthood in order to prevent or postpone further lung function deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSc6IBWE8rpU__I8Jvzw4xCfW6udTcc2eZRCa2CnIYMarntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fls1eiug%253D%253D&md5=32b1519a6f90109b77873d988bf12630</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.160.6.9812100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.160.6.9812100%26sid%3Dliteratum%253Aachs%26aulast%3DGrol%26aufirst%3DM.%2BH.%26aulast%3DGerritsen%26aufirst%3DJ.%26aulast%3DVonk%26aufirst%3DJ.%2BM.%26aulast%3DSchouten%26aufirst%3DJ.%2BP.%26aulast%3DKo%25C3%25ABter%26aufirst%3DG.%2BH.%26aulast%3DRijcken%26aufirst%3DB.%26aulast%3DPostma%26aufirst%3DD.%2BS.%26atitle%3DRisk%2520factors%2520for%2520growth%2520and%2520decline%2520of%2520lung%2520function%2520in%2520asthmatic%2520individuals%2520up%2520to%2520age%252042%2520years.%2520A%252030-year%2520follow-up%2520study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1999%26volume%3D160%26spage%3D1830%26epage%3D1837%26doi%3D10.1164%2Fajrccm.160.6.9812100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbee, R. A.</span></span> <span> </span><span class="NLM_article-title">Asthma as a risk factor for COPD in a longitudinal study</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1378/chest.126.1.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1378%2Fchest.126.1.59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15249443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2czks1WqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=59-65&author=G.+E.+Silvaauthor=D.+L.+Sherrillauthor=S.+Guerraauthor=R.+A.+Barbee&title=Asthma+as+a+risk+factor+for+COPD+in+a+longitudinal+study&doi=10.1378%2Fchest.126.1.59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Asthma as a risk factor for COPD in a longitudinal study</span></div><div class="casAuthors">Silva Graciela E; Sherrill Duane L; Guerra Stefano; Barbee Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-65</span>
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    </div><div class="casAbstract">BACKGROUND:  For several years, asthma and COPD have been regarded as distinct entities, with distinct clinical courses.  However, despite distinctive physiologic features at the time of diagnosis, and different risk factors, the two diseases over time may develop features that are quite similar.  STUDY OBJECTIVE:  To evaluate the association between physician-diagnosed asthma and the subsequent development of COPD in a cohort of 3,099 adult subjects from Tucson, AZ.  DESIGN AND METHODS:  A prospective observational study.  Participants completed up to 12 standard respiratory questionnaires and 11 spirometry lung function measurements over a period of 20 years.  Survival curves (with time to development of COPD as the dependent variable) were compared between subjects with asthma and subjects without asthma at the initial survey.  RESULTS:  Subjects with active asthma (n = 192) had significantly higher hazard ratios than inactive (n = 156) or nonasthmatic subjects (n = 2751) for acquiring COPD.  As compared with nonasthmatics, active asthmatics had a 10-times-higher risk for acquiring symptoms of chronic bronchitis (95% confidence interval [CI], 4.94 to 20.25), 17-times-higher risk of receiving a diagnosis of emphysema (95% CI, 8.31 to 34.83), and 12.5-times-higher risk of fulfilling COPD criteria (95% CI, 6.84 to 22.84), even after adjusting for smoking history and other potential confounders.  CONCLUSIONS:  Physician-diagnosed asthma is significantly associated with an increased risk for CB, emphysema, and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTD7169-4f_KjQLBVDQn4bCfW6udTcc2ebcl19HC7NhmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czks1WqtA%253D%253D&md5=43529b3ffb47cd25e853797d2e3997e5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1378%2Fchest.126.1.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.126.1.59%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DG.%2BE.%26aulast%3DSherrill%26aufirst%3DD.%2BL.%26aulast%3DGuerra%26aufirst%3DS.%26aulast%3DBarbee%26aufirst%3DR.%2BA.%26atitle%3DAsthma%2520as%2520a%2520risk%2520factor%2520for%2520COPD%2520in%2520a%2520longitudinal%2520study%26jtitle%3DChest%26date%3D2004%26volume%3D126%26spage%3D59%26epage%3D65%26doi%3D10.1378%2Fchest.126.1.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span> <span> </span><span class="NLM_article-title">Risk factors and intervention for chronic obstructive pulmonary disease in China</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1111/resp.12190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fresp.12190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24188198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2c7mtVOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=4-9&author=Y.+Zhouauthor=R.+Chen&title=Risk+factors+and+intervention+for+chronic+obstructive+pulmonary+disease+in+China&doi=10.1111%2Fresp.12190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors and intervention for chronic obstructive pulmonary disease in China</span></div><div class="casAuthors">Zhou Yumin; Chen Rongchang</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18 Suppl 3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In China, chronic obstructive pulmonary disease (COPD) is one of the most common chronic diseases with a prevalence of 8.2% in the population over 40 years of age.  In 2006, it was the third most common cause of death in China accounting for 17.6% of all deaths.  Although worldwide smoking is the most common risk factor for COPD, in China, additional important risk factors include environmental tobacco smoke, biomass smoke and post-pulmonary tuberculosis.  Interventions based on mitigating these risk factors have a particularly important role in strategies aimed at preventing COPD in China.  Indeed, preliminary research findings have shown that early intervention based on minimizing these risk factors might be a cost-effective way to prevent COPD in China.  Future research should focus on large scale, randomized and controlled prospective studies to address the efficacy, feasibility and health economics of minimizing these important risk factors in China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWFwyRaxVGWdts4TFFB11gfW6udTcc2ebcl19HC7NhmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7mtVOksg%253D%253D&md5=5f41949b50c0b0a92833a4cd8595635d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fresp.12190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fresp.12190%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DR.%26atitle%3DRisk%2520factors%2520and%2520intervention%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520China%26jtitle%3DRespirology%26date%3D2013%26volume%3D18%26spage%3D4%26epage%3D9%26doi%3D10.1111%2Fresp.12190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Immunology of asthma and chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/nri2254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnri2254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18274560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVKjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=183-192&author=P.+J.+Barnes&title=Immunology+of+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnri2254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-192</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Asthma and chronic obstructive pulmonary disease (COPD) are both obstructive airway diseases that involve chronic inflammation of the respiratory tract, but the type of inflammation is markedly different between these diseases, with different patterns of inflammatory cells and mediators being involved.  As described in this Review, these inflammatory profiles are largely detd. by the involvement of different immune cells, which orchestrate the recruitment and activation of inflammatory cells that drive the distinct patterns of structural changes in these diseases.  However, it is now becoming clear that the distinction between these diseases becomes blurred in patients with severe asthma, in asthmatic subjects who smoke and during acute exacerbations.  This has important implications for the development of new therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKkJK_5vmv57Vg90H21EOLACvtfcHk0lhKhFfJAL7nWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVKjsrs%253D&md5=a1d09a214bbd87e31e0c714039077289</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnri2254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2254%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DImmunology%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D183%26epage%3D192%26doi%3D10.1038%2Fnri2254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brusselle, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joos, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracke, K. R.</span></span> <span> </span><span class="NLM_article-title">New insights into the immunology of chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1026</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60988-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2811%2960988-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21907865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCqs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=1015-1026&author=G.+G.+Brusselleauthor=G.+F.+Joosauthor=K.+R.+Bracke&title=New+insights+into+the+immunology+of+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2811%2960988-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the immunology of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Brusselle, Guy G.; Joos, Guy F.; Bracke, Ken R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9795</span>),
    <span class="NLM_cas:pages">1015-1026</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Chronic obstructive pulmonary disease (COPD) is a heterogeneous syndrome assocd. with abnormal inflammatory immune responses of the lung to noxious particles and gases.  Cigarette smoke activates innate immune cells such as epithelial cells and macrophages by triggering pattern recognition receptors, either directly or indirectly via the release of damage-assocd. mol. patterns from stressed or dying cells.  Activated dendritic cells induce adaptive immune responses encompassing T helper (Th1 and Th17) CD4+ T cells, CD8+ cytotoxicity, and B-cell responses, which lead to the development of lymphoid follicles on chronic inflammation.  Viral and bacterial infections not only cause acute exacerbations of COPD, but also amplify and perpetuate chronic inflammation in stable COPD via pathogen-assocd. mol. patterns.  We discuss the role of autoimmunity (autoantibodies), remodelling, extracellular matrix-derived fragments, impaired innate lung defences, oxidative stress, hypoxia, and dysregulation of microRNAs in the persistence of the pulmonary inflammation despite smoking cessation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS6dNX1v0BN7Vg90H21EOLACvtfcHk0lhKuFdjdd0wfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCqs77O&md5=f2efdec16bd951c0155442c9024666f9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960988-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960988-4%26sid%3Dliteratum%253Aachs%26aulast%3DBrusselle%26aufirst%3DG.%2BG.%26aulast%3DJoos%26aufirst%3DG.%2BF.%26aulast%3DBracke%26aufirst%3DK.%2BR.%26atitle%3DNew%2520insights%2520into%2520the%2520immunology%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D1015%26epage%3D1026%26doi%3D10.1016%2FS0140-6736%2811%2960988-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wedzicha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seemungal, T. A.</span></span> <span> </span><span class="NLM_article-title">COPD exacerbations: defining their cause and prevention</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(07)61382-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2807%2961382-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17765528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srhs1Sitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=786-796&author=J.+A.+Wedzichaauthor=T.+A.+Seemungal&title=COPD+exacerbations%3A+defining+their+cause+and+prevention&doi=10.1016%2FS0140-6736%2807%2961382-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">COPD exacerbations: defining their cause and prevention</span></div><div class="casAuthors">Wedzicha Jadwiga A; Seemungal Terence A R</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">9589</span>),
    <span class="NLM_cas:pages">786-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality.  COPD exacerbations are associated with increased airway and systemic inflammation and physiological changes, especially the development of hyperinflation.  They are triggered mainly by respiratory viruses and bacteria, which infect the lower airway and increase airway inflammation.  Some patients are particularly susceptible to exacerbations, and show worse health status and faster disease progression than those who have infrequent exacerbations.  Several pharmacological interventions are effective for the reduction of exacerbation frequency and severity in COPD such as inhaled steroids, long-acting bronchodilators, and their combinations.  Non-pharmacological therapies such as pulmonary rehabilitation, self-management, and home ventilatory support are becoming increasingly important, but still need to be studied in controlled trials.  The future of exacerbation prevention is in assessment of optimum combinations of pharmacological and non-pharmacological therapies that will result in improvement of health status, and reduction of hospital admission and mortality associated with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTAJAVB43A0pw7prLlxLOzfW6udTcc2eaJhzX8LETd_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srhs1Sitw%253D%253D&md5=76655b3b851f0169f5b3ba1dda2c22e9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2807%2961382-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252807%252961382-8%26sid%3Dliteratum%253Aachs%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DSeemungal%26aufirst%3DT.%2BA.%26atitle%3DCOPD%2520exacerbations%253A%2520defining%2520their%2520cause%2520and%2520prevention%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D786%26epage%3D796%26doi%3D10.1016%2FS0140-6736%2807%2961382-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkham, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress in COPD</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1378/chest.12-2664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1378%2Fchest.12-2664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23880677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Chtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2013&pages=266-273&author=P.+A.+Kirkhamauthor=P.+J.+Barnes&title=Oxidative+stress+in+COPD&doi=10.1378%2Fchest.12-2664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress in COPD</span></div><div class="casAuthors">Kirkham, Paul A.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">266-273</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">A review.  Oxidative stress is now recognized as a major predisposing factor in the pathogenesis of COPD.  Existing therapies for COPD are ineffective at halting disease progression, with bronchodilators being the mainstay of pharmacotherapy, providing symptomatic relief only.  It is, therefore, important for a better understanding of the underlying mechanisms by which oxidative stress drives disease pathogenesis to develop novel and more effective therapies.  Antioxidant capacity in COPD is substantially reduced as a result of cigarette smoking and exacerbations, with oxidative stress persisting long after the cessation of cigarette smoking or exacerbation, due to the continued prodn. of reactive oxygen species from endogenous sources.  We discuss (1) how oxidative stress arises in the lung, (2) how it is neutralized, (3) what genetic factors may predispose to the development of COPD, and (4) how this impacts inflammation and autoimmunity in the development of emphysema and small airways disease.  Finally, various strategies have been considered to neutralize the increased oxidative burden present in COPD.  This review highlights why current antioxidant strategies have so far failed and what promising alternatives are on the horizon.  Moreover, a no. of studies have shown that there is no single "magic bullet" to combat oxidative stress, but instead a combination therapy, targeting oxidative stress in the various subcellular compartments, may prove to be more effective in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpkJCKDjIPbVg90H21EOLACvtfcHk0lhKuFdjdd0wfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Chtb3E&md5=895fa4278d4021be1292d6d1abcc892e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1378%2Fchest.12-2664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.12-2664%26sid%3Dliteratum%253Aachs%26aulast%3DKirkham%26aufirst%3DP.%2BA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DOxidative%2520stress%2520in%2520COPD%26jtitle%3DChest%26date%3D2013%26volume%3D144%26spage%3D266%26epage%3D273%26doi%3D10.1378%2Fchest.12-2664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chillappagari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preuss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahavadi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarode, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahrlich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, M. O.</span></span> <span> </span><span class="NLM_article-title">Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">85</span>, <span class="refDoi"> DOI: 10.1186/s12931-015-0247-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2Fs12931-015-0247-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26169056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FivVKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=85&author=S.+Chillappagariauthor=J.+Preussauthor=S.+Lichtauthor=C.+M%C3%BCllerauthor=P.+Mahavadiauthor=G.+Sarodeauthor=C.+Vogelmeierauthor=A.+Guentherauthor=L.+Nahrlichauthor=B.+K.+Rubinauthor=M.+O.+Henke&title=Altered+protease+and+antiprotease+balance+during+a+COPD+exacerbation+contributes+to+mucus+obstruction&doi=10.1186%2Fs12931-015-0247-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction</span></div><div class="casAuthors">Chillappagari Shashi; Nahrlich Lutz; Chillappagari Shashi; Mahavadi Poornima; Guenther Andreas; Chillappagari Shashi; Preuss Jenni; Licht Sebastian; Muller Christian; Vogelmeier Claus; Henke Markus O; Chillappagari Shashi; Mahavadi Poornima; Guenther Andreas; Nahrlich Lutz; Sarode Gaurav; Henke Markus O; Sarode Gaurav; Henke Markus O; Guenther Andreas; Guenther Andreas; Rubin Bruce K</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Proteases have been shown to degrade airway mucin proteins and to damage the epithelium impairing mucociliary clearance.  There are increased proteases in the COPD airway but changes in protease-antiprotease balance and mucin degradation have not been investigated during the course of a COPD exacerbation.  We hypothesized that increased protease levels would lead to mucin degradation in acute COPD exacerbations.  METHODS:  We measured neutrophil elastase (NE) and alpha 1 protease inhibitor (A1-PI) levels using immunoblotting, and conducted protease inhibitor studies, zymograms, elastin substrate assays and cigarette smoke condensate experiments to evaluate the stability of the gel-forming mucins, MUC5AC and MUC5B, before and 5-6 weeks after an acute pulmonary exacerbation of COPD (n = 9 subjects).  RESULTS:  Unexpectedly, mucin concentration and mucin stability were highest at the start of the exacerbation and restored to baseline after 6 weeks.  Consistent with these data, immunoblots and zymograms confirmed decreased NE concentration and activity and increased A1-PI at the start of the exacerbation.  After recovery there was an increase in NE activity and a decrease in A1-PI levels.  In vitro, protease inhibitor studies demonstrated that serine proteases played a key role in mucin degradation.  Mucin stability was further enhanced upon treating with cigarette smoke condensate (CSC).  CONCLUSION:  There appears to be rapid consumption of secreted proteases due to an increase in antiproteases, at the start of a COPD exacerbation.  This leads to increased mucin gel stability which may be important in trapping and clearing infectious and inflammatory mediators, but this may also contribute acutely to mucus retention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-fuLe5VCDtK-9TkgmBqTqfW6udTcc2eaJhzX8LETd_bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FivVKrsA%253D%253D&md5=a285e6600fc7af294c94a7cf0478f678</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2Fs12931-015-0247-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-015-0247-x%26sid%3Dliteratum%253Aachs%26aulast%3DChillappagari%26aufirst%3DS.%26aulast%3DPreuss%26aufirst%3DJ.%26aulast%3DLicht%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DMahavadi%26aufirst%3DP.%26aulast%3DSarode%26aufirst%3DG.%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DGuenther%26aufirst%3DA.%26aulast%3DNahrlich%26aufirst%3DL.%26aulast%3DRubin%26aufirst%3DB.%2BK.%26aulast%3DHenke%26aufirst%3DM.%2BO.%26atitle%3DAltered%2520protease%2520and%2520antiprotease%2520balance%2520during%2520a%2520COPD%2520exacerbation%2520contributes%2520to%2520mucus%2520obstruction%26jtitle%3DRespir.%2520Res.%26date%3D2015%26volume%3D16%26spage%3D85%26doi%3D10.1186%2Fs12931-015-0247-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Frontrunners in novel pharmacotherapy of COPD</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2008.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.coph.2008.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18457992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVyls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=300-307&author=P.+J.+Barnes&title=Frontrunners+in+novel+pharmacotherapy+of+COPD&doi=10.1016%2Fj.coph.2008.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Frontrunners in novel pharmacotherapy of COPD</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">300-307</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The mainstay of current drug therapy is long-acting bronchodilators; several longer acting inhaled β2-agonists and muscarinic antagonists (and combinations) are now in development.  No treatments reduce the progression or suppress the inflammation of COPD.  With better understanding of the inflammatory and destructive process, several new targets have been identified.  Several mediator antagonists tested in COPD have been disappointing, but of CXCR2 antagonists that block pulmonary neutrophil and monocyte recruitment may be more promising.  Broad spectrum anti-inflammatory drugs may be more effective, and include inhibitors of PDE4, p38 MAPK and NF-κB, but side effects will be a major limitation so that inhaled delivery will be necessary.  Perhaps the most promising approach is reversal corticosteroid resistance through increasing HDAC2 activity.  This may be achieved by theophylline-like drugs, more effective antioxidants and non-antibiotic macrolides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMyLX0gSpk6rVg90H21EOLACvtfcHk0lhFZsQAFzJXgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVyls74%253D&md5=b17303237111da63aba568a301b132fb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DFrontrunners%2520in%2520novel%2520pharmacotherapy%2520of%2520COPD%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26spage%3D300%26epage%3D307%26doi%3D10.1016%2Fj.coph.2008.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansel, T. T.</span></span> <span> </span><span class="NLM_article-title">Prospects for new drugs for chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)17025-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2804%2917025-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15364192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFSitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=985-996&author=P.+J.+Barnesauthor=T.+T.+Hansel&title=Prospects+for+new+drugs+for+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2804%2917025-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for new drugs for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.; Hansel, Trevor T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">9438</span>),
    <span class="NLM_cas:pages">985-996</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  No currently available treatments have been shown to slow the progression of chronic obstructive pulmonary disease (COPD) or suppress the inflammation in small airways and lung parenchyma.  However, several new treatments are in clin. development; some target the inflammatory process and others are directed against structural cells.  A group of specific therapies are directed against the influx of inflammatory cells into the airways and lung parenchyma that occurs in COPD; these include agents directed against adhesion mols. and chemokines, as well as therapies to oppose tumor necrosis factor α and increase interleukin 10.  Broad-range anti-inflammatory drugs are now in phase III development for COPD; they include inhibitors of phosphodiesterase 4.  Other drugs that inhibit cell signaling include inhibitors of p38 mitogen-activated protein kinase, nuclear factor κB, and phosphoinositide-3-kinase γ.  More specific approaches are to give antioxidants, inhibitors of inducible nitric oxide synthase, and antagonists of leukotriene B4 receptor.  Inhibitors of epidermal-growth-factor-receptor kinase and calcium-activated chloride channels have the potential to prevent overprodn. of mucus.  Therapy to inhibit fibrosis is being developed against transforming growth factor β1 and protease-activated receptor 2.  There is also a search for inhibitors of serine proteinases and matrix metalloproteinases to prevent lung destruction and the development of emphysema, as well as drugs such as retinoids that might even reverse this process.  Effective delivery of drugs to the sites of disease in the peripheral lung is an important consideration, and there is a need for validated biomarkers and monitoring techniques in early clin. studies with new therapies for COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGVjB6gIMp8rVg90H21EOLACvtfcHk0lhFZsQAFzJXgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFSitLg%253D&md5=cbfe89460d92c0cb47f9d10111f95585</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917025-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917025-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DHansel%26aufirst%3DT.%2BT.%26atitle%3DProspects%2520for%2520new%2520drugs%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D985%26epage%3D996%26doi%3D10.1016%2FS0140-6736%2804%2917025-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montuschi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciabattoni, G.</span></span> <span> </span><span class="NLM_article-title">Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4131</span>– <span class="NLM_lpage">4164</span>, <span class="refDoi"> DOI: 10.1021/jm5013227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5013227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4131-4164&author=P.+Montuschiauthor=G.+Ciabattoni&title=Bronchodilating+drugs+for+chronic+obstructive+pulmonary+disease%3A+current+status+and+future+trends&doi=10.1021%2Fjm5013227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends</span></div><div class="casAuthors">Montuschi, Paolo; Ciabattoni, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4131-4164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacol. treatment of stable chronic obstructive pulmonary disease (COPD).  Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h.  New LAMA are under development for COPD.  Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration.  New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development.  LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler.  Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a std. pharmacol. strategy for COPD.  Inhaled dual-pharmacol. compds., combining muscarinic antagonism and β2-agonism (MABA) in a single mol., potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β2-agonist monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLB6Vc0-8tzbVg90H21EOLACvtfcHk0lhFZsQAFzJXgg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVygtA%253D%253D&md5=816e44be469a0396d859cd3576514085</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm5013227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5013227%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DCiabattoni%26aufirst%3DG.%26atitle%3DBronchodilating%2520drugs%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520current%2520status%2520and%2520future%2520trends%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4131%26epage%3D4164%26doi%3D10.1021%2Fjm5013227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L.
E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2006.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.tips.2006.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16911834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Wgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=546-553&author=L.%0AE.+Donnellyauthor=P.+J.+Barnes&title=Chemokine+receptors+as+therapeutic+targets+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.tips.2006.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Donnelly, Louise E.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">546-553</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is an increasing global health problem for which there are no effective disease-modifying therapies.  COPD involves chronic inflammation of small airways and lung parenchyma, with the recruitment of inflammatory cells.  This inflammatory-cell trafficking is orchestrated by multiple chemokines, so the blockade of chemokine receptors with selective antagonists might be an effective anti-inflammatory strategy in this disease.  Several studies support the implication of several chemokines and their receptors in COPD, including chemokine receptors CXCR2 and CXCR3, with small-mol. receptor antagonists that are in development being potential anti-inflammatory therapies.  Such a pharmacol. strategy would provide a mechanism with which to inhibit leukocyte recruitment and, hence, reduce the inflammatory profile in COPD, which is currently unaffected by pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXBb0OZsgMvbVg90H21EOLACvtfcHk0lgfSKsV9Zrc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Wgtr4%253D&md5=5c6ebf9f4cadfd30df7dbe3586fb624a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2006.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2006.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DChemokine%2520receptors%2520as%2520therapeutic%2520targets%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D546%26epage%3D553%26doi%3D10.1016%2Fj.tips.2006.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Mediators of chronic obstructive pulmonary disease</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1124/pr.56.4.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fpr.56.4.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15602009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=515-548&author=P.+J.+Barnes&title=Mediators+of+chronic+obstructive+pulmonary+disease&doi=10.1124%2Fpr.56.4.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mediators of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">515-548</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem that is now a leading cause of death.  COPD is assocd. with a chronic inflammatory response, predominantly in small airways and lung parenchyma, which is characterized by increased nos. of macrophages, neutrophils, and T lymphocytes.  The inflammatory mediators involved in COPD have not been clearly defined, in contrast to asthma, but it is now apparent that many lipid mediators, inflammatory peptides, reactive oxygen and nitrogen species, chemokines, cytokines, and growth factors are involved in orchestrating the complex inflammatory process that results in small airway fibrosis and alveolar destruction.  Many proteases are also involved in the inflammatory process and are responsible for the destruction of elastin fibers in the lung parenchyma, which is the hallmark of emphysema.  The identification of inflammatory mediators and understanding their interactions is important for the development of anti-inflammatory treatments for this important disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpISgwqcjIYtLVg90H21EOLACvtfcHk0lgfSKsV9Zrc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWlt7s%253D&md5=937a8351bde4c91872e956746a7d46e2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fpr.56.4.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.56.4.2%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DMediators%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2004%26volume%3D56%26spage%3D515%26epage%3D548%26doi%3D10.1124%2Fpr.56.4.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, R.
A.</span></span> <span> </span><span class="NLM_article-title">Neutrophils and protease/antiprotease imbalance</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">S49</span>– <span class="NLM_lpage">S52</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.160.supplement_1.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Fajrccm.160.supplement_1.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10556170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FksFSiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1999&pages=S49-S52&author=R.%0AA.+Stockley&title=Neutrophils+and+protease%2Fantiprotease+imbalance&doi=10.1164%2Fajrccm.160.supplement_1.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophils and protease/antiprotease imbalance</span></div><div class="casAuthors">Stockley R A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5 Pt 2</span>),
    <span class="NLM_cas:pages">S49-52</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">An imbalance between neutrophil proteases and the surrounding antiproteases is critical in the normal functioning of the neutrophil.  Enzyme activity is of importance in cell migration and may play a role in some beneficial aspects of host defense.  However, when persistent or excessive this imbalance can be detrimental and (even in the absence of antiprotease deficiency) central to most of the pathogenic processes in COPD.  Understanding of these complex relationships that alter a beneficial host defense response to a destructive one will be critical in the development of long-term therapeutic strategies.  Stockley RA.  Neutrophils and protease/antiprotease imbalance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbByo80RnNtWxpATR2EQURfW6udTcc2eYX94GTlJ944bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FksFSiuw%253D%253D&md5=0ba262d3baca6bcfc298595e7bafddeb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.160.supplement_1.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.160.supplement_1.13%26sid%3Dliteratum%253Aachs%26aulast%3DStockley%26aufirst%3DR.%2BA.%26atitle%3DNeutrophils%2520and%2520protease%252Fantiprotease%2520imbalance%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1999%26volume%3D160%26spage%3DS49%26epage%3DS52%26doi%3D10.1164%2Fajrccm.160.supplement_1.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belvisi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, K. M.</span></span> <span> </span><span class="NLM_article-title">The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1007/s000110300020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs000110300020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12755372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFSru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2003&pages=95-100&author=M.+G.+Belvisiauthor=K.+M.+Bottomley&title=The+role+of+matrix+metalloproteinases+%28MMPs%29+in+the+pathophysiology+of+chronic+obstructive+pulmonary+disease+%28COPD%29%3A+a+therapeutic+role+for+inhibitors+of+MMPs%3F&doi=10.1007%2Fs000110300020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): A therapeutic role for inhibitors of MMPs?</span></div><div class="casAuthors">Belvisi, M. G.; Bottomley, K. M.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">95-100</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is the collective term describing two sep. chronic lung disease diseases: emphysema and chronic bronchitis (1).  Initial clin. symptoms are shortness of breath and occasional cough.  As the disease progresses difficulties in breathing becomes more pronounced, the cough more persistent and becomes assocd. with prodn. of a clear sputum.  In severe cases there are addnl. heart complications.  The major risk factor for COPD is cigarette smoking.  Between 1980 and 1990 there was a 22% increase in the occurrence of the disease with attributed 84,000 deaths in 1990 in the USA.  Current therapies address the symptoms and range from bronchodilators, corticosteroids to oxygen.  While there are no effective cures, although the disease can be prevented and progress slowed in many cases by removing the principal risk factor: cigarette smoking.  Progression of the disease is assocd. with degrdn. of elastin in the walls of the alveoli, resulting in the functional destruction of the these organs.  The net increase in proteolytic activity leading to this loss of alveoli function is a growing focus of pharmaceutical efforts for identification of a therapy for the amelioration of this disease.  Of specific interest for this review has been the potential roles of members of the MMP family in both the destruction of elastin and the aberrant remodeling of damaged alveoli.  An example of such a MMP is Metalloelastase.  Metalloelastase (MMP-12) is (as the name suggests) capable of degrading elastin, as well as other extra-cellular matrix components.  It is produced predominantly by infiltrating macrophages and appears essential for macrophage migration through extra-cellular matrix (2).  Mouse metalloelastase knock-out studies implicate this enzyme as a key mediator in the pathol. assocd. with cigarette smoke induced emphysema (3).  There is also associative evidence from human genetic and animal studies suggesting a pathol. link with other MMPs, such as MMPs 1,2,3,8&9.  The evidence for the role of these MMPs in the pathol. processes assocd. with COPD and prospects for MMP inhibitors as the basis for future therapies will be addressed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRV6cfvmbSIrVg90H21EOLACvtfcHk0lgO4-3yrxaVCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFSru7Y%253D&md5=3fb02f6b319c9c5f3707de0a1a7e7737</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs000110300020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs000110300020%26sid%3Dliteratum%253Aachs%26aulast%3DBelvisi%26aufirst%3DM.%2BG.%26aulast%3DBottomley%26aufirst%3DK.%2BM.%26atitle%3DThe%2520role%2520of%2520matrix%2520metalloproteinases%2520%2528MMPs%2529%2520in%2520the%2520pathophysiology%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%253A%2520a%2520therapeutic%2520role%2520for%2520inhibitors%2520of%2520MMPs%253F%26jtitle%3DInflammation%2520Res.%26date%3D2003%26volume%3D52%26spage%3D95%26epage%3D100%26doi%3D10.1007%2Fs000110300020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodimuthali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabaris, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5471</span>– <span class="NLM_lpage">5489</span>, <span class="refDoi"> DOI: 10.1021/jm800582j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800582j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1alsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5471-5489&author=A.+Kodimuthaliauthor=S.+S.+Jabarisauthor=M.+Pal&title=Recent+advances+on+phosphodiesterase+4+inhibitors+for+the+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm800582j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances on Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Kodimuthali, Arumugam; Jabaris, S. Sugin Lal; Pal, Manojit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5471-5489</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDQPTfmPINKbVg90H21EOLACvtfcHk0lgO4-3yrxaVCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1alsbg%253D&md5=d4502dc5ce4b8b17d5b1d4d853403768</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm800582j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800582j%26sid%3Dliteratum%253Aachs%26aulast%3DKodimuthali%26aufirst%3DA.%26aulast%3DJabaris%26aufirst%3DS.%2BS.%26aulast%3DPal%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520on%2520phosphodiesterase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5471%26epage%3D5489%26doi%3D10.1021%2Fjm800582j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">New anti-inflammatory targets for chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1038/nrd4025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrd4025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23977698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3sbisVyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=543-559&author=P.+J.+Barnes&title=New+anti-inflammatory+targets+for+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnrd4025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">New anti-inflammatory targets for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">543-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is associated with chronic inflammation of the peripheral airways and lung parenchyma, which leads to progressive obstruction of the airways.  Current management with long-acting bronchodilators does not reduce disease progression, and there are no treatments that effectively suppress chronic inflammation in COPD.  An increased understanding of the inflammatory processes that are involved in the pathophysiology of COPD has identified several new therapeutic targets.  This Review discusses some of the most promising of these targets, including new antioxidants, kinase inhibitors and drugs that target cellular senescence, microbial colonization, epigenetic regulation of inflammatory gene expression and corticosteroid resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRombdIqyOV5mHOrQ6qeX-mfW6udTcc2eb7H2eZFvEx3rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbisVyiuw%253D%253D&md5=fa75de40a57b035f9b7351f4ad77beeb</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd4025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4025%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520anti-inflammatory%2520targets%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D543%26epage%3D559%26doi%3D10.1038%2Fnrd4025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polosa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, M. R.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2009.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.tips.2009.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19762093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyqtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=528-535&author=R.+Polosaauthor=M.+R.+Blackburn&title=Adenosine+receptors+as+targets+for+therapeutic+intervention+in+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.tips.2009.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Polosa, Riccardo; Blackburn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">528-535</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Asthma and chronic obstructive pulmonary disease (COPD) are pulmonary disorders characterized by various degrees of inflammation and tissue remodeling.  Adenosine is a signaling mol. that is elevated in the lungs of patients with asthma and COPD.  Adenosine elicits its actions by engaging cell surface adenosine receptors, and substantial preclin. evidence suggests that targeting these receptors will provide novel approaches for the treatment of asthma and COPD.  Studies in animal models of airway disease suggest that there may be clin. benefit to the use of A1, A3 and A2B adenosine receptor antagonists in the treatment of features of asthma and/or COPD, while A2A agonists may also prove effective.  Several adenosine receptor based pharmacol. agents have entered clin. development for the treatment of asthma and COPD; however, the studies have been limited and the efficacy of such approaches is not yet clear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLEk1XfcyAcrVg90H21EOLACvtfcHk0liXhJfnzM_IdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyqtb3N&md5=d26adeb209992cfea4be52a789f4b2b3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DPolosa%26aufirst%3DR.%26aulast%3DBlackburn%26aufirst%3DM.%2BR.%26atitle%3DAdenosine%2520receptors%2520as%2520targets%2520for%2520therapeutic%2520intervention%2520in%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D528%26epage%3D535%26doi%3D10.1016%2Fj.tips.2009.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. V.</span></span> <span> </span><span class="NLM_article-title">Immunomodulatory cell therapy to target cystic fibrosis inflammation</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2017-0160TR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1165%2Frcmb.2017-0160TR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28707978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKit7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=12-20&author=O.+Khouryauthor=C.+Barriosauthor=V.+Ortegaauthor=A.+Atalaauthor=S.+V.+Murphy&title=Immunomodulatory+cell+therapy+to+target+cystic+fibrosis+inflammation&doi=10.1165%2Frcmb.2017-0160TR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory cell therapy to target cystic fibrosis inflammation</span></div><div class="casAuthors">Khoury, Oula; Barrios, Christopher; Ortega, Victor; Atala, Anthony; Murphy, Sean V.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-20</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is assocd. with exaggerated and prolonged inflammation in the lungs, which contributes to lung injury, airway mucus obstruction, bronchiectasis, and loss of lung function.  This hyperinflammatory phenotype appears to be caused by an imbalance between the pro- and antiinflammatory regulatory pathways, with heightened proinflammatory stimuli, a decreased counter-regulatory response, and reduced effectiveness of immune cell function and inflammatory resoln.  Thus, therapies that can target this inflammatory environment would have a major impact on preventing the progression of lung disease.  Because of the complex phenotype of CF inflammation, current antiinflammatory regimens have proven to be inadequate for the targeting of these multiple dysregulated pathways and effects.  Several approaches using cell therapies have shown potential therapeutic benefit for the treatment of CF inflammation.  This review provides an overview of the immune dysfunctions in CF and current therapeutic regimens; explores the field of cell therapy as a treatment for CF inflammation; and focuses on the various cell types used, their immunomodulatory functions, and the current approaches to mitigate the inflammatory response and reduce the long-term damage for patients with CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptSS-d0ulMO7Vg90H21EOLACvtfcHk0liXhJfnzM_IdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKit7rN&md5=0f20254f728a37fba53027e8a51d80c9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2017-0160TR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2017-0160TR%26sid%3Dliteratum%253Aachs%26aulast%3DKhoury%26aufirst%3DO.%26aulast%3DBarrios%26aufirst%3DC.%26aulast%3DOrtega%26aufirst%3DV.%26aulast%3DAtala%26aufirst%3DA.%26aulast%3DMurphy%26aufirst%3DS.%2BV.%26atitle%3DImmunomodulatory%2520cell%2520therapy%2520to%2520target%2520cystic%2520fibrosis%2520inflammation%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2018%26volume%3D58%26spage%3D12%26epage%3D20%26doi%3D10.1165%2Frcmb.2017-0160TR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P.</span></span> <span> </span><span class="NLM_article-title">Tiotropium in early-stage chronic obstructive pulmonary disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1700228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJMoa1700228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28877027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=923-935&author=Y.+Zhouauthor=N.+S.+Zhongauthor=X.+Liauthor=S.+Chenauthor=J.+Zhengauthor=D.+Zhaoauthor=W.+Yaoauthor=R.+Zhiauthor=L.+Weiauthor=B.+Heauthor=X.+Zhangauthor=C.+Yangauthor=Y.+Liauthor=F.+Liauthor=J.+Duauthor=J.+Guiauthor=B.+Huauthor=C.+Baiauthor=P.+Huangauthor=G.+Chenauthor=Y.+Xuauthor=C.+Wangauthor=B.+Liangauthor=Y.+Liauthor=G.+Huauthor=H.+Tanauthor=X.+Yeauthor=X.+Maauthor=Y.+Chenauthor=X.+Huauthor=J.+Tianauthor=X.+Zhuauthor=Z.+Shiauthor=X.+Duauthor=M.+Liauthor=S.+Liuauthor=R.+Yuauthor=J.+Zhaoauthor=Q.+Maauthor=C.+Xieauthor=X.+Liauthor=T.+Chenauthor=Y.+Linauthor=L.+Zengauthor=C.+Yeauthor=W.+Yeauthor=X.+Luoauthor=L.+Zengauthor=S.+Yuauthor=W.+J.+Guanauthor=P.+Ran&title=Tiotropium+in+early-stage+chronic+obstructive+pulmonary+disease&doi=10.1056%2FNEJMoa1700228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium in early-stage chronic obstructive pulmonary disease</span></div><div class="casAuthors">Zhou, Y.; Zhong, N.; Li, Xiaochen; Chen, S.; Zheng, J.; Zhao, D.; Yao, W.; Zhi, R.; Wei, L.; He, B.; Zhang, X.; Yang, C.; Li, Ying; Li, F.; Du, J.; Gui, J.; Hu, B.; Bai, C.; Huang, P.; Chen, G.; Xu, Y.; Wang, C.; Liang, B.; Li, Yinhuan; Hu, G.; Tan, H.; Ye, X.; Ma, X.; Chen, Y.; Hu, X.; Tian, J.; Zhu, X.; Shi, Z.; Du, X.; Li, M.; Liu, S.; Yu, R.; Zhao, J.; Ma, Q.; Xie, C.; Li, Xiongbin; Chen, T.; Lin, Y.; Zeng, Lizhen; Ye, C.; Ye, W.; Luo, X.; Zeng, Lingshan; Yu, S.; Guan, W.; Ran, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">923-935</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Patients with mild or moderate chronic obstructive pulmonary disease (COPD) rarely receive medications, because they have few symptoms.  We hypothesized that long-term use of tiotropium would improve lung function and ameliorate the decline in lung function in patients with mild or moderate COPD.  METHODS In a multicenter, randomized, double-blind, placebo-controlled trial that was conducted in China, we randomly assigned 841 patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 (mild) or 2 (moderate) severity to receive a once-daily inhaled dose (18 μg) of tiotropium (419 patients) or matching placebo (422) for 2 years.  The primary end point was the between-group difference in the change from baseline to 24 mo in the forced expiratory vol. in 1 s (FEV♂) before bronchodilator use.  Secondary end points included the between-group difference in the change from baseline to 24 mo in the FEV♂ after bronchodilator use and the between-group difference in the annual decline in the FEV♂ before and after bronchodilator use from day 30 to month 24.  RESULTS Of 841 patients who underwent randomization, 388 patients in the tiotropium group and 383 in the placebo group were included in the full anal. set.  The FEV♂ in patients who received tiotropium was higher than in those who received placebo throughout the trial (ranges of mean differences, 127 to 169 mL before bronchodilator use and 71 to 133 mL after bronchodilator use; P<0.001 for all comparisons).  There was no significant amelioration of the mean (±SE) annual decline in the FEV♂ before bronchodilator use: the decline was 38±6 mL per yr in the tiotropium group and 53±6 mL per yr in the placebo group (difference, 15 mL per yr; 95% confidence interval [CI], -1 to 31; P = 0.06).  In contrast, the annual decline in the FEV♂ after bronchodilator use was significantly less in the tiotropium group than in the placebo group (29±5 mL per yr vs. 51±6 mL per yr; difference, 22 mL per yr [95% CI, 6 to 37]; P = 0.006).  The incidence of adverse events was generally similar in the two groups.  CONCLUSIONS Tiotropium resulted in a higher FEV♂ than placebo at 24 mo and ameliorated the annual decline in the FEV♂ after bronchodilator use in patients with COPD of GOLD stage 1 or 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9MyyszWE8kLVg90H21EOLACvtfcHk0liXhJfnzM_IdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nN&md5=a402c9da20dddbe47b55f260417b62a0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1700228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1700228%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DN.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DZhi%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DGui%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DBai%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DGuan%26aufirst%3DW.%2BJ.%26aulast%3DRan%26aufirst%3DP.%26atitle%3DTiotropium%2520in%2520early-stage%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D923%26epage%3D935%26doi%3D10.1056%2FNEJMoa1700228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belmonte, K. E.</span></span> <span> </span><span class="NLM_article-title">Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease</span>. <i>Proc. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1513/pats.200504-043SR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1513%2Fpats.200504-043SR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16267352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlams7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=297-304&author=K.+E.+Belmonte&title=Cholinergic+pathways+in+the+lungs+and+anticholinergic+therapy+for+chronic+obstructive+pulmonary+disease&doi=10.1513%2Fpats.200504-043SR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Belmonte, Kristen E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-304</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Abundant data from animal models and humans support the hypothesis that changes at the level of parasympathetic neuronal control of airway smooth muscle result in increased bronchoconstriction in response to vagal stimulation, leading to airway hyper-responsiveness.  Neuronal inhibitory M2 muscarinic acetylcholine receptors on parasympathetic nerves are responsible for limiting acetylcholine release from these nerves.  In humans with asthma, and after pulmonary inflammatory events in exptl. animals, these receptors are dysfunctional, which results in airway hyper-responsiveness.  Although it is unknown what mechanisms underlie airway hyperresponsiveness in chronic obstructive pulmonary disease, loss of parasympathetic control of airway smooth muscle is thought to be a contributing mechanism.  As such, anticholinergic therapy is used extensively and with a high degree of success in the treatment of this condition.  The future for inhaled anticholinergic compds. for the treatment of chronic obstructive pulmonary disease appears to rest in their combination with other agents, such as β2 agonists and phosphodiesterase-4 inhibitors.  Nonselective anticholinergic agents might be the best choice, because M2 muscarinic receptors on airway smooth muscle inhibit the generation and accumulation of cyclic adenosine monophosphate.  Adequate concurrent blockade of M3 muscarinic receptors would be expected to counteract the enhanced acetylcholine release that would result from blockade of neuronal inhibitory M2 muscarinic receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf5AsHs2UOPLVg90H21EOLACvtfcHk0lhwEsvmEjHEpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlams7vO&md5=98f86ecd7332496401526820d4efe9d7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1513%2Fpats.200504-043SR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.200504-043SR%26sid%3Dliteratum%253Aachs%26aulast%3DBelmonte%26aufirst%3DK.%2BE.%26atitle%3DCholinergic%2520pathways%2520in%2520the%2520lungs%2520and%2520anticholinergic%2520therapy%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2005%26volume%3D2%26spage%3D297%26epage%3D304%26doi%3D10.1513%2Fpats.200504-043SR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span> <span> </span><span class="NLM_article-title">The β-adrenoceptor</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">S146</span>– <span class="NLM_lpage">S153</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.158.supplement_2.13tac110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Fajrccm.158.supplement_2.13tac110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=9817738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADyaK1M%252FlsFSksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=1998&pages=S146-S153&author=M.+Johnson&title=The+%CE%B2-adrenoceptor&doi=10.1164%2Fajrccm.158.supplement_2.13tac110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The beta-adrenoceptor</span></div><div class="casAuthors">Johnson M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">5 Pt 3</span>),
    <span class="NLM_cas:pages">S146-53</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The human beta-adrenoceptor is a member of the seven-transmembrane family of receptors, encoded by a gene on chromosome 5. beta-Adrenoceptors have been classified into beta1, beta2, and beta3 subgroups, with beta2-receptors being widely distributed in the respiratory tract, particularly in airway smooth muscle.  Intracellular signaling following beta2-adrenoceptor activation is largely affected through a trimeric Gs protein coupled to adenylate cyclase.  Cyclic AMP (cAMP) induces airway relaxation through phosphorylation of muscle regulatory proteins and attenuation of cellular Ca2+ concentrations.  Alternative cAMP-independent pathways involving activation of membrane maxi-K+ channels and coupling through Gi to the MAP kinase system have also been described.  Site-directed mutagenesis has identified Asp 113 and Ser 204/207 within the third and fourth membrane domains as the active site of the beta2-receptor, critical for beta2-agonist binding and activity. beta2-Agonists have been characterized as those that directly activate the receptor (albuterol), those that are taken up into a membrane depot (formoterol), and those that interact with a receptor-specific auxiliary binding site (salmeterol).  These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in patients with asthma. beta-Adrenoceptor desensitization associated with beta2-agonist activation is a consequence of phosphorylation by beta-ARK and uncoupling of the receptor from Gs following beta-arrestin binding, of internalization and recycling of the receptor through processes of sequestration and resensitization and downregulation, modulated by an effect on receptor gene expression.  The degree of receptor desensitization appears to differ, depending on the cell or tissue type, and is reflected in the different profiles of clinical tolerance to chronic beta2-agonist therapy.  A number of polymorphisms of the beta2-receptor have been described that appear to alter the behavior of the receptor following agonist exposure.  These include Arg-Gly 16, Glu-Gln 27, and Thr-lle 164.  The Gly 16 receptor downregulates to a greater extent and is associated with increased airway hyperreactivity, nocturnal symptoms, and more severe asthma.  The Glu 27 form appears to protect against downregulation and is associated with less reactive airways.  An individual can be homozygous or heterozygous for given polymorphisms, and large populations will have to be studied to determine their importance to the asthma phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7eYHSZZemQ9yzdcP07UmufW6udTcc2ea3D8sw9BsMXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FlsFSksg%253D%253D&md5=b35ba94acecce6e5da1f0373051d5c7f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.158.supplement_2.13tac110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.158.supplement_2.13tac110%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DThe%2520%25CE%25B2-adrenoceptor%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1998%26volume%3D158%26spage%3DS146%26epage%3DS153%26doi%3D10.1164%2Fajrccm.158.supplement_2.13tac110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido-Rios, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasper, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammen, M.</span></span> <span> </span><span class="NLM_article-title">In vitro characterization of TD-4208, a lung-selective and long-acting muscarinic antagonist bronchodilator</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">A4553</span>, <span class="refDoi"> DOI: 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A4553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2009&pages=A4553&author=T.+Steinfeldauthor=M.+T.+Pulido-Riosauthor=K.+Chinauthor=K.+Kingauthor=J.+X.+Huangauthor=T.+W.+Leeauthor=J.+R.+Jasperauthor=Y.+Jiauthor=S.+Hegdeauthor=M.+Mammen&title=In+vitro+characterization+of+TD-4208%2C+a+lung-selective+and+long-acting+muscarinic+antagonist+bronchodilator&doi=10.1164%2Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1164%2Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553%26sid%3Dliteratum%253Aachs%26aulast%3DSteinfeld%26aufirst%3DT.%26aulast%3DPulido-Rios%26aufirst%3DM.%2BT.%26aulast%3DChin%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DJ.%2BX.%26aulast%3DLee%26aufirst%3DT.%2BW.%26aulast%3DJasper%26aufirst%3DJ.%2BR.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DMammen%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520characterization%2520of%2520TD-4208%252C%2520a%2520lung-selective%2520and%2520long-acting%2520muscarinic%2520antagonist%2520bronchodilator%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D179%26spage%3DA4553%26doi%3D10.1164%2Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pudi, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haumann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, E.</span></span> <span> </span><span class="NLM_article-title">A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">182</span>, <span class="refDoi"> DOI: 10.1186/s12931-017-0647-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2Fs12931-017-0647-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29096627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyrsr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=182&author=K.+K.+Pudiauthor=C.+N.+Barnesauthor=E.+J.+Moranauthor=B.+Haumannauthor=E.+Kerwin&title=A+28-day%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel+group+study+of+nebulized+revefenacin+in+patients+with+chronic+obstructive+pulmonary+disease&doi=10.1186%2Fs12931-017-0647-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Pudi, Krishna K.; Barnes, Chris N.; Moran, Edmund J.; Haumann, Brett; Kerwin, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">182/1-182/11</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Revefenacin is a once-daily long-acting muscarinic antagonist (LAMA) in clin. development for the treatment of patients with chronic obstructive pulmonary disease (COPD).  In a dose-ranging study, nebulized oncedaily revefenacin had a long duration of action in patients after 7 days' administration of doses up to 700 μg.  In this multiple-dose study, the bronchodilation efficacy and adverse events profile were characterized in patients administered nebulized revefenacin once daily for 28 days.  Methods: A total of 355 COPD patients (mean age 62 years, mean forced expiratory vol. in 1 s [FEV1] 44% of predicted) were randomized in a double-blind, placebo-controlled parallel group study.  Inhaled corticosteroids as well as short-acting bronchodilators were permitted.  Once-daily treatments (44, 88, 175 or 350 μg revefenacin or matching placebo) were administered by a std. jet nebulizer, for 28 days.  The primary endpoint was change from baseline in D28 trough FEV1, and secondary endpoints included weighted mean FEV1 over 0 to 24 h and rescue medication (albuterol) use.  Safety evaluations included adverse events, lab. assessments, electrocardiograms and 24-h Holter profiles.  Results: Revefenacin (88, 175 and 350 μg) significantly improved D28 trough FEV1 over placebo (187.4, 166.6 and 170.6 mL, resp., all p < 0.001); 44 μg produced a sub-therapeutic response.  At doses ≥88 μg, more than 80% of patients achieved at least a 100-mL increase from baseline FEV1 in the first 4 h post dose compared with 33% of placebo patients.  For doses ≥88 μg, D28 24 h weighted mean differences from placebo for FEV1 were numerically similar to resp. trough FEV1 values, indicating bronchodilation was sustained for 24 h post dose.  Doses ≥88 μg reduced the av. no. of albuterol puffs/day by more than one puff/day.  The 350 μg dose did not demonstrate addnl. efficacy over that obsd. with 175 μg revefenacin.  Revefenacin was generally well tolerated, with minimal reports of systemic anti-cholinergic effects.  Conclusions: These data suggest that 88 and 175 μg revefenacin are appropriate doses for use in longer-term safety and efficacy trials.  Revefenacin offers the potential for the first once-daily LAMA for nebulization in patients with COPD who require or prefer a nebulized drug delivery option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooD2n8krBRPLVg90H21EOLACvtfcHk0li_qTHs1jUKfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyrsr%252FL&md5=3ebf961fdc817888271751b77f125755</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1186%2Fs12931-017-0647-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-017-0647-1%26sid%3Dliteratum%253Aachs%26aulast%3DPudi%26aufirst%3DK.%2BK.%26aulast%3DBarnes%26aufirst%3DC.%2BN.%26aulast%3DMoran%26aufirst%3DE.%2BJ.%26aulast%3DHaumann%26aufirst%3DB.%26aulast%3DKerwin%26aufirst%3DE.%26atitle%3DA%252028-day%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel%2520group%2520study%2520of%2520nebulized%2520revefenacin%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Res.%26date%3D2017%26volume%3D18%26spage%3D182%26doi%3D10.1186%2Fs12931-017-0647-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y. A.</span></span> <span> </span><span class="NLM_article-title">Revefenacin: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1036-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs40265-018-1036-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=30560478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=85-91&author=Y.+A.+Heo&title=Revefenacin%3A+first+global+approval&doi=10.1007%2Fs40265-018-1036-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Revefenacin: First Global Approval</span></div><div class="casAuthors">Heo, Young-A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-91</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Revefenacin (YUPELRI) inhalation soln., a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD).  In Nov. 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD.  This article summarizes the milestones in the development of revefenacin leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreKt8JGiq2GLVg90H21EOLACvtfcHk0lgHw8x6LsXm_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F&md5=09384e244c9d6b3f9b4d39dd87705057</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1036-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1036-x%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.%2BA.%26atitle%3DRevefenacin%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D85%26epage%3D91%26doi%3D10.1007%2Fs40265-018-1036-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q. M.</span></span> <span> </span><span class="NLM_article-title">Characterization of bencycloquidium bromide, a novel muscarinic M3 receptor antagonist in guinea pig airways</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>655</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.ejphar.2011.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21272572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFKisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=655&publication_year=2011&pages=74-82&author=J.+X.+Jiangauthor=R.+Caoauthor=W.+D.+Dengauthor=F.+Jinauthor=X.+W.+Dongauthor=Y.+Zhuauthor=X.+P.+Chenauthor=Y.+C.+Xieauthor=M.+J.+Baoauthor=F.+F.+Liauthor=Q.+M.+Xie&title=Characterization+of+bencycloquidium+bromide%2C+a+novel+muscarinic+M3+receptor+antagonist+in+guinea+pig+airways&doi=10.1016%2Fj.ejphar.2011.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of bencycloquidium bromide, a novel muscarinic M3 receptor antagonist in guinea pig airways</span></div><div class="casAuthors">Jiang, Jun-Xia; Cao, Rui; Deng, Wan-Ding; Jin, Fang; Dong, Xin-Wei; Zhu, Yu; Chen, Xiao-Ping; Xie, Yi-Cheng; Bao, Meng-Jing; Li, Fen-Fen; Xie, Qiang-Min</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">655</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">74-82</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study we have investigated the antagonist affinity, efficacy, and duration of action of bencycloquidium bromide (BCQB), a selective muscarinic M3 receptor antagonist, as a possible clin. bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.  In competition studies, BCQB showed high affinity toward the M3 receptor in Chinese hamster ovary (CHO) cells (M3 pKi = 8.21, M2 pKi = 7.21, and M1 pKi = 7.86); pA2 = 8.85, 8.71, and 8.57 in methacholine-induced contraction of trachea, ileum, and urinary bladder, 8.19 in methacholine-induced bradycardia of right atrium in vitro, resp.  In function studies, duration of inhibition of carbachol-induced tonic contraction, BCQB and ipratropium had a very similar onset and offset of action, but onset faster and offset slower than that of tiotropium.  After treatment with intratracheally instilled or the inhalation route, BCQB protects against methacholine or antigen-induced bronchoconstriction in a dose-dependent manner in the normal and sensitized guinea pigs in vivo.  BCQB and ipratropium-induced inhibitory activity was short lasting, as it declined quickly when compared to tiotropium.  These results suggest that BCQB bind muscarinic M3 receptors with high affinity.  On this basis we speculate that a putative BCQB-based therapy for COPD might require more than once-a-day administration to be as effective as the currently employed once-daily therapy with tiotropium.  Nevertheless, inhalable M3-selective compds. may spare M2-cardiac receptors and reduce the risks of cardiovascular events assocd. with the long-term treatment of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj0aNvoEtwBbVg90H21EOLACvtfcHk0lgHw8x6LsXm_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFKisbo%253D&md5=2a45a4d8cd0eddc8107ee6cd9eacaee3</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%2BX.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DDeng%26aufirst%3DW.%2BD.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%2BP.%26aulast%3DXie%26aufirst%3DY.%2BC.%26aulast%3DBao%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DF.%2BF.%26aulast%3DXie%26aufirst%3DQ.%2BM.%26atitle%3DCharacterization%2520of%2520bencycloquidium%2520bromide%252C%2520a%2520novel%2520muscarinic%2520M3%2520receptor%2520antagonist%2520in%2520guinea%2520pig%2520airways%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D655%26spage%3D74%26epage%3D82%26doi%3D10.1016%2Fj.ejphar.2011.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span> <span> </span><span class="NLM_article-title">Trachea relaxing effects and beta(2)-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1248/bpb.26.323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1248%2Fbpb.26.323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12612441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVajurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=323-328&author=L.+L.+Ganauthor=M.+W.+Wangauthor=M.+Chengauthor=L.+Pan&title=Trachea+relaxing+effects+and+beta%282%29-selectivity+of+SPFF%2C+a+newly+developed+bronchodilating+agent%2C+in+guinea+pigs+and+rabbits&doi=10.1248%2Fbpb.26.323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Trachea relaxing effects and β2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits</span></div><div class="casAuthors">Gan, Le-Ling; Wang, Min-Wei; Cheng, Mao-Sheng; Pan, Li</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">In this paper we evaluated the bronchodilator effects of SPFF [2-(4-amino-3-chloro-5-trifluomethyl-phenyl)- 2-tert-butylamino-ethanol chloride], a newly synthesized β2 adrenergic agonist in guinea pigs and rabbits, in comparison with other β2 adrenergic agonists, isoprenaline or salbutamol.  We studied in vitro the bronchodilator effects of SPFF and isoprenaline on isolated guinea pig trachea strips with or without the precontraction of bronchocontractors (acetylcholine and histamine).  The pos. chronotropic effects of SPFF and isoprenaline on isolated guinea pig left atria were also tested in vitro.  Potency values (pD2, pA2 or ED50) were detd. from the cumulative concn.-response curves.  The results showed that SPFF and isoprenaline dose-dependently relaxed the isolated guinea pig trachea strips and the pD2 values of both drugs were 7.66±0.68 and 8.79±0.19, resp.  Moreover, we confirmed that the bronchodilator effect of SPFF was due to the activation of β2 adrenoceptor because this effect was easily antagonized by ICI-118551 (pA2 8.90±0.01), a specific β2 adrenoceptor antagonist.  SPFF also dose-dependently relaxed the isolated guinea pig trachea strip precontraction with acetylcholine or histamine with ED50 values of 10.2±0.7 μM and 550±38.2 nM, resp.  Furthermore, the pos. chronotropic effect of SPFF on isolated guinea pig left atria (pD2 5.41±0.38) was much weaker than that of isoprenaline (pD2 8.75±0.24), which implied that SPFF was more selective to airway β2 adrenoceptor than isoprenaline; the β1/β2 selectivity assay also showed that SPFF was about 162 times more selective to β2 adrenoceptor than isoprenaline.  A radioligand binding expt. using guinea pig lung and cardiac ventricle as β2 and β1 adrenoceptor sources, resp., also demonstrated that SPFF possesses high affinity (27.3 nM) and selectivity (4.6 fold) to β2 adrenoceptors.  The protective effects of SPFF and salbutamol on bronchospasm induced by bronchoconstrictor aerosol in guinea pigs in vivo were investigated, and the Konzett and Rossler expt. in rabbits in vivo was also carried out.  SPFF significantly prolonged the latency time of histamine and acetylcholine induced asphyxiation collapse in guinea pigs: the ED50 value of SPFF i.g. was 0.32±0.05 mg·kg-1 in this expt.  Meanwhile, the ED50 values of salbutamol was 2.37±0.22, which meant that the bronchorelaxation effect of salbutamol was about 6 times less potent than that of SPFF.  The Konzett and Rossler expt. performed in anesthetized rabbit showed that intraduodenal administration of SPFF exerted action of longer duration than salbutamol.  From the results above we suggested that SPFF was a potent, long-acting bronchodilator with relatively higher β2 adrenoceptor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgmv60MqHPLVg90H21EOLACvtfcHk0lgHw8x6LsXm_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVajurY%253D&md5=87227d7e445c13d7b74f1adf69cfaee9</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1248%2Fbpb.26.323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.26.323%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DM.%2BW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DPan%26aufirst%3DL.%26atitle%3DTrachea%2520relaxing%2520effects%2520and%2520beta%25282%2529-selectivity%2520of%2520SPFF%252C%2520a%2520newly%2520developed%2520bronchodilating%2520agent%252C%2520in%2520guinea%2520pigs%2520and%2520rabbits%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2003%26volume%3D26%26spage%3D323%26epage%3D328%26doi%3D10.1248%2Fbpb.26.323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span> </span><span class="NLM_article-title">Pharmacokinetics
study of trantinterol hydrochloride tablets in the
elderly volunteers after a single dose administration</span>.  <i>Chinese Clinical Trials Registry</i>; <span class="NLM_publisher-name">Chictr.org</span>, <span class="NLM_year">2016</span>; <a href="http://www.chictr.org.cn/showprojen.aspx?proj=4773" class="extLink">http://www.chictr.org.cn/showprojen.aspx?proj=4773</a> (accessed Dec 9, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pharmacokinetics%0Astudy+of+trantinterol+hydrochloride+tablets+in+the%0Aelderly+volunteers+after+a+single+dose+administration.+Chinese+Clinical+Trials+Registry%3B+Chictr.org%2C+2016%3B+http%3A%2F%2Fwww.chictr.org.cn%2Fshowprojen.aspx%3Fproj%3D4773+%28accessed+Dec+9%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPharmacokinetics%250Astudy%2520of%2520trantinterol%2520hydrochloride%2520tablets%2520in%2520the%250Aelderly%2520volunteers%2520after%2520a%2520single%2520dose%2520administration%26jtitle%3DChinese%2520Clinical%2520Trials%2520Registry%26pub%3DChictr.org%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A.
D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasper, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido-Rios, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammen, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β<sub>2</sub> agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2609</span>– <span class="NLM_lpage">2622</span>, <span class="refDoi"> DOI: 10.1021/jm501915g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501915g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12lsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2609-2622&author=A.%0AD.+Hughesauthor=Y.+Chenauthor=S.+S.+Hegdeauthor=J.+R.+Jasperauthor=S.+Jaw-Tsaiauthor=T.+W.+Leeauthor=A.+McNamaraauthor=M.+T.+Pulido-Riosauthor=T.+Steinfeldauthor=M.+Mammen&title=Discovery+of+%28R%29-1-%283-%28%282-chloro-4-%28%28%282-hydroxy-2-%288-hydroxy-2-oxo-1%2C2-dihydroquinolin-5-yl%29ethyl%29amino%29methyl%29-5-methoxyphenyl%29amino%29-3-oxopropyl%29piperidin-4-yl+%5B1%2C1%E2%80%B2-biphenyl%5D-2-ylcarbamate+%28TD-5959%2C+GSK961081%2C+batefenterol%29%3A+first-in-class+dual+pharmacology+multivalent+muscarinic+antagonist+and+%CE%B22+agonist+%28MABA%29+for+the+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&doi=10.1021%2Fjm501915g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β2 Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)</span></div><div class="casAuthors">Hughes, Adam D.; Chen, Yan; Hegde, Sharath S.; Jasper, Jeffrey R.; Jaw-Tsai, Sarah; Lee, Tae-Weon; McNamara, Alexander; Pulido-Rios, M. Teresa; Steinfeld, Tod; Mammen, Mathai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2609-2622</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through application of the multivalent approach to drug discovery the authors previously reported the first discovery of dual pharmacol. MABA bronchodilators.  Herein the authors describe the subsequent lead optimization of both muscarinic antagonist and β2 agonist activities, through modification of the linker motif, to achieve 24 h duration of action in a guinea pig bronchoprotection model.  Concomitantly the authors targeted high lung selectivities, low systemic exposures and identified cryst. forms suitable for inhalation devices.  This article culminates with the discovery of the first clin. candidate I (TD-5959, GSK961081, batefenterol).  In a phase 2b trial, batefenterol produced statistical and clin. significant differences compared to placebo and numerically greater improvements in the primary end point of trough FEV1 compared to salmeterol after 4 wk of dosing in patients with moderate to severe chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-S4hJ7DcVbVg90H21EOLACvtfcHk0liRv24x910rlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12lsLg%253D&md5=f6f73dff89172f8b60890ba4c2b207fe</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm501915g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501915g%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DA.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHegde%26aufirst%3DS.%2BS.%26aulast%3DJasper%26aufirst%3DJ.%2BR.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DT.%2BW.%26aulast%3DMcNamara%26aufirst%3DA.%26aulast%3DPulido-Rios%26aufirst%3DM.%2BT.%26aulast%3DSteinfeld%26aufirst%3DT.%26aulast%3DMammen%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%2528%25282-chloro-4-%2528%2528%25282-hydroxy-2-%25288-hydroxy-2-oxo-1%252C2-dihydroquinolin-5-yl%2529ethyl%2529amino%2529methyl%2529-5-methoxyphenyl%2529amino%2529-3-oxopropyl%2529piperidin-4-yl%2520%255B1%252C1%25E2%2580%25B2-biphenyl%255D-2-ylcarbamate%2520%2528TD-5959%252C%2520GSK961081%252C%2520batefenterol%2529%253A%2520first-in-class%2520dual%2520pharmacology%2520multivalent%2520muscarinic%2520antagonist%2520and%2520%25CE%25B22%2520agonist%2520%2528MABA%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2609%26epage%3D2622%26doi%3D10.1021%2Fjm501915g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span> </span><span class="NLM_article-title">AZD8871 delivered
significant bronchodilation in two-week study</span>.  <i>Chest Physician</i>; <span class="NLM_publisher-name">Frontline Medical
Communications Inc</span>, <span class="NLM_year">2018</span>; <a href="https://www.mdedge.com/chestphysician/article/167156/copd/azd8871-delivered-significant-bronchodilation-two-week-study" class="extLink">https://www.mdedge.com/chestphysician/article/167156/copd/azd8871-delivered-significant-bronchodilation-two-week-study</a> (accessed Jun 3, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AZD8871+delivered%0Asignificant+bronchodilation+in+two-week+study.+Chest+Physician%3B+Frontline+Medical%0ACommunications+Inc%2C+2018%3B+https%3A%2F%2Fwww.mdedge.com%2Fchestphysician%2Farticle%2F167156%2Fcopd%2Fazd8871-delivered-significant-bronchodilation-two-week-study+%28accessed+Jun+3%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAZD8871%2520delivered%250Asignificant%2520bronchodilation%2520in%2520two-week%2520study%26jtitle%3DChest%2520Physician%26pub%3DFrontline%2520Medical%250ACommunications%2520Inc%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aparici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist/β<sub>2</sub>-adrenoceptor agonist (MABA) molecule</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2017.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28729041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOrsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=1-10&author=M.+Apariciauthor=C.+Carcasonaauthor=I.+Ramosauthor=J.+L.+Monteroauthor=J.+L.+Ortizauthor=J.+Cortijoauthor=C.+Puigauthor=D.+Vilellaauthor=C.+Doeauthor=A.+Gavald%C3%A0author=M.+Miralpeix&title=Pharmacological+preclinical+characterization+of+LAS190792%2C+a+novel+inhaled+bifunctional+muscarinic+receptor+antagonist%2F%CE%B22-adrenoceptor+agonist+%28MABA%29+molecule&doi=10.1016%2Fj.pupt.2017.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) molecule</span></div><div class="casAuthors">Aparici, Monica; Carcasona, Carla; Ramos, Israel; Montero, Jose Luis; Ortiz, Jose Luis; Cortijo, Julio; Puig, Carlos; Vilella, Dolors; Doe, Chris; Gavalda, Amadeu; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">LAS190792 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic respiratory diseases.  This study investigated the pharmacol. profile of LAS190792 in comparison to batefenterol, tiotropium, indacaterol and olodaterol.  LAS190792 is potent at the human M3 receptor (pIC50: 8.8 in binding assays).  It is selective for the β2-adrenoceptor over the β1-and β3-adrenoceptor, and shows a functional potency in a similar range to batefenterol and LABA compds. (pEC50 in spontaneous tone isolated trachea: 9.6).  The relaxant potency of LAS190792 in elec. stimulated tissue is similar to batefenterol, with an antimuscarinic activity in presence of propranolol slightly higher than batefenterol (pIC50 of 8.3 vs. 7.9 in human tissue).  LAS190792 exhibits a sustained duration of action in isolated tissue longer than that of batefenterol.  Nebulized LAS190792 inhibits acetylcholine-induced bronchoconstriction in dog with minimal cardiac effects and sustained bronchodilation (t1/2: 13.3 h).  In conclusion, these studies suggest that LAS190792 is a dual-acting muscarinic antagonist β2-adrenoceptor agonist that has the potential to be a next generation bronchodilator with long-lasting effects and wide safety margin in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4xsgKu0EdJ7Vg90H21EOLACvtfcHk0liRv24x910rlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOrsbrJ&md5=c4199d8a8fccd880ff64bb6a07bd8a1d</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%26aulast%3DOrtiz%26aufirst%3DJ.%2BL.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DPharmacological%2520preclinical%2520characterization%2520of%2520LAS190792%252C%2520a%2520novel%2520inhaled%2520bifunctional%2520muscarinic%2520receptor%2520antagonist%252F%25CE%25B22-adrenoceptor%2520agonist%2520%2528MABA%2529%2520molecule%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.pupt.2017.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annunziato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnani, S.</span></span> <span> </span><span class="NLM_article-title">The 3 major types of innate and adaptive cell-mediated effector immunity</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2014.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.jaci.2014.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25528359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVSlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=626-635&author=F.+Annunziatoauthor=C.+Romagnaniauthor=S.+Romagnani&title=The+3+major+types+of+innate+and+adaptive+cell-mediated+effector+immunity&doi=10.1016%2Fj.jaci.2014.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The 3 major types of innate and adaptive cell-mediated effector immunity</span></div><div class="casAuthors">Annunziato, Francesco; Romagnani, Chiara; Romagnani, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">626-635</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The immune system has tailored its effector functions to optimally respond to distinct species of microbes.  Based on emerging knowledge on the different effector T-cell and innate lymphoid cell (ILC) lineages, it is clear that the innate and adaptive immune systems converge into 3 major kinds of cell-mediated effector immunity, which we propose to categorize as type 1, type 2, and type 3.  Type 1 immunity consists of T-bet+ IFN-γ-producing group 1 ILCs (ILC1 and natural killer cells), CD8+ cytotoxic T cells (TC1), and CD4+ TH1 cells, which protect against intracellular microbes through activation of mononuclear phagocytes.  Type 2 immunity consists of GATA-3+ ILC2s, TC2 cells, and TH2 cells producing IL-4, IL-5, and IL-13, which induce mast cell, basophil, and eosinophil activation, as well as IgE antibody prodn., thus protecting against helminthes and venoms.  Type 3 immunity is mediated by retinoic acid-related orphan receptor γt+ ILC3s, TC17 cells, and TH17 cells producing IL-17, IL-22, or both, which activate mononuclear phagocytes but also recruit neutrophils and induce epithelial antimicrobial responses, thus protecting against extracellular bacteria and fungi.  On the other hand, type 1 and 3 immunity mediate autoimmune diseases, whereas type 2 responses can cause allergic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobOlI4X4Np67Vg90H21EOLACvtfcHk0lhMnMOsNFvltQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVSlsr8%253D&md5=16371c1d39a427d5ea96f9237e7b4d5a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2014.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2014.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DAnnunziato%26aufirst%3DF.%26aulast%3DRomagnani%26aufirst%3DC.%26aulast%3DRomagnani%26aufirst%3DS.%26atitle%3DThe%25203%2520major%2520types%2520of%2520innate%2520and%2520adaptive%2520cell-mediated%2520effector%2520immunity%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D135%26spage%3D626%26epage%3D635%26doi%3D10.1016%2Fj.jaci.2014.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Targeting cytokines to treat asthma and chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1038/s41577-018-0006-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fs41577-018-0006-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29626211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWqs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=454-466&author=P.+J.+Barnes&title=Targeting+cytokines+to+treat+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fs41577-018-0006-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cytokines to treat asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">454-466</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cytokines play a key role in orchestrating and perpetuating the chronic airway inflammation in asthma and chronic obstructive pulmonary disease (COPD), making them attractive targets for treating these disorders.  Asthma and some cases of COPD are mainly driven by type 2 immune responses, which comprise increased airway eosinophils, T helper 2 (TH2) cells and group 2 innate lymphoid cells (ILC2s) and the secretion of IL-4, IL-5 and IL-13.  Clin. trials of antibodies that block these interleukins have shown reduced acute exacerbations and oral corticosteroid use and improvements in lung function and symptoms in selected patients.  More recent approaches that block upstream cytokines, such as thymic stromal lymphopoietin (TSLP), show promise in improving patient outcome.  Importantly, the clin. trials in cytokine blockade have highlighted the crucial importance of patient selection for the successful use of these expensive therapies and the need for biomarkers to better predict drug responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCkQgpQoVN0LVg90H21EOLACvtfcHk0lhMnMOsNFvltQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWqs7jO&md5=6110ff640aee238d10b3096957fbd866</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fs41577-018-0006-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41577-018-0006-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DTargeting%2520cytokines%2520to%2520treat%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D454%26epage%3D466%26doi%3D10.1038%2Fs41577-018-0006-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeh, J.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">38S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=38S&author=H.+Magnussenauthor=O.+Holzauthor=H.+Watzauthor=M.+Sauerauthor=I.+Khanskayaauthor=L.+Gannauthor=P.+Stryszakauthor=J.+Sadeh&title=Safety+and+efficacy+of+SCH527123%2C+a+novel+CXCR2+antagonist%2C+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DHolz%26aufirst%3DO.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DSauer%26aufirst%3DM.%26aulast%3DKhanskaya%26aufirst%3DI.%26aulast%3DGann%26aufirst%3DL.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DSadeh%26aufirst%3DJ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520SCH527123%252C%2520a%2520novel%2520CXCR2%2520antagonist%252C%2520in%2520patients%2520with%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D36%26spage%3D38S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexis, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span> <span> </span><span class="NLM_article-title">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2011.03968.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1365-2125.2011.03968.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21426372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=282-293&author=A.%0AL.+Lazaarauthor=L.+E.+Sweeneyauthor=A.+J.+MacDonaldauthor=N.+E.+Alexisauthor=C.+Chenauthor=R.+Tal-Singer&title=SB-656933%2C+a+novel+CXCR2+selective+antagonist%2C+inhibits+ex+vivo+neutrophil+activation+and+ozone-induced+airway+inflammation+in+humans&doi=10.1111%2Fj.1365-2125.2011.03968.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span></div><div class="casAuthors">Lazaar, Aili L.; Sweeney, Lisa E.; MacDonald, Alexander J.; Alexis, Neil E.; Chen, Chao; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS To det. the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects.  METHODS Flow cytometric detn. of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg).  A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers.  RESULTS Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg.  Maximum inhibition (70%) relative to placebo was obsd. following administration of SB-656933 400 mg (95% CI 60%, 77%).  This was sustained up to a dose of 1100 mg.  Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner.  Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, resp.  There was a corresponding redn. in myeloperoxidase concns. in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3).  SB-656933 was safe and well-tolerated at all doses.  CONCLUSIONS SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.  These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj4fRS8HijE7Vg90H21EOLACvtfcHk0lhMnMOsNFvltQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO&md5=cd2f3253ca0b12435a59634ecb63ceea</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03968.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03968.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DSweeney%26aufirst%3DL.%2BE.%26aulast%3DMacDonald%26aufirst%3DA.%2BJ.%26aulast%3DAlexis%26aufirst%3DN.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DSB-656933%252C%2520a%2520novel%2520CXCR2%2520selective%2520antagonist%252C%2520inhibits%2520ex%2520vivo%2520neutrophil%2520activation%2520and%2520ozone-induced%2520airway%2520inflammation%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D282%26epage%3D293%26doi%3D10.1111%2Fj.1365-2125.2011.03968.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsberger, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilian, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonchuk, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span> <span> </span><span class="NLM_article-title">Danirixin: A reversible and selective antagonist of the CXC chemokine receptor 2</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.240705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.117.240705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28611093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CmtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=338-346&author=J.+Busch-Petersenauthor=D.+C.+Carpenterauthor=M.+Burmanauthor=J.+Foleyauthor=G.+E.+Hunsbergerauthor=D.+J.+Kilianauthor=M.+Salmonauthor=R.+J.+Mayerauthor=J.+G.+Yonchukauthor=R.+Tal-Singer&title=Danirixin%3A+A+reversible+and+selective+antagonist+of+the+CXC+chemokine+receptor+2&doi=10.1124%2Fjpet.117.240705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Danirixin: a reversible and selective antagonist of the CXC chemokine receptor 2</span></div><div class="casAuthors">Busch-Petersen, Jakob; Carpenter, Donald C.; Burman, Miriam; Foley, James; Hunsberger, Gerald E.; Kilian, David J.; Salmon, Michael; Mayer, Ruth J.; Yonchuk, John G.; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">338-346</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CXC chemokine receptor 2 (CXCR2) is a key receptor in the chemotaxis of neutrophils to sites of inflammation.  The studies reported here describe the pharmacol. characterization of danirixin, a CXCR2 antagonist in the diaryl urea chem. class.  Danirixin has high affinity for CXCR2, with a neg. log of the 50% inhibitory concn. (pIC50) of 7.9 for binding to Chinese hamster ovary cell (CHO)-expressed human CXCR2, and 78-fold selectivity over binding to CHO-expressed CXCR1.  Danirixin is a competitive antagonist against CXCL8 in Ca2+-mobilization assays, with a KB (the concn. of antagonist that binds 50% of the receptor population) of 6.5 nM and antagonist potency (pA2) of 8.44, and is fully reversible in washout expts. over 180 min.  In rat and human whole-blood studies assessing neutrophil activation by surface CD11b expression following CXCL2 (rat) or CXCL1 (human) challenge, danirixin blocks the CD11b upregulation with pIC50s of 6.05 and 6.3, resp.  Danirixin dosed orally also blocked the influx of neutrophils into the lung in vivo in rats following aerosol lipopolysaccharide or ozone challenge, with median EDs (ED50s) of 1.4 and 16 mg/kg resp.  Thus, danirixin would be expected to block chemotaxis in disease states in which neutrophils are increased in response to inflammation, such as pulmonary diseases.  In comparison with navarixin, a CXCR2 antagonist from a different chem. class, the binding characterization of danirixin is distinct.  These observations may offer insight into the previously obsd. clin. differences in induction of neutropenia between these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVM2WbEvWO5LVg90H21EOLACvtfcHk0lg6LgeFBqesvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CmtbbK&md5=c4795989e2556f36d03aa9dd2f2307d2</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.240705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.240705%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DCarpenter%26aufirst%3DD.%2BC.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DJ.%26aulast%3DHunsberger%26aufirst%3DG.%2BE.%26aulast%3DKilian%26aufirst%3DD.%2BJ.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DR.%2BJ.%26aulast%3DYonchuk%26aufirst%3DJ.%2BG.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DDanirixin%253A%2520A%2520reversible%2520and%2520selective%2520antagonist%2520of%2520the%2520CXC%2520chemokine%2520receptor%25202%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D338%26epage%3D346%26doi%3D10.1124%2Fjpet.117.240705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leaker, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">137</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-14-137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2F1465-9921-14-137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24341382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVOks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=137&author=B.+R.+Leakerauthor=P.+J.+Barnesauthor=B.+O%E2%80%99Connor&title=Inhibition+of+LPS-induced+airway+neutrophilic+inflammation+in+healthy+volunteers+with+an+oral+CXCR2+antagonist&doi=10.1186%2F1465-9921-14-137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist</span></div><div class="casAuthors">Leaker, Brian R.; Barnes, Peter J.; O'Connor, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137/1-137/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Inhaled lipopolysaccharide (LPS) induces a dose-dependent, acute neutrophilic response in the airways of healthy volunteers that can be quantified in induced sputum.  Chemokines, such as CXCL1 and CXCL8, play an important role in neutrophilic inflammation in the lung through the activation of CXCR2 and small mol. antagonists of these receptors have now been developed.  We investigated the effect of AZD8309, a CXCR2 antagonist, compared with placebo on LPS-induced inflammation measured in sputum of healthy volunteers.  Methods: Twenty healthy subjects were randomized in a double-blind placebo-controlled, cross-over study.  AZD8309 (300 mg) or placebo was dosed twice daily orally for 3 days prior to challenge with inhaled LPS and induced sputum was collected 6 h later.  Results: Treatment with AZD8309 showed a mean 77% redn. in total sputum cells (p<0.001) and 79% redn. in sputum neutrophils (p<0.05) compared with placebo after LPS challenge.  There was also a redn. in neutrophil elastase activity (p<0.05) and CXCL1 (p<0.05) and trends for redns. in sputum macrophages (47%), leukotriene B4 (39%) and CXCL8 (52%).  Conclusions: AZD8309 inhibited LPS-induced inflammation measured in induced sputum of normal volunteers, indicating that this treatment may be useful in the treatment of neutrophilic diseases of the airways, such as COPD, severe asthma and cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFlOITn_IsH7Vg90H21EOLACvtfcHk0lg6LgeFBqesvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVOks78%253D&md5=d6e7617d2b9abb891b9c5b6e13a2d4c4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-14-137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-14-137%26sid%3Dliteratum%253Aachs%26aulast%3DLeaker%26aufirst%3DB.%2BR.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520LPS-induced%2520airway%2520neutrophilic%2520inflammation%2520in%2520healthy%2520volunteers%2520with%2520an%2520oral%2520CXCR2%2520antagonist%26jtitle%3DRespir.%2520Res.%26date%3D2013%26volume%3D14%26spage%3D137%26doi%3D10.1186%2F1465-9921-14-137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntosh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardh, C. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.221358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.114.221358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25736418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=340-350&author=D.+J.+Nichollsauthor=K.+Wileyauthor=I.+Daintyauthor=F.+MacIntoshauthor=C.+Phillipsauthor=A.+Gawauthor=C.+K.+Mardh&title=Pharmacological+characterization+of+AZD5069%2C+a+slowly+reversible+CXC+chemokine+receptor+2+antagonist&doi=10.1124%2Fjpet.114.221358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</span></div><div class="casAuthors">Nicholls, David J.; Wiley, Katherine; Dainty, Ian; MacIntosh, Fraser; Phillips, Caroline; Gaw, Alasdair; Mardh, Carina Karrman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">340-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In normal physiol. responses to injury and infection, inflammatory cells enter tissue and sites of inflammation through a chemotactic process regulated by several families of proteins, including inflammatory chemokines, a family of small inducible cytokines.  In neutrophils, chemokines chemokine (CXC motif) ligand 1 (CXCL1) and CXCL8 are potent chemoattractants and activate G protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXCR2.  Several small-mol. antagonists of CXCR2 have been developed to inhibit the inflammatory responses mediated by this receptor.  Here, we present the data describing the pharmacol. of AZD5069 [N-(2-(2,3-difluorobenzylthio)-6-((2R,3S)-3,4-dihydroxybutan-2-yloxy)[2,4,5,6-13C4, 1,3-15N-2]pyrimidin-4-yl)azetidine-1-sulfonamide,[15N2,13C4]N-(2-(2,3-difluoro-6-[3H]-benzylthio)-6-((2R,3S)-3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide], a novel antagonist of CXCR2.  AZD5069 was shown to inhibit binding of radio-labeled CXCL8 to human CXCR2 with a pIC50 value of 9.1.  Furthermore, AZD5069 inhibited neutrophil chemotaxis, with a pA2 of approx. 9.6, and adhesion mol. expression, with a pA2 of 6.9, in response to CXCL1.  AZD5069 was a slowly reversible antagonist of CXCR2 with effects of time and temp. evident on the pharmacol. and binding kinetics.  With short incubation times, AZD5069 appeared to have an antagonist profile with insurmountable antagonism of calcium response curves.  This behavior was also obsd. in vivo in an acute lipopolysaccharide-induced lung inflammation model.  Altogether, the data presented here show that AZD5069 represents a novel, potent, and selective CXCR2 antagonist with potential as a therapeutic agent in inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj1gxnHr4vbbVg90H21EOLACvtfcHk0lg6LgeFBqesvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWnu7g%253D&md5=1ffebbdc9c02dbd015d985062ac820f2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.221358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.221358%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DWiley%26aufirst%3DK.%26aulast%3DDainty%26aufirst%3DI.%26aulast%3DMacIntosh%26aufirst%3DF.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DGaw%26aufirst%3DA.%26aulast%3DMardh%26aufirst%3DC.%2BK.%26atitle%3DPharmacological%2520characterization%2520of%2520AZD5069%252C%2520a%2520slowly%2520reversible%2520CXC%2520chemokine%2520receptor%25202%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D340%26epage%3D350%26doi%3D10.1124%2Fjpet.114.221358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, F.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 1-cyclopentenyl-3-phenylureas as selective, brain penetrant, and orally bioavailable CXCR2 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2518</span>– <span class="NLM_lpage">2532</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01854</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01854" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2mtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2518-2532&author=H.+Luauthor=T.+Yangauthor=Z.+Xuauthor=X.+Linauthor=Q.+Dingauthor=Y.+Zhangauthor=X.+Caiauthor=K.+Dongauthor=S.+Gongauthor=W.+Zhangauthor=M.+Patelauthor=R.+C.+B.+Copleyauthor=J.+Xiangauthor=X.+Guanauthor=P.+Wrenauthor=F.+Ren&title=Discovery+of+novel+1-cyclopentenyl-3-phenylureas+as+selective%2C+brain+penetrant%2C+and+orally+bioavailable+CXCR2+antagonists&doi=10.1021%2Facs.jmedchem.7b01854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists</span></div><div class="casAuthors">Lu, Hongfu; Yang, Ting; Xu, Zhongmiao; Lin, Xichen; Ding, Qian; Zhang, Yueting; Cai, Xin; Dong, Kelly; Gong, Sophie; Zhang, Wei; Patel, Metul; Copley, Royston C. B.; Xiang, Jianing; Guan, Xiaoming; Wren, Paul; Ren, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2518-2532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurol. abnormalities in the central nervous system (CNS).  Herein, we describe the discovery of a novel 1-cyclopentenyl-3-phenylurea series as potent and CNS penetrant CXCR2 antagonists.  Extensive SAR studies, wherein mols.' property forecast index (PFI) was carefully optimized for overall balanced developability profiles, led to the discovery of the advanced lead compd. I with a desirable PFI.  Compd. I demonstrated good in vitro pharmacol. with excellent selectivity over CXCR1 and other chemokine receptors.  Rat and dog pharmacokinetics (PK) revealed good oral bioavailability, high oral exposure, and desirable elimination half-life of the compd. in both species.  In addn., the compd. demonstrated dose-dependent efficacy in the in vivo pharmacol. neutrophil infiltration "air pouch" model in rodents after oral administration.  Further, compd. I is a CNS penetrant mol. with high unbound fraction in brain tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoQpdzgs6WLVg90H21EOLACvtfcHk0ljAsLI2b0mzSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2mtLY%253D&md5=883ab4646ae2318790c4b036b601930d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01854%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DK.%26aulast%3DGong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DXiang%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DWren%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520novel%25201-cyclopentenyl-3-phenylureas%2520as%2520selective%252C%2520brain%2520penetrant%252C%2520and%2520orally%2520bioavailable%2520CXCR2%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2518%26epage%3D2532%26doi%3D10.1021%2Facs.jmedchem.7b01854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirpotina, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicomb, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebala, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-[5-(4-Fluorophenylcarbamoyl) pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517): noncompetitive boronic acid antagonist of CXCR1 and CXCR2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8378</span>– <span class="NLM_lpage">8397</span>, <span class="refDoi"> DOI: 10.1021/jm500827t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500827t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wksr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8378-8397&author=D.+Y.+Maedaauthor=A.+M.+Peckauthor=A.+D.+Schulerauthor=M.+T.+Quinnauthor=L.+N.+Kirpotinaauthor=W.+N.+Wicombauthor=G.+H.+Fanauthor=J.+A.+Zebala&title=Discovery+of+2-%5B5-%284-Fluorophenylcarbamoyl%29+pyridin-2-ylsulfanylmethyl%5Dphenylboronic+acid+%28SX-517%29%3A+noncompetitive+boronic+acid+antagonist+of+CXCR1+and+CXCR2&doi=10.1021%2Fjm500827t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2</span></div><div class="casAuthors">Maeda, Dean Y.; Peck, Angela M.; Schuler, Aaron D.; Quinn, Mark T.; Kirpotina, Liliya N.; Wicomb, Winston N.; Fan, Guo-Huang; Zebala, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8378-8397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis.  In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2).  Structure-activity studies that examd. the effect of a novel series of S-substituted 6-mercapto-N-phenyl-nicotinamides on CXCL1-stimulated Ca2+ flux in whole human PMNs led to the discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517), a potent noncompetitive boronic acid CXCR1/2 antagonist.  SX-517 inhibited CXCL1-induced Ca2+ flux (IC50 = 38 nM) in human PMNs but had no effect on the Ca2+ flux induced by C5a, fMLF, or PAF.  In recombinant HEK293 cells that stably expressed CXCR2, SX-517 antagonized CXCL8-induced [35S]GTPγS binding (IC50 = 60 nM) and ERK1/2 phosphorylation.  Inhibition was noncompetitive, with SX-517 unable to compete the binding of [125I]-CXCL8 to CXCR2 membranes.  SX-517 (0.2 mg/kg iv) significantly inhibited inflammation in an in vivo murine model.  SX-517 is the first reported boronic acid chemokine antagonist and represents a novel pharmacophore for CXCR1/2 antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoojKLcTCrPlbVg90H21EOLACvtfcHk0ljAsLI2b0mzSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wksr%252FE&md5=7808e8ab0cec509d7e6a6cabe1b52907</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm500827t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500827t%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DPeck%26aufirst%3DA.%2BM.%26aulast%3DSchuler%26aufirst%3DA.%2BD.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26aulast%3DKirpotina%26aufirst%3DL.%2BN.%26aulast%3DWicomb%26aufirst%3DW.%2BN.%26aulast%3DFan%26aufirst%3DG.%2BH.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25202-%255B5-%25284-Fluorophenylcarbamoyl%2529%2520pyridin-2-ylsulfanylmethyl%255Dphenylboronic%2520acid%2520%2528SX-517%2529%253A%2520noncompetitive%2520boronic%2520acid%2520antagonist%2520of%2520CXCR1%2520and%2520CXCR2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8378%26epage%3D8397%26doi%3D10.1021%2Fjm500827t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerstjens, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjermer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlström, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span> <span> </span><span class="NLM_article-title">Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">1297</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2010.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.rmed.2010.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20466530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3cjjtlygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=1297-1303&author=H.+A.+Kerstjensauthor=L.+Bjermerauthor=L.+Erikssonauthor=K.+Dahlstr%C3%B6mauthor=J.+Vestbo&title=Tolerability+and+efficacy+of+inhaled+AZD4818%2C+a+CCR1+antagonist%2C+in+moderate+to+severe+COPD+patients&doi=10.1016%2Fj.rmed.2010.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients</span></div><div class="casAuthors">Kerstjens Huib A; Bjermer Leif; Eriksson Leif; Dahlstrom Kerstin; Vestbo Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1297-303</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study evaluated the tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in patients with COPD.  METHODS:  This double-blind, placebo-controlled study (NCT00629239) randomised patients with moderate to severe COPD to AZD4818 300mug or placebo twice daily via Turbuhaler((R)) for 4 weeks.  Safety, lung function, functional capacity and health status measures were measured.  Plasma concentrations of AZD4818 were measured after the first dose and after 2 and 4 weeks' treatment.  RESULTS:  Sixty-five patients (47 male; median age 65.6 years) received AZD4818 (n=33) or placebo (n=32).  There was no statistically significant difference between AZD4818 and placebo in change from baseline to endpoint for FEV(1) (AZD4818-placebo: 0.026L, p=0.69), morning PEF (-6L/min, p=0.23), or other lung function measures.  There was no difference between treatment groups in the 6-min walk test, MMRC dyspnoea index, BODE index and CCQ scores.  Plasma concentrations indicated that patients were exposed to AZD4818 as expected.  AZD4818 was well tolerated: 27 treatment-related adverse events (13 with AZD4818, 14 with placebo), 2 serious adverse events (both AZD4818: exacerbation [considered not treatment-related] and deep vein thrombosis [considered treatment-related]) and 11 discontinuations (7 with AZD4818).  CONCLUSIONS:  Inhaled AZD4818 was well tolerated at 300mug twice daily for 4 weeks in patients with COPD; however, there was no indication of a beneficial treatment effect despite exposure as expected.  These findings in COPD are in line with other studies reporting a lack of clinical efficacy with CCR1 antagonists in other therapy areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReNiH0l3TS4ZWtyewyzkyLfW6udTcc2ebXXfBXktiO5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjjtlygsg%253D%253D&md5=157554642d8a8d754ca22d56328ce6f7</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DKerstjens%26aufirst%3DH.%2BA.%26aulast%3DBjermer%26aufirst%3DL.%26aulast%3DEriksson%26aufirst%3DL.%26aulast%3DDahlstr%25C3%25B6m%26aufirst%3DK.%26aulast%3DVestbo%26aufirst%3DJ.%26atitle%3DTolerability%2520and%2520efficacy%2520of%2520inhaled%2520AZD4818%252C%2520a%2520CCR1%2520antagonist%252C%2520in%2520moderate%2520to%2520severe%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2010%26volume%3D104%26spage%3D1297%26epage%3D1303%26doi%3D10.1016%2Fj.rmed.2010.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. J.</span></span> <span> </span><span class="NLM_article-title">Small molecule CXCR3 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2894</span>– <span class="NLM_lpage">2917</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2894-2917&author=S.+P.+Andrewsauthor=R.+J.+Cox&title=Small+molecule+CXCR3+antagonists&doi=10.1021%2Facs.jmedchem.5b01337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule CXCR3 Antagonists</span></div><div class="casAuthors">Andrews, Stephen P.; Cox, Rhona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2894-2917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chemokines and their receptors are known to play important roles in disease.  More than 40 chemokine ligands and 20 chemokine receptors have been identified, but, to date, only two small mol. chemokine receptor antagonists have been approved by the FDA.  The chemokine receptor CXCR3 was identified in 1996, and nearly 20 years later, new areas of CXCR3 disease biol. continue to emerge.  Several classes of small mol. CXCR3 antagonists have been developed, and two have shown efficacy in preclin. models of inflammatory disease.  However, only one CXCR3 antagonist has been evaluated in clin. trials, and there remain many opportunities to further investigate known classes of CXCR3 antagonists and to identify new chemotypes.  This Perspective reviews the known CXCR3 antagonists and considers future opportunities for the development of small mols. for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOCEhO7Ug3ULVg90H21EOLACvtfcHk0lgWZ0RVrhB2MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCnsrk%253D&md5=5e05dd6a3c7df567b579933f7d110f71</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01337%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26atitle%3DSmall%2520molecule%2520CXCR3%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2894%26epage%3D2917%26doi%3D10.1021%2Facs.jmedchem.5b01337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span> <span> </span><span class="NLM_article-title">Activation and regulation of the inflammasomes</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1038/nri3452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnri3452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23702978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFSgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=397-411&author=E.+Latzauthor=T.+S.+Xiaoauthor=A.+Stutz&title=Activation+and+regulation+of+the+inflammasomes&doi=10.1038%2Fnri3452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and regulation of the inflammasomes</span></div><div class="casAuthors">Latz, Eicke; Xiao, T. Sam; Stutz, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">397-411</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inflammasomes are key signalling platforms that detect pathogenic microorganisms and sterile stressors, and that activate the highly pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18.  In this Review, we discuss the complex regulatory mechanisms that facilitate a balanced but effective inflammasome-mediated immune response, and we highlight the similarities to another mol. signalling platform - the apoptosome - that monitors cellular health.  Extracellular regulatory mechanisms are discussed, as well as the intracellular control of inflammasome assembly, for example, via ion fluxes, free radicals and autophagy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom16nKHEVN3bVg90H21EOLACvtfcHk0lgWZ0RVrhB2MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFSgsLw%253D&md5=86c377fdd6dc6759679f4e410fad96af</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnri3452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3452%26sid%3Dliteratum%253Aachs%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DT.%2BS.%26aulast%3DStutz%26aufirst%3DA.%26atitle%3DActivation%2520and%2520regulation%2520of%2520the%2520inflammasomes%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D397%26epage%3D411%26doi%3D10.1038%2Fnri3452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surprenant, A.</span></span> <span> </span><span class="NLM_article-title">Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2×7 receptor</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5071</span>– <span class="NLM_lpage">5082</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fsj.emboj.7601378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17036048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFChsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=5071-5082&author=P.+Pelegrinauthor=A.+Surprenant&title=Pannexin-1+mediates+large+pore+formation+and+interleukin-1%CE%B2+release+by+the+ATP-gated+P2%C3%977+receptor&doi=10.1038%2Fsj.emboj.7601378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2X7 receptor</span></div><div class="casAuthors">Pelegrin, Pablo; Surprenant, Annmarie</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5071-5082</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">P2X7 receptors are ATP-gated cation channels; their activation in macrophage also leads to rapid opening of a membrane pore permeable to dyes such as ethidium, and to release of the pro-inflammatory cytokine, interleukin-1β (IL-1β).  It has not been known what this dye-uptake path is, or whether it is involved in downstream signaling to IL-1β release.  Here, we identify pannexin-1, a recently described mammalian protein that functions as a hemichannel when ectopically expressed, as this dye-uptake pathway and show that signaling through pannexin-1 is required for processing of caspase-1 and release of mature IL-1β induced by P2X7 receptor activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKvoL27FfqbVg90H21EOLACvtfcHk0lgOuElANm0OUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFChsrzM&md5=9b4bb218bde9ee4145bd3f70d900012c</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601378%26sid%3Dliteratum%253Aachs%26aulast%3DPelegrin%26aufirst%3DP.%26aulast%3DSurprenant%26aufirst%3DA.%26atitle%3DPannexin-1%2520mediates%2520large%2520pore%2520formation%2520and%2520interleukin-1%25CE%25B2%2520release%2520by%2520the%2520ATP-gated%2520P2%25C3%25977%2520receptor%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D5071%26epage%3D5082%26doi%3D10.1038%2Fsj.emboj.7601378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosseinian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockey, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolliputi, N.</span></span> <span> </span><span class="NLM_article-title">The role of the NLRP3 inflammasome in pulmonary diseases</span>. <i>Ther. Adv. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1177/1753465815586335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1177%2F1753465815586335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26012351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpsleqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=188-197&author=N.+Hosseinianauthor=Y.+Choauthor=R.+F.+Lockeyauthor=N.+Kolliputi&title=The+role+of+the+NLRP3+inflammasome+in+pulmonary+diseases&doi=10.1177%2F1753465815586335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the NLRP3 inflammasome in pulmonary diseases</span></div><div class="casAuthors">Hosseinian, Nima; Cho, Young; Lockey, Richard F.; Kolliputi, Narasaiah</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Respiratory Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">188-197</span>CODEN:
                <span class="NLM_cas:coden">TARDCZ</span>;
        ISSN:<span class="NLM_cas:issn">1753-4658</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Respiratory diseases and lung injuries are one of the leading causes of death in the world.  One crit. component of these diseases is exaggerated inflammatory response.  The recently discovered inflammasome is believed to play a key role in inflammation.  The inflammasome is an oligomer of intracellular proteins that, once activated by an insult or damage signal, produces mature cytokines from the interleukin-1 family that mediate an inflammatory response.  Previous research has provided evidence that suggests the role of the inflammasome in the pathogenesis of many chronic respiratory diseases and acute lung injuries, such as transfusion-related acute lung injury, ventilator-induced lung injury, asthma, chronic obstructive pulmonary disease and pulmonary fibrosis.  This article summarizes recent research on the inflammasome and reviews proposed mol. models of the role of the inflammasome in several prominent lung diseases and injuries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNTrnjBuYwzrVg90H21EOLACvtfcHk0lgOuElANm0OUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpsleqs7g%253D&md5=053acd2cf38af5f251818ce64f10f297</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1177%2F1753465815586335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1753465815586335%26sid%3Dliteratum%253Aachs%26aulast%3DHosseinian%26aufirst%3DN.%26aulast%3DCho%26aufirst%3DY.%26aulast%3DLockey%26aufirst%3DR.%2BF.%26aulast%3DKolliputi%26aufirst%3DN.%26atitle%3DThe%2520role%2520of%2520the%2520NLRP3%2520inflammasome%2520in%2520pulmonary%2520diseases%26jtitle%3DTher.%2520Adv.%2520Respir.%2520Dis.%26date%3D2015%26volume%3D9%26spage%3D188%26epage%3D197%26doi%3D10.1177%2F1753465815586335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rovina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dima, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerassimou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollintza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratziou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussos, C.</span></span> <span> </span><span class="NLM_article-title">Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1056</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2009.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.rmed.2009.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19208460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1MvhsFGjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2009&pages=1056-1062&author=N.+Rovinaauthor=E.+Dimaauthor=C.+Gerassimouauthor=A.+Kollintzaauthor=C.+Gratziouauthor=C.+Roussos&title=Interleukin-18+in+induced+sputum%3A+association+with+lung+function+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.rmed.2009.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rovina Nikoletta; Dima Efrossini; Gerassimou Christina; Kollintza Androniki; Gratziou Christina; Roussos Charis</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1056-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  It has been shown that interleukin (IL)-18 levels in induced sputum are reduced in asthmatic and healthy smokers.  However, in chronic obstructive pulmonary disease (COPD) patients, recent data show an overproduction in the lungs and increased serum levels of IL-18, suggesting that IL-18 may be involved in the pathogenesis of COPD.  METHOD:  In order to assess the relation of IL-18 with pulmonary function and airway inflammation in COPD, IL-18, tumour necrosis factor-alpha, and IL-8 levels were measured by ELISA in sputum supernatants obtained from patients with bronchitis type COPD (n=28), and healthy subjects (18 smokers and 17 non-smokers).  Cellular localization of IL-18 was assessed by immunocytochemistry.  RESULTS:  The levels of IL-18 were significantly higher in sputum supernatants of COPD patients compared to healthy smokers and non-smokers (p<0.05).  IL-18 production was localized to sputum macrophages.  IL-18 levels were inversely correlated with FEV(1) (% predicted) (r=-0.572, p=0.002) and FEV(1)/FVC ratio in COPD smokers (r=-0.608, p=0.001).  No correlations were found between IL-18 levels and inflammatory markers studied in induced sputum obtained from COPD patients, healthy smokers and non-smokers.  CONCLUSION:  In patients with COPD, increased levels of IL-18 in induced sputum were associated with airflow limitation, suggesting that IL-18 may be implicated in the pathogenesis of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTxbea41UcSDDnmmyUf5qOfW6udTcc2ebbuQ6ezzHKF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvhsFGjtQ%253D%253D&md5=93e127d7873d267f22ac0ef2ce56a1f6</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2009.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2009.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DRovina%26aufirst%3DN.%26aulast%3DDima%26aufirst%3DE.%26aulast%3DGerassimou%26aufirst%3DC.%26aulast%3DKollintza%26aufirst%3DA.%26aulast%3DGratziou%26aufirst%3DC.%26aulast%3DRoussos%26aufirst%3DC.%26atitle%3DInterleukin-18%2520in%2520induced%2520sputum%253A%2520association%2520with%2520lung%2520function%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Med.%26date%3D2009%26volume%3D103%26spage%3D1056%26epage%3D1062%26doi%3D10.1016%2Fj.rmed.2009.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Anti-IL-1β therapies</span>. <i>Recent Pat. DNA Gene Sequences</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.2174/187221511796392024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2174%2F187221511796392024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21762108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFelu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=126-135&author=H.+Zhang&title=Anti-IL-1%CE%B2+therapies&doi=10.2174%2F187221511796392024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-IL-1 β therapies</span></div><div class="casAuthors">Zhang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on DNA & Gene Sequences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-135</span>CODEN:
                <span class="NLM_cas:coden">RPDGBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-2156</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  IL-1β is one of the major cytokines implicated in the pathogenesis of many inflammatory-assocd. diseases.  Recent studies demonstrate that IL-1β is activated through inflammasomes, which are formed upon recognition of danger signals by the immune system.  IL-1β is, therefore, becoming a focus for the development of new anti-inflammatory drug products.  Current issued patents mainly covered the methods and the use of four types of IL-1β blockade compds., namely anti-IL-1β antibody, IL-1 receptor antagonists such as sIL-1Ra and icIL-1Ra and IL1 trap.  Two agents, Rilonacept and canakinumab were approved by the US FDA and others are in trial, in which beneficial results have been reported.  One can expect that upcoming patents in the field of inflammasome research will facilitate the development of new therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLkAs7WFiHQLVg90H21EOLACvtfcHk0ljJOCcK6D0x8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFelu74%253D&md5=a22112be11c56a44e3faced8420b3f61</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2174%2F187221511796392024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187221511796392024%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DAnti-IL-1%25CE%25B2%2520therapies%26jtitle%3DRecent%2520Pat.%2520DNA%2520Gene%2520Sequences%26date%3D2011%26volume%3D5%26spage%3D126%26epage%3D135%26doi%3D10.2174%2F187221511796392024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brough, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span> <span> </span><span class="NLM_article-title">Inhibiting the inflammasome: a chemical perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1710</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1691-1710&author=A.+G.+Baldwinauthor=D.+Broughauthor=S.+Freeman&title=Inhibiting+the+inflammasome%3A+a+chemical+perspective&doi=10.1021%2Facs.jmedchem.5b01091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the Inflammasome: A Chemical Perspective</span></div><div class="casAuthors">Baldwin, Alex G.; Brough, David; Freeman, Sally</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1691-1710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inflammasomes are high mol. wt. complexes that sense and react to injury and infection.  Their activation induces caspase-1 activation and release of interleukin-1β, a pro-inflammatory cytokine involved in both acute and chronic inflammatory responses.  There is increasing evidence that inflammasomes, particularly the NLRP3 inflammasome, act as guardians against noninfectious material.  Inappropriate activation of the NLRP3 inflammasome contributes to the progression of many noncommunicable diseases such as gout, type II diabetes, and Alzheimer's disease.  Inhibiting the inflammasome may significantly reduce damaging inflammation and is therefore regarded as a therapeutic target.  Currently approved inhibitors of interleukin-1β are rilonacept, canakinumab, and anakinra.  However, these proteins do not possess ideal pharmacokinetic properties and are unlikely to easily cross the blood-brain barrier.  Because inflammation can contribute to neurol. disorders, this review focuses on the development of small-mol. inhibitors of the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjTr3TikmZprVg90H21EOLACvtfcHk0ljJOCcK6D0x8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7rE&md5=754a1ef05e17cd82a376bf5105a23990</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01091%26sid%3Dliteratum%253Aachs%26aulast%3DBaldwin%26aufirst%3DA.%2BG.%26aulast%3DBrough%26aufirst%3DD.%26aulast%3DFreeman%26aufirst%3DS.%26atitle%3DInhibiting%2520the%2520inflammasome%253A%2520a%2520chemical%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1691%26epage%3D1710%26doi%3D10.1021%2Facs.jmedchem.5b01091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangan, M. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roush, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Targeting the NLRP3 inflammasome in inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrd.2018.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=30026524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGlt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=588-606&author=M.+S.+J.+Manganauthor=E.+J.+Olhavaauthor=W.+R.+Roushauthor=H.+M.+Seidelauthor=G.+D.+Glickauthor=E.+Latz&title=Targeting+the+NLRP3+inflammasome+in+inflammatory+diseases&doi=10.1038%2Fnrd.2018.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the NLRP3 inflammasome in inflammatory diseases</span></div><div class="casAuthors">Mangan, Matthew S. J.; Olhava, Edward J.; Roush, William R.; Seidel, H. Martin; Glick, Gary D.; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-606</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Danger signals are a hallmark of many common inflammatory diseases, and these stimuli can function to activate the cytosolic innate immune signalling receptor NLRP3 (NOD-, LRR- and pyrin domain-contg. 3).  Once activated, NLRP3 nucleates the assembly of an inflammasome, leading to caspase 1-mediated proteolytic activation of the interleukin-1β (IL-1β) family of cytokines, and induces an inflammatory, pyroptotic cell death.  Pharmacol. inhibition of NLRP3 activation results in potent therapeutic effects in a wide variety of rodent models of inflammatory diseases, effects that are mirrored by genetic ablation of NLRP3.  Although these findings highlight the potential of NLRP3 as a drug target, an understanding of NLRP3 structure and activation mechanisms is incomplete, which has hampered the discovery and development of novel therapeutics against this target.  Here, we review recent advances in our understanding of NLRP3 activation and regulation, highlight the evolving landscape of NLRP3 modulators and discuss opportunities for pharmacol. targeting NLRP3 with novel small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw2JAJ8RPRXrVg90H21EOLACvtfcHk0ljJOCcK6D0x8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGlt7bM&md5=57b064477ea056dc859f6c90c4d00c36</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.97%26sid%3Dliteratum%253Aachs%26aulast%3DMangan%26aufirst%3DM.%2BS.%2BJ.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DRoush%26aufirst%3DW.%2BR.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DTargeting%2520the%2520NLRP3%2520inflammasome%2520in%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D588%26epage%3D606%26doi%3D10.1038%2Fnrd.2018.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coll, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Planillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inserra, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dungan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croker, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haneklaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L. A.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1038/nm.3806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnm.3806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25686105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=248-255&author=R.+C.+Collauthor=A.+A.+Robertsonauthor=J.+J.+Chaeauthor=S.+C.+Higginsauthor=R.+Mu%C3%B1oz-Planilloauthor=M.+C.+Inserraauthor=I.+Vetterauthor=L.+S.+Dunganauthor=B.+G.+Monksauthor=A.+Stutzauthor=D.+E.+Crokerauthor=M.+S.+Butlerauthor=M.+Haneklausauthor=C.+E.+Suttonauthor=G.+N%C3%BA%C3%B1ezauthor=E.+Latzauthor=D.+L.+Kastnerauthor=K.+H.+Millsauthor=S.+L.+Mastersauthor=K.+Schroderauthor=M.+A.+Cooperauthor=L.+A.+O%E2%80%99Neill&title=A+small-molecule+inhibitor+of+the+NLRP3+inflammasome+for+the+treatment+of+inflammatory+diseases&doi=10.1038%2Fnm.3806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases</span></div><div class="casAuthors">Coll, Rebecca C.; Robertson, Avril A. B.; Chae, Jae Jin; Higgins, Sarah C.; Munoz-Planillo, Raul; Inserra, Marco C.; Vetter, Irina; Dungan, Lara S.; Monks, Brian G.; Stutz, Andrea; Croker, Daniel E.; Butler, Mark S.; Haneklaus, Moritz; Sutton, Caroline E.; Nunez, Gabriel; Latz, Eicke; Kastner, Daniel L.; Mills, Kingston H. G.; Masters, Seth L.; Schroder, Kate; Cooper, Matthew A.; O'Neill, Luke A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-255</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The NOD-like receptor (NLR) family, pyrin domain-contg. protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-assocd. periodic syndrome (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis.  We describe the development of MCC950, a potent, selective, small-mol. inhibitor of NLRP3.  MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concns.  MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes.  MCC950 reduced interleukin-1β (IL-1β) prodn. in vivo and attenuated the severity of exptl. autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis.  Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle-Wells syndrome.  MCC950 is thus a potential therapeutic for NLRP3-assocd. syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBPny7QJdNA7Vg90H21EOLACvtfcHk0li7cbT4-dOplw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSit7g%253D&md5=5ffe3683cc33ded3c3b18421e987cac5</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnm.3806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3806%26sid%3Dliteratum%253Aachs%26aulast%3DColl%26aufirst%3DR.%2BC.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%26aulast%3DChae%26aufirst%3DJ.%2BJ.%26aulast%3DHiggins%26aufirst%3DS.%2BC.%26aulast%3DMu%25C3%25B1oz-Planillo%26aufirst%3DR.%26aulast%3DInserra%26aufirst%3DM.%2BC.%26aulast%3DVetter%26aufirst%3DI.%26aulast%3DDungan%26aufirst%3DL.%2BS.%26aulast%3DMonks%26aufirst%3DB.%2BG.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DCroker%26aufirst%3DD.%2BE.%26aulast%3DButler%26aufirst%3DM.%2BS.%26aulast%3DHaneklaus%26aufirst%3DM.%26aulast%3DSutton%26aufirst%3DC.%2BE.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DG.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DKastner%26aufirst%3DD.%2BL.%26aulast%3DMills%26aufirst%3DK.%2BH.%26aulast%3DMasters%26aufirst%3DS.%2BL.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520the%2520NLRP3%2520inflammasome%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D248%26epage%3D255%26doi%3D10.1038%2Fnm.3806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvat, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbro, P. M.</span></span> <span> </span><span class="NLM_article-title">Inflammasomes in COPD and neutrophilic asthma</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1201</span>, <span class="refDoi"> DOI: 10.1136/thoraxjnl-2014-206736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1136%2Fthoraxjnl-2014-206736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26493990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28zksFSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=1199-1201&author=R.+Y.+Kimauthor=J.+W.+Pinkertonauthor=P.+G.+Gibsonauthor=M.+A.+Cooperauthor=J.+C.+Horvatauthor=P.+M.+Hansbro&title=Inflammasomes+in+COPD+and+neutrophilic+asthma&doi=10.1136%2Fthoraxjnl-2014-206736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammasomes in COPD and neutrophilic asthma</span></div><div class="casAuthors">Kim Richard Y; Pinkerton James W; Gibson Peter G; Horvat Jay C; Hansbro Philip M; Cooper Matthew A</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-201</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR84wrLFcBzAXELvajU9pjPfW6udTcc2eYxSXKL-9HzBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zksFSltA%253D%253D&md5=18de0090f99e02e25157853a9304c884</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2014-206736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2014-206736%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%2BY.%26aulast%3DPinkerton%26aufirst%3DJ.%2BW.%26aulast%3DGibson%26aufirst%3DP.%2BG.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DHorvat%26aufirst%3DJ.%2BC.%26aulast%3DHansbro%26aufirst%3DP.%2BM.%26atitle%3DInflammasomes%2520in%2520COPD%2520and%2520neutrophilic%2520asthma%26jtitle%3DThorax%26date%3D2015%26volume%3D70%26spage%3D1199%26epage%3D1201%26doi%3D10.1136%2Fthoraxjnl-2014-206736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kean, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, W. W.</span></span> <span> </span><span class="NLM_article-title">Auranofin</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1093/rheumatology/36.5.560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1093%2Frheumatology%2F36.5.560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1ert70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=560-572&author=W.+F.+Keanauthor=L.+Hartauthor=W.+W.+Buchanan&title=Auranofin&doi=10.1093%2Frheumatology%2F36.5.560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Auranofin</span></div><div class="casAuthors">Kean, W. F.; Hart, L.; Buchanan, W. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Rheumatology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">560-572</span>CODEN:
                <span class="NLM_cas:coden">BJRHDF</span>;
        ISSN:<span class="NLM_cas:issn">0263-7103</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 110 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDkbAGdbOko7Vg90H21EOLACvtfcHk0li7cbT4-dOplw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1ert70%253D&md5=988732af6d9cd13a33abb16114550422</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2F36.5.560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252F36.5.560%26sid%3Dliteratum%253Aachs%26aulast%3DKean%26aufirst%3DW.%2BF.%26aulast%3DHart%26aufirst%3DL.%26aulast%3DBuchanan%26aufirst%3DW.%2BW.%26atitle%3DAuranofin%26jtitle%3DRheumatology%26date%3D1997%26volume%3D36%26spage%3D560%26epage%3D572%26doi%3D10.1093%2Frheumatology%2F36.5.560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span> <span> </span><span class="NLM_article-title">Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages</span>. <i>Arch. Pharmacal Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1007/s12272-008-1122-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs12272-008-1122-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18277610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlyitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=67-74&author=S.+Hanauthor=K.+Kimauthor=H.+Kimauthor=J.+Kwonauthor=Y.+H.+Leeauthor=C.+K.+Leeauthor=Y.+Songauthor=S.+J.+Leeauthor=N.+Haauthor=K.+Kim&title=Auranofin+inhibits+overproduction+of+pro-inflammatory+cytokines%2C+cyclooxygenase+expression+and+PGE2+production+in+macrophages&doi=10.1007%2Fs12272-008-1122-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages</span></div><div class="casAuthors">Han, Shinha; Kim, Kwanghee; Kim, Hyunyul; Kwon, Jeunghak; Lee, Young-Hee; Lee, Chong-Kil; Song, Youngcheon; Lee, Sang-Jin; Ha, Namjoo; Kim, Kyungjae</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">Auranofin (AF), a gold compd., is an orally active therapeutic agent used to treat rheumatoid arthritis (RA), a self-perpetuating inflammatory disease.  RA is characterized by autoimmune-mediated proliferation of synovial cells that leads to inflammation, pain, and swelling in most major joints.  However, the mechanism as to how AF relieves RA symptoms has not been fully elucidated.  The object of this study was to examine the ability of AF to immunomodulate macrophages as antigen presenting cells (APCs).  Macrophages are recognized as playing an important role in the pathogenesis of RA, in that there is a relative abundance of macrophage-derived cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in rheumatoid synovium.  In this work, we tested whether AF (2.5-20 mM) could inhibit inflammatory activity in the macrophage cell line RAW 264.7.  AF decreased prodn. of nitric oxide (NO) and the pro-inflammatory cytokines, TNF-α, IL-1β and IL-6 in macrophages.  Furthermore, AF inhibited cyclooxygenase-2 (COX-2)-dependent prostaglandin E2 (PGE2) prodn. in a concn.-dependent manner.  In conclusion, these findings may provide an explanation for the clin. effects of AF in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOHN1I7ymmfbVg90H21EOLACvtfcHk0lhE-Pa-5qHcaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlyitLo%253D&md5=d050c6b43efddff06983e01e1652354a</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs12272-008-1122-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-008-1122-9%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKwon%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DHa%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DK.%26atitle%3DAuranofin%2520inhibits%2520overproduction%2520of%2520pro-inflammatory%2520cytokines%252C%2520cyclooxygenase%2520expression%2520and%2520PGE2%2520production%2520in%2520macrophages%26jtitle%3DArch.%2520Pharmacal%2520Res.%26date%3D2008%26volume%3D31%26spage%3D67%26epage%3D74%26doi%3D10.1007%2Fs12272-008-1122-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1504</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2013.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bcp.2013.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23506741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1ejs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=1504-1512&author=W.+Liuauthor=W.+Guoauthor=J.+Wuauthor=Q.+Luoauthor=F.+Taoauthor=Y.+Guauthor=Y.+Shenauthor=J.+Liauthor=R.+Tanauthor=Q.+Xuauthor=Y.+Sun&title=A+novel+benzo%5Bd%5Dimidazole+derivate+prevents+the+development+of+dextran+sulfate+sodium-induced+murine+experimental+colitis+via+inhibition+of+NLRP3+inflammasome&doi=10.1016%2Fj.bcp.2013.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome</span></div><div class="casAuthors">Liu, Wen; Guo, Wenjie; Wu, Jing; Luo, Qiong; Tao, Feifei; Gu, Yanhong; Shen, Yan; Li, Jianxin; Tan, Renxiang; Xu, Qiang; Sun, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1504-1512</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">NLRP3 inflammasome has been reported to be assocd. with various kinds of immunol. diseases including colitis.  However, there are few drug candidates targeting inflammasomes for the treatment of colitis.  In the present study, we aimed at examg. the effect of 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small mol. compd. also named Fc11a-2, for the treatment of dextran sulfate sodium (DSS)-induced exptl. colitis in mice via targeting NLRP3 inflammasome.  Treatment with Fc11a-2 dose-dependently attenuated the loss of body wt. and shortening of colon length induced by DSS.  In addn., the disease activity index, histopathol. scores and myeloperoxidase activity were also significantly reduced by Fc11a-2 treatment.  Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by Fc11a-2.  Furthermore, a decreased CD11c+ macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice.  The mechanism of action of Fc11a-2 was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1β and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.  Taken together, our results demonstrate the ability of Fc11a-2 to inhibit NLRP3 inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC4yBlq18j1bVg90H21EOLACvtfcHk0lhE-Pa-5qHcaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1ejs7s%253D&md5=28fe5ced430f1f103df5b34d7c5b0306</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DTao%26aufirst%3DF.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DA%2520novel%2520benzo%255Bd%255Dimidazole%2520derivate%2520prevents%2520the%2520development%2520of%2520dextran%2520sulfate%2520sodium-induced%2520murine%2520experimental%2520colitis%2520via%2520inhibition%2520of%2520NLRP3%2520inflammasome%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D1504%26epage%3D1512%26doi%3D10.1016%2Fj.bcp.2013.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchimori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ii, M.</span></span> <span> </span><span class="NLM_article-title">TAK-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1124/mol.110.068064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fmol.110.068064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20881006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1ehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=34-41&author=N.+Matsunagaauthor=N.+Tsuchimoriauthor=T.+Matsumotoauthor=M.+Ii&title=TAK-242+%28resatorvid%29%2C+a+small-molecule+inhibitor+of+toll-like+receptor+%28TLR%29+4+signaling%2C+binds+selectively+to+TLR4+and+interferes+with+interactions+between+TLR4+and+its+adaptor+molecules&doi=10.1124%2Fmol.110.068064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules</span></div><div class="casAuthors">Matsunaga, Naoko; Tsuchimori, Noboru; Matsumoto, Tatsumi; Ii, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-41</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">TAK-242 (resatorvid), a small-mol.-specific inhibitor of Toll-like receptor (TLR) 4 signaling, inhibits the prodn. of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.  Cys747 in TLR4 has been identified previously as the binding site of TAK-242.  However, the mechanism by which TAK-242 inhibits TLR4 signaling after binding to TLR4 remains unknown.  The present study demonstrated, using coimmunopptn., that TAK-242 interferes with protein-protein interactions between TLR4 and its adaptor mols.  Among 10 different human TLRs, TAK-242 selectively bound to TLR4.  The time course of the inhibitory effect of TAK-242 on inflammatory mediator prodn. corresponded to that of the binding of TAK-242 to TLR4.  TAK-242 inhibited the assocn. of TLR4 with Toll/interleukin-1 receptor domain-contg. adaptor protein (TIRAP) or Toll/interleukin-1 receptor domain-contg. adaptor protein inducing interferon-β-related adaptor mol. (TRAM) in human embryonic kidney (HEK) 293 cells overexpressing TLR4, MD-2, and TIRAP or TRAM, resp.  TAK-242 inhibited the TIRAP-mediated activation of nuclear factor βB (NF-κB) and the TRAM-mediated activation of NF-κB and interferon-sensitive response element in HEK293 cells stably expressing TLR4, MD-2, and CD14.  The activation of endogenous interleukin-1 receptor-assocd. kinase in RAW264.7 cells was also inhibited by TAK-242 treatment.  These findings suggest that TAK-242 binds selectively to TLR4 and subsequently disrupts the interaction of TLR4 with adaptor mols., thereby inhibiting TLR4 signal transduction and its downstream signaling events.  This work proposes a novel paradigm of a small mol. capable of disrupting protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEHy_7WltDNbVg90H21EOLACvtfcHk0lhE-Pa-5qHcaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1ehuw%253D%253D&md5=c3ce97a9ab69101a59117c80c8f01044</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.068064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.068064%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DN.%26aulast%3DTsuchimori%26aufirst%3DN.%26aulast%3DMatsumoto%26aufirst%3DT.%26aulast%3DIi%26aufirst%3DM.%26atitle%3DTAK-242%2520%2528resatorvid%2529%252C%2520a%2520small-molecule%2520inhibitor%2520of%2520toll-like%2520receptor%2520%2528TLR%2529%25204%2520signaling%252C%2520binds%2520selectively%2520to%2520TLR4%2520and%2520interferes%2520with%2520interactions%2520between%2520TLR4%2520and%2520its%2520adaptor%2520molecules%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D79%26spage%3D34%26epage%3D41%26doi%3D10.1124%2Fmol.110.068064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, F.</span></span> <span> </span><span class="NLM_article-title">Chemical probing reveals insights into the signaling mechanism of inflammasome activation</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1038/cr.2010.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fcr.2010.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20856264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1289-1305&author=Y.+N.+Gongauthor=X.+Wangauthor=J.+Wangauthor=Z.+Yangauthor=S.+Liauthor=J.+Yangauthor=L.+Liuauthor=X.+Leiauthor=F.+Shao&title=Chemical+probing+reveals+insights+into+the+signaling+mechanism+of+inflammasome+activation&doi=10.1038%2Fcr.2010.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical probing reveals insights into the signaling mechanism of inflammasome activation</span></div><div class="casAuthors">Gong, Yi-Nan; Wang, Xiaoming; Wang, Jiayi; Yang, Zhenxiao; Li, Shan; Yang, Jieling; Liu, Liping; Lei, Xiaoguang; Shao, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1289-1305</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Caspase-1-mediated IL-1β prodn. is generally controlled by two pathways.  Toll-like receptors (TLRs) recognize pathogen-derived products and induce NF-κB-dependent pro-IL-1β transcription; NOD-like receptors (NLRs) assemble caspase-1-activating inflammasome complexes that sense bacterial products/danger signals.  Through a targeted chem. screen, we identify bromoxone, a marine natural product, as a specific and potent inhibitor of the caspase-1 pathway.  Bromoxone is effective over diverse inflammatory stimuli including TLR ligands plus ATP/nigericin, cytosolic DNA, flagellin and Bacillus anthracis lethal toxin.  Bromoxone also efficiently suppresses caspase-1 activation triggered by several types of bacterial infection.  Bromoxone acts upstream or at the level of the inflammasome in a transcription-independent manner.  Bromoxone also inhibits pro-IL-1β expression by targeting components upstream of IKK in the TLR-NF-κB pathway.  The unique dual activities of bromoxone are shared by the known TAK1 inhibitor that specifically blocks Nalp3 inflammasome activation.  Hinted from the mechanistic and pharmacol. properties of bromoxone, we further discover that several known NF-κB inhibitors that act upstream of IKK, but not those targeting IKK or IKK downstream, are potent blockers of different NLRs-mediated caspase-1 activation.  Our study uncovers a possible non-transcriptional mol. link between the NLR (Nalp3)-mediated inflammasome pathway and TLR-NF-κB signaling, and suggests a potential strategy to develop new anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppjC16zIWsMbVg90H21EOLACvtfcHk0lgjlIIpiOAVnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqu7nP&md5=efe3462264b2a58c9d54fd8fee8a06b1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fcr.2010.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2010.135%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DY.%2BN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DF.%26atitle%3DChemical%2520probing%2520reveals%2520insights%2520into%2520the%2520signaling%2520mechanism%2520of%2520inflammasome%2520activation%26jtitle%3DCell%2520Res.%26date%3D2010%26volume%3D20%26spage%3D1289%26epage%3D1305%26doi%3D10.1038%2Fcr.2010.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suissa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, M.</span></span> <span> </span><span class="NLM_article-title">TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2007.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2007.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17517530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=234-238&author=S.+Suissaauthor=P.+Ernstauthor=M.+Hudson&title=TNF-alpha+antagonists+and+the+prevention+of+hospitalisation+for+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.pupt.2007.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Suissa, Samy; Ernst, Pierre; Hudson, Marie</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-238</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: TNF-α may be important in the pathogenesis of COPD.  Consequently, the use of TNF-α antagonists has been advocated for its treatment.  Methods: We conducted an observational study to evaluate the effectiveness of TNF-α antagonists in preventing COPD hospitalizations in a cohort of patients diagnosed with both RA and COPD identified from a health claims database.  A nested case-control approach was used to match each case hospitalized to 10 controls on age and cohort entry date.  Data on prescribed medications during the year prior to the index date were obtained.  Rate ratios (RR) of COPD hospitalization were estd. by conditional logistic regression, after adjustment for COPD severity and concomitant RA medication use.  Results: The cohort included 15,771 subjects with both RA and COPD, of which 1205 were hospitalized for COPD during follow-up.  The adjusted RR of COPD hospitalization assocd. with the use of TNF-α antagonists was 0.62 (95% confidence interval (CI) 0.43-0.89).  This rate redn. was due to etanercept (RR 0.49, 95% CI 0.29-0.82) but not infliximab (RR 0.95, 95% CI 0.59-1.52).  Conclusion: Our finding of a halving in the rate of COPD hospitalization assocd. with the use of etanercept corroborates the potential importance of TNF-α in the pathogenesis of COPD.  This study supports the initiation of randomized controlled trials of this TNF-α antagonist among COPD patients at high risk of severe exacerbations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFXVPGvLzbkbVg90H21EOLACvtfcHk0lgjlIIpiOAVnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVahtA%253D%253D&md5=68e5f1bf814578bf4248cf0bd2cec11a</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2007.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2007.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DSuissa%26aufirst%3DS.%26aulast%3DErnst%26aufirst%3DP.%26aulast%3DHudson%26aufirst%3DM.%26atitle%3DTNF-alpha%2520antagonists%2520and%2520the%2520prevention%2520of%2520hospitalisation%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2008%26volume%3D21%26spage%3D234%26epage%3D238%26doi%3D10.1016%2Fj.pupt.2007.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokomizo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span> <span> </span><span class="NLM_article-title">Leukotriene B4: metabolism and signal transduction</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1006/abbi.2000.2168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1006%2Fabbi.2000.2168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11368003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2001&pages=231-241&author=T.+Yokomizoauthor=T.+Izumiauthor=T.+Shimizu&title=Leukotriene+B4%3A+metabolism+and+signal+transduction&doi=10.1006%2Fabbi.2000.2168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene B4: Metabolism and Signal Transduction</span></div><div class="casAuthors">Yokomizo, Takehiko; Izumi, Takashi; Shimizu, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-241</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 107 refs.  Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases.  Enzymes involved in the biosynthesis and metab. of LTB4 have been cloned, and their properties are well understood.  Two G-protein-coupled receptors (BLT1 and BLT2) have been cloned and characterized.  BLT1 and BLT2 are high- and low-affinity LTB4 receptors, resp., and form a gene cluster in human and mouse.  In this article recent findings on the metab. of and the receptors for LTB4 are reviewed.  The authors also discuss briefly a coreceptor role of BLT in HIV infection, and ion channel modification by LTB4.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTGxA2t0BHibVg90H21EOLACvtfcHk0lgjlIIpiOAVnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFyiuw%253D%253D&md5=0bb5184aec44c54e40cacfbe907ca04a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1006%2Fabbi.2000.2168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.2000.2168%26sid%3Dliteratum%253Aachs%26aulast%3DYokomizo%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DT.%26aulast%3DShimizu%26aufirst%3DT.%26atitle%3DLeukotriene%2520B4%253A%2520metabolism%2520and%2520signal%2520transduction%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2001%26volume%3D385%26spage%3D231%26epage%3D241%26doi%3D10.1006%2Fabbi.2000.2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundeen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span> <span> </span><span class="NLM_article-title">Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">3439</span>– <span class="NLM_lpage">3447</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.177.5.3439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4049%2Fjimmunol.177.5.3439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16920986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1Cjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2006&pages=3439-3447&author=K.+A.+Lundeenauthor=B.+Sunauthor=L.+Karlssonauthor=A.+M.+Fourie&title=Leukotriene+B4+receptors+BLT1+and+BLT2%3A+expression+and+function+in+human+and+murine+mast+cells&doi=10.4049%2Fjimmunol.177.5.3439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene B4 Receptors BLT1 and BLT2: Expression and Function in Human and Murine Mast Cells</span></div><div class="casAuthors">Lundeen, Katherine A.; Sun, Binggang; Karlsson, Lars; Fourie, Anne M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3439-3447</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Leukotriene B4 (LTB4) is a potent activator and chemoattractant for leukocytes and is implicated in several inflammatory diseases.  The actions of LTB4 are mediated by two cell surface receptors, BLT1, which is predominantly expressed in peripheral blood leukocytes, and BLT2, which is expressed more ubiquitously.  Recently, BLT1 expression and LTB4-dependent chemotaxis have been reported in immature mast cells (MCs).  We now show the first evidence for BLT2 mRNA expression, in addn. to BLT1, in murine bone marrow-derived MCs (mBMMCs) and in a human MC line (HMC-1).  Protein expression of BLT1 was confirmed by mAb staining in HMC-1 cells and shown to be predominantly intracellular.  Both HMC-1 cells and mBMMCs migrated to LTB4 in a dose-dependent manner in chemotaxis assays.  Migration to LTB4 could be inhibited by either a BLT1- or BLT2-selective antagonist.  Significant dose-dependent migration of mBMMCs also was obsd. to 12-(S)-hydroxyeicosatetraenoic acid, a BLT2-selective agonist, demonstrating functional BLT2 activity in these cells.  Stimulation of mBMMCs with LTB4 induced transient, dose-dependent, ERK phosphorylation and changes in Akt phosphorylation.  Dose-dependent ERK phosphorylation also was obsd. in response to 12-(S)-hydroxyeicosatetraenoic acid, indicating signaling downstream of BLT2.  Pretreatment of mBMMCs with stem cell factor significantly down-regulated expression of BLT1 and BLT2 mRNA and inhibited their migration to LTB4.  This study demonstrates expression of functional LTB4 receptors, both BLT1 and BLT2, in murine and human MCs and a regulatory role for stem cell factor in their expression.  These receptors may mediate recruitment and accumulation of MCs in response to LTB4 prodn. in areas of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDKctQ7LxVu7Vg90H21EOLACvtfcHk0lj5ckvN1QjKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1Cjtbw%253D&md5=ae3816d3728de47d180dcc3b9afb73ee</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.177.5.3439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.177.5.3439%26sid%3Dliteratum%253Aachs%26aulast%3DLundeen%26aufirst%3DK.%2BA.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DKarlsson%26aufirst%3DL.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26atitle%3DLeukotriene%2520B4%2520receptors%2520BLT1%2520and%2520BLT2%253A%2520expression%2520and%2520function%2520in%2520human%2520and%2520murine%2520mast%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D177%26spage%3D3439%26epage%3D3447%26doi%3D10.4049%2Fjimmunol.177.5.3439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monkarsh, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodnow, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1909</span>– <span class="NLM_lpage">1920</span>, <span class="refDoi"> DOI: 10.1517/13543784.16.12.1909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543784.16.12.1909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18042000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=1909-1920&author=A.+Hicksauthor=S.+P.+Monkarshauthor=A.+F.+Hoffmanauthor=R.+Goodnow&title=Leukotriene+B4+receptor+antagonists+as+therapeutics+for+inflammatory+disease%3A+preclinical+and+clinical+developments&doi=10.1517%2F13543784.16.12.1909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments</span></div><div class="casAuthors">Hicks, Alexandra; Monkarsh, Seth P.; Hoffman, Ann F.; Goodnow, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1909-1920</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Leukotriene B4 (LTB4) is a lipid inflammatory mediator derived from membrane phospholipids by the sequential actions of cytosolic phospholipase A2 (PLA2), 5-lipoxygenase (5-LO) and leukotriene A4 (LTA4) hydrolase.  Several inflammatory diseases, including asthma, chronic obstructive pulmonary disease, arthritis and inflammatory bowel disease, have been assocd. with elevated levels of LTB4.  As a result, pharmacol. strategies to modulate the synthesis of LTB4 (inhibition of PLA2, 5-LO or LTA4 hydrolase) or the effects of LTB4 itself (antagonism of LTB4 receptors) are being developed by several companies.  Two G-protein-coupled receptors mediate the effects of LTB4, namely BLT1 and BLT2.  The pharmacol., expression and function of these two receptors were last reviewed by Tager and Luster in 2004.  Since then, there has been an increased understanding of the function of these receptors, in particular for the lesser understood of the two receptors, BLT2.  Furthermore, since last reviewed in 1996, there have been several clin. developments in the use of BLT receptor antagonists for inflammatory diseases.  This review summarizes the latest preclin. and clin. developments in BLT antagonism for inflammatory diseases and discusses potential future developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKU0SsXiyMCrVg90H21EOLACvtfcHk0lj5ckvN1QjKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmu7%252FI&md5=7409513efd3c2dbdc101fb9565067896</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.12.1909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.12.1909%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DMonkarsh%26aufirst%3DS.%2BP.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DGoodnow%26aufirst%3DR.%26atitle%3DLeukotriene%2520B4%2520receptor%2520antagonists%2520as%2520therapeutics%2520for%2520inflammatory%2520disease%253A%2520preclinical%2520and%2520clinical%2520developments%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D1909%26epage%3D1920%26doi%3D10.1517%2F13543784.16.12.1909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Profita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccobono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paternò, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirabella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonsignore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignola, A. M.</span></span> <span> </span><span class="NLM_article-title">15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis</span>. <i>Am. J. Physiol. Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">C1249</span>– <span class="NLM_lpage">C1258</span>, <span class="refDoi"> DOI: 10.1152/ajpcell.2000.279.4.C1249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1152%2Fajpcell.2000.279.4.C1249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11003605" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2000&pages=C1249-C1258&author=M.+Profitaauthor=A.+Salaauthor=L.+Riccobonoauthor=E.+Paceauthor=A.+Patern%C3%B2author=S.+Zariniauthor=L.+Sienaauthor=A.+Mirabellaauthor=G.+Bonsignoreauthor=A.+M.+Vignola&title=15%28S%29-HETE+modulates+LTB%284%29+production+and+neutrophil+chemotaxis+in+chronic+bronchitis&doi=10.1152%2Fajpcell.2000.279.4.C1249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.2000.279.4.C1249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.2000.279.4.C1249%26sid%3Dliteratum%253Aachs%26aulast%3DProfita%26aufirst%3DM.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DRiccobono%26aufirst%3DL.%26aulast%3DPace%26aufirst%3DE.%26aulast%3DPatern%25C3%25B2%26aufirst%3DA.%26aulast%3DZarini%26aufirst%3DS.%26aulast%3DSiena%26aufirst%3DL.%26aulast%3DMirabella%26aufirst%3DA.%26aulast%3DBonsignore%26aufirst%3DG.%26aulast%3DVignola%26aufirst%3DA.%2BM.%26atitle%3D15%2528S%2529-HETE%2520modulates%2520LTB%25284%2529%2520production%2520and%2520neutrophil%2520chemotaxis%2520in%2520chronic%2520bronchitis%26jtitle%3DAm.%2520J.%2520Physiol.%2520Cell%2520Physiol.%26date%3D2000%26volume%3D279%26spage%3DC1249%26epage%3DC1258%26doi%3D10.1152%2Fajpcell.2000.279.4.C1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span> <span> </span><span class="NLM_article-title">Resolution of acute inflammation in the lung</span>. <i>Annu. Rev. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1146/annurev-physiol-021113-170408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1146%2Fannurev-physiol-021113-170408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24313723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVCmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=467-492&author=B.+D.+Levyauthor=C.+N.+Serhan&title=Resolution+of+acute+inflammation+in+the+lung&doi=10.1146%2Fannurev-physiol-021113-170408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Resolution of acute inflammation in the lung</span></div><div class="casAuthors">Levy, Bruce D.; Serhan, Charles N.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">467-492</span>CODEN:
                <span class="NLM_cas:coden">ARPHAD</span>;
        ISSN:<span class="NLM_cas:issn">0066-4278</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Acute inflammation in the lung is essential to health.  So too is its resoln.  In response to invading microbes, noxious stimuli, or tissue injury, an acute inflammatory response is mounted to protect the host.  To limit inflammation and prevent collateral injury of healthy, uninvolved tissue, the lung orchestrates the formation of specialized proresolving mediators, specifically lipoxins, resolvins, protectins, and maresins.  These immunoresolvents are agonists for resoln. that interact with specific receptors on leukocytes and structural cells to blunt further inflammation and promote catabasis.  This process appears to be defective in several common lung diseases that are characterized by excess or chronic inflammation.  Here, we review the mol. and cellular effectors of resoln. of acute inflammation in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNJh0sArfJMrVg90H21EOLACvtfcHk0lj5ckvN1QjKnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVCmsbc%253D&md5=b28ca357369a3387b978f18cf52bd331</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1146%2Fannurev-physiol-021113-170408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-physiol-021113-170408%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DB.%2BD.%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26atitle%3DResolution%2520of%2520acute%2520inflammation%2520in%2520the%2520lung%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2014%26volume%3D76%26spage%3D467%26epage%3D492%26doi%3D10.1146%2Fannurev-physiol-021113-170408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roinestad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E. B.</span></span> <span> </span><span class="NLM_article-title">Recent advances in clinical development of leukotriene B4 pathway drugs</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.smim.2017.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.smim.2017.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29042030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=65-73&author=L.+Bhattauthor=K.+Roinestadauthor=T.+Vanauthor=E.+B.+Springman&title=Recent+advances+in+clinical+development+of+leukotriene+B4+pathway+drugs&doi=10.1016%2Fj.smim.2017.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in clinical development of leukotriene B4 pathway drugs</span></div><div class="casAuthors">Bhatt, L.; Roinestad, K.; Van, T.; Springman, E. B.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The LTB4 pathway is an attractive target for therapeutic drug development.  Two broad classes of drugs have been pursued: antagonists of the primary LTB4 receptors (BLT1 and BLT2) and inhibitors of LTA4 Hydrolase (LTA4H), the rate limiting enzyme in the prodn. of LTB4.  An initial wave of effort culminated in the 1990s.  Over the past 15 years, a second wave of more selective drug candidates, including at least 5 BLT antagonists and 6 LTA4H inhibitors, have reached Phase 2 clin. trials.  Despite the extensive efforts to discover and develop LTB4 pathway targeting drugs, only one has reached the market to date.  Recently discovered complexities in the pathway and challenges in matching pathway intervention with therapeutic effect could explain the limited clin. success of LTB4 pathway drugs, even though there is a large body of scientific evidence linking LTB4 to human diseases and demonstrating efficacy of these compds. in a wide array of preclin. models.  Herein, we describe the clin. programs for the most prominent recent examples from each broad class and discuss the clin. outcomes and their implications for future development of LTB4 pathway drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomAJhLJFJTE7Vg90H21EOLACvtfcHk0liMEOVvtKX58A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfN&md5=a45e8c63d30430dbd71821c36b90c4ae</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2017.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2017.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DBhatt%26aufirst%3DL.%26aulast%3DRoinestad%26aufirst%3DK.%26aulast%3DVan%26aufirst%3DT.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DRecent%2520advances%2520in%2520clinical%2520development%2520of%2520leukotriene%2520B4%2520pathway%2520drugs%26jtitle%3DSemin.%2520Immunol.%26date%3D2017%26volume%3D33%26spage%3D65%26epage%3D73%26doi%3D10.1016%2Fj.smim.2017.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chillappagari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preuss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahavadi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarode, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahrlich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, M. O.</span></span> <span> </span><span class="NLM_article-title">Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">85</span>, <span class="refDoi"> DOI: 10.1186/s12931-015-0247-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2Fs12931-015-0247-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26169056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FivVKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=85&author=S.+Chillappagariauthor=J.+Preussauthor=S.+Lichtauthor=C.+M%C3%BCllerauthor=P.+Mahavadiauthor=G.+Sarodeauthor=C.+Vogelmeierauthor=A.+Guentherauthor=L.+Nahrlichauthor=B.+K.+Rubinauthor=M.+O.+Henke&title=Altered+protease+and+antiprotease+balance+during+a+COPD+exacerbation+contributes+to+mucus+obstruction&doi=10.1186%2Fs12931-015-0247-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction</span></div><div class="casAuthors">Chillappagari Shashi; Nahrlich Lutz; Chillappagari Shashi; Mahavadi Poornima; Guenther Andreas; Chillappagari Shashi; Preuss Jenni; Licht Sebastian; Muller Christian; Vogelmeier Claus; Henke Markus O; Chillappagari Shashi; Mahavadi Poornima; Guenther Andreas; Nahrlich Lutz; Sarode Gaurav; Henke Markus O; Sarode Gaurav; Henke Markus O; Guenther Andreas; Guenther Andreas; Rubin Bruce K</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Proteases have been shown to degrade airway mucin proteins and to damage the epithelium impairing mucociliary clearance.  There are increased proteases in the COPD airway but changes in protease-antiprotease balance and mucin degradation have not been investigated during the course of a COPD exacerbation.  We hypothesized that increased protease levels would lead to mucin degradation in acute COPD exacerbations.  METHODS:  We measured neutrophil elastase (NE) and alpha 1 protease inhibitor (A1-PI) levels using immunoblotting, and conducted protease inhibitor studies, zymograms, elastin substrate assays and cigarette smoke condensate experiments to evaluate the stability of the gel-forming mucins, MUC5AC and MUC5B, before and 5-6 weeks after an acute pulmonary exacerbation of COPD (n = 9 subjects).  RESULTS:  Unexpectedly, mucin concentration and mucin stability were highest at the start of the exacerbation and restored to baseline after 6 weeks.  Consistent with these data, immunoblots and zymograms confirmed decreased NE concentration and activity and increased A1-PI at the start of the exacerbation.  After recovery there was an increase in NE activity and a decrease in A1-PI levels.  In vitro, protease inhibitor studies demonstrated that serine proteases played a key role in mucin degradation.  Mucin stability was further enhanced upon treating with cigarette smoke condensate (CSC).  CONCLUSION:  There appears to be rapid consumption of secreted proteases due to an increase in antiproteases, at the start of a COPD exacerbation.  This leads to increased mucin gel stability which may be important in trapping and clearing infectious and inflammatory mediators, but this may also contribute acutely to mucus retention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-fuLe5VCDtK-9TkgmBqTqfW6udTcc2ebXXINdXW-Ehrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FivVKrsA%253D%253D&md5=a285e6600fc7af294c94a7cf0478f678</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1186%2Fs12931-015-0247-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-015-0247-x%26sid%3Dliteratum%253Aachs%26aulast%3DChillappagari%26aufirst%3DS.%26aulast%3DPreuss%26aufirst%3DJ.%26aulast%3DLicht%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DMahavadi%26aufirst%3DP.%26aulast%3DSarode%26aufirst%3DG.%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DGuenther%26aufirst%3DA.%26aulast%3DNahrlich%26aufirst%3DL.%26aulast%3DRubin%26aufirst%3DB.%2BK.%26aulast%3DHenke%26aufirst%3DM.%2BO.%26atitle%3DAltered%2520protease%2520and%2520antiprotease%2520balance%2520during%2520a%2520COPD%2520exacerbation%2520contributes%2520to%2520mucus%2520obstruction%26jtitle%3DRespir.%2520Res.%26date%3D2015%26volume%3D16%26spage%3D85%26doi%3D10.1186%2Fs12931-015-0247-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gudmann, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manon-Jensen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sand, J. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diefenbach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsdal, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeming, D. J.</span></span> <span> </span><span class="NLM_article-title">Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">1284</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bbrc.2018.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=30017196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlart73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2018&pages=1284-1290&author=N.+S.+Gudmannauthor=T.+Manon-Jensenauthor=J.+M.+B.+Sandauthor=C.+Diefenbachauthor=S.+Sunauthor=A.+Danielsenauthor=M.+A.+Karsdalauthor=D.+J.+Leeming&title=Lung+tissue+destruction+by+proteinase+3+and+cathepsin+G+mediated+elastin+degradation+is+elevated+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.bbrc.2018.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Gudmann, Natasja Staehr; Manon-Jensen, Tina; Sand, Jannie Marie Bulow; Diefenbach, Claudia; Sun, Shu; Danielsen, Annette; Karsdal, Morten Asser; Leeming, Diana Julie</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1284-1290</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is characterized by high levels of protease activity leading to degrdn. of elastin followed by loss of elasticity of the lung and the development of emphysema.  Elastin is an essential structural component of the lung parenchyma to support the expansion and recoil of the alveoli during breathing.  The lung extracellular matrix is vulnerable to pathol. structural changes upon upregulation of serine proteases, including cathepsin G (CG) and proteinase 3 (PR3).  In this study, we explored the diagnostic features of elastin neo-epitopes generated by CG and PR3.  Two novel competitive enzyme-linked immunosorbent assays (ELISA) measuring CG and PR3 generated elastin fragments (EL-CG and ELP-3 resp.) were developed for assessment in serum.  Both assays were tech. robust and biol. validated in serum from patients with COPD.  Serol. levels of both elastin fragments were significantly elevated in patients with COPD compared to healthy controls.  These data suggest that EL-CG and ELP-3 may serve as plausible biol. markers of destructive changes in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps5lOyntqj07Vg90H21EOLACvtfcHk0lhIM64NNaNFTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlart73O&md5=a0cacd904df6c629630aab578cf6ad2c</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DGudmann%26aufirst%3DN.%2BS.%26aulast%3DManon-Jensen%26aufirst%3DT.%26aulast%3DSand%26aufirst%3DJ.%2BM.%2BB.%26aulast%3DDiefenbach%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DDanielsen%26aufirst%3DA.%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26aulast%3DLeeming%26aufirst%3DD.%2BJ.%26atitle%3DLung%2520tissue%2520destruction%2520by%2520proteinase%25203%2520and%2520cathepsin%2520G%2520mediated%2520elastin%2520degradation%2520is%2520elevated%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D503%26spage%3D1284%26epage%3D1290%26doi%3D10.1016%2Fj.bbrc.2018.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sjö, P.</span></span> <span> </span><span class="NLM_article-title">Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4155%2Ffmc.12.17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22458683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC38rgsF2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=651-660&author=P.+Sj%C3%B6&title=Neutrophil+elastase+inhibitors%3A+recent+advances+in+the+development+of+mechanism-based+and+nonelectrophilic+inhibitors&doi=10.4155%2Ffmc.12.17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors</span></div><div class="casAuthors">Sjo Peter</div><div class="citationInfo"><span class="NLM_cas:title">Future medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">651-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Due to its implication in pathologies of prevalent diseases such as chronic obstructive pulmonary disease, fibrosis, bronchiectasis and ARDS, the serine protease, human neutrophil elastase, has been in focus for drug-development efforts over the last two decades.  In recent years, continued efforts to identify and optimize novel mechanism-based inhibitors have led to a number of new inhibitors being reported.  These compounds show promising potency and selectivity profiles, although their use is still limited by their inherent stability.  Recently, two novel classes of potent and selective, synthetic, nonelectrophilic human neutrophil elastase inhibitors that display improved stability and overall drug-like properties have been reported.  The most advanced compound from these classes, AZD9668, has been reported to show significant effects on relevant biomarkers in bronchiectasis and cystic fibrosis patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnXplirlesAUmhnSqMnvzDfW6udTcc2ebQeYcpwtwG_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rgsF2gsg%253D%253D&md5=d3f350f9e0d9ebdcb7deb695f46fea48</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.17%26sid%3Dliteratum%253Aachs%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DNeutrophil%2520elastase%2520inhibitors%253A%2520recent%2520advances%2520in%2520the%2520development%2520of%2520mechanism-based%2520and%2520nonelectrophilic%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D651%26epage%3D660%26doi%3D10.4155%2Ffmc.12.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gremillion, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, T.</span></span> <span> </span><span class="NLM_article-title">Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress (ARDS): a systematic review and meta-analysis</span>. <i>Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2423</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.2169/internalmedicine.49.4010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2169%2Finternalmedicine.49.4010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21088343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3cbotVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=2423-2432&author=K.+Iwataauthor=A.+Doiauthor=G.+Ohjiauthor=H.+Okaauthor=Y.+Obaauthor=K.+Takimotoauthor=W.+Igarashiauthor=D.+H.+Gremillionauthor=T.+Shimada&title=Effect+of+neutrophil+elastase+inhibitor+%28sivelestat+sodium%29+in+the+treatment+of+acute+lung+injury+%28ALI%29+and+acute+respiratory+distress+%28ARDS%29%3A+a+systematic+review+and+meta-analysis&doi=10.2169%2Finternalmedicine.49.4010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis</span></div><div class="casAuthors">Iwata Kentaro; Doi Asako; Ohji Goh; Oka Hideaki; Oba Yuichiro; Takimoto Kohei; Igarashi Wataru; Gremillion David H; Shimada Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Internal medicine (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2423-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Sivelestat is neutrophil elastase inhibitor, which is widely used in Japan for the treatment of acute lung injury.  However, the clinical efficacy of the medication has not been convincingly demonstrated.  METHODS:  We conducted a systematic review and meta-analysis of randomized controlled trials on sivelestat for the treatment of acute lung injury and acute respiratory distress syndrome.  Studies were identified using MEDLINE, EMBASE, Cochrane library, conference proceedings, and references of included studies.  Authors were contacted if necessary.  ICHUSHI, the Japanese database for medical literature and conference proceedings was also used for the search, since many studies on sivelestat were published in Japanese language and not registered in major databases such as MEDLINE.  The primary outcome was mortality within 28-30 days after randomization.  Relative risks were pooled with the random effect model.  RESULTS:  8 trials were included in the analysis.  There was no difference in mortality within 28-30 days after randomization (relative risk 0.95, 95% confidence interval 0.72 to 1.26).  Subgroup analysis conducted only on studies conducted in Japan showed the same result (0.59, 0.28 to 1.28).  There was no difference in mechanical ventilation days (standardized mean difference -0.43, -1.12 to 0.27), but sivelestat was associated with a better short term PaO(2)/FiO(2) ratio (0.30, 0.05 to 0.56).  Heterogeneity was not significant for the main analysis and funnel plot did not suggest publication bias.  CONCLUSION:  Sivelestat was not associated with decreased mortality, even when including studies published in Japanese language.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRv_-Z2qP_xPh3YQQtAhNufW6udTcc2ebQeYcpwtwG_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbotVelsQ%253D%253D&md5=12473c878a1d894ff1847afb7a655f04</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2169%2Finternalmedicine.49.4010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2169%252Finternalmedicine.49.4010%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DA.%26aulast%3DOhji%26aufirst%3DG.%26aulast%3DOka%26aufirst%3DH.%26aulast%3DOba%26aufirst%3DY.%26aulast%3DTakimoto%26aufirst%3DK.%26aulast%3DIgarashi%26aufirst%3DW.%26aulast%3DGremillion%26aufirst%3DD.%2BH.%26aulast%3DShimada%26aufirst%3DT.%26atitle%3DEffect%2520of%2520neutrophil%2520elastase%2520inhibitor%2520%2528sivelestat%2520sodium%2529%2520in%2520the%2520treatment%2520of%2520acute%2520lung%2520injury%2520%2528ALI%2529%2520and%2520acute%2520respiratory%2520distress%2520%2528ARDS%2529%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DIntern.%2520Med.%26date%3D2010%26volume%3D49%26spage%3D2423%26epage%3D2432%26doi%3D10.2169%2Finternalmedicine.49.4010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerheiligen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anlauf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bärfacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbeck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gielen-Haertwig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haning, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karthaus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosentreter, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telan, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tersteegen, A.</span></span> <span> </span><span class="NLM_article-title">Freezing the bioactive conformation to boost potency: the identification of BAY 85–8501, a selective and potent inhibitor of human neutrophil elastase for pulmonary diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1173</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1002%2Fcmdc.201500131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26083237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1163-1173&author=F.+von%0ANussbaumauthor=V.+M.+Liauthor=S.+Allerheiligenauthor=S.+Anlaufauthor=L.+B%C3%A4rfackerauthor=M.+Bechemauthor=M.+Delbeckauthor=M.+F.+Fitzgeraldauthor=M.+Gerischauthor=H.+Gielen-Haertwigauthor=H.+Haningauthor=D.+Karthausauthor=D.+Langauthor=K.+Lustigauthor=D.+Meibomauthor=J.+Mittendorfauthor=U.+Rosentreterauthor=M.+Sch%C3%A4ferauthor=S.+Sch%C3%A4ferauthor=J.+Schambergerauthor=L.+A.+Telanauthor=A.+Tersteegen&title=Freezing+the+bioactive+conformation+to+boost+potency%3A+the+identification+of+BAY+85%E2%80%938501%2C+a+selective+and+potent+inhibitor+of+human+neutrophil+elastase+for+pulmonary+diseases&doi=10.1002%2Fcmdc.201500131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases</span></div><div class="casAuthors">von Nussbaum, Franz; Li, Volkhart M.-J.; Allerheiligen, Swen; Anlauf, Sonja; Baerfacker, Lars; Bechem, Martin; Delbeck, Martina; Fitzgerald, Mary F.; Gerisch, Michael; Gielen-Haertwig, Heike; Haning, Helmut; Karthaus, Dagmar; Lang, Dieter; Lustig, Klemens; Meibom, Daniel; Mittendorf, Joachim; Rosentreter, Ulrich; Schaefer, Martina; Schaefer, Stefan; Schamberger, Jens; Telan, Leila A.; Tersteegen, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1163-1173</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Human neutrophil elastase (HNE) is a key protease for matrix degrdn.  High HNE activity is obsd. in inflammatory diseases.  Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH).  HNE inhibitors should reestablish the protease-anti-protease balance.  By means of medicinal chem. a novel dihydropyrimidinone lead-structure class was identified.  Further chem. optimization yielded orally active compds. with favorable pharmacokinetics such as the chem. probe BAY-678.  While maintaining outstanding target selectivity, picomolar potency was achieved by locking the bioactive conformation of these inhibitors with a strategically positioned Me sulfone substituent.  An induced-fit binding mode allowed tight interactions with the S2 and S1 pockets of HNE.  BAY 85-8501 ((4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile) was shown to be efficacious in a rodent animal model related to ALI.  BAY 85-8501 is currently being tested in clin. studies for the treatment of pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWfeHJY2lnE7Vg90H21EOLACvtfcHk0lgkhI0DDix1ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtb3N&md5=bb2997077d114dde6769896f50574d3c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500131%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DV.%2BM.%26aulast%3DAllerheiligen%26aufirst%3DS.%26aulast%3DAnlauf%26aufirst%3DS.%26aulast%3DB%25C3%25A4rfacker%26aufirst%3DL.%26aulast%3DBechem%26aufirst%3DM.%26aulast%3DDelbeck%26aufirst%3DM.%26aulast%3DFitzgerald%26aufirst%3DM.%2BF.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DGielen-Haertwig%26aufirst%3DH.%26aulast%3DHaning%26aufirst%3DH.%26aulast%3DKarthaus%26aufirst%3DD.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DLustig%26aufirst%3DK.%26aulast%3DMeibom%26aufirst%3DD.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DRosentreter%26aufirst%3DU.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DS.%26aulast%3DSchamberger%26aufirst%3DJ.%26aulast%3DTelan%26aufirst%3DL.%2BA.%26aulast%3DTersteegen%26aufirst%3DA.%26atitle%3DFreezing%2520the%2520bioactive%2520conformation%2520to%2520boost%2520potency%253A%2520the%2520identification%2520of%2520BAY%252085%25E2%2580%25938501%252C%2520a%2520selective%2520and%2520potent%2520inhibitor%2520of%2520human%2520neutrophil%2520elastase%2520for%2520pulmonary%2520diseases%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1163%26epage%3D1173%26doi%3D10.1002%2Fcmdc.201500131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crocetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepetkin, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilibrizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giomi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khlebnikov, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannoni, M. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">6259</span>– <span class="NLM_lpage">6272</span>, <span class="refDoi"> DOI: 10.1021/jm400742j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400742j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSis7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6259-6272&author=L.+Crocettiauthor=I.+A.+Schepetkinauthor=A.+Cilibrizziauthor=A.+Grazianoauthor=C.+Vergelliauthor=D.+Giomiauthor=A.+I.+Khlebnikovauthor=M.+T.+Quinnauthor=M.+P.+Giovannoni&title=Optimization+of+N-benzoylindazole+derivatives+as+inhibitors+of+human+neutrophil+elastase&doi=10.1021%2Fjm400742j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of N-Benzoylindazole Derivatives as Inhibitors of Human Neutrophil Elastase</span></div><div class="casAuthors">Crocetti, Letizia; Schepetkin, Igor A.; Cilibrizzi, Agostino; Graziano, Alessia; Vergelli, Claudia; Giomi, Donatella; Khlebnikov, Andrei I.; Quinn, Mark T.; Giovannoni, Maria Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6259-6272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases.  Previously, we identified novel N-benzoylindazole derivs. as potent, competitive, and pseudoirreversible HNE inhibitors.  Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads.  Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ∼10 nM) and modifications at position 3 resulted the most potent compd. in this series, the 3-CN deriv. 5b (IC50 = 7 nM); both derivs. demonstrated good stability and specificity for HNE vs. other serine proteases.  Mol. docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes.  Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTvXsdp5MK8bVg90H21EOLACvtfcHk0lgkhI0DDix1ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSis7bM&md5=edcc9aaa1c3589c5b044f12138c15986</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm400742j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400742j%26sid%3Dliteratum%253Aachs%26aulast%3DCrocetti%26aufirst%3DL.%26aulast%3DSchepetkin%26aufirst%3DI.%2BA.%26aulast%3DCilibrizzi%26aufirst%3DA.%26aulast%3DGraziano%26aufirst%3DA.%26aulast%3DVergelli%26aufirst%3DC.%26aulast%3DGiomi%26aufirst%3DD.%26aulast%3DKhlebnikov%26aufirst%3DA.%2BI.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26aulast%3DGiovannoni%26aufirst%3DM.%2BP.%26atitle%3DOptimization%2520of%2520N-benzoylindazole%2520derivatives%2520as%2520inhibitors%2520of%2520human%2520neutrophil%2520elastase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6259%26epage%3D6272%26doi%3D10.1021%2Fjm400742j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enghild, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrydstrup, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7900</span>– <span class="NLM_lpage">7908</span>, <span class="refDoi"> DOI: 10.1021/jm301000k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301000k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOru77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7900-7908&author=J.+L.+Madsenauthor=T.+L.+Andersenauthor=S.+Santamariaauthor=H.+Nagaseauthor=J.+J.+Enghildauthor=T.+Skrydstrup&title=Synthesis+and+evaluation+of+silanediols+as+highly+selective+uncompetitive+inhibitors+of+human+neutrophil+elastase&doi=10.1021%2Fjm301000k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase</span></div><div class="casAuthors">Madsen, Julie L. H.; Andersen, Thomas L.; Santamaria, Salvatore; Nagase, Hideaki; Enghild, Jan J.; Skrydstrup, Troels</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7900-7908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is an increasing health problem and is estd. to be the fifth leading cause of death in 2020 according to the World Health Organization.  Current treatments are only palliative, and therefore the development of new medicine for the treatment of COPD is urgent.  Human Neutrophil Elastase (HNE) is a serine protease that is heavily involved in the progression of COPD through inflammatory breakdown of lung tissue.  Consequently, inhibitors of HNE are of great interest as therapeutics.  In this article, the development of silanediol peptide isostere as inhibitors of HNE is presented.  Kinetic studies revealed that incorporation of a silanediol isostere in the inhibitor structure resulted in an uncompetitive mechanism of inhibition, which further resulted in excellent selectivity.  The peculiar mechanism of inhibition and the resulting selectivity makes the presented inhibitors promising leads for the development of new HNE-inhibitor-based therapeutics for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0hSNFQQrF0LVg90H21EOLACvtfcHk0lgkhI0DDix1ng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOru77F&md5=24f9ceffc1ab93a172f9fdb887120cac</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm301000k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301000k%26sid%3Dliteratum%253Aachs%26aulast%3DMadsen%26aufirst%3DJ.%2BL.%26aulast%3DAndersen%26aufirst%3DT.%2BL.%26aulast%3DSantamaria%26aufirst%3DS.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DEnghild%26aufirst%3DJ.%2BJ.%26aulast%3DSkrydstrup%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520silanediols%2520as%2520highly%2520selective%2520uncompetitive%2520inhibitors%2520of%2520human%2520neutrophil%2520elastase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7900%26epage%3D7908%26doi%3D10.1021%2Fjm301000k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Costa, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, R. C.</span></span> <span> </span><span class="NLM_article-title">Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9802</span>– <span class="NLM_lpage">9806</span>, <span class="refDoi"> DOI: 10.1021/jm4011725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOmsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9802-9806&author=S.+D.+Lucasauthor=L.+M.+Gon%C3%A7alvesauthor=L.+A.+Carvalhoauthor=H.+F.+Correiaauthor=E.+M.+Da+Costaauthor=R.+A.+Guedesauthor=R.+Moreiraauthor=R.+C.+Guedes&title=Optimization+of+O3-acyl+kojic+acid+derivatives+as+potent+and+selective+human+neutrophil+elastase+inhibitors&doi=10.1021%2Fjm4011725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of O3-Acyl Kojic Acid Derivatives as Potent and Selective Human Neutrophil Elastase Inhibitors</span></div><div class="casAuthors">Lucas, Susana D.; Goncalves, Lidia M.; Carvalho, Luis A. R.; Correia, Henrique F.; Da Costa, Eduardo M. R.; Guedes, Romina A.; Moreira, Rui; Guedes, Rita C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9802-9806</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human neutrophil elastase (HNE) is an attractive target for treating chronic and acute inflammatory lung diseases.  An optimization campaign of the kojic acid scaffold to develop new potent HNE inhibitors is reported.  O3-Pivaloyl derivs. I (X = O, R1 = Q, Q1; X = NPh, R1 = Q1) were shown to be the most potent inhibitors with IC5o values down to 80 nM.  These compds. presented excellent selectivity and cytotoxicity profiles with suitable ligand efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa_3ZDmgEbCLVg90H21EOLACvtfcHk0lieXM_hmdKWag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOmsrvE&md5=ca456fa874a24666466f53f359aa8b4d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjm4011725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011725%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%2BD.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DL.%2BM.%26aulast%3DCarvalho%26aufirst%3DL.%2BA.%26aulast%3DCorreia%26aufirst%3DH.%2BF.%26aulast%3DDa%2BCosta%26aufirst%3DE.%2BM.%26aulast%3DGuedes%26aufirst%3DR.%2BA.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DGuedes%26aufirst%3DR.%2BC.%26atitle%3DOptimization%2520of%2520O3-acyl%2520kojic%2520acid%2520derivatives%2520as%2520potent%2520and%2520selective%2520human%2520neutrophil%2520elastase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9802%26epage%3D9806%26doi%3D10.1021%2Fjm4011725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearing, A. J.</span></span> <span> </span><span class="NLM_article-title">Design and therapeutic application of matrix metalloproteinase inhibitors</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">2735</span>– <span class="NLM_lpage">2776</span>, <span class="refDoi"> DOI: 10.1021/cr9804543</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9804543" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK1MXls1Kku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=2735-2776&author=M.+Whittakerauthor=C.+D.+Floydauthor=P.+Brownauthor=A.+J.+Gearing&title=Design+and+therapeutic+application+of+matrix+metalloproteinase+inhibitors&doi=10.1021%2Fcr9804543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors</span></div><div class="casAuthors">Whittaker, Mark; Floyd, Christopher D.; Brown, Peter; Gearing, Andrew J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2735-2776</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 389 refs.  MMP inhibitors may be an important new class of therapeutic agents for the treatment of diseases characterized by excessive extracellular matrix degrdn. and/or remodelling, such as cancer and chronic inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and MS.  This review describes progress in the design of MMP inhibitors and outlines the results of early clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGACjaK8AEZbVg90H21EOLACvtfcHk0lieXM_hmdKWag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXls1Kku7c%253D&md5=e226080188f791f5d1ce8c61b64ad33a</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fcr9804543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9804543%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DC.%2BD.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DGearing%26aufirst%3DA.%2BJ.%26atitle%3DDesign%2520and%2520therapeutic%2520application%2520of%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DChem.%2520Rev.%26date%3D1999%26volume%3D99%26spage%3D2735%26epage%3D2776%26doi%3D10.1021%2Fcr9804543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. L.</span></span> <span> </span><span class="NLM_article-title">Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1164/rccm.200212-1396OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200212-1396OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12522030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD3s7psF2htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2003&pages=1083-1089&author=A.+Churgauthor=R.+D.+Wangauthor=H.+Taiauthor=X.+Wangauthor=C.+Xieauthor=J.+Daiauthor=S.+D.+Shapiroauthor=J.+L.+Wright&title=Macrophage+metalloelastase+mediates+acute+cigarette+smoke-induced+inflammation+via+tumor+necrosis+factor-alpha+release&doi=10.1164%2Frccm.200212-1396OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release</span></div><div class="casAuthors">Churg Andrew; Wang Rong D; Tai Hsin; Wang Xiaoshan; Xie Changshi; Dai Jin; Shapiro Steven D; Wright Joanne L</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1083-9</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The cells and proteases that mediate cigarette smoke-induced emphysema are controversial, with evidence favoring either neutrophils and neutrophil-derived serine proteases or macrophages and macrophage-derived metalloproteases as the important effectors.  We recently reported that both macrophage metalloelastase (MMP-12) and neutrophils are required for acute cigarette smoke-induced connective tissue breakdown, the precursor of emphysema.  Here we show how these disparate observations can be linked.  Both wild-type (MMP-12 +/+) mice and mice lacking MMP-12 (MMP-12 -/-) demonstrated rapid increases in whole-lung nuclear factor-kappaB activation and gene expression of proinflammatory cytokines after cigarette smoke exposure, indicating that a lack of MMP-12 does not produce a global failure to upregulate inflammatory mediators.  However, only MMP-12 +/+ mice demonstrated increased whole-lung tumor necrosis factor-alpha (TNF-alpha) protein or release of TNF-alpha from cultured alveolar macrophages exposed to smoke in vitro.  Levels of whole-lung E-selectin, an endothelial activation marker, were increased in only MMP-12 +/+ mice.  These findings suggest that, acutely, MMP-12 mediates smoke-induced inflammation by releasing TNF-alpha from macrophages, with subsequent endothelial activation, neutrophil influx, and proteolytic matrix breakdown caused by neutrophil-derived proteases.  TNF-alpha release may be a general mechanism whereby metalloproteases drive cigarette smoke-induced inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWRAWObDPcQNTiMd2aNQVUfW6udTcc2eZL8zUbDSrgRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s7psF2htw%253D%253D&md5=19f670fda0e1eb5db6980ce4418e11d9</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1164%2Frccm.200212-1396OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200212-1396OC%26sid%3Dliteratum%253Aachs%26aulast%3DChurg%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DR.%2BD.%26aulast%3DTai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DShapiro%26aufirst%3DS.%2BD.%26aulast%3DWright%26aufirst%3DJ.%2BL.%26atitle%3DMacrophage%2520metalloelastase%2520mediates%2520acute%2520cigarette%2520smoke-induced%2520inflammation%2520via%2520tumor%2520necrosis%2520factor-alpha%2520release%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2003%26volume%3D167%26spage%3D1083%26epage%3D1089%26doi%3D10.1164%2Frccm.200212-1396OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hautamaki, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senior, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S. D.</span></span> <span> </span><span class="NLM_article-title">Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">2002</span>– <span class="NLM_lpage">2004</span>, <span class="refDoi"> DOI: 10.1126/science.277.5334.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1126%2Fscience.277.5334.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=9302297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK2sXmt12qt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=2002-2004&author=R.+D.+Hautamakiauthor=D.+K.+Kobayashiauthor=R.+M.+Seniorauthor=S.+D.+Shapiro&title=Requirement+for+macrophage+elastase+for+cigarette+smoke-induced+emphysema+in+mice&doi=10.1126%2Fscience.277.5334.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice</span></div><div class="casAuthors">Hautamaki, R. Dean; Kobayashi, Dale K.; Senior, Robert M.; Shapiro, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5334</span>),
    <span class="NLM_cas:pages">2002-2004</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">To det. which proteinases are responsible for the lung destruction characteristic of pulmonary emphysema, macrophage elastase-deficient (MME-/-) mice were subjected to cigarette smoke.  In contrast to wild-type mice, MME-/- mice did not have increased nos. of macrophages in their lungs and did not develop emphysema in response to long-term exposure to cigarette smoke.  Smoke-exposed MME-/- mice that received monthly intratracheal instillations of monocyte chemoattractant protein-1 showed accumulation of alveolar macrophages but did not develop air space enlargement.  Thus, macrophage elastase is probably sufficient for the development of emphysema that result from chronic inhalation of cigarette smoke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqojA6ekXaolLVg90H21EOLACvtfcHk0lgYV40PPKfgyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt12qt7Y%253D&md5=32540b3d50176e2276dc4493e1e7e50b</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5334.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5334.2002%26sid%3Dliteratum%253Aachs%26aulast%3DHautamaki%26aufirst%3DR.%2BD.%26aulast%3DKobayashi%26aufirst%3DD.%2BK.%26aulast%3DSenior%26aufirst%3DR.%2BM.%26aulast%3DShapiro%26aufirst%3DS.%2BD.%26atitle%3DRequirement%2520for%2520macrophage%2520elastase%2520for%2520cigarette%2520smoke-induced%2520emphysema%2520in%2520mice%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D2002%26epage%3D2004%26doi%3D10.1126%2Fscience.277.5334.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nénan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagente, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planquois, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boichot, E.</span></span> <span> </span><span class="NLM_article-title">Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.11.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.ejphar.2006.11.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17234180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Kitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2007&pages=75-81&author=S.+N%C3%A9nanauthor=V.+Lagenteauthor=J.+M.+Planquoisauthor=S.+Hitierauthor=P.+Bernaauthor=C.+P.+Bertrandauthor=E.+Boichot&title=Metalloelastase+%28MMP-12%29+induced+inflammatory+response+in+mice+airways%3A+effects+of+dexamethasone%2C+rolipram+and+marimastat&doi=10.1016%2Fj.ejphar.2006.11.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Metalloelastase (MMP-12) induced inflammatory response in mice airways: Effects of dexamethasone, rolipram and marimastat</span></div><div class="casAuthors">Nenan, Soazig; Lagente, Vincent; Planquois, Jean-Michel; Hitier, Simon; Berna, Patrick; Bertrand, Claude P.; Boichot, Elisabeth</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Direct instillation of a recombinant human form of MMP-12 (rhMMP-12) in mice airways elicited an early inflammatory response characterized by neutrophil influx, cytokine release and gelatinase activation followed by a delayed response, mainly characterized by macrophage recruitment.  As this exptl. model of lung inflammation partially mimics some features of chronic obstructive pulmonary disease (COPD), we have investigated the effects of treatment by anti-inflammatory compds., dexamethasone and rolipram and a non-specific matrix metalloproteinase (MMP) inhibitor, marimastat.  The compds. were administered orally, 1 h before rhMMP-12 instillation (8×10- 3 U/mouse).  Total and differential cell counts were evaluated in the bronchoalveolar lavage fluids.  Cytokines and MMP-9 were quantified in bronchoalveolar lavage fluids and in lung homogenate supernatants.  Marimastat (100 mg/kg), dexamethasone (10 mg/kg) and rolipram (0.1 and 0.3 mg/kg) were able to decrease significantly neutrophil recruitment at 4 and 24 h after rhMMP-12 instillation, but only marimastat (30 and 100 mg/kg) was effective at decreasing the macrophage recruitment occurring at day 7.  Marimastat (100 mg/kg), dexamethasone (10 mg/kg) and rolipram (0.3 mg/kg) reduced significantly IL-6, KC/CXCL1, MIP-1α/CCL3 and MMP-9 levels in bronchoalveolar lavage fluid.  Similar results were obtained in lung homogenates except with rolipram.  Dexamethasone and rolipram were able to inhibit the early inflammatory response but were ineffective to limit the macrophage influx.  In contrast, marimastat was able to reduce early and late response.  These data indicate that MMP-12 instillation in mice could highlight some of the inflammatory response seen in COPD and could be used for the pharmacol. evaluation of new anti-inflammatory mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx-wOWDKdj5bVg90H21EOLACvtfcHk0lhxSKH6rtNYQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Kitbs%253D&md5=0d6476f6791c47f68fc63beab8ee35bc</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.11.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.11.070%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25A9nan%26aufirst%3DS.%26aulast%3DLagente%26aufirst%3DV.%26aulast%3DPlanquois%26aufirst%3DJ.%2BM.%26aulast%3DHitier%26aufirst%3DS.%26aulast%3DBerna%26aufirst%3DP.%26aulast%3DBertrand%26aufirst%3DC.%2BP.%26aulast%3DBoichot%26aufirst%3DE.%26atitle%3DMetalloelastase%2520%2528MMP-12%2529%2520induced%2520inflammatory%2520response%2520in%2520mice%2520airways%253A%2520effects%2520of%2520dexamethasone%252C%2520rolipram%2520and%2520marimastat%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D559%26spage%3D75%26epage%3D81%26doi%3D10.1016%2Fj.ejphar.2006.11.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imrie, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neoptolemos, J. P.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of marimastat in advanced pancreatic cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1865</span>– <span class="NLM_lpage">1870</span>, <span class="refDoi"> DOI: 10.1054/bjoc.2001.2168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1054%2Fbjoc.2001.2168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11747327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=1865-1870&author=J.+D.+Evansauthor=A.+Starkauthor=C.+D.+Johnsonauthor=F.+Danielauthor=J.+Carmichaelauthor=J.+Buckelsauthor=C.+W.+Imrieauthor=P.+Brownauthor=J.+P.+Neoptolemos&title=A+phase+II+trial+of+marimastat+in+advanced+pancreatic+cancer&doi=10.1054%2Fbjoc.2001.2168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of marimastat in advanced pancreatic cancer</span></div><div class="casAuthors">Evans, J. D.; Stark, A.; Johnson, C. D.; Daniel, F.; Carmichael, J.; Buckels, J.; Imrie, C. W.; Brown, P.; Neoptolemos, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1865-1870</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy.  Inhibition of matrix metalloproteinase activity involved in tumor invasion and metastases is a novel biol. approach for cancer treatment.  This multicenter phase II clin. trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer.  A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14).  Patients with a response to treatment could continue marimastat beyond 28 days.  Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment.  The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study.  There were 31 patients (27%) who required dose modification.  Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9.  Of 83 patients with radiol. assessable disease, 41 (49%) had stable disease.  The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9.  The overall survival was 3.8 mo. 5.9 mo for stage II, 4.7 mo for stage III and 3 mo for stage IV disease.  Of 90 patients, 46 (51%) had stabilization or redn. in pain, mobility and analgesia scores.  Further development and clin. evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcKXN9MYpukLVg90H21EOLACvtfcHk0lhxSKH6rtNYQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVWnuro%253D&md5=dacde8515ddb3ae90c2e6cd5b40cc7aa</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.2168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.2168%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DJ.%2BD.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DC.%2BD.%26aulast%3DDaniel%26aufirst%3DF.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DBuckels%26aufirst%3DJ.%26aulast%3DImrie%26aufirst%3DC.%2BW.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DNeoptolemos%26aufirst%3DJ.%2BP.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520marimastat%2520in%2520advanced%2520pancreatic%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D85%26spage%3D1865%26epage%3D1870%26doi%3D10.1054%2Fbjoc.2001.2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bramhall, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallissey, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholefield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maughan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielding, J. W.</span></span> <span> </span><span class="NLM_article-title">Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1864</span>– <span class="NLM_lpage">1870</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6600310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fsj.bjc.6600310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12085177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVaiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2002&pages=1864-1870&author=S.+R.+Bramhallauthor=M.+T.+Hallisseyauthor=J.+Whitingauthor=J.+Scholefieldauthor=G.+Tierneyauthor=R.+C.+Stuartauthor=R.+E.+Hawkinsauthor=P.+McCullochauthor=T.+Maughanauthor=P.+D.+Brownauthor=M.+Bailletauthor=J.+W.+Fielding&title=Marimastat+as+maintenance+therapy+for+patients+with+advanced+gastric+cancer%3A+a+randomised+trial&doi=10.1038%2Fsj.bjc.6600310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial</span></div><div class="casAuthors">Bramhall, S. R.; Hallissey, M. T.; Whiting, J.; Scholefield, J.; Tierney, G.; Stuart, R. C.; Hawkins, R. E.; McCulloch, P.; Maughan, T.; Brown, P. D.; Baillet, M.; Fielding, J. W. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1864-1870</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This randomized, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastroesophageal adenocarcinoma.  Three hundred sixty-nine patients with histol. proof of adenocarcinoma, who had received no more than a single regimen of 5-fluorouracil-based chemotherapy, were randomized to receive either marimastat (10 mg b.d.) or placebo.  Patients were treated for as long as was tolerable.  The primary endpoint was overall survival with secondary endpoints of time to disease progression and quality of life.  At the point of protocol-defined study completion (85% mortality in the placebo arm) there was a modest difference in survival in the intention-to-treat population in favor of marimastat (P=0.07 log-rank test, hazard ratio=1.23 (95% confidence interval 0.98-1.55)).  This survival benefit was maintained over a further 2 yr of follow-up (P=0.024, hazard ratio=1.27 (1.03-1.57)).  The median survival was 138 days for placebo and 160 days for marimastat, with 2-yr survival of 3% and 9% resp.  A significant survival benefit was identified at study completion in the pre-defined sub-group of 123 patients who had received prior chemotherapy (P=0.045, hazard ratio=1.53 (1.00-2.34)).  This benefit increased with 2 yr addnl. follow-up (P=0.006, hazard ratio=1.68 (1.16-2.44)), with 2-yr survival of 5% and 18% resp.  Progression-free survival was also significantly longer for patients receiving marimastat compared to placebo (P=0.009, hazard ratio=1.32 (1.07-1.63)).  Marimastat treatment was assocd. with the development of musculoskeletal pain and inflammation.  Events of anemia, abdominal pain, jaundice and wt. loss were more common in the placebo arm.  This is one of the first demonstrations of a therapeutic benefit for a matrix metalloproteinase inhibitor in cancer patients.  The greatest benefit was obsd. in patients who had previously received chemotherapy.  A further randomised study of marimastat in these patients is warranted. doi:10.1038/sj.bjc.6600310 www.bjcancer.com.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsDzh16ALsKbVg90H21EOLACvtfcHk0lhN96-7fMLx3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVaiurY%253D&md5=a9a36c873c4c5e73526dd47ffddf87cb</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600310%26sid%3Dliteratum%253Aachs%26aulast%3DBramhall%26aufirst%3DS.%2BR.%26aulast%3DHallissey%26aufirst%3DM.%2BT.%26aulast%3DWhiting%26aufirst%3DJ.%26aulast%3DScholefield%26aufirst%3DJ.%26aulast%3DTierney%26aufirst%3DG.%26aulast%3DStuart%26aufirst%3DR.%2BC.%26aulast%3DHawkins%26aufirst%3DR.%2BE.%26aulast%3DMcCulloch%26aufirst%3DP.%26aulast%3DMaughan%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DP.%2BD.%26aulast%3DBaillet%26aufirst%3DM.%26aulast%3DFielding%26aufirst%3DJ.%2BW.%26atitle%3DMarimastat%2520as%2520maintenance%2520therapy%2520for%2520patients%2520with%2520advanced%2520gastric%2520cancer%253A%2520a%2520randomised%2520trial%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D86%26spage%3D1864%26epage%3D1870%26doi%3D10.1038%2Fsj.bjc.6600310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onnervik, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. L.</span></span> <span> </span><span class="NLM_article-title">Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">713</span>, <span class="refDoi"> DOI: 10.1136/thx.2006.068353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1136%2Fthx.2006.068353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17311841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2svms1SktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=706-713&author=A.+Churgauthor=R.+Wangauthor=X.+Wangauthor=P.+O.+Onnervikauthor=K.+Thimauthor=J.+L.+Wright&title=Effect+of+an+MMP-9%2FMMP-12+inhibitor+on+smoke-induced+emphysema+and+airway+remodelling+in+guinea+pigs&doi=10.1136%2Fthx.2006.068353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs</span></div><div class="casAuthors">Churg Andrew; Wang Rona; Wang Xiaoshan; Onnervik Per-Ola; Thim Kerstin; Wright Joanne L</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">706-13</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Matrix metalloproteases (MMPs) are believed to be important in the pathogenesis of cigarette smoke-induced emphysema, but this hypothesis has only been proved in the mouse and its applicability to other species, particularly humans, is uncertain.  The role of MMPs in smoke-induced small airway remodelling is unknown.  METHODS:  The effects of a dual MMP-9/MMP-12 inhibitor, AZ11557272, on the development of anatomical and functional changes of chronic obstructive pulmonary disease (COPD) in guinea pigs exposed daily to cigarette smoke for up to 6 months were examined.  RESULTS:  At all times, smoke-induced increases in lavage inflammatory cells, lavage desmosine (a marker of elastin breakdown) and serum tumour necrosis factor alpha (TNFalpha) were completely abolished by AZ11557272.  At 6 months there was an increase in lung volumes and airspace size.  AZ11557272 returned the pressure- volume curve to control levels, decreased smoke-induced increases in total lung capacity, residual volume and vital capacity by about 70%, and also reversed smoke-induced airspace enlargement by about 70%.  There was a very strong correlation between surface to volume ratio and both lavage desmosine and serum TNFalpha levels.  AZ11557272 protected against smoke-mediated increases in small airway wall thickness but did not prevent smoke-induced increases in mean pulmonary artery pressure.  CONCLUSIONS:  An MMP-9/MMP-12 inhibitor can substantially ameliorate morphological emphysema, small airway remodelling and the functional consequences of these lesions in a non-murine species.  These findings strengthen the idea that MMPs are important mediators of the anatomical changes behind COPD in humans, and suggest that MMP-9 and MMP-12 may be potential intervention targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfSjig6ZE6a6qcneEtCi92fW6udTcc2eYd6M-mpsdfyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svms1SktA%253D%253D&md5=fe30cef0ff1e1dde6d64fa1f71acc747</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1136%2Fthx.2006.068353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2006.068353%26sid%3Dliteratum%253Aachs%26aulast%3DChurg%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DOnnervik%26aufirst%3DP.%2BO.%26aulast%3DThim%26aufirst%3DK.%26aulast%3DWright%26aufirst%3DJ.%2BL.%26atitle%3DEffect%2520of%2520an%2520MMP-9%252FMMP-12%2520inhibitor%2520on%2520smoke-induced%2520emphysema%2520and%2520airway%2520remodelling%2520in%2520guinea%2520pigs%26jtitle%3DThorax%26date%3D2007%26volume%3D62%26spage%3D706%26epage%3D713%26doi%3D10.1136%2Fthx.2006.068353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titlestad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wielders, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wray, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuelsson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span> <span> </span><span class="NLM_article-title">Effects of an oral MMP-9 and −12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2011.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2011.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22306193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1yjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=169-177&author=R.+Dahlauthor=I.+Titlestadauthor=A.+Lindqvistauthor=P.+Wieldersauthor=H.+Wrayauthor=M.+Wangauthor=V.+Samuelssonauthor=J.+Moauthor=A.+Holt&title=Effects+of+an+oral+MMP-9+and+%E2%88%9212+inhibitor%2C+AZD1236%2C+on+biomarkers+in+moderate%2Fsevere+COPD%3A+a+randomised+controlled+trial&doi=10.1016%2Fj.pupt.2011.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomized controlled trial</span></div><div class="casAuthors">Dahl, Ronald; Titlestad, Ingrid; Lindqvist, Ari; Wielders, Pascal; Wray, Heather; Wang, Millie; Samuelsson, Viktoria; Mo, John; Holt, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: There is a pressing need for new forms of treatment for COPD.  Based on the known pathophysiol. of COPD, inhibition of matrix metalloproteinases is a theor. promising approach.  This Phase IIa study evaluated the effects of AZD1236, a selective MMP-9 and MMP-12 inhibitor, on the biomarkers of inflammation and emphysematous lung tissue degrdn. in patients with moderate-to-severe COPD.  Methods: This was a multinational, randomized, double-blind, placebo-controlled signal-searching study conducted in men and women aged ≥40 years with stable moderate-to-severe COPD.  After a 2-6-wk period to eliminate any remaining effects of previous medication, 55 patients received oral AZD1236 75 mg or matching placebo twice daily for 6 wk.  Differential cell count and TNF-α levels in induced sputum and 24-h urinary desmosine excretion were the main study variables, but a range of exploratory biomarkers was also assessed in induced sputum, blood and urine.  Secondary variables included lung function and patient-recorded Clin. COPD Questionnaire (CCQ) responses and diary records of symptoms, adverse events, use of rescue medication and AZD1236 plasma concns.  Results: The majority of variables showed little change compared to placebo although there was a possible, but not statistically significant redn. in urinary desmosine excretion and redns. in the no. and percentage of lymphocytes in sputum and blood with AZD1236.  No effect was seen on clin. parameters after 6 wk of treatment.  The proportion of patients experiencing adverse events was similar in both treatment groups.  Conclusions: AZD1236 dosed orally at 75 mg twice daily was generally well tolerated over 6 wk in patients with moderate-to-severe COPD.  No clin. efficacy of AZD1236 was demonstrated in this short-term signal-searching study, although possible evidence of an impact on desmosine may suggest the potential value of selective inhibitors of MMPs in the treatment of COPD in longer term trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQRT3GXQkab7Vg90H21EOLACvtfcHk0ljBxlEsXej2qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1yjs7s%253D&md5=94d79657c3d6adde061b9e8016cf39dc</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2011.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2011.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DTitlestad%26aufirst%3DI.%26aulast%3DLindqvist%26aufirst%3DA.%26aulast%3DWielders%26aufirst%3DP.%26aulast%3DWray%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSamuelsson%26aufirst%3DV.%26aulast%3DMo%26aufirst%3DJ.%26aulast%3DHolt%26aufirst%3DA.%26atitle%3DEffects%2520of%2520an%2520oral%2520MMP-9%2520and%2520%25E2%2588%259212%2520inhibitor%252C%2520AZD1236%252C%2520on%2520biomarkers%2520in%2520moderate%252Fsevere%2520COPD%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D25%26spage%3D169%26epage%3D177%26doi%3D10.1016%2Fj.pupt.2011.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocourek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maskos, K.</span></span> <span> </span><span class="NLM_article-title">Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2001.4954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1006%2Fjmbi.2001.4954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11575928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntV2ms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2001&pages=731-742&author=R.+Langauthor=A.+Kocourekauthor=M.+Braunauthor=H.+Tschescheauthor=R.+Huberauthor=W.+Bodeauthor=K.+Maskos&title=Substrate+specificity+determinants+of+human+macrophage+elastase+%28MMP-12%29+based+on+the+1.1+A+crystal+structure&doi=10.1006%2Fjmbi.2001.4954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate Specificity Determinants of Human Macrophage Elastase (MMP-12) Based on the 1.1 Å Crystal Structure</span></div><div class="casAuthors">Lang, Rupert; Kocourek, Andreas; Braun, Marianne; Tschesche, Harald; Huber, Robert; Bode, Wolfram; Maskos, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">731-742</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The macrophage elastase enzyme (MMP-12) expressed mainly in alveolar macrophages has been identified in the mouse lung as the main destructive agent assocd. with cigarette smoking, which gives rise to emphysema, both directly via elastin degrdn. and indirectly by disturbing the proteinase/antiproteinase balance via inactivation of the α1-proteinase inhibitor (α1-PI), the antagonist of the leukocyte elastase.  The catalytic domain of human recombinant MMP-12 has been crystd. in complex with the broad-specificity inhibitor batimastat (BB-94).  The crystal structure anal. of this complex, detd. using X-ray data to 1.1 Å and refined to an R-value of 0.165, reveals an overall fold similar to that of other MMPs.  However, the S-shaped double loop connecting strands III and IV is fixed closer to the β-sheet and projects its His172 side-chain further into the rather hydrophobic active-site cleft, defining the S3 and the S1-pockets and sepg. them from each other to a larger extent than is obsd. in other MMPs.  The S2-site is planar, while the characteristic S1'-subsite is a continuous tube rather than a pocket, in which the MMP-12-specific Thr215 replaces a Val residue otherwise highly conserved in almost all other MMPs.  This alteration might allow MMP-12 to accept P1' Arg residues, making it unique among MMPs.  The active-site cleft of MMP-12 is well equipped to bind and efficiently cleave the AlaMetPhe-LeuGluAla sequence in the reactive-site loop of α1-PI, as occurs exptl.  Similarities in contouring and particularly a common surface hydrophobicity both inside and distant from the active-site cleft explain why MMP-12 shares many substrates with matrilysin (MMP-7).  The MMP-12 structure is an excellent template for the structure-based design of specific inhibitors for emphysema therapy and for the construction of mutants to clarify the role of this MMP.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1dZcnkP3FQbVg90H21EOLACvtfcHk0ljBxlEsXej2qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntV2ms7Y%253D&md5=ac2502bc9d98fa05d8d05f183878d8ef</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.4954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.4954%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DR.%26aulast%3DKocourek%26aufirst%3DA.%26aulast%3DBraun%26aufirst%3DM.%26aulast%3DTschesche%26aufirst%3DH.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DBode%26aufirst%3DW.%26aulast%3DMaskos%26aufirst%3DK.%26atitle%3DSubstrate%2520specificity%2520determinants%2520of%2520human%2520macrophage%2520elastase%2520%2528MMP-12%2529%2520based%2520on%2520the%25201.1%2520A%2520crystal%2520structure%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D312%26spage%3D731%26epage%3D742%26doi%3D10.1006%2Fjmbi.2001.4954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Quément, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guénon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valença, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayron-Elizondo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagente, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boichot, E.</span></span> <span> </span><span class="NLM_article-title">The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1206</span>– <span class="NLM_lpage">1215</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fbjp.2008.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18493250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1206-1215&author=C.+Le+Qu%C3%A9mentauthor=I.+Gu%C3%A9nonauthor=J.+Y.+Gillonauthor=S.+Valen%C3%A7aauthor=V.+Cayron-Elizondoauthor=V.+Lagenteauthor=E.+Boichot&title=The+selective+MMP-12+inhibitor%2C+AS111793+reduces+airway+inflammation+in+mice+exposed+to+cigarette+smoke&doi=10.1038%2Fbjp.2008.180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke</span></div><div class="casAuthors">Le Quement, C.; Guenon, I.; Gillon, J.-Y.; Valenca, S.; Cayron-Elizondo, V.; Lagente, V.; Boichot, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1206-1215</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Macrophage elastase (MMP-12) is involved in the inflammatory process of chronic obstructive pulmonary disease (COPD).  The aim of this study was to investigate in mice the effect of MMP-12 inhibition on the inflammatory process induced by cigarette smoke (CS) or by lipopolysaccharide (LPS) exposure of the airways.  Exptl. approach: C57BL/6 mice were given, orally, either the selective MMP-12 inhibitor AS111793 (3, 10, 30 and 100 mg kg-1), the PDE-4 inhibitor roflumilast (3 mg kg-1) or vehicle, then exposed to CS (for 3 days) or to LPS (100 μg mL-1, 30 min).  Subsequent to the last smoke or LPS exposure, bronchoalveolar lavages (BAL) were performed and lungs were removed and homogenized to analyze various markers of inflammation at appropriate times.  Key results: Inhibition of MMP-12 by AS111793 (10 and 30 mg kg-1) was assocd. with a redn. of the increase in neutrophil no. in BAL fluids after 4 days and of macrophages after 11 days.  On day 4, AS111793 also significantly reduced all the inflammation markers that had increased after CS exposure, including sol. TNF receptors I and II, MIP-1γ, IL-6 and pro-MMP-9 activity in BAL fluids, and KC/CXCL1, fractalkine/CX3CL1, TIMP-1 and I-TAC/CXCL11 in lung parenchyma.  In contrast, inhibition of MMP-12 did not reduce neutrophil influx, pro-MMP-9 activity or KC/CXCL1 release in BAL fluids of mice exposed to LPS.  Conclusion: Inhibition of MMP-12 with AS111793, reduced the inflammatory process assocd. with exposure of mice to CS, strongly suggesting a specific involvement of MMP-12 in lung inflammation following CS exposure.  British Journal of Pharmacol. (2008) 154, 1206-1215; doi:10.1038/bjp.2008.180; published online 19 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLwKquaUjjcbVg90H21EOLACvtfcHk0liVClxriJ8t1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCjtLY%253D&md5=c1daa3f322c9af9b0486a00e258161cd</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.180%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BQu%25C3%25A9ment%26aufirst%3DC.%26aulast%3DGu%25C3%25A9non%26aufirst%3DI.%26aulast%3DGillon%26aufirst%3DJ.%2BY.%26aulast%3DValen%25C3%25A7a%26aufirst%3DS.%26aulast%3DCayron-Elizondo%26aufirst%3DV.%26aulast%3DLagente%26aufirst%3DV.%26aulast%3DBoichot%26aufirst%3DE.%26atitle%3DThe%2520selective%2520MMP-12%2520inhibitor%252C%2520AS111793%2520reduces%2520airway%2520inflammation%2520in%2520mice%2520exposed%2520to%2520cigarette%2520smoke%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1206%26epage%3D1215%26doi%3D10.1038%2Fbjp.2008.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1021/jm051101g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051101g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlantL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=456-458&author=D.+Maauthor=Y.+Jiangauthor=F.+Chenauthor=L.+K.+Gongauthor=K.+Dingauthor=Y.+Xuauthor=R.+Wangauthor=A.+Geauthor=J.+Renauthor=J.+Liauthor=J.+Liauthor=Q.+Ye&title=Selective+inhibition+of+matrix+metalloproteinase+isozymes+and+in+vivo+protection+against+emphysema+by+substituted+gamma-keto+carboxylic+acids&doi=10.1021%2Fjm051101g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Matrix Metalloproteinase Isozymes and in Vivo Protection against Emphysema by Substituted γ-Keto Carboxylic Acids</span></div><div class="casAuthors">Ma, Dawei; Jiang, Yongwen; Chen, Fangping; Gong, Li-Kun; Ding, Ke; Xu, Yong; Wang, Renxiao; Ge, Aihua; Ren, Jin; Li, Jingya; Li, Jia; Ye, Qizhuang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">456-458</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and matrix metalloproteinase (MMP) inhibitory activity of a series of γ-keto carboxylic acids are described.  Among nine MMP isoenzymes tested, compd. 1j displays selective inhibition of MMP-2, -9, and -12 with IC50 values between 0.20 and 1.51 μM, and in male golden Syrian hamsters, it shows protection against PPE-induced emphysema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzNqGR3Guk6rVg90H21EOLACvtfcHk0liVClxriJ8t1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlantL7E&md5=d9d29336a364e9f95b8a6e90f209e394</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm051101g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051101g%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGong%26aufirst%3DL.%2BK.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DGe%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DQ.%26atitle%3DSelective%2520inhibition%2520of%2520matrix%2520metalloproteinase%2520isozymes%2520and%2520in%2520vivo%2520protection%2520against%2520emphysema%2520by%2520substituted%2520gamma-keto%2520carboxylic%2520acids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D456%26epage%3D458%26doi%3D10.1021%2Fjm051101g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nuti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avramova, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cercignani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amelio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uggeri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossello, A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6347</span>– <span class="NLM_lpage">6361</span>, <span class="refDoi"> DOI: 10.1021/jm900335a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900335a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKkt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6347-6361&author=E.+Nutiauthor=L.+Panelliauthor=F.+Casaliniauthor=S.+I.+Avramovaauthor=E.+Orlandiniauthor=S.+Santamariaauthor=S.+Nencettiauthor=T.+Tuccinardiauthor=A.+Martinelliauthor=G.+Cercignaniauthor=N.+D%E2%80%99Amelioauthor=A.+Maiocchiauthor=F.+Uggeriauthor=A.+Rossello&title=Design%2C+synthesis%2C+biological+evaluation%2C+and+NMR+studies+of+a+new+series+of+arylsulfones+as+selective+and+potent+matrix+metalloproteinase-12+inhibitors&doi=10.1021%2Fjm900335a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors</span></div><div class="casAuthors">Nuti, Elisa; Panelli, Laura; Casalini, Francesca; Avramova, Stanislava I.; Orlandini, Elisabetta; Santamaria, Salvatore; Nencetti, Susanna; Tuccinardi, Tiziano; Martinelli, Adriano; Cercignani, Giovanni; D'Amelio, Nicola; Maiocchi, Alessandro; Uggeri, Fulvio; Rossello, Armando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6347-6361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of macrophage elastase (MMP-12), a member of the matrix metalloproteinases family, can be linked to tissue remodeling and degrdn. in some inflammatory processes, such as chronic obstructive pulmonary disease (COPD), emphysema, rheumatoid arthritis (RA), and atherosclerosis.  On this basis, MMP-12 can be considered an attractive target for studying selective inhibitors that are useful in the development of new therapies for COPD and other inflammatory diseases.  The design, synthesis, and in vitro evaluation of a new series of compds., possessing an arylsulfonyl scaffold, for their potential as selective inhibitors of MMP-12, are herein reported.  The best compd. I in the series showed an IC50 value of 0.2 nM, with good selectivity over MMP-1 and MMP-14.  A docking study was carried out on I in order to investigate its binding interactions with MMP-12, and NMR studies on the complex with the MMP-12 catalytic domain were able to validate the proposed binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofjDYuIX_eNLVg90H21EOLACvtfcHk0lj2HKp5d1QTzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKkt7bN&md5=d71adf7f0859928c645d8822d7b12136</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm900335a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900335a%26sid%3Dliteratum%253Aachs%26aulast%3DNuti%26aufirst%3DE.%26aulast%3DPanelli%26aufirst%3DL.%26aulast%3DCasalini%26aufirst%3DF.%26aulast%3DAvramova%26aufirst%3DS.%2BI.%26aulast%3DOrlandini%26aufirst%3DE.%26aulast%3DSantamaria%26aufirst%3DS.%26aulast%3DNencetti%26aufirst%3DS.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DMartinelli%26aufirst%3DA.%26aulast%3DCercignani%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Amelio%26aufirst%3DN.%26aulast%3DMaiocchi%26aufirst%3DA.%26aulast%3DUggeri%26aufirst%3DF.%26aulast%3DRossello%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520NMR%2520studies%2520of%2520a%2520new%2520series%2520of%2520arylsulfones%2520as%2520selective%2520and%2520potent%2520matrix%2520metalloproteinase-12%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6347%26epage%3D6361%26doi%3D10.1021%2Fjm900335a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchandani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlerman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sypek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3 methylbutanoic acid (MMP408)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1799</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/jm900093d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900093d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1799-1802&author=W.+Liauthor=J.+Liauthor=Y.+Wuauthor=J.+Wuauthor=R.+Hotchandaniauthor=K.+Cunninghamauthor=I.+McFadyenauthor=J.+Bardauthor=P.+Morganauthor=F.+Schlermanauthor=X.+Xuauthor=S.+Tamauthor=S.+J.+Goldmanauthor=C.+Williamsauthor=J.+Sypekauthor=T.+S.+Mansour&title=A+selective+matrix+metalloprotease+12+inhibitor+for+potential+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29%3A+discovery+of+%28S%29-2-%288-%28methoxycarbonylamino%29dibenzo%5Bb%2Cd%5Dfuran-3-sulfonamido%29-3+methylbutanoic+acid+%28MMP408%29&doi=10.1021%2Fjm900093d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">A Selective Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Chronic Obstructive Pulmonary Disease (COPD): Discovery of (S)-2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)</span></div><div class="casAuthors">Li, Wei; Li, Jianchang; Wu, Yuchuan; Wu, Junjun; Hotchandani, Rajeev; Cunningham, Kristina; McFadyen, Iain; Bard, Joel; Morgan, Paul; Schlerman, Franklin; Xu, Xin; Tam, Steve; Goldman, Samuel J.; Williams, Cara; Sypek, Joseph; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1799-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Matrix metalloprotease 12 plays a significant role in airway inflammation and remodeling.  Increased expression and prodn. of MMP-12 have been found in the lung of human COPD patients.  MMP408 (14), a potent and selective MMP-12 inhibitor, was derived from a potent matrix metalloprotease 2 and 13 inhibitor via lead optimization and has good phys. properties and bioavailability.  The compd. blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4TF1h22v7zbVg90H21EOLACvtfcHk0lj2HKp5d1QTzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSitr4%253D&md5=63c1b38560e93775a33adc50354c30e3</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm900093d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900093d%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DHotchandani%26aufirst%3DR.%26aulast%3DCunningham%26aufirst%3DK.%26aulast%3DMcFadyen%26aufirst%3DI.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSchlerman%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DS.%2BJ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DSypek%26aufirst%3DJ.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DA%2520selective%2520matrix%2520metalloprotease%252012%2520inhibitor%2520for%2520potential%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%253A%2520discovery%2520of%2520%2528S%2529-2-%25288-%2528methoxycarbonylamino%2529dibenzo%255Bb%252Cd%255Dfuran-3-sulfonamido%2529-3%2520methylbutanoic%2520acid%2520%2528MMP408%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1799%26epage%3D1802%26doi%3D10.1021%2Fjm900093d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rancati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raveglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchandani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krykbaev, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sypek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.11.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bmcl.2011.11.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22153340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVOrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=138-143&author=Y.+Wuauthor=J.+Liauthor=J.+Wuauthor=P.+Morganauthor=X.+Xuauthor=F.+Rancatiauthor=S.+Valleseauthor=L.+Ravegliaauthor=R.+Hotchandaniauthor=N.+Fullerauthor=J.+Bardauthor=K.+Cunninghamauthor=S.+Fishauthor=R.+Krykbaevauthor=S.+Tamauthor=S.+J.+Goldmanauthor=C.+Williamsauthor=T.+S.+Mansourauthor=E.+Saiahauthor=J.+Sypekauthor=W.+Li&title=Discovery+of+potent+and+selective+matrix+metalloprotease+12+inhibitors+for+the+potential+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&doi=10.1016%2Fj.bmcl.2011.11.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)</span></div><div class="casAuthors">Wu, Yuchuan; Li, Jianchang; Wu, Junjun; Morgan, Paul; Xu, Xin; Rancati, Fabio; Vallese, Stefania; Raveglia, Luca; Hotchandani, Rajeev; Fuller, Nathan; Bard, Joel; Cunningham, Kristina; Fish, Susan; Krykbaev, Rustem; Tam, Steve; Goldman, Samuel J.; Williams, Cara; Mansour, Tarek S.; Saiah, Eddine; Sypek, Joseph; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">138-143</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease assocd. with irreversible progressive airflow limitation.  Matrix metalloproteinase-12 (MMP-12) has been characterized to be one of the major proteolytic enzymes to induce airway remodeling, destruction of elastin and the aberrant remodeling of damaged alveoli in COPD and asthma.  The goal of this project is to develop and identify an orally potent and selective small mol. inhibitor of MMP-12 for treatment of COPD and asthma.  Syntheses and structure-activity relationship (SAR) studies of a series of dibenzofuran (DBF) sulfonamides as MMP-12 inhibitors are described.  Potent inhibitors of MMP-12 with excellent selectivity against other MMPs were identified.  Compd. I (MMP118), which exhibits excellent oral efficacy in the MMP-12 induced ear-swelling inflammation and lung inflammation mouse models, had been successfully advanced into Development Track status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK4jcjsJ4QiLVg90H21EOLACvtfcHk0ljPoZGlTMfEzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVOrtg%253D%253D&md5=8dd9fd541978708294aef0d526a8c17e</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.046%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DRancati%26aufirst%3DF.%26aulast%3DVallese%26aufirst%3DS.%26aulast%3DRaveglia%26aufirst%3DL.%26aulast%3DHotchandani%26aufirst%3DR.%26aulast%3DFuller%26aufirst%3DN.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%26aulast%3DFish%26aufirst%3DS.%26aulast%3DKrykbaev%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DS.%2BJ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSypek%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520matrix%2520metalloprotease%252012%2520inhibitors%2520for%2520the%2520potential%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D138%26epage%3D143%26doi%3D10.1016%2Fj.bmcl.2011.11.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butsch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwegmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riemann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span> <span> </span><span class="NLM_article-title">Design, (radio)synthesis, and in vitro and in vivo evaluation of highly selective and potent matrix metalloproteinase 12 (MMP-12) inhibitors as radiotracers for positron emission tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4115</span>– <span class="NLM_lpage">4134</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1OjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4115-4134&author=V.+Butschauthor=F.+B%C3%B6rgelauthor=F.+Gallaauthor=K.+Schwegmannauthor=S.+Hermannauthor=M.+Sch%C3%A4fersauthor=B.+Riemannauthor=B.+W%C3%BCnschauthor=S.+Wagner&title=Design%2C+%28radio%29synthesis%2C+and+in+vitro+and+in+vivo+evaluation+of+highly+selective+and+potent+matrix+metalloproteinase+12+%28MMP-12%29+inhibitors+as+radiotracers+for+positron+emission+tomography&doi=10.1021%2Facs.jmedchem.8b00200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Design, (Radio)Synthesis, and in Vitro and in Vivo Evaluation of Highly Selective and Potent Matrix Metalloproteinase 12 (MMP-12) Inhibitors as Radiotracers for Positron Emission Tomography</span></div><div class="casAuthors">Butsch, Viktoria; Boergel, Frederik; Galla, Fabian; Schwegmann, Katrin; Hermann, Sven; Schaefers, Michael; Riemann, Burkhard; Wuensch, Bernhard; Wagner, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4115-4134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulated levels of activated matrix metalloproteinases (MMPs) are linked to different pathologies, such as cancer, atherosclerosis, neuroinflammation, and arthritis.  Therefore, imaging of MMPs with positron-emission tomog. (PET) represents a powerful tool for the diagnosis of MMP-assocd. diseases.  Moreover, to distinguish between the distinct functions and roles of individual MMPs in particular pathophysiol. processes, their specific imaging must be realized with radiolabeled tracers, such as fluorine-18-labeled MMP inhibitors (MMPIs).  Therefore, fluorinated dibenzofuransulfonamide-based MMPIs showing excellent inhibition of MMP-12 and selectivity for MMP-12 over other MMPs were prepd.  MMP-12 is a key enzyme in diseases such as chronic obstructive pulmonary disease (COPD) and atherosclerosis.  Because of their promising in vitro properties, three candidates [{[8-(4-(3-Fluoropropyl)-1H-1,2,3-triazol-1-yl)dibenzo[b,d]furan-3-yl]sulfonyl}-(S)-valine (4), {[8-(1-(2-Fluoroethyl)-1,2,3-triazol-4-yl)dibenzo[b,d]furan-3-yl]sulfonyl}-(S)-valine (9), and ({8-[1-(2-Fluoroethyl)pyrazol-4-yl]dibenzo[b,d]furan-3-yl}sulfonyl)-(S)-valine (19)] were selected from this library, and radiofluorinated analogs ([18F]4, [18F]9, and [18F]19) were successfully synthesized.  Initial in vitro serum stability and in vivo biodistribution studies of the radiolabeled MMPIs with PET demonstrated their potential benefit for preferable MMP-12 imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqkbPFGaMBErVg90H21EOLACvtfcHk0lh747uwxoBx1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1OjtLo%253D&md5=d49976fbe3046bf45321fcfaa8a20f77</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00200%26sid%3Dliteratum%253Aachs%26aulast%3DButsch%26aufirst%3DV.%26aulast%3DB%25C3%25B6rgel%26aufirst%3DF.%26aulast%3DGalla%26aufirst%3DF.%26aulast%3DSchwegmann%26aufirst%3DK.%26aulast%3DHermann%26aufirst%3DS.%26aulast%3DSch%25C3%25A4fers%26aufirst%3DM.%26aulast%3DRiemann%26aufirst%3DB.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26aulast%3DWagner%26aufirst%3DS.%26atitle%3DDesign%252C%2520%2528radio%2529synthesis%252C%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520highly%2520selective%2520and%2520potent%2520matrix%2520metalloproteinase%252012%2520%2528MMP-12%2529%2520inhibitors%2520as%2520radiotracers%2520for%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4115%26epage%3D4134%26doi%3D10.1021%2Facs.jmedchem.8b00200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nuti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuffaro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camodeca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciccone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepshi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stura, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossello, A.</span></span> <span> </span><span class="NLM_article-title">Development of thioaryl-based matrix metalloproteinase-12 inhibitors with alternative zinc-binding groups: synthesis, potentiometric, NMR, and crystallographic studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4421</span>– <span class="NLM_lpage">4443</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00096</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptVWis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4421-4443&author=E.+Nutiauthor=D.+Cuffaroauthor=E.+Bernardiniauthor=C.+Camodecaauthor=L.+Panelliauthor=S.+Chavesauthor=L.+Cicconeauthor=L.+Tepshiauthor=L.+Veraauthor=E.+Orlandiniauthor=S.+Nencettiauthor=E.+A.+Sturaauthor=M.+A.+Santosauthor=V.+Diveauthor=A.+Rossello&title=Development+of+thioaryl-based+matrix+metalloproteinase-12+inhibitors+with+alternative+zinc-binding+groups%3A+synthesis%2C+potentiometric%2C+NMR%2C+and+crystallographic+studies&doi=10.1021%2Facs.jmedchem.8b00096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies</span></div><div class="casAuthors">Nuti, Elisa; Cuffaro, Doretta; Bernardini, Elisa; Camodeca, Caterina; Panelli, Laura; Chaves, Silvia; Ciccone, Lidia; Tepshi, Livia; Vera, Laura; Orlandini, Elisabetta; Nencetti, Susanna; Stura, Enrico A.; Santos, M. Amelia; Dive, Vincent; Rossello, Armando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4421-4435</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Matrix metalloproteinase-12 (MMP-12) selective inhibitors could play a role in the treatment of lung inflammatory and cardiovascular diseases.  In the present study, the previously reported 4-methoxybiphenylsulfonyl hydroxamate and carboxylate based inhibitors (I and II) were modified to enhance their selectivity for MMP-12.  In the newly synthesized thioaryl derivs., the nature of the zinc binding group (ZBG) and the sulfur oxidn. state were changed.  Biol. assays carried out in vitro on human MMPs with the resulting compds. led to identification of a sulfide, III, bearing an N-1-hydroxypiperidine-2,6-dione (HPD) group as new ZBG.  Compd. III is a promising hit compd. since it displayed a nanomolar affinity for MMP-12 with a marked selectivity over MMP-9, MMP-1, and MMP-14.  Soln. complexation studies with Zn2+ were performed to characterize the chelating abilities of the new compds. and confirmed the bidentate binding mode of HPD derivs.  X-ray crystallog. studies using MMP-12 and MMP-9 catalytic domains were carried out to rationalize the biol. results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGompUvE-tYWNLVg90H21EOLACvtfcHk0lh747uwxoBx1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptVWis7Y%253D&md5=2b8d3c42ee0eb148735605580ae9172d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00096%26sid%3Dliteratum%253Aachs%26aulast%3DNuti%26aufirst%3DE.%26aulast%3DCuffaro%26aufirst%3DD.%26aulast%3DBernardini%26aufirst%3DE.%26aulast%3DCamodeca%26aufirst%3DC.%26aulast%3DPanelli%26aufirst%3DL.%26aulast%3DChaves%26aufirst%3DS.%26aulast%3DCiccone%26aufirst%3DL.%26aulast%3DTepshi%26aufirst%3DL.%26aulast%3DVera%26aufirst%3DL.%26aulast%3DOrlandini%26aufirst%3DE.%26aulast%3DNencetti%26aufirst%3DS.%26aulast%3DStura%26aufirst%3DE.%2BA.%26aulast%3DSantos%26aufirst%3DM.%2BA.%26aulast%3DDive%26aufirst%3DV.%26aulast%3DRossello%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520thioaryl-based%2520matrix%2520metalloproteinase-12%2520inhibitors%2520with%2520alternative%2520zinc-binding%2520groups%253A%2520synthesis%252C%2520potentiometric%252C%2520NMR%252C%2520and%2520crystallographic%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4421%26epage%3D4443%26doi%3D10.1021%2Facs.jmedchem.8b00096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dublanchet, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducrot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrianjara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Gara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compère, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cluzeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courté, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prunet, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tertre, A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3787</span>– <span class="NLM_lpage">3790</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.05.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bmcl.2005.05.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16002291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3787-3790&author=A.+C.+Dublanchetauthor=P.+Ducrotauthor=C.+Andrianjaraauthor=M.+O%E2%80%99Garaauthor=R.+Moralesauthor=D.+Comp%C3%A8reauthor=A.+Denisauthor=S.+Blaisauthor=P.+Cluzeauauthor=K.+Court%C3%A9author=J.+Hamonauthor=F.+Moreauauthor=M.+L.+Prunetauthor=A.+Tertre&title=Structure-based+design+and+synthesis+of+novel+non-zinc+chelating+MMP-12+inhibitors&doi=10.1016%2Fj.bmcl.2005.05.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors</span></div><div class="casAuthors">Dublanchet, Anne-Claude; Ducrot, Pierre; Andrianjara, Charles; O'Gara, Margaret; Morales, Renaud; Compere, Delphine; Denis, Alexis; Blais, Stephane; Cluzeau, Philippe; Courte, Karine; Hamon, Jacques; Moreau, Francois; Prunet, Marie-Laure; Tertre, Anita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3787-3790</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A class of MMP-12 inhibitors (arylthienylamides) was discovered and optimized using structure-based drug design methods.  Modeling studies using a known MMP-12 crystal structure identified an interaction mode for these arylthienylamide MMP-12 inhibitors.  Further optimization resulted in the discovery of a compd. displaying nanomolar activity against MMP-12 and which was co-crystd. with MMP-12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-McBvzCs6T7Vg90H21EOLACvtfcHk0lgSeE80FjzTxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlKiu7o%253D&md5=06ba7fba14c771b2a9f0dd2457b21349</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.079%26sid%3Dliteratum%253Aachs%26aulast%3DDublanchet%26aufirst%3DA.%2BC.%26aulast%3DDucrot%26aufirst%3DP.%26aulast%3DAndrianjara%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Gara%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DR.%26aulast%3DComp%25C3%25A8re%26aufirst%3DD.%26aulast%3DDenis%26aufirst%3DA.%26aulast%3DBlais%26aufirst%3DS.%26aulast%3DCluzeau%26aufirst%3DP.%26aulast%3DCourt%25C3%25A9%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DMoreau%26aufirst%3DF.%26aulast%3DPrunet%26aufirst%3DM.%2BL.%26aulast%3DTertre%26aufirst%3DA.%26atitle%3DStructure-based%2520design%2520and%2520synthesis%2520of%2520novel%2520non-zinc%2520chelating%2520MMP-12%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D3787%26epage%3D3790%26doi%3D10.1016%2Fj.bmcl.2005.05.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajjar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broemstrup, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witko-Sarsat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, N.</span></span> <span> </span><span class="NLM_article-title">Structures of human proteinase 3 and neutrophil elastase–so similar yet so different</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">2238</span>– <span class="NLM_lpage">2254</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2010.07659.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1742-4658.2010.07659.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20423453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtlakurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2010&pages=2238-2254&author=E.+Hajjarauthor=T.+Broemstrupauthor=C.+Kantariauthor=V.+Witko-Sarsatauthor=N.+Reuter&title=Structures+of+human+proteinase+3+and+neutrophil+elastase%E2%80%93so+similar+yet+so+different&doi=10.1111%2Fj.1742-4658.2010.07659.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human proteinase 3 and neutrophil elastase - so similar yet so different</span></div><div class="casAuthors">Hajjar, Eric; Broemstrup, Torben; Kantari, Chahrazade; Witko-Sarsat, Veronique; Reuter, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2238-2254</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Proteinase 3 and neutrophil elastase are serine proteinases of polymorphonuclear neutrophils, which are considered to have both similar localization and ligand specificity because of their high sequence similarity.  However, recent studies indicate that they might have different and yet complementary physiol. roles.  Specifically, proteinase 3 has intracellular specific protein substrates resulting in its involvement in the regulation of intracellular functions such as proliferation or apoptosis.  It behaves as a peripheral membrane protein and its membrane expression is a risk factor in chronic inflammatory diseases.  Moreover, in contrast to human neutrophil elastase, proteinase 3 is the preferred target antigen in Wegener's granulomatosis, a particular type of vasculitis.  Here, the authors review the structural basis for the different ligand specificities and membrane binding mechanisms of both enzymes, as well as the putative anti-neutrophil cytoplasm autoantibody epitopes on human neutrophil elastase 3.  The authors also address the differences existing between murine and human enzymes, and their consequences with respect to the development of animal models for the study of human proteinase 3-related pathologies.  By integrating the functional and the structural data, the authors assemble many pieces of a complicated puzzle to provide a new perspective on the structure-function relations of human proteinase 3 and its interaction with membrane, partner proteins or cleavable substrates.  Hence, precise and meticulous structural studies are essential tools for the rational design of specific proteinase 3 substrates or competitive ligands that modulate its activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK4_ZkL2JJXLVg90H21EOLACvtfcHk0lgSeE80FjzTxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtlakurY%253D&md5=c98feddf9fc134871fd8983e39375cf4</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2010.07659.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2010.07659.x%26sid%3Dliteratum%253Aachs%26aulast%3DHajjar%26aufirst%3DE.%26aulast%3DBroemstrup%26aufirst%3DT.%26aulast%3DKantari%26aufirst%3DC.%26aulast%3DWitko-Sarsat%26aufirst%3DV.%26aulast%3DReuter%26aufirst%3DN.%26atitle%3DStructures%2520of%2520human%2520proteinase%25203%2520and%2520neutrophil%2520elastase%25E2%2580%2593so%2520similar%2520yet%2520so%2520different%26jtitle%3DFEBS%2520J.%26date%3D2010%26volume%3D277%26spage%3D2238%26epage%3D2254%26doi%3D10.1111%2Fj.1742-4658.2010.07659.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budnjo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narawane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauffel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schillinger, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haug, B. E.</span></span> <span> </span><span class="NLM_article-title">Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9396</span>– <span class="NLM_lpage">9408</span>, <span class="refDoi"> DOI: 10.1021/jm500782s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500782s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9396-9408&author=A.+Budnjoauthor=S.+Narawaneauthor=C.+Grauffelauthor=A.+S.+Schillingerauthor=T.+Fossenauthor=N.+Reuterauthor=B.+E.+Haug&title=Reversible+ketomethylene-based+inhibitors+of+human+neutrophil+proteinase+3&doi=10.1021%2Fjm500782s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Ketomethylene-Based Inhibitors of Human Neutrophil Proteinase 3</span></div><div class="casAuthors">Budnjo, Adnan; Narawane, Shailesh; Grauffel, Cedric; Schillinger, Anne-Sophie; Fossen, Torgils; Reuter, Nathalie; Haug, Bengt Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9396-9408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neutrophil serine proteases, proteinase 3 (PR3) and human neutrophil elastase (HNE), are considered as targets for chronic inflammatory diseases.  Despite sharing high sequence similarity, the two enzymes have different substrate specificities and functions.  While a plethora of HNE inhibitors exist, PR3 specific inhibitors are still in their infancy.  We have designed ketomethylene-based inhibitors for PR3 that show low micromolar IC50 values.  Their synthesis was made possible by amending a previously reported synthesis of ketomethylene dipeptide isosteres to allow for the prepn. of derivs. suitable for solid phase peptide synthesis.  The best inhibitor (Abz-VADnV[Ψ](COCH2)ADYQ-EDDnp) was found to be selective for PR3 over HNE and to display a competitive and reversible inhibition mechanism.  Mol. dynamics simulations show that the interactions between enzyme and ketomethylene-contg. inhibitors are similar to those with the corresponding substrates.  We also confirm that N- and C-terminal FRET groups are important for securing high inhibitory potency toward PR3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQQ0hqDoTShrVg90H21EOLACvtfcHk0liLxnGnwAP-QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7%252FL&md5=72379c3b173508e375d35baa86122639</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm500782s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500782s%26sid%3Dliteratum%253Aachs%26aulast%3DBudnjo%26aufirst%3DA.%26aulast%3DNarawane%26aufirst%3DS.%26aulast%3DGrauffel%26aufirst%3DC.%26aulast%3DSchillinger%26aufirst%3DA.%2BS.%26aulast%3DFossen%26aufirst%3DT.%26aulast%3DReuter%26aufirst%3DN.%26aulast%3DHaug%26aufirst%3DB.%2BE.%26atitle%3DReversible%2520ketomethylene-based%2520inhibitors%2520of%2520human%2520neutrophil%2520proteinase%25203%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9396%26epage%3D9408%26doi%3D10.1021%2Fjm500782s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guarino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruba, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzywa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyguda-Kazimierowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Łȩgowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoreński, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallet-Choisy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand-Adam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellenberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieńczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkmaz, B.</span></span> <span> </span><span class="NLM_article-title">Exploiting the S4-S5 specificity of human neutrophil proteinase 3 to improve the potency of peptidyl di(chlorophenyl)-phosphonate ester inhibitors: a kinetic and molecular modeling analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1858</span>– <span class="NLM_lpage">1870</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1858-1870&author=C.+Guarinoauthor=N.+Grubaauthor=R.+Grzywaauthor=E.+Dyguda-Kazimierowiczauthor=Y.+Hamonauthor=M.+%C5%81%C8%A9gowskaauthor=M.+Skore%C5%84skiauthor=S.+Dallet-Choisyauthor=S.+Marchand-Adamauthor=C.+Kellenbergerauthor=D.+E.+Jenneauthor=M.+Sie%C5%84czykauthor=A.+Lesnerauthor=F.+Gauthierauthor=B.+Korkmaz&title=Exploiting+the+S4-S5+specificity+of+human+neutrophil+proteinase+3+to+improve+the+potency+of+peptidyl+di%28chlorophenyl%29-phosphonate+ester+inhibitors%3A+a+kinetic+and+molecular+modeling+analysis&doi=10.1021%2Facs.jmedchem.7b01416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the S4-S5 Specificity of Human Neutrophil Proteinase 3 to Improve the Potency of Peptidyl Di(chlorophenyl)-phosphonate Ester Inhibitors: A Kinetic and Molecular Modeling Analysis</span></div><div class="casAuthors">Guarino, Carla; Gruba, Natalia; Grzywa, Renata; Dyguda-Kazimierowicz, Edyta; Hamon, Yveline; Legowska, Monika; Skorenski, Marcin; Dallet-Choisy, Sandrine; Marchand-Adam, Sylvain; Kellenberger, Christine; Jenne, Dieter E.; Sienczyk, Marcin; Lesner, Adam; Gauthier, Francis; Korkmaz, Brice</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1858-1870</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The neutrophilic serine protease proteinase 3 (PR3) is involved in inflammation and immune response and thus appears as a therapeutic target for a variety of infectious and inflammatory diseases.  Here we combined kinetic and mol. docking studies to increase the potency of peptidyl-diphenyl phosphonate PR3 inhibitors.  Occupancy of the S1 subsite of PR3 by a nVal residue and of the S4-S5 subsites by a biotinylated Val residue as obtained in biotin-VYDnVP(O-C6H4-4-Cl)2 enhanced the second-order inhibition const. k obs/[I] toward PR3 by more than 10 times (k obs/[I] = 73000 ± 5000 M-1 s-1) as compared to the best phosphonate PR3 inhibitor previously reported.  This inhibitor shows no significant inhibitory activity toward human neutrophil elastase and resists proteolytic degrdn. in sputa from cystic fibrosis patients.  It also inhibits macaque PR3 but not the PR3 from rodents and can thus be used for in vivo assays in a primate model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUBhR1OA7i7Vg90H21EOLACvtfcHk0liLxnGnwAP-QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCgsb0%253D&md5=1253f68919d227fb58edb495fa9c49c6</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01416%26sid%3Dliteratum%253Aachs%26aulast%3DGuarino%26aufirst%3DC.%26aulast%3DGruba%26aufirst%3DN.%26aulast%3DGrzywa%26aufirst%3DR.%26aulast%3DDyguda-Kazimierowicz%26aufirst%3DE.%26aulast%3DHamon%26aufirst%3DY.%26aulast%3D%25C5%2581%25C8%25A9gowska%26aufirst%3DM.%26aulast%3DSkore%25C5%2584ski%26aufirst%3DM.%26aulast%3DDallet-Choisy%26aufirst%3DS.%26aulast%3DMarchand-Adam%26aufirst%3DS.%26aulast%3DKellenberger%26aufirst%3DC.%26aulast%3DJenne%26aufirst%3DD.%2BE.%26aulast%3DSie%25C5%2584czyk%26aufirst%3DM.%26aulast%3DLesner%26aufirst%3DA.%26aulast%3DGauthier%26aufirst%3DF.%26aulast%3DKorkmaz%26aufirst%3DB.%26atitle%3DExploiting%2520the%2520S4-S5%2520specificity%2520of%2520human%2520neutrophil%2520proteinase%25203%2520to%2520improve%2520the%2520potency%2520of%2520peptidyl%2520di%2528chlorophenyl%2529-phosphonate%2520ester%2520inhibitors%253A%2520a%2520kinetic%2520and%2520molecular%2520modeling%2520analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1858%26epage%3D1870%26doi%3D10.1021%2Facs.jmedchem.7b01416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alliston, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lushington, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span> <span> </span><span class="NLM_article-title">Utilization of the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold in the design of potential inhibitors of human neutrophil proteinase 3</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1102</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.12.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bmc.2009.12.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20061159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=1093-1102&author=D.+Douauthor=G.+Heauthor=Y.+Liauthor=Z.+Laiauthor=L.+Weiauthor=K.+R.+Allistonauthor=G.+H.+Lushingtonauthor=D.+M.+Eichhornauthor=W.+C.+Groutas&title=Utilization+of+the+1%2C2%2C3%2C5-thiatriazolidin-3-one+1%2C1-dioxide+scaffold+in+the+design+of+potential+inhibitors+of+human+neutrophil+proteinase+3&doi=10.1016%2Fj.bmc.2009.12.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Utilization of the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold in the design of potential inhibitors of human neutrophil proteinase 3</span></div><div class="casAuthors">Dou, Dengfeng; He, Guijia; Li, Yi; Lai, Zhong; Wei, Liuqing; Alliston, Kevin R.; Lushington, Gerald H.; Eichhorn, David M.; Groutas, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1093-1102</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The S' subsites of human neutrophil proteinase 3 (Pr 3) were probed by constructing diverse libraries of compds. based on the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide using combinational and click chem. methods.  The multiple points of diversity embodied in the heterocyclic scaffold render it well-suited to the exploration of the S' subsites of Pr 3.  Mol. modeling studies suggest that further exploration of the S' subsites of Pr 3 using the aforementioned heterocyclic scaffold may lead to the identification of highly selective, reversible competitive inhibitors of Pr 3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3ktbTJ8S5arVg90H21EOLACvtfcHk0lh5-YY7uDiHmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGisrY%253D&md5=b951e7219c7308302c64e22e44ce4499</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.12.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.12.057%26sid%3Dliteratum%253Aachs%26aulast%3DDou%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DAlliston%26aufirst%3DK.%2BR.%26aulast%3DLushington%26aufirst%3DG.%2BH.%26aulast%3DEichhorn%26aufirst%3DD.%2BM.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26atitle%3DUtilization%2520of%2520the%25201%252C2%252C3%252C5-thiatriazolidin-3-one%25201%252C1-dioxide%2520scaffold%2520in%2520the%2520design%2520of%2520potential%2520inhibitors%2520of%2520human%2520neutrophil%2520proteinase%25203%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D1093%26epage%3D1102%26doi%3D10.1016%2Fj.bmc.2009.12.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozinovski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlahos, R.</span></span> <span> </span><span class="NLM_article-title">Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pharmthera.2015.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26297673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlylsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2015&pages=60-79&author=I.+Bernardoauthor=S.+Bozinovskiauthor=R.+Vlahos&title=Targeting+oxidant-dependent+mechanisms+for+the+treatment+of+COPD+and+its+comorbidities&doi=10.1016%2Fj.pharmthera.2015.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities</span></div><div class="casAuthors">Bernardo, Ivan; Bozinovski, Steven; Vlahos, Ross</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-79</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is an incurable global health burden and is characterized by progressive airflow limitation and loss of lung function.  In addn. to the pulmonary impact of the disease, COPD patients often develop comorbid diseases such as cardiovascular disease, skeletal muscle wasting, lung cancer and osteoporosis.  One key feature of COPD, yet often underappreciated, is the contribution of oxidative stress in the onset and development of the disease.  Patients experience an increased burden of oxidative stress due to the combined effects of excess reactive oxygen species (ROS) and nitrogen species (RNS) generation, antioxidant depletion and reduced antioxidant enzyme activity.  Currently, there is a lack of effective treatments for COPD, and an even greater lack of research regarding interventions that treat both COPD and its comorbidities.  Due to the involvement of oxidative stress in the pathogenesis of COPD and many of its comorbidities, a unique therapeutic opportunity arises where the treatment of a multitude of diseases may be possible with only one therapeutic target.  In this review, oxidative stress and the roles of ROS/RNS in the context of COPD and comorbid cardiovascular disease, skeletal muscle wasting, lung cancer, and osteoporosis are discussed and the potential for therapeutic benefit of anti-oxidative treatment in these conditions is outlined.  Because of the unique interplay between oxidative stress and these diseases, oxidative stress represents a novel target for the treatment of COPD and its comorbidities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLiusRfdJwGLVg90H21EOLACvtfcHk0lh5-YY7uDiHmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlylsL%252FN&md5=9cff79e8eb94f846d8ece7ff8e0c97af</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DBernardo%26aufirst%3DI.%26aulast%3DBozinovski%26aufirst%3DS.%26aulast%3DVlahos%26aufirst%3DR.%26atitle%3DTargeting%2520oxidant-dependent%2520mechanisms%2520for%2520the%2520treatment%2520of%2520COPD%2520and%2520its%2520comorbidities%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D155%26spage%3D60%26epage%3D79%26doi%3D10.1016%2Fj.pharmthera.2015.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergakis, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koozehchian, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stimpfl, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Best, T. M.</span></span> <span> </span><span class="NLM_article-title">Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments</span>. <i>Am. J. Physiol. Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">L205</span>– <span class="NLM_lpage">L218</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00330.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1152%2Fajplung.00330.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24879054" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2014&pages=L205-L218&author=L.+Zuoauthor=F.+Heauthor=G.+G.+Sergakisauthor=M.+S.+Koozehchianauthor=J.+N.+Stimpflauthor=Y.+Rongauthor=P.+T.+Diazauthor=T.+M.+Best&title=Interrelated+role+of+cigarette+smoking%2C+oxidative+stress%2C+and+immune+response+in+COPD+and+corresponding+treatments&doi=10.1152%2Fajplung.00330.2013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00330.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00330.2013%26sid%3Dliteratum%253Aachs%26aulast%3DZuo%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DSergakis%26aufirst%3DG.%2BG.%26aulast%3DKoozehchian%26aufirst%3DM.%2BS.%26aulast%3DStimpfl%26aufirst%3DJ.%2BN.%26aulast%3DRong%26aufirst%3DY.%26aulast%3DDiaz%26aufirst%3DP.%2BT.%26aulast%3DBest%26aufirst%3DT.%2BM.%26atitle%3DInterrelated%2520role%2520of%2520cigarette%2520smoking%252C%2520oxidative%2520stress%252C%2520and%2520immune%2520response%2520in%2520COPD%2520and%2520corresponding%2520treatments%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2014%26volume%3D307%26spage%3DL205%26epage%3DL218%26doi%3D10.1152%2Fajplung.00330.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N. S.</span></span> <span> </span><span class="NLM_article-title">PANTHEON study committee. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study</span>. <i>COPD</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.3109/15412555.2012.732628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.3109%2F15412555.2012.732628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23061828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FkslyktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=164-171&author=J.+P.+Zhengauthor=F.+Q.+Wenauthor=C.+X.+Baiauthor=H.+Y.+Wanauthor=J.+Kangauthor=P.+Chenauthor=W.+Z.+Yaoauthor=L.+J.+Maauthor=Q.+K.+Xiaauthor=Y.+Gaoauthor=N.+S.+Zhong&title=PANTHEON+study+committee.+High-dose+N-acetylcysteine+in+the+prevention+of+COPD+exacerbations%3A+rationale+and+design+of+the+PANTHEON+study&doi=10.3109%2F15412555.2012.732628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study</span></div><div class="casAuthors">Zheng Jin-Ping; Wen Fu-Qiang; Bai Chun-Xue; Wan Huan-Ying; Kang Jian; Chen Ping; Yao Wan-Zhen; Ma Li-Jun; Xia Qi-Kui; Gao Yi; Zhong Nan-Shan</div><div class="citationInfo"><span class="NLM_cas:title">COPD</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">164-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation; from a pathophysiological point of view it involves many components, including mucus hypersecretion, oxidative stress and inflammation.  N-acetylcysteine (NAC) is a mucolytic agent with antioxidant and anti-inflammatory properties.  Long-term efficacy of NAC 600mg/d in COPD is controversial; a dose-effect relationship has been demonstrated, but at present it is not known whether a higher dose provides clinical benefits.  The PANTHEON Study is a prospective, ICS stratified, randomized, double-blind, placebo-controlled, parallel-group, multi-center trial designed to assess the efficacy and safety of high-dose (1200 mg/daily) NAC treatment for one year in moderate-to-severe COPD patients.  The primary endpoint is the annual exacerbation rate.  Secondary endpoints include recurrent exacerbations hazard ratio, time to first exacerbation, as well as quality of life and pulmonary function.  The hypothesis, design and methodology are described and baseline characteristics of recruited patients are presented. 1006 COPD patients (444 treated with maintenance ICS, 562 ICS naive, aged 66.27±8.76 yrs, average post-bronchodilator FEV1 48.95±11.80 of predicted) have been randomized at 34 hospitals in China.  Final results of this study will provide objective data on the effects of high-dose (1200 mg/daily) long-term NAC treatment in the prevention of COPD exacerbations and other outcome variables.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWKv4F72J5Deb6AVA-44PTfW6udTcc2eYYCFDVBxlZOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FkslyktA%253D%253D&md5=402e02791cdc668a779be893ba09eef1</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.3109%2F15412555.2012.732628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15412555.2012.732628%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DJ.%2BP.%26aulast%3DWen%26aufirst%3DF.%2BQ.%26aulast%3DBai%26aufirst%3DC.%2BX.%26aulast%3DWan%26aufirst%3DH.%2BY.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DYao%26aufirst%3DW.%2BZ.%26aulast%3DMa%26aufirst%3DL.%2BJ.%26aulast%3DXia%26aufirst%3DQ.%2BK.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DN.%2BS.%26atitle%3DPANTHEON%2520study%2520committee.%2520High-dose%2520N-acetylcysteine%2520in%2520the%2520prevention%2520of%2520COPD%2520exacerbations%253A%2520rationale%2520and%2520design%2520of%2520the%2520PANTHEON%2520study%26jtitle%3DCOPD%26date%3D2013%26volume%3D10%26spage%3D164%26epage%3D171%26doi%3D10.3109%2F15412555.2012.732628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dal Negro, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedzicha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicero, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calverley, P. M. A.</span></span>; <span class="NLM_contrib-group">RESTORE group; RESTORE study</span> <span> </span><span class="NLM_article-title">Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1700711</span>, <span class="refDoi"> DOI: 10.1183/13993003.00711-2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1183%2F13993003.00711-2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29025888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOqs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1700711&author=R.+W.+Dal+Negroauthor=J.+A.+Wedzichaauthor=M.+Iversenauthor=G.+Fontanaauthor=C.+Pageauthor=A.+F.+Ciceroauthor=E.+Pozziauthor=P.+M.+A.+Calverleyauthor=RESTORE+group%3B+RESTORE+study&title=Effect+of+erdosteine+on+the+rate+and+duration+of+COPD+exacerbations%3A+the+RESTORE+study&doi=10.1183%2F13993003.00711-2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study</span></div><div class="casAuthors">Dal Negro, Roberto W.; Wedzicha, Jadwiga A.; Iversen, Martin; Fontana, Giovanni; Page, Clive; Cicero, Arrigo F.; Pozzi, Edoardo; Calverley, Peter M. A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1700711/1-1700711/10</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs on exacerbation duration.  The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrolling patients aged 40̂aeuro"80 years with Global Initiative for Chronic Obstructive Lung Disease stage II/III.  Patients received erdosteine 300 mg twice daily or placebo added to usual COPD therapy for 12 mo.  The primary outcome was the no. of acute exacerbations during the study.  In the pre-specified intention-to-treat population of 445 patients (74% male; mean age 64.8 years, forced expiratory vol. in 1 s 51.8% predicted) erdosteine reduced the exacerbation rate by 19.4% (0.91 vs. 1.13 exacerbations·patient-1·year-11 for erdosteine and placebo, resp.; p=0.01), due to an effect on mild events; the redn. in the rate of mild exacerbations was 57.1% (0.23 vs. 0.54 exacerbations·patient-1·year-1 for erdosteine and placebo, resp.; p=0.002).  No significant difference was obsd. in the rate of moderate and severe exacerbations (0.68 vs. 0.59 exacerbations·patient-1·year-1 for erdosteine and placebo, resp.; p=0.054) despite a trend in favor of the comparison group.  Erdosteine decreased the exacerbation duration irresp. of event severity by 24.6% (9.55 vs. 12.63 days for erdosteine and placebo, resp.; p=0.023).  Erdosteine significantly improved subject and physician subjective severity scores ( p=0.022 and p=0.048, resp.), and reduced the use of reliever medication ( p>0.001), but did not affect the St George's Respiratory Questionnaire score or the time to first exacerbation.  In patients with COPD, erdosteine can reduce both the rate and duration of exacerbations.  The percentage of patients with adverse events was similar in both the placebo and erdosteine treatment groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMOfz4ayrHvbVg90H21EOLACvtfcHk0lgfq-AhGqqVmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOqs77L&md5=4568dbddfeb048d7c33d4eb3d182d4ec</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1183%2F13993003.00711-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.00711-2017%26sid%3Dliteratum%253Aachs%26aulast%3DDal%2BNegro%26aufirst%3DR.%2BW.%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DIversen%26aufirst%3DM.%26aulast%3DFontana%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DCicero%26aufirst%3DA.%2BF.%26aulast%3DPozzi%26aufirst%3DE.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3D%26atitle%3DEffect%2520of%2520erdosteine%2520on%2520the%2520rate%2520and%2520duration%2520of%2520COPD%2520exacerbations%253A%2520the%2520RESTORE%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2017%26volume%3D50%26spage%3D1700711%26doi%3D10.1183%2F13993003.00711-2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slocum, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoko, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span> <span> </span><span class="NLM_article-title">When NRF2 talks, who’s listening?</span>. <i>Antioxid. Redox Signaling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1663</span>, <span class="refDoi"> DOI: 10.1089/ars.2010.3216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1089%2Fars.2010.3216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20367496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ltL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1649-1663&author=N.+Wakabayashiauthor=S.+L.+Slocumauthor=J.+J.+Skokoauthor=S.+Shinauthor=T.+W.+Kensler&title=When+NRF2+talks%2C+who%E2%80%99s+listening%3F&doi=10.1089%2Fars.2010.3216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">When NRF2 Talks, Who's Listening?</span></div><div class="casAuthors">Wakabayashi, Nobunao; Slocum, Stephen L.; Skoko, John J.; Shin, Soona; Kensler, Thomas W.</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1663</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  Activation of the KEAP1-NRF2 signaling pathway is an adaptive response to environmental and endogenous stresses and serves to render animals resistant to chem. carcinogenesis and other forms of toxicity, whereas disruption of the pathway exacerbates these outcomes.  This pathway, which can be activated by sulfhydryl-reactive, small-mol. pharmacol. agents, regulates the inducible expression of an extended battery of cytoprotective genes, often by direct binding of the transcription factor to antioxidant response elements in the promoter regions of target genes.  However, it is becoming evident that some of the protective effects may be mediated indirectly through cross talk with addnl. pathways affecting cell survival and other aspects of cell fate.  These interactions provide a multi-tiered, integrated response to chem. stresses.  This review highlights recent observations on the mol. interactions and their functional consequences between NRF2 and the arylhydrocarbon receptor (AhR), NF-κB, p53, and Notch1 signaling pathways.  Antioxid. Redox Signal. 13, 1649-1663.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWKHQAx_wKmLVg90H21EOLACvtfcHk0lgfq-AhGqqVmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ltL%252FJ&md5=86d2677f284fc1c881f6be885f1eac5c</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1089%2Fars.2010.3216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2010.3216%26sid%3Dliteratum%253Aachs%26aulast%3DWakabayashi%26aufirst%3DN.%26aulast%3DSlocum%26aufirst%3DS.%2BL.%26aulast%3DSkoko%26aufirst%3DJ.%2BJ.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26atitle%3DWhen%2520NRF2%2520talks%252C%2520who%25E2%2580%2599s%2520listening%253F%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2010%26volume%3D13%26spage%3D1649%26epage%3D1663%26doi%3D10.1089%2Fars.2010.3216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mercado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thimmulappa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chana, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2011.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bbrc.2011.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21320471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFKjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2011&pages=292-298&author=N.+Mercadoauthor=R.+Thimmulappaauthor=C.+M.+Thomasauthor=P.+S.+Fenwickauthor=K.+K.+Chanaauthor=L.+E.+Donnellyauthor=S.+Biswalauthor=K.+Itoauthor=P.+J.+Barnes&title=Decreased+histone+deacetylase+2+impairs+Nrf2+activation+by+oxidative+stress&doi=10.1016%2Fj.bbrc.2011.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress</span></div><div class="casAuthors">Mercado, Nicolas; Thimmulappa, Rajesh; Thomas, Catherine M. R.; Fenwick, Peter S.; Chana, Kirandeep K.; Donnelly, Louise E.; Biswal, Shyam; Ito, Kazuhiro; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">292-298</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nuclear factor erythroid 2-related factor 2 (Nrf2) plays a crucial role in cellular defense against oxidative stress by inducing the expression of multiple anti-oxidant genes.  However, where high levels of oxidative stress are obsd., such as chronic obstructive pulmonary disease (COPD), Nrf2 activity is reduced, although the mol. mechanism for this defect is uncertain.  Here, we show that down-regulation of histone deacetylase (HDAC) 2 causes Nrf2 instability, resulting in reduced antioxidant gene expression and increase sensitivity to oxidative stress.  Although Nrf2 protein was clearly stabilized after hydrogen peroxide (H2O2) stimulation in a bronchial epithelial cell line (BEAS2B), Nrf2 stability was decreased and Nrf2 acetylation increased in the presence of an HDAC inhibitor, trichostatin A (TSA).  TSA also reduced Nrf2-regulated heme-oxygenase-1 (HO-1) expression in these cells, and this was confirmed in acute cigarette-smoke exposed mice in vivo.  HDAC2 knock-down by RNA interference resulted in reduced H2O2-induced Nrf2 protein stability and activity in BEAS2B cells, whereas HDAC1 knockdown had no effect.  Furthermore, monocyte-derived macrophages obtained from healthy volunteers (non-smokers and smokers) and COPD patients showed a significant correlation between HDAC2 expression and Nrf2 expression (r = 0.92, p < 0.0001).  Thus, reduced HDAC2 activity in COPD may account for increased Nrf2 acetylation, reduced Nrf2 stability and impaired antioxidant defenses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhCb73e5Pa97Vg90H21EOLACvtfcHk0lgfq-AhGqqVmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFKjtL8%253D&md5=0b8be3847ba23c211040ba339e7b0f69</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2011.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2011.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DMercado%26aufirst%3DN.%26aulast%3DThimmulappa%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DC.%2BM.%26aulast%3DFenwick%26aufirst%3DP.%2BS.%26aulast%3DChana%26aufirst%3DK.%2BK.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26aulast%3DBiswal%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DDecreased%2520histone%2520deacetylase%25202%2520impairs%2520Nrf2%2520activation%2520by%2520oxidative%2520stress%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2011%26volume%3D406%26spage%3D292%26epage%3D298%26doi%3D10.1016%2Fj.bbrc.2011.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wise, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayapudi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudini, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugar, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thimmulappa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talalay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahey, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span>; <span class="NLM_contrib-group">Broccoli Sprout Extract Trial Research Group</span> <span> </span><span class="NLM_article-title">Lack of effect of oral sulforaphane administration on Nrf2 expression in COPD: a randomized, double-blind, placebo controlled trial</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0163716</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0163716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1371%2Fjournal.pone.0163716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=27832073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0163716&author=R.+A.+Wiseauthor=J.+T.+Holbrookauthor=G.+Crinerauthor=S.+Sethiauthor=S.+Rayapudiauthor=K.+R.+Sudiniauthor=E.+A.+Sugarauthor=A.+Burkeauthor=R.+Thimmulappaauthor=A.+Singhauthor=P.+Talalayauthor=J.+W.+Faheyauthor=C.+S.+Berensonauthor=M.+R.+Jacobsauthor=S.+Biswalauthor=Broccoli+Sprout+Extract+Trial+Research+Group&title=Lack+of+effect+of+oral+sulforaphane+administration+on+Nrf2+expression+in+COPD%3A+a+randomized%2C+double-blind%2C+placebo+controlled+trial&doi=10.1371%2Fjournal.pone.0163716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of effect of oral sulforaphane administration on Nrf2 expression in COPD: a randomized, double-blind, placebo controlled trial</span></div><div class="casAuthors">Wise, Robert A.; Holbrook, Janet T.; Criner, Gerard; Sethi, Sanjay; Rayapudi, Sobharani; Sudini, Kuladeep R.; Sugar, Elizabeth A.; Burke, Alyce; Thimmulappa, Rajesh; Singh, Anju; Talalay, Paul; Fahey, Jed W.; Berenson, Charles S.; Jacobs, Michael R.; Biswal, Shyam; Leatherman, Gwen; Daniel, Marie; Marchetti, Nathaniel; Kim, Victor; Shenoy, Kartik; Smith, Heidi; Rosario, Maria; Bolla, Sudheer; Mandapati, Chenna; Eberhardt, Ellana; Kruzel, Ragina; Kumar, Sarvesh; Noel, Sanjeev; Amend-Libercci, Debra; Ewing, Cathy; Hart, Adante; Lears, Andrea; Nowakowski, Deborah; Shade, David; Yasin, Razan; Brown, Ellen; Wang, Lucy; O'Connor, George; Strange, Charlie; Wendt, Christine; Punturieri, Anthony; Viviano, Lisa Weber</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0163716/1-e0163716/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background COPD patients have high pulmonary and systemic oxidative stress that correlates with severity of disease.  Sulforaphane has been shown to induce expression of antioxidant genes via activation of a transcription factor, nuclear factor erythroid-2 related factor 2 (Nrf2).  Methods This parallel, placebo-controlled, phase 2, randomized trial was conducted at three US academic medical centers.  Patients who met GOLD criteria for COPD and were able to tolerate bronchoscopies were randomly assigned (1:1:1) to receive placebo, 25 μmoles, or 150 μmoles sulforaphane daily by mouth for four weeks.  The primary outcomes were changes in Nrf2 target gene expression (NQ01, HO1, AKR1C1 and AKR1C3) in alveolar macrophages and bronchial epithelial cells.  Secondary outcomes included measures of oxidative stress and airway inflammation, and pulmonary function tests.  Results Between July 2011 and May 2013, 89 patients were enrolled and randomized.  Sulforaphane was absorbed in the patients as evident from their plasma metabolite levels.  Changes in Nrf2 target gene expression relative to baseline ranged from 0.79 to 1.45 and there was no consistent pattern among the three groups; the changes were not statistically significantly different from baseline.  Changes in measures of inflammation and pulmonary function tests were not different among the groups.  Sulforaphane was well tolerated at both dose levels.  Conclusion Sulforaphane administered for four weeks at doses of 25 μmoles and 150 μmoles to patients with COPD did not stimulate the expression of Nrf2 target genes or have an effect on levels of other anti-oxidants or markers of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgs8FbgXmo9rVg90H21EOLACvtfcHk0lg8DZIHk41m1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWnur0%253D&md5=d40f0614bb7da8ec2cb1b3db5169ee37</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0163716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0163716%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DR.%2BA.%26aulast%3DHolbrook%26aufirst%3DJ.%2BT.%26aulast%3DCriner%26aufirst%3DG.%26aulast%3DSethi%26aufirst%3DS.%26aulast%3DRayapudi%26aufirst%3DS.%26aulast%3DSudini%26aufirst%3DK.%2BR.%26aulast%3DSugar%26aufirst%3DE.%2BA.%26aulast%3DBurke%26aufirst%3DA.%26aulast%3DThimmulappa%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DTalalay%26aufirst%3DP.%26aulast%3DFahey%26aufirst%3DJ.%2BW.%26aulast%3DBerenson%26aufirst%3DC.%2BS.%26aulast%3DJacobs%26aufirst%3DM.%2BR.%26aulast%3DBiswal%26aufirst%3DS.%26aulast%3D%26atitle%3DLack%2520of%2520effect%2520of%2520oral%2520sulforaphane%2520administration%2520on%2520Nrf2%2520expression%2520in%2520COPD%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo%2520controlled%2520trial%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0163716%26doi%3D10.1371%2Fjournal.pone.0163716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sussan, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangasamy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Haddad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedja, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kombairaju, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liby, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sporn, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champion, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuder, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1073/pnas.0804333106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1073%2Fpnas.0804333106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19104057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=250-255&author=T.+E.+Sussanauthor=T.+Rangasamyauthor=D.+J.+Blakeauthor=D.+Malhotraauthor=H.+El-Haddadauthor=D.+Bedjaauthor=M.+S.+Yatesauthor=P.+Kombairajuauthor=M.+Yamamotoauthor=K.+T.+Libyauthor=M.+B.+Spornauthor=K.+L.+Gabrielsonauthor=H.+C.+Championauthor=R.+M.+Tuderauthor=T.+W.+Kenslerauthor=S.+Biswal&title=Targeting+Nrf2+with+the+triterpenoid+CDDO-imidazolide+attenuates+cigarette+smoke-induced+emphysema+and+cardiac+dysfunction+in+mice&doi=10.1073%2Fpnas.0804333106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice</span></div><div class="casAuthors">Sussan, Thomas E.; Rangasamy, Tirumalai; Blake, David J.; Malhotra, Deepti; El-Haddad, Hazim; Bedja, Djahida; Yates, Melinda S.; Kombairaju, Ponvijay; Yamamoto, Masayuki; Liby, Karen T.; Sporn, Michael B.; Gabrielson, Kathleen L.; Champion, Hunter C.; Tuder, Rubin M.; Kensler, Thomas W.; Biswal, Shyam</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250-255</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD), which comprises emphysema and chronic bronchitis resulting from prolonged exposure to cigarette smoke (CS), is a major public health burden with no effective treatment.  Emphysema is also assocd. with pulmonary hypertension, which can progress to right ventricular failure, an important cause of morbidity and mortality among patients with COPD.  Nuclear erythroid 2 p45 related factor-2 (Nrf2) is a redox-sensitive transcription factor that up-regulates a battery of antioxidative genes and cytoprotective enzymes that constitute the defense against oxidative stress.  Recently, it has been shown that patients with advanced COPD have a decline in expression of the Nrf2 pathway in lungs, suggesting that loss of this antioxidative protective response is a key factor in the pathophysiol. progression of emphysema.  Furthermore, genetic disruption of Nrf2 in mice causes early-onset and severe emphysema.  The present study evaluated whether the strategy of activation of Nrf2 and its downstream network of cytoprotective genes with a small mol. would attenuate CS-induced oxidative stress and emphysema.  Nrf2+/+ and Nrf2-/- mice were fed a diet contg. the potent Nrf2 activator, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im), while being exposed to CS for 6 mo.  CDDO-Im significantly reduced lung oxidative stress, alveolar cell apoptosis, alveolar destruction, and pulmonary hypertension in Nrf2+/+ mice caused by chronic exposure to CS.  This protection from CS-induced emphysema depended on Nrf2, as Nrf2-/- mice failed to show significant redn. in alveolar cell apoptosis and alveolar destruction after treatment with CDDO-lm.  These results suggest that targeting the Nrf2 pathway during the etiopathogenesis of emphysema may represent an important approach for prophylaxis against COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqH3swF6L7GbVg90H21EOLACvtfcHk0ljaxSyX4ZTMqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltF2kuw%253D%253D&md5=0358617e58e2eb22a74dd008f0d3f116</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0804333106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0804333106%26sid%3Dliteratum%253Aachs%26aulast%3DSussan%26aufirst%3DT.%2BE.%26aulast%3DRangasamy%26aufirst%3DT.%26aulast%3DBlake%26aufirst%3DD.%2BJ.%26aulast%3DMalhotra%26aufirst%3DD.%26aulast%3DEl-Haddad%26aufirst%3DH.%26aulast%3DBedja%26aufirst%3DD.%26aulast%3DYates%26aufirst%3DM.%2BS.%26aulast%3DKombairaju%26aufirst%3DP.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DLiby%26aufirst%3DK.%2BT.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DGabrielson%26aufirst%3DK.%2BL.%26aulast%3DChampion%26aufirst%3DH.%2BC.%26aulast%3DTuder%26aufirst%3DR.%2BM.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26aulast%3DBiswal%26aufirst%3DS.%26atitle%3DTargeting%2520Nrf2%2520with%2520the%2520triterpenoid%2520CDDO-imidazolide%2520attenuates%2520cigarette%2520smoke-induced%2520emphysema%2520and%2520cardiac%2520dysfunction%2520in%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D250%26epage%3D255%26doi%3D10.1073%2Fpnas.0804333106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thimmulappa, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S. V.</span></span> <span> </span><span class="NLM_article-title">Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4147</span>– <span class="NLM_lpage">4159</span>, <span class="refDoi"> DOI: 10.1021/jm2002348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2002348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlWrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4147-4159&author=V.+Kumarauthor=S.+Kumarauthor=M.+Hassanauthor=H.+Wuauthor=R.+K.+Thimmulappaauthor=A.+Kumarauthor=S.+K.+Sharmaauthor=V.+S.+Parmarauthor=S.+Biswalauthor=S.+V.+Malhotra&title=Novel+chalcone+derivatives+as+potent+Nrf2+activators+in+mice+and+human+lung+epithelial+cells&doi=10.1021%2Fjm2002348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Chalcone Derivatives as Potent Nrf2 Activators in Mice and Human Lung Epithelial Cells</span></div><div class="casAuthors">Kumar, Vineet; Kumar, Sarvesh; Hassan, Mohammad; Wu, Hailong; Thimmulappa, Rajesh K.; Kumar, Amit; Sharma, Sunil K.; Parmar, Virinder S.; Biswal, Shyam; Malhotra, Sanjay V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4147-4159</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nrf2-mediated activation of antioxidant response element is a central part of mol. mechanisms governing the protective function of phase II detoxification and antioxidant enzymes against carcinogenesis, oxidative stress, and inflammation.  Nrf2 is sequestered in the cytoplasm by its repressor, Keap1.  We have designed and synthesized novel chalcone derivs. as Nrf2 activators.  The potency of these compds. was measured by the expression of Nrf2 dependent antioxidant genes GCLM, NQO1, and HO1 in human lung epithelial cells, while the cytotoxicity was analyzed using MTT assay.  In vivo potency of identified lead compds. to activate Nrf2 was evaluated using a mouse model.  Our studies showed 2-trifluoromethyl-2'-methoxychalone (2b) to be a potent activator of Nrf2, both in vitro and in mice.  Addnl. expts. showed that the activation of Nrf2 by this compd. is independent of reactive oxygen species or redox changes.  We have discussed a quant. structure-activity relationship and proposed a possible mechanism of Nrf2 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouqD-6d2SPCLVg90H21EOLACvtfcHk0ljaxSyX4ZTMqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlWrsb0%253D&md5=8a6b7ab0af403bc3d0b2c52f7fcf84cd</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Fjm2002348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2002348%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DHassan%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DThimmulappa%26aufirst%3DR.%2BK.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DParmar%26aufirst%3DV.%2BS.%26aulast%3DBiswal%26aufirst%3DS.%26aulast%3DMalhotra%26aufirst%3DS.%2BV.%26atitle%3DNovel%2520chalcone%2520derivatives%2520as%2520potent%2520Nrf2%2520activators%2520in%2520mice%2520and%2520human%2520lung%2520epithelial%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4147%26epage%3D4159%26doi%3D10.1021%2Fjm2002348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of kelch-like ECH-associated protein 1. nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction inhibitors: achievements, challenges, and future directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10837</span>– <span class="NLM_lpage">10858</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00586</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00586" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Smtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10837-10858&author=Z.+Y.+Jiangauthor=M.+C.+Luauthor=Q.+D.+You&title=Discovery+and+development+of+kelch-like+ECH-associated+protein+1.+nuclear+factor+erythroid+2-related+factor+2+%28KEAP1%3ANRF2%29+protein-protein+interaction+inhibitors%3A+achievements%2C+challenges%2C+and+future+directions&doi=10.1021%2Facs.jmedchem.6b00586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions</span></div><div class="casAuthors">Jiang, Zheng-Yu; Lu, Meng-Chen; You, Qi-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10837-10858</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The transcription factor Nrf2 is the primary regulator of the cellular defense system, and enhancing Nrf2 activity has potential usages in various diseases, esp. chronic age-related and inflammatory diseases.  Recently, directly targeting Keap1-Nrf2 protein-protein interaction (PPI) has been an emerging strategy to selectively and effectively activate Nrf2.  This Perspective summarizes the progress in the discovery and development of Keap1-Nrf2 PPI inhibitors, including the Keap1-Nrf2 regulatory mechanisms, biochem. techniques for inhibitor identification, and approaches for identifying peptide and small-mol. inhibitors, as well as discusses privileged structures and future directions for further development of Keap1-Nrf2 PPI inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCuMv4k9xi9LVg90H21EOLACvtfcHk0ljJHVBfpu6uTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Smtb%252FO&md5=487aa677ae8a86d71e2b15561656b0b7</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00586%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DLu%26aufirst%3DM.%2BC.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26atitle%3DDiscovery%2520and%2520development%2520of%2520kelch-like%2520ECH-associated%2520protein%25201.%2520nuclear%2520factor%2520erythroid%25202-related%2520factor%25202%2520%2528KEAP1%253ANRF2%2529%2520protein-protein%2520interaction%2520inhibitors%253A%2520achievements%252C%2520challenges%252C%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10837%26epage%3D10858%26doi%3D10.1021%2Facs.jmedchem.6b00586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the negative regulator of Nrf2, Keap1: a historical overview</span>. <i>Antioxid. Redox Signaling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1665</span>– <span class="NLM_lpage">1678</span>, <span class="refDoi"> DOI: 10.1089/ars.2010.3222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1089%2Fars.2010.3222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20446768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1665-1678&author=K.+Itohauthor=J.+Mimuraauthor=M.+Yamamoto&title=Discovery+of+the+negative+regulator+of+Nrf2%2C+Keap1%3A+a+historical+overview&doi=10.1089%2Fars.2010.3222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the negative regulator of Nrf2, Keap1: A historical overview</span></div><div class="casAuthors">Itoh, Ken; Mimura, Junsei; Yamamoto, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1665-1678</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  An antioxidant response element (ARE) or an electrophile responsive element (EpRE) regulate the transcriptional induction of a battery of drug-detoxifying enzymes that are protective against electrophiles.  Based on the high similarity of the ARE consensus sequence to an erythroid gene regulatory element NF-E2 binding site, the authors have found that transcription factor Nrf2 is indispensable for the ARE-mediated induction of drug-metabolizing enzymes.  Recent genome-wide anal. demonstrated that Nrf2 regulates hundreds of genes that are involved in the cytoprotective response against oxidative stress.  In-depth anal. of Nrf2 regulatory mechanisms led the authors to the discovery of a novel protein, which they designated Keap1.  Keap1 suppresses Nrf2 activity by specifically binding to its evolutionarily conserved N-terminal Neh2 regulatory domain.  Here, the authors summarize findings and observations that have lead to the discovery of the Nrf2-Keap1 system.  Furthermore, the authors briefly discuss the function of the Nrf2-Keap1 system under the regulation of the endogenous electrophilic compd., 15-deoxy-Δ12,14-prostaglandin J2.  The authors propose that Nrf2-Keap1 plays a significant physiol. role in the response to endogenous, environmental, and pharmacol. electrophiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYEEgix9Qpi7Vg90H21EOLACvtfcHk0ljJHVBfpu6uTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ltL%252FK&md5=2c3e700515df4eb5bb8414c8d69bfc9f</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1089%2Fars.2010.3222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2010.3222%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DK.%26aulast%3DMimura%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520negative%2520regulator%2520of%2520Nrf2%252C%2520Keap1%253A%2520a%2520historical%2520overview%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2010%26volume%3D13%26spage%3D1665%26epage%3D1678%26doi%3D10.1089%2Fars.2010.3222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wixted, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths-Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hearn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottom, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonchuk, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldser, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognese, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podolin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, J. K.</span></span> <span> </span><span class="NLM_article-title">Monoacidic inhibitors of the kelch-like ECH-associated protein 1: nuclear factor eythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">4006</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00228</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00228" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1Gjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3991-4006&author=T.+G.+Daviesauthor=W.+E.+Wixtedauthor=J.+E.+Coyleauthor=C.+Griffiths-Jonesauthor=K.+Hearnauthor=R.+McMenaminauthor=D.+Nortonauthor=S.+J.+Richauthor=C.+Richardsonauthor=G.+Saxtyauthor=H.+M.+Willemsauthor=A.+J.+Woolfordauthor=J.+E.+Cottomauthor=J.+P.+Kouauthor=J.+G.+Yonchukauthor=H.+G.+Feldserauthor=Y.+Sanchezauthor=J.+P.+Foleyauthor=B.+J.+Bologneseauthor=G.+Loganauthor=P.+L.+Podolinauthor=H.+Yanauthor=J.+F.+Callahanauthor=T.+D.+Heightmanauthor=J.+K.+Kerns&title=Monoacidic+inhibitors+of+the+kelch-like+ECH-associated+protein+1%3A+nuclear+factor+eythroid+2-related+factor+2+%28KEAP1%3ANRF2%29+protein-protein+interaction+with+high+cell+potency+identified+by+fragment-based+discovery&doi=10.1021%2Facs.jmedchem.6b00228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery</span></div><div class="casAuthors">Davies, Thomas G.; Wixted, William E.; Coyle, Joseph E.; Griffiths-Jones, Charlotte; Hearn, Keisha; McMenamin, Rachel; Norton, David; Rich, Sharna J.; Richardson, Caroline; Saxty, Gordon; Willems, Henriette M. G.; Woolford, Alison J.-A.; Cottom, Joshua E.; Kou, Jen-Pyng; Yonchuk, John G.; Feldser, Heidi G.; Sanchez, Yolanda; Foley, Joseph P.; Bolognese, Brian J.; Logan, Gregory; Podolin, Patricia L.; Yan, Hongxing; Callahan, James F.; Heightman, Tom D.; Kerns, Jeffrey K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3991-4006</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KEAP1 is the key regulator of the NRF2-mediated cytoprotective response, and increasingly recognized as a target for diseases involving oxidative stress.  Pharmacol. intervention has focused on mols. that decrease NRF2-ubiquitination through covalent modification of KEAP1 cysteine residues, but such electrophilic compds. lack selectivity and may be assocd. with off-target toxicity.  We report here the first use of a fragment-based approach to directly target the KEAP1 Kelch-NRF2 interaction.  X-ray crystallog. screening identified three distinct "hot-spots" for fragment binding within the NRF2 binding pocket of KEAP1, allowing progression of a weak fragment hit to mols. with nanomolar affinity for KEAP1 while maintaining drug-like properties.  This work resulted in a promising lead compd. (I) which exhibits tight and selective binding to KEAP1, and activates the NRF2 antioxidant response in cellular and in vivo models, thereby providing a high quality chem. probe to explore the therapeutic potential of disrupting the KEAP1-NRF2 interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq-gfBTuYreLVg90H21EOLACvtfcHk0lgOUlUNJ-5Caw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1Gjtr0%253D&md5=ae42cc9f06d14b340cb3a8f5d6c157a7</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00228%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DWixted%26aufirst%3DW.%2BE.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DGriffiths-Jones%26aufirst%3DC.%26aulast%3DHearn%26aufirst%3DK.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DNorton%26aufirst%3DD.%26aulast%3DRich%26aufirst%3DS.%2BJ.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DWillems%26aufirst%3DH.%2BM.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26aulast%3DCottom%26aufirst%3DJ.%2BE.%26aulast%3DKou%26aufirst%3DJ.%2BP.%26aulast%3DYonchuk%26aufirst%3DJ.%2BG.%26aulast%3DFeldser%26aufirst%3DH.%2BG.%26aulast%3DSanchez%26aufirst%3DY.%26aulast%3DFoley%26aufirst%3DJ.%2BP.%26aulast%3DBolognese%26aufirst%3DB.%2BJ.%26aulast%3DLogan%26aufirst%3DG.%26aulast%3DPodolin%26aufirst%3DP.%2BL.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DCallahan%26aufirst%3DJ.%2BF.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DKerns%26aufirst%3DJ.%2BK.%26atitle%3DMonoacidic%2520inhibitors%2520of%2520the%2520kelch-like%2520ECH-associated%2520protein%25201%253A%2520nuclear%2520factor%2520eythroid%25202-related%2520factor%25202%2520%2528KEAP1%253ANRF2%2529%2520protein-protein%2520interaction%2520with%2520high%2520cell%2520potency%2520identified%2520by%2520fragment-based%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3991%26epage%3D4006%26doi%3D10.1021%2Facs.jmedchem.6b00228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q. D.</span></span> <span> </span><span class="NLM_article-title">Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar keap1-nrf2 protein-protein interaction inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6410</span>– <span class="NLM_lpage">6421</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12ksb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6410-6421&author=Z.+Y.+Jiangauthor=L.+L.+Xuauthor=M.+C.+Luauthor=Z.+Y.+Chenauthor=Z.+W.+Yuanauthor=X.+L.+Xuauthor=X.+K.+Guoauthor=X.+J.+Zhangauthor=H.+P.+Sunauthor=Q.+D.+You&title=Structure-activity+and+structure-property+relationship+and+exploratory+in+vivo+evaluation+of+the+nanomolar+keap1-nrf2+protein-protein+interaction+inhibitor&doi=10.1021%2Facs.jmedchem.5b00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor</span></div><div class="casAuthors">Jiang, Zheng-Yu; Xu, Li-Li; Lu, Meng-Chen; Chen, Zhi-Yun; Yuan, Zhen-Wei; Xu, Xiao-Li; Guo, Xiao-Ke; Zhang, Xiao-Jin; Sun, Hao-Peng; You, Qi-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6410-6421</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Directly disrupting the Keap1-Nrf2 protein-protein interaction (PPI) is an effective way to activate Nrf2.  Using the potent Keap1-Nrf2 PPI inhibitor that was reported by our group, we conducted a preliminary investigation of the structure-activity and structure-property relationships of the ring systems to improve the drug-like properties.  Compd. 18e (I), which bore p-acetamido substituents on the side chain Ph rings, was the best choice for balancing PPI inhibition activity, physicochem. properties, and cellular Nrf2 activity.  Cell-based expts. with 18e showed that the Keap1-Nrf2 PPI inhibitor can activate Nrf2 and induce the expression of Nrf2 downstream proteins in an Nrf2-dependent manner.  An exploratory in vivo expt. was carried out to further evaluate the anti-inflammatory effects of 18e in a LPS-challenged mouse model.  The primary results indicated that 18e could reduce the level of circulating pro-inflammatory cytokines induced by LPS and relieve the inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzcdu5HL_rp7Vg90H21EOLACvtfcHk0lgOUlUNJ-5Caw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12ksb7N&md5=458f0a612c34156a137759d99b741e3a</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00185%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DXu%26aufirst%3DL.%2BL.%26aulast%3DLu%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DZ.%2BY.%26aulast%3DYuan%26aufirst%3DZ.%2BW.%26aulast%3DXu%26aufirst%3DX.%2BL.%26aulast%3DGuo%26aufirst%3DX.%2BK.%26aulast%3DZhang%26aufirst%3DX.%2BJ.%26aulast%3DSun%26aufirst%3DH.%2BP.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26atitle%3DStructure-activity%2520and%2520structure-property%2520relationship%2520and%2520exploratory%2520in%2520vivo%2520evaluation%2520of%2520the%2520nanomolar%2520keap1-nrf2%2520protein-protein%2520interaction%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6410%26epage%3D6421%26doi%3D10.1021%2Facs.jmedchem.5b00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cifuentes-Pagano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csanyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, P. J.</span></span> <span> </span><span class="NLM_article-title">NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2315</span>– <span class="NLM_lpage">2325</span>, <span class="refDoi"> DOI: 10.1007/s00018-012-1009-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs00018-012-1009-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22585059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2315-2325&author=E.+Cifuentes-Paganoauthor=G.+Csanyiauthor=P.+J.+Pagano&title=NADPH+oxidase+inhibitors%3A+a+decade+of+discovery+from+Nox2ds+to+HTS&doi=10.1007%2Fs00018-012-1009-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS</span></div><div class="casAuthors">Cifuentes-Pagano, Eugenia; Csanyi, Gabor; Pagano, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2315-2325</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  NADPH oxidases (Nox) are established as major sources of reactive oxygen species (ROS).  Over the past two decades, Nox-derived ROS have emerged as pivotal in the development of myriad diseases involving oxidative stress.  In contrast, Nox are also involved in signaling mechanisms necessary for normal cell function.  The study of these enzymes in physiol. and pathophysiol. conditions is made considerably more complex by the discovery of 7 isoforms: Nox1 through 5 as well as Duox1 and 2, each with its own specific cytosolic components, regulatory control mechanisms, subcellular localization and/or tissue distribution.  A clear understanding of the role individual isoforms play in a given system is hindered by the lack of isoform-specific inhibitors.  In animal models, knockdown or knockout methodologies are providing definitive answers to perplexing questions of the complex interplay of multiple Nox isoforms in cell and tissue signaling.  However, the complex structures and interactions of these heteromeric isoenzymes predict pleiotropic actions of the Nox subunits and thus suppression of these proteins is almost certain to have untoward effects.  Thus, as both therapies and pharmacol. tools, mol.-based inhibitors continue to prove extremely useful and rational in design.  Unfortunately, many of the available inhibitors have proven non-specific, falling into the category of scavengers or inhibitors of more than one source of ROS.  Here, we will review some of the efforts that have been undertaken to develop specific inhibitors of NADPH oxidase over the past decade, from the peptidic inhibitor Nox2ds-tat to more recent small mol. inhibitors that have emerged from high-throughput screening campaigns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplbm_6Ei6UqrVg90H21EOLACvtfcHk0lh9lPVAyqgufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWhtLw%253D&md5=3eea0331d80eec7d9aa53d93418dda70</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1007%2Fs00018-012-1009-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-012-1009-2%26sid%3Dliteratum%253Aachs%26aulast%3DCifuentes-Pagano%26aufirst%3DE.%26aulast%3DCsanyi%26aufirst%3DG.%26aulast%3DPagano%26aufirst%3DP.%2BJ.%26atitle%3DNADPH%2520oxidase%2520inhibitors%253A%2520a%2520decade%2520of%2520discovery%2520from%2520Nox2ds%2520to%2520HTS%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26spage%3D2315%26epage%3D2325%26doi%3D10.1007%2Fs00018-012-1009-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagirdar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckhardt, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennathur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thannickal, V. J.</span></span> <span> </span><span class="NLM_article-title">NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1077</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.1038/nm.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnm.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19701206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVersbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1077-1081&author=L.+Heckerauthor=R.+Vittalauthor=T.+Jonesauthor=R.+Jagirdarauthor=T.+R.+Luckhardtauthor=J.+C.+Horowitzauthor=S.+Pennathurauthor=F.+J.+Martinezauthor=V.+J.+Thannickal&title=NADPH+oxidase-4+mediates+myofibroblast+activation+and+fibrogenic+responses+to+lung+injury&doi=10.1038%2Fnm.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</span></div><div class="casAuthors">Hecker, Louise; Vittal, Ragini; Jones, Tamara; Jagirdar, Rajesh; Luckhardt, Tracy R.; Horowitz, Jeffrey C.; Pennathur, Subramaniam; Martinez, Fernando J.; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1077-1081</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Members of the NADPH oxidase (NOX) family of enzymes, which catalyze the redn. of O2 to reactive oxygen species, have increased in no. during eukaryotic evolution.  Seven isoforms of the NOX gene family have been identified in mammals; however, specific roles of NOX enzymes in mammalian physiol. and pathophysiol. have not been fully elucidated.  The best established physiol. role of NOX enzymes is in host defense against pathogen invasion in diverse species, including plants.  The prototypical member of this family, NOX-2 (gp91phox), is expressed in phagocytic cells and mediates microbicidal activities.  Here we report a role for the NOX4 isoform in tissue repair functions of myofibroblasts and fibrogenesis.  Transforming growth factor-β1 (TGF-β1) induces NOX-4 expression in lung mesenchymal cells via SMAD-3, a receptor-regulated protein that modulates gene transcription.  NOX-4-dependent generation of hydrogen peroxide (H2O2) is required for TGF-β1-induced myofibroblast differentiation, extracellular matrix (ECM) prodn. and contractility.  NOX-4 is upregulated in lungs of mice subjected to noninfectious injury and in cases of human idiopathic pulmonary fibrosis (IPF).  Genetic or pharmacol. targeting of NOX-4 abrogates fibrogenesis in two murine models of lung injury.  These studies support a function for NOX4 in tissue fibrogenesis and provide proof of concept for therapeutic targeting of NOX-4 in recalcitrant fibrotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmporyhulB_bVg90H21EOLACvtfcHk0lh9lPVAyqgufg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVersbjM&md5=7b7eaee1597ce9e91807879f5d0f7f1d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1038%2Fnm.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2005%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DL.%26aulast%3DVittal%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DJagirdar%26aufirst%3DR.%26aulast%3DLuckhardt%26aufirst%3DT.%2BR.%26aulast%3DHorowitz%26aufirst%3DJ.%2BC.%26aulast%3DPennathur%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DNADPH%2520oxidase-4%2520mediates%2520myofibroblast%2520activation%2520and%2520fibrogenic%2520responses%2520to%2520lung%2520injury%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D1077%26epage%3D1081%26doi%3D10.1038%2Fnm.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stielow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catar, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morawietz, H.</span></span> <span> </span><span class="NLM_article-title">Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2006.03.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bbrc.2006.03.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16603125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFWnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2006&pages=200-205&author=C.+Stielowauthor=R.+A.+Catarauthor=G.+Mullerauthor=K.+Winglerauthor=P.+Scheurerauthor=H.+H.+Schmidtauthor=H.+Morawietz&title=Novel+Nox+inhibitor+of+oxLDL-induced+reactive+oxygen+species+formation+in+human+endothelial+cells&doi=10.1016%2Fj.bbrc.2006.03.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells</span></div><div class="casAuthors">Stielow, Claudia; Catar, Rusan A.; Muller, Gregor; Wingler, Kirstin; Scheurer, Peter; Schmidt, Harald H. H. W.; Morawietz, Henning</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">200-205</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this study, we investigated effects of a novel NAD(P)H oxidase (Nox)-inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine (VAS2870) on oxidized low-d. lipoprotein (oxLDL)-mediated reactive oxygen species (ROS) formation in human endothelial cells.  Primary cultures of human umbilical vein endothelial cells were cultured to confluence and ROS formation was induced with 50 μg/mL oxLDL for 2 h.  ROS formation was detected by chemiluminescence (CL) using the Diogenes reagent.  OxLDL induced ROS formation in human endothelial cells (171±12%; n = 10, P < 0.05 vs. control).  This augmented ROS formation in response to oxLDL was completely inhibited by the Nox inhibitor VAS2870 (101±9%; n = 7, P < 0.05 vs. oxLDL).  Similar results were obtained with superoxide dismutase (91±7%; n = 7, P < 0.05 vs. oxLDL).  However, the Nox4 mRNA expression level was neither changed by oxLDL nor VAS2870.  We conclude that VAS2870 could provide a novel strategy to inhibit the augmented endothelial superoxide anion formation in response to cardiovascular risk factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry4cCjOVh9GLVg90H21EOLACvtfcHk0lgie3YFGVIwQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFWnsLs%253D&md5=9c2b5961569232bd80072deb21409a33</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2006.03.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2006.03.114%26sid%3Dliteratum%253Aachs%26aulast%3DStielow%26aufirst%3DC.%26aulast%3DCatar%26aufirst%3DR.%2BA.%26aulast%3DMuller%26aufirst%3DG.%26aulast%3DWingler%26aufirst%3DK.%26aulast%3DScheurer%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DMorawietz%26aufirst%3DH.%26atitle%3DNovel%2520Nox%2520inhibitor%2520of%2520oxLDL-induced%2520reactive%2520oxygen%2520species%2520formation%2520in%2520human%2520endothelial%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2006%26volume%3D344%26spage%3D200%26epage%3D205%26doi%3D10.1016%2Fj.bbrc.2006.03.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laleu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orchard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioraso-Cartier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagnon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houngninou-Molango, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duboux, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szyndralewiez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, P.</span></span> <span> </span><span class="NLM_article-title">First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7715</span>– <span class="NLM_lpage">7730</span>, <span class="refDoi"> DOI: 10.1021/jm100773e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100773e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7715-7730&author=B.+Laleuauthor=F.+Gagginiauthor=M.+Orchardauthor=L.+Fioraso-Cartierauthor=L.+Cagnonauthor=S.+Houngninou-Molangoauthor=A.+Gradiaauthor=G.+Dubouxauthor=C.+Merlotauthor=F.+Heitzauthor=C.+Szyndralewiezauthor=P.+Page&title=First+in+class%2C+potent%2C+and+orally+bioavailable+NADPH+oxidase+isoform+4+%28Nox4%29+inhibitors+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1021%2Fjm100773e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Laleu, Benoit; Gaggini, Francesca; Orchard, Mike; Fioraso-Cartier, Laetitia; Cagnon, Laurene; Houngninou-Molango, Sophie; Gradia, Angelo; Duboux, Guillaume; Merlot, Cedric; Heitz, Freddy; Szyndralewiez, Cedric; Page, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7715-7730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and optimization of first-in-class series of inhibitors I (R1 = H, MeCO, 4-FC6H4CH2, etc.; R2 = Ph, 2-ClC6H4, 2-benzothiazolyl, etc.; R3 = Me, 2-FC6H4, 1-pyrrolidinylmethyl, PhCH2NMeCH2, etc.; R4 = MeOCH2CH2, 3-pyridylmethyl, 4-morpholinyl, etc.) of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease, is described.  Initially, several moderately potent pyrazolopyridine dione derivs. were found during a high-throughput screening campaign.  SAR investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) prodn., showing high potency on Nox4 and Nox1.  The compds. have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms.  The specificity of these compds. was confirmed in an extensive in vitro pharmacol. profile, as well as in a counterscreening assay for potential ROS scavenging.  Concomitant benefits are good oral bioavailability and high plasma concns. in vivo, allowing further clin. trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSPjijoh4dLVg90H21EOLACvtfcHk0lgie3YFGVIwQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OqtbzI&md5=39f3be6bed0d02fce6693e626788f125</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm100773e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100773e%26sid%3Dliteratum%253Aachs%26aulast%3DLaleu%26aufirst%3DB.%26aulast%3DGaggini%26aufirst%3DF.%26aulast%3DOrchard%26aufirst%3DM.%26aulast%3DFioraso-Cartier%26aufirst%3DL.%26aulast%3DCagnon%26aufirst%3DL.%26aulast%3DHoungninou-Molango%26aufirst%3DS.%26aulast%3DGradia%26aufirst%3DA.%26aulast%3DDuboux%26aufirst%3DG.%26aulast%3DMerlot%26aufirst%3DC.%26aulast%3DHeitz%26aufirst%3DF.%26aulast%3DSzyndralewiez%26aufirst%3DC.%26aulast%3DPage%26aufirst%3DP.%26atitle%3DFirst%2520in%2520class%252C%2520potent%252C%2520and%2520orally%2520bioavailable%2520NADPH%2520oxidase%2520isoform%25204%2520%2528Nox4%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7715%26epage%3D7730%26doi%3D10.1021%2Fjm100773e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Güner, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassègue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griendling, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, J. P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bmc.2017.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29426628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=989-998&author=Q.+Xuauthor=A.+A.+Kulkarniauthor=A.+M.+Sajithauthor=D.+Husseinauthor=D.+Brownauthor=O.+F.+G%C3%BCnerauthor=M.+D.+Reddyauthor=E.+B.+Watkinsauthor=B.+Lass%C3%A8gueauthor=K.+K.+Griendlingauthor=J.+P.+Bowen&title=Design%2C+synthesis%2C+and+biological+evaluation+of+inhibitors+of+the+NADPH+oxidase%2C+Nox4&doi=10.1016%2Fj.bmc.2017.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4</span></div><div class="casAuthors">Xu, Qian; Kulkarni, Amol A.; Sajith, Ayyiliath M.; Hussein, Dilbi; Brown, David; Guner, Osman F.; Reddy, M. Damoder; Watkins, E. Blake; Lassegue, Bernard; Griendling, Kathy K.; Bowen, J. Phillip</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">989-998</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">NADPH oxidases (Nox enzymes) are crit. mediators of both physiol. and pathophysiol. processes.  Nox enzymes catalyze NADPH-dependent generation of reactive oxygen species (ROS), including superoxide and hydrogen peroxide.  Until recently, Nox4 was proposed to be involved exclusively in normal physiol. functions.  Compelling evidence, however, suggests that Nox4 plays a crit. role in fibrosis, as well as a host of pathologies and diseases.  These considerations led to a search for novel, small mol. inhibitors of this important enzyme.  Ultimately, a series of novel tertiary sulfonylureas was designed using pharmacophore modeling, synthesized, and evaluated for inhibition of Nox4-dependent signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRNfIi9OVqT7Vg90H21EOLACvtfcHk0lhryWQz2xdzgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSqur8%253D&md5=3c63c9b9af0b92e36e1b84713518bbbd</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKulkarni%26aufirst%3DA.%2BA.%26aulast%3DSajith%26aufirst%3DA.%2BM.%26aulast%3DHussein%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DG%25C3%25BCner%26aufirst%3DO.%2BF.%26aulast%3DReddy%26aufirst%3DM.%2BD.%26aulast%3DWatkins%26aufirst%3DE.%2BB.%26aulast%3DLass%25C3%25A8gue%26aufirst%3DB.%26aulast%3DGriendling%26aufirst%3DK.%2BK.%26aulast%3DBowen%26aufirst%3DJ.%2BP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520inhibitors%2520of%2520the%2520NADPH%2520oxidase%252C%2520Nox4%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D989%26epage%3D998%26doi%3D10.1016%2Fj.bmc.2017.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tidén, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjögren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernlind, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthilmohan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auchère, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgren, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustavsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundquist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magon, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jameson, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, A. J.</span></span> <span> </span><span class="NLM_article-title">2-Thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">37578</span>– <span class="NLM_lpage">37589</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.266981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1074%2Fjbc.M111.266981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21880720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGnsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=37578-37589&author=A.+K.+Tid%C3%A9nauthor=T.+Sj%C3%B6grenauthor=M.+Svenssonauthor=A.+Bernlindauthor=R.+Senthilmohanauthor=F.+Auch%C3%A8reauthor=H.+Normanauthor=P.+O.+Markgrenauthor=S.+Gustavssonauthor=S.+Schmidtauthor=S.+Lundquistauthor=L.+V.+Forbesauthor=N.+J.+Magonauthor=L.+N.+Patonauthor=G.+N.+Jamesonauthor=H.+Erikssonauthor=A.+J.+Kettle&title=2-Thioxanthines+are+mechanism-based+inactivators+of+myeloperoxidase+that+block+oxidative+stress+during+inflammation&doi=10.1074%2Fjbc.M111.266981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">2-Thioxanthines Are Mechanism-based Inactivators of Myeloperoxidase That Block Oxidative Stress during Inflammation</span></div><div class="casAuthors">Tiden, Anna-Karin; Sjoegren, Tove; Svensson, Mats; Bernlind, Alexandra; Senthilmohan, Revathy; Auchere, Francoise; Norman, Henrietta; Markgren, Per-Olof; Gustavsson, Susanne; Schmidt, Staffan; Lundquist, Stefan; Forbes, Louisa V.; Magon, Nicholas J.; Paton, Louise N.; Jameson, Guy N. L.; Eriksson, Hakan; Kettle, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">37578-37589, S37578/1-S37578/13</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Myeloperoxidase (MPO) is a prime candidate for promoting oxidative stress during inflammation.  This abundant enzyme of neutrophils uses hydrogen peroxide to oxidize chloride to highly reactive and toxic chlorine bleach.  We have identified 2-thioxanthines as potent mechanism-based inactivators of MPO.  Mass spectrometry and x-ray crystal structures revealed that these inhibitors become covalently attached to the heme prosthetic groups of the enzyme.  We propose a mechanism whereby 2-thioxanthines are oxidized, and their incipient free radicals react with the heme groups of the enzyme before they can exit the active site. 2-Thioxanthines inhibited MPO in plasma and decreased protein chlorination in a mouse model of peritonitis.  They slowed but did not prevent neutrophils from killing bacteria and were poor inhibitors of thyroid peroxidase.  Our study shows that MPO is susceptible to the free radicals it generates, and this Achilles' heel of the enzyme can be exploited to block oxidative stress during inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm809SqpfydLVg90H21EOLACvtfcHk0lhryWQz2xdzgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGnsL3L&md5=66dcb9676c492df0a20df2523c879cb4</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.266981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.266981%26sid%3Dliteratum%253Aachs%26aulast%3DTid%25C3%25A9n%26aufirst%3DA.%2BK.%26aulast%3DSj%25C3%25B6gren%26aufirst%3DT.%26aulast%3DSvensson%26aufirst%3DM.%26aulast%3DBernlind%26aufirst%3DA.%26aulast%3DSenthilmohan%26aufirst%3DR.%26aulast%3DAuch%25C3%25A8re%26aufirst%3DF.%26aulast%3DNorman%26aufirst%3DH.%26aulast%3DMarkgren%26aufirst%3DP.%2BO.%26aulast%3DGustavsson%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DLundquist%26aufirst%3DS.%26aulast%3DForbes%26aufirst%3DL.%2BV.%26aulast%3DMagon%26aufirst%3DN.%2BJ.%26aulast%3DPaton%26aufirst%3DL.%2BN.%26aulast%3DJameson%26aufirst%3DG.%2BN.%26aulast%3DEriksson%26aufirst%3DH.%26aulast%3DKettle%26aufirst%3DA.%2BJ.%26atitle%3D2-Thioxanthines%2520are%2520mechanism-based%2520inactivators%2520of%2520myeloperoxidase%2520that%2520block%2520oxidative%2520stress%2520during%2520inflammation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D37578%26epage%3D37589%26doi%3D10.1074%2Fjbc.M111.266981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thain, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soars, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinder, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. L.</span></span> <span> </span><span class="NLM_article-title">Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1164/rccm.201103-0468OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.201103-0468OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21997333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XitF2rsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2012&pages=34-43&author=A.+Churgauthor=C.+V.+Marshallauthor=D.+D.+Sinauthor=S.+Boltonauthor=S.+Zhouauthor=K.+Thainauthor=E.+B.+Cadoganauthor=J.+Maltbyauthor=M.+G.+Soarsauthor=P.+R.+Mallinderauthor=J.+L.+Wright&title=Late+intervention+with+a+myeloperoxidase+inhibitor+stops+progression+of+experimental+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.201103-0468OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease</span></div><div class="casAuthors">Churg, Andrew; Marshall, Caroline V.; Sin, Don D.; Bolton, Sarah; Zhou, Steven; Thain, Katherine; Cadogan, Elaine B.; Maltby, Justine; Soars, Matthew G.; Mallinder, Philip R.; Wright, Joanne L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-43</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Inflammation and oxidative stress are linked to the deleterious effects of cigarette smoke in producing chronic obstructive pulmonary disease (COPD).  Myeloperoxidase (MPO), a neutrophil and macrophage product, is important in bacterial killing, but also drives inflammatory reactions and tissue oxidn.  Objectives: To det. the role of MPO in COPD.  Methods: We treated guinea pigs with a 2-thioxanthine MPO inhibitor, AZ1, in a 6-mo cigarette smoke exposure model, with one group receiving compd. from Smoking Day 1 and another group treated after 3 mo of smoke exposure.  Results: At 6 mo both treatments abolished smoke-induced increases in lavage inflammatory cells, largely ameliorated physiol. changes, and prevented or stopped progression of morphol. emphysema and small airway remodeling.  Cigarette smoke caused a marked increase in immunohistochem. staining for the myeloperoxidase-generated protein oxidn. marker dityrosine, and this effect was considerably decreased with both treatment arms.  Serum 8-isoprostane, another marker of oxidative stress, showed similar trends.  Both treatments also prevented muscularization of the small intrapulmonary arteries, but only partially ameliorated smoke-induced pulmonary hypertension.  Acutely, AZ1 prevented smoke-induced increases in expression of cytokine mediators and nuclear factor-κB binding.  Conclusions: We conclude that an MPO inhibitor is able to stop progression of emphysema and small airway remodeling and to partially protect against pulmonary hypertension, even when treatment starts relatively late in the course of long-term smoke exposure, suggesting that inhibition of MPO may be a novel and useful therapeutic treatment for COPD.  Protection appears to relate to inhibition of oxidative damage and down-regulation of the smoke-induced inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm-d4sj2ZP6LVg90H21EOLACvtfcHk0lj48svFXIeUDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitF2rsL4%253D&md5=2ed38089e836610c8e067acbac2015ad</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1164%2Frccm.201103-0468OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201103-0468OC%26sid%3Dliteratum%253Aachs%26aulast%3DChurg%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DC.%2BV.%26aulast%3DSin%26aufirst%3DD.%2BD.%26aulast%3DBolton%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DThain%26aufirst%3DK.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26aulast%3DMaltby%26aufirst%3DJ.%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DMallinder%26aufirst%3DP.%2BR.%26aulast%3DWright%26aufirst%3DJ.%2BL.%26atitle%3DLate%2520intervention%2520with%2520a%2520myeloperoxidase%2520inhibitor%2520stops%2520progression%2520of%2520experimental%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D185%26spage%3D34%26epage%3D43%26doi%3D10.1164%2Frccm.201103-0468OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocke, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmus, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlicka, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okerberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spath, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): a highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8513</span>– <span class="NLM_lpage">8528</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOrt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8513-8528&author=R.+B.+Ruggeriauthor=L.+Buckbinderauthor=S.+W.+Bagleyauthor=P.+A.+Carpinoauthor=E.+L.+Connauthor=M.+S.+Dowlingauthor=D.+P.+Fernandoauthor=W.+Jiaoauthor=D.+W.+Kungauthor=S.+T.+Orrauthor=Y.+Qiauthor=B.+N.+Rockeauthor=A.+Smithauthor=J.+S.+Warmusauthor=Y.+Zhangauthor=D.+Bowlesauthor=D.+W.+Widlickaauthor=H.+Engauthor=T.+Ryderauthor=R.+Sharmaauthor=A.+Wolfordauthor=C.+Okerbergauthor=K.+Waltersauthor=T.+S.+Maurerauthor=Y.+Zhangauthor=P.+D.+Boninauthor=S.+N.+Spathauthor=G.+Xingauthor=D.+Hepworthauthor=K.+Ahnauthor=A.+S.+Kalgutkar&title=Discovery+of+2-%286-%285-Chloro-2-methoxyphenyl%29-4-oxo-2-thioxo-3%2C4-dihydropyrimidin-1%282H%29-yl%29acetamide+%28PF-06282999%29%3A+a+highly+selective+mechanism-based+myeloperoxidase+inhibitor+for+the+treatment+of+cardiovascular+diseases&doi=10.1021%2Facs.jmedchem.5b00963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases</span></div><div class="casAuthors">Ruggeri, Roger B.; Buckbinder, Leonard; Bagley, Scott W.; Carpino, Philip A.; Conn, Edward L.; Dowling, Matthew S.; Fernando, Dilinie P.; Jiao, Wenhua; Kung, Daniel W.; Orr, Suvi T. M.; Qi, Yingmei; Rocke, Benjamin N.; Smith, Aaron; Warmus, Joseph S.; Zhang, Yan; Bowles, Daniel; Widlicka, Daniel W.; Eng, Heather; Ryder, Tim; Sharma, Raman; Wolford, Angela; Okerberg, Carlin; Walters, Karen; Maurer, Tristan S.; Zhang, Yanwei; Bonin, Paul D.; Spath, Samantha N.; Xing, Gang; Hepworth, David; Ahn, Kay; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8513-8528</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the prodn. of hypochlorous acid.  Clin. evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying that MPO inhibitors may represent a therapeutic treatment option.  Herein, we present the design, synthesis, and preclin. evaluation of N1-substituted-6-arylthiouracils as potent and selective inhibitors of MPO.  Inhibition proceeded in a time-dependent manner by a covalent, irreversible mechanism, which was dependent upon MPO catalysis, consistent with mechanism-based inactivation.  N1-Substituted-6-arylthiouracils exhibited low partition ratios and high selectivity for MPO over thyroid peroxidase and cytochrome P 450 isoforms.  N1-Substituted-6-arylthiouracils also demonstrated inhibition of MPO activity in lipopolysaccharide-stimulated human whole blood.  Robust inhibition of plasma MPO activity was demonstrated with the lead compd. 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999, I) upon oral administration to lipopolysaccharide-treated cynomolgus monkeys.  On the basis of its pharmacol. and pharmacokinetic profile, I has been advanced to first-in-human pharmacokinetic and safety studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgGF9fQeccCrVg90H21EOLACvtfcHk0lj48svFXIeUDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOrt7%252FK&md5=3526e7d4753b59d99da66efdd3a628bb</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00963%26sid%3Dliteratum%253Aachs%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DBagley%26aufirst%3DS.%2BW.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DConn%26aufirst%3DE.%2BL.%26aulast%3DDowling%26aufirst%3DM.%2BS.%26aulast%3DFernando%26aufirst%3DD.%2BP.%26aulast%3DJiao%26aufirst%3DW.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DRocke%26aufirst%3DB.%2BN.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBowles%26aufirst%3DD.%26aulast%3DWidlicka%26aufirst%3DD.%2BW.%26aulast%3DEng%26aufirst%3DH.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DWolford%26aufirst%3DA.%26aulast%3DOkerberg%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DSpath%26aufirst%3DS.%2BN.%26aulast%3DXing%26aufirst%3DG.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DDiscovery%2520of%25202-%25286-%25285-Chloro-2-methoxyphenyl%2529-4-oxo-2-thioxo-3%252C4-dihydropyrimidin-1%25282H%2529-yl%2529acetamide%2520%2528PF-06282999%2529%253A%2520a%2520highly%2520selective%2520mechanism-based%2520myeloperoxidase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8513%26epage%3D8528%26doi%3D10.1021%2Facs.jmedchem.5b00963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjögren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auchère, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laughton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, A.</span></span> <span> </span><span class="NLM_article-title">Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">36636</span>– <span class="NLM_lpage">36647</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.507756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1074%2Fjbc.M113.507756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24194519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFyls7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=36636-36647&author=L.+Forbesauthor=T.+Sj%C3%B6grenauthor=F.+Auch%C3%A8reauthor=D.+Jenkinsauthor=B.+Thongauthor=D.+Laughtonauthor=P.+Hemsleyauthor=G.+Pairaudeauauthor=R.+Turnerauthor=H.+Erikssonauthor=J.+Unittauthor=A.+Kettle&title=Potent+reversible+inhibition+of+myeloperoxidase+by+aromatic+hydroxamates&doi=10.1074%2Fjbc.M113.507756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates</span></div><div class="casAuthors">Forbes, Louisa V.; Sjogren, Tove; Auchere, Francoise; Jenkins, David W.; Thong, Bob; Laughton, David; Hemsley, Paul; Pairaudeau, Garry; Turner, Rufus; Eriksson, Hakan; Unitt, John F.; Kettle, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">36636-36647</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Neutrophil myeloperoxidase (MPO) promotes oxidative stress in numerous inflammatory pathologies by producing hypohalous acids.  Its inadvertent activity is a prime target for pharmacol. control.  Previously, salicylhydroxamic acid was reported to be a weak reversible inhibitor of MPO.  Here, the authors aimed to identify related hydroxamates that are good inhibitors of the enzyme.  The authors report on 3 arom. hydroxamates as the 1st potent reversible inhibitors of MPO.  The chlorination activity of purified MPO was inhibited by 50% by a 5-nM concn. of a trifluoromethyl-substituted arom. hydroxamate, HX1.  The hydroxamates were specific for MPO in neutrophils and more potent toward MPO compared with a broad range of redox enzymes and alternative targets.  Surface plasmon resonance measurements showed that the strength of binding of hydroxamates to MPO correlated with the degree of enzyme inhibition.  The crystal structure of the MPO-HX1 complex revealed that the inhibitor was bound within the active site cavity above the heme and blocked the substrate channel.  HX1 was a mixed-type inhibitor of the halogenation activity of MPO with respect to both H2O2 and halide.  Spectral analyses demonstrated that hydroxamates could act variably as substrates for MPO and convert the enzyme to a nitrosyl ferrous intermediate.  This property was unrelated to their ability to inhibit MPO.  The authors proposed that arom. hydroxamates bind tightly to the active site of MPO and prevent it from producing hypohalous acids.  This mode of reversible inhibition has potential for blocking the activity of MPO and limiting oxidative stress during inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXRB0FCV7Qq7Vg90H21EOLACvtfcHk0lj26W9D4wSwFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFyls7rM&md5=07dc6967210567a68683138ec3bd7978</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.507756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.507756%26sid%3Dliteratum%253Aachs%26aulast%3DForbes%26aufirst%3DL.%26aulast%3DSj%25C3%25B6gren%26aufirst%3DT.%26aulast%3DAuch%25C3%25A8re%26aufirst%3DF.%26aulast%3DJenkins%26aufirst%3DD.%26aulast%3DThong%26aufirst%3DB.%26aulast%3DLaughton%26aufirst%3DD.%26aulast%3DHemsley%26aufirst%3DP.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DTurner%26aufirst%3DR.%26aulast%3DEriksson%26aufirst%3DH.%26aulast%3DUnitt%26aufirst%3DJ.%26aulast%3DKettle%26aufirst%3DA.%26atitle%3DPotent%2520reversible%2520inhibition%2520of%2520myeloperoxidase%2520by%2520aromatic%2520hydroxamates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D36636%26epage%3D36647%26doi%3D10.1074%2Fjbc.M113.507756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soubhye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfving, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtmüller, P.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podrecca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conotte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colet, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarakbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaeverbeek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nève, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prévost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zouaoui Boudjeltia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufrasne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Antwerpen, P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3943</span>– <span class="NLM_lpage">3958</span>, <span class="refDoi"> DOI: 10.1021/jm4001538</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4001538" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVSrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3943-3958&author=J.+Soubhyeauthor=I.+Aldibauthor=B.+Elfvingauthor=M.+Gelbckeauthor=P.%0AG.+Furtm%C3%BCllerauthor=M.+Podreccaauthor=R.+Conotteauthor=J.+M.+Coletauthor=A.+Rousseauauthor=F.+Reyeauthor=A.+Sarakbiauthor=M.+Vanhaeverbeekauthor=J.+M.+Kauffmannauthor=C.+Obingerauthor=J.+N%C3%A8veauthor=M.+Pr%C3%A9vostauthor=K.+Zouaoui+Boudjeltiaauthor=F.+Dufrasneauthor=P.+Van+Antwerpen&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+novel+3-alkylindole+derivatives+as+selective+and+highly+potent+myeloperoxidase+inhibitors&doi=10.1021%2Fjm4001538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Novel 3-Alkylindole Derivatives as Selective and Highly Potent Myeloperoxidase Inhibitors</span></div><div class="casAuthors">Soubhye, Jalal; Aldib, Iyas; Elfving, Betina; Gelbcke, Michel; Furtmuller, Paul G.; Podrecca, Manuel; Conotte, Raphael; Colet, Jean-Marie; Rousseau, Alexandre; Reye, Florence; Sarakbi, Ahmad; Vanhaeverbeek, Michel; Kauffmann, Jean-Michel; Obinger, Christian; Neve, Jean; Prevost, Martine; Zouaoui Boudjeltia, Karim; Dufrasne, Francois; Van Antwerpen, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3943-3958</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Due to its prodn. of potent antimicrobial oxidants including hypochlorous acid, human myeloperoxidase (MPO) plays a crit. role in innate immunity and inflammatory diseases.  Thus MPO is an attractive target in drug design.  (Aminoalkyl)fluoroindole derivs. were detected to be very potent MPO inhibitors; however, they also promote inhibition of the serotonin reuptake transporter (SERT) at the same concn. range.  Via structure-based drug design, a new series of MPO inhibitors derived from 3-alkylindole were synthesized and their effects were assessed on MPO-mediated taurine chlorination and low-d. lipoprotein oxidn. as well as on inhibition of SERT.  The fluoroindole compd. I with three carbons in the side chain and one amide group exhibited a selectivity index of 35 (Ki/IC50) with high inhibition of MPO activity (IC50 = 18 nM), whereas its effect on SERT was in the micromolar range.  Structure-function relationships, mechanism of action, and safety of the mol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRZx1jHWC8t7Vg90H21EOLACvtfcHk0lj9xL50jncfzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVSrsrc%253D&md5=63d0c4859e9b378933acbd6c7cdbb43c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm4001538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4001538%26sid%3Dliteratum%253Aachs%26aulast%3DSoubhye%26aufirst%3DJ.%26aulast%3DAldib%26aufirst%3DI.%26aulast%3DElfving%26aufirst%3DB.%26aulast%3DGelbcke%26aufirst%3DM.%26aulast%3DFurtm%25C3%25BCller%26aufirst%3DP.%2BG.%26aulast%3DPodrecca%26aufirst%3DM.%26aulast%3DConotte%26aufirst%3DR.%26aulast%3DColet%26aufirst%3DJ.%2BM.%26aulast%3DRousseau%26aufirst%3DA.%26aulast%3DReye%26aufirst%3DF.%26aulast%3DSarakbi%26aufirst%3DA.%26aulast%3DVanhaeverbeek%26aufirst%3DM.%26aulast%3DKauffmann%26aufirst%3DJ.%2BM.%26aulast%3DObinger%26aufirst%3DC.%26aulast%3DN%25C3%25A8ve%26aufirst%3DJ.%26aulast%3DPr%25C3%25A9vost%26aufirst%3DM.%26aulast%3DZouaoui%2BBoudjeltia%26aufirst%3DK.%26aulast%3DDufrasne%26aufirst%3DF.%26aulast%3DVan%2BAntwerpen%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520novel%25203-alkylindole%2520derivatives%2520as%2520selective%2520and%2520highly%2520potent%2520myeloperoxidase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3943%26epage%3D3958%26doi%3D10.1021%2Fjm4001538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soubhye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikh Alard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prévost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Carvalho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtmüller, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemmig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadrent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nève, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zouaoui
Boudjeltia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufrasne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Antwerpen, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel potent reversible and irreversible myeloperoxidase inhibitors using virtual screening procedure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6563</span>– <span class="NLM_lpage">6586</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2ru7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6563-6586&author=J.+Soubhyeauthor=I.+Chikh+Alardauthor=I.+Aldibauthor=M.+Pr%C3%A9vostauthor=M.+Gelbckeauthor=A.+De+Carvalhoauthor=P.+G.+Furtm%C3%BCllerauthor=C.+Obingerauthor=J.+Flemmigauthor=S.+Tadrentauthor=F.+Meyerauthor=A.+Rousseauauthor=J.+N%C3%A8veauthor=V.+Mathieuauthor=K.+Zouaoui%0ABoudjeltiaauthor=F.+Dufrasneauthor=P.+Van+Antwerpen&title=Discovery+of+novel+potent+reversible+and+irreversible+myeloperoxidase+inhibitors+using+virtual+screening+procedure&doi=10.1021%2Facs.jmedchem.7b00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure</span></div><div class="casAuthors">Soubhye, Jalal; Chikh Alard, Ibaa; Aldib, Iyas; Prevost, Martine; Gelbcke, Michel; De Carvalho, Annelise; Furtmuller, Paul G.; Obinger, Christian; Flemmig, Jorg; Tadrent, Sara; Meyer, Franck; Rousseau, Alexandre; Neve, Jean; Mathieu, Veronique; Zouaoui Boudjeltia, Karim; Dufrasne, Francois; Van Antwerpen, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6563-6586</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The heme enzyme myeloperoxidase (MPO) participates in innate immune defense mechanism through formation of microbicidal reactive oxidants.  However, evidence has emerged that MPO-derived oxidants contribute to propagation of inflammatory diseases.  Because of the deleterious effects of circulating MPO, there is a great interest in the development of new efficient and specific inhibitors.  Here, we have performed a novel virtual screening procedure, depending on ligand-based pharmacophore modeling followed by structure-based virtual screening.  Starting from a set of 727842 compds., 28 mols. were selected by this virtual method and tested on MPO in vitro.  Twelve out of 28 compds. were found to have an IC50 less than 5 μM.  The best inhibitors were 2-(7-methoxy-4-methylquinazolin-2-yl)guanidine (28) and (R)-2-(1-((2,3-dihydro-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo[d]imidazole (42) with IC50 values of 44 and 50 nM, resp.  Studies on the mechanism of inhibition suggest that 28 is the first potent mechanism-based inhibitor and inhibits irreversibly MPO at nanomolar concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGQnLIYtnYX7Vg90H21EOLACvtfcHk0lhigwOTPSU0IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2ru7fM&md5=fb3aed6a078040c2dfee51b74ee903c0</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00285%26sid%3Dliteratum%253Aachs%26aulast%3DSoubhye%26aufirst%3DJ.%26aulast%3DChikh%2BAlard%26aufirst%3DI.%26aulast%3DAldib%26aufirst%3DI.%26aulast%3DPr%25C3%25A9vost%26aufirst%3DM.%26aulast%3DGelbcke%26aufirst%3DM.%26aulast%3DDe%2BCarvalho%26aufirst%3DA.%26aulast%3DFurtm%25C3%25BCller%26aufirst%3DP.%2BG.%26aulast%3DObinger%26aufirst%3DC.%26aulast%3DFlemmig%26aufirst%3DJ.%26aulast%3DTadrent%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DF.%26aulast%3DRousseau%26aufirst%3DA.%26aulast%3DN%25C3%25A8ve%26aufirst%3DJ.%26aulast%3DMathieu%26aufirst%3DV.%26aulast%3DZouaoui%2BBoudjeltia%26aufirst%3DK.%26aulast%3DDufrasne%26aufirst%3DF.%26aulast%3DVan%2BAntwerpen%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520novel%2520potent%2520reversible%2520and%2520irreversible%2520myeloperoxidase%2520inhibitors%2520using%2520virtual%2520screening%2520procedure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6563%26epage%3D6586%26doi%3D10.1021%2Facs.jmedchem.7b00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domej, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oetll, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, W.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress and free radicals in COPD--implications and relevance for treatment</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.2147/COPD.S51226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2147%2FCOPD.S51226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25378921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGgsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1207-1224&author=W.+Domejauthor=K.+Oetllauthor=W.+Renner&title=Oxidative+stress+and+free+radicals+in+COPD%2D%2Dimplications+and+relevance+for+treatment&doi=10.2147%2FCOPD.S51226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress and free radicals in COPD - implications and relevance for treatment</span></div><div class="casAuthors">Domej, Wolfgang; Oettl, Karl; Renner, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1207-1224, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Oxidative stress occurs when free radicals and other reactive species overwhelm the availability of antioxidants.  Reactive oxygen species (ROS), reactive nitrogen species, and their counterpart antioxidant agents are essential for physiol. signaling and host defense, as well as for the evolution and persistence of inflammation.  When their normal steady state is disturbed, imbalances between oxidants and antioxidants may provoke pathol. reactions causing a range of nonrespiratory and respiratory diseases, particularly chronic obstructive pulmonary disease (COPD).  In the respiratory system, ROS may be either exogenous from more or less inhalative gaseous or particulate agents such as air pollutants, cigarette smoke, ambient high-altitude hypoxia, and some occupational dusts, or endogenously generated in the context of defense mechanisms against such infectious pathogens as bacteria, viruses, or fungi.  ROS may also damage body tissues depending on the amt. and duration of exposure and may further act as triggers for enzymically generated ROS released from respiratory, immune, and inflammatory cells.  This paper focuses on the general relevance of free radicals for the development and progression of both COPD and pulmonary emphysema as well as novel perspectives on therapeutic options.  Unfortunately, current treatment options do not suffice to prevent chronic airway inflammation and are not yet able to substantially alter the course of COPD.  Effective therapeutic antioxidant measures are urgently needed to control and mitigate local as well as systemic oxygen bursts in COPD and other respiratory diseases.  In addn. to current therapeutic prospects and aspects of genomic medicine, trending research topics in COPD are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtbWBt_nTZEbVg90H21EOLACvtfcHk0lhigwOTPSU0IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGgsLrO&md5=06bb8247587b67d7b281f54309049d50</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S51226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S51226%26sid%3Dliteratum%253Aachs%26aulast%3DDomej%26aufirst%3DW.%26aulast%3DOetll%26aufirst%3DK.%26aulast%3DRenner%26aufirst%3DW.%26atitle%3DOxidative%2520stress%2520and%2520free%2520radicals%2520in%2520COPD--implications%2520and%2520relevance%2520for%2520treatment%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2014%26volume%3D9%26spage%3D1207%26epage%3D1224%26doi%3D10.2147%2FCOPD.S51226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunday, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crapo, J. D.</span></span> <span> </span><span class="NLM_article-title">A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1164/rccm.200203-232OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200203-232OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12502477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252Fitlemuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2003&pages=57-64&author=L.+Y.+Changauthor=M.+Subramaniamauthor=B.+A.+Yoderauthor=B.+J.+Dayauthor=M.+C.+Ellisonauthor=M.+E.+Sundayauthor=J.+D.+Crapo&title=A+catalytic+antioxidant+attenuates+alveolar+structural+remodeling+in+bronchopulmonary+dysplasia&doi=10.1164%2Frccm.200203-232OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia</span></div><div class="casAuthors">Chang Ling-Yi L; Subramaniam Meera; Yoder Bradley A; Day Brian J; Ellison Misoo C; Sunday Mary E; Crapo James D</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-64</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Superoxide anion and other oxygen-free radicals have been implicated in the pathogenesis of bronchopulmonary dysplasia.  We tested the hypothesis that a catalytic antioxidant metalloporphyrin AEOL 10113 can protect against hyperoxia-induced lung injury using a fetal baboon model of bronchopulmonary dysplasia.  Fetal baboons were delivered by hysterotomy at 140 days of gestation (term = 185 days) and given 100% oxygen for 10 days.  Morphometric analysis of alveolar structure showed that fetal baboons on 100% oxygen alone had increased parenchymal mast cells and eosinophils, increased alveolar tissue volume and septal thickness, and decreased alveolar surface area compared with animals given oxygen as needed.  Treatment with AEOL 10113 (continuous intravenous infusion) during 100% oxygen exposure partially reversed these oxygen-induced changes.  Hyperoxia increased the number of neuroendocrine cells in the peripheral lung, which was preceded by increased levels of urine bombesin-like peptide at 48 hours of age.  AEOL 10113 inhibited the hyperoxia-induced increases in urine bombesin-like peptide and numbers of neuroendocrine cells.  An increasing trend in oxygenation index over time was observed in the 100% oxygen group but not the mimetic-treated group.  These results suggest that AEOL 10113 might reduce the risk of pulmonary oxygen toxicity in prematurely born infants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxiraH1KEj9tbHMBt0mMIXfW6udTcc2eYnfuUEfV0Fy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252Fitlemuw%253D%253D&md5=9f3a33636d2fdfef543f8ce5b7afaf54</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1164%2Frccm.200203-232OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200203-232OC%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DL.%2BY.%26aulast%3DSubramaniam%26aufirst%3DM.%26aulast%3DYoder%26aufirst%3DB.%2BA.%26aulast%3DDay%26aufirst%3DB.%2BJ.%26aulast%3DEllison%26aufirst%3DM.%2BC.%26aulast%3DSunday%26aufirst%3DM.%2BE.%26aulast%3DCrapo%26aufirst%3DJ.%2BD.%26atitle%3DA%2520catalytic%2520antioxidant%2520attenuates%2520alveolar%2520structural%2520remodeling%2520in%2520bronchopulmonary%2520dysplasia%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2003%26volume%3D167%26spage%3D57%26epage%3D64%26doi%3D10.1164%2Frccm.200203-232OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuzzocrea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota-Filipe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiemermann, C.</span></span> <span> </span><span class="NLM_article-title">Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1046/j.1523-1755.2000.00212.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1046%2Fj.1523-1755.2000.00212.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10916089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlvFagsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2000&pages=658-673&author=P.+K.+Chatterjeeauthor=S.+Cuzzocreaauthor=P.+A.+Brownauthor=K.+Zacharowskiauthor=K.+N.+Stewartauthor=H.+Mota-Filipeauthor=C.+Thiemermann&title=Tempol%2C+a+membrane-permeable+radical+scavenger%2C+reduces+oxidant+stress-mediated+renal+dysfunction+and+injury+in+the+rat&doi=10.1046%2Fj.1523-1755.2000.00212.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat</span></div><div class="casAuthors">Chatterjee, Prabal K.; Cuzzocrea, Salvatore; Brown, Paul A. J.; Zacharowski, Kai; Stewart, Keith N.; Mota-Filipe, Helder; Thiemermann, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">658-673</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">The generation of reactive oxygen species (ROS) contributes to the pathogenesis of renal ischemia-reperfusion injury.  The aim of this study was to investigate the effects of tempol in (1) an in vivo rat model of renal ischemia/reperfusion injury and on (2) cellular injury and death of rat renal proximal tubular (PT) cells exposed to oxidant stress in the form of H2O2.  Male Wistar rats underwent bilateral renal pedicle clamping for 45 min followed by reperfusion for 6 h.  Tempol (30 mg/kg/h), desferrioxamine (DEF; 40 mg/kg/h), or a combination of tempol (30 mg/kg/h) and DEF (40 mg/kg/h) were administered prior to and throughout reperfusion.  Blood plasma concns. of urea, creatinine, Na+, γ-glutamyl transferase (γGT), aspartate aminotransferase (AST), and urinary Na+ and N-acetyl-β-D-glucosaminidase (NAG) were measured for the assessment of renal function and reperfusion injury.  Kidney myeloperoxidase (MPO) activity and malondialdehyde (MDA) levels were measured for assessment of polymorphonuclear (PMN) cell infiltration and lipid peroxidn., resp.  Renal sections were used for histol. grading of renal injury and for immunohistochem. localization of nitrotyrosine and poly(ADP-ribose) synthetase (PARS).  Primary cultures of rat PT cells were incubated with H2O2 (1 mmol/L for 4 h) either in the absence or presence of increasing concns. of tempol (0.03 to 10 mmol/L), DEF (0.03 to 10 mmol/L), or a combination of tempol (3 mmol/L) or DEF (3 mmol/L).  PT cell injury and death were detd. by evaluating mitochondrial respiration and lactate dehydrogenase (LDH) release, resp.  In vivo, tempol reduced the increase in urea, creatinine, γGT, AST, NAG, and FENa produced by renal ischemia/reperfusion, suggesting an improvement in both renal function and injury.  Tempol also reduced kidney MPO activity and MDA levels, indicating a redn. in PMN infiltration and lipid peroxidn., resp.  Tempol reduced the histol. evidence of renal damage assocd. with ischemia/reperfusion and caused a substantial redn. in the staining for nitrotyrosine and PARS, suggesting reduced nitrosative and oxidative stress.  In vitro, tempol attenuated H2O2-mediated decrease in mitochondrial respiration and increase in LDH release from rat PT cells, indicating a redn. in cell injury and death.  Both in vivo and in vitro, the beneficial actions of tempol were similar to those obtained using the Fe2+ chelator DEF.  However, coadministration of DEF and tempol did not produce any addnl. beneficial actions against renal ischemia/reperfusion injury or against oxidative stress-mediated PT cell injury/death.  The authors' results suggest that the membrane-permeable radical scavenger, tempol, reduces the renal dysfunction and injury assocd. with ischemia/reperfusion of the kidney.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMfF0lpCUlprVg90H21EOLACvtfcHk0lioeEvQTLnjeg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlvFagsrg%253D&md5=83c6f9013f0d0c95d835893a24ba7cfc</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1755.2000.00212.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1755.2000.00212.x%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DP.%2BK.%26aulast%3DCuzzocrea%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DP.%2BA.%26aulast%3DZacharowski%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DK.%2BN.%26aulast%3DMota-Filipe%26aufirst%3DH.%26aulast%3DThiemermann%26aufirst%3DC.%26atitle%3DTempol%252C%2520a%2520membrane-permeable%2520radical%2520scavenger%252C%2520reduces%2520oxidant%2520stress-mediated%2520renal%2520dysfunction%2520and%2520injury%2520in%2520the%2520rat%26jtitle%3DKidney%2520Int.%26date%3D2000%26volume%3D58%26spage%3D658%26epage%3D673%26doi%3D10.1046%2Fj.1523-1755.2000.00212.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffin, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, R. M.</span></span> <span> </span><span class="NLM_article-title">NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1161/01.STR.32.1.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1161%2F01.STR.32.1.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11136936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFKhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2001&pages=190-198&author=J.+W.+Marshallauthor=K.+J.+Duffinauthor=A.+R.+Greenauthor=R.+M.+Ridley&title=NXY-059%2C+a+free+radical%2D%2Dtrapping+agent%2C+substantially+lessens+the+functional+disability+resulting+from+cerebral+ischemia+in+a+primate+species&doi=10.1161%2F01.STR.32.1.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species</span></div><div class="casAuthors">Marshall, Jonathan W. B.; Duffin, Katharine J.; Green, A. Richard; Ridley, Rosalind M.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">190-198</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">NXY-059 is a novel nitrone with free radical-trapping properties that has a considerable neuroprotective effect in rats.  We have now examd. the efficacy of this drug at reducing long-term functional disability in a primate model of stroke.  Twelve monkeys were trained and tested on a variety of behavioral tasks used to dissoc. and quantify motor and spatial deficits.  Five minutes after permanent occlusion of the right middle cerebral artery, monkeys received a 1-mL i.v. infusion of either saline or NXY-059 (28 mg/kg), and osmotic minipumps, model 2001D, were implanted s.c. to provide continuous drug or saline infusion for 48 h.  Drug-filled pumps released NXY-059 at 16 mg/kg/h.  The monkeys were retested 3 and 10 wk after surgery to assess functional disability.  Surgery, behavioral testing, and histol. were all done blinded to treatment condition.  NXY-059-treated monkeys were significantly better at reaching with their hemiparetic arm than were saline-treated monkeys when retested 3 wk and 10 wk after surgery.  Drug treatment also significantly lessened the degree of spatial perceptual neglect, a debilitating though ameliorating consequence of this infarct.  NXY-059 treatment reduced the overall amt. of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter.  This novel drug has a substantial protective effect, lessening the disability caused by an exptl. induced stroke in a primate species.  These findings provide considerable encouragement for the clin. development of NXY-059.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-BC-S0fNDn7Vg90H21EOLACvtfcHk0liRcnnrH7HdEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFKhs74%253D&md5=ad0cf46f1fb7916a110ee31dc9096dfd</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1161%2F01.STR.32.1.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.STR.32.1.190%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DJ.%2BW.%26aulast%3DDuffin%26aufirst%3DK.%2BJ.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26aulast%3DRidley%26aufirst%3DR.%2BM.%26atitle%3DNXY-059%252C%2520a%2520free%2520radical--trapping%2520agent%252C%2520substantially%2520lessens%2520the%2520functional%2520disability%2520resulting%2520from%2520cerebral%2520ischemia%2520in%2520a%2520primate%2520species%26jtitle%3DStroke%26date%3D2001%26volume%3D32%26spage%3D190%26epage%3D198%26doi%3D10.1161%2F01.STR.32.1.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seimetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parajuli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwapiszewska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisel, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egemnazarov, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydykov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medebach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaksch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumitrascu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voswinckel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span> <span> </span><span class="NLM_article-title">Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.cell.2011.08.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22000010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaksb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2011&pages=293-305&author=M.+Seimetzauthor=N.+Parajuliauthor=A.+Pichlauthor=F.+Veitauthor=G.+Kwapiszewskaauthor=F.+C.+Weiselauthor=K.+Milgerauthor=B.+Egemnazarovauthor=A.+Turowskaauthor=B.+Fuchsauthor=S.+Nikamauthor=M.+Rothauthor=A.+Sydykovauthor=T.+Medebachauthor=W.+Klepetkoauthor=P.+Jakschauthor=R.+Dumitrascuauthor=H.+Garnauthor=R.+Voswinckelauthor=S.+Kostinauthor=W.+Seegerauthor=R.+T.+Schermulyauthor=F.+Grimmingerauthor=H.+A.+Ghofraniauthor=N.+Weissmann&title=Inducible+NOS+inhibition+reverses+tobacco-smoke-induced+emphysema+and+pulmonary+hypertension+in+mice&doi=10.1016%2Fj.cell.2011.08.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice</span></div><div class="casAuthors">Seimetz, Michael; Parajuli, Nirmal; Pichl, Alexandra; Veit, Florian; Kwapiszewska, Grazyna; Weisel, Friederike C.; Milger, Katrin; Egemnazarov, Bakytbek; Turowska, Agnieszka; Fuchs, Beate; Nikam, Sandeep; Roth, Markus; Sydykov, Akylbek; Medebach, Thomas; Klepetko, Walter; Jaksch, Peter; Dumitrascu, Rio; Garn, Holger; Voswinckel, Robert; Kostin, Sawa; Seeger, Werner; Schermuly, Ralph T.; Grimminger, Friedrich; Ghofrani, Hossein A.; Weissmann, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-305</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is one of the most common causes of death worldwide.  We report in an emphysema model of mice chronically exposed to tobacco smoke that pulmonary vascular dysfunction, vascular remodeling, and pulmonary hypertension (PH) precede development of alveolar destruction.  We provide evidence for a causative role of inducible nitric oxide synthase (iNOS) and peroxynitrite in this context.  Mice lacking iNOS were protected against emphysema and PH.  Treatment of wild-type mice with the iNOS inhibitor N6-(1-iminoethyl)-L-lysine (L-NIL) prevented structural and functional alterations of both the lung vasculature and alveoli and also reversed established disease.  In chimeric mice lacking iNOS in bone marrow (BM)-derived cells, PH was dependent on iNOS from BM-derived cells, whereas emphysema development was dependent on iNOS from non-BM-derived cells.  Similar regulatory and structural alterations as seen in mouse lungs were found in lung tissue from humans with end-stage COPD.  Smoking-related damage can be reversed by inhibition of iNOS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothjrcUQAAE7Vg90H21EOLACvtfcHk0liRcnnrH7HdEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaksb3O&md5=ddebfbf25933ed6f6d1f590e6bde0269</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DSeimetz%26aufirst%3DM.%26aulast%3DParajuli%26aufirst%3DN.%26aulast%3DPichl%26aufirst%3DA.%26aulast%3DVeit%26aufirst%3DF.%26aulast%3DKwapiszewska%26aufirst%3DG.%26aulast%3DWeisel%26aufirst%3DF.%2BC.%26aulast%3DMilger%26aufirst%3DK.%26aulast%3DEgemnazarov%26aufirst%3DB.%26aulast%3DTurowska%26aufirst%3DA.%26aulast%3DFuchs%26aufirst%3DB.%26aulast%3DNikam%26aufirst%3DS.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DSydykov%26aufirst%3DA.%26aulast%3DMedebach%26aufirst%3DT.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DJaksch%26aufirst%3DP.%26aulast%3DDumitrascu%26aufirst%3DR.%26aulast%3DGarn%26aufirst%3DH.%26aulast%3DVoswinckel%26aufirst%3DR.%26aulast%3DKostin%26aufirst%3DS.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DWeissmann%26aufirst%3DN.%26atitle%3DInducible%2520NOS%2520inhibition%2520reverses%2520tobacco-smoke-induced%2520emphysema%2520and%2520pulmonary%2520hypertension%2520in%2520mice%26jtitle%3DCell%26date%3D2011%26volume%3D147%26spage%3D293%26epage%3D305%26doi%3D10.1016%2Fj.cell.2011.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span> <span> </span><span class="NLM_article-title">Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7600</span>– <span class="NLM_lpage">7612</span>, <span class="refDoi"> DOI: 10.1021/jm5007534</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5007534" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7600-7612&author=W.+Tangauthor=J.+Xieauthor=S.+Xuauthor=H.+Lvauthor=M.+Linauthor=S.+Yuanauthor=J.+Baiauthor=Q.+Houauthor=S.+Yu&title=Novel+nitric+oxide-releasing+derivatives+of+brusatol+as+anti-inflammatory+agents%3A+design%2C+synthesis%2C+biological+evaluation%2C+and+nitric+oxide+release+studies&doi=10.1021%2Fjm5007534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nitric Oxide-Releasing Derivatives of Brusatol as Anti-Inflammatory Agents: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies</span></div><div class="casAuthors">Tang, Weibin; Xie, Jianlin; Xu, Song; Lv, Haining; Lin, Mingbao; Yuan, Shaopeng; Bai, Jinye; Hou, Qi; Yu, Shishan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7600-7612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Brusatol (I), a biol. active natural product, was modified in four distinct positions through the covalent attachment of a furoxan moiety, which acts as a nitric oxide (NO) donor.  Forty derivs. were synthesized and evaluated for their inhibitory effects on excess NO biosynthesis in activated macrophages.  Among them, compd. II demonstrated inhibition (IC50 = 0.067 μM) comparable to that of brusatol but was less cytotoxic.  More importantly, even at very low doses (2 μmol/kg/day), compd. II also showed substantial inhibitory efficacy against chronic obstructive pulmonary disease (COPD)-like inflammation in the mouse model induced by cigarette smoke (CS) and lipopolysaccharide (LPS).  Particularly, this compd. was over 100-fold less toxic (LD50 > 3852 μmol/kg) than brusatol and could be a promising lead for further studies.  Notably, the improved properties of this deriv. are assocd. with its NO-releasing capability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof9TEp1CBXfrVg90H21EOLACvtfcHk0ljlmaz_OXxYJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtL%252FE&md5=d998e9259ca559dcf096c59173b75e80</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm5007534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007534%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLv%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DS.%26atitle%3DNovel%2520nitric%2520oxide-releasing%2520derivatives%2520of%2520brusatol%2520as%2520anti-inflammatory%2520agents%253A%2520design%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520nitric%2520oxide%2520release%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7600%26epage%3D7612%26doi%3D10.1021%2Fjm5007534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors: the road ahead</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrd.2018.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29545548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=353-377&author=F.+M.+Fergusonauthor=N.+S.+Gray&title=Kinase+inhibitors%3A+the+road+ahead&doi=10.1038%2Fnrd.2018.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors: the road ahead</span></div><div class="casAuthors">Ferguson, Fleur M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-377</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase signaling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy.  However, kinase deregulation has been firmly demonstrated to play an essential role in virtually all major disease areas.  Kinase inhibitor drug discovery programs have recently broadened their focus to include an expanded range of kinase targets and therapeutic areas.  In this Review, we provide an overview of the novel targets, biol. processes and disease areas that kinase-targeting small mols. are being developed against, highlight the assocd. challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZPospb1TP7Vg90H21EOLACvtfcHk0ljlmaz_OXxYJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D&md5=34e42911d8a70301905460c3507e737a</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.21%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%253A%2520the%2520road%2520ahead%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D353%26epage%3D377%26doi%3D10.1038%2Fnrd.2018.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. S.</span></span> <span> </span><span class="NLM_article-title">Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1307</span>– <span class="NLM_lpage">1311</span>, <span class="refDoi"> DOI: 10.1111/cbdd.13032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fcbdd.13032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28557295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2017&pages=1307-1311&author=Y.+R.+Liauthor=C.+C.+Linauthor=C.+Y.+Huangauthor=Y.+H.+Wongauthor=C.+H.+Hsiehauthor=H.+W.+Wuauthor=J.+J.+W.+Chenauthor=Y.+S.+Wu&title=Study+of+the+inhibitory+effects+on+TNF-%CE%B1-induced+NF-%CE%BAB+activation+of+IMD0354+analogs&doi=10.1111%2Fcbdd.13032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs</span></div><div class="casAuthors">Li, Yi-Rong; Lin, Chi-Chen; Huang, Chih-Yuan; Wong, Yung-Hao; Hsieh, Cheng-Hung; Wu, Han-Wei; Chen, Jeremy J. W.; Wu, Yu-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1307-1311</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Nuclear factor-κB (NF-κB) is an important nuclear transcription factor which regulates pro-inflammatory cytokines such as TNF-α, IL-6.  Its role as immunoregulatory mediator makes it an attractive target in the development of treatments for inflammatory and autoimmune diseases.  In this study, we synthesized derivs. of IMD0354, a known inhibitor for NF-κB, in attempt to understand the effect of benzanilide substitutions on its activity.  The inhibition of these analogs on NF-κB activation was analyzed by luciferase assay.  The inhibition of IKKβ phosphorylation and pro-inflammatory cytokines was detd. by Western blot and real-time PCR.  The structure activity relationships showed that the hydroxyl group on IMD0354 is a crit. moiety that resulting in the inhibition of NF-κB.  Derivs. 1m, 2b, and 2c were shown to inhibit pro-inflammatory cytokine prodn. at low concn.  These newly synthesized compds. may be useful for the treatment of chronic inflammatory disorders or for cancer prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKT7Cu5CCzMrVg90H21EOLACvtfcHk0lgQCEdNkcGqKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrurrF&md5=bb435591664cb6f04682dbc8cd88fa11</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.13032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.13032%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BR.%26aulast%3DLin%26aufirst%3DC.%2BC.%26aulast%3DHuang%26aufirst%3DC.%2BY.%26aulast%3DWong%26aufirst%3DY.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BH.%26aulast%3DWu%26aufirst%3DH.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%2BW.%26aulast%3DWu%26aufirst%3DY.%2BS.%26atitle%3DStudy%2520of%2520the%2520inhibitory%2520effects%2520on%2520TNF-%25CE%25B1-induced%2520NF-%25CE%25BAB%2520activation%2520of%2520IMD0354%2520analogs%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2017%26volume%3D90%26spage%3D1307%26epage%3D1311%26doi%3D10.1111%2Fcbdd.13032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sone, S.</span></span> <span> </span><span class="NLM_article-title">Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1159/000161579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1159%2F000161579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18849610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Kis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2009&pages=186-198&author=A.+Sugitaauthor=H.+Ogawaauthor=M.+Azumaauthor=S.+Mutoauthor=A.+Honjoauthor=H.+Yanagawaauthor=Y.+Nishiokaauthor=K.+Taniauthor=A.+Itaiauthor=S.+Sone&title=Antiallergic+and+anti-inflammatory+effects+of+a+novel+I+kappaB+kinase+beta+inhibitor%2C+IMD-0354%2C+in+a+mouse+model+of+allergic+inflammation&doi=10.1159%2F000161579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Antiallergic and anti-inflammatory effects of a novel IκB Kinase β inhibitor, IMD-0354, in a mouse model of allergic inflammation</span></div><div class="casAuthors">Sugita, Akemi; Ogawa, Hirohisa; Azuma, Masahiko; Muto, Susumu; Honjo, Akifumi; Yanagawa, Hiroaki; Nishioka, Yasuhiko; Tani, Kenji; Itai, Akiko; Sone, Saburo</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-198</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Nuclear factor (NF)-κB is a transcription factor known to regulate allergy-assocd. cytokine and chemokine prodn. related to the induction of inflammation.  IκB kinase β (IKKβ), which is responsible for activation of the NF-κB pathway, may be an ideal mol. target to inhibit this process.  IMD-0354 [N-(3,5-bis-trifluoromethyl-phenyl)-5-chloro-2-hydroxy-benzamide] is an attractive novel IKKβ inhibitor that prevents the prodn. of inflammatory cytokines in various diseases, although it is not known if IMD-0354 is effective against allergic inflammation.  This study aimed to elucidate the antiallergic effects of a newly synthesized IKKβ inhibitor, IMD-0354, in a mouse model of allergic inflammation.  Methods: We generated ovalbumin (OVA)-sensitized mice which were then challenged with OVA.  IMD-0354 was administered i.p. to therapeutic groups.  Lung histopathol. and the concns. of cytokines and chemokines in bronchoalveolar lavage fluid (BALF) and supernatants of lung homogenates were detd.  Results: Administration of IMD-0354 ameliorated airway hyperresponsiveness and reduced the nos. of bronchial eosinophils and mucus-producing cells in OVA-sensitized mice.  The total nos. of cells and eosinophils in BALF were also reduced by treatment with IMD-0354.  Treatment with IMD-0354 inhibited the prodn. of Th2 cytokines such as interleukin (IL)-5 and IL-13 and eotaxin in the airways and/or lungs of OVA-sensitized mice, but it did not affect the restoration of Th1 cytokines such as IL-12 and interferon-γ under the same exptl. conditions.  IgE prodn. was also inhibited by IMD-0354.  Conclusion: A specific IKKβ inhibitor, IMD-0354, improved allergic airway inflammation and hyperresponsiveness in mice.  IMD-0354 may have therapeutic potential for bronchial asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyHAFj_1oj87Vg90H21EOLACvtfcHk0lgQCEdNkcGqKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Kis74%253D&md5=bd9d5d904d37150cfa91b4a1f028b4dc</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1159%2F000161579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000161579%26sid%3Dliteratum%253Aachs%26aulast%3DSugita%26aufirst%3DA.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DMuto%26aufirst%3DS.%26aulast%3DHonjo%26aufirst%3DA.%26aulast%3DYanagawa%26aufirst%3DH.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DTani%26aufirst%3DK.%26aulast%3DItai%26aufirst%3DA.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DAntiallergic%2520and%2520anti-inflammatory%2520effects%2520of%2520a%2520novel%2520I%2520kappaB%2520kinase%2520beta%2520inhibitor%252C%2520IMD-0354%252C%2520in%2520a%2520mouse%2520model%2520of%2520allergic%2520inflammation%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2009%26volume%3D148%26spage%3D186%26epage%3D198%26doi%3D10.1159%2F000161579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1124/pr.116.012518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fpr.116.012518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=27363440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFCrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=788-815&author=P.+J.+Barnes&title=Kinases+as+novel+therapeutic+targets+in+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1124%2Fpr.116.012518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">788-815</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Multiple kinases play a crit. role in orchestrating the chronic inflammation and structural changes in the respiratory tract of patients with asthma and chronic obstructive pulmonary disease (COPD).  Kinases activate signaling pathways that lead to contraction of airway smooth muscle and release of inflammatory mediators (such as cytokines, chemokines, growth factors) as well as cell migration, activation, and proliferation.  For this reason there has been great interest in the development of kinase inhibitors as anti-inflammatory therapies, particular where corticosteroids are less effective, as in severe asthma and COPD.  However, it has proven difficult to develop selective kinase inhibitors that are both effective and safe after oral administration and this has led to a search for inhaled kinase inhibitors, which would reduce systemic exposure.  Although many kinases have been implicated in inflammation and remodeling of airway disease, very few classes of drug have reached the stage of clin. studies in these diseases.  The most promisingdrugs arep38MAPkinases, isoenzyme-selective PI3-kinases, Janus-activated kinases, and Syk-kinases, and inhaled formulations of these drugs are now in development.  There has also been interest in developing inhibitors that block more than one kinase, because these drugs may be more effective and with less risk of losing efficacy with time.  No kinase inhibitors are yet on the market for the treatment of airway diseases, but as kinase inhibitors are improved from other therapeutic areas there is hope that these drugs may eventually prove useful in treating refractory asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeztyKAL-brVg90H21EOLACvtfcHk0lgQCEdNkcGqKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFCrs7k%253D&md5=b1124d17b06af2c9577db2967d4914a9</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fpr.116.012518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.116.012518%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DKinases%2520as%2520novel%2520therapeutic%2520targets%2520in%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D788%26epage%3D815%26doi%3D10.1124%2Fpr.116.012518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazzan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turato, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maestrelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maselli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vatrella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsico, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saetta, M.</span></span> <span> </span><span class="NLM_article-title">Increased activation of p38 MAPK in COPD</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1183/09031936.00036707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1183%2F09031936.00036707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17959643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvVCgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=62-69&author=T.+Rendaauthor=S.+Baraldoauthor=G.+Pelaiaauthor=E.+Bazzanauthor=G.+Turatoauthor=A.+Papiauthor=P.+Maestrelliauthor=R.+Maselliauthor=A.+Vatrellaauthor=L.+M.+Fabbriauthor=R.+Zuinauthor=S.+A.+Marsicoauthor=M.+Saetta&title=Increased+activation+of+p38+MAPK+in+COPD&doi=10.1183%2F09031936.00036707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Increased activation of p38 MAPK in COPD</span></div><div class="casAuthors">Renda, T.; Baraldo, S.; Pelaia, G.; Bazzan, E.; Turato, G.; Papi, A.; Maestrelli, P.; Maselli, R.; Vatrella, A.; Fabbri, L. M.; Zuin, R.; Marsico, S. A.; Saetta, M.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-69</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Inflammation, oxidative stress and apoptosis, which are involved in chronic obstructive pulmonary disease (COPD) pathogenesis, may activate the p38 subgroup of mitogen-activated protein kinases (MAPKs).  Therefore, the aim of the present study was to evaluate the expression of the phosphorylated, active form of p38 MAPK (phospho-p38) in the lungs of COPD patients.  Surgical specimens were obtained from 18 smokers with COPD at different stages of disease severity, plus nine smoking and eight nonsmoking subjects with normal lung function.  Phospho-p38+ cells were quantified by immunohistochem. in both alveolar spaces and alveolar walls.  Moreover, a Western blot anal. of phospho-p38 and total p38α isoform expressed by alveolar macrophages was performed.  Phospho-p38+ alveolar macrophages and phospho-p38+ cells in alveolar walls were increased in patients with severe and mild/moderate COPD, compared with smoking and nonsmoking controls.  Moreover, they were inversely correlated to values of forced expiratory vol. in one second (FEV1) and FEV1/forced vital capacity.  Western blot anal. showed that phosphorylated p38, but not the total p38α isoform, was specifically increased in alveolar macrophages from COPD patients.  Activation of the p38 mitogen-activated protein kinase pathway appears to be involved in the pathogenesis of chronic obstructive pulmonary disease.  The present findings suggest that this protein may be a suitable pharmacol. target for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtAB3KTmtt7bVg90H21EOLACvtfcHk0lgPIQejFVLr9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvVCgs7g%253D&md5=39f304338b1fab6a54221a1ed305d220</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1183%2F09031936.00036707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00036707%26sid%3Dliteratum%253Aachs%26aulast%3DRenda%26aufirst%3DT.%26aulast%3DBaraldo%26aufirst%3DS.%26aulast%3DPelaia%26aufirst%3DG.%26aulast%3DBazzan%26aufirst%3DE.%26aulast%3DTurato%26aufirst%3DG.%26aulast%3DPapi%26aufirst%3DA.%26aulast%3DMaestrelli%26aufirst%3DP.%26aulast%3DMaselli%26aufirst%3DR.%26aulast%3DVatrella%26aufirst%3DA.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DZuin%26aufirst%3DR.%26aulast%3DMarsico%26aufirst%3DS.%2BA.%26aulast%3DSaetta%26aufirst%3DM.%26atitle%3DIncreased%2520activation%2520of%2520p38%2520MAPK%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2008%26volume%3D31%26spage%3D62%26epage%3D69%26doi%3D10.1183%2F09031936.00036707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millan, D. S.</span></span> <span> </span><span class="NLM_article-title">What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1635</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4155%2Ffmc.11.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21942253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1635-1645&author=D.+S.+Millan&title=What+is+the+potential+for+inhaled+p38+inhibitors+in+the+treatment+of+chronic+obstructive+pulmonary+disease%3F&doi=10.4155%2Ffmc.11.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?</span></div><div class="casAuthors">Millan, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1635-1645</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  P38 has been an intensely studied therapeutic target in the pharmaceutical industry.  With more than 20 compds. entering human trials, none have progressed beyond Phase II to the best of our knowledge.  The transient efficacy seen in many of the Phase II trials has raised some concerns for the future potential of this target, particularly in rheumatoid arthritis.  With this caveat, there is good evidence for p38 inhibition to be efficacious in chronic obstructive pulmonary disease and there are now several oral compds. currently in development for this disease, with encouraging data beginning to emerge.  With an inhaled agent likely to improve the therapeutic window between efficacy and some of the common adverse events obsd. with oral p38 inhibitors it would seem a sensible approach to take for a disease of the lung.  This review will highlight the potential for an inhaled p38 inhibitor in chronic obstructive pulmonary disease, as well as some of the design principles that are important to consider when developing an inhaled kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4waRvOu6S_LVg90H21EOLACvtfcHk0lgPIQejFVLr9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvK&md5=81104fda424ad56be567693b9207b4f3</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.96%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26atitle%3DWhat%2520is%2520the%2520potential%2520for%2520inhaled%2520p38%2520inhibitors%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1635%26epage%3D1645%26doi%3D10.4155%2Ffmc.11.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1006358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543784.2015.1006358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25599809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVKrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=383-392&author=P.+Norman&title=Investigational+p38+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1517%2F13543784.2015.1006358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The p38 protein kinases, in particular p38α and p38β, regulate the prodn. of multiple inflammatory mediators.  Consequentially, considerable effort has been focused on trying to develop p38 inhibitors for the treatment of inflammatory diseases.  Some 20 p38 inhibitors have progressed to clin. development, mostly for the treatment of rheumatoid arthritis, but with little success.  Increasingly, interest has turned to their use in other indications and notably chronic obstructive pulmonary disease (COPD).  Areas covered: In this review, the author discusses the eight p38 inhibitors that have been clin. evaluated.  Acumapimod is the only one of four orally delivered inhibitors that remains in active development while Phase II results of PH-797804 and losmapimod are compared.  The activity of two inhibitors designed for inhaled delivery, RV-568 and PF-03715455, is compared but little is known about AZD-7624 or the discontinued GSK-610677.  Expert opinion: Results from animal models provide a clear rationale for developing p38 inhibitors for COPD, and appear to be (partially) validated by the efficacy seen with PH-797804 and losmapimod.  Inhaled delivery provides the opportunity to enhance p38 inhibition in the lung while reducing unwanted systemic effects of p38 inhibition.  Validation of this hypothesis should come from the results of the recently completed Phase II study with RV-568.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKUbGhXQAMzrVg90H21EOLACvtfcHk0ljlUf3M8-etVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVKrtLk%253D&md5=97485678de1e2d15bf1ace5139cba51e</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1006358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1006358%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInvestigational%2520p38%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D383%26epage%3D392%26doi%3D10.1517%2F13543784.2015.1006358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medicherla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protter, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L. S.</span></span> <span> </span><span class="NLM_article-title">p38α-Selective MAP kinase inhibitor, SD-282, reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.127092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.107.127092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18056868" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2007&pages=921-929&author=S.+Medicherlaauthor=M.+Fitzgeraldauthor=D.+Spicerauthor=P.+Woodmanauthor=J.+Y.+Maauthor=A.+M.+Kapounauthor=S.+Chakravartyauthor=S.+Dugarauthor=A.+A.+Protterauthor=L.+S.+Higgins&title=p38%CE%B1-Selective+MAP+kinase+inhibitor%2C+SD-282%2C+reduces+inflammation+in+a+sub-chronic+model+of+tobacco+smoke-induced+airway+inflammation&doi=10.1124%2Fjpet.107.127092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.127092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.127092%26sid%3Dliteratum%253Aachs%26aulast%3DMedicherla%26aufirst%3DS.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DSpicer%26aufirst%3DD.%26aulast%3DWoodman%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DJ.%2BY.%26aulast%3DKapoun%26aufirst%3DA.%2BM.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DDugar%26aufirst%3DS.%26aulast%3DProtter%26aufirst%3DA.%2BA.%26aulast%3DHiggins%26aufirst%3DL.%2BS.%26atitle%3Dp38%25CE%25B1-Selective%2520MAP%2520kinase%2520inhibitor%252C%2520SD-282%252C%2520reduces%2520inflammation%2520in%2520a%2520sub-chronic%2520model%2520of%2520tobacco%2520smoke-induced%2520airway%2520inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D324%26spage%3D921%26epage%3D929%26doi%3D10.1124%2Fjpet.107.127092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotzer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochnowicz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griswold, D. E.</span></span> <span> </span><span class="NLM_article-title">SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10734180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFGhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2000&pages=281-288&author=D.+C.+Underwoodauthor=R.+R.+Osbornauthor=C.+J.+Kotzerauthor=J.+L.+Adamsauthor=J.+C.+Leeauthor=E.+F.+Webbauthor=D.+C.+Carpenterauthor=S.+Bochnowiczauthor=H.+C.+Thomasauthor=D.+W.+P.+Hayauthor=D.+E.+Griswold&title=SB+239063%2C+a+potent+p38+MAP+kinase+inhibitor%2C+reduces+inflammatory+cytokine+production%2C+airways+eosinophil+infiltration%2C+and+persistence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence</span></div><div class="casAuthors">Underwood, David C.; Osborn, Ruth R.; Kotzer, Charles J.; Adams, Jerry L.; Lee, John C.; Webb, Edward F.; Carpenter, Donald C.; Bochnowicz, Steven; Thomas, Heath C.; Hay, Douglas W. P.; Griswold, Don E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-288</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The anti-inflammatory/antiallergic activity of a novel second-generation p38 mitogen-activated protein kinase inhibitor, SB 239063 [trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridim idin-4-yl)imidazole], was investigated in vivo and in vitro.  SB 239063 had an IC50 of 44 nM for inhibition of recombinant purified human p38α.  In lipopolysaccharide-stimulated human peripheral blood monocytes, SB 239063 inhibited interleukin-1 and tumor necrosis factor-α prodn. (IC50 values = 0.12 and 0.35 μM, resp.).  A role for p38 kinase in cytokine-assocd. inflammation in the mouse was shown by p38 activation in the lung and inhibition of lipopolysaccharide-induced tumor necrosis factor-α prodn. by SB 239063 (ED50 = 5.8 mg/kg p.o.).  Antiallergic activity was demonstrated by essential abolition (∼93% inhibition) of inhaled ovalbumin (OA)-induced airway eosinophilia by SB 239063 (12 mg/kg p.o.), measured by bronchoalveolar lavage (BAL) in OA-sensitized mice.  In addn., p38 kinase was found by Western anal. to be activated in guinea pig lung.  Administration of SB 239063 (10 or 30 mg/kg p.o.) in conscious guinea pigs markedly reduced (∼50% inhibition) OA-induced pulmonary eosinophil influx, measured by BAL 24 h after antigen.  SB 239063 (10 mg/kg b.i.d. p.o.) administered after leukotriene D4 inhalation, reduced by 60% the persistent airway eosinophilia seen at 4 days.  Apoptosis of cultured eosinophils isolated from guinea pig BAL was increased by SB 239063 (1-10 μM) in the presence of interleukin-5.  These results indicate that SB 239063 is a potent inhibitor of inflammatory cytokine prodn., inhibits eosinophil recruitment, in addn. to enhancing apoptosis of these cells.  Collectively, the results support the potential utility of p38 kinase inhibitors, such as SB 239063 for the treatment of asthma and other inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLFMXLD74MwLVg90H21EOLACvtfcHk0ljlUf3M8-etVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFGhuro%253D&md5=3a09fb3f2b3c67d8b359cea1d73ef27b</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUnderwood%26aufirst%3DD.%2BC.%26aulast%3DOsborn%26aufirst%3DR.%2BR.%26aulast%3DKotzer%26aufirst%3DC.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DCarpenter%26aufirst%3DD.%2BC.%26aulast%3DBochnowicz%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%2BC.%26aulast%3DHay%26aufirst%3DD.%2BW.%2BP.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26atitle%3DSB%2520239063%252C%2520a%2520potent%2520p38%2520MAP%2520kinase%2520inhibitor%252C%2520reduces%2520inflammatory%2520cytokine%2520production%252C%2520airways%2520eosinophil%2520infiltration%252C%2520and%2520persistence%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D293%26spage%3D281%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onions, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frickel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King-Underwood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapeport, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taddei, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of narrow spectrum kinase inhibitors: new therapeutic agents for the treatment of COPD and steroid-resistant asthma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1727</span>– <span class="NLM_lpage">1746</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01029</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ahtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1727-1746&author=S.+T.+Onionsauthor=K.+Itoauthor=C.+E.+Charronauthor=R.+J.+Brownauthor=M.+Colucciauthor=F.+Frickelauthor=G.+Hardyauthor=K.+Jolyauthor=J.+King-Underwoodauthor=Y.+Kizawaauthor=I.+Knowlesauthor=P.+J.+Murrayauthor=A.+Novakauthor=A.+Raniauthor=G.+Rapeportauthor=A.+Smithauthor=P.+Strongauthor=D.+M.+Taddeiauthor=J.+G.+Williams&title=Discovery+of+narrow+spectrum+kinase+inhibitors%3A+new+therapeutic+agents+for+the+treatment+of+COPD+and+steroid-resistant+asthma&doi=10.1021%2Facs.jmedchem.5b01029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma</span></div><div class="casAuthors">Onions, Stuart T.; Ito, Kazuhiro; Charron, Catherine E.; Brown, Richard J.; Colucci, Marie; Frickel, Fritz; Hardy, George; Joly, Kevin; King-Underwood, John; Kizawa, Yasuo; Knowles, Ian; Murray, P. John; Novak, Andrew; Rani, Anjna; Rapeport, Garth; Smith, Alun; Strong, Peter; Taddei, David M.; Williams, Jonathan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1727-1746</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a novel series of therapeutic agents that has been designed and optimized for treating chronic obstructive pulmonary disease is reported (I).  The pharmacol. strategy was based on the identification of compds. that inhibit a defined subset of kinase enzymes modulating inflammatory processes that would be effective against steroid refractory disease and exhibit a sustained duration of action after inhaled delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogkSJ05_wxaLVg90H21EOLACvtfcHk0lg17VeHJ3vOZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ahtbk%253D&md5=1aa6f8356d2e2a18ce9ac8906c46a6d1</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01029%26sid%3Dliteratum%253Aachs%26aulast%3DOnions%26aufirst%3DS.%2BT.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DCharron%26aufirst%3DC.%2BE.%26aulast%3DBrown%26aufirst%3DR.%2BJ.%26aulast%3DColucci%26aufirst%3DM.%26aulast%3DFrickel%26aufirst%3DF.%26aulast%3DHardy%26aufirst%3DG.%26aulast%3DJoly%26aufirst%3DK.%26aulast%3DKing-Underwood%26aufirst%3DJ.%26aulast%3DKizawa%26aufirst%3DY.%26aulast%3DKnowles%26aufirst%3DI.%26aulast%3DMurray%26aufirst%3DP.%2BJ.%26aulast%3DNovak%26aufirst%3DA.%26aulast%3DRani%26aufirst%3DA.%26aulast%3DRapeport%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DStrong%26aufirst%3DP.%26aulast%3DTaddei%26aufirst%3DD.%2BM.%26aulast%3DWilliams%26aufirst%3DJ.%2BG.%26atitle%3DDiscovery%2520of%2520narrow%2520spectrum%2520kinase%2520inhibitors%253A%2520new%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520COPD%2520and%2520steroid-resistant%2520asthma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1727%26epage%3D1746%26doi%3D10.1021%2Facs.jmedchem.5b01029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2979</span>– <span class="NLM_lpage">2994</span>, <span class="refDoi"> DOI: 10.2174/092986705774462914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2174%2F092986705774462914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16378500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Grt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=2979-2994&author=M.+R.+Leeauthor=C.+Dominguez&title=MAP+kinase+p38+inhibitors%3A+clinical+results+and+an+intimate+look+at+their+interactions+with+p38alpha+protein&doi=10.2174%2F092986705774462914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38α protein</span></div><div class="casAuthors">Lee, Matthew R.; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2979-2994</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes.  There are four isoforms p38α, p38β, p38γ, and p38δ.  The most thoroughly studied isoform is p38α, whose activation has been obsd. in many hematopoietic and non-hematopoietic cell types upon appropriate stimuli.  Subsequently, p38α kinase has been shown to be involved in the biosynthesis of TNFα and IL-1β at the translational and transcriptional level.  MAP kinase p38α represents a point of convergence for multiple signaling processes that are activated in inflammation and thus a key potential target for the modulation of cytokine prodn.  The discovery and publication of p38α and the pyridinyl-imidazole inhibitor initiated a huge effort by many companies to develop p38α inhibitors as potential treatment for inflammatory diseases.  Herein we provide a brief overview of recent reported clin. results for AMG 548, BIRB 796, VX 702, SCIO 469, and SCIO 323.  However, our focus will be on the binding modes of these inhibitors and other p38 inhibitors in the recent literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZSldsfUAO6bVg90H21EOLACvtfcHk0lhxbwabM7EOIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Grt7jF&md5=eb21253fcc2df76280cd9a1812ed1015</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.2174%2F092986705774462914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986705774462914%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DMAP%2520kinase%2520p38%2520inhibitors%253A%2520clinical%2520results%2520and%2520an%2520intimate%2520look%2520at%2520their%2520interactions%2520with%2520p38alpha%2520protein%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2005%26volume%3D12%26spage%3D2979%26epage%3D2994%26doi%3D10.2174%2F092986705774462914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8559</span>– <span class="NLM_lpage">8581</span>, <span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+A.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+targets+for+autoimmune+and+inflammatory+diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span></div><div class="casAuthors">Cushing, Timothy D.; Metz, Daniela P.; Whittington, Douglas A.; McGee, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8559-8581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeting signaling mols. that are required for the activation of multiple immune cells may be a more likely route to success in combating chronic, immune cell-mediated diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and asthma).  This review will highlight two such signaling mols., the related lipid kinases, class I PI3K (phosphoinositide 3-kinase) δ and γ, both of which are primarily expressed in leukocytes and seem to play important roles in their function and activation.  This review will compare and contrast these two kinases as targets for autoimmune and inflammatory diseases and summarize efforts toward the development of small mol. inhibitors of PI3Kδ and PI3Kγ.  Phosphoinositides (PIs) act as second messengers in a wide variety of cellular roles including signal transduction, control of membrane trafficking and transport, cytoskeleton organization, cell survival and death, among many other functions.  The target of PI3K kinase activity is the phosphoinositides within cell membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqItqgMiGp7Vg90H21EOLACvtfcHk0lhxbwabM7EOIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL&md5=76fc05c3bf303174add4aca98f526f8f</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520targets%2520for%2520autoimmune%2520and%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Down, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunniss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span> <span> </span><span class="NLM_article-title">Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase δ for the treatment of respiratory disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7381</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7381-7399&author=K.+Downauthor=A.+Amourauthor=I.+R.+Baldwinauthor=A.+W.+Cooperauthor=A.+M.+Deakinauthor=L.+M.+Feltonauthor=S.+B.+Guntripauthor=C.+Hardyauthor=Z.+A.+Harrisonauthor=K.+L.+Jonesauthor=P.+Jonesauthor=S.+E.+Keelingauthor=J.+Leauthor=S.+Liviaauthor=F.+Lucasauthor=C.+J.+Lunnissauthor=N.+J.+Parrauthor=E.+Robinsonauthor=P.+Rowlandauthor=S.+Smithauthor=D.+A.+Thomasauthor=G.+Vitulliauthor=Y.+Washioauthor=J.+N.+Hamblin&title=Optimization+of+novel+indazoles+as+highly+potent+and+selective+inhibitors+of+phosphoinositide+3-kinase+%CE%B4+for+the+treatment+of+respiratory+disease&doi=10.1021%2Facs.jmedchem.5b00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Down, Kenneth; Amour, Augustin; Baldwin, Ian R.; Cooper, Anthony W. J.; Deakin, Angela M.; Felton, Leigh M.; Guntrip, Stephen B.; Hardy, Charlotte; Harrison, Zoe A.; Jones, Katherine L.; Jones, Paul; Keeling, Suzanne E.; Le, Joelle; Livia, Stefano; Lucas, Fiona; Lunniss, Christopher J.; Parr, Nigel J.; Robinson, Ed; Rowland, Paul; Smith, Sarah; Thomas, Daniel A.; Vitulli, Giovanni; Washio, Yoshiaki; Hamblin, J. Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7381-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of lead compd., through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clin. candidates I (GSK2269557) and II (GSK2292767) for the treatment of respiratory indications via inhalation.  Compds. I and II are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYzpPxn_ArbVg90H21EOLACvtfcHk0lg_Scb7uuli4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ&md5=2fe8e51a64e6f7c798bdcb63781d02ad</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00767%26sid%3Dliteratum%253Aachs%26aulast%3DDown%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBaldwin%26aufirst%3DI.%2BR.%26aulast%3DCooper%26aufirst%3DA.%2BW.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DFelton%26aufirst%3DL.%2BM.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHardy%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DZ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLivia%26aufirst%3DS.%26aulast%3DLucas%26aufirst%3DF.%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26atitle%3DOptimization%2520of%2520novel%2520indazoles%2520as%2520highly%2520potent%2520and%2520selective%2520inhibitors%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B4%2520for%2520the%2520treatment%2520of%2520respiratory%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7381%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.5b00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunsire, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriskantharajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montembault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leemereise, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinanes-Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span> <span> </span><span class="NLM_article-title">Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2017.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28823947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKnsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=69-77&author=A.+Cahnauthor=J.+N.+Hamblinauthor=M.+Beggauthor=R.+Wilsonauthor=L.+Dunsireauthor=S.+Sriskantharajahauthor=M.+Montembaultauthor=C.+N.+Leemereiseauthor=L.+Galinanes-Garciaauthor=H.+Watzauthor=A.+M.+Kirstenauthor=R.+Fuhrauthor=E.+M.+Hessel&title=Safety%2C+pharmacokinetics+and+dose-response+characteristics+of+GSK2269557%2C+an+inhaled+PI3K%CE%B4+inhibitor+under+development+for+the+treatment+of+COPD&doi=10.1016%2Fj.pupt.2017.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD</span></div><div class="casAuthors">Cahn, A.; Hamblin, J. N.; Begg, M.; Wilson, R.; Dunsire, L.; Sriskantharajah, S.; Montembault, M.; Leemereise, C. N.; Galinanes-Garcia, L.; Watz, H.; Kirsten, A. M.; Fuhr, R.; Hessel, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-77</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">While current therapies reduce symptoms in chronic obstructive pulmonary disease (COPD) patients, substantial unmet need remains and novel treatments are highly desired.  Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase specifically expressed in leukocytes and involved in their recruitment and activation.  This study evaluated the safety, pharmacokinetics (PK) and dose-response characteristics of inhaled GSK2269557, a PI3Kδ inhibitor, in moderate-to-severe COPD patients with stable disease.  In this randomised, double-blind, placebo controlled, parallel group study, patients received once daily inhaled treatment with GSK2269557 1000 μg or placebo for 14 days (Part A, primary aim safety, N = 28 patients).  In part B of the study (primary aim pharmacodynamic dose-response, N = 36 patients), GSK2269557 100, 200, 500, 700, 1000, 2000 μg or placebo was given for 14 days.  In both Part A and B, GSK2269557 was added to the usual maintenance therapy.  Safety, PK assessments and induced sputum collection for cytokine anal. were conducted at baseline and after 7 and 14 days of treatment.  Adverse events (AEs) were monitored throughout.In Part A, mean age was 61.7 years (SD 6.7), 29% were females, and mean FEV1% predicted was 59.7% (SD 11.4)2.  In Part B, mean age was 63.3 years (SD 6.3), 44% were females, and mean FEV1% predicted was 56.5% (SD 11.5)2.  GSK2269557 was well tolerated in both parts of the study; the most commonly reported AEs were cough and headache, with cough being reported with a greater incidence in the GSK2269557 groups vs. placebo (Part A: 19% vs. 14% and Part B: range of 0-80% for different doses vs. 0% on placebo).  No drug-related serious AEs or clin. significant changes in any other safety parameters were reported.  GSK2269557 was rapidly absorbed into plasma following all doses with a max. peak at approx. 2 h.  Following repeat administration, accumulation in plasma was approx. 2-3 fold from Day 1 to Day 7.  At Day 14, relative to placebo, sputum interleukin (IL)-8 and IL-6 levels were reduced on av. by 32% and 29% resp. after inhalation of GSK2269557 1000 μg in Part A.  In Part B, although inhibition of both IL-8 and IL-6 levels was obsd., the levels were variable and there was insufficient evidence to support a monotonic dose-response.  In this study, inhaled GSK2269557 had an acceptable safety profile for progression into larger studies in COPD patients.  Moreover, inhalation of GSK2269557 resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known anti-inflammatory activity of a PI3Kδ inhibitor.  Inhibition of inflammatory cytokines in the airway compartment may contribute to the potential therapeutic benefit of a PI3Kδ inhibitor in chronically inflamed COPD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLev2M055yDLVg90H21EOLACvtfcHk0lg_Scb7uuli4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKnsb7M&md5=bf5733fdf1e02f3804724f1a523c758b</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DDunsire%26aufirst%3DL.%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DMontembault%26aufirst%3DM.%26aulast%3DLeemereise%26aufirst%3DC.%2BN.%26aulast%3DGalinanes-Garcia%26aufirst%3DL.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DKirsten%26aufirst%3DA.%2BM.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26atitle%3DSafety%252C%2520pharmacokinetics%2520and%2520dose-response%2520characteristics%2520of%2520GSK2269557%252C%2520an%2520inhaled%2520PI3K%25CE%25B4%2520inhibitor%2520under%2520development%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D69%26epage%3D77%26doi%3D10.1016%2Fj.pupt.2017.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doukas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racanelli-Layton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellamary, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dneprovskaia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrasidlo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100–115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.144311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.108.144311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19056934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislals78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2009&pages=758-765&author=J.+Doukasauthor=L.+Eideauthor=K.+Stebbinsauthor=A.+Racanelli-Laytonauthor=L.+Dellamaryauthor=M.+Martinauthor=E.+Dneprovskaiaauthor=G.+Noronhaauthor=R.+Sollauthor=W.+Wrasidloauthor=L.+M.+Acevedoauthor=D.+A.+Cheresh&title=Aerosolized+phosphoinositide+3-kinase+gamma%2Fdelta+inhibitor+TG100%E2%80%93115+%5B3-%5B2%2C4-diamino-6-%283-hydroxyphenyl%29pteridin-7-yl%5Dphenol%5D+as+a+therapeutic+candidate+for+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1124%2Fjpet.108.144311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Aerosolized phosphoinositide 3-kinase γ/δ inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Doukas, John; Eide, Lisa; Stebbins, Karin; Racanelli-Layton, Adrienne; Dellamary, Luis; Martin, Michael; Dneprovskaia, Elena; Noronha, Glenn; Soll, Richard; Wrasidlo, Wolfgang; Acevedo, Lisette M.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">758-765</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinases (PI3Ks) are key elements in the signaling cascades that lie downstream of many cellular receptors.  In particular, PI3K δ and γ isoforms contribute to inflammatory cell recruitment and subsequent activation.  For this reason, in a series of preclin. studies, we tested the potential of a recently developed small-mol. inhibitor of these two isoforms, TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).  To det. pharmacokinetic profiles, aerosolized formulations of the drug were delivered to mice by a nose-only inhalation route, yielding high pulmonary TG100-115 levels with minimal systemic exposure.  Safety assessments were favorable, with no clin. or histol. changes noted after 21 days of daily dosing.  In a murine asthma model, aerosolized TG100-115 markedly reduced the pulmonary eosinophilia and the concomitant interleukin-13 and mucin accumulation characteristic of this disease.  As a functional benefit, interventional dosing schedules of this inhibitor also reduced airway hyper-responsiveness.  To model the pulmonary neutrophilia characteristic of COPD, mice were exposed to either intranasal lipopolysaccharide or inhaled smoke.  Aerosolized TG100-115 again inhibited these inflammatory patterns, most notably in the smoke model, where interventional therapy overcame the steroid-resistant nature of the pulmonary inflammation.  In conclusion, aerosolized TG100-115 displays pharmacokinetic, safety, and biol. activity profiles favorable for further development as a therapy for both asthma and COPD.  Furthermore, these studies support the hypothesis that PI3K δ and γ are suitable mol. targets for these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoidXci0t94JrVg90H21EOLACvtfcHk0ljRQWl-qF8v9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislals78%253D&md5=ec9227c014cdcdd0637e1bec10446255</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.144311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.144311%26sid%3Dliteratum%253Aachs%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DEide%26aufirst%3DL.%26aulast%3DStebbins%26aufirst%3DK.%26aulast%3DRacanelli-Layton%26aufirst%3DA.%26aulast%3DDellamary%26aufirst%3DL.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DWrasidlo%26aufirst%3DW.%26aulast%3DAcevedo%26aufirst%3DL.%2BM.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DAerosolized%2520phosphoinositide%25203-kinase%2520gamma%252Fdelta%2520inhibitor%2520TG100%25E2%2580%2593115%2520%255B3-%255B2%252C4-diamino-6-%25283-hydroxyphenyl%2529pteridin-7-yl%255Dphenol%255D%2520as%2520a%2520therapeutic%2520candidate%2520for%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D328%26spage%3D758%26epage%3D765%26doi%3D10.1124%2Fjpet.108.144311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tame, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uddin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellaway, N.</span></span> <span> </span><span class="NLM_article-title">Evolution of a novel, orally bioavailable series of PI3Kδ inhibitors from an inhaled lead for the treatment of respiratory disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7239</span>– <span class="NLM_lpage">7251</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00799</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00799" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyitLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7239-7251&author=A.+Amourauthor=N.+Bartonauthor=A.+W.+Cooperauthor=G.+Inglisauthor=C.+Jamiesonauthor=C.+N.+Luscombeauthor=J.+Morrellauthor=S.+Peaceauthor=D.+Perezauthor=P.+Rowlandauthor=C.+J.+Tameauthor=S.+Uddinauthor=G.+Vitulliauthor=N.+Wellaway&title=Evolution+of+a+novel%2C+orally+bioavailable+series+of+PI3K%CE%B4+inhibitors+from+an+inhaled+lead+for+the+treatment+of+respiratory+disease&doi=10.1021%2Facs.jmedchem.6b00799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Amour, Augustin; Barton, Nick; Cooper, Anthony W. J.; Inglis, Graham; Jamieson, Craig; Luscombe, Christopher N.; Morrell, Josie; Peace, Simon; Perez, David; Rowland, Paul; Tame, Christopher J.; Uddin, Sorif; Vitulli, Giovanni; Wellaway, Natalie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7239-7251</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A four-step process of high-quality modeling of existing data, deconstruction, identification of replacement cores, and an innovative synthetic regrowth strategy led to the rapid discovery of a novel oral series of PI3Kδ inhibitors with promising selectivity and excellent in vivo characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKbdEJSHwYD7Vg90H21EOLACvtfcHk0ljRQWl-qF8v9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyitLnN&md5=ab4641778d1c80f0dd9551d6d75ff4ef</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00799%26sid%3Dliteratum%253Aachs%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBarton%26aufirst%3DN.%26aulast%3DCooper%26aufirst%3DA.%2BW.%26aulast%3DInglis%26aufirst%3DG.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DMorrell%26aufirst%3DJ.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DPerez%26aufirst%3DD.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DTame%26aufirst%3DC.%2BJ.%26aulast%3DUddin%26aufirst%3DS.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWellaway%26aufirst%3DN.%26atitle%3DEvolution%2520of%2520a%2520novel%252C%2520orally%2520bioavailable%2520series%2520of%2520PI3K%25CE%25B4%2520inhibitors%2520from%2520an%2520inhaled%2520lead%2520for%2520the%2520treatment%2520of%2520respiratory%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7239%26epage%3D7251%26doi%3D10.1021%2Facs.jmedchem.6b00799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gréco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturla, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gràcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domínguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabaté, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armengol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available PI3Kδ inhibitor for the treatment of inflammatory diseases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00438</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00438" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyntrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=118-123&author=M.+Erraauthor=J.+Taltavullauthor=A.+Gr%C3%A9coauthor=F.+J.+Bernalauthor=J.+F.+Caturlaauthor=J.+Gr%C3%A0ciaauthor=M.+Dom%C3%ADnguezauthor=M.+Sabat%C3%A9author=S.+Parisauthor=S.+Soriaauthor=B.+Hern%C3%A1ndezauthor=C.+Armengolauthor=J.+Cabedoauthor=M.+Bravoauthor=E.+Calamaauthor=M.+Miralpeixauthor=M.+D.+Lehner&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+PI3K%CE%B4+inhibitor+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Facsmedchemlett.6b00438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Erra, Montse; Taltavull, Joan; Greco, Angelique; Bernal, Francisco Javier; Caturla, Juan Francisco; Gracia, Jordi; Dominguez, Maria; Sabate, Mar; Paris, Stephane; Soria, Salome; Hernandez, Begona; Armengol, Clara; Cabedo, Judit; Bravo, Monica; Calama, Elena; Miralpeix, Montserrat; Lehner, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-123</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The delta isoform of the phosphatidylinositol 3-kinase (PI3Kδ) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases.  Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3Kδ inhibitors is described.  The main challenge of the optimization process was to identify an orally available compd. with a good pharmacokinetic profile in preclin. species that predicted a suitable dosing regimen in humans.  Structure-activity relationships and structure-property relationships are discussed.  This medicinal chem. exercise led to the identification of LAS191954 as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGKftcFDPpSLVg90H21EOLACvtfcHk0lgQryP9NYjPQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyntrzN&md5=120b642b7adb9a5e2a1014abc93aaa98</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00438%26sid%3Dliteratum%253Aachs%26aulast%3DErra%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DGr%25C3%25A9co%26aufirst%3DA.%26aulast%3DBernal%26aufirst%3DF.%2BJ.%26aulast%3DCaturla%26aufirst%3DJ.%2BF.%26aulast%3DGr%25C3%25A0cia%26aufirst%3DJ.%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DM.%26aulast%3DSabat%25C3%25A9%26aufirst%3DM.%26aulast%3DParis%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DS.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DArmengol%26aufirst%3DC.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DBravo%26aufirst%3DM.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520PI3K%25CE%25B4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D118%26epage%3D123%26doi%3D10.1021%2Facsmedchemlett.6b00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L. E.</span></span> <span> </span><span class="NLM_article-title">Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0128757</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0128757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1371%2Fjournal.pone.0128757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26090665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Ort7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0128757&author=P.+S.+Fenwickauthor=P.+Macedoauthor=I.+C.+Kiltyauthor=P.+J.+Barnesauthor=L.+E.+Donnelly&title=Effect+of+JAK+inhibitors+on+release+of+CXCL9%2C+CXCL10+and+CXCL11+from+human+airway+epithelial+cells&doi=10.1371%2Fjournal.pone.0128757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells</span></div><div class="casAuthors">Fenwick, Peter S.; Macedo, Patricia; Kilty, Iain C.; Barnes, Peter J.; Donnelly, Louise E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0128757/1-e0128757/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: CD8+ T-cells are located in the small airways of COPD patients and may contribute to pathophysiol.  CD8+ cells express the chemokine receptor, CXCR3 that binds CXCL9, CXCL10 and CXCL11, which are elevated in the airways of COPD patients.  These chemokines are released from airway epithelial cells via activation of receptor assocd. Janus kinases (JAK).  This study compared the efficacy of two structurally dissimilar pan-JAK inhibitors, PF956980 and PF1367550, and the glucocorticosteroid dexamethasone, in BEAS-2B and human primary airway epithelial cells from COPD patients and control subjects.  Methods: Cells were stimulated with either IFNγ alone or with TNFα, and release of CXCL9, CXCL10 and CXCL11 measured by ELISA and expression of CXCL9, CXCL10 and CXCL11 by qPCR.  Activation of JAK signalling was assessed by STAT1 phosphorylation and DNA binding.  Results: There were no differences in the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells from any of the subjects or following stimulation with either IFNγ alone or with TNFα.  Dexamethasone did not inhibit CXCR3 chemokine release from stimulated BEAS-2B or primary airway epithelial cells.  However, both JAK inhibitors suppressed this response with PF1367550 being ∼50-65-fold more potent than PF956980.  The response of cells from COPD patients did not differ from controls with similar responses regardless of whether inhibitors were added prophylactically or concomitant with stimuli.  These effects were mediated by JAK inhibition as both compds. suppressed STAT1 phosphorylation and DNA-binding of STAT1 and gene transcription.  Conclusions: These data suggest that the novel JAK inhibitor, PF1367550, is more potent than PF956980 and that JAK pathway inhibition in airway epithelium could provide an alternative anti-inflammatory approach for glucocorticosteroid-resistant diseases including COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8eUxA3RAYYbVg90H21EOLACvtfcHk0lgQryP9NYjPQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Ort7zK&md5=62be1664fe95083198f4c3f32b8c5e2c</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0128757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0128757%26sid%3Dliteratum%253Aachs%26aulast%3DFenwick%26aufirst%3DP.%2BS.%26aulast%3DMacedo%26aufirst%3DP.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DEffect%2520of%2520JAK%2520inhibitors%2520on%2520release%2520of%2520CXCL9%252C%2520CXCL10%2520and%2520CXCL11%2520from%2520human%2520airway%2520epithelial%2520cells%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0128757%26doi%3D10.1371%2Fjournal.pone.0128757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takezawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor inhibitor AG1478 inhibits mucus hypersecretion in airway epithelium</span>. <i>Am. J. Rhinol. Allergy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">e1</span>– <span class="NLM_lpage">e6</span>, <span class="refDoi"> DOI: 10.2500/ajra.2016.30.4263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2500%2Fajra.2016.30.4263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26867523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28jgtV2qtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=e1-e6&author=K.+Takezawaauthor=T.+Ogawaauthor=S.+Shimizuauthor=T.+Shimizu&title=Epidermal+growth+factor+receptor+inhibitor+AG1478+inhibits+mucus+hypersecretion+in+airway+epithelium&doi=10.2500%2Fajra.2016.30.4263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor inhibitor AG1478 inhibits mucus hypersecretion in airway epithelium</span></div><div class="casAuthors">Takezawa Kumiko; Ogawa Takao; Shimizu Shino; Shimizu Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">American journal of rhinology & allergy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mucus hypersecretion and neutrophil infiltration are important characteristics of airway inflammation.  Epidermal growth factor receptor (EGFR) transactivation induces mucus and inflammatory cytokine secretion from airway epithelial cells.  To elucidate the roles of EGFR in airway inflammation, the in vitro effects on mucin production and interleukin (IL) 8 secretion from cultured airway epithelial cells and the in vivo effects on mucus hypersecretion and neutrophil infiltration in rat nasal mucosa of the EGFR tyrosine kinase inhibitor AG1478 were examined.  METHODS:  The in vitro effects of AG1478 treatment of cultured NCI-H292 cells on lipopolysaccharide (LPS) induced or tumor necrosis factor (TNF) α induced MUC5AC mucin and IL-8 secretion were evaluated.  Hypertrophic and metaplastic changes of goblet cells, mucus production and neutrophil infiltration in rat nasal epithelium were induced by intranasal instillation of LPS in vivo, and the inhibitory effects of AG1478 by intraperitoneal injection or intranasal instillation were examined.  RESULTS:  AG1478 (1-1000 nM) significantly inhibited both LPS-induced and TNF-α-induced secretion of MUC5AC and IL-8 from cultured NCI-H292 cells in a dose-dependent manner.  The expression of MUC5AC and IL-8 messenger RNAs was also significantly inhibited.  Intranasal instillation of AG1478 one hour after intranasal LPS instillation significantly inhibited LPS-induced goblet cell metaplasia, mucus production, and neutrophil infiltration in rat nasal epithelium, as did intraperitoneal injection of AG1478 one hour before LPS instillation.  CONCLUSIONS:  These results indicated that EGFR transactivation plays an important role in mucin and IL-8 secretion from airway epithelial cells.  Intranasal instillation of an EGFR tyrosine kinase inhibitor may be a new therapeutic approach for the treatment of upper airway inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5p3FFJVZp31WTCLT8lX9SfW6udTcc2eY7Utbf2XITJLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jgtV2qtQ%253D%253D&md5=efbd7a5096d76f55f1d0634329043903</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.2500%2Fajra.2016.30.4263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2500%252Fajra.2016.30.4263%26sid%3Dliteratum%253Aachs%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DT.%26aulast%3DShimizu%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DT.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520AG1478%2520inhibits%2520mucus%2520hypersecretion%2520in%2520airway%2520epithelium%26jtitle%3DAm.%2520J.%2520Rhinol.%2520Allergy%26date%3D2016%26volume%3D30%26spage%3De1%26epage%3De6%26doi%3D10.2500%2Fajra.2016.30.4263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hegab, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiwamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekizawa, K.</span></span> <span> </span><span class="NLM_article-title">Niflumic acid and AG-1478 reduce cigarette smoke-induced mucin synthesis: the role of hCLCA1</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1156</span>, <span class="refDoi"> DOI: 10.1378/chest.06-2031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1378%2Fchest.06-2031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17426222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1149-1156&author=A.+E.+Hegabauthor=T.+Sakamotoauthor=A.+Nomuraauthor=Y.+Ishiiauthor=Y.+Morishimaauthor=T.+Iizukaauthor=T.+Kiwamotoauthor=Y.+Matsunoauthor=S.+Hommaauthor=K.+Sekizawa&title=Niflumic+acid+and+AG-1478+reduce+cigarette+smoke-induced+mucin+synthesis%3A+the+role+of+hCLCA1&doi=10.1378%2Fchest.06-2031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Niflumic acid and AG-1478 reduce cigarette smoke-induced mucin synthesis. The Role of hCLCAI</span></div><div class="casAuthors">Hegab, Ahmed E.; Sakamoto, Tohru; Nomura, Akihiro; Ishii, Yukio; Morishima, Yuko; Iizuka, Takashi; Kiwamoto, Takumi; Matsuno, Yosuke; Homma, Shinsuke; Sekizawa, Kiyohisa</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1149-1156</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">Background: Cigarette smoke induces bronchial mucus secretion.  However, the mechanism of this induction is still unidentified.  In this study, we investigated the role of the putative calcium-activated chloride channel 1 (CLCA1) and its blocker, niflumic acid, in cigarette smoke-induced mucin synthesis both in vivo and in vitro.  Methods and results: Sprague-Dawley rats were exposed to cigarette smoke for 4 wk.  The CLCA1, epidermal growth factor receptor (EGFR), and MUC5AC expressions were increased in the trachea and lung tissues.  Goblet-cell hyperplasia with marked mucin staining was detected in the tracheal and bronchial epithelium.  In the human bronchial epithelial cell line NCI-H292, cigarette smoke soln. also induced mucin prodn. as well as the RNA and protein expressions of CLCA1, EGFR, and MUC5AC.  Both in vivo and in vitro, the induction of MUC5AC and mucin synthesis were inhibited by niflumic acid, and/or a selective EGFR tyrosine kinase inhibitor, AG-1478.  Niflumic acid also blocked the epidermal growth factor-induced MUC5AC and mucin staining in the NCI-H292 cell line.  Conclusion: Both EGFR and niflumic acid-sensitive chloride channels (probably CLCA1) are dependently affecting the mucin prodn. as a part of a single complex signaling pathway.  CLCA1 may be a key signaling member that can be targeted with pharmacol. interventions to treat mucus hypersecretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7ZC4IKE2DTLVg90H21EOLACvtfcHk0lh9mDAsru4bVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFOjtLg%253D&md5=dd253656133165eb89c71f76c332afcd</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1378%2Fchest.06-2031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.06-2031%26sid%3Dliteratum%253Aachs%26aulast%3DHegab%26aufirst%3DA.%2BE.%26aulast%3DSakamoto%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DA.%26aulast%3DIshii%26aufirst%3DY.%26aulast%3DMorishima%26aufirst%3DY.%26aulast%3DIizuka%26aufirst%3DT.%26aulast%3DKiwamoto%26aufirst%3DT.%26aulast%3DMatsuno%26aufirst%3DY.%26aulast%3DHomma%26aufirst%3DS.%26aulast%3DSekizawa%26aufirst%3DK.%26atitle%3DNiflumic%2520acid%2520and%2520AG-1478%2520reduce%2520cigarette%2520smoke-induced%2520mucin%2520synthesis%253A%2520the%2520role%2520of%2520hCLCA1%26jtitle%3DChest%26date%3D2007%26volume%3D131%26spage%3D1149%26epage%3D1156%26doi%3D10.1378%2Fchest.06-2031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohlfeld, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criner, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nivens, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1164/rccm.200909-1415OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200909-1415OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20007923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVSgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2010&pages=438-445&author=P.+G.+Woodruffauthor=M.+Wolffauthor=J.+M.+Hohlfeldauthor=N.+Krugauthor=M.+T.+Dransfieldauthor=E.+R.+Sutherlandauthor=G.+J.+Crinerauthor=V.+Kimauthor=A.+Prasseauthor=M.+C.+Nivensauthor=K.+Tetzlaffauthor=R.+Heilkerauthor=J.+V.+Fahy&title=Safety+and+efficacy+of+an+inhaled+epidermal+growth+factor+receptor+inhibitor+%28BIBW+2948+BS%29+in+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.200909-1415OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Woodruff, Prescott G.; Wolff, Michael; Hohlfeld, Jens M.; Krug, Norbert; Dransfield, Mark T.; Sutherland, E. Rand; Criner, Gerard J.; Kim, Victor; Prasse, Antje; Nivens, Michael C.; Tetzlaff, Kay; Heilker, Ralf; Fahy, John V.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">438-445</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Epidermal growth factor receptor (EGFR) activation is implicated in mucin hypersecretion in chronic obstructive pulmonary disease (COPD).  Objectives: To investigate the safety and efficacy of an inhaled EGFR antagonist (BIBW 2948) in COPD.  Methods: Multicenter, double-blind, placebo-controlled trial of 4 wk of treatment with two doses of BIBW 2948 (15 and 30 mg twice a day) on safety and mucin-related outcomes in 48 patients with COPD.  The effect of BIBW 2948 on EGFR activation in airway epithelial cells was assessed using an ex vivo assay.  Efficacy measures included the vol. of mucin in the airway epithelium (Vs mu,bala) in bronchial biopsies and the expression of mucin genes in bronchial brushings.  Measurements and Main Results: Inhaled BIBW 2948 induced a dose-related inhibition of EGFR internalization (reflecting decreased EGFR activation) in epithelial cells from treated subjects.  However, BIBW 2948 was assocd. with a dose-related increase in adverse events, including reversible liver enzyme elevation (n = 2), and redn. in FEV1.  The changes in mucin stores and mucin gene expression were not significantly different in the pooled BIBW 2948 group vs. placebo (vol. of mucin per surface area of basal lamina = 0.22 ± 7.11 vs. 0.47 ± 8.06 μm3/μm2; P = 0.93).  However, in the 30 mg twice a day group, the redn. in epithelial mucin stores was greatest in subjects with the greatest degree of EGFR inhibition (Pearson r = 0.98; 95% confidence interval, 0.71-0.99).  Conclusions: Four-week treatment with BIBW 2948 did not significantly decrease epithelial mucin stores and was poorly tolerated in patients with COPD.  Ex vivo analyses suggest that higher doses may be more effective at both EGFR inhibition and decreases in mucin stores but that adverse events should be expected.  Clin. trial registered with www.clinicaltrials.gov (NCT00423137).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ1HZh3exTorVg90H21EOLACvtfcHk0lh9mDAsru4bVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVSgsbY%253D&md5=6691e62b4ebfa5ee86fef185a1c37138</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1164%2Frccm.200909-1415OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200909-1415OC%26sid%3Dliteratum%253Aachs%26aulast%3DWoodruff%26aufirst%3DP.%2BG.%26aulast%3DWolff%26aufirst%3DM.%26aulast%3DHohlfeld%26aufirst%3DJ.%2BM.%26aulast%3DKrug%26aufirst%3DN.%26aulast%3DDransfield%26aufirst%3DM.%2BT.%26aulast%3DSutherland%26aufirst%3DE.%2BR.%26aulast%3DCriner%26aufirst%3DG.%2BJ.%26aulast%3DKim%26aufirst%3DV.%26aulast%3DPrasse%26aufirst%3DA.%26aulast%3DNivens%26aufirst%3DM.%2BC.%26aulast%3DTetzlaff%26aufirst%3DK.%26aulast%3DHeilker%26aufirst%3DR.%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520an%2520inhaled%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520%2528BIBW%25202948%2520BS%2529%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D181%26spage%3D438%26epage%3D445%26doi%3D10.1164%2Frccm.200909-1415OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganiello, V. C.</span></span> <span> </span><span class="NLM_article-title">Advances in targeting cyclic nucleotide phosphodiesterases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1038/nrd4228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrd4228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24687066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=290-314&author=D.+H.+Mauriceauthor=H.+Keauthor=F.+Ahmadauthor=Y.+Wangauthor=J.+Chungauthor=V.+C.+Manganiello&title=Advances+in+targeting+cyclic+nucleotide+phosphodiesterases&doi=10.1038%2Fnrd4228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeting cyclic nucleotide phosphodiesterases</span></div><div class="casAuthors">Maurice, Donald H.; Ke, Hengming; Ahmad, Faiyaz; Wang, Yousheng; Chung, Jay; Manganiello, Vincent C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cyclic GMP, thereby regulating the intracellular concns. of these cyclic nucleotides, their signalling pathways and, consequently, myriad biol. responses in health and disease.  Currently, a small no. of PDE inhibitors are used clin. for treating the pathophysiol. dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease.  However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMRfUs-zUmLVg90H21EOLACvtfcHk0lh1i5472qN7Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D&md5=410c8d5bb5fbd7d2906e30dc1b5f2876</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fnrd4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4228%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DD.%2BH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DManganiello%26aufirst%3DV.%2BC.%26atitle%3DAdvances%2520in%2520targeting%2520cyclic%2520nucleotide%2520phosphodiesterases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D290%26epage%3D314%26doi%3D10.1038%2Fnrd4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulhall, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Droege, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panos, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zafar, M. A.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1597</span>– <span class="NLM_lpage">1611</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1094054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543784.2015.1094054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26419847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1597-1611&author=A.+M.+Mulhallauthor=C.+A.+Droegeauthor=N.+E.+Ernstauthor=R.+J.+Panosauthor=M.+A.+Zafar&title=Phosphodiesterase+4+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+review+of+current+and+developing+drugs&doi=10.1517%2F13543784.2015.1094054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span></div><div class="casAuthors">Mulhall, Aaron M.; Droege, Christopher A.; Ernst, Neil E.; Panos, Ralph J.; Zafar, Muhammad A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1597-1611</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells.  Roflumilast is the only approved PDE-4 inhibitor (PDE4I) for use in chronic obstructive pulmonary disease (COPD).  Its beneficial clin. effects occur preferentially in patients with chronic bronchitis and frequent COPD exacerbations.  Use of roflumilast as adjunctive or alternate therapy to other COPD medications reduces exacerbations and modestly improves lung function.  This article reviews the current role of PDE4I in COPD treatment emphasizing roflumilast's clin. efficacy and adverse effects.  This article also reviews developing PDE4Is in early clin. trials and in preclin. studies.  After decades of research in drug development, PDE4Is are a welcomed addn. to the COPD therapeutic armamentarium.  In its current clin. role, the salubrious clin. effects of PDE4I in reducing exacerbations and stabilizing the frequent exacerbator phenotype have to be cautiously balanced with numerous adverse effects.  Developing drugs may provide similar or better clin. benefits while minimizing adverse effects by changing the mode of drug delivery to inhaled formulations, combining dual PDE isoenzyme inhibitors (PDE1/4I and PDE3/4I) and by forming hybrid mols. with other bronchodilators (muscarinic receptor antagonist/PDE4I and β2-agonist/PDE4I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNEyjtRW-erVg90H21EOLACvtfcHk0lh1i5472qN7Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ&md5=8d5130af94558b2950f624ae1528c86f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1094054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1094054%26sid%3Dliteratum%253Aachs%26aulast%3DMulhall%26aufirst%3DA.%2BM.%26aulast%3DDroege%26aufirst%3DC.%2BA.%26aulast%3DErnst%26aufirst%3DN.%2BE.%26aulast%3DPanos%26aufirst%3DR.%2BJ.%26aulast%3DZafar%26aufirst%3DM.%2BA.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520review%2520of%2520current%2520and%2520developing%2520drugs%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1597%26epage%3D1611%26doi%3D10.1517%2F13543784.2015.1094054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fertig, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span> <span> </span><span class="NLM_article-title">PDE4-mediated cAMP signalling</span>. <i>J. Cardiovasc. Dev. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.3390/jcdd5010008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.3390%2Fjcdd5010008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslyrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=8&author=B.+A.+Fertigauthor=G.+S.+Baillie&title=PDE4-mediated+cAMP+signalling&doi=10.3390%2Fjcdd5010008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4-mediated cAMP signalling</span></div><div class="casAuthors">Fertig, Bracy A.; Baillie, George S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Development and Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8/1-8/14</span>CODEN:
                <span class="NLM_cas:coden">JCDDB4</span>;
        ISSN:<span class="NLM_cas:issn">2308-3425</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  CAMP is the archetypal and ubiquitous second messenger utilized for the fine control of many cardiovascular cell signalling systems.  The ability of cAMP to elicit cell surface receptor-specific responses relies on its compartmentalisation by cAMP hydrolyzing enzymes known as phosphodiesterases.  One family of these enzymes, PDE4, is particularly important in the cardiovascular system, where it has been extensively studied and shown to orchestrate complex, localised signalling that underpins many crucial functions of the heart.  In the cardiac myocyte, cAMP activates PKA, which phosphorylates a small subset of mostly sarcoplasmic substrate proteins that drive β-adrenergic enhancement of cardiac function.  The phosphorylation of these substrates, many of which are involved in cardiac excitation-contraction coupling, has been shown to be tightly regulated by highly localised pools of individual PDE4 isoforms.  The spatial and temporal regulation of cardiac signalling is made possible by the formation of macromol. "signalosomes", which often include a cAMP effector, such as PKA, its substrate, PDE4 and an anchoring protein such as an AKAP.  Studies described in the present review highlight the importance of this relationship for individual cardiac PKA substrates and we provide an overview of how this signalling paradigm is coordinated to promote efficient adrenergic enhancement of cardiac function.  The role of PDE4 also extends to the vascular endothelium, where it regulates vascular permeability and barrier function.  In this distinct location, PDE4 interacts with adherens junctions to regulate their stability.  These highly specific, non-redundant roles for PDE4 isoforms have far reaching therapeutic potential.  PDE inhibitors in the clinic have been plagued with problems due to the active site-directed nature of the compds. which concomitantly attenuate PDE activity in all highly localised "signalosomes".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG1GQOAKh0NLVg90H21EOLACvtfcHk0lh1i5472qN7Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslyrurs%253D&md5=55ab00b9daa0cd96454807732bd5f4bc</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.3390%2Fjcdd5010008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcdd5010008%26sid%3Dliteratum%253Aachs%26aulast%3DFertig%26aufirst%3DB.%2BA.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26atitle%3DPDE4-mediated%2520cAMP%2520signalling%26jtitle%3DJ.%2520Cardiovasc.%2520Dev.%2520Dis.%26date%3D2018%26volume%3D5%26spage%3D8%26doi%3D10.3390%2Fjcdd5010008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabe, K. F.</span></span> <span> </span><span class="NLM_article-title">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1476-5381.2011.01218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21232047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=53-67&author=K.+F.+Rabe&title=Update+on+roflumilast%2C+a+phosphodiesterase+4+inhibitor+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1476-5381.2011.01218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-67</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main PDE isoenzyme occurring in cells involved in inflammatory airway disease such as chronic obstructive pulmonary disease (COPD).  COPD is a preventable and treatable disease and is characterized by airflow obstruction that is not fully reversible.  Chronic progressive symptoms, particularly dyspnea, chronic bronchitis and impaired overall health are worse in those who have frequent, acute episodes of symptom exacerbation.  Although several exptl. PDE4 inhibitors are in clin. development, roflumilast, a highly selective PDE4 inhibitor, is the first in its class to be licensed, and has recently been approved in several countries for oral, once-daily treatment of severe COPD.  Clin. trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency in COPD.  Furthermore, its unique mode of action may offer the potential to target the inflammatory processes underlying COPD.  Roflumilast is effective when used concomitantly with all forms of bronchodilator and even in patients treated with inhaled corticosteroids.  Roflumilast thus represents an important addn. to current therapeutic options for COPD patients with chronic bronchitis, including those who remain symptomatic despite treatment.  This article reviews the current status of PDE4 inhibitors, focusing on the pharmacokinetics, efficacy and safety of roflumilast.  In particular, it provides an overview of the effects of roflumilast on lung function and exacerbations, glucose homoeostasis and wt. loss, and the concomitant use of long-acting beta2-adrenergic receptor agonists and short-acting muscarinic receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryBUcu0ToPGrVg90H21EOLACvtfcHk0lgL1MzZHDsjQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D&md5=c6ac3310e2d9ff1c7de86aecbd1356bb</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01218.x%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DUpdate%2520on%2520roflumilast%252C%2520a%2520phosphodiesterase%25204%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D53%26epage%3D67%26doi%3D10.1111%2Fj.1476-5381.2011.01218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Facius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marostica, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahu, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic modelling to characterize the tolerability of alternative up-titration regimens of roflumilast in patients with chronic obstructive pulmonary disease</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1007/s40262-018-0671-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs40262-018-0671-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29797235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1029-1038&author=A.+Faciusauthor=E.+Marosticaauthor=P.+Gardinerauthor=H.+Watzauthor=G.+Lahu&title=Pharmacokinetic+and+pharmacodynamic+modelling+to+characterize+the+tolerability+of+alternative+up-titration+regimens+of+roflumilast+in+patients+with+chronic+obstructive+pulmonary+disease&doi=10.1007%2Fs40262-018-0671-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Facius, Axel; Marostica, Eleonora; Gardiner, Philip; Watz, Henrik; Lahu, Gezim</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1029-1038</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background: In the OPTIMIZE study, 4 wk of roflumilast 250 μg once daily before escalation to the approved 500 μg once daily maintenance dose reduced treatment discontinuations and improved tolerability to roflumilast among patients with chronic obstructive pulmonary disease (COPD).  In this study, we present the pharmacokinetic (PK) results and PK/pharmacodynamic (PD) modeling data from OPTIMIZE.  Methods: OPTIMIZE was a multicentre, double-blind, phase III study in which patients with severe COPD were randomized 1:1:1 to receive oral roflumilast 250 μg once daily, 500 μg every other day, or 500 μg once daily for 4 wk, followed by 500 μg once daily for 8 wk.  A population PK (popPK) model characterized roflumilast exposure levels (total phosphodiesterase-4 inhibition [tPDE4i]).  Furthermore, models characterized the percentage of patients with adverse events (AEs) of interest (PK/AE model), and time to discontinuation due to such AEs (PK/time-to-event model).  Results: The popPK model adequately described av. plasma concns. and variability from 1238 patients.  The percentage of patients with AEs of interest increased with predicted tPDE4i exposure (logit scale slope 0.484; confidence interval 0.262-0.706; p = 2 × 10-5).  PK/time-to-event model anal. predicted that patients receiving the 250 μg up-titrn. regimen had significantly lower discontinuation rates and longer time to discontinuation compared with roflumilast 500 μg every other day or 500 μg once daily (p = 0.0014).  Conclusions: In this PK/PD model, a 4-wk up-titrn. regimen with roflumilast 250 μg once daily was found to reduce discontinuations and improve tolerability, confirming the main clin. findings of the OPTIMIZE study.  However, use of this lower dose as long-term maintenance therapy may not induce sufficient phosphodiesterase-4 inhibition to exert clin. efficacy, supporting the approval of 500 μg as maintenance dose.  Trial Registration: OPTIMIZE: NCT02165826; REACT: NCT01329029.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIZaLOcoi8U7Vg90H21EOLACvtfcHk0lgL1MzZHDsjQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmu77N&md5=4efe7c4a9d05eff11ce32ffcf6478dfb</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1007%2Fs40262-018-0671-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-018-0671-4%26sid%3Dliteratum%253Aachs%26aulast%3DFacius%26aufirst%3DA.%26aulast%3DMarostica%26aufirst%3DE.%26aulast%3DGardiner%26aufirst%3DP.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DLahu%26aufirst%3DG.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520modelling%2520to%2520characterize%2520the%2520tolerability%2520of%2520alternative%2520up-titration%2520regimens%2520of%2520roflumilast%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2018%26volume%3D57%26spage%3D1029%26epage%3D1038%26doi%3D10.1007%2Fs40262-018-0671-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2006.02640.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1365-2125.2006.02640.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16842388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=138-152&author=M.+A.+Giembycz&title=An+update+and+appraisal+of+the+cilomilast+phase+III+clinical+development+programme+for+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1365-2125.2006.02640.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-152</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD).  The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clin. meaningful extent, which has led to a comprehensive Phase III program of research evaluating efficacy, safety and mechanism of action.  However, the results of those Phase III studies are unremarkable and disappointing, raising doubt over the future of cilomilast as a novel therapy for COPD.  This review summarizes data obtained from the Phase III clin. development program, highlights some of the potential concerns both specific to cilomilast and to PDE4 inhibitors in general and assesses the likelihood that cilomilast will reach the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3j4h3elSNrVg90H21EOLACvtfcHk0lgDURSDdfvBsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D&md5=0d8f4c3833a446ed6a43cc9b355a2c46</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02640.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02640.x%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DAn%2520update%2520and%2520appraisal%2520of%2520the%2520cilomilast%2520phase%2520III%2520clinical%2520development%2520programme%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26spage%3D138%26epage%3D152%26doi%3D10.1111%2Fj.1365-2125.2006.02640.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamatiou, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tattersall, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. C.</span></span> <span> </span><span class="NLM_article-title">PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/S0028-3908(00)00142-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0028-3908%2800%2900142-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11114405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslCksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=262-269&author=A.+Robichaudauthor=C.+Savoieauthor=P.+B.+Stamatiouauthor=F.+D.+Tattersallauthor=C.+C.+Chan&title=PDE4+inhibitors+induce+emesis+in+ferrets+via+a+noradrenergic+pathway&doi=10.1016%2FS0028-3908%2800%2900142-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway</span></div><div class="casAuthors">Robichaud, A.; Savoie, C.; Stamatiou, P. B.; Tattersall, F. D.; Chan, C. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-269</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The objective of this work was to assess the role of alpha2-adrenoceptors in emesis induced by inhibitors of type 4 phosphodiesterase (PDE4) in ferrets.  Pre-treatment with yohimbine, MK-912 or MK-467 (alpha2-adrenoceptor antagonists) caused sudden and unexpected vomiting.  In contrast, clonidine (alpha2-adrenoceptor agonist) did not induce emesis at doses ranging from 62.5-250 μg/kg s.c.  At the dose of 250 μg/kg, clonidine also provided protection against emesis induced by the PDE4 inhibitors, PMNPQ (i.e. 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline), CT-2450 and R-rolipram.  It was postulated that PDE4 inhibitors trigger emesis by mimicking the pharmacol. actions of alpha2-adrenoceptor antagonists.  This hypothesis was strengthened by the demonstration that PDE4 inhibitors can reverse the hypnotic effect of an alpha2-adrenoceptor mediated anesthetic regimen in rats and ferrets.  Similar to alpha2-adrenoceptor antagonists, PMNPQ, R-rolipram and S-rolipram dose-dependently decreased the duration of anesthesia in rats injected with the combination xylazine/ketamine.  While s.c. injections of CT-2450 (3-30 mg/kg) were without effect, a central infusion (6 μg i.c.v.) decreased the duration of anesthesia.  These studies suggest that the ferret is an appropriate model to study emesis induced by PDE4 inhibitors and that these compds. trigger the emetic reflex via a noradrenergic pathway, mimicking the pharmacol. actions of a pre-synaptic alpha2-adrenoceptor inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtP8JquEn-FbVg90H21EOLACvtfcHk0lgDURSDdfvBsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslCksrc%253D&md5=ac72fb4c3a03d03424ed19d6d0550d51</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2800%2900142-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252800%252900142-8%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DSavoie%26aufirst%3DC.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DTattersall%26aufirst%3DF.%2BD.%26aulast%3DChan%26aufirst%3DC.%2BC.%26atitle%3DPDE4%2520inhibitors%2520induce%2520emesis%2520in%2520ferrets%2520via%2520a%2520noradrenergic%2520pathway%26jtitle%3DNeuropharmacology%26date%3D2001%26volume%3D40%26spage%3D262%26epage%3D269%26doi%3D10.1016%2FS0028-3908%2800%2900142-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livi, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span> <span> </span><span class="NLM_article-title">Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=8863835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK28XmsFGgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=891-899&author=S.+Jacobitzauthor=M.+M.+McLaughlinauthor=G.+P.+Liviauthor=M.+Burmanauthor=T.+J.+Torphy&title=Mapping+the+functional+domains+of+human+recombinant+phosphodiesterase+4A%3A+structural+requirements+for+catalytic+activity+and+rolipram+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding</span></div><div class="casAuthors">Jacobitz, Susanne; McLaughlin, Megan M.; Livi, George P.; Burman, Miriam; Torphy, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">To identify functional domains of the 886-amino acid human recombinant cAMP-specific phosphodiesterase (PDE) subtype A (rhPDE4A), we engineered the expression of seven mutant proteins contg. both NH2- and COOH-terminal truncations.  The level of rhPDE4A protein expression in yeast was monitored by immunoblotting using enzyme-specific antisera.  Biochem. profiles of the mutant proteins were compared with those of the full-length protein or a fully active truncated form of the enzyme (rhPDE4A Met265-886), lacking the first 264 amino acids.  The smallest catalytically active fragment generated was Met332-722, which at 45 kDa is less than half the mass of the full-length enzyme (∼110 kDa) but spans the most highly conserved region of the PDE superfamily.  Two prototypical PDE4 inhibitors, rolipram and RP 73401, inhibited cAMP-hydrolyzing activity of all truncated forms of the enzyme, with IC50 values of 70-2000 nM and 0.2-0.6 nM, resp.  [3H](R)-Rolipram bound to two sites on Met265-886, a high affinity site (Kd1 = 0.7 ± 0.3 nM) and a low affinity site (Kd2 = 34 ± 10 nM).  Interestingly, [3H](R)-rolipram failed to bind to Met332-886 with high affinity, indicating that high affinity binding is not required for inhibition of enzyme activity.  Low affinity rolipram-binding was still present in Met332-886 (Kd = 101 ± 7 nM).  In contrast to [3H](R)-rolipram, [3H]RP 73401 bound to a single class of high affinity sites on Met265-886 (Kd = 0.4 ± 0.1 nM).  Further truncation of the enzyme to Met332-886 had no effect on [3H]RP 73401 binding (Kd = 0.2 ± 0.03 nM).  We conclude that the catalytic center of rhPDE4A lies between amino acids 332 and 722.  Furthermore, amino acids 265-332 may form a high affinity binding site for rolipram that is outside the catalytic domain.  As a more likely alternative, these amino acids may not form a distinct binding site but instead may be required for the recombinant enzyme to assume a conformation that binds rolipram at the catalytic domain with a high affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQO9hB-XY4nrVg90H21EOLACvtfcHk0lgiEXJMkNugTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsFGgurs%253D&md5=17e514f10560b1472aedbac336b58882</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacobitz%26aufirst%3DS.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DLivi%26aufirst%3DG.%2BP.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26atitle%3DMapping%2520the%2520functional%2520domains%2520of%2520human%2520recombinant%2520phosphodiesterase%25204A%253A%2520structural%2520requirements%2520for%2520catalytic%2520activity%2520and%2520rolipram%2520binding%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D50%26spage%3D891%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFα responses</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">7628</span>– <span class="NLM_lpage">7633</span>, <span class="refDoi"> DOI: 10.1073/pnas.122041599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1073%2Fpnas.122041599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12032334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7628-7633&author=S.+L.+Jinauthor=M.+Conti&title=Induction+of+the+cyclic+nucleotide+phosphodiesterase+PDE4B+is+essential+for+LPS-activated+TNF%CE%B1+responses&doi=10.1073%2Fpnas.122041599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span></div><div class="casAuthors">Jin, S.-L. Catherine; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7628-7633</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS) stimulation of the innate immune response requires the activation of signaling cascades that culminate in the synthesis and secretion of proinflammatory cytokines.  Given the inhibitory effects of phosphodiesterase (PDE) inhibitors on LPS-induced cytokine prodn., the authors have investigated LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.  LPS stimulation of mouse peripheral leukocytes induced PDE4B mRNA accumulation and increased PDE4 activity.  This response was completely absent in mice deficient in PDE4B but not PDE4D.  LPS induction of tumor necrosis factor-α secretion by circulating leukocytes was decreased by approx. 90% in mice deficient in PDE4B but not in mice lacking PDE4D.  The impaired LPS response was evident regardless of the LPS dose used for stimulation and was assocd. with a more than 90% decrease in tumor necrosis factor-α mRNA accumulation.  A decreased responsiveness to LPS was also present in other inflammatory cells, including peritoneal and lung macrophages.  These findings demonstrate that PDE4B gene activation by LPS constitutes a feedback regulation essential for an efficient immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczHCRpXjcOrVg90H21EOLACvtfcHk0lgiEXJMkNugTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D&md5=69e2c4452ce3aa7729376db46cba6a07</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1073%2Fpnas.122041599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.122041599%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DInduction%2520of%2520the%2520cyclic%2520nucleotide%2520phosphodiesterase%2520PDE4B%2520is%2520essential%2520for%2520LPS-activated%2520TNF%25CE%25B1%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D7628%26epage%3D7633%26doi%3D10.1073%2Fpnas.122041599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">4D or not 4D-the emetogenic basis of PDE4 inhibitors uncovered?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">548</span>, <span class="refDoi"> DOI: 10.1016/S0165-6147(02)02089-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0165-6147%2802%2902089-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12457768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFensr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=548&author=M.+A.+Giembycz&title=4D+or+not+4D-the+emetogenic+basis+of+PDE4+inhibitors+uncovered%3F&doi=10.1016%2FS0165-6147%2802%2902089-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered?</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">548</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGossZAwrzef07Vg90H21EOLACvtfcHk0ljWloegQSYTUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFensr4%253D&md5=45902ac9158ac09999bc5303d96e284a</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2802%2902089-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252802%252902089-8%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3D4D%2520or%2520not%25204D-the%2520emetogenic%2520basis%2520of%2520PDE4%2520inhibitors%2520uncovered%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2002%26volume%3D23%26spage%3D548%26doi%3D10.1016%2FS0165-6147%2802%2902089-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastre-y-Hernandez, M.</span></span> <span> </span><span class="NLM_article-title">Clinical effects of neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports</span>. <i>Curr. Ther. Res.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">29</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1985&pages=23-29&author=R.+Horowskiauthor=M.+Sastre-y-Hernandez&title=Clinical+effects+of+neurotropic+selective+cAMP+phosphodiesterase+inhibitor+rolipram+in+depressed+patients%3A+Global+evaluation+of+the+preliminary+reports"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorowski%26aufirst%3DR.%26aulast%3DSastre-y-Hernandez%26aufirst%3DM.%26atitle%3DClinical%2520effects%2520of%2520neurotropic%2520selective%2520cAMP%2520phosphodiesterase%2520inhibitor%2520rolipram%2520in%2520depressed%2520patients%253A%2520Global%2520evaluation%2520of%2520the%2520preliminary%2520reports%26jtitle%3DCurr.%2520Ther.%2520Res.%26date%3D1985%26volume%3D38%26spage%3D23%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A.
B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrafnsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nbt.1598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnbt.1598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20037581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=63-70&author=A.%0AB.+Burginauthor=O.+T.+Magnussonauthor=J.+Singhauthor=P.+Witteauthor=B.+L.+Stakerauthor=J.+M.+Bjornssonauthor=M.+Thorsteinsdottirauthor=S.+Hrafnsdottirauthor=T.+Hagenauthor=A.+S.+Kiselyovauthor=L.+J.+Stewartauthor=M.+E.+Gurney&title=Design+of+phosphodiesterase+4D+%28PDE4D%29+allosteric+modulators+for+enhancing+cognition+with+improved+safety&doi=10.1038%2Fnbt.1598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span></div><div class="casAuthors">Burgin, Alex B.; Magnusson, Olafur T.; Singh, Jasbir; Witte, Pam; Staker, Bart L.; Bjornsson, Jon M.; Thorsteinsdottir, Margret; Hrafnsdottir, Sigrun; Hagen, Timothy; Kiselyov, Alex S.; Stewart, Lance J.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.  Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation.  This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-mol. allosteric modulators of PDE4D that do not completely inhibit enzymic activity (Imax ∼ 80-90%).  These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biol. activity in cellular and in vivo models.  Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr18KdQE2oVsbVg90H21EOLACvtfcHk0ljWloegQSYTUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ&md5=1e8651a7116206eefddb9fa6b79d5112</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1598%26sid%3Dliteratum%253Aachs%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DP.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DBjornsson%26aufirst%3DJ.%2BM.%26aulast%3DThorsteinsdottir%26aufirst%3DM.%26aulast%3DHrafnsdottir%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDesign%2520of%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520modulators%2520for%2520enhancing%2520cognition%2520with%2520improved%2520safety%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D63%26epage%3D70%26doi%3D10.1038%2Fnbt.1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weers, J. G.</span></span> <span> </span><span class="NLM_article-title">Enhanced design of inhaled therapeutics: what does the future hold?</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.4155/tde-2016-0004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4155%2Ftde-2016-0004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26893244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XislSgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=145-148&author=J.+G.+Weers&title=Enhanced+design+of+inhaled+therapeutics%3A+what+does+the+future+hold%3F&doi=10.4155%2Ftde-2016-0004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced design of inhaled therapeutics: what does the future hold?</span></div><div class="casAuthors">Weers, Jeffry G.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">145-148</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Overall, advances in the design of respiratory therapeutics and the aspiration to reduce or eliminate sources of error will necessitate novel particle engineering and advanced delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqygT9Abzh797Vg90H21EOLACvtfcHk0ljOTR9mGAiXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XislSgt7w%253D&md5=be69799788093a0d41759fe9cd31568c</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.4155%2Ftde-2016-0004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde-2016-0004%26sid%3Dliteratum%253Aachs%26aulast%3DWeers%26aufirst%3DJ.%2BG.%26atitle%3DEnhanced%2520design%2520of%2520inhaled%2520therapeutics%253A%2520what%2520does%2520the%2520future%2520hold%253F%26jtitle%3DTher.%2520Delivery%26date%3D2016%26volume%3D7%26spage%3D145%26epage%3D148%26doi%3D10.4155%2Ftde-2016-0004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span>; <span class="NLM_contrib-group">IPC101939 investigators</span> <span> </span><span class="NLM_article-title">Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2013.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2013.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23701917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFOmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=588-595&author=H.+Watzauthor=S.+J.+Mistryauthor=A.+L.+Lazaarauthor=IPC101939+investigators&title=Safety+and+tolerability+of+the+inhaled+phosphodiesterase+4+inhibitor+GSK256066+in+moderate+COPD&doi=10.1016%2Fj.pupt.2013.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD</span></div><div class="casAuthors">Watz, Henrik; Mistry, Sunil J.; Lazaar, Aili L.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">588-595</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inhibition of phosphodiesterase 4 (PDE4) represents an approach to anti-inflammatory therapy in chronic obstructive pulmonary disease (COPD).  GSK256066 is a potent and selective inhaled PDE4 inhibitor.  The aim of this study was to investigate the safety and tolerability of 28 days repeat inhaled dosing with GSK256066 in moderate COPD.  This was a Phase IIa, multicenter, parallel-group, double-blind, three-arm, placebo-controlled, four-week, randomized study with two doses of GSK256066 (25 μg, 87.5 μg).  The primary endpoint was safety and tolerability.  Secondary endpoints included changes in inflammatory markers in induced sputum and blood, lung function (spirometry, body plethysmog., impulse oscillometry), and pharmacokinetics.104 patients were randomized and 94 patients completed the study.  The incidence and intensity of treatment-related adverse events were similar between treatment groups.  The most frequent adverse event was nasopharyngitis and there were no serious adverse events in patients receiving GSK256066.  The overall incidence of gastrointestinal adverse events was low in all treatment groups.  There were no statistically significant changes in inflammatory markers in induced sputum and blood following treatment with GSK256066.  Anal. of sputum mRNA suggested engagement of pharmacol., based on increased expression of cAMP-dependent genes including amphiregulin and CREM in subjects receiving GSK256066.  There was a trend for an increase in post-bronchodilator FEV1 for both doses of GSK256066; in addn., for the 87.5 μg group, there was a mean redn. in residual vol. of 0.367 L (95% confidence interval: 0.112, 0.622 L) relative to placebo.Administration of inhaled GSK256066 was well-tolerated in patients with moderate COPD.  Further studies would be required to confirm the favorable safety profile and to demonstrate clin. efficacy of this compd.(ClinicalTrials.gov identifier: NCT00549679).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroY6YfcG-nOrVg90H21EOLACvtfcHk0ljOTR9mGAiXgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFOmur8%253D&md5=c0acb259a830da14112b673fa9623b7e</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2013.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2013.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DMistry%26aufirst%3DS.%2BJ.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3D%26atitle%3DSafety%2520and%2520tolerability%2520of%2520the%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520GSK256066%2520in%2520moderate%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D588%26epage%3D595%26doi%3D10.1016%2Fj.pupt.2013.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccellati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span> <span> </span><span class="NLM_article-title">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.114.220541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25576075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=559-567&author=N.+Morettoauthor=P.+Carusoauthor=R.+Boscoauthor=G.+Marchiniauthor=F.+Pastoreauthor=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=E.+Ghidiniauthor=R.+De+Fantiauthor=C.+Capaldiauthor=L.+Carzanigaauthor=E.+Hirschauthor=C.+Buccellatiauthor=A.+Salaauthor=C.+Carniniauthor=R.+Patacchiniauthor=M.+Delcanaleauthor=M.+Civelliauthor=G.+Villettiauthor=F.+Facchinetti&title=CHF6001+I%3A+a+novel+highly+potent+and+selective+phosphodiesterase+4+inhibitor+with+robust+anti-inflammatory+activity+and+suitable+for+topical+pulmonary+administration&doi=10.1124%2Fjpet.114.220541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span></div><div class="casAuthors">Moretto, Nadia; Caruso, Paola; Bosco, Raffaella; Marchini, Gessica; Pastore, Fiorella; Armani, Elisabetta; Amari, Gabriele; Rizzi, Andrea; Ghidini, Eleonora; De Fanti, Renato; Capaldi, Carmelida; Carzaniga, Laura; Hirsch, Emilio; Buccellati, Carola; Sala, Angelo; Carnini, Chiara; Patacchini, Riccardo; Delcanale, Maurizio; Civelli, Maurizio; Villetti, Gino; Facchinetti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-567, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study examd. the pharmacol. characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide], a novel phosphodiesterase (PDE)4 inhibitor designed for treating pulmonary inflammatory diseases via inhaled administration.  CHF6001 was 7- and 923-fold more potent than roflumilast and cilomilast, resp., in inhibiting PDE4 enzymic activity (IC50 = 0.026 ± 0.006 nM).  CHF6001 inhibited PDE4 isoforms A-D with equal potency, showed an elevated ratio of high-affinity rolipram binding site vs. low-affinity rolipram binding site (i.e., >40) and displayed >20,000-fold selectivity vs. PDE4 compared with a panel of PDEs.  CHF6001 effectively inhibited (subnanomolar IC50 values) the release of tumor necrosis factor-α from human peripheral blood mononuclear cells, human acute monocytic leukemia cell line macrophages (THP-1), and rodent macrophages (RAW264.7 and NR8383).  Moreover, CHF6001 potently inhibited the activation of oxidative burst in neutrophils and eosinophils, neutrophil chemotaxis, and the release of interferon-γ from CD4+ T cells.  In all these functional assays, CHF6001 was more potent than previously described PDE4 inhibitors, including roflumilast, UK-500,001 [2-(3,4-difluorophenoxy)-5-fluoro-N-((1S,4S)-4-(2-hydroxy-5-methylbenzamido)cyclohexyl)nicotinamide], and cilomilast, and it was comparable to GSK256066 [6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide].  When administered intratracheally to rats as a micronized dry powder, CHF6001 inhibited liposaccharide-induced pulmonary neutrophilia (ED50 = 0.205 μmol/kg) and leukocyte infiltration (ED50 = 0.188 μmol/kg) with an efficacy comparable to a high dose of budesonide (1 μmol/kg i.p.).  In sum, CHF6001 has the potential to be an effective topical treatment of conditions assocd. with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYb2WLQC5SbVg90H21EOLACvtfcHk0lhvlnrJ9Skk4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D&md5=2be98d624fe49f7aba8673fa8aea8688</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220541%26sid%3Dliteratum%253Aachs%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBosco%26aufirst%3DR.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DFacchinetti%26aufirst%3DF.%26atitle%3DCHF6001%2520I%253A%2520a%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520with%2520robust%2520anti-inflammatory%2520activity%2520and%2520suitable%2520for%2520topical%2520pulmonary%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D559%26epage%3D567%26doi%3D10.1124%2Fjpet.114.220541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peretto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Porta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolzoni, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenacchi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catinella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span> <span> </span><span class="NLM_article-title">Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">816</span>, <span class="refDoi"> DOI: 10.1021/jm401549m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401549m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFGltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=793-816&author=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=R.+De+Fantiauthor=E.+Ghidiniauthor=C.+Capaldiauthor=L.+Carzanigaauthor=P.+Carusoauthor=M.+Gualaauthor=I.+Perettoauthor=E.+La+Portaauthor=P.+T.+Bolzoniauthor=F.+Facchinettiauthor=C.+Carniniauthor=N.+Morettoauthor=R.+Patacchiniauthor=F.+Bassaniauthor=V.+Cenacchiauthor=R.+Voltaauthor=F.+Amadeiauthor=S.+Capacchiauthor=M.+Delcanaleauthor=P.+Pucciniauthor=S.+Catinellaauthor=M.+Civelliauthor=G.+Villetti&title=Novel+class+of+benzoic+acid+ester+derivatives+as+potent+PDE4+inhibitors+for+inhaled+administration+in+the+treatment+of+respiratory+diseases&doi=10.1021%2Fjm401549m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases</span></div><div class="casAuthors">Armani, Elisabetta; Amari, Gabriele; Rizzi, Andrea; Fanti, Renato De; Ghidini, Eleonora; Capaldi, Carmelida; Carzaniga, Laura; Caruso, Paola; Guala, Matilde; Peretto, Ilaria; La Porta, Elena; Bolzoni, Pier T.; Facchinetti, Fabrizio; Carnini, Chiara; Moretto, Nadia; Patacchini, Riccardo; Bassani, Franco; Cenacchi, Valentina; Volta, Roberta; Amadei, Francesco; Capacchi, Silvia; Delcanale, Maurizio; Puccini, Paola; Catinella, Silvia; Civelli, Maurizio; Villetti, Gino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">793-816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first steps in the selection process of a new anti-inflammatory drug for the inhaled treatment of asthma and chronic obstructive pulmonary disease are herein described.  A series of novel ester derivs. of 1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-dichloropyridin-4-yl) ethanol, e.g. I, have been synthesized and evaluated for inhibitory activity toward cAMP-specific phosphodiesterase-4 (PDE4).  In particular, esters of variously substituted benzoic acids were extensively explored, and structural modification of the alc. and benzoic moieties were performed to maximize the inhibitory potency.  Several compds. with high activity in cell-free and cell-based assays were obtained.  Through the evaluation of opportune in vitro ADME properties, a potential candidate suitable for inhaled administration in respiratory diseases was identified and tested in an in vivo model of pulmonary inflammation, proving its efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJlqwIuol5_rVg90H21EOLACvtfcHk0lhvlnrJ9Skk4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFGltA%253D%253D&md5=f272457442613574579ae4681b1261f0</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1021%2Fjm401549m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401549m%26sid%3Dliteratum%253Aachs%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DGuala%26aufirst%3DM.%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DLa%2BPorta%26aufirst%3DE.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DAmadei%26aufirst%3DF.%26aulast%3DCapacchi%26aufirst%3DS.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DPuccini%26aufirst%3DP.%26aulast%3DCatinella%26aufirst%3DS.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26atitle%3DNovel%2520class%2520of%2520benzoic%2520acid%2520ester%2520derivatives%2520as%2520potent%2520PDE4%2520inhibitors%2520for%2520inhaled%2520administration%2520in%2520the%2520treatment%2520of%2520respiratory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D793%26epage%3D816%26doi%3D10.1021%2Fjm401549m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battipaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenacchi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnacani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catinella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of thiazolidinyl and pyrrolidinyl derivatives as inhaled PDE4 inhibitors for respiratory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10026</span>– <span class="NLM_lpage">10046</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhs7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10026-10046&author=L.+Carzanigaauthor=G.+Amariauthor=A.+Rizziauthor=C.+Capaldiauthor=R.+De+Fantiauthor=E.+Ghidiniauthor=G.+Villettiauthor=C.+Carniniauthor=N.+Morettoauthor=F.+Facchinettiauthor=P.+Carusoauthor=G.+Marchiniauthor=L.+Battipagliaauthor=R.+Patacchiniauthor=V.+Cenacchiauthor=R.+Voltaauthor=F.+Amadeiauthor=A.+Pappaniauthor=S.+Capacchiauthor=V.+Bagnacaniauthor=M.+Delcanaleauthor=P.+Pucciniauthor=S.+Catinellaauthor=M.+Civelliauthor=E.+Armani&title=Discovery+and+optimization+of+thiazolidinyl+and+pyrrolidinyl+derivatives+as+inhaled+PDE4+inhibitors+for+respiratory+diseases&doi=10.1021%2Facs.jmedchem.7b01044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases</span></div><div class="casAuthors">Carzaniga, Laura; Amari, Gabriele; Rizzi, Andrea; Capaldi, Carmelida; De Fanti, Renato; Ghidini, Eleonora; Villetti, Gino; Carnini, Chiara; Moretto, Nadia; Facchinetti, Fabrizio; Caruso, Paola; Marchini, Gessica; Battipaglia, Loredana; Patacchini, Riccardo; Cenacchi, Valentina; Volta, Roberta; Amadei, Francesco; Pappani, Alice; Capacchi, Silvia; Bagnacani, Valentina; Delcanale, Maurizio; Puccini, Paola; Catinella, Silvia; Civelli, Maurizio; Armani, Elisabetta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10026-10046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacol. inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD).  Herein, the authors describe a drug discovery program aiming at the identification of novel classes of potent PDE4 inhibitors suitable for pulmonary administration.  Starting from a previous series of benzoic acid esters, the authors explored the chem. space in the solvent-exposed region of the enzyme catalytic binding pocket.  Extensive structural modifications led to the discovery of a no. of heterocycloalkyl esters as potent in vitro PDE4 inhibitors.  (S*,S**)-18e (3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((S)-1-((3-(dimethylcarbamoyl)phenyl)sulfonyl)pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide) and (S*,S**)-22e (3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide), in particular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in an exptl. animal model.  The optimal biol. profile as well as the excellent solid-state properties suggest that both compds. have the potential to be effective topical agents for treating respiratory inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgCLI9kb8q57Vg90H21EOLACvtfcHk0lh8bcbNqX0fqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhs7rI&md5=44f2dc4fbac0d34580ff06d6cbca352d</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01044%26sid%3Dliteratum%253Aachs%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DBattipaglia%26aufirst%3DL.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DAmadei%26aufirst%3DF.%26aulast%3DPappani%26aufirst%3DA.%26aulast%3DCapacchi%26aufirst%3DS.%26aulast%3DBagnacani%26aufirst%3DV.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DPuccini%26aufirst%3DP.%26aulast%3DCatinella%26aufirst%3DS.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DArmani%26aufirst%3DE.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520thiazolidinyl%2520and%2520pyrrolidinyl%2520derivatives%2520as%2520inhaled%2520PDE4%2520inhibitors%2520for%2520respiratory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10026%26epage%3D10046%26doi%3D10.1021%2Facs.jmedchem.7b01044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gràcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buil, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagès, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Biphenyl pyridazinone derivatives as inhaled PDE4 inhibitors: structural biology and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10479</span>– <span class="NLM_lpage">10497</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10479-10497&author=J.+Gr%C3%A0ciaauthor=M.+A.+Builauthor=J.+Castroauthor=P.+Eichhornauthor=M.+Ferrerauthor=A.+Gavald%C3%A0author=B.+Hern%C3%A1ndezauthor=V.+Segarraauthor=M.+D.+Lehnerauthor=I.+Morenoauthor=L.+Pag%C3%A8sauthor=R.+S.+Robertsauthor=J.+Serratauthor=S.+Sevillaauthor=J.+Taltavullauthor=M.+Andr%C3%A9sauthor=J.+Cabedoauthor=D.+Vilellaauthor=E.+Calamaauthor=C.+Carcasonaauthor=M.+Miralpeix&title=Biphenyl+pyridazinone+derivatives+as+inhaled+PDE4+inhibitors%3A+structural+biology+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.6b00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships</span></div><div class="casAuthors">Gracia, Jordi; Buil, Maria Antonia; Castro, Jordi; Eichhorn, Peter; Ferrer, Manel; Gavalda, Amadeu; Hernandez, Begona; Segarra, Victor; Lehner, Martin D.; Moreno, Imma; Pages, Lluis; Roberts, Richard S.; Serrat, Jordi; Sevilla, Sara; Taltavull, Joan; Andres, Miriam; Cabedo, Judit; Vilella, Dolors; Calama, Elena; Carcasona, Carla; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10479-10497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic nucleotide cAMP is an ubiquitous second messenger involved in a plethora of cellular responses to biol. agents involving activation of adenylyl cyclase.  Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs.  In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD.  Here the authors describe efforts to discover novel, highly potent inhaled inhibitors of PDE4.  Through structure based design, with the intervention of a wide variety of functional groups and physichochem. profiles to occupy the solvent-filled pocket of the PDE4 enzyme, the authors modified the structure of the authors' oral PDE4 inhibitors to reach compds. up to picomolar enzymic potencies.  In vitro potencies were demonstrated in a rat lung neutrophilia model by suspension microspray administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCrwH5GRUxx7Vg90H21EOLACvtfcHk0ljj82tR8MRHvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE&md5=13709b5d62c06b553655f88f65ff3bdf</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00829%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A0cia%26aufirst%3DJ.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DEichhorn%26aufirst%3DP.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DMoreno%26aufirst%3DI.%26aulast%3DPag%25C3%25A8s%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSerrat%26aufirst%3DJ.%26aulast%3DSevilla%26aufirst%3DS.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DBiphenyl%2520pyridazinone%2520derivatives%2520as%2520inhaled%2520PDE4%2520inhibitors%253A%2520structural%2520biology%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10479%26epage%3D10497%26doi%3D10.1021%2Facs.jmedchem.6b00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gràcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as inhaled phosphodiesterase type 4 (PDE4) inhibitors: structural biology and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2472</span>– <span class="NLM_lpage">2489</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01751</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01751" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslKqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2472-2489&author=R.+S.+Robertsauthor=S.+Sevillaauthor=M.+Ferrerauthor=J.+Taltavullauthor=B.+Hern%C3%A1ndezauthor=V.+Segarraauthor=J.+Gr%C3%A0ciaauthor=M.+D.+Lehnerauthor=A.+Gavald%C3%A0author=M.+Andr%C3%A9sauthor=J.+Cabedoauthor=D.+Vilellaauthor=P.+Eichhornauthor=E.+Calamaauthor=C.+Carcasonaauthor=M.+Miralpeix&title=4-Amino-7%2C8-dihydro-1%2C6-naphthyridin-5%286+H%29-ones+as+inhaled+phosphodiesterase+type+4+%28PDE4%29+inhibitors%3A+structural+biology+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.7b01751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships</span></div><div class="casAuthors">Roberts, Richard S.; Sevilla, Sara; Ferrer, Manel; Taltavull, Joan; Hernandez, Begona; Segarra, Victor; Gracia, Jordi; Lehner, Martin D.; Gavalda, Amadeu; Andres, Miriam; Cabedo, Judit; Vilella, Dolors; Eichhorn, Peter; Calama, Elena; Carcasona, Carla; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2472-2489</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rational design of a novel template of naphthyridinones rapidly led to PDE4 inhibitors with subnanomolar enzymic potencies.  X-ray crystallog. confirmed the binding mode of this novel template.  We achieved compds. with double-digit picomolar enzymic potencies through further structure-based design by targeting both the PDE4 enzyme metal-binding pocket and occupying the solvent-filled pocket.  A strategy for lung retention and long duration of action based on low aq. soly. was followed.  In vivo efficacies were measured in a rat lung neutrophilia model by suspension microspray and dry powder administration.  Suspension microspray of potent compds. showed in vivo efficacy with a clear dose-response.  Despite sustained lung levels, dry powder administration performed much less well and without proper dose-response, highlighting clear differences between the two formulations.  This indicates a deficiency in the low aq. soly. strategy for long duration lung efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLargrI2V0NrVg90H21EOLACvtfcHk0ljj82tR8MRHvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslKqs70%253D&md5=7b7b232d52ec716a6289f5aa9fdae41b</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01751%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSevilla%26aufirst%3DS.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DGr%25C3%25A0cia%26aufirst%3DJ.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DEichhorn%26aufirst%3DP.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3D4-Amino-7%252C8-dihydro-1%252C6-naphthyridin-5%25286%2520H%2529-ones%2520as%2520inhaled%2520phosphodiesterase%2520type%25204%2520%2528PDE4%2529%2520inhibitors%253A%2520structural%2520biology%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2472%26epage%3D2489%26doi%3D10.1021%2Facs.jmedchem.7b01751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbott-Banner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1111/bcpt.12209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fbcpt.12209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24517491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVSitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=365-376&author=K.+H.+Abbott-Bannerauthor=C.+P.+Page&title=Dual+PDE3%2F4+and+PDE4+inhibitors%3A+novel+treatments+for+COPD+and+other+inflammatory+airway+diseases&doi=10.1111%2Fbcpt.12209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases</span></div><div class="casAuthors">Abbott-Banner, Katharine H.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-376</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Selective phosphodiesterase (PDE) 4 and dual PDE3/4 inhibitors have attracted considerable interest as potential therapeutic agents for the treatment of respiratory diseases, largely by virtue of their anti-inflammatory (PDE4) and bifunctional bronchodilator/anti-inflammatory (PDE3/4) effects.  Many of these agents have, however, failed in early development for various reasons, including dose-limiting side effects when administered orally and lack of sufficient activity when inhaled.  Indeed, only one selective PDE4 inhibitor, the orally active roflumilast-n-oxide, has to date received marketing authorization.  The majority of the compds. that have failed were, however, orally administered and non-selective for either PDE3 (A,B) or PDE4 (A,B,C,D) subtypes.  Developing an inhaled dual PDE3/4 inhibitor that is rapidly cleared from the systemic circulation, potentially with subtype specificity, may represent one strategy to improve the therapeutic index and also exhibit enhanced efficacy vs. inhibition of either PDE3 or PDE4 alone, given the potential pos. interactions with regard to anti-inflammatory and bronchodilator effects that have been obsd. pre-clin. with dual inhibition of PDE3 and PDE4 compared with inhibition of either isoenzyme alone.  This MiniReview will summarize recent clin. data obtained with PDE inhibitors and the potential for these drugs to treat COPD and other inflammatory airways diseases such as asthma and cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj1ILnRPA11rVg90H21EOLACvtfcHk0lin_goGNWtCnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVSitL4%253D&md5=d29edfe27d2514633d532bdd47d938d4</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12209%26sid%3Dliteratum%253Aachs%26aulast%3DAbbott-Banner%26aufirst%3DK.%2BH.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DDual%2520PDE3%252F4%2520and%2520PDE4%2520inhibitors%253A%2520novel%2520treatments%2520for%2520COPD%2520and%2520other%2520inflammatory%2520airway%2520diseases%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26spage%3D365%26epage%3D376%26doi%3D10.1111%2Fbcpt.12209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franciosi, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamant, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuiker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamerling, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kam, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burggraaf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(13)70187-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS2213-2600%2813%2970187-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24429275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=714-727&author=L.+G.+Franciosiauthor=Z.+Diamantauthor=K.+H.+Bannerauthor=R.+Zuikerauthor=N.+Morelliauthor=I.+M.+Kamerlingauthor=M.+L.+de+Kamauthor=J.+Burggraafauthor=A.+F.+Cohenauthor=M.+Cazzolaauthor=L.+Calzettaauthor=D.+Singhauthor=D.+Spinaauthor=M.+J.+Walkerauthor=C.+P.+Page&title=Efficacy+and+safety+of+RPL554%2C+a+dual+PDE3+and+PDE4+inhibitor%2C+in+healthy+volunteers+and+in+patients+with+asthma+or+chronic+obstructive+pulmonary+disease%3A+findings+from+four+clinical+trials&doi=10.1016%2FS2213-2600%2813%2970187-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials</span></div><div class="casAuthors">Franciosi, Lui G.; Diamant, Zuzana; Banner, Katharine H.; Zuiker, Rob; Morelli, Nicoletta; Kamerling, Ingrid M. C.; de Kam, Marieke L.; Burggraaf, Jacobus; Cohen, Adam F.; Cazzola, Mario; Calzetta, Luigino; Singh, Dave; Spina, Domenico; Walker, Michael J. A.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">714-727</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug.  We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.  Between Feb., 2009, and Jan., 2013, we undertook four proof-of-concept clin. trials in the Netherlands, Italy, and the UK.  Nebulised RPL554 was examd. in study 1 for safety in 18 healthy men who were randomly assigned (1:1:1) to receive an inhaled dose of RPL554 (0·003 mg/kg or 0·009 mg/kg) or placebo by a computer-generated randomisation table.  Subsequently, six non-smoking men with mild allergic asthma received single doses of RPL554 (three received 0·009 mg/kg and three received 0·018 mg/kg) in an open-label, adaptive study, and then ten men with mild allergic asthma were randomly assigned to receive placebo or RPL554 (0·018 mg/kg) by a computer-generated randomisation table for an assessment of safety, bronchodilation, and bronchoprotection.  Study 2 examd. the reproducibility of the bronchodilator response to a daily dose of nebulised RPL554 (0·018 mg/kg) for 6 consecutive days in a single-blind (patients masked), placebo-controlled study in 12 men with clin. stable asthma.  The safety and bronchodilator effect of RPL554 (0·018 mg/kg) was assessed in study 3, an open-label, placebo-controlled crossover trial, in 12 men with mild-to-moderate COPD.  In study 4, a placebo-controlled crossover trial, the effect of RPL554 (0·018 mg/kg) on lipopolysaccharide-induced inflammatory cell infiltration in induced sputum was investigated in 21 healthy men.  In studies 3 and 4, randomisation was done by computer-generated permutation with a block size of two for study 3 and four for study 4.  Unless otherwise stated, participants and clinicians were masked to treatment assignment.  Analyses were by intention to treat.  All trials were registered with EudraCT, nos. 2008-005048-17, 2011-001698-22, 2010-023573-18, and 2012-000742-34.  Safety was a primary endpoint of studies 1 and 3 and a secondary endpoint of studies 2 and 4.  Overall, RPL554 was well tolerated, and adverse events were generally mild and of equal frequency between placebo and active treatment groups.  Efficacy was a primary endpoint of study 2 and a secondary endpoint of studies 1 and 3.  Study 1 measured change in forced expiratory vol. in 1 s (FEV1) and provocative concn. of methacholine causing a 20% fall in FEV1 (PC20MCh) in participants with asthma.  RPL554 produced rapid bronchodilation in patients with asthma with an FEV1 increase at 1 h of 520 mL (95% CI 320-720; p<0·0001), which was a 14% increase from placebo, and increased the PC20MCh by 1·5 doubling doses (95% CI 0·63-2·28; p=0·004) compared with placebo.  The primary endpoint of study 2 was max. FEV1 reached during 6 h after dosing with RPL554 in patients with asthma.  RPL554 produced a similar max. mean increase in FEV1 from placebo on day 1 (555 mL, 95% CI 442-668), day 3 (505 mL, 392-618), and day 6 (485 mL, 371-598; overall p<0·0001).  A secondary endpoint of study 3 (patients with COPD) was the increase from baseline in FEV1.  RPL554 produced bronchodilation with a mean max. FEV1 increase of 17·2% (SE 5·2).  In healthy individuals (study 4), the primary endpoint was percentage change in neutrophil counts in induced sputum 6 h after lipopolysaccharide challenge.  RPL554 (0·018 mg/kg) did not significantly reduce the percentage of neutrophils in sputum (80·3% in the RPL554 group vs 84·2% in the placebo group; difference -3·9%, 95% CI -9·4 to 1·6, p=0·15), since RPL554 significantly reduced neutrophils (p=0·002) and total cells (p=0·002) to a similar degree.  In four exploratory studies, inhaled RPL554 is an effective and well tolerated bronchodilator, bronchoprotector, and anti-inflammatory drug and further studies will establish the full potential of this new drug for the treatment of patients with COPD or asthma.Verona Pharma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrFl2Dd6i-MbVg90H21EOLACvtfcHk0lhzMCb1iYQOZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCmsro%253D&md5=6dda9a9076d111b844540ea8add319fa</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2813%2970187-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252813%252970187-5%26sid%3Dliteratum%253Aachs%26aulast%3DFranciosi%26aufirst%3DL.%2BG.%26aulast%3DDiamant%26aufirst%3DZ.%26aulast%3DBanner%26aufirst%3DK.%2BH.%26aulast%3DZuiker%26aufirst%3DR.%26aulast%3DMorelli%26aufirst%3DN.%26aulast%3DKamerling%26aufirst%3DI.%2BM.%26aulast%3Dde%2BKam%26aufirst%3DM.%2BL.%26aulast%3DBurggraaf%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DA.%2BF.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSpina%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DM.%2BJ.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520RPL554%252C%2520a%2520dual%2520PDE3%2520and%2520PDE4%2520inhibitor%252C%2520in%2520healthy%2520volunteers%2520and%2520in%2520patients%2520with%2520asthma%2520or%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520findings%2520from%2520four%2520clinical%2520trials%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2013%26volume%3D1%26spage%3D714%26epage%3D727%26doi%3D10.1016%2FS2213-2600%2813%2970187-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, V. K.</span></span> <span> </span><span class="NLM_article-title">Lipopolysaccharide binds to and activates A(1) adenosine receptors on human pulmonary artery endothelial cells</span>. <i>J. Endotoxin Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1179/096805102125000470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1179%2F096805102125000470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12230916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot1ajtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=263-271&author=C.+N.+Wilsonauthor=V.+K.+Batra&title=Lipopolysaccharide+binds+to+and+activates+A%281%29+adenosine+receptors+on+human+pulmonary+artery+endothelial+cells&doi=10.1179%2F096805102125000470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Lipopolysaccharide binds to and activates A1 adenosine receptors on human pulmonary artery endothelial cells</span></div><div class="casAuthors">Wilson, Constance Neely; Batra, Vinod K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endotoxin Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-271</span>CODEN:
                <span class="NLM_cas:coden">JENREB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0519</span>.
    
            (<span class="NLM_cas:orgname">Maney Publishing</span>)
        </div><div class="casAbstract">Previously, it was reported that A1 adenosine receptor antagonists prevent endotoxin-induced acute lung injury and pulmonary arterial endothelial cell damage.  In competition radioligand binding expts. in membranes prepd. from human pulmonary artery endothelial cells (PAECs), lipopolysaccharides (LPSs) of Escherichia coli, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa displaced the binding of a selective A1 adenosine receptor antagonist [125I]-BWA844U (IC50 values: 195 ng/mL, 290 ng/mL, 602 ng/mL, and 693 ng/mL, resp.) in a dose-dependent, competitive manner.  There was no displacement of this radioligand by enterotoxin (≤ 10 μg/mL), diphosphoryl lipid A (≤ 10 μg/mL), and glycolipids, monosialoganglioside (≤ 1 μg/mL), lactocerebroside (≤ 100 μg/mL), or NBD galactocerebroside (≤ 100 μg/mL).  Based on calcd. IC50 values, LPS (E. coli, IC50 111 ng/mL) displaced the selective A1 adenosine receptor agonist, [3H]-2-chloro, N6-cyclopentyladenosine (CCPA) in human PAECs with a potency profile, CCPA > LPS > 2-phenylaminoadenosine (CV 1808), a selective A2 adenosine receptor agonist.  The potency profile for displacement of the selective A2a adenosine receptor agonist [3H]-CGS 21680 was CV 1808 > CCPA.  LPS (E. coli 0.1 pg/mL-10 μg/mL) did not displace [3H]-CGS 21680 binding.  In human PAECs, IL-6 and TXA2 release induced by LPS (0-1 μg/mL) or CCPA (0-1 μM) at high doses was significantly reduced by the selective A1 adenosine receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 1 μM).  These data suggest that LPS binds to and activates A1 adenosine receptors on human PAECs to induce the release of IL-6 and TXA2.  Activation of A1 adenosine receptors on human PAECs by LPS may contribute to the pathophysiol. of acute lung injury assocd. with Gram-neg. septicemia and endotoxemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpilSpTohXHwrVg90H21EOLACvtfcHk0lhzMCb1iYQOZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot1ajtrg%253D&md5=eb4d2173d4f468af1863346cb8c95a52</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1179%2F096805102125000470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1179%252F096805102125000470%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%2BN.%26aulast%3DBatra%26aufirst%3DV.%2BK.%26atitle%3DLipopolysaccharide%2520binds%2520to%2520and%2520activates%2520A%25281%2529%2520adenosine%2520receptors%2520on%2520human%2520pulmonary%2520artery%2520endothelial%2520cells%26jtitle%3DJ.%2520Endotoxin%2520Res.%26date%3D2002%26volume%3D8%26spage%3D263%26epage%3D271%26doi%3D10.1179%2F096805102125000470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lappas, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> agonists in development for the treatment of inflammation</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">806</span>, <span class="refDoi"> DOI: 10.1517/13543784.14.7.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543784.14.7.797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16022569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFelsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2005&pages=797-806&author=C.+M.+Lappasauthor=G.+W.+Sullivanauthor=J.+Linden&title=Adenosine+A2A+agonists+in+development+for+the+treatment+of+inflammation&doi=10.1517%2F13543784.14.7.797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A agonists in development for the treatment of inflammation</span></div><div class="casAuthors">Lappas, Courtney M.; Sullivan, Gail W.; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">797-806</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Extracellular adenosine binds specifically to a family of four G protein-coupled cell-surface adenosine receptors (ARs).  As the activation of the A2AAR modulates the activity of multiple inflammatory cells including neutrophils, macrophages and T lymphocytes, the receptor is considered to be a promising pharmacol. target for the treatment of inflammatory disorders.  Although adenosine binds nonselectively to all four AR subtypes, A2AAR selective agonists have been developed and shown to inhibit multiple manifestations of inflammatory cell activation including superoxide anion generation, cytokine prodn. and adhesion mol. expression.  A2AAR agonists are also vasodilators, but the inhibition of inflammation occurs at low doses that produce few or no cardiovascular side effects.  Therefore, the selective activation of the A2AAR by these compds. holds significant potential in the treatment of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX_jD7VYc8h7Vg90H21EOLACvtfcHk0lgrFUUf8R1Ehw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFelsb0%253D&md5=4e6dd54f575fad5993e4b294ef83b94f</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1517%2F13543784.14.7.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.14.7.797%26sid%3Dliteratum%253Aachs%26aulast%3DLappas%26aufirst%3DC.%2BM.%26aulast%3DSullivan%26aufirst%3DG.%2BW.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520agonists%2520in%2520development%2520for%2520the%2520treatment%2520of%2520inflammation%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2005%26volume%3D14%26spage%3D797%26epage%3D806%26doi%3D10.1517%2F13543784.14.7.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincenzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adcock, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casolari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclennan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span> <span> </span><span class="NLM_article-title">Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1164/rccm.200506-869OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200506-869OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16322645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28XmslSlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2006&pages=398-406&author=K.+Varaniauthor=G.+Caramoriauthor=F.+Vincenziauthor=I.+Adcockauthor=P.+Casolariauthor=E.+Leungauthor=S.+Maclennanauthor=S.+Gessiauthor=S.+Morelloauthor=P.+J.+Barnesauthor=K.+Itoauthor=K.+F.+Chungauthor=G.+Cavallescoauthor=G.+Azzenaauthor=A.+Papiauthor=P.+A.+Borea&title=Alteration+of+adenosine+receptors+in+patients+with+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.200506-869OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Varani, Katia; Caramori, Gaetano; Vincenzi, Fabrizio; Adcock, Ian; Casolari, Paolo; Leung, Edward; MacLennan, Stephen; Gessi, Stefania; Morello, Silvania; Barnes, Peter J.; Ito, Kazuhiro; Chung, Kian Fan; Cavallesco, Giorgio; Azzena, Gianfranco; Papi, Alberto; Borea, Pier Andrea</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-406</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality worldwide.  Adenosine is an inflammatory regulator that acts through four distinct receptors to mediate pro- and antiinflammatory effects.  Objectives: The primary aim of this study was to investigate the expression, affinity, and d. of adenosine receptors in peripheral lung parenchyma from age-matched smokers with COPD (n = 14) and smokers with normal lung function (control group; n = 20).  Methods: Adenosine receptors were analyzed by immunohistochem. and satn. binding assays using typical antagonist radioligands.  Results: A1, A2A, A2B, and A3 receptors were expressed in different cells in peripheral lung parenchyma.  The affinity of A1, A2A, and A3 receptors was significantly decreased in patients with COPD compared with the control group (KD[A1] = 3.15 ± 0.19 vs. 1.70 ± 0.14 nM; KD[A2A] = 7.88 ± 0.68 vs. 1.87 ± 0.09 nM; KD[A3] = 9.34 ± 0.27 vs. 4.41 ± 0.25 nM; p < 0.01), whereas their d. was increased (Bmax[A1] = 53 ± 4 vs. 32 ± 3 fmol/mg protein; Bmax[A2A] = 852 ± 50 vs. 302 ± 12 fmol/mg protein; Bmax[A3] = 2,078 ± 108 vs. 770 ± 34 fmol/mg protein; p < 0.01).  The affinity of A2B receptors was not altered, but the d. was significantly decreased in patients with COPD compared with the control group (Bmax = 66 ± 5 vs. 189 ± 16 fmol/mg protein; p < 0.01).  A significant correlation was found between the affinity and d. of the adenosine receptors and the FEV1/FVC ratio.  Conclusions: This is the first report showing the presence of adenosine receptors in lung parenchyma in subjects with COPD compared with control smokers.  These novel findings strengthen the hypothesis of a potential role played by adenosine receptors in the pathogenesis of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBVPEVprddDbVg90H21EOLACvtfcHk0lgrFUUf8R1Ehw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmslSlu78%253D&md5=0c6087812da1f8adad7ac5e9ac9defee</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1164%2Frccm.200506-869OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200506-869OC%26sid%3Dliteratum%253Aachs%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DCaramori%26aufirst%3DG.%26aulast%3DVincenzi%26aufirst%3DF.%26aulast%3DAdcock%26aufirst%3DI.%26aulast%3DCasolari%26aufirst%3DP.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DMaclennan%26aufirst%3DS.%26aulast%3DGessi%26aufirst%3DS.%26aulast%3DMorello%26aufirst%3DS.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DChung%26aufirst%3DK.%2BF.%26aulast%3DCavallesco%26aufirst%3DG.%26aulast%3DAzzena%26aufirst%3DG.%26aulast%3DPapi%26aufirst%3DA.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DAlteration%2520of%2520adenosine%2520receptors%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2006%26volume%3D173%26spage%3D398%26epage%3D406%26doi%3D10.1164%2Frccm.200506-869OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, M. R.</span></span> <span> </span><span class="NLM_article-title">A<sub>3</sub> adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1380</span>– <span class="NLM_lpage">1389</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.173.2.1380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4049%2Fjimmunol.173.2.1380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15240734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsVGiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2004&pages=1380-1389&author=H.+W.+Youngauthor=J.+G.+Molinaauthor=D.+Diminaauthor=H.+Zhongauthor=M.+Jacobsonauthor=L.+N.+Chanauthor=T.+S.+Chanauthor=J.+J.+Leeauthor=M.+R.+Blackburn&title=A3+adenosine+receptor+signaling+contributes+to+airway+inflammation+and+mucus+production+in+adenosine+deaminase-deficient+mice&doi=10.4049%2Fjimmunol.173.2.1380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">A3 Adenosine Receptor Signaling Contributes to Airway Inflammation and Mucus Production in Adenosine Deaminase-Deficient Mice</span></div><div class="casAuthors">Young, Hays W. J.; Molina, Jose G.; Dimina, Dawn; Zhong, Hongyan; Jacobson, Marlene; Chan, Lee-Nien L.; Chan, Teh-Sheng; Lee, James J.; Blackburn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1380-1389</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Adenosine signaling has been implicated in chronic lung diseases such as asthma and chronic obstructive pulmonary disease; however, the specific roles of the various adenosine receptors in processes central to these disorders are not well understood.  In this study, the authors have investigated the role(s) of the A3 adenosine receptor in adenosine-dependent pulmonary inflammation obsd. in adenosine deaminase (ADA)-deficient mice.  The A3 receptor (A3R) was expressed in eosinophils and mucus-producing cells in the airways of ADA-deficient mice.  Treatment of ADA-deficient mice with MRS 1523, a selective A3R antagonist, prevented airway eosinophilia and mucus prodn.  Similar findings were seen in the lungs of ADA/A3 double knockout mice.  Although eosinophils were decreased in the airways of ADA-deficient mice following antagonism or removal of the A3R, elevations in circulating and lung interstitial eosinophils persisted, suggesting signaling through the A3R is needed for the migration of eosinophils into the airways.  These findings identify an important role for the A3R in regulating lung eosinophilia and mucus prodn. in an environment of elevated adenosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUukkD1DW_rLVg90H21EOLACvtfcHk0ljZcU9b9BtCsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsVGiu7Y%253D&md5=ea93b9057fda0a0070db5e3d14e98708</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.173.2.1380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.173.2.1380%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DH.%2BW.%26aulast%3DMolina%26aufirst%3DJ.%2BG.%26aulast%3DDimina%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DL.%2BN.%26aulast%3DChan%26aufirst%3DT.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DBlackburn%26aufirst%3DM.%2BR.%26atitle%3DA3%2520adenosine%2520receptor%2520signaling%2520contributes%2520to%2520airway%2520inflammation%2520and%2520mucus%2520production%2520in%2520adenosine%2520deaminase-deficient%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2004%26volume%3D173%26spage%3D1380%26epage%3D1389%26doi%3D10.4049%2Fjimmunol.173.2.1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obiefuna, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, S. J.</span></span> <span> </span><span class="NLM_article-title">A novel A1 adenosine receptor antagonist, L-97–1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7 dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.088179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.105.088179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16020631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=329-336&author=P.+C.+Obiefunaauthor=V.+K.+Batraauthor=A.+Nadeemauthor=P.+Borronauthor=C.+N.+Wilsonauthor=S.+J.+Mustafa&title=A+novel+A1+adenosine+receptor+antagonist%2C+L-97%E2%80%931+%5B3-%5B2-%284-aminophenyl%29-ethyl%5D-8-benzyl-7-%7B2-ethyl-%282-hydroxy-ethyl%29-amino%5D-ethyl%7D-1-propyl-3%2C7+dihydro-purine-2%2C6-dione%5D%2C+reduces+allergic+responses+to+house+dust+mite+in+an+allergic+rabbit+model+of+asthma&doi=10.1124%2Fjpet.105.088179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino] -ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma</span></div><div class="casAuthors">Obiefuna, P. C. M.; Batra, V. K.; Nadeem, A.; Borron, P.; Wilson, C. N.; Mustafa, S. Jamal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Adenosine, an important signaling mol. in asthma, produces bronchoconstriction in asthmatics.  Adenosine produces bronchoconstriction in allergic rabbits, primates, and humans by activating A1 adenosine receptors (ARs).  Effects of L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione] a water-sol., small mol. A1 AR antagonist were investigated on early and late phase allergic responses (EAR and LAR) in a hyper-responsive rabbit model of asthma.  Rabbits were made allergic by i.p. injections of house dust mite [HDM; 312 allergen units (AU)] ext. within 24 h of their birth.  Booster HDM injections were given weekly for 1 mo, bi-weekly for 4 mo, and continued monthly thereafter.  Hyper-responsiveness was monitored by measuring lung dynamic compliance (Cdyn), after histamine or adenosine aerosol challenge in allergic rabbits.  Hyper-responsive rabbits were subjected to aerosol of HDM (2500 AU), 1 h after intragastric administration of L-97-1 (10 mg/kg) soln. or an equiv. vol. of saline.  Cdyn was significantly higher after treatment with L-97-1 compared with untreated controls (p < 0.05 n = 5).  Histamine PC30 was significantly higher (p < 0.05; n = 5) after L-97-1 at 24 h compared with histamine PC30 at 24 h after HDM.  Adenosine PC30 was significantly higher at 15 min and 6 h after L-97-1 compared with control (p < 0.05; n = 5).  L-97-1 showed strong affinity for human A1 ARs in radioligand binding studies and no inhibition toward human phosphodiesterase II, III, IV, and V enzymes.  These data suggest that L-97-1 produces a significant redn. of histamine or adenosine-induced hyper-responsiveness and HDM-induced EAR and LAR in allergic rabbits by blocking A1 ARs and may be beneficial as an oral therapy for human asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrANyGMjnvs_bVg90H21EOLACvtfcHk0ljZcU9b9BtCsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7vL&md5=097275b3ea3879fe8e5c582a73a00051</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.088179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.088179%26sid%3Dliteratum%253Aachs%26aulast%3DObiefuna%26aufirst%3DP.%2BC.%26aulast%3DBatra%26aufirst%3DV.%2BK.%26aulast%3DNadeem%26aufirst%3DA.%26aulast%3DBorron%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DC.%2BN.%26aulast%3DMustafa%26aufirst%3DS.%2BJ.%26atitle%3DA%2520novel%2520A1%2520adenosine%2520receptor%2520antagonist%252C%2520L-97%25E2%2580%25931%2520%255B3-%255B2-%25284-aminophenyl%2529-ethyl%255D-8-benzyl-7-%257B2-ethyl-%25282-hydroxy-ethyl%2529-amino%255D-ethyl%257D-1-propyl-3%252C7%2520dihydro-purine-2%252C6-dione%255D%252C%2520reduces%2520allergic%2520responses%2520to%2520house%2520dust%2520mite%2520in%2520an%2520allergic%2520rabbit%2520model%2520of%2520asthma%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D329%26epage%3D336%26doi%3D10.1124%2Fjpet.105.088179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Maatougui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuaje, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Gómez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escalante, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Mera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez-de-Terán, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotelo, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and highly selective A<sub>2B</sub> adenosine receptor antagonist chemotypes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1967</span>– <span class="NLM_lpage">1983</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01586</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01586" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1967-1983&author=A.+El+Maatouguiauthor=J.+Azuajeauthor=M.+Gonz%C3%A1lez-G%C3%B3mezauthor=G.+Miguezauthor=A.+Crespoauthor=C.+Carbajalesauthor=L.+Escalanteauthor=X.+Garc%C3%ADa-Meraauthor=H.+Guti%C3%A9rrez-de-Ter%C3%A1nauthor=E.+Sotelo&title=Discovery+of+potent+and+highly+selective+A2B+adenosine+receptor+antagonist+chemotypes&doi=10.1021%2Facs.jmedchem.5b01586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes</span></div><div class="casAuthors">El Maatougui, Abdelaziz; Azuaje, Jhonny; Gonzalez-Gomez, Manuel; Miguez, Gabriel; Crespo, Abel; Carbajales, Carlos; Escalante, Luz; Garcia-Mera, Xerardo; Gutierrez-de-Teran, Hugo; Sotelo, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1967-1983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three novel families of A2B adenosine receptor antagonists were identified in the context of the structural exploration of the 3,4-dihydropyrimidin-2(1H)-one chemotype.  The most appealing series contain imidazole, 1,2,4-triazole, or benzimidazole rings fused to the 2,3-positions of the parent diazinone core.  The optimization process enabled identification of a highly potent (3.49 nM) A2B ligand that exhibits complete selectivity toward A1, A2A, and A3 receptors.  The results of functional cAMP expts. confirmed the antagonistic behavior of representative ligands.  The main SAR trends identified within the series were substantiated by a mol. modeling study based on a receptor-driven docking model constructed on the basis of the crystal structure of the human A2A receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRWpBQuLXYG7Vg90H21EOLACvtfcHk0ljpDQaC77ax9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKnu7g%253D&md5=4df99ab9a9e7dea11b5592ba9d64b334</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01586%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BMaatougui%26aufirst%3DA.%26aulast%3DAzuaje%26aufirst%3DJ.%26aulast%3DGonz%25C3%25A1lez-G%25C3%25B3mez%26aufirst%3DM.%26aulast%3DMiguez%26aufirst%3DG.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DCarbajales%26aufirst%3DC.%26aulast%3DEscalante%26aufirst%3DL.%26aulast%3DGarc%25C3%25ADa-Mera%26aufirst%3DX.%26aulast%3DGuti%25C3%25A9rrez-de-Ter%25C3%25A1n%26aufirst%3DH.%26aulast%3DSotelo%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520highly%2520selective%2520A2B%2520adenosine%2520receptor%2520antagonist%2520chemotypes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1967%26epage%3D1983%26doi%3D10.1021%2Facs.jmedchem.5b01586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, K.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of A<sub>3</sub> adenosine receptor modulators: pharmacological activities and therapeutic implications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5676</span>– <span class="NLM_lpage">5703</span>, <span class="refDoi"> DOI: 10.1021/jm300087j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300087j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5676-5703&author=P.+G.+Baraldiauthor=D.+Pretiauthor=P.+A.+Boreaauthor=K.+Varani&title=Medicinal+chemistry+of+A3+adenosine+receptor+modulators%3A+pharmacological+activities+and+therapeutic+implications&doi=10.1021%2Fjm300087j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal Chemistry of A3 Adenosine Receptor Modulators: Pharmacological Activities and Therapeutic Implications</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Preti, Delia; Borea, Pier Andrea; Varani, Katia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5676-5703</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_0_ZpkzjfnbVg90H21EOLACvtfcHk0ljpDQaC77ax9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOnsrk%253D&md5=6b85d21f7be2a968d291ce6f73c54d46</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm300087j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300087j%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DVarani%26aufirst%3DK.%26atitle%3DMedicinal%2520chemistry%2520of%2520A3%2520adenosine%2520receptor%2520modulators%253A%2520pharmacological%2520activities%2520and%2520therapeutic%2520implications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5676%26epage%3D5703%26doi%3D10.1021%2Fjm300087j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P.
J.</span></span> <span> </span><span class="NLM_article-title">Theophylline</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1164/rccm.201302-0388PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.201302-0388PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23672674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslymsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2013&pages=901-906&author=P.%0AJ.+Barnes&title=Theophylline&doi=10.1164%2Frccm.201302-0388PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Theophylline</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">901-906</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Theophylline (dimethylxanthine) has been used to treat airway diseases for more than 80 years.  It was originally used as a bronchodilator, but the relatively high doses required are assocd. with frequent side effects, so its use declined as inhaled β2-agonists became more widely used.  More recently it has been shown to have antiinflammatory effects in asthma and chronic obstructive pulmonary disease (COPD) at lower concns.  The mol. mechanism of bronchodilation is inhibition of phosphodiesterase (PDE)3, but the antiinflammatory effect may be due to inhibition of PDE4 and histone deacetylase-2 activation, resulting in switching off of activated inflammatory genes.  Through this mechanism, theophylline also reverses corticosteroid resistance, and this may be of particular value in severe asthma and COPD, wherein histone deacetylase-2 activity is reduced.  Theophylline is given systemically (orally as slow-release prepns. for chronic treatment and i.v. for acute exacerbations of asthma).  Efficacy is related to blood concns., which are detd. mainly by hepatic metab., which may be increased or decreased in several diseases and by concomitant drug therapy.  Theophylline is now usually used as an add-on therapy in patients with asthma not well controlled on inhaled corticosteroids with or without long-acting β2-agonists and in patients with COPD with severe disease not controlled by bronchodilator therapy.  Side effects are related to plasma concns. and include nausea, vomiting, and headaches due to PDE inhibition and at higher concns. to cardiac arrhythmias and seizures due to adenosine A1-receptor antagonism.  In the future, low-dose theophylline may be useful in reversing corticosteroid resistance in COPD and severe asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqniUExR5YzkrVg90H21EOLACvtfcHk0lgMTUf0BRiEeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslymsLfI&md5=5ad4233b2b1860d403de0d0fd1d6e85f</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1164%2Frccm.201302-0388PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201302-0388PP%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DTheophylline%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2013%26volume%3D188%26spage%3D901%26epage%3D906%26doi%3D10.1164%2Frccm.201302-0388PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manocha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease</span>. <i>J. Basic Clin. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">451</span>, <span class="refDoi"> DOI: 10.1515/jbcpp-2015-0006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1515%2Fjbcpp-2015-0006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25894641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OnsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=443-451&author=D.+Lalauthor=S.+Manochaauthor=A.+Rayauthor=V.+K.+Vijayanauthor=R.+Kumar&title=Comparative+study+of+the+efficacy+and+safety+of+theophylline+and+doxofylline+in+patients+with+bronchial+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1515%2Fjbcpp-2015-0006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Lal, Dushyant; Manocha, Sachin; Ray, Arunabha; Vijayan, V. K.; Kumar, Raj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Basic and Clinical Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">443-451</span>CODEN:
                <span class="NLM_cas:coden">JBPPES</span>;
        ISSN:<span class="NLM_cas:issn">0792-6855</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">Background: Bronchial asthma and chronic obstructive pulmonary disease (COPD) are the major obstructive disorders that may contribute to the severity in individual patients.  The present study was designed to compare the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and COPD.  Methods: A total of 60 patients, 30 each with bronchial asthma and COPD, were enrolled for the study.  Each group of 30 patients received std. treatment for asthma and COPD.  Each group was again subdivided into two with 15 patients each, who received theophylline or doxofylline in addn. to std. therapy, for a period of 2 mo.  Each patient was followed up fortnightly for the assessment of efficacy parameters using a pulmonary function test (PFT), clin. symptoms and emergency drug use, and safety was assessed by recording adverse drug reactions.  Results: Both theophylline and doxofylline produced enhancements in PFT at different time intervals in both asthma and COPD patients.  The max. beneficial effects were seen at 6 wk for asthma patients and at 8 wk for COPD patients for both theophylline and doxofylline.  Conclusions: The comparative study showed that doxofylline was more effective as evidenced by improvement in PFT as well as clin. symptoms, and reduced incidence of adverse effects and emergency bronchodilator use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY4bwKNqTCILVg90H21EOLACvtfcHk0lgMTUf0BRiEeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OnsL%252FO&md5=58eaa00ab6e4a4ba98cc3662af7cc7de</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1515%2Fjbcpp-2015-0006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fjbcpp-2015-0006%26sid%3Dliteratum%253Aachs%26aulast%3DLal%26aufirst%3DD.%26aulast%3DManocha%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DVijayan%26aufirst%3DV.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DComparative%2520study%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520theophylline%2520and%2520doxofylline%2520in%2520patients%2520with%2520bronchial%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Basic%2520Clin.%2520Physiol.%2520Pharmacol.%26date%3D2015%26volume%3D26%26spage%3D443%26epage%3D451%26doi%3D10.1515%2Fjbcpp-2015-0006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span> <span> </span><span class="NLM_article-title">Doxofylline is not just another theophylline!</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3487</span>– <span class="NLM_lpage">3493</span>, <span class="refDoi"> DOI: 10.2147/COPD.S150887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2147%2FCOPD.S150887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29255355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntVKnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=3487-3493&author=M.+G.+Materaauthor=C.+Pageauthor=M.+Cazzola&title=Doxofylline+is+not+just+another+theophylline%21&doi=10.2147%2FCOPD.S150887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Doxofylline is not just another theophylline!</span></div><div class="casAuthors">Matera, Maria Gabriella; Page, Clive; Cazzola, Mario</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3487-3493</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Doxofylline, which differs from theophylline in contg. the dioxalane group at position 7, has comparable efficacy to theophylline in the treatment of respiratory diseases, but with an improved tolerability profile and a favorable risk-to-benefit ratio.  Furthermore, it does not have significant drug-drug interactions as exhibited with theophylline, which make using theophylline more challenging, esp. in elderly patients with co-morbidities receiving multiple classes of drug.  It is now clear that doxofylline also possesses a distinct pharmacol. profile from theophylline (no significant effect on any of the known phosphodiesterase isoforms, no significant adenosine receptor antagonism, no direct effect on histone deacetylases, interaction with β2-adrenoceptors) and therefore, should not be considered as just a modified theophylline.  Randomized clin. trials of doxofylline to investigate the use of this drug to reduce exacerbations and hospitalizations due to asthma or COPD as an alternative to expensive biologics, and certainly as an alternative to theophylline are to be encouraged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW97uF_60k7bVg90H21EOLACvtfcHk0lgMTUf0BRiEeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntVKnsb4%253D&md5=5d94dfedf43b6ebab35b7858f12984e8</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S150887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S150887%26sid%3Dliteratum%253Aachs%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DDoxofylline%2520is%2520not%2520just%2520another%2520theophylline%2521%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2017%26volume%3D12%26spage%3D3487%26epage%3D3493%26doi%3D10.2147%2FCOPD.S150887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshie, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenmotsu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichimasa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, K.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1084/jem.193.2.255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1084%2Fjem.193.2.255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11208866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksl2msg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2001&pages=255-261&author=H.+Hiraiauthor=K.+Tanakaauthor=O.+Yoshieauthor=K.+Ogawaauthor=K.+Kenmotsuauthor=Y.+Takamoriauthor=M.+Ichimasaauthor=K.+Sugamuraauthor=M.+Nakamuraauthor=S.+Takanoauthor=K.+Nagata&title=Prostaglandin+D2+selectively+induces+chemotaxis+in+T+helper+type+2+cells%2C+eosinophils%2C+and+basophils+via+seven-transmembrane+receptor+CRTH2&doi=10.1084%2Fjem.193.2.255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2</span></div><div class="casAuthors">Hirai, Hiroyuki; Tanaka, Kazuya; Yoshie, Osamu; Ogawa, Kazuyuki; Kenmotsu, Kazumi; Takamori, Yasushi; Ichimasa, Michiko; Sugamura, Kazuo; Nakamura, Masataka; Takano, Shoichi; Nagata, Kinya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Prostaglandin (PG)D2, which has long been implicated in allergic diseases, is currently considered to elicit its biol. actions through the DP receptor (DP).  Involvement of DP in the formation of allergic asthma was recently demonstrated with DP-deficient mice.  However, proinflammatory functions of PGD2 cannot be explained by DP alone.  The authors show here that a 7-transmembrane receptor, CRTH2, which is preferentially expressed in T helper type 2 (Th2) cells, eosinophils, and basophils in humans, serves as the novel receptor for PGD2.  In response to PGD2, CRTH2 induces intracellular Ca2+ mobilization and chemotaxis in Th2 cells in a Gαi-dependent manner.  In addn., CRTH2, but not DP, mediates PGD2-dependent cell migration of blood eosinophils and basophils.  Thus, PGD2 is likely involved in multiple aspects of allergic inflammation through its dual receptor systems, DP and CRTH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzrVzvfWtBArVg90H21EOLACvtfcHk0lhinbHTbNeHBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksl2msg%253D%253D&md5=be2c6671805c587029df75738463ccd3</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1084%2Fjem.193.2.255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.193.2.255%26sid%3Dliteratum%253Aachs%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DYoshie%26aufirst%3DO.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DKenmotsu%26aufirst%3DK.%26aulast%3DTakamori%26aufirst%3DY.%26aulast%3DIchimasa%26aufirst%3DM.%26aulast%3DSugamura%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DTakano%26aufirst%3DS.%26aulast%3DNagata%26aufirst%3DK.%26atitle%3DProstaglandin%2520D2%2520selectively%2520induces%2520chemotaxis%2520in%2520T%2520helper%2520type%25202%2520cells%252C%2520eosinophils%252C%2520and%2520basophils%2520via%2520seven-transmembrane%2520receptor%2520CRTH2%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2001%26volume%3D193%26spage%3D255%26epage%3D261%26doi%3D10.1084%2Fjem.193.2.255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagyo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaka, A.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin D2-induced eosinophilic airways inflammation is mediated by CRTH2 receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.078212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.104.078212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15528449" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2004&pages=954-960&author=Y.+Shiraishiauthor=K.+Asanoauthor=T.+Nakajimaauthor=T.+Ogumaauthor=Y.+Suzukiauthor=T.+Shiomiauthor=K.+Sayamaauthor=K.+Niimiauthor=M.+Wakakiauthor=J.+Kagyoauthor=E.+Ikedaauthor=H.+Hiraiauthor=K.+Yamaguchiauthor=A.+Ishizaka&title=Prostaglandin+D2-induced+eosinophilic+airways+inflammation+is+mediated+by+CRTH2+receptor&doi=10.1124%2Fjpet.104.078212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.078212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.078212%26sid%3Dliteratum%253Aachs%26aulast%3DShiraishi%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DOguma%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DShiomi%26aufirst%3DT.%26aulast%3DSayama%26aufirst%3DK.%26aulast%3DNiimi%26aufirst%3DK.%26aulast%3DWakaki%26aufirst%3DM.%26aulast%3DKagyo%26aufirst%3DJ.%26aulast%3DIkeda%26aufirst%3DE.%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DIshizaka%26aufirst%3DA.%26atitle%3DProstaglandin%2520D2-induced%2520eosinophilic%2520airways%2520inflammation%2520is%2520mediated%2520by%2520CRTH2%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D312%26spage%3D954%26epage%3D960%26doi%3D10.1124%2Fjpet.104.078212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borish, L.</span></span> <span> </span><span class="NLM_article-title">Eosinophils and mast cells in aspirin-exacerbated respiratory disease</span>. <i>Immunol. Allergy Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1016/j.iac.2016.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.iac.2016.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=27712766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2svnvFWntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=719-734&author=J.+W.+Steinkeauthor=S.+C.+Payneauthor=L.+Borish&title=Eosinophils+and+mast+cells+in+aspirin-exacerbated+respiratory+disease&doi=10.1016%2Fj.iac.2016.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease</span></div><div class="casAuthors">Steinke John W; Payne Spencer C; Borish Larry</div><div class="citationInfo"><span class="NLM_cas:title">Immunology and allergy clinics of North America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-734</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aspirin-exacerbated respiratory disease (AERD) involves overexpression of proinflammatory mediators, including 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes.  Mast cells and eosinophils have roles in mediating many of the observed effects.  Increased levels of both interleukin-4 (IL-4) and interferon (IFN)-γ are present in the tissue of patients with AERD.  Previous studies showed that IL-4 is primarily responsible for the upregulation of LTC4S by mast cells.  Our studies show that IFN-γ, but not IL-4, drives this process in eosinophils.  This article examines the overall role that eosinophils and mast cells contribute to the pathophysiology of AERD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKUjf8dgw-aXELvajU9pjPfW6udTcc2eY8EfUrQnrtxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnvFWntA%253D%253D&md5=6c71572c54fe92bf92b3d44ea87fefee</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.iac.2016.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.iac.2016.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DSteinke%26aufirst%3DJ.%2BW.%26aulast%3DPayne%26aufirst%3DS.%2BC.%26aulast%3DBorish%26aufirst%3DL.%26atitle%3DEosinophils%2520and%2520mast%2520cells%2520in%2520aspirin-exacerbated%2520respiratory%2520disease%26jtitle%3DImmunol.%2520Allergy%2520Clin.%2520North%2520Am.%26date%3D2016%26volume%3D36%26spage%3D719%26epage%3D734%26doi%3D10.1016%2Fj.iac.2016.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D. S.</span></span> <span> </span><span class="NLM_article-title">DP2 receptor antagonists: novel therapeutic target for COPD</span>. <i>Mol. Cell. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.4255/mcpharmacol.10.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4255%2Fmcpharmacol.10.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFGltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=89-96&author=K.+J.+Stebbinsauthor=J.+F.+Evansauthor=D.+S.+Lorrain&title=DP2+receptor+antagonists%3A+novel+therapeutic+target+for+COPD&doi=10.4255%2Fmcpharmacol.10.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">DP2 receptor antagonists: novel therapeutic target for COPD</span></div><div class="casAuthors">Stebbins, Karin J.; Evans, Jilly F.; Lorrain, Daniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">89-96</span>CODEN:
                <span class="NLM_cas:coden">MCPOCT</span>;
        ISSN:<span class="NLM_cas:issn">1938-1247</span>.
    
            (<span class="NLM_cas:orgname">LumiText Publishing</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease of the small airways and lung parenchyma that is characterized by chronic airway inflammation, airway remodeling and parenchymal destruction.  Current treatment options for patients with COPD consist primarily of long acting bronchodilators.  Inhaled corticosteroids provide benefit for exacerbations but have little impact on the persistent inflammation.  At present, there are no approved drugs that are disease modifying to treat the underlying causes of COPD.  One pharmacol. mechanism we and others are exploring as a therapeutic target for COPD is antagonism of the DP2 receptor (also known as chemoattractant receptor-homologous mol. expressed on Th2 cells, CRTh2).  Since cigarette smoking is a risk factor for COPD, we used mouse models of acute and subchronic cigarette smoke exposure to explore the role of DP2 in COPD.  We obsd. an increase in prostaglandin D2 (PGD2), the natural ligand for DP2, in the mouse lungs following subchronic smoke exposure.  We demonstrated that DP2 antagonism alleviated much of the cigarette smoke-induced lung phenotype, including cellular inflammation, mucus cell metaplasia and epithelial hyperplasia.  Although the role of PGD2 and DP2 in COPD is yet to be fully elucidated, our results support the development of DP2 antagonists clin. as a novel pharmacol. mechanism to treat COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAgc2PbdqO7rVg90H21EOLACvtfcHk0lihJjHWoUNf5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFGltbY%253D&md5=a155d881b3fec80fcb4ad0a6fad6c1a0</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.4255%2Fmcpharmacol.10.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4255%252Fmcpharmacol.10.12%26sid%3Dliteratum%253Aachs%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26atitle%3DDP2%2520receptor%2520antagonists%253A%2520novel%2520therapeutic%2520target%2520for%2520COPD%26jtitle%3DMol.%2520Cell.%2520Pharmacol.%26date%3D2010%26volume%3D2%26spage%3D89%26epage%3D96%26doi%3D10.4255%2Fmcpharmacol.10.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1722</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2013.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.rmed.2013.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23827726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3sjotFKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2013&pages=1722-1730&author=N.+Snellauthor=M.+Fosterauthor=J.+Vestbo&title=Efficacy+and+safety+of+AZD1981%2C+a+CRTH2+receptor+antagonist%2C+in+patients+with+moderate+to+severe+COPD&doi=10.1016%2Fj.rmed.2013.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD</span></div><div class="casAuthors">Snell Noel; Foster Martyn; Vestbo Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1722-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To evaluate the efficacy and tolerability of the selective CRTh2 (DP2) receptor antagonist AZD1981 compared with placebo in patients with moderate to severe COPD.  METHODS:  In this multicentre, randomised, double-blind, parallel-group, phase IIa study (ClinicalTrials.gov identifier: NCT00690482) patients with moderate to severe COPD received either AZD1981 1000 mg twice daily or matching placebo for 4 weeks.  Inhaled terbutaline was used as-needed as reliever medication throughout.  The co-primary endpoints were change from baseline to end of treatment in pre-bronchodilator forced expiratory volume in 1 s [FEV1] and the Clinical COPD Questionnaire (CCQ).  Additional endpoints included other lung function measures, 6-min walk test (6-MWT), COPD symptom score, reliever medication use and tolerability.  RESULTS:  118 patients were randomised to treatment (AZD1981 n = 61; placebo n = 57); 83% of patients were male and the mean age was 63 years (range 43-83).  There were no significant differences in the mean difference in change from baseline to end of treatment between AZD1981 and placebo for the co-primary endpoints of pre-bronchodilator FEV1 (AZD1981-placebo: -0.015, 95% CI: -0.10 to 0.070; p = 0.72) and CCQ total score (difference: 0.042, 95% CI: -0.21 to 0.30; p = 0.75).  Similarly, no differences were observed between treatments for the other outcomes of lung function, COPD symptom score, 6-MWT, BODE index, and use of reliever medication.  AZD1981 was well tolerated.  CONCLUSION:  There was no beneficial clinical effect of AZD1981, at a dose of 1000 mg twice daily for 4 weeks, in patients with moderate to severe COPD.  AZD1981 was well tolerated and no safety concerns were identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPSqgbSDH0Dhcr74wzj5o5fW6udTcc2eZEhkv_PAqHdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjotFKktg%253D%253D&md5=1cb066d5739b23480039c884b1950ccd</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2013.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2013.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DSnell%26aufirst%3DN.%26aulast%3DFoster%26aufirst%3DM.%26aulast%3DVestbo%26aufirst%3DJ.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520AZD1981%252C%2520a%2520CRTH2%2520receptor%2520antagonist%252C%2520in%2520patients%2520with%2520moderate%2520to%2520severe%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2013%26volume%3D107%26spage%3D1722%26epage%3D1730%26doi%3D10.1016%2Fj.rmed.2013.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhead, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troung, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.180430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.111.180430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21487069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFChsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=290-301&author=G.+Bainauthor=D.+S.+Lorrainauthor=K.+J.+Stebbinsauthor=A.+R.+Broadheadauthor=A.+M.+Santiniauthor=P.+Prodanovichauthor=J.+Darlingtonauthor=C.+D.+Kingauthor=C.+Leeauthor=C.+Bacceiauthor=B.+Stearnsauthor=Y.+Troungauthor=J.+H.+Hutchinsonauthor=P.+Prasitauthor=J.+F.+Evans&title=Pharmacology+of+AM211%2C+a+potent+and+selective+prostaglandin+D2+receptor+type+2+antagonist+that+is+active+in+animal+models+of+allergic+inflammation&doi=10.1124%2Fjpet.111.180430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation</span></div><div class="casAuthors">Bain, Gretchen; Lorrain, Daniel S.; Stebbins, Karin J.; Broadhead, Alex R.; Santini, Angelina M.; Prodanovich, Pat; Darlington, Janice; King, Christopher D.; Lee, Catherine; Baccei, Christopher; Stearns, Brian; Troung, Yen; Hutchinson, John H.; Prasit, Peppi; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">290-301</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The prostaglandin D2 (PGD2) receptor type 2 (DP2) is a G protein-coupled receptor that has been shown to be involved in a variety of allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis.  In this study, we describe the preclin. pharmacol. and pharmacokinetic properties of the small-mol. DP2 antagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid (AM211).  We det. that AM211 has high affinity for human, mouse, rat, and guinea pig DP2 and it shows selectivity over other prostanoid receptors and enzymes.  Antagonist activity of AM211 at the DP2 receptor was confirmed by inhibition of PGD2-stimulated guanosine 5'-O-[γ-thio]triphosphate binding to membranes expressing human DP2.  A basophil activation assay and a whole-blood assay of eosinophil shape change were used to demonstrate the ability of AM211 to potently antagonize PGD2-stimulated functional responses in relevant human cells and in the context of a physiol. relevant environment.  AM211 exhibits good oral bioavailability in rats and dogs and dose-dependently inhibits 13,14-dihydro-15-keto-PGD2-induced leukocytosis in a guinea pig pharmacodynamic assay.  AM211 demonstrates efficacy in two animal models of allergic inflammation, including an ovalbumin-induced lung inflammation model in guinea pigs and an ovalbumin-induced mouse model of allergic rhinitis.  AM211 represents a potent and selective antagonist of DP2 that may be used clin. to evaluate the role of DP2 in T helper 2-driven allergic inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0R5IR6qyfzLVg90H21EOLACvtfcHk0lg8r9yML2n4Gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFChsrY%253D&md5=85947de08474cbc68015b481097e2bd2</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.180430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.180430%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DG.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DBroadhead%26aufirst%3DA.%2BR.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBaccei%26aufirst%3DC.%26aulast%3DStearns%26aufirst%3DB.%26aulast%3DTroung%26aufirst%3DY.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DPharmacology%2520of%2520AM211%252C%2520a%2520potent%2520and%2520selective%2520prostaglandin%2520D2%2520receptor%2520type%25202%2520antagonist%2520that%2520is%2520active%2520in%2520animal%2520models%2520of%2520allergic%2520inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D290%26epage%3D301%26doi%3D10.1124%2Fjpet.111.180430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearmond, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holme, K.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1482</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.1177/0091270011421912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1177%2F0091270011421912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22110163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyqsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1482-1493&author=G.+Bainauthor=C.+D.+Kingauthor=J.+Brittainauthor=J.+P.+Hartungauthor=I.+Dearmondauthor=B.+Stearnsauthor=Y.+P.+Truongauthor=J.+H.+Hutchinsonauthor=J.+F.+Evansauthor=K.+Holme&title=Pharmacodynamics%2C+pharmacokinetics%2C+and+safety+of+AM211%3A+a+novel+and+potent+antagonist+of+the+prostaglandin+D2+receptor+type+2&doi=10.1177%2F0091270011421912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2</span></div><div class="casAuthors">Bain, G.; King, C. D.; Brittain, J.; Hartung, J. P.; De Armond, I.; Stearns, B.; Truong, Y. P.; Hutchinson, J. H.; Evans, J. F.; Holme, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1482-1493</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The prostaglandin D2 receptor type 2 (DP2) and its ligand, PGD2, have been implicated in the development of asthma and other inflammatory diseases.  The authors evaluated the pharmacodynamics, pharmacokinetics and safety of [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid sodium salt (AM211), a novel and potent DP2 antagonist, in healthy participants.  Single and multiple doses of AM211 demonstrated dose-dependent inhibition of eosinophil shape change in blood with near-complete inhibition obsd. at trough after dosing 200 mg once daily for 7 days.  Maximum plasma concns. and exposures of AM211 increased in a greater-than-dose-proportional manner after single and multiple dosing.  After multiple dosing, the exposures on day 7 were higher than on day 1 with accumulation ratio values ranging from 1.4 to 1.5.  Mean terminal half-life values ranged from 14 to 25 h across the dose range of 100 to 600 mg.  AM211 was well tolerated at all doses in both the single- and multiple-dose cohorts.  These data support addnl. clin. studies to evaluate AM211 in asthma and other inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgTV_Wdw_bxLVg90H21EOLACvtfcHk0lgQcDALDYfEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyqsLfP&md5=bb5cf8f73626f6181d435b37265d10ce</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1177%2F0091270011421912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270011421912%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DG.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DBrittain%26aufirst%3DJ.%26aulast%3DHartung%26aufirst%3DJ.%2BP.%26aulast%3DDearmond%26aufirst%3DI.%26aulast%3DStearns%26aufirst%3DB.%26aulast%3DTruong%26aufirst%3DY.%2BP.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DHolme%26aufirst%3DK.%26atitle%3DPharmacodynamics%252C%2520pharmacokinetics%252C%2520and%2520safety%2520of%2520AM211%253A%2520a%2520novel%2520and%2520potent%2520antagonist%2520of%2520the%2520prostaglandin%2520D2%2520receptor%2520type%25202%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D52%26spage%3D1482%26epage%3D1493%26doi%3D10.1177%2F0091270011421912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1931</span>– <span class="NLM_lpage">1936</span>, <span class="refDoi"> DOI: 10.1517/13543776.2011.636738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543776.2011.636738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22082220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyksrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1931-1936&author=P.+Norman&title=A+novel+DP2+receptor+antagonist+%28AM-461%29%3A+a+patent+evaluation+of+WO2011085033&doi=10.1517%2F13543776.2011.636738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1931-1936</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  This application claims salts and cryst. forms of a previously disclosed DP2 receptor antagonist (2-[3-[2-(tert-butylsulfanylmethyl)-4-(2,2-dimethylpropanoylamino)phenoxy]-4-methoxy-phenyl]acetic acid (1)).  It also claims compns. contg. the free acid and its salts, esp. the sodium salt and their use in the treatment of inflammatory and respiratory diseases, esp. asthma.  Notably, the application presents Phase I clin. data on compd. (1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgHu0_v41IFrVg90H21EOLACvtfcHk0lgQcDALDYfEtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyksrvL&md5=5899d49348c46eedb55efc71bf699910</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1517%2F13543776.2011.636738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2011.636738%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DA%2520novel%2520DP2%2520receptor%2520antagonist%2520%2528AM-461%2529%253A%2520a%2520patent%2520evaluation%2520of%2520WO2011085033%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2011%26volume%3D21%26spage%3D1931%26epage%3D1936%26doi%3D10.1517%2F13543776.2011.636738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span> <span> </span><span class="NLM_article-title">Novel CRTH2 antagonists: a review of patents from 2006 to 2009</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1530</span>, <span class="refDoi"> DOI: 10.1517/13543776.2010.525506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543776.2010.525506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20946089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1505-1530&author=T.+Ulvenauthor=E.+Kostenis&title=Novel+CRTH2+antagonists%3A+a+review+of+patents+from+2006+to+2009&doi=10.1517%2F13543776.2010.525506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Novel CRTH2 antagonists: a review of patents from 2006 to 2009</span></div><div class="casAuthors">Ulven, Trond; Kostenis, Evi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1505-1530</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The receptor CRTH2 (also known as DP2) is an important mediator of the inflammatory effects of prostaglandin D2 and has attracted much attention as a therapeutic target for the treatment of conditions such as asthma, COPD, allergic rhinitis and atopic dermatitis.  Areas covered in this review: The validation of CRTH2 as a therapeutic target and the early antagonists are summarized, CRTH2 antagonists published in the patent literature from 2006 to 2009 are comprehensively covered and a general update on the recent progress in the development of CRTH2 antagonists for the treatment of inflammatory diseases is provided.  What the reader will gain: Insight into the validation of CRTH2 as a therapeutic target, a comprehensive overview of the development of new CRTH2 ligands between 2006 and 2009, and a general overview of the state of the art.  Take home message: Many diverse potent CRTH2 antagonists are now available, and several are in or on the way into the clinic.  It is still early to draw final conclusions, but preliminary results give reason for optimism, and the prospect that we will see new CRTH2 antagonists reaching the market for the treatment of asthma, rhinitis, atopic dermatitis and/or COPD seems good.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0vwLWB8G_DbVg90H21EOLACvtfcHk0lg6PLrEx6JkMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtL%252FE&md5=0600e42595e4de51ab405331687630ca</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1517%2F13543776.2010.525506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2010.525506%26sid%3Dliteratum%253Aachs%26aulast%3DUlven%26aufirst%3DT.%26aulast%3DKostenis%26aufirst%3DE.%26atitle%3DNovel%2520CRTH2%2520antagonists%253A%2520a%2520review%2520of%2520patents%2520from%25202006%2520to%25202009%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D1505%26epage%3D1530%26doi%3D10.1517%2F13543776.2010.525506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupré, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAbee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassir, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderslice, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R. A.</span></span> <span> </span><span class="NLM_article-title">Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1099</span>– <span class="NLM_lpage">1111</span>, <span class="refDoi"> DOI: 10.1021/jm9704917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9704917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK1cXhs12ks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1099-1111&author=T.+P.+Koganauthor=B.+Dupr%C3%A9author=H.+Buiauthor=K.+L.+McAbeeauthor=J.+M.+Kassirauthor=I.+L.+Scottauthor=X.+Huauthor=P.+Vandersliceauthor=P.+J.+Beckauthor=R.+A.+Dixon&title=Novel+synthetic+inhibitors+of+selectin-mediated+cell+adhesion%3A+synthesis+of+1%2C6-bis%5B3-%283-carboxymethylphenyl%29-4-%282-alpha-D-+mannopyranosyloxy%29phenyl%5Dhexane+%28TBC1269%29&doi=10.1021%2Fjm9704917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Synthetic Inhibitors of Selectin-Mediated Cell Adhesion: Synthesis of 1,6-Bis[3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)phenyl]hexane (TBC1269)</span></div><div class="casAuthors">Kogan, Timothy P.; Dupre, Brian; Bui, Huong; McAbee, Kathy L.; Kassir, Jamal M.; Scott, Ian L.; Hu, Xin; Vanderslice, Peter; Beck, Pamela J.; Dixon, Richard A. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1099-1111</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reports of a high-affinity ligand for E-selectin, sialyl di-Lewisx motivated the authors to incorporate modifications to previously reported biphenyl-based inhibitors that would provide addnl. interactions with the protein.  These compds. were assayed for the ability to inhibit the binding of sialyl Lewisx (sLex) bearing HL-60 cells to E-, P-, and L-selectin fusion proteins.  The authors report that dimeric or trimeric compds. contg. multiple components of simple nonoligosaccharide selectin antagonists inhibit sLex-dependent binding with significantly enhanced potency over the monomeric compd.  The enhanced potency is consistent with addnl. binding interactions within a single selectin lectin domain; however, multivalent interaction with multiple lectin domains as a possible alternative cannot be ruled out.  Compd. I (TBC 1269) showed optimal in vitro activity from this class of antagonists and is currently under development for use in the treatment of asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUeXjoakahVLVg90H21EOLACvtfcHk0lg6PLrEx6JkMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhs12ks70%253D&md5=da0974c175dcb37e2aad448636be74f9</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Fjm9704917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9704917%26sid%3Dliteratum%253Aachs%26aulast%3DKogan%26aufirst%3DT.%2BP.%26aulast%3DDupr%25C3%25A9%26aufirst%3DB.%26aulast%3DBui%26aufirst%3DH.%26aulast%3DMcAbee%26aufirst%3DK.%2BL.%26aulast%3DKassir%26aufirst%3DJ.%2BM.%26aulast%3DScott%26aufirst%3DI.%2BL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DVanderslice%26aufirst%3DP.%26aulast%3DBeck%26aufirst%3DP.%2BJ.%26aulast%3DDixon%26aufirst%3DR.%2BA.%26atitle%3DNovel%2520synthetic%2520inhibitors%2520of%2520selectin-mediated%2520cell%2520adhesion%253A%2520synthesis%2520of%25201%252C6-bis%255B3-%25283-carboxymethylphenyl%2529-4-%25282-alpha-D-%2520mannopyranosyloxy%2529phenyl%255Dhexane%2520%2528TBC1269%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1099%26epage%3D1111%26doi%3D10.1021%2Fjm9704917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singanayagam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallia, P.</span></span> <span> </span><span class="NLM_article-title">Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(14)70169-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS2213-2600%2814%2970169-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25240963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsF2mu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=919-932&author=L.+Finneyauthor=M.+Berryauthor=A.+Singanayagamauthor=S.+L.+Elkinauthor=S.+L.+Johnstonauthor=P.+Mallia&title=Inhaled+corticosteroids+and+pneumonia+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS2213-2600%2814%2970169-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Finney, Lydia; Berry, Matthew; Singanayagam, Aran; Elkin, Sarah L.; Johnston, Sebastian L.; Mallia, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">919-932</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhaled corticosteroids are widely used in chronic obstructive pulmonary disease (COPD) and, in combination with long-acting β2 agonists, reduce exacerbations and improve lung function and quality of life.  However, inhaled corticosteroids have been linked with an increased risk of pneumonia in individuals with COPD, but the magnitude of this risk, the effects of different prepns. and doses, and the mechanisms of this effect remain unclear.  Therefore, making informed clin. decisions-balancing the beneficial and adverse effects of inhaled corticosteroids in individuals with COPD-is difficult.  Understanding of the mechanisms of increased pneumonia risk with inhaled corticosteroids is urgently needed to clarify their role in the management of COPD and to aid the development of new, safer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6TwIovcm_c7Vg90H21EOLACvtfcHk0ljYGWoxBaEHlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsF2mu7nL&md5=93731fb68654146c29e6bb8426df568c</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2814%2970169-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252814%252970169-9%26sid%3Dliteratum%253Aachs%26aulast%3DFinney%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DSinganayagam%26aufirst%3DA.%26aulast%3DElkin%26aufirst%3DS.%2BL.%26aulast%3DJohnston%26aufirst%3DS.%2BL.%26aulast%3DMallia%26aufirst%3DP.%26atitle%3DInhaled%2520corticosteroids%2520and%2520pneumonia%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2014%26volume%3D2%26spage%3D919%26epage%3D932%26doi%3D10.1016%2FS2213-2600%2814%2970169-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagappan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, D.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(12)70052-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS2213-2600%2812%2970052-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24321804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=51-60&author=C.+F.+Vogelmeierauthor=E.+D.+Batemanauthor=J.+Pallanteauthor=V.+K.+Alagappanauthor=P.+D%E2%80%99Andreaauthor=H.+Chenauthor=D.+Banerji&title=Efficacy+and+safety+of+once-daily+QVA149+compared+with+twice-daily+salmeterol-fluticasone+in+patients+with+chronic+obstructive+pulmonary+disease+%28ILLUMINATE%29%3A+a+randomised%2C+double-blind%2C+parallel+group+study&doi=10.1016%2FS2213-2600%2812%2970052-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</span></div><div class="casAuthors">Vogelmeier, Claus F.; Bateman, Eric D.; Pallante, John; Alagappan, Vijay K. T.; D'Andrea, Peter; Chen, Hungta; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-60</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">QVA149 is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive pulmonary disease (COPD).  It combines indacaterol (a longacting β2-agonist) with glycopyrronium (a longacting muscarinic antagonist) as a dual bronchodilator.  We aimed to compare the efficacy, safety, and tolerability of QVA149 vs. salmeterol-fluticasone (SFC) over 26 wk in patients with moderate-to-severe COPD.  In this multicentre double-blind, double-dummy, parallel-group study, 523 patients (age 40 years or older, Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages II-III, without exacerbations in the previous year) were randomly assigned (1:1; via automated, interactive response technol. and stratified for smoking status) to once-daily QVA149 110/50 μg or twice-daily SFC 50/500 μg for 26 wk.  Efficacy was assessed in the full anal. set (randomised patients who received at least one dose of study drug); safety was assessed in all patients who received at least one dose of study drug.  The primary endpoint was to demonstrate the superiority of QVA149 compared with SFC for the standardized area under the curve from 0 to 12 h post dose for forced expiratory vol. in 1 s (FEV1 AUC0-12h) after 26 wk of treatment.  This trial was registered at ClinicalTrial.gov, NCT01315249.  Between March 25, 2011, and March 12, 2012, 259 patients were randomly assigned to receive QVA149 and 264 to receive SFC.  At week 26, FEV1 AUC0-12h was significantly higher with QVA149 than with SFC (treatment difference 0·138 L; 95% CI 0·100-0·176; p<0·0001).  Overall incidence of adverse events (including COPD exacerbations) was 55·4% (143 of 258) for the QVA149 group and 60·2% (159 of 264) for the SFC group.  Incidence of serious adverse events was similar between treatment groups (QVA149, 13 of 258 [5·0%]; SFC 14 of 264 [5·3%]); COPD worsening was the most frequent serious adverse event (one of 13 [0·4%] and three of 14 [1·1%], resp.).  Once-daily QVA149 provides significant, sustained, and clin. meaningful improvements in lung function vs. twice-daily SFC, with significant symptomatic benefit.  These results indicate the potential of dual bronchodilation as a treatment option for non-exacerbating symptomatic COPD patients.Novartis Pharma AG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOxmQ6p9ONmbVg90H21EOLACvtfcHk0ljYGWoxBaEHlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCmtr4%253D&md5=c39b6cf8dd09f1165ee0373328493090</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2812%2970052-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252812%252970052-8%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%2BF.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DPallante%26aufirst%3DJ.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520QVA149%2520compared%2520with%2520twice-daily%2520salmeterol-fluticasone%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528ILLUMINATE%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520parallel%2520group%2520study%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2013%26volume%3D1%26spage%3D51%26epage%3D60%26doi%3D10.1016%2FS2213-2600%2812%2970052-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span>Global Strategy
for
Diagnosis, Management and Prevention of COPD, GOLD, 2019.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+Strategy%0Afor%0ADiagnosis%2C+Management+and+Prevention+of+COPD%2C+GOLD%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tannheimer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span> <span> </span><span class="NLM_article-title">Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2012.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2012.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22306235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=178-184&author=S.+L.+Tannheimerauthor=E.+A.+Sorensenauthor=A.+C.+Haranauthor=C.+N.+Mansfieldauthor=C.+D.+Wrightauthor=M.+Salmon&title=Additive+anti-inflammatory+effects+of+beta+2+adrenoceptor+agonists+or+glucocorticosteroid+with+roflumilast+in+human+peripheral+blood+mononuclear+cells&doi=10.1016%2Fj.pupt.2012.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells</span></div><div class="casAuthors">Tannheimer, Stacey L.; Sorensen, Eric A.; Haran, Aaron C.; Mansfield, Christopher N.; Wright, Clifford D.; Salmon, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-184</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphodiesterase 4 inhibitor (PDE4i) roflumilast has been approved in the US and EU for treatment of GOLD stage 3 and 4 chronic obstructive pulmonary disease (COPD).  Inhaled β2 adrenoceptor agonist bronchodilators and anti-inflammatory glucocorticosteroids are also used as std. of care in COPD.  We investigated the anti-inflammatory interaction of roflumilast in combination with long-acting β2 agonists (LABA), salmeterol or formoterol, or a glucocorticosteroid, dexamethasone, on cytokine prodn. from LPS-stimulated human primary peripheral blood mononuclear cells (PBMC).  Salmeterol or formoterol caused a concn.-dependent inhibition of tumor necrosis factor-α (TNFα) secretion with an IC50 of 0.33 pM (C.I. 0.006-19) and 34 pM (C.I. 13-87), resp.  When roflumilast was evaluated, the addn. of salmeterol (1 nM) to roflumilast caused the IC50 for roflumilast to shift from 1.8 nM (C.I. 0.8-4) to 4.1 pM (C.I.0.3-69) (p < 0.01), and maximal inhibition increased from 72.5 ± 3.2% to 90.9 ± 3.1%.  Addn. of formoterol to roflumilast also produced an increased TNFα inhibition more than either drug alone (p < 0.05).  The inhibition of TNFα prodn. with salmeterol was both β2 adrenoceptor- and protein kinase A-dependent.  Addn. of roflumilast (10 nM) in the presence of dexamethasone increased the inhibition of LPS-induced TNFα and CCL3.  Roflumilast in combination with salmeterol, formoterol, or dexamethasone increased the inhibition of LPS-induced TNFα from human PBMC, in an additive manner.  Addn. of roflumilast to either a β2 adrenoceptor agonist or a glucocorticosteroid may provide superior anti-inflammatory activity and greater efficacy in COPD patients and be dose sparing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozTD47FfS8ibVg90H21EOLACvtfcHk0lgHxw2HfaPIFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhu7k%253D&md5=3b0486800c03c9a934909e9ee9a7fa8b</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2012.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2012.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DTannheimer%26aufirst%3DS.%2BL.%26aulast%3DSorensen%26aufirst%3DE.%2BA.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DMansfield%26aufirst%3DC.%2BN.%26aulast%3DWright%26aufirst%3DC.%2BD.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DAdditive%2520anti-inflammatory%2520effects%2520of%2520beta%25202%2520adrenoceptor%2520agonists%2520or%2520glucocorticosteroid%2520with%2520roflumilast%2520in%2520human%2520peripheral%2520blood%2520mononuclear%2520cells%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D25%26spage%3D178%26epage%3D184%26doi%3D10.1016%2Fj.pupt.2012.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Anjou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gougeon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moktefi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouissi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Séguin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Séguin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renzi, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, N.</span></span> <span> </span><span class="NLM_article-title">A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">39</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-10-39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2F1465-9921-10-39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19457265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1MvitVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=39&author=M.+Fortinauthor=H.+D%E2%80%99Anjouauthor=M.+E.+Higginsauthor=J.+Gougeonauthor=P.+Aub%C3%A9author=K.+Moktefiauthor=S.+Mouissiauthor=S.+S%C3%A9guinauthor=R.+S%C3%A9guinauthor=P.+M.+Renziauthor=L.+Paquetauthor=N.+Ferrari&title=A+multi-target+antisense+approach+against+PDE4+and+PDE7+reduces+smoke-induced+lung+inflammation+in+mice&doi=10.1186%2F1465-9921-10-39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice</span></div><div class="casAuthors">Fortin Marylene; D'Anjou Helene; Higgins Marie-Eve; Gougeon Jasmine; Aube Pamela; Moktefi Kamel; Mouissi Sonia; Seguin Serge; Seguin Rosanne; Renzi Paolo M; Paquet Luc; Ferrari Nicolay</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent development in the field of COPD has focused on strategies aimed at reducing the underlying inflammation through selective inhibition of the phosphodiesterase type IV (PDE4) isoform.  Although the anti-inflammatory and bronchodilator activity of selective PDE4 inhibitors has been well documented, their low therapeutic ratio and dose-dependent systemic side effects have limited their clinical utility.  This study examined the effect of 2'-deoxy-2'-Fluoro-beta-D-Arabinonucleic Acid (FANA)-containing antisense oligonucleotides (AON) targeting the mRNA for the PDE4B/4D and 7A subtypes on lung inflammatory markers, both in vitro and in vivo.  METHODS:  Normal human bronchial epithelial (NHBE) cells were transfected with FANA AON against PDE4B/4D and 7A alone or in combination. mRNA levels for target PDE subtypes, as well as secretion of pro-inflammatory chemokines were then measured following cell stimulation.  Mice were treated with combined PDE4B/4D and 7A AON via endo-tracheal delivery, or with roflumilast via oral delivery, and exposed to cigarette smoke for one week.  Target mRNA inhibition, as well as influx of inflammatory cells and mediators were measured in lung lavages.  A two-week smoke exposure protocol was also used to test the longer term potency of PDE4B/4D and 7A AONs.  RESULTS:  In NHBE cells, PDE4B/4D and 7A AONs dose-dependently and specifically inhibited expression of their respective target mRNA.  When used in combination, PDE4B/4D and 7A AONs significantly abrogated the cytokine-induced secretion of IL-8 and MCP-1 to near baseline levels.  In mice treated with combined PDE4B/4D and 7A AONs and exposed to cigarette smoke, significant protection against the smoke-induced recruitment of neutrophils and production of KC and pro-MMP-9 was obtained, which was correlated with inhibition of target mRNA in cells from lung lavages.  In this model, PDE AONs exerted more potent and broader anti-inflammatory effects against smoke-induced lung inflammation than roflumilast.  Moreover, the protective effect of PDE4B/4D and 7A AON was maintained when a once-weekly treatment schedule was used.  CONCLUSION:  These results indicate that inhaled AON against PDE4B/4D and 7A have unique effects on biomarkers that are believed to be important in the pathophysiology of COPD, which supports further development as a potential therapy in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSgo7GQRV05jToTC3aBaesfW6udTcc2ebf--f3HP1x2rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvitVWnsg%253D%253D&md5=27d1b8e274312718032163bb017e2717</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-10-39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-10-39%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Anjou%26aufirst%3DH.%26aulast%3DHiggins%26aufirst%3DM.%2BE.%26aulast%3DGougeon%26aufirst%3DJ.%26aulast%3DAub%25C3%25A9%26aufirst%3DP.%26aulast%3DMoktefi%26aufirst%3DK.%26aulast%3DMouissi%26aufirst%3DS.%26aulast%3DS%25C3%25A9guin%26aufirst%3DS.%26aulast%3DS%25C3%25A9guin%26aufirst%3DR.%26aulast%3DRenzi%26aufirst%3DP.%2BM.%26aulast%3DPaquet%26aufirst%3DL.%26aulast%3DFerrari%26aufirst%3DN.%26atitle%3DA%2520multi-target%2520antisense%2520approach%2520against%2520PDE4%2520and%2520PDE7%2520reduces%2520smoke-induced%2520lung%2520inflammation%2520in%2520mice%26jtitle%3DRespir.%2520Res.%26date%3D2009%26volume%3D10%26spage%3D39%26doi%3D10.1186%2F1465-9921-10-39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tannheimer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span> <span> </span><span class="NLM_article-title">The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.210997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.113.210997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24513870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVOiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=85-93&author=S.+L.+Tannheimerauthor=E.+A.+Sorensenauthor=Z.+H.+Cuiauthor=M.+Kimauthor=L.+Patelauthor=W.+R.+Bakerauthor=G.+B.+Phillipsauthor=C.+D.+Wrightauthor=M.+Salmon&title=The+in+vitro+pharmacology+of+GS-5759%2C+a+novel+bifunctional+phosphodiesterase+4+inhibitor+and+long+acting+%CE%B22-adrenoceptor+agonist&doi=10.1124%2Fjpet.113.210997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist</span></div><div class="casAuthors">Tannheimer, Stacey L.; Sorensen, Eric A.; Cui, Zhi-Hua; Kim, Musong; Patel, Leena; Baker, William R.; Phillips, Gary B.; Wright, Clifford D.; Salmon, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-93, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhaled long-acting β2-adrenoceptor agonists (LABA) that act as bronchodilators and the oral anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor roflumilast are both approved therapies for chronic obstructive pulmonary disease (COPD).  Here we describe the activity of a novel, inhaled, bifunctional, small mol. (R)-6-[(3-{[4-(5-{[2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}pent-1-yn-1-yl)phenyl]carbamoyl}phenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide (GS-5759), which has specific β2 agonist and PDE4 inhibitory activity.  GS-5759 demonstrated potent and full agonist activity at β2 adrenoceptors (EC50 = 8 ± 4 nM) and is a potent inhibitor of the PDE4 enzyme (IC50 = 5 ± 3 nM).  In cell assays, GS-5759 inhibited lipopolysaccharide (LPS)-induced tumor necrosis factor α (TNFα) prodn. in human peripheral mononuclear cells (PBMC) with an IC50 = 0.3 nM [confidence interval (CI) 0.1-0.6] and in human neutrophils formyl-methionyl-leucyl-phenylalanine (fMLP)-induced super oxide anion prodn. with an IC50 = 3 nM (CI 0.8-8).  The addn. of the β2 antagonist ICI 118551 shifted the IC50 in these cell assays to 4 and 38 nM, resp., demonstrating the contribution of both β2 agonist and PDE4 inhibitory activity to GS-5759.  GS-5759 was also a potent inhibitor of profibrotic and proinflammatory mediator release from human lung fibroblasts.  GS-5759 relaxed guinea pig airway smooth muscle strips precontracted with carbachol in a concn.-dependent manner with an EC50 = 0.5 μM (CI 0.2-2) and had slow dissocn. kinetics with an Off T1/2 > 720 min at an EC80 concn. of 3 μM.  GS-5759 is a novel bifunctional mol. with both potent β2 agonist and PDE4 inhibitor activity that could provide inhaled bronchodilator and anti-inflammatory therapy for COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj_BKbLa3cVLVg90H21EOLACvtfcHk0ljLu4YexQIpWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVOiu7Y%253D&md5=b0017107ab4935141406708f98a8eec3</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.210997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.210997%26sid%3Dliteratum%253Aachs%26aulast%3DTannheimer%26aufirst%3DS.%2BL.%26aulast%3DSorensen%26aufirst%3DE.%2BA.%26aulast%3DCui%26aufirst%3DZ.%2BH.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26aulast%3DPhillips%26aufirst%3DG.%2BB.%26aulast%3DWright%26aufirst%3DC.%2BD.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DThe%2520in%2520vitro%2520pharmacology%2520of%2520GS-5759%252C%2520a%2520novel%2520bifunctional%2520phosphodiesterase%25204%2520inhibitor%2520and%2520long%2520acting%2520%25CE%25B22-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D85%26epage%3D93%26doi%3D10.1124%2Fjpet.113.210997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-{4-[5-(4-fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a dual p38α MAPK/PDE-4 inhibitor with activity against TNFα-related diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5290</span>– <span class="NLM_lpage">5305</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01647</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSjtrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5290-5305&author=W.+Albrechtauthor=A.+Ungerauthor=S.+M.+Bauerauthor=S.+A.+Laufer&title=Discovery+of+N-%7B4-%5B5-%284-fluorophenyl%29-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl%5D-pyridin-2-yl%7D-acetamide+%28CBS-3595%29%2C+a+dual+p38%CE%B1+MAPK%2FPDE-4+inhibitor+with+activity+against+TNF%CE%B1-related+diseases&doi=10.1021%2Facs.jmedchem.6b01647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases</span></div><div class="casAuthors">Albrecht, Wolfgang; Unger, Anke; Bauer, Silke M.; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5290-5305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anti-inflammatory potential of p38 mitogen-activated protein kinase (MAPK) inhibitors was coincidentally expanded to a dual inhibition of p38α MAPK and phosphodiesterase 4 (PDE4), and the potential benefits arising from the blockage of both inflammation-related enzymes were thoroughly investigated.  The most promising compd., CBS-3595 (1), was successively evaluated in in vitro expts. as well as in ex vivo and in vivo preclin. studies after administration of 1 to rodents, dogs, and monkeys.  The resulting data clearly indicated a potent suppression of tumor necrosis factor alpha release.  For reconfirming the findings of the animal studies when administering 1 to healthy human volunteers, a phase I clin. trial was conducted.  Apart from further information regarding the pharmacokinetic and pharmacodynamic characteristics of 1, it was demonstrated that dual inhibition of p38α MAPK and PDE4 is able to synergistically attenuate the excessive anti-inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn0tCfKq3bG7Vg90H21EOLACvtfcHk0ljLu4YexQIpWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSjtrvL&md5=fb0a040161db70ade8a3032b0c978537</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01647%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDiscovery%2520of%2520N-%257B4-%255B5-%25284-fluorophenyl%2529-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl%255D-pyridin-2-yl%257D-acetamide%2520%2528CBS-3595%2529%252C%2520a%2520dual%2520p38%25CE%25B1%2520MAPK%252FPDE-4%2520inhibitor%2520with%2520activity%2520against%2520TNF%25CE%25B1-related%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5290%26epage%3D5305%26doi%3D10.1021%2Facs.jmedchem.6b01647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seemungal, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapsford, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedzicha, J. A.</span></span> <span> </span><span class="NLM_article-title">Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1147</span>, <span class="refDoi"> DOI: 10.1164/rccm.200801-145OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200801-145OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18723437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvVenuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2008&pages=1139-1147&author=T.+A.+Seemungalauthor=T.+M.+Wilkinsonauthor=J.+R.+Hurstauthor=W.+R.+Pereraauthor=R.+J.+Sapsfordauthor=J.+A.+Wedzicha&title=Long-term+erythromycin+therapy+is+associated+with+decreased+chronic+obstructive+pulmonary+disease+exacerbations&doi=10.1164%2Frccm.200801-145OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations</span></div><div class="casAuthors">Seemungal, Terence A. R.; Wilkinson, Tom M. A.; Hurst, John R.; Perera, Wayomi R.; Sapsford, Ray J.; Wedzicha, Jadwiga A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1139-1147</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Frequent chronic obstructive pulmonary disease (COPD) exacerbations are a major cause of hospital admission and mortality and are assocd. with increased airway inflammation.  Macrolides have airway antiinflammatory actions and may reduce the incidence of COPD exacerbations.  To det. whether regular therapy with macrolides reduces exacerbation frequency.  We performed a randomized, double-blind, placebo-controlled study of erythromycin administered at 250 mg twice daily to patients with COPD over 12 mo, with primary outcome variable being the no. of moderate and/or severe exacerbations (treated with systemic steroids, treated with antibiotics, or hospitalized).  We randomized 109 outpatients: 69 (63%) males, 52 (48%) current smokers, mean (SD) age 67.2 (8.6) years, FEV1 1.32 (0.53) L, FEV1% predicted 50 (18)%.  Thirty-eight (35%) of the patients had three or more exacerbations in the year before recruitment, with no differences between treatment groups.  There were a total of 206 moderate to severe exacerbations: 125 occurred in the placebo arm.  Ten in the placebo group and nine in the macrolide group withdrew.  Generalized linear modeling showed that the rate ratio for exacerbations for the macrolide-treated patients compared with placebo-treated patients was 0.648 (95% confidence interval: 0.489, 0.859; P = 0.003) and that these patients had shorter duration exacerbations compared with placebo.  There were no differences between the macrolide and placebo arms in terms of stable FEV1, sputum IL-6, IL-8, myeloperoxidase, bacterial flora, serum C-reactive protein, or serum IL-6 or in changes in these parameters from baseline to first exacerbation over the 1-yr study period.  Macrolide therapy was assocd. with a significant redn. in exacerbations compared with placebo and may be useful in decreasing the excessive disease burden in this important patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqrSa10DhQS7Vg90H21EOLACvtfcHk0libqKL-UhY_FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvVenuw%253D%253D&md5=d31d00823f09f2c0039625cf014c84d4</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1164%2Frccm.200801-145OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200801-145OC%26sid%3Dliteratum%253Aachs%26aulast%3DSeemungal%26aufirst%3DT.%2BA.%26aulast%3DWilkinson%26aufirst%3DT.%2BM.%26aulast%3DHurst%26aufirst%3DJ.%2BR.%26aulast%3DPerera%26aufirst%3DW.%2BR.%26aulast%3DSapsford%26aufirst%3DR.%2BJ.%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26atitle%3DLong-term%2520erythromycin%2520therapy%2520is%2520associated%2520with%2520decreased%2520chronic%2520obstructive%2520pulmonary%2520disease%2520exacerbations%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D178%26spage%3D1139%26epage%3D1147%26doi%3D10.1164%2Frccm.200801-145OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belkina, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajczyk, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, G. V.</span></span> <span> </span><span class="NLM_article-title">BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">3670</span>– <span class="NLM_lpage">3678</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4049%2Fjimmunol.1202838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23420887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVynsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2013&pages=3670-3678&author=A.+C.+Belkinaauthor=B.+S.+Nikolajczykauthor=G.+V.+Denis&title=BET+protein+function+is+required+for+inflammation%3A+Brd2+genetic+disruption+and+BET+inhibitor+JQ1+impair+mouse+macrophage+inflammatory+responses&doi=10.4049%2Fjimmunol.1202838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses</span></div><div class="casAuthors">Belkina, Anna C.; Nikolajczyk, Barbara S.; Denis, Gerald V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3670-3678</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Histone acetylation regulates activation and repression of multiple inflammatory genes known to play crit. roles in chronic inflammatory diseases.  However, proteins responsible for translating the histone acetylation code into an orchestrated proinflammatory cytokine response remain poorly characterized.  Bromodomain and extraterminal (BET) proteins are "readers" of histone acetylation marks, with demonstrated roles in gene transcription, but the ability of BET proteins to coordinate the response of inflammatory cytokine genes through translation of histone marks is unknown.  We hypothesize that members of the BET family of dual bromodomain-contg. transcriptional regulators directly control inflammatory genes.  We examd. the genetic model of brd2 lo mice, a BET protein hypomorph, to show that Brd2 is essential for proinflammatory cytokine prodn. in macrophages.  Studies that use small interfering RNA knockdown and a small-mol. inhibitor of BET protein binding, JQ1, independently demonstrate BET proteins are crit. for macrophage inflammatory responses.  Furthermore, we show that Brd2 and Brd4 phys. assoc. with the promoters of inflammatory cytokine genes in macrophages.  This assocn. is absent in the presence of BET inhibition by JQ1.  Finally, we demonstrate that JQ1 ablates cytokine prodn. in vitro and blunts the "cytokine storm" in endotoxemic mice by reducing levels of IL-6 and TNF-α while rescuing mice from LPS-induced death.  We propose that targeting BET proteins with small-mol. inhibitors will benefit hyperinflammatory conditions assocd. with high levels of cytokine prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrbebEe0G277Vg90H21EOLACvtfcHk0libqKL-UhY_FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVynsbk%253D&md5=8c4f69177b9ed814a7db339a8e2ab7ed</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202838%26sid%3Dliteratum%253Aachs%26aulast%3DBelkina%26aufirst%3DA.%2BC.%26aulast%3DNikolajczyk%26aufirst%3DB.%2BS.%26aulast%3DDenis%26aufirst%3DG.%2BV.%26atitle%3DBET%2520protein%2520function%2520is%2520required%2520for%2520inflammation%253A%2520Brd2%2520genetic%2520disruption%2520and%2520BET%2520inhibitor%2520JQ1%2520impair%2520mouse%2520macrophage%2520inflammatory%2520responses%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D190%26spage%3D3670%26epage%3D3678%26doi%3D10.4049%2Fjimmunol.1202838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joberty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diallo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveridge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Molina, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span> <span> </span><span class="NLM_article-title">A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1038/nature11262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnature11262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22842901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=404-408&author=L.+Kruidenierauthor=C.+W.+Chungauthor=Z.+Chengauthor=J.+Liddleauthor=K.+Cheauthor=G.+Jobertyauthor=M.+Bantscheffauthor=C.+Bountraauthor=A.+Bridgesauthor=H.+Dialloauthor=D.+Eberhardauthor=S.+Hutchinsonauthor=E.+Jonesauthor=R.+Katsoauthor=M.+Leveridgeauthor=P.+K.+Manderauthor=J.+Mosleyauthor=C.+Ramirez-Molinaauthor=P.+Rowlandauthor=C.+J.+Schofieldauthor=R.+J.+Sheppardauthor=J.+E.+Smithauthor=C.+Swalesauthor=R.+Tannerauthor=P.+Thomasauthor=A.+Tumberauthor=G.+Drewesauthor=U.+Oppermannauthor=D.+J.+Patelauthor=K.+Leeauthor=D.+M.+Wilson&title=A+selective+jumonji+H3K27+demethylase+inhibitor+modulates+the+proinflammatory+macrophage+response&doi=10.1038%2Fnature11262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response</span></div><div class="casAuthors">Kruidenier, Laurens; Chung, Chun-wa; Cheng, Zhongjun; Liddle, John; Che, Ka Hing; Joberty, Gerard; Bantscheff, Marcus; Bountra, Chas; Bridges, Angela; Diallo, Hawa; Eberhard, Dirk; Hutchinson, Sue; Jones, Emma; Katso, Roy; Leveridge, Melanie; Mander, Palwinder K.; Mosley, Julie; Ramirez-Molina, Cesar; Rowland, Paul; Schofield, Christopher J.; Sheppard, Robert J.; Smith, Julia E.; Swales, Catherine; Tanner, Robert; Thomas, Pamela; Tumber, Anthony; Drewes, Gerard; Oppermann, Udo; Patel, Dinshaw J.; Lee, Kevin; Wilson, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7411</span>),
    <span class="NLM_cas:pages">404-408</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The jumonji (JMJ) family of histone demethylases are Fe2+- and α-ketoglutarate-dependent oxygenases that are essential components of regulatory transcriptional chromatin complexes.  These enzymes demethylate lysine residues in histones in a methylation-state and sequence-specific context.  Considerable effort has been devoted to gaining a mechanistic understanding of the roles of histone lysine demethylases in eukaryotic transcription, genome integrity and epigenetic inheritance, as well as in development, physiol. and disease.  However, because of the absence of any selective inhibitors, the relevance of the demethylase activity of JMJ enzymes in regulating cellular responses remains poorly understood.  Here we present a structure-guided small-mol. and chemoproteomics approach to elucidating the functional role of the H3K27me3-specific demethylase subfamily (KDM6 subfamily members JMJD3 and UTX).  The liganded structures of human and mouse JMJD3 provide novel insight into the specificity determinants for cofactor, substrate and inhibitor recognition by the KDM6 subfamily of demethylases.  We exploited these structural features to generate the first small-mol. catalytic site inhibitor that is selective for the H3K27me3-specific JMJ subfamily.  We demonstrate that this inhibitor binds in a novel manner and reduces lipopolysaccharide-induced proinflammatory cytokine prodn. by human primary macrophages, a process that depends on both JMJD3 and UTX.  Our results resolve the ambiguity assocd. with the catalytic function of H3K27-specific JMJs in regulating disease-relevant inflammatory responses and provide encouragement for designing small-mol. inhibitors to allow selective pharmacol. intervention across the JMJ family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-lxSNmxjfsbVg90H21EOLACvtfcHk0lhpJHTp3mgLTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtbfI&md5=a4fa470a86070b4777e16a71e51763c8</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1038%2Fnature11262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11262%26sid%3Dliteratum%253Aachs%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DLiddle%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DK.%26aulast%3DJoberty%26aufirst%3DG.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBridges%26aufirst%3DA.%26aulast%3DDiallo%26aufirst%3DH.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DHutchinson%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DKatso%26aufirst%3DR.%26aulast%3DLeveridge%26aufirst%3DM.%26aulast%3DMander%26aufirst%3DP.%2BK.%26aulast%3DMosley%26aufirst%3DJ.%26aulast%3DRamirez-Molina%26aufirst%3DC.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSchofield%26aufirst%3DC.%2BJ.%26aulast%3DSheppard%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BE.%26aulast%3DSwales%26aufirst%3DC.%26aulast%3DTanner%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DP.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DOppermann%26aufirst%3DU.%26aulast%3DPatel%26aufirst%3DD.%2BJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DA%2520selective%2520jumonji%2520H3K27%2520demethylase%2520inhibitor%2520modulates%2520the%2520proinflammatory%2520macrophage%2520response%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D404%26epage%3D408%26doi%3D10.1038%2Fnature11262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lock-Johansson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, G. L.</span></span> <span> </span><span class="NLM_article-title">Surfactant protein D, club cell protein 16, pulmonary and activation-regulated chemokine, C-reactive protein, and fibrinogen biomarker variation in chronic obstructive lung disease</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">147</span>, <span class="refDoi"> DOI: 10.1186/s12931-014-0147-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2Fs12931-014-0147-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25425298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2MzgvVShtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=147&author=S.+Lock-Johanssonauthor=J.+Vestboauthor=G.+L.+Sorensen&title=Surfactant+protein+D%2C+club+cell+protein+16%2C+pulmonary+and+activation-regulated+chemokine%2C+C-reactive+protein%2C+and+fibrinogen+biomarker+variation+in+chronic+obstructive+lung+disease&doi=10.1186%2Fs12931-014-0147-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease</span></div><div class="casAuthors">Lock-Johansson Sofie; Sorensen Grith Lykke; Vestbo Jorgen; Vestbo Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a multifaceted condition that cannot be fully described by the severity of airway obstruction.  The limitations of spirometry and clinical history have prompted researchers to investigate a multitude of surrogate biomarkers of disease for the assessment of patients, prediction of risk, and guidance of treatment.  The aim of this review is to provide a comprehensive summary of observations for a selection of recently investigated pulmonary inflammatory biomarkers (Surfactant protein D (SP-D), Club cell protein 16 (CC-16), and Pulmonary and activation-regulated chemokine (PARC/CCL-18)) and systemic inflammatory biomarkers (C-reactive protein (CRP) and fibrinogen) with COPD.  The relevance of these biomarkers for COPD is discussed in terms of their biological plausibility, their independent association to disease and hard clinical outcomes, their modification by interventions, and whether changes in clinical outcomes are reflected by changes in the biomarker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRakau9BP_N15NiNltV31zlfW6udTcc2eacnLhF42nKKLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzgvVShtA%253D%253D&md5=e3fa237cd9d20cea61ef2b04cc6c7e5a</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1186%2Fs12931-014-0147-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-014-0147-5%26sid%3Dliteratum%253Aachs%26aulast%3DLock-Johansson%26aufirst%3DS.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DSorensen%26aufirst%3DG.%2BL.%26atitle%3DSurfactant%2520protein%2520D%252C%2520club%2520cell%2520protein%252016%252C%2520pulmonary%2520and%2520activation-regulated%2520chemokine%252C%2520C-reactive%2520protein%252C%2520and%2520fibrinogen%2520biomarker%2520variation%2520in%2520chronic%2520obstructive%2520lung%2520disease%26jtitle%3DRespir.%2520Res.%26date%3D2014%26volume%3D15%26spage%3D147%26doi%3D10.1186%2Fs12931-014-0147-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ke-Xin Huang, Ming-Sheng Xie, Ji-Wei Sang, Gui-Rong Qu, <span class="NLM_string-name hlFld-ContribAuthor">Hai-Ming Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Synthesis of 3-Amine-tetrahydrothiophenes with a Quaternary Stereocenter via Nickel(II)/Trisoxazoline-Catalyzed Sulfa-Michael/Aldol Cascade Reaction: Divergent Access to Chiral Thionucleosides. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2021,</strong> <em>23 </em>
                                    (1)
                                     , 81-86. <a href="https://doi.org/10.1021/acs.orglett.0c03747" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03747</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03747%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DAsymmetric%252BSynthesis%252Bof%252B3-Amine-tetrahydrothiophenes%252Bwith%252Ba%252BQuaternary%252BStereocenter%252Bvia%252BNickel%252528II%252529%25252FTrisoxazoline-Catalyzed%252BSulfa-Michael%25252FAldol%252BCascade%252BReaction%25253A%252BDivergent%252BAccess%252Bto%252BChiral%252BThionucleosides%26aulast%3DHuang%26aufirst%3DKe-Xin%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D10112020%26date%3D17122020%26volume%3D23%26issue%3D1%26spage%3D81%26epage%3D86" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feng Li, Xiaofei Liang, Zongru Jiang, Aoli Wang, Junjie Wang, Cheng Chen, Wenliang Wang, Fengming Zou, Ziping Qi, Qingwang Liu, Zhenquan Hu, Jiangyan Cao, Hong Wu, Beilei Wang, Li Wang, Jing Liu, <span class="NLM_string-name hlFld-ContribAuthor">Qingsong Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (S)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13973-13993. <a href="https://doi.org/10.1021/acs.jmedchem.0c01544" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01544</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01544&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01544%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528S%252529-2-%2525281-%2525284-Amino-3-%2525283-fluoro-4-methoxyphenyl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-1-yl%252529propyl%252529-3-cyclopropyl-5-fluoroquinazolin-4%2525283H%252529-one%252B%252528IHMT-PI3K%2525CE%2525B4-372%252529%252Bas%252Ba%252BPotent%252Band%252BSelective%252BPI3K%2525CE%2525B4%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DLi%26aufirst%3DFeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03092020%26date%3D12112020%26volume%3D63%26issue%3D22%26spage%3D13973%26epage%3D13993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xianwen  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Zhong</span>, <span class="hlFld-ContribAuthor ">Jianxiang  Li</span>, <span class="hlFld-ContribAuthor ">Zhuang  Liu</span>, <span class="hlFld-ContribAuthor ">Liang  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Inorganic nanomaterials with rapid clearance for biomedical applications. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2021,</strong> <em>50 </em>
                                    (15)
                                     , 8669-8742. <a href="https://doi.org/10.1039/D0CS00461H" title="DOI URL">https://doi.org/10.1039/D0CS00461H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0CS00461H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0CS00461H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DInorganic%252Bnanomaterials%252Bwith%252Brapid%252Bclearance%252Bfor%252Bbiomedical%252Bapplications%26aulast%3DWang%26aufirst%3DXianwen%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D15%26spage%3D8669%26epage%3D8742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luciana Pádua  Tavares</span>, <span class="hlFld-ContribAuthor ">Izabela  Galvão</span>, <span class="hlFld-ContribAuthor ">Maximiliano R  Ferrero</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Immunomodulatory Therapies for Respiratory Pathologies. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00073-6" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00073-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00073-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00073-6%26sid%3Dliteratum%253Aachs%26atitle%3DNovel%252BImmunomodulatory%252BTherapies%252Bfor%252BRespiratory%252BPathologies%26aulast%3DTavares%26aufirst%3DLuciana%2BP%25C3%25A1dua%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nabijan  Mohammadtursun</span>, <span class="hlFld-ContribAuthor ">Qiuping  Li</span>, <span class="hlFld-ContribAuthor ">Muhammadjan  Abuduwaki</span>, <span class="hlFld-ContribAuthor ">Shan  Jiang</span>, <span class="hlFld-ContribAuthor ">Hu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jing  Sun</span>, <span class="hlFld-ContribAuthor ">Jingcheng  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Loki zupa alleviates inflammatory and fibrotic responses in cigarette smoke induced rat model of chronic obstructive pulmonary disease. </span><span class="cited-content_cbyCitation_journal-name">Chinese Medicine</span><span> <strong>2020,</strong> <em>15 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13020-020-00373-3" title="DOI URL">https://doi.org/10.1186/s13020-020-00373-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13020-020-00373-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13020-020-00373-3%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Medicine%26atitle%3DLoki%252Bzupa%252Balleviates%252Binflammatory%252Band%252Bfibrotic%252Bresponses%252Bin%252Bcigarette%252Bsmoke%252Binduced%252Brat%252Bmodel%252Bof%252Bchronic%252Bobstructive%252Bpulmonary%252Bdisease%26aulast%3DMohammadtursun%26aufirst%3DNabijan%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramachandran  Vidhya</span>, <span class="hlFld-ContribAuthor ">Velmurugan Ilavarasi  Anbumani</span>, <span class="hlFld-ContribAuthor ">Ampasala  Dinakara Rao</span>, <span class="hlFld-ContribAuthor ">Carani Venkatraman  Anuradha</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel human neutrophil elastase inhibitors from dietary phytochemicals using
              in silico
              and
              in vitro
              studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2020,</strong> <em>10 </em>, 1-11. <a href="https://doi.org/10.1080/07391102.2020.1847685" title="DOI URL">https://doi.org/10.1080/07391102.2020.1847685</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1847685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1847685%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIdentification%252Bof%252Bnovel%252Bhuman%252Bneutrophil%252Belastase%252Binhibitors%252Bfrom%252Bdietary%252Bphytochemicals%252Busing%252Bin%252Bsilico%252Band%252Bin%252Bvitro%252Bstudies%26aulast%3DVidhya%26aufirst%3DRamachandran%26date%3D2020%26date%3D2020%26volume%3D10%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhibin  Li</span>, <span class="hlFld-ContribAuthor ">Guanghong  Luo</span>, <span class="hlFld-ContribAuthor ">Wei‐Ping  Hu</span>, <span class="hlFld-ContribAuthor ">Jian‐Lan  Hua</span>, <span class="hlFld-ContribAuthor ">Shengyong  Geng</span>, <span class="hlFld-ContribAuthor ">Paul K.  Chu</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Huaiyu  Wang</span>, <span class="hlFld-ContribAuthor ">Xue‐Feng  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Mediated Drug Release from Nanovehicles by Black Phosphorus Quantum Dots for Efficient Therapy of Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2020,</strong> <em>132 </em>
                                    (46)
                                     , 20749-20757. <a href="https://doi.org/10.1002/ange.202008379" title="DOI URL">https://doi.org/10.1002/ange.202008379</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202008379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202008379%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DMediated%252BDrug%252BRelease%252Bfrom%252BNanovehicles%252Bby%252BBlack%252BPhosphorus%252BQuantum%252BDots%252Bfor%252BEfficient%252BTherapy%252Bof%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DLi%26aufirst%3DZhibin%26date%3D2020%26date%3D2020%26volume%3D132%26issue%3D46%26spage%3D20749%26epage%3D20757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhibin  Li</span>, <span class="hlFld-ContribAuthor ">Guanghong  Luo</span>, <span class="hlFld-ContribAuthor ">Wei‐Ping  Hu</span>, <span class="hlFld-ContribAuthor ">Jian‐Lan  Hua</span>, <span class="hlFld-ContribAuthor ">Shengyong  Geng</span>, <span class="hlFld-ContribAuthor ">Paul K.  Chu</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Huaiyu  Wang</span>, <span class="hlFld-ContribAuthor ">Xue‐Feng  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Mediated Drug Release from Nanovehicles by Black Phosphorus Quantum Dots for Efficient Therapy of Chronic Obstructive Pulmonary Disease. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2020,</strong> <em>59 </em>
                                    (46)
                                     , 20568-20576. <a href="https://doi.org/10.1002/anie.202008379" title="DOI URL">https://doi.org/10.1002/anie.202008379</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202008379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202008379%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DMediated%252BDrug%252BRelease%252Bfrom%252BNanovehicles%252Bby%252BBlack%252BPhosphorus%252BQuantum%252BDots%252Bfor%252BEfficient%252BTherapy%252Bof%252BChronic%252BObstructive%252BPulmonary%252BDisease%26aulast%3DLi%26aufirst%3DZhibin%26date%3D2020%26date%3D2020%26volume%3D59%26issue%3D46%26spage%3D20568%26epage%3D20576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0026.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Relationships between airflow limitation, chronic bronchitis, emphysema, asthma, and COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0027.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Risk factors for COPD during different stages of life.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0028.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inflammatory pathways and potential molecular targets for COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0029.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mode of action of bronchodilators in COPD. ACh, acetylcholine; mAChRs, muscarinic acetylcholine receptors; SAMA, short-acting muscarinic antagonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β<sub>2</sub>-adrenoreceptor agonist; LABA, long-acting β<sub>2</sub>-adrenoreceptor agonist.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Chemical Structures of Some LAMAs and LABAs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Chart 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 2. Chemical Structures of Some MABAs</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0030.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Primary inflammatory pathways of nontype 2 immunities in airway diseases. CXCL, CXC-chemokine ligand; CXCR, CXC-chemokine receptor.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Chart 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 3. Chemical Structures of Representative Chemokine Receptor Antagonists</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0031.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Priming and activation of the NLRP3 inflammasome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht4" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Chart 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 4. Chemical Structures of Selected NLRP3 Inflammasome Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0032.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Imbalance between proteases and antiproteases in COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Chart 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 5. Chemical Structures of HNE Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht6" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Chart 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 6. Chemical Structures of the Nonselective MMP Inhibitors Marimastat and AZD1236</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0033.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Rational design of MMP-12 inhibitors. (A) Structural features of specific MMP-12 inhibitors. (B) Active site of MMP-12 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JK3">1JK3</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht7" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Chart 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 7. Chemical Structures of Selected MMP-12 Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht8" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Chart 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 8. Chemical Structures of Reported PR3 Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0034.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Oxidative stress in COPD and potential therapeutic targets for antioxidants. Nrf2, nuclear factor erythroid 2-derived factor 2; NOX, NADPH oxidase; MPO, myeloperoxidase; SOD, superoxide dismutase; iNOS, inducible nitric oxide synthase; NO, nitric oxide.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht9" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Chart 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 9. Chemical Structures of NAC, Erdosteine, and Carbocisteine</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht10" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Chart 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 10. Chemical Structures of Some Known Nrf2 Activators</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht11" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Chart 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 11. Chemical Structures of VAS2870, GKT136901, and Compound <b>16</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht12" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Chart 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 12. Chemical Structures of Some MPO Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht13" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Chart 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 13. Chemical Structures of AEOL 10113, Tempol, NXY-059, L-NIL, and Compound <b>21</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht14" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Chart 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 14. Chemical Structures of Some IKKβ Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht15" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Chart 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 15. Chemical Structures of Talmapimod, SB-239063, and Compound <b>22</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0035.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. 2D model of the interactions between selected p38 inhibitors and p38α kinase. (A) Representative compound of the teardrop binders (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1A9U">1A9U</a>). (B) Representative compound of the linear binders (PDB entry). (C) Representative compound of the extended binders (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht16" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Chart 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 16. Chemical Structures of Some Reported PI3K Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht17" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Chart 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 17. Chemical Structures of pan-JAK Inhibitor PF1367550 and EGFR Inhibitor AG-1478</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0036.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Synthesis and degradation of cAMP. cAMP is synthesized from ATP by adenylate cyclase (AC) and hydrolyzed by cAMP-specific PDEs such as PDE4 to produce 5′AMP. ATP, adenosine triphosphate; M<sup>2+</sup>, divalent metal ion; 5′AMP, adenosine 5′-monophosphate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0037.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Roles of PDE4 inhibitors and cAMP in COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0038.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Four groups of PDE4 isoforms and subtypes. UCR, upstream conserved region; LR, linker region.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht18" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Chart 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 18. Chemical Structures of Selected Oral PDE4 Inhibitors</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht19" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Chart 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 19. Chemical Structures of the PDE4 Allosteric Modulators Rolipram, RS25344, and D159404</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0039.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. (A) The interaction of the UCR2 helix (blue) and active site (cyan) of PDE4D. (B) The “closed” conformation was locked in by D159404. (C) Design of PDE4 allosteric modulators.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0040.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0040.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Overlay of CHF6001 (in magenta) with the crystal structure of the catalytic domain of human PDE4B in complex with roflumilast (in yellow; PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU">1XMU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0040.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0041.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0041.jpeg" id="rightTab-gr40" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) Design of compounds <b>24</b> and <b>25</b>. (B) Design of compound <b>26</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0041.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht20" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Chart 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 20. Chemical Structure of RPL554</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0042.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0042.jpeg" id="rightTab-gr41" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Role of adenosine and its modulators in COPD.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0042.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht21" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Chart 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 21. Chemical Structures of UK-432,097, L-97-1, and GW-328267X</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht22" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Chart 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0023.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 22. Chemical Structures of Theophylline and Doxofylline</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht23" data-index="40" class="article__inlineFigure"><h2 class="fig-label">Chart 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0024.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 23. Chemical Structures of Ramatroban, AZD-1981, AM-211, and AM-461</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht24" data-index="41" class="article__inlineFigure"><h2 class="fig-label">Chart 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/medium/jm-2018-01520k_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0025.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 24. Chemical Structures of GS-5759 and CBS-3595</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.8b01520/20190705/images/large/jm-2018-01520k_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01520&amp;id=cht24"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i93">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80764" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80764" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 226 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burney, P. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celli, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedzicha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wouters, E. F. M.</span></span> <span> </span><span class="NLM_article-title">Chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Primers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15076</span>, <span class="refDoi"> DOI: 10.1038/nrdp.2015.76</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrdp.2015.76" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=27189863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1eisA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15076&author=P.+J.+Barnesauthor=P.+G.+J.+Burneyauthor=E.+K.+Silvermanauthor=B.+R.+Celliauthor=J.+Vestboauthor=J.+A.+Wedzichaauthor=E.+F.+M.+Wouters&title=Chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnrdp.2015.76"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes Peter J; Wedzicha Jadwiga A; Burney Peter G J; Silverman Edwin K; Celli Bartolome R; Vestbo Jorgen; Wouters Emiel F M</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Disease primers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15076</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a common disease with high global morbidity and mortality.  COPD is characterized by poorly reversible airway obstruction, which is confirmed by spirometry, and includes obstruction of the small airways (chronic obstructive bronchiolitis) and emphysema, which lead to air trapping and shortness of breath in response to physical exertion.  The most common risk factor for the development of COPD is cigarette smoking, but other environmental factors, such as exposure to indoor air pollutants - especially in developing countries - might influence COPD risk.  Not all smokers develop COPD and the reasons for disease susceptibility in these individuals have not been fully elucidated.  Although the mechanisms underlying COPD remain poorly understood, the disease is associated with chronic inflammation that is usually corticosteroid resistant.  In addition, COPD involves accelerated ageing of the lungs and an abnormal repair mechanism that might be driven by oxidative stress.  Acute exacerbations, which are mainly triggered by viral or bacterial infections, are important as they are linked to a poor prognosis.  The mainstay of the management of stable disease is the use of inhaled long-acting bronchodilators, whereas corticosteroids are beneficial primarily in patients who have coexisting features of asthma, such as eosinophilic inflammation and more reversibility of airway obstruction.  Apart from smoking cessation, no treatments reduce disease progression.  More research is needed to better understand disease mechanisms and to develop new treatments that reduce disease activity and progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcrna7Vp9c5EewzGPswiWOfW6udTcc2eZHn9LD7NhGELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252Fgs1eisA%253D%253D&md5=278360c87e28cdb595b55776f4ce6554</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrdp.2015.76&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrdp.2015.76%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DBurney%26aufirst%3DP.%2BG.%2BJ.%26aulast%3DSilverman%26aufirst%3DE.%2BK.%26aulast%3DCelli%26aufirst%3DB.%2BR.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DWouters%26aufirst%3DE.%2BF.%2BM.%26atitle%3DChronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Primers%26date%3D2015%26volume%3D1%26spage%3D15076%26doi%3D10.1038%2Fnrdp.2015.76" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P.</span></span> <span> </span><span class="NLM_article-title">Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">753</span>– <span class="NLM_lpage">760</span>, <span class="refDoi"> DOI: 10.1164/rccm.200612-1749OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200612-1749OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17575095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srptFCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2007&pages=753-760&author=N.+Zhongauthor=C.+Wangauthor=W.+Yaoauthor=P.+Chenauthor=J.+Kangauthor=S.+Huangauthor=B.+Chenauthor=C.+Wangauthor=D.+Niauthor=Y.+Zhouauthor=S.+Liuauthor=X.+Wangauthor=D.+Wangauthor=J.+Luauthor=J.+Zhengauthor=P.+Ran&title=Prevalence+of+chronic+obstructive+pulmonary+disease+in+China%3A+a+large%2C+population-based+survey&doi=10.1164%2Frccm.200612-1749OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey</span></div><div class="casAuthors">Zhong Nanshan; Wang Chen; Yao Wanzhen; Chen Ping; Kang Jian; Huang Shaoguang; Chen Baoyuan; Wang Changzheng; Ni Diantao; Zhou Yumin; Liu Shengming; Wang Xiaoping; Wang Dali; Lu Jiachun; Zheng Jingping; Ran Pixin</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">753-60</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">RATIONALE:  The prevalence of chronic obstructive pulmonary disease (COPD) in China is largely unknown.  OBJECTIVES:  To obtain the COPD prevalence in China through a large-population, spirometry-based, cross-sectional survey of COPD.  METHODS:  Urban and rural population-based cluster samples were randomly selected from seven provinces/cities.  All residents 40 years of age or older in the selected clusters were interviewed with a standardized questionnaire revised from the international BOLD (Burden of Obstructive Lung Diseases) study.  Spirometry was performed on all eligible participants.  Patients with airflow limitation (FEV(1)/FVC < 0.70) were further examined by post-bronchodilator spirometry, chest radiograph, and electrocardiogram.  Post-bronchodilator FEV(1)/FVC of less than 70% was defined as the diagnostic criterion of COPD.  MEASUREMENTS AND MAIN RESULTS:  Among 25,627 sampling subjects, 20,245 participants completed the questionnaire and spirometry (response rate, 79.0%).  The overall prevalence of COPD was 8.2% (men, 12.4%; women, 5.1%).  The prevalence of COPD was significantly higher in rural residents, elderly patients, smokers, in those with lower body mass index, less education, and poor ventilation in the kitchen, in those who were exposed to occupational dusts or biomass fuels, and in those with pulmonary problems in childhood and family history of pulmonary diseases.  Among the patients who had COPD, 35.3% were asymptomatic; only 35.1% reported lifetime diagnosis of bronchitis, emphysema, or other COPD; and only 6.5% have been tested with spirometry.  CONCLUSIONS:  COPD is prevalent in individuals 40 years of age or older in China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTroqdm9wT0W90Q2ypr7jHkfW6udTcc2eY37Z-TGXVmV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srptFCgsA%253D%253D&md5=121c7caef419af320f3d5cc1649f82be</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1164%2Frccm.200612-1749OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200612-1749OC%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DNi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DRan%26aufirst%3DP.%26atitle%3DPrevalence%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520China%253A%2520a%2520large%252C%2520population-based%2520survey%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2007%26volume%3D176%26spage%3D753%26epage%3D760%26doi%3D10.1164%2Frccm.200612-1749OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buist, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBurnie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmer, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burney, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mannino, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulsvik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizankowska-Mogilnicka, E.</span></span>; <span class="NLM_contrib-group">BOLD Collaborative Research Group</span> <span> </span><span class="NLM_article-title">International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(07)61377-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2807%2961377-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17765523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srhs1Sisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=741-750&author=A.+S.+Buistauthor=M.+A.+McBurnieauthor=W.+M.+Vollmerauthor=S.+Gillespieauthor=P.+Burneyauthor=D.+M.+Manninoauthor=A.+M.+Menezesauthor=S.+D.+Sullivanauthor=T.+A.+Leeauthor=K.+B.+Weissauthor=R.+L.+Jensenauthor=G.+B.+Marksauthor=A.+Gulsvikauthor=E.+Nizankowska-Mogilnickaauthor=BOLD+Collaborative+Research+Group&title=International+variation+in+the+prevalence+of+COPD+%28the+BOLD+Study%29%3A+a+population-based+prevalence+study&doi=10.1016%2FS0140-6736%2807%2961377-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study</span></div><div class="casAuthors">Buist A Sonia; McBurnie Mary Ann; Vollmer William M; Gillespie Suzanne; Burney Peter; Mannino David M; Menezes Ana M B; Sullivan Sean D; Lee Todd A; Weiss Kevin B; Jensen Robert L; Marks Guy B; Gulsvik Amund; Nizankowska-Mogilnicka Ewa</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">9589</span>),
    <span class="NLM_cas:pages">741-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) is a growing cause of morbidity and mortality worldwide, and accurate estimates of the prevalence of this disease are needed to anticipate the future burden of COPD, target key risk factors, and plan for providing COPD-related health services.  We aimed to measure the prevalence of COPD and its risk factors and investigate variation across countries by age, sex, and smoking status.  METHODS:  Participants from 12 sites (n=9425) completed postbronchodilator spirometry testing plus questionnaires about respiratory symptoms, health status, and exposure to COPD risk factors.  COPD prevalence estimates based on the Global Initiative for Chronic Obstructive Lung Disease staging criteria were adjusted for the target population.  Logistic regression was used to estimate adjusted odds ratios (ORs) for COPD associated with 10-year age increments and 10-pack-year (defined as the number of cigarettes smoked per day divided by 20 and multiplied by the number of years that the participant smoked) increments.  Meta-analyses provided pooled estimates for these risk factors.  FINDINGS:  The prevalence of stage II or higher COPD was 10.1% (SE 4.8) overall, 11.8% (7.9) for men, and 8.5% (5.8) for women.  The ORs for 10-year age increments were much the same across sites and for women and men.  The overall pooled estimate was 1.94 (95% CI 1.80-2.10) per 10-year increment.  Site-specific pack-year ORs varied significantly in women (pooled OR=1.28, 95% CI 1.15-1.42, p=0.012), but not in men (1.16, 1.12-1.21, p=0.743).  INTERPRETATION:  This worldwide study showed higher levels and more advanced staging of spirometrically confirmed COPD than have typically been reported.  However, although age and smoking are strong contributors to COPD, they do not fully explain variations in disease prevalence-other factors also seem to be important.  Although smoking cessation is becoming an increasingly urgent objective for an ageing worldwide population, a better understanding of other factors that contribute to COPD is crucial to assist local public-health officials in developing the best possible primary and secondary prevention policies for their regions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTAJAVB43A0lUIs6wFK5xJfW6udTcc2eY37Z-TGXVmV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srhs1Sisg%253D%253D&md5=5f6b58f94a5407c1bd75f5ac62245ac6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2807%2961377-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252807%252961377-4%26sid%3Dliteratum%253Aachs%26aulast%3DBuist%26aufirst%3DA.%2BS.%26aulast%3DMcBurnie%26aufirst%3DM.%2BA.%26aulast%3DVollmer%26aufirst%3DW.%2BM.%26aulast%3DGillespie%26aufirst%3DS.%26aulast%3DBurney%26aufirst%3DP.%26aulast%3DMannino%26aufirst%3DD.%2BM.%26aulast%3DMenezes%26aufirst%3DA.%2BM.%26aulast%3DSullivan%26aufirst%3DS.%2BD.%26aulast%3DLee%26aufirst%3DT.%2BA.%26aulast%3DWeiss%26aufirst%3DK.%2BB.%26aulast%3DJensen%26aufirst%3DR.%2BL.%26aulast%3DMarks%26aufirst%3DG.%2BB.%26aulast%3DGulsvik%26aufirst%3DA.%26aulast%3DNizankowska-Mogilnicka%26aufirst%3DE.%26aulast%3D%26atitle%3DInternational%2520variation%2520in%2520the%2520prevalence%2520of%2520COPD%2520%2528the%2520BOLD%2520Study%2529%253A%2520a%2520population-based%2520prevalence%2520study%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D741%26epage%3D750%26doi%3D10.1016%2FS0140-6736%2807%2961377-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agustí, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzueto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Roisin, R.</span></span> <span> </span><span class="NLM_article-title">Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">347</span>– <span class="NLM_lpage">365</span>, <span class="refDoi"> DOI: 10.1164/rccm.201204-0596PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.201204-0596PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22878278" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktVGhs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2013&pages=347-365&author=J.+Vestboauthor=S.+S.+Hurdauthor=A.+G.+Agust%C3%ADauthor=P.+W.+Jonesauthor=C.+Vogelmeierauthor=A.+Anzuetoauthor=P.+J.+Barnesauthor=L.+M.+Fabbriauthor=F.+J.+Martinezauthor=M.+Nishimuraauthor=R.+A.+Stockleyauthor=D.+D.+Sinauthor=R.+Rodriguez-Roisin&title=Global+strategy+for+the+diagnosis%2C+management+and+prevention+of+chronic+obstructive+pulmonary+disease%2C+GOLD+executive+summary&doi=10.1164%2Frccm.201204-0596PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</span></div><div class="casAuthors">Vestbo, Jorgen; Hurd, Suzanne S.; Agusti, Alvar G.; Jones, Paul W.; Vogelmeier, Claus; Anzueto, Antonio; Barnes, Peter J.; Fabbri, Leonardo M.; Martinez, Fernando J.; Nishimura, Masaharu; Stockley, Robert A.; Sin, Don D.; Rodriguez-Roisin, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">347-365</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a global health problem, and since 2001, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published its strategy document for the diagnosis and management of COPD.  This executive summary presents the main contents of the second 5-yr revision of the GOLD document that has implemented some of the vast knowledge about COPD accumulated over the last years.  Today, GOLD recommends that spirometry is required for the clin. diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.  The document highlights that the assessment of the patient with COPD should always include assessment of (1) symptoms, (2) severity of airflow limitation, (3) history of exacerbations, and (4) comorbidities.  The first three points can be used to evaluate level of symptoms and risk of future exacerbations, and this is done in a way that splits patients with COPD into four categories-A, B, C, and D.  Nonpharmacol. and pharmacol. management of COPD match this assessment in an evidence-based attempt to relieve symptoms and reduce risk of exacerbations.  Identification and treatment of comorbidities must have high priority, and a sep. section in the document addresses management of comorbidities as well as COPD in the presence of comorbidities.  The revised document also contains a new section on exacerbations of COPD.  The GOLD initiative will continue to bring COPD to the attention of all relevant shareholders and will hopefully inspire future national and local guidelines on the management of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXROvO3tH2OLVg90H21EOLACvtfcHk0ljtduszkxdsSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktVGhs7Y%253D&md5=c2b519b14e69420564a575d40a449e5d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1164%2Frccm.201204-0596PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201204-0596PP%26sid%3Dliteratum%253Aachs%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DHurd%26aufirst%3DS.%2BS.%26aulast%3DAgust%25C3%25AD%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DP.%2BW.%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DAnzueto%26aufirst%3DA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DNishimura%26aufirst%3DM.%26aulast%3DStockley%26aufirst%3DR.%2BA.%26aulast%3DSin%26aufirst%3DD.%2BD.%26aulast%3DRodriguez-Roisin%26aufirst%3DR.%26atitle%3DGlobal%2520strategy%2520for%2520the%2520diagnosis%252C%2520management%2520and%2520prevention%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%252C%2520GOLD%2520executive%2520summary%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2013%26volume%3D187%26spage%3D347%26epage%3D365%26doi%3D10.1164%2Frccm.201204-0596PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Chronic obstructive pulmonary disease: a growing but neglected epidemic</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e112</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0040112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1371%2Fjournal.pmed.0040112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17503959" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2007&pages=e112&author=P.+J.+Barnes&title=Chronic+obstructive+pulmonary+disease%3A+a+growing+but+neglected+epidemic&doi=10.1371%2Fjournal.pmed.0040112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0040112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0040112%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DChronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520growing%2520but%2520neglected%2520epidemic%26jtitle%3DPLoS%2520Med.%26date%3D2007%26volume%3D4%26spage%3De112%26doi%3D10.1371%2Fjournal.pmed.0040112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span> <i>Chronic Obstructive Pulmonary Disease (COPD)</i>; <span class="NLM_publisher-name">Centers for Disease Control and Prevention</span>: <span class="NLM_publisher-loc">Atlanta</span>, <span class="NLM_year">2018</span>; <a href="https://www.cdc.gov/copd/index.html" class="extLink">https://www.cdc.gov/copd/index.html</a> (accessed Aug. 4, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chronic+Obstructive+Pulmonary+Disease+%28COPD%29%3B+Centers+for+Disease+Control+and+Prevention%3A+Atlanta%2C+2018%3B+https%3A%2F%2Fwww.cdc.gov%2Fcopd%2Findex.html+%28accessed+Aug.+4%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DChronic%2520Obstructive%2520Pulmonary%2520Disease%2520%2528COPD%2529%26pub%3DCenters%2520for%2520Disease%2520Control%2520and%2520Prevention%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">GBD
2015 Chronic Respiratory Disease Collaborators</span> <span> </span><span class="NLM_article-title">Global, regional, and national deaths,
prevalence, disability-adjusted life years, and years lived with disability
for chronic obstructive pulmonary disease and asthma, 1990–2015:
a systematic analysis for the global burden of disease study 2015. <i>Lancet</i></span>. <i>Respir Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">691</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(17)30293-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS2213-2600%2817%2930293-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=691-706&author=GBD%0A2015+Chronic+Respiratory+Disease+Collaborators&title=Global%2C+regional%2C+and+national+deaths%2C%0Aprevalence%2C+disability-adjusted+life+years%2C+and+years+lived+with+disability%0Afor+chronic+obstructive+pulmonary+disease+and+asthma%2C+1990%E2%80%932015%3A%0Aa+systematic+analysis+for+the+global+burden+of+disease+study+2015.+Lancet&doi=10.1016%2FS2213-2600%2817%2930293-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2817%2930293-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252817%252930293-X%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DGlobal%252C%2520regional%252C%2520and%2520national%2520deaths%252C%250Aprevalence%252C%2520disability-adjusted%2520life%2520years%252C%2520and%2520years%2520lived%2520with%2520disability%250Afor%2520chronic%2520obstructive%2520pulmonary%2520disease%2520and%2520asthma%252C%25201990%25E2%2580%25932015%253A%250Aa%2520systematic%2520analysis%2520for%2520the%2520global%2520burden%2520of%2520disease%2520study%25202015.%2520Lancet%26jtitle%3DRespir%2520Med.%26date%3D2017%26volume%3D5%26spage%3D691%26epage%3D706%26doi%3D10.1016%2FS2213-2600%2817%2930293-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teo, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abisheganaden, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, B. H.</span></span> <span> </span><span class="NLM_article-title">Economic burden of chronic obstructive pulmonary disease</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1111/j.1440-1843.2011.02073.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1440-1843.2011.02073.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21954985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FptVOqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=120-126&author=W.+S.+Teoauthor=W.+S.+Tanauthor=W.+F.+Chongauthor=J.+Abisheganadenauthor=Y.+J.+Lewauthor=T.+K.+Limauthor=B.+H.+Heng&title=Economic+burden+of+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1440-1843.2011.02073.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Economic burden of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Teo W-S Kelvin; Tan Woan-Shin; Chong Wai-Fung; Abisheganaden John; Lew Yii-Jen; Lim Tow-Keang; Heng Bee-Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND OBJECTIVE:  The aim of this study was to estimate the direct medical costs of COPD in two public health clusters in Singapore from 2005 to 2009.  METHODS:  Patients aged 40 years and over, who had been diagnosed with COPD, were identified in a Chronic Disease Management Data-mart.  Annual utilization of health services in inpatient, specialist outpatient, emergency department and primary care settings was extracted from the Chronic Disease Management Data-mart.  Trends in attributable costs, proportions of costs and health-care utilization were analyzed across each level of care.  A weighted attribution approach was used to allocate costs to each health-care utilization episode, depending on the relevance of co-morbidities.  RESULTS:  The mean total cost was approximately $9.9 million per year.  Inpatient admissions were the major cost driver, contributing an average of $7.2 million per year.  The proportion of hospitalization costs declined from 75% in 2005 to 68% in 2009.  Based on the 5-year average, attendances at primary care clinics, emergency department and specialist clinics contributed 3%, 5% and 17%, respectively, of overall COPD costs.  On average, 42% of the total cost burden was incurred for the medical management of COPD.  The share of cost incurred for the treatment of conditions related and unrelated to COPD were 29% and 26%, respectively, of the total average costs.  CONCLUSIONS:  COPD is likely to represent a significant burden to the public health system in most countries.  The findings are particularly relevant to understanding the allocation of health-care resources and informing appropriate cost containment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROsHOCQUWjJSCEBeYuoi7AfW6udTcc2eb4xVi8HE3PSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FptVOqtQ%253D%253D&md5=9366bb24664acaa1af55a3ce9167fe63</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fj.1440-1843.2011.02073.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1440-1843.2011.02073.x%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DW.%2BS.%26aulast%3DTan%26aufirst%3DW.%2BS.%26aulast%3DChong%26aufirst%3DW.%2BF.%26aulast%3DAbisheganaden%26aufirst%3DJ.%26aulast%3DLew%26aufirst%3DY.%2BJ.%26aulast%3DLim%26aufirst%3DT.%2BK.%26aulast%3DHeng%26aufirst%3DB.%2BH.%26atitle%3DEconomic%2520burden%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespirology%26date%3D2012%26volume%3D17%26spage%3D120%26epage%3D126%26doi%3D10.1111%2Fj.1440-1843.2011.02073.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burney, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naghavi, M.</span></span> <span> </span><span class="NLM_article-title">Global and regional trends in COPD mortality, 1990–2010</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">1239</span>– <span class="NLM_lpage">1247</span>, <span class="refDoi"> DOI: 10.1183/09031936.00142414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1183%2F09031936.00142414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25837037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2MjgsFCmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=1239-1247&author=P.+G.+Burneyauthor=J.+Patelauthor=R.+Newsonauthor=C.+Minelliauthor=M.+Naghavi&title=Global+and+regional+trends+in+COPD+mortality%2C+1990%E2%80%932010&doi=10.1183%2F09031936.00142414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Global and regional trends in COPD mortality, 1990-2010</span></div><div class="casAuthors">Burney Peter G J; Patel Jaymini; Newson Roger; Minelli Cosetta; Naghavi Mohsen</div><div class="citationInfo"><span class="NLM_cas:title">The European respiratory journal</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1239-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Between 1990 and 2010, chronic obstructive pulmonary disease (COPD) moved from the fourth to third most common cause of death worldwide.  Using data from the Global Burden of Disease programme we quantified regional changes in the number of COPD deaths and COPD mortality rates between 1990 and 2010.  We estimated the proportion of the change that was attributable to gross national income per capita and an index of cumulative smoking exposure, and quantified the difference in mortality rates attributable to demographic changes.  Despite a substantial decrease in COPD mortality rates, COPD deaths fell only slightly, from three million in 1990 to 2.8 million in 2010, because the mean age of the population increased.  The number of COPD deaths in 2010 would have risen to 5.2 million if the age- and sex-specific mortality rates had remained constant.  Changes in smoking led to only a small increase in age- and sex-specific mortality rates, which were strongly associated with changes in gross national income.  The increased burden of COPD mortality was mainly driven by changes in age distribution, but age- and sex-specific rates fell as incomes rose.  The rapid response to increasing affluence suggests that changes in COPD mortality are not entirely explained by changes in early life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_uq_pzhUCkVZoq0fPSOTvfW6udTcc2eZ1rZwEzYv12Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjgsFCmuw%253D%253D&md5=ac0b863a4349debb4d01467223ca7e19</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1183%2F09031936.00142414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00142414%26sid%3Dliteratum%253Aachs%26aulast%3DBurney%26aufirst%3DP.%2BG.%26aulast%3DPatel%26aufirst%3DJ.%26aulast%3DNewson%26aufirst%3DR.%26aulast%3DMinelli%26aufirst%3DC.%26aulast%3DNaghavi%26aufirst%3DM.%26atitle%3DGlobal%2520and%2520regional%2520trends%2520in%2520COPD%2520mortality%252C%25201990%25E2%2580%25932010%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2015%26volume%3D45%26spage%3D1239%26epage%3D1247%26doi%3D10.1183%2F09031936.00142414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span> <i>Chronic Obstructive Pulmonary Disease (COPD)</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2018</span>; <a href="http://www.who.int/respiratory/copd/en/" class="extLink">http://www.who.int/respiratory/copd/en/</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Chronic+Obstructive+Pulmonary+Disease+%28COPD%29%3B+World+Health+Organization%3A+Geneva%2C+2018%3B+http%3A%2F%2Fwww.who.int%2Frespiratory%2Fcopd%2Fen%2F."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DChronic%2520Obstructive%2520Pulmonary%2520Disease%2520%2528COPD%2529%26pub%3DWorld%2520Health%2520Organization%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonough, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seyednejad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gefter, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litzky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coxson, H. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paré, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McWilliams, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span> <span> </span><span class="NLM_article-title">Small-airway obstruction and emphysema in chronic obstructive pulmonary disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">1567</span>– <span class="NLM_lpage">1575</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1106955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJMoa1106955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22029978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSrsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1567-1575&author=J.+E.+McDonoughauthor=R.+Yuanauthor=M.+Suzukiauthor=N.+Seyednejadauthor=W.+M.+Elliottauthor=P.+G.+Sanchezauthor=A.+C.+Wrightauthor=W.+B.+Gefterauthor=L.+Litzkyauthor=H.+O.+Coxsonauthor=P.+D.+Par%C3%A9author=D.+D.+Sinauthor=R.+A.+Pierceauthor=J.+C.+Woodsauthor=A.+M.+McWilliamsauthor=J.+R.+Mayoauthor=S.+C.+Lamauthor=J.+D.+Cooperauthor=J.+C.+Hogg&title=Small-airway+obstruction+and+emphysema+in+chronic+obstructive+pulmonary+disease&doi=10.1056%2FNEJMoa1106955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Small-airway obstruction and emphysema in chronic obstructive pulmonary disease</span></div><div class="casAuthors">McDonough, John E.; Yuan, Ren; Suzuki, Masaru; Seyednejad, Nazgol; Elliott, W. Mark; Sanchez, Pablo G.; Wright, Alexander C.; Gefter, Warren B.; Litzky, Leslie; Coxson, Harvey O.; Pare, Peter D.; Sin, Don D.; Pierce, Richard A.; Woods, Jason C.; McWilliams, Annette M.; Mayo, John R.; Lam, Stephen C.; Cooper, Joel D.; Hogg, James C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1567-1575</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND The major sites of obstruction in chronic obstructive pulmonary disease (COPD) are small airways (<2 mm in diam.).  We wanted to det. whether there was a relationship between small-airway obstruction and emphysematous destruction in COPD.  METHODS We used multidetector computed tomog. (CT) to compare the no. of airways measuring 2.0 to 2.5 mm in 78 patients who had various stages of COPD, as judged by scoring on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) scale, in isolated lungs removed from patients with COPD who underwent lung transplantation, and in donor (control) lungs.  MicroCT was used to measure the extent of emphysema (mean linear intercept), the no. of terminal bronchioles per mL of lung vol., and the min. diams. and cross-sectional areas of terminal bronchioles.  RESULTS On multidetector CT, in samples from patients with COPD, as compared with control samples, the no. of airways measuring 2.0 to 2.5 mm in diam. was reduced in patients with GOLD stage 1 disease (P = 0.001), GOLD stage 2 disease (P = 0.02), and GOLD stage 3 or 4 disease (P < 0.001).  MicroCT of isolated samples of lungs removed from patients with GOLD stage 4 disease showed a redn. of 81 to 99.7% in the total cross-sectional area of terminal bronchioles and a redn. of 72 to 89% in the no. of terminal bronchioles (P < 0.001).  A comparison of the no. of terminal bronchioles and dimensions at different levels of emphysematous destruction (i.e., an increasing value for the mean linear intercept) showed that the narrowing and loss of terminal bronchioles preceded emphysematous destruction in COPD (P < 0.001).  CONCLUSIONS These results show that narrowing and disappearance of small conducting airways before the onset of emphysematous destruction can explain the increased peripheral airway resistance reported in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUaZj-JIivxbVg90H21EOLACvtfcHk0ljFZxPiIC5T-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSrsrbM&md5=7c79a7a19ed50dc69016eff9972db616</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1106955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1106955%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonough%26aufirst%3DJ.%2BE.%26aulast%3DYuan%26aufirst%3DR.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DSeyednejad%26aufirst%3DN.%26aulast%3DElliott%26aufirst%3DW.%2BM.%26aulast%3DSanchez%26aufirst%3DP.%2BG.%26aulast%3DWright%26aufirst%3DA.%2BC.%26aulast%3DGefter%26aufirst%3DW.%2BB.%26aulast%3DLitzky%26aufirst%3DL.%26aulast%3DCoxson%26aufirst%3DH.%2BO.%26aulast%3DPar%25C3%25A9%26aufirst%3DP.%2BD.%26aulast%3DSin%26aufirst%3DD.%2BD.%26aulast%3DPierce%26aufirst%3DR.%2BA.%26aulast%3DWoods%26aufirst%3DJ.%2BC.%26aulast%3DMcWilliams%26aufirst%3DA.%2BM.%26aulast%3DMayo%26aufirst%3DJ.%2BR.%26aulast%3DLam%26aufirst%3DS.%2BC.%26aulast%3DCooper%26aufirst%3DJ.%2BD.%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26atitle%3DSmall-airway%2520obstruction%2520and%2520emphysema%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1567%26epage%3D1575%26doi%3D10.1056%2FNEJMoa1106955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mapel, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalal, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchette, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, G. T.</span></span> <span> </span><span class="NLM_article-title">Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.2147/COPD.S16975</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2147%2FCOPD.S16975" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22135490" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC38%252FktlChsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=573-581&author=D.+W.+Mapelauthor=A.+A.+Dalalauthor=C.+M.+Blanchetteauthor=H.+Petersenauthor=G.+T.+Ferguson&title=Severity+of+COPD+at+initial+spirometry-confirmed+diagnosis%3A+data+from+medical+charts+and+administrative+claims&doi=10.2147%2FCOPD.S16975"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims</span></div><div class="casAuthors">Mapel Douglas W; Dalal Anand A; Blanchette Christopher M; Petersen Hans; Ferguson Gary T</div><div class="citationInfo"><span class="NLM_cas:title">International journal of chronic obstructive pulmonary disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">573-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  This study was conducted to determine COPD severity at the time of diagnosis as confirmed by spirometry in patients treated in a US managed care setting.  PATIENTS AND METHODS:  All patients with one or more inpatient stays, one or more emergency department visits, or two or more outpatient visits with diagnosis codes for COPD during 1994-2006 were identified from the Lovelace Patient Database.  From this group, a subset of continuously enrolled patients with evidence in claims of a first available pulmonary function test or pulmonary clinic visit and a confirmatory claim for a COPD diagnosis was selected.  Medical chart abstraction was undertaken for this subset to gather information for diagnosis and severity staging of each patient based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for COPD.  RESULTS:  Of the 12,491 patients with a primary or secondary COPD diagnosis between 1994 and 2006, there were 1520 continuously enrolled patients who comprised the study cohort.  Among the 648 eligible records from patients with evidence of a pulmonary function test, 366 were identified by spirometry as having COPD of GOLD stage I or higher (average percentage of predicted forced expiratory volume in 1 second: 60%): 19% were diagnosed at the stage of mild disease (GOLD stage I); 50% at moderate disease (GOLD stage II); and 31% at severe or very severe disease (GOLD stage III or IV, respectively).  The majority of patients in these groups were not receiving maintenance treatment.  CONCLUSION:  The results demonstrate a very low incidence of early-stage diagnosis, confirmed by a pulmonary function test, of COPD in a large US sample and support calls for increased screening for COPD and treatment upon diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQtz4ddVfs_c2K_SFaaT9INfW6udTcc2easYuQWrykBlbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38%252FktlChsQ%253D%253D&md5=42511d3257e465c1dc44996ebf8837bd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S16975&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S16975%26sid%3Dliteratum%253Aachs%26aulast%3DMapel%26aufirst%3DD.%2BW.%26aulast%3DDalal%26aufirst%3DA.%2BA.%26aulast%3DBlanchette%26aufirst%3DC.%2BM.%26aulast%3DPetersen%26aufirst%3DH.%26aulast%3DFerguson%26aufirst%3DG.%2BT.%26atitle%3DSeverity%2520of%2520COPD%2520at%2520initial%2520spirometry-confirmed%2520diagnosis%253A%2520data%2520from%2520medical%2520charts%2520and%2520administrative%2520claims%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2011%26volume%3D6%26spage%3D573%26epage%3D581%26doi%3D10.2147%2FCOPD.S16975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, J. C.</span></span> <span> </span><span class="NLM_article-title">Pathophysiology of airflow limitation in chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">709</span>– <span class="NLM_lpage">721</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)16900-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2804%2916900-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15325838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2cvhvFKntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=709-721&author=J.+C.+Hogg&title=Pathophysiology+of+airflow+limitation+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2804%2916900-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pathophysiology of airflow limitation in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Hogg James C</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">9435</span>),
    <span class="NLM_cas:pages">709-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The airflow limitation that defines chronic obstructive pulmonary disease (COPD) is the result of a prolonged time constant for lung emptying, caused by increased resistance of the small conducting airways and increased compliance of the lung as a result of emphysematous destruction.  These lesions are associated with a chronic innate and adaptive inflammatory immune response of the host to a lifetime exposure to inhaled toxic gases and particles.  Processes contributing to obstruction in the small conducting airways include disruption of the epithelial barrier, interference with mucociliary clearance apparatus that results in accumulation of inflammatory mucous exudates in the small airway lumen, infiltration of the airway walls by inflammatory cells, and deposition of connective tissue in the airway wall.  This remodelling and repair thickens the airway walls, reduces lumen calibre, and restricts the normal increase in calibre produced by lung inflation.  Emphysematous lung destruction is associated with an infiltration of the same type of inflammatory cells found in the airways.  The centrilobular pattern of emphysematous destruction is most closely associated with cigarette smoking, and although it is initially focused on respiratory bronchioles, separate lesions coalesce to destroy large volumes of lung tissue.  The panacinar pattern of emphysema is characterised by a more even involvement of the acinus and is associated with alpha1 antitrypsin deficiency.  The technology needed to diagnose and quantitate the individual small airway and emphysema phenotypes present in people with COPD is being developed, and should prove helpful in the assessment of therapeutic interventions designed to modify the progress of either phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTicL3IkZ1Ezq91pGlMMoT5fW6udTcc2eYwe4quXijuBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cvhvFKntw%253D%253D&md5=020c93595544690ab6519a8d88cfb9ee</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2916900-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252916900-6%26sid%3Dliteratum%253Aachs%26aulast%3DHogg%26aufirst%3DJ.%2BC.%26atitle%3DPathophysiology%2520of%2520airflow%2520limitation%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D709%26epage%3D721%26doi%3D10.1016%2FS0140-6736%2804%2916900-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hui, C. K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. F.</span></span> <span> </span><span class="NLM_article-title">Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD</span>. <i>Expert Rev. Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1586/ers.10.91</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1586%2Fers.10.91" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21348581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVemtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=9-16&author=C.+K.+M.+Huiauthor=K.+F.+Chung&title=Indacaterol%3A+pharmacologic+profile%2C+efficacy+and+safety+in+the+treatment+of+adults+with+COPD&doi=10.1586%2Fers.10.91"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Indacaterol: pharmacologic profile, efficacy and safety in the treatment of adults with COPD</span></div><div class="casAuthors">Hui, Christopher K. M.; Chung, Kian F.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Respiratory Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-16</span>CODEN:
                <span class="NLM_cas:coden">ERRMBF</span>;
        ISSN:<span class="NLM_cas:issn">1747-6348</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Indacaterol is a novel once-daily long-acting β2-agonist (LABA) for the treatment of chronic obstructive pulmonary disease (COPD) that is currently completing Phase II and Phase III trials.  It represents the first of a group of drugs now referred to as theultra-LABAs''.  It has recently gained approval in Europe, and is pending regulatory review in the USA.  Indacaterol produces a rapid and sustained bronchodilation that lasts for at least 24 h in patients with COPD.  To date, 1-yr studies with indacaterol indicate that it can be taken once daily with good overall safety and tolerability profiles.  The therapeutic potential for indacaterol is supported by data on patient-reported outcomes with an improvement in symptoms such as dyspnea, exercise capacity and quality of life, and a redn. in exacerbations.  It is likely that indacaterol could be used in conjunction with other agents such as inhaled corticosteroids and anticholinergics for the treatment of COPD as a single once-daily combination treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5viZJwdQIsrVg90H21EOLACvtfcHk0lj4rzRYVik4Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVemtrg%253D&md5=cd1765d5b63fb8aaddd4cc60009447d5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1586%2Fers.10.91&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fers.10.91%26sid%3Dliteratum%253Aachs%26aulast%3DHui%26aufirst%3DC.%2BK.%2BM.%26aulast%3DChung%26aufirst%3DK.%2BF.%26atitle%3DIndacaterol%253A%2520pharmacologic%2520profile%252C%2520efficacy%2520and%2520safety%2520in%2520the%2520treatment%2520of%2520adults%2520with%2520COPD%26jtitle%3DExpert%2520Rev.%2520Respir.%2520Med.%26date%3D2011%26volume%3D5%26spage%3D9%26epage%3D16%26doi%3D10.1586%2Fers.10.91" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postma, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabe, K. F.</span></span> <span> </span><span class="NLM_article-title">The asthma-COPD overlap syndrome</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">1241</span>– <span class="NLM_lpage">1249</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1411863</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJMra1411863" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26398072" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XkslCitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1241-1249&author=D.+S.+Postmaauthor=K.+F.+Rabe&title=The+asthma-COPD+overlap+syndrome&doi=10.1056%2FNEJMra1411863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">the asthma-COPD overlap syndrome</span></div><div class="casAuthors">Postma, Dirkje S.; Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1241-1249</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A review.  This article describes about asthma-chronic obstructive pulmonary disease overlap syndrome a condition in which a person has clin. features of both asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9FzMKOH3BmLVg90H21EOLACvtfcHk0lj85S4bX4LMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkslCitA%253D%253D&md5=172afa6a356861b696efe8fa3af1e9cc</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1411863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1411863%26sid%3Dliteratum%253Aachs%26aulast%3DPostma%26aufirst%3DD.%2BS.%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DThe%2520asthma-COPD%2520overlap%2520syndrome%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1241%26epage%3D1249%26doi%3D10.1056%2FNEJMra1411863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Asthma-COPD overlap</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">8</span>, <span class="refDoi"> DOI: 10.1016/j.chest.2015.08.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.chest.2015.08.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26757281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28rpslGnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2016&pages=7-8&author=P.+J.+Barnes&title=Asthma-COPD+overlap&doi=10.1016%2Fj.chest.2015.08.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Asthma-COPD Overlap</span></div><div class="casAuthors">Barnes Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKuc2YiC6XWgxyojvcjibhfW6udTcc2eYMygUu0lxRFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rpslGnsw%253D%253D&md5=f3f6da66140e57913074411b9721f02e</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.chest.2015.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chest.2015.08.017%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DAsthma-COPD%2520overlap%26jtitle%3DChest%26date%3D2016%26volume%3D149%26spage%3D7%26epage%3D8%26doi%3D10.1016%2Fj.chest.2015.08.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agustí, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Divo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marott, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Camblor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto-Plata, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnohr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sood, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesfaigzi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span> <span> </span><span class="NLM_article-title">Lung-function trajectories leading to chronic obstructive pulmonary disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>373</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1411532</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJMoa1411532" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26154786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12qurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=111-122&author=P.+Langeauthor=B.+Celliauthor=A.+Agust%C3%ADauthor=G.+B.+Jensenauthor=M.+Divoauthor=R.+Fanerauthor=S.+Guerraauthor=J.+L.+Marottauthor=F.+D.+Martinezauthor=P.+Martinez-Camblorauthor=P.+Meekauthor=C.+Owenauthor=H.+Petersenauthor=V.+Pinto-Plataauthor=P.+Schnohrauthor=A.+Soodauthor=J.+B.+Sorianoauthor=Y.+Tesfaigziauthor=J.+Vestbo&title=Lung-function+trajectories+leading+to+chronic+obstructive+pulmonary+disease&doi=10.1056%2FNEJMoa1411532"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Lung-function trajectories leading to chronic obstructive pulmonary disease</span></div><div class="casAuthors">Lange, Peter; Celli, Bartolome; Agusti, Alvar; Jensen, Gorm Boje; Divo, Miguel; Faner, Rosa; Guerra, Stefano; Marott, Jacob Louis; Martinez, Fernando D.; Martinez-Camblor, Pablo; Meek, Paula; Owen, Caroline A.; Petersen, Hans; Pinto-Plata, Victor; Schnohr, Peter; Sood, Akshay; Soriano, Joan B.; Tesfaigzi, Yohannes; Vestbo, Joergen</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-122</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Chronic obstructive pulmonary disease (COPD) is thought to result from an accelerated decline in forced expiratory vol. in 1 s (FEV1) over time.  Yet it is possible that a normal decline in FEV1 could also lead to COPD in persons whose maximally attained FEV1 is less than population norms. methods We stratified participants in three independent cohorts (the Framingham Offspring Cohort, the Copenhagen City Heart Study, and the Lovelace Smokers Cohort) according to lung function (FEV1 ≥80% or <80% of the predicted value) at cohort inception (mean age of patients, approx. 40 years) and the presence or absence of COPD at the last study visit.  We then detd. the rate of decline in FEV1 over time among the participants according to their FEV1 at cohort inception and COPD status at study end. results Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation (P<0.001).  Approx. half the 332 persons with COPD at the end of the observation period had had a normal FEV1 before 40 years of age and had a rapid decline in FEV1 thereafter, with a mean (±SD) decline of 53 ± 21 mL per yr.  The remaining half had had a low FEV1 in early adulthood and a subsequent mean decline in FEV1 of 27 ± 18 mL per yr (P<0.001), despite similar smoking exposure. conclusions Our study suggests that low FEV1 in early adulthood is important in the genesis of COPD and that accelerated decline in FEV1 is not an obligate feature of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2S2XiqyOZAbVg90H21EOLACvtfcHk0lj85S4bX4LMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12qurfN&md5=7aaffaf1e9dc958f362b5dd3aea4aea0</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1411532&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1411532%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DP.%26aulast%3DCelli%26aufirst%3DB.%26aulast%3DAgust%25C3%25AD%26aufirst%3DA.%26aulast%3DJensen%26aufirst%3DG.%2BB.%26aulast%3DDivo%26aufirst%3DM.%26aulast%3DFaner%26aufirst%3DR.%26aulast%3DGuerra%26aufirst%3DS.%26aulast%3DMarott%26aufirst%3DJ.%2BL.%26aulast%3DMartinez%26aufirst%3DF.%2BD.%26aulast%3DMartinez-Camblor%26aufirst%3DP.%26aulast%3DMeek%26aufirst%3DP.%26aulast%3DOwen%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DH.%26aulast%3DPinto-Plata%26aufirst%3DV.%26aulast%3DSchnohr%26aufirst%3DP.%26aulast%3DSood%26aufirst%3DA.%26aulast%3DSoriano%26aufirst%3DJ.%2BB.%26aulast%3DTesfaigzi%26aufirst%3DY.%26aulast%3DVestbo%26aufirst%3DJ.%26atitle%3DLung-function%2520trajectories%2520leading%2520to%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D111%26epage%3D122%26doi%3D10.1056%2FNEJMoa1411532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferris, B. G.</span></span> <span> </span><span class="NLM_article-title">Role of tobacco smoking in the causation of chronic respiratory disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>267</i></span>,  <span class="NLM_fpage">787</span>– <span class="NLM_lpage">794</span>, <span class="refDoi"> DOI: 10.1056/NEJM196210182671601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJM196210182671601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=14012834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADyaF383gsVOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=267&publication_year=1962&pages=787-794&author=D.+O.+Andersonauthor=B.+G.+Ferris&title=Role+of+tobacco+smoking+in+the+causation+of+chronic+respiratory+disease&doi=10.1056%2FNEJM196210182671601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Role of tobacco smoking in the causation of chronic respiratory disease</span></div><div class="casAuthors">ANDERSON D O; FERRIS B G Jr</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">787-94</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTtiJI_FX8GiA3UY9EwTNrfW6udTcc2eY4xXRd9t4sErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF383gsVOksg%253D%253D&md5=035917f73dd54de8f0c5a87bfe5de82c</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJM196210182671601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM196210182671601%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DD.%2BO.%26aulast%3DFerris%26aufirst%3DB.%2BG.%26atitle%3DRole%2520of%2520tobacco%2520smoking%2520in%2520the%2520causation%2520of%2520chronic%2520respiratory%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1962%26volume%3D267%26spage%3D787%26epage%3D794%26doi%3D10.1056%2FNEJM196210182671601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salvi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Chronic obstructive pulmonary disease in non-smokers</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">743</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(09)61303-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2809%2961303-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19716966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1MrovFymuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2009&pages=733-743&author=S.+S.+Salviauthor=P.+J.+Barnes&title=Chronic+obstructive+pulmonary+disease+in+non-smokers&doi=10.1016%2FS0140-6736%2809%2961303-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic obstructive pulmonary disease in non-smokers</span></div><div class="casAuthors">Salvi Sundeep S; Barnes Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">9691</span>),
    <span class="NLM_cas:pages">733-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide.  Tobacco smoking is established as a major risk factor, but emerging evidence suggests that other risk factors are important, especially in developing countries.  An estimated 25-45% of patients with COPD have never smoked; the burden of non-smoking COPD is therefore much higher than previously believed.  About 3 billion people, half the worldwide population, are exposed to smoke from biomass fuel compared with 1.01 billion people who smoke tobacco, which suggests that exposure to biomass smoke might be the biggest risk factor for COPD globally.  We review the evidence for the association of COPD with biomass fuel, occupational exposure to dusts and gases, history of pulmonary tuberculosis, chronic asthma, respiratory-tract infections during childhood, outdoor air pollution, and poor socioeconomic status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqLnV-F6XH0eIHSmpohpd0fW6udTcc2eY4xXRd9t4sErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrovFymuw%253D%253D&md5=7293ed37beeda2a3119a8312bb423810</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2809%2961303-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252809%252961303-9%26sid%3Dliteratum%253Aachs%26aulast%3DSalvi%26aufirst%3DS.%2BS.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DChronic%2520obstructive%2520pulmonary%2520disease%2520in%2520non-smokers%26jtitle%3DLancet%26date%3D2009%26volume%3D374%26spage%3D733%26epage%3D743%26doi%3D10.1016%2FS0140-6736%2809%2961303-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, C. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adab, P.</span></span> <span> </span><span class="NLM_article-title">Passive smoking exposure and risk of COPD among adults in China: the Guangzhou biobank cohort study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">757</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(07)61378-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2807%2961378-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17765524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srhs1Sisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=751-757&author=P.+Yinauthor=C.+Q.+Jiangauthor=K.+K.+Chengauthor=T.+H.+Lamauthor=K.+H.+Lamauthor=M.+R.+Millerauthor=W.+S.+Zhangauthor=G.+N.+Thomasauthor=P.+Adab&title=Passive+smoking+exposure+and+risk+of+COPD+among+adults+in+China%3A+the+Guangzhou+biobank+cohort+study&doi=10.1016%2FS0140-6736%2807%2961378-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study</span></div><div class="casAuthors">Yin P; Jiang C Q; Cheng K K; Lam T H; Lam K H; Miller M R; Zhang W S; Thomas G N; Adab P</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">9589</span>),
    <span class="NLM_cas:pages">751-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality in China, where the population is also exposed to high levels of passive smoking, yet little information exists on the effects of such exposure on COPD.  We examined the relation between passive smoking and COPD and respiratory symptoms in an adult Chinese population.  METHODS:  We used baseline data from the Guangzhou Biobank Cohort Study.  Of 20 430 men and women over the age of 50 recruited in 2003-06, 15,379 never smokers (6497 with valid spirometry) were included in this cross-sectional analysis.  We measured passive smoking exposure at home and work by two self-reported measures (density and duration of exposure).  Diagnosis of COPD was based on spirometry and defined according to the GOLD guidelines.  FINDINGS:  There was an association between risk of COPD and self-reported exposure to passive smoking at home and work (adjusted odds ratio 1.48, 95% CI 1.18-1.85 for high level exposure; equivalent to 40 h a week for more than 5 years).  There were significant associations between reported respiratory symptoms and increasing passive smoking exposure (1.16, 1.07-1.25 for any symptom).  INTERPRETATION:  Exposure to passive smoking is associated with an increased prevalence of COPD and respiratory symptoms.  If this association is causal, we estimate that 1.9 million excess deaths from COPD among never smokers could be attributable to passive smoking in the current population in China.  Our findings provide strong evidence for urgent measures against passive smoking in China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTAJAVB43A0sK3uFsUIZtkfW6udTcc2ebykTy8JMcucbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srhs1Sisw%253D%253D&md5=d8d2dfceafd085479ec868505e2b63be</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2807%2961378-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252807%252961378-6%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DP.%26aulast%3DJiang%26aufirst%3DC.%2BQ.%26aulast%3DCheng%26aufirst%3DK.%2BK.%26aulast%3DLam%26aufirst%3DT.%2BH.%26aulast%3DLam%26aufirst%3DK.%2BH.%26aulast%3DMiller%26aufirst%3DM.%2BR.%26aulast%3DZhang%26aufirst%3DW.%2BS.%26aulast%3DThomas%26aufirst%3DG.%2BN.%26aulast%3DAdab%26aufirst%3DP.%26atitle%3DPassive%2520smoking%2520exposure%2520and%2520risk%2520of%2520COPD%2520among%2520adults%2520in%2520China%253A%2520the%2520Guangzhou%2520biobank%2520cohort%2520study%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D751%26epage%3D757%26doi%3D10.1016%2FS0140-6736%2807%2961378-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fullerton, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. B.</span></span> <span> </span><span class="NLM_article-title">Indoor air pollution from biomass fuel smoke is a major health concern in the developing world</span>. <i>Trans. R. Soc. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">851</span>, <span class="refDoi"> DOI: 10.1016/j.trstmh.2008.05.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.trstmh.2008.05.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18639310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1cvpvFWmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2008&pages=843-851&author=D.+G.+Fullertonauthor=N.+Bruceauthor=S.+B.+Gordon&title=Indoor+air+pollution+from+biomass+fuel+smoke+is+a+major+health+concern+in+the+developing+world&doi=10.1016%2Fj.trstmh.2008.05.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Indoor air pollution from biomass fuel smoke is a major health concern in the developing world</span></div><div class="casAuthors">Fullerton Duncan G; Bruce Nigel; Gordon Stephen B</div><div class="citationInfo"><span class="NLM_cas:title">Transactions of the Royal Society of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">843-51</span>
        ISSN:<span class="NLM_cas:issn">0035-9203</span>.
    </div><div class="casAbstract">One-third of the world's population burn organic material such as wood, dung or charcoal (biomass fuel) for cooking, heating and lighting.  This form of energy usage is associated with high levels of indoor air pollution and an increase in the incidence of respiratory infections, including pneumonia, tuberculosis and chronic obstructive pulmonary disease, low birthweight, cataracts, cardiovascular events and all-cause mortality both in adults and children.  The mechanisms behind these associations are not fully understood.  This review summarises the available information on biomass fuel use and health, highlighting the current gaps in knowledge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeQ5PhyrCF7UH3Rlp_k91zfW6udTcc2ebykTy8JMcucbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvpvFWmtg%253D%253D&md5=9ac0accfb7c2975b286361f055d62142</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.trstmh.2008.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trstmh.2008.05.028%26sid%3Dliteratum%253Aachs%26aulast%3DFullerton%26aufirst%3DD.%2BG.%26aulast%3DBruce%26aufirst%3DN.%26aulast%3DGordon%26aufirst%3DS.%2BB.%26atitle%3DIndoor%2520air%2520pollution%2520from%2520biomass%2520fuel%2520smoke%2520is%2520a%2520major%2520health%2520concern%2520in%2520the%2520developing%2520world%26jtitle%3DTrans.%2520R.%2520Soc.%2520Trop.%2520Med.%2520Hyg.%26date%3D2008%26volume%3D102%26spage%3D843%26epage%3D851%26doi%3D10.1016%2Fj.trstmh.2008.05.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P.</span></span> <span> </span><span class="NLM_article-title">Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural south China</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">897</span>, <span class="refDoi"> DOI: 10.1136/thx.2006.061457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1136%2Fthx.2006.061457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17483137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srosVChsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=889-897&author=S.+Liuauthor=Y.+Zhouauthor=X.+Wangauthor=D.+Wangauthor=J.+Luauthor=J.+Zhengauthor=N.+Zhongauthor=P.+Ran&title=Biomass+fuels+are+the+probable+risk+factor+for+chronic+obstructive+pulmonary+disease+in+rural+south+China&doi=10.1136%2Fthx.2006.061457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China</span></div><div class="casAuthors">Liu Shengming; Zhou Yumin; Wang Xiaoping; Wang Dali; Lu Jiachun; Zheng Jingping; Zhong Nanshan; Ran Pixin</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">889-97</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  There is increasing evidence for a possible association between chronic obstructive pulmonary disease (COPD) and the use of biomass fuels for cooking and heating in developing countries.  Data on the prevalence of COPD and objective measurements of indoor pollution from biomass fuel have not been widely available from China.  A study was undertaken to investigate the prevalence of COPD in two study communities in Guangdong province in China and to measure the association between COPD and indoor biomass fuel air pollution.  METHODS:  A cluster disproportional random sampling survey was performed in populations aged over 40 years in urban (Liwang) and rural (Yunyan) areas in Guangdong, China.  Spirometry was performed in all subjects and a post-bronchodilator ratio of the forced expiratory volume in 1 s to forced vital capacity of <0.70 was defined as COPD.  Measurements of indoor and outdoor air pollutants were also performed in a random sample of households.  RESULTS:  The overall prevalence of COPD in the two areas (Liwang and Yunyan) was 9.4%.  The prevalence of COPD in both the whole population and a subpopulation of non-smoking women in rural Yunyan was significantly higher than in urban Liwang (12.0% vs 7.4%, and 7.2% vs 2.5%, respectively).  The use of biomass fuel was higher in rural Yunyan than in urban Liwang (88.1% vs 0.7%).  Univariate analysis showed a significant association between COPD and exposure to biomass fuel for cooking.  Multivariate analysis showed a positive association between COPD and urban/rural area (surrogate for fuel type and local exhaust ventilation in kitchen) after adjustment for sex, age group, body mass index, education, occupational exposure, respiratory disease in family, smoking status, life quality and cough in childhood; similar results were found in non-smoking women.  Pollutants measurements showed that concentrations of carbon monoxide, particulate matter with an aerodynamic diameter <or=10 microm, sulphur dioxide and nitrogen dioxide in the kitchen during biomass fuel combustion were significantly higher than those during LPG combustion.  CONCLUSIONS:  Indoor pollutants from biomass fuels may be an important risk factor for COPD in rural South China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRsG4DBTFKwYOQ4Pl9hzjQhfW6udTcc2eaoR-lyteyPK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srosVChsg%253D%253D&md5=0e13d942464b8a36b5f5ba3d7a927cca</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1136%2Fthx.2006.061457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2006.061457%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DN.%26aulast%3DRan%26aufirst%3DP.%26atitle%3DBiomass%2520fuels%2520are%2520the%2520probable%2520risk%2520factor%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520rural%2520south%2520China%26jtitle%3DThorax%26date%3D2007%26volume%3D62%26spage%3D889%26epage%3D897%26doi%3D10.1136%2Fthx.2006.061457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kendall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippmann, M.</span></span> <span> </span><span class="NLM_article-title">Factors affecting personal exposure to thoracic and fine particles and their components</span>. <i>J. Exposure Sci. Environ. Epidemiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">439</span>– <span class="NLM_lpage">447</span>, <span class="refDoi"> DOI: 10.1038/jes.2012.23</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fjes.2012.23" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22760443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GjtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=439-447&author=S.+I.+Hsuauthor=K.+Itoauthor=M.+Kendallauthor=M.+Lippmann&title=Factors+affecting+personal+exposure+to+thoracic+and+fine+particles+and+their+components&doi=10.1038%2Fjes.2012.23"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Factors affecting personal exposure to thoracic and fine particles and their components</span></div><div class="casAuthors">Hsu, Shao-I.; Ito, Kazuhiko; Kendall, Michaela; Lippmann, Morton</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Exposure Science & Environmental Epidemiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">439-447</span>CODEN:
                <span class="NLM_cas:coden">JESEBS</span>;
        ISSN:<span class="NLM_cas:issn">1559-0631</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Central monitoring site (CMS) concns. have been used to represent population-based personal exposures to particulate matter (PM) of ambient origin.  The authors investigated the assocns. of the concns. of PM2.5 and PM10 and their elemental components for elderly clinic patients with chronic obstructive pulmonary disease in two cities with different PM compns., i.e., New York City (NYC) and Seattle.  Daily measurements of CMS, outdoor residential, and indoor PM10 and PM2.5 concns., as well as personal PM10, were made concurrently for 12-consecutive winter days at 9 NYC and 15 Seattle residences, as well for 9 NYC residences in summer.  Filters were analyzed for elemental components using X-ray fluorescence (XRF), and for black carbon (BC) by light reflectance, and outdoor-indoor-personal relationships of PM components were examd. using mixed-effect models.  Using sulfur (S) as a tracer of PM of ambient origin, the mean contributions of outdoor PM2.5 was 55.2% of the indoor concns. in NYC, and 80.0% in Seattle, and outdoor PM2.5 in NYC and Seattle were 19.7 and 18.5% of personal PM2.5 concn.  S was distributed homogeneously in both cities (R2=0.65), whereas nickel (R2=0.23) was much more spatially heterogeneous.  Thus, CMS measurements can adequately reflect personal exposures for spatially uniform components, such as sulfate, but they are not adequate for components from more local sources.  Journal of Exposure Science and Environmental Epidemiol. (2012) 22, 439-447; doi:10.1038/jes.2012.23; published online 4 July 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBaUY8iaMvYLVg90H21EOLACvtfcHk0licUZ_78Ht0nw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GjtrjP&md5=4b29d33f5724b63c5bbbeed406038049</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fjes.2012.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjes.2012.23%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DS.%2BI.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DKendall%26aufirst%3DM.%26aulast%3DLippmann%26aufirst%3DM.%26atitle%3DFactors%2520affecting%2520personal%2520exposure%2520to%2520thoracic%2520and%2520fine%2520particles%2520and%2520their%2520components%26jtitle%3DJ.%2520Exposure%2520Sci.%2520Environ.%2520Epidemiol.%26date%3D2012%26volume%3D22%26spage%3D439%26epage%3D447%26doi%3D10.1038%2Fjes.2012.23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chester, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krause, F. D.</span></span> <span> </span><span class="NLM_article-title">The prevalence of chronic obstructive pulmonary disease in chlorine gas workers</span>. <i>Am. Rev. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">373</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=5765628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADyaF1M7hsVWntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1969&pages=365-373&author=E.+H.+Chesterauthor=D.+G.+Gillespieauthor=F.+D.+Krause&title=The+prevalence+of+chronic+obstructive+pulmonary+disease+in+chlorine+gas+workers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The prevalence of chronic obstructive pulmonary disease in chlorine gas workers</span></div><div class="casAuthors">Chester E H; Gillespie D G; Krause F D</div><div class="citationInfo"><span class="NLM_cas:title">The American review of respiratory disease</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">365-73</span>
        ISSN:<span class="NLM_cas:issn">0003-0805</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSUQZJZoYVNdczK395ZObgVfW6udTcc2eZvJSJLTZxfKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaF1M7hsVWntA%253D%253D&md5=16817892f35808d4987cb34aa1463088</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChester%26aufirst%3DE.%2BH.%26aulast%3DGillespie%26aufirst%3DD.%2BG.%26aulast%3DKrause%26aufirst%3DF.%2BD.%26atitle%3DThe%2520prevalence%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520chlorine%2520gas%2520workers%26jtitle%3DAm.%2520Rev.%2520Respir.%2520Dis.%26date%3D1969%26volume%3D99%26spage%3D365%26epage%3D373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eduard, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearce, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douwes, J.</span></span> <span> </span><span class="NLM_article-title">Chronic bronchitis, COPD, and lung function in farmers: the role of biological agents</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>136</i></span>,  <span class="NLM_fpage">716</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1378/chest.08-2192</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1378%2Fchest.08-2192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19318669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1MngsVyrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2009&pages=716-725&author=W.+Eduardauthor=N.+Pearceauthor=J.+Douwes&title=Chronic+bronchitis%2C+COPD%2C+and+lung+function+in+farmers%3A+the+role+of+biological+agents&doi=10.1378%2Fchest.08-2192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic bronchitis, COPD, and lung function in farmers: the role of biological agents</span></div><div class="casAuthors">Eduard Wijnand; Pearce Neil; Douwes Jeroen</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">716-725</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Farmers have an increased risk of respiratory morbidity and mortality.  The causal agents have not been fully established.  METHODS:  In a cross-sectional study of 4,735 Norwegian farmers, we assessed respiratory symptoms and lung function.  Atopy was assessed in a subsample (n = 1,213).  Personal exposures to dust, fungal spores, actinomycete spores, endotoxins, bacteria, storage mites, (1-->3)-ss-D-glucans, fungal antigens, organic dust, inorganic dust, silica, ammonia, and hydrogen sulfide were measured for 127 randomly selected farms.  RESULTS:  Compared to crop farmers, livestock farmers were more likely to have chronic bronchitis (odds ratio [OR], 1.9; 95% confidence interval [CI], 1.4 to 2.6) and COPD (OR, 1.4; 95% CI, 1.1 to 1.7).  FEV(1) (-41 mL; 95% CI, -75 to -7) was significantly reduced, but FVC (-15 mL; 95% CI, -54 to 24) was not.  Exposure to most agents were predictors of respiratory morbidity, except FVC.  Ammonia, hydrogen sulfide, and inorganic dust were most strongly associated in multiple regression models adjusted for coexposures, but the effects of specific biological agents could not be assessed in multiple regression models because they were too highly correlated.  Farmers with atopy had a significantly lower FEV(1) (OR, -87 mL; 95% CI, -170 to -7), but atopy was not directly associated with chronic bronchitis, COPD, and FVC.  However, the effects of farming and specific exposures on COPD were substantially greater in farmers with atopy.  CONCLUSIONS:  Livestock farmers have an increased risk of chronic bronchitis, COPD, and reduced FEV(1).  Ammonia, hydrogen sulfide, inorganic dust, and organic dust may be causally involved, but a role for specific biological agents cannot be excluded.  Farmers with atopy appear more susceptible to develop farming-related COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQa3PQttJFn2_3jf77P2BG3fW6udTcc2eZvJSJLTZxfKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MngsVyrug%253D%253D&md5=e13c54c1d92a1ad6d0824002e0f2aa27</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1378%2Fchest.08-2192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.08-2192%26sid%3Dliteratum%253Aachs%26aulast%3DEduard%26aufirst%3DW.%26aulast%3DPearce%26aufirst%3DN.%26aulast%3DDouwes%26aufirst%3DJ.%26atitle%3DChronic%2520bronchitis%252C%2520COPD%252C%2520and%2520lung%2520function%2520in%2520farmers%253A%2520the%2520role%2520of%2520biological%2520agents%26jtitle%3DChest%26date%3D2009%26volume%3D136%26spage%3D716%26epage%3D725%26doi%3D10.1378%2Fchest.08-2192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Husman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koskenvuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaprio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terho, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vohlonen, I.</span></span> <span> </span><span class="NLM_article-title">Role of environment in the development of chronic bronchitis</span>. <i>Eur. J. Respir. Dis. Suppl.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=3499347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADyaL1c%252FivFyhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=1987&pages=57-63&author=K.+Husmanauthor=M.+Koskenvuoauthor=J.+Kaprioauthor=E.+O.+Terhoauthor=I.+Vohlonen&title=Role+of+environment+in+the+development+of+chronic+bronchitis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Role of environment in the development of chronic bronchitis</span></div><div class="casAuthors">Husman K; Koskenvuo M; Kaprio J; Terho E O; Vohlonen I</div><div class="citationInfo"><span class="NLM_cas:title">European journal of respiratory diseases. Supplement</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57-63</span>
        ISSN:<span class="NLM_cas:issn">0106-4347</span>.
    </div><div class="casAbstract">Based on data in the Finnish Twin Registry, which was obtained by postal questionnaire, the prevalence of chronic bronchitis among non-smoking farmers was 3.6% and among a corresponding group of non-farmers (reference subjects) 3.4%.  The six-year incidences of chronic bronchitis for these 2 groups were 2.7% and 0.7%, respectively.  The difference in incidence between these groups was significant (p less than 0.001).  The fact that the incidence among farming subjects was three times the incidence among non-farming subjects indicates that chronic bronchitis is a work-related disease among farmers.  This is analogous to previous findings that symptoms compatible with chronic bronchitis occur more often among grain elevator workers than among urban dwellers.  The occurrence of chronic bronchitis among both farmers and grain elevator workers probably is associated with exposure to grain dusts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT__Tb7vkptBxLDWw4HIq2sfW6udTcc2eaRhWPZxYdKqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c%252FivFyhsQ%253D%253D&md5=4d0685d142920315337ceb01924c706c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHusman%26aufirst%3DK.%26aulast%3DKoskenvuo%26aufirst%3DM.%26aulast%3DKaprio%26aufirst%3DJ.%26aulast%3DTerho%26aufirst%3DE.%2BO.%26aulast%3DVohlonen%26aufirst%3DI.%26atitle%3DRole%2520of%2520environment%2520in%2520the%2520development%2520of%2520chronic%2520bronchitis%26jtitle%3DEur.%2520J.%2520Respir.%2520Dis.%2520Suppl.%26date%3D1987%26volume%3D152%26spage%3D57%26epage%3D63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weinmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollmer, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breen, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hnizdo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villnave, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziani, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBurnie, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buist, A. S.</span></span> <span> </span><span class="NLM_article-title">COPD and occupational exposures: a case-control study</span>. <i>J. Occup. Environ. Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">569</span>, <span class="refDoi"> DOI: 10.1097/JOM.0b013e3181651556</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1097%2FJOM.0b013e3181651556" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18469625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltl2hsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2008&pages=561-569&author=S.+Weinmannauthor=W.+M.+Vollmerauthor=V.+Breenauthor=M.+Heumannauthor=E.+Hnizdoauthor=J.+Villnaveauthor=B.+Doneyauthor=M.+Grazianiauthor=M.+A.+McBurnieauthor=A.+S.+Buist&title=COPD+and+occupational+exposures%3A+a+case-control+study&doi=10.1097%2FJOM.0b013e3181651556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">COPD and occupational exposures: A case-control study</span></div><div class="casAuthors">Weinmann, Sheila; Vollmer, William M.; Breen, Victor; Heumann, Michael; Hnizdo, Eva; Villnave, Jacqueline; Doney, Brent; Graziani, Monica; McBurnie, Mary Ann; Buist, A. Sonia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Occupational and Environmental Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">561-569</span>CODEN:
                <span class="NLM_cas:coden">JOEMFM</span>;
        ISSN:<span class="NLM_cas:issn">1076-2752</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Evidence demonstrates that occupational exposures are causally linked with chronic obstructive pulmonary disease (COPD).  This case-control study evaluated the assocn. between occupational exposures and prevalent COPD based on lifetime occupational history.  Cases (n = 388) aged 45 years and older with COPD were compared with controls (n = 356), frequency matched on age, sex, and cigarette smoking history.  Odds ratios for exposure to each of eight occupational hazard categories and three composite measures of exposure were computed using logistic regression.  Occupational exposures most strongly assocd. with COPD were diesel exhaust, irritant gases and vapors, mineral dust, and metal dust.  The composite measures describing aggregate exposure to gases, vapors, solvents, or sensitizers (GVSS) and aggregate exposure to dust, GVSS, or diesel exhaust were also assocd. with COPD.  In the small group of never-smokers, a similar pattern was evident.  These population-based findings add to the literature linking occupational exposures to COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfK17DueBkxLVg90H21EOLACvtfcHk0lgr7gR5rb_UdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltl2hsbc%253D&md5=da0c0b203e23bcc37d243ae494ff26b6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1097%2FJOM.0b013e3181651556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJOM.0b013e3181651556%26sid%3Dliteratum%253Aachs%26aulast%3DWeinmann%26aufirst%3DS.%26aulast%3DVollmer%26aufirst%3DW.%2BM.%26aulast%3DBreen%26aufirst%3DV.%26aulast%3DHeumann%26aufirst%3DM.%26aulast%3DHnizdo%26aufirst%3DE.%26aulast%3DVillnave%26aufirst%3DJ.%26aulast%3DDoney%26aufirst%3DB.%26aulast%3DGraziani%26aufirst%3DM.%26aulast%3DMcBurnie%26aufirst%3DM.%2BA.%26aulast%3DBuist%26aufirst%3DA.%2BS.%26atitle%3DCOPD%2520and%2520occupational%2520exposures%253A%2520a%2520case-control%2520study%26jtitle%3DJ.%2520Occup.%2520Environ.%2520Med.%26date%3D2008%26volume%3D50%26spage%3D561%26epage%3D569%26doi%3D10.1097%2FJOM.0b013e3181651556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gershon, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascagnette, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Victor, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, T.</span></span> <span> </span><span class="NLM_article-title">Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">991</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60990-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2811%2960990-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21907862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3Mfislykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=991-996&author=A.+S.+Gershonauthor=L.+Warnerauthor=P.+Cascagnetteauthor=J.+C.+Victorauthor=T.+To&title=Lifetime+risk+of+developing+chronic+obstructive+pulmonary+disease%3A+a+longitudinal+population+study&doi=10.1016%2FS0140-6736%2811%2960990-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study</span></div><div class="casAuthors">Gershon Andrea S; Warner Laura; Cascagnette Paul; Victor J Charles; To Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9795</span>),
    <span class="NLM_cas:pages">991-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Although chronic obstructive pulmonary disease (COPD) is one of the most deadly, prevalent, and costly chronic diseases, no comprehensive estimates of the risk of developing COPD in the general population have been published.  We aimed to quantify the lifetime risk of developing physician-diagnosed COPD in a large, multicultural North American population.  METHODS:  We did a retrospective longitudinal cohort study using population-based health administrative data from Ontario, Canada (total population roughly 13 million).  All individuals free of COPD in 1996 were monitored for up to 14 years for three possible outcomes; diagnosis of COPD by a physician, reached 80 years of age, or death.  COPD was identified with a previously validated case definition based on COPD health services claims.  The cumulative incidence of physician-diagnosed COPD over a lifetime adjusted for the competing risk of death was calculated by a modified survival analysis technique.  Results were stratified by sex, socioeconomic status, and whether individuals lived in a rural or urban setting.  FINDINGS:  A total of 579,466 individuals were diagnosed with COPD by a physician over the study period.  The overall lifetime risk of physician-diagnosed COPD at age 80 years was 27·6%.  Lifetime risk was higher in men than in women (29·7%vs 25·6%), individuals of lower socioeconomic status than in those of higher socioeconomic status (32·1%vs 23·0%), and individuals who lived in a rural setting than in those who lived in an urban setting (32·4%vs 26·7%).  INTERPRETATION:  About one in four individuals are likely to be diagnosed and receive medical attention for COPD during their lifetime.  Clinical evidence-based approaches, public health action, and more research are needed to identify effective strategies to prevent COPD and ensure that those with the disease have the highest quality of life possible.  FUNDING:  Government of Ontario, Canada.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRf9_DAJUZjPrqxQ2mb9Pu8fW6udTcc2eZY4ZVr1HnN-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3Mfislykuw%253D%253D&md5=f9ab88b566a86e8045f4a91fb1b26863</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960990-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960990-2%26sid%3Dliteratum%253Aachs%26aulast%3DGershon%26aufirst%3DA.%2BS.%26aulast%3DWarner%26aufirst%3DL.%26aulast%3DCascagnette%26aufirst%3DP.%26aulast%3DVictor%26aufirst%3DJ.%2BC.%26aulast%3DTo%26aufirst%3DT.%26atitle%3DLifetime%2520risk%2520of%2520developing%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520longitudinal%2520population%2520study%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D991%26epage%3D996%26doi%3D10.1016%2FS0140-6736%2811%2960990-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogliani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cesario, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span> <span> </span><span class="NLM_article-title">New treatments for COPD in the elderly</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5968</span>– <span class="NLM_lpage">5982</span>, <span class="refDoi"> DOI: 10.2174/1381612820666140314154331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2174%2F1381612820666140314154331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24641227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Gmtr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5968-5982&author=M.+G.+Materaauthor=L.+Calzettaauthor=P.+Roglianiauthor=A.+Cesarioauthor=M.+Cazzola&title=New+treatments+for+COPD+in+the+elderly&doi=10.2174%2F1381612820666140314154331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">New Treatments for COPD in the Elderly</span></div><div class="casAuthors">Matera, Maria Gabriella; Calzetta, Luigino; Rogliani, Paola; Cesario, Alfredo; Cazzola, Mario</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">5968-5982</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In elderly people the respiratory function is affected by anatomical and physiol. modifications caused by aging.  Elderly COPD patients are characterized by a complexity due to an increasing prevalence of comorbidities related to the age that suggest peculiar care in prescribing the therapy in those patients, also considering other disabilities that are not related with respiratory disorders as phys. and mental limitations.  Nowadays a therapy that allows modifying the long-term decline in lung function of patients suffering from COPD does not yet exist and, therefore, the treatment of this disease is mainly focused on the administration of bronchodilators and the use of inhaled glucocorticoids.  As for younger subjects, also in elderly patients the main classes of bronchodilators used in the treatment of COPD include β 2-agonists, anticholinergics and methylxanthines.  The inflammatory response suppression represents another mechanistic approach for treating COPD in the elderly, although the use of inhaled corticosteroids is limited to specific indications.  Indeed, nowadays there is a strong medical need for novel treatments of COPD in the elderly.  These are mainly represented by agents that reduce the spillover of inflammatory mediators from the lung and by compds. that inhibit the chronic systemic inflammatory syndrome.  The therapeutic approach of COPD in elderly patients remains a topic of increasing interest, however the development of novel compds. for preventing the COPD progression in the elderly, other than bronchodilators and corticosteroids, remains a challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE51_hCOsNYLVg90H21EOLACvtfcHk0lhaG020etii3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Gmtr%252FJ&md5=42405593a73f52de86628c394d0df02e</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F1381612820666140314154331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612820666140314154331%26sid%3Dliteratum%253Aachs%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DRogliani%26aufirst%3DP.%26aulast%3DCesario%26aufirst%3DA.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DNew%2520treatments%2520for%2520COPD%2520in%2520the%2520elderly%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2014%26volume%3D20%26spage%3D5968%26epage%3D5982%26doi%3D10.2174%2F1381612820666140314154331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitfessel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillissen, A.</span></span> <span> </span><span class="NLM_article-title">Maternal smoking promotes chronic obstructive lung disease in the offspring as adults</span>. <i>Eur. J. Med. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">31</span>, <span class="refDoi"> DOI: 10.1186/2047-783X-14-S4-27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2F2047-783X-14-S4-27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20156720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3cnmsValsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=27-31&author=D.+Beyerauthor=H.+Mitfesselauthor=A.+Gillissen&title=Maternal+smoking+promotes+chronic+obstructive+lung+disease+in+the+offspring+as+adults&doi=10.1186%2F2047-783X-14-S4-27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Maternal smoking promotes chronic obstructive lung disease in the offspring as adults</span></div><div class="casAuthors">Beyer D; Mitfessel H; Gillissen A</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medical research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14 Suppl 4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-31</span>
        ISSN:<span class="NLM_cas:issn">0949-2321</span>.
    </div><div class="casAbstract">INTRODUCTION:  In utero and/or childhood environmental tobacco smoke exposure is well known to adversely affect lung function and to depreciate child's health in many ways.  Fewer studies have assessed the long-term effects on COPD development and disease severity in later adulthood.  METHODS:  COPD patients were interviewed using a structured questionnaire regarding their personal as well as the smoking habits of their parents.  Data were compared with the disease history, e.g.  COPD exacerbation rate, and their lung function data.  RESULTS:  Between 2003 and 2004 COPD patients were recruited a) in a private practice specialized in pulmonary medicine (n = 133) and b) in a hospital (n = 158). 75% of their fathers and only 15.4 of all mothers smoked regularly.  COPD patients from smoking mothers had lower FEV1 predicted than those raised in household without maternal smoking exposure: 39.4 +/- 9.5% vs. 51.9 +/- 6.0% (P = 0.037).  Fathers had no effect on FEV1 regardless if they are smokers or non-smokers.  Rate of severe exacerbations requiring hospitalization remained unaffected by parental second hand smoke exposure.  CONCLUSION:  Maternal smoking negatively affects lung function of their offspring even in late adulthood when they develop COPD.  It even aggravates the cumulative effect of active cigarette consumption.  Clinical course of the COPD remained unaffected.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSS1i4bhTL7ilWTCLT8lX9SfW6udTcc2ebErqAQBCVW-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cnmsValsw%253D%253D&md5=a9518771d9fe45dd47fb05f071c0355e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2F2047-783X-14-S4-27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F2047-783X-14-S4-27%26sid%3Dliteratum%253Aachs%26aulast%3DBeyer%26aufirst%3DD.%26aulast%3DMitfessel%26aufirst%3DH.%26aulast%3DGillissen%26aufirst%3DA.%26atitle%3DMaternal%2520smoking%2520promotes%2520chronic%2520obstructive%2520lung%2520disease%2520in%2520the%2520offspring%2520as%2520adults%26jtitle%3DEur.%2520J.%2520Med.%2520Res.%26date%3D2009%26volume%3D14%26spage%3D27%26epage%3D31%26doi%3D10.1186%2F2047-783X-14-S4-27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Postma, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Berge, M.</span></span> <span> </span><span class="NLM_article-title">Risk factors and early origins of chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">899</span>– <span class="NLM_lpage">909</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(14)60446-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2814%2960446-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25123778" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252FhslWkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2015&pages=899-909&author=D.+S.+Postmaauthor=A.+Bushauthor=M.+van+den+Berge&title=Risk+factors+and+early+origins+of+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2814%2960446-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors and early origins of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Postma Dirkje S; Bush Andrew; van den Berge Maarten</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">9971</span>),
    <span class="NLM_cas:pages">899-909</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease is mainly a smoking-related disorder and affects millions of people worldwide, with a large effect on individual patients and society as a whole.  Although the disease becomes clinically apparent around the age of 40-50 years, its origins can begin very early in life.  Different risk factors in very early life--ie, in utero and during early childhood--drive the development of clinically apparent chronic obstructive pulmonary disease in later life.  In discussions of which risk factors drive chronic obstructive pulmonary disease, it is important to realise that the disease is very heterogeneous and at present is largely diagnosed by lung function only.  In this Review, we will discuss the evidence for risk factors for the various phenotypes of chronic obstructive pulmonary disease during different stages of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvZ_LAXZIzn3RxY89Cm6SyfW6udTcc2ebErqAQBCVW-rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252FhslWkug%253D%253D&md5=f8ab6f1e12fcf7733aaf6fbd79dad09a</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2814%2960446-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252814%252960446-3%26sid%3Dliteratum%253Aachs%26aulast%3DPostma%26aufirst%3DD.%2BS.%26aulast%3DBush%26aufirst%3DA.%26aulast%3Dvan%2Bden%2BBerge%26aufirst%3DM.%26atitle%3DRisk%2520factors%2520and%2520early%2520origins%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2015%26volume%3D385%26spage%3D899%26epage%3D909%26doi%3D10.1016%2FS0140-6736%2814%2960446-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grol, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerritsen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vonk, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schouten, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koëter, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rijcken, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postma, D. S.</span></span> <span> </span><span class="NLM_article-title">Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 30-year follow-up study</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">1830</span>– <span class="NLM_lpage">1837</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.160.6.9812100</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Fajrccm.160.6.9812100" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10588593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252Fls1eiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1999&pages=1830-1837&author=M.+H.+Grolauthor=J.+Gerritsenauthor=J.+M.+Vonkauthor=J.+P.+Schoutenauthor=G.+H.+Ko%C3%ABterauthor=B.+Rijckenauthor=D.+S.+Postma&title=Risk+factors+for+growth+and+decline+of+lung+function+in+asthmatic+individuals+up+to+age+42+years.+A+30-year+follow-up+study&doi=10.1164%2Fajrccm.160.6.9812100"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors for growth and decline of lung function in asthmatic individuals up to age 42 years. A 30-year follow-up study</span></div><div class="casAuthors">Grol M H; Gerritsen J; Vonk J M; Schouten J P; Koeter G H; Rijcken B; Postma D S</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1830-7</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Little is known about factors determining the outcome of childhood asthma.  The purpose of this longitudinal study was to assess the factors in childhood that determine the level of FEV(1) in early adulthood in asthmatic individuals, and to examine factors associated with decline in FEV(1) during adulthood.  Between 1966 and 1969, 119 allergic asthmatic subjects aged 5 to 14 yr were studied (Visit 1).  Of these subjects, 101 (85%) were reinvestigated at ages 22 to 32 yr (Visit 2) and 32 to 42 yr (Visit 3).  At the first survey and during follow-up, a standardized questionnaire was used, serum total IgE and peripheral blood eosinophils were measured, and physical examination, skin tests, lung function tests, and histamine challenge (provocative concentration causing a 10% decline in FEV(1); PC(10)) tests were performed according to the same protocol.  Multiple linear regression analyses were performed with FEV(1) at Visit 2 and with the change of FEV(1) from Visit 2 to Visit 3 as outcome variables.  A low FEV(1)% predicted at Visit 1 and PC(10) </= 16 mg/ml at Visit 1 were significantly associated with a lower level of FEV(1) at Visit 2.  Subjects who quit smoking and subjects who continued to use inhaled corticosteroids had a significantly smaller annual decline in FEV(1) from Visit 2 to Visit 3, adjusted for attained level of FEV(1) at Visit 2.  In conclusion, bronchial hyperresponsiveness and a low level of lung function in childhood are independent risk factors for a low level of FEV(1) in early adulthood.  A smaller decline in FEV(1) after ages 22 to 32 yr occurs in asthmatics who quit smoking and who continue to use inhaled corticosteroids.  Our data stress the importance of studying intervention strategies for asthma in young childhood and early adulthood in order to prevent or postpone further lung function deficits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSc6IBWE8rpU__I8Jvzw4xCfW6udTcc2eZjUXa8wTMlJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252Fls1eiug%253D%253D&md5=32b1519a6f90109b77873d988bf12630</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.160.6.9812100&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.160.6.9812100%26sid%3Dliteratum%253Aachs%26aulast%3DGrol%26aufirst%3DM.%2BH.%26aulast%3DGerritsen%26aufirst%3DJ.%26aulast%3DVonk%26aufirst%3DJ.%2BM.%26aulast%3DSchouten%26aufirst%3DJ.%2BP.%26aulast%3DKo%25C3%25ABter%26aufirst%3DG.%2BH.%26aulast%3DRijcken%26aufirst%3DB.%26aulast%3DPostma%26aufirst%3DD.%2BS.%26atitle%3DRisk%2520factors%2520for%2520growth%2520and%2520decline%2520of%2520lung%2520function%2520in%2520asthmatic%2520individuals%2520up%2520to%2520age%252042%2520years.%2520A%252030-year%2520follow-up%2520study%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1999%26volume%3D160%26spage%3D1830%26epage%3D1837%26doi%3D10.1164%2Fajrccm.160.6.9812100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silva, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherrill, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbee, R. A.</span></span> <span> </span><span class="NLM_article-title">Asthma as a risk factor for COPD in a longitudinal study</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1378/chest.126.1.59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1378%2Fchest.126.1.59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15249443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2czks1WqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=59-65&author=G.+E.+Silvaauthor=D.+L.+Sherrillauthor=S.+Guerraauthor=R.+A.+Barbee&title=Asthma+as+a+risk+factor+for+COPD+in+a+longitudinal+study&doi=10.1378%2Fchest.126.1.59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Asthma as a risk factor for COPD in a longitudinal study</span></div><div class="casAuthors">Silva Graciela E; Sherrill Duane L; Guerra Stefano; Barbee Robert A</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-65</span>
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    </div><div class="casAbstract">BACKGROUND:  For several years, asthma and COPD have been regarded as distinct entities, with distinct clinical courses.  However, despite distinctive physiologic features at the time of diagnosis, and different risk factors, the two diseases over time may develop features that are quite similar.  STUDY OBJECTIVE:  To evaluate the association between physician-diagnosed asthma and the subsequent development of COPD in a cohort of 3,099 adult subjects from Tucson, AZ.  DESIGN AND METHODS:  A prospective observational study.  Participants completed up to 12 standard respiratory questionnaires and 11 spirometry lung function measurements over a period of 20 years.  Survival curves (with time to development of COPD as the dependent variable) were compared between subjects with asthma and subjects without asthma at the initial survey.  RESULTS:  Subjects with active asthma (n = 192) had significantly higher hazard ratios than inactive (n = 156) or nonasthmatic subjects (n = 2751) for acquiring COPD.  As compared with nonasthmatics, active asthmatics had a 10-times-higher risk for acquiring symptoms of chronic bronchitis (95% confidence interval [CI], 4.94 to 20.25), 17-times-higher risk of receiving a diagnosis of emphysema (95% CI, 8.31 to 34.83), and 12.5-times-higher risk of fulfilling COPD criteria (95% CI, 6.84 to 22.84), even after adjusting for smoking history and other potential confounders.  CONCLUSIONS:  Physician-diagnosed asthma is significantly associated with an increased risk for CB, emphysema, and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTD7169-4f_KjQLBVDQn4bCfW6udTcc2eZjUXa8wTMlJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czks1WqtA%253D%253D&md5=43529b3ffb47cd25e853797d2e3997e5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1378%2Fchest.126.1.59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.126.1.59%26sid%3Dliteratum%253Aachs%26aulast%3DSilva%26aufirst%3DG.%2BE.%26aulast%3DSherrill%26aufirst%3DD.%2BL.%26aulast%3DGuerra%26aufirst%3DS.%26aulast%3DBarbee%26aufirst%3DR.%2BA.%26atitle%3DAsthma%2520as%2520a%2520risk%2520factor%2520for%2520COPD%2520in%2520a%2520longitudinal%2520study%26jtitle%3DChest%26date%3D2004%26volume%3D126%26spage%3D59%26epage%3D65%26doi%3D10.1378%2Fchest.126.1.59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span> <span> </span><span class="NLM_article-title">Risk factors and intervention for chronic obstructive pulmonary disease in China</span>. <i>Respirology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1111/resp.12190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fresp.12190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24188198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2c7mtVOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=4-9&author=Y.+Zhouauthor=R.+Chen&title=Risk+factors+and+intervention+for+chronic+obstructive+pulmonary+disease+in+China&doi=10.1111%2Fresp.12190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Risk factors and intervention for chronic obstructive pulmonary disease in China</span></div><div class="casAuthors">Zhou Yumin; Chen Rongchang</div><div class="citationInfo"><span class="NLM_cas:title">Respirology (Carlton, Vic.)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18 Suppl 3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In China, chronic obstructive pulmonary disease (COPD) is one of the most common chronic diseases with a prevalence of 8.2% in the population over 40 years of age.  In 2006, it was the third most common cause of death in China accounting for 17.6% of all deaths.  Although worldwide smoking is the most common risk factor for COPD, in China, additional important risk factors include environmental tobacco smoke, biomass smoke and post-pulmonary tuberculosis.  Interventions based on mitigating these risk factors have a particularly important role in strategies aimed at preventing COPD in China.  Indeed, preliminary research findings have shown that early intervention based on minimizing these risk factors might be a cost-effective way to prevent COPD in China.  Future research should focus on large scale, randomized and controlled prospective studies to address the efficacy, feasibility and health economics of minimizing these important risk factors in China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQWFwyRaxVGWdts4TFFB11gfW6udTcc2eaSnNesrDthprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c7mtVOksg%253D%253D&md5=5f41949b50c0b0a92833a4cd8595635d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1111%2Fresp.12190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fresp.12190%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DR.%26atitle%3DRisk%2520factors%2520and%2520intervention%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520China%26jtitle%3DRespirology%26date%3D2013%26volume%3D18%26spage%3D4%26epage%3D9%26doi%3D10.1111%2Fresp.12190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Immunology of asthma and chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1038/nri2254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnri2254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18274560" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisVKjsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=183-192&author=P.+J.+Barnes&title=Immunology+of+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnri2254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Immunology of asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">183-192</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Asthma and chronic obstructive pulmonary disease (COPD) are both obstructive airway diseases that involve chronic inflammation of the respiratory tract, but the type of inflammation is markedly different between these diseases, with different patterns of inflammatory cells and mediators being involved.  As described in this Review, these inflammatory profiles are largely detd. by the involvement of different immune cells, which orchestrate the recruitment and activation of inflammatory cells that drive the distinct patterns of structural changes in these diseases.  However, it is now becoming clear that the distinction between these diseases becomes blurred in patients with severe asthma, in asthmatic subjects who smoke and during acute exacerbations.  This has important implications for the development of new therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKkJK_5vmv57Vg90H21EOLACvtfcHk0liT2eKyJogSHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisVKjsrs%253D&md5=a1d09a214bbd87e31e0c714039077289</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnri2254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2254%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DImmunology%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D183%26epage%3D192%26doi%3D10.1038%2Fnri2254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brusselle, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joos, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracke, K. R.</span></span> <span> </span><span class="NLM_article-title">New insights into the immunology of chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1015</span>– <span class="NLM_lpage">1026</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(11)60988-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2811%2960988-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21907865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCqs77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=1015-1026&author=G.+G.+Brusselleauthor=G.+F.+Joosauthor=K.+R.+Bracke&title=New+insights+into+the+immunology+of+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2811%2960988-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the immunology of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Brusselle, Guy G.; Joos, Guy F.; Bracke, Ken R.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">9795</span>),
    <span class="NLM_cas:pages">1015-1026</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Chronic obstructive pulmonary disease (COPD) is a heterogeneous syndrome assocd. with abnormal inflammatory immune responses of the lung to noxious particles and gases.  Cigarette smoke activates innate immune cells such as epithelial cells and macrophages by triggering pattern recognition receptors, either directly or indirectly via the release of damage-assocd. mol. patterns from stressed or dying cells.  Activated dendritic cells induce adaptive immune responses encompassing T helper (Th1 and Th17) CD4+ T cells, CD8+ cytotoxicity, and B-cell responses, which lead to the development of lymphoid follicles on chronic inflammation.  Viral and bacterial infections not only cause acute exacerbations of COPD, but also amplify and perpetuate chronic inflammation in stable COPD via pathogen-assocd. mol. patterns.  We discuss the role of autoimmunity (autoantibodies), remodelling, extracellular matrix-derived fragments, impaired innate lung defences, oxidative stress, hypoxia, and dysregulation of microRNAs in the persistence of the pulmonary inflammation despite smoking cessation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS6dNX1v0BN7Vg90H21EOLACvtfcHk0liT2eKyJogSHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCqs77O&md5=f2efdec16bd951c0155442c9024666f9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2960988-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252960988-4%26sid%3Dliteratum%253Aachs%26aulast%3DBrusselle%26aufirst%3DG.%2BG.%26aulast%3DJoos%26aufirst%3DG.%2BF.%26aulast%3DBracke%26aufirst%3DK.%2BR.%26atitle%3DNew%2520insights%2520into%2520the%2520immunology%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D1015%26epage%3D1026%26doi%3D10.1016%2FS0140-6736%2811%2960988-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wedzicha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seemungal, T. A.</span></span> <span> </span><span class="NLM_article-title">COPD exacerbations: defining their cause and prevention</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">796</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(07)61382-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2807%2961382-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17765528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2srhs1Sitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2007&pages=786-796&author=J.+A.+Wedzichaauthor=T.+A.+Seemungal&title=COPD+exacerbations%3A+defining+their+cause+and+prevention&doi=10.1016%2FS0140-6736%2807%2961382-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">COPD exacerbations: defining their cause and prevention</span></div><div class="casAuthors">Wedzicha Jadwiga A; Seemungal Terence A R</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">9589</span>),
    <span class="NLM_cas:pages">786-96</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of worsening of symptoms, leading to substantial morbidity and mortality.  COPD exacerbations are associated with increased airway and systemic inflammation and physiological changes, especially the development of hyperinflation.  They are triggered mainly by respiratory viruses and bacteria, which infect the lower airway and increase airway inflammation.  Some patients are particularly susceptible to exacerbations, and show worse health status and faster disease progression than those who have infrequent exacerbations.  Several pharmacological interventions are effective for the reduction of exacerbation frequency and severity in COPD such as inhaled steroids, long-acting bronchodilators, and their combinations.  Non-pharmacological therapies such as pulmonary rehabilitation, self-management, and home ventilatory support are becoming increasingly important, but still need to be studied in controlled trials.  The future of exacerbation prevention is in assessment of optimum combinations of pharmacological and non-pharmacological therapies that will result in improvement of health status, and reduction of hospital admission and mortality associated with COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTAJAVB43A0pw7prLlxLOzfW6udTcc2eZLsoxlyJysibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2srhs1Sitw%253D%253D&md5=76655b3b851f0169f5b3ba1dda2c22e9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2807%2961382-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252807%252961382-8%26sid%3Dliteratum%253Aachs%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DSeemungal%26aufirst%3DT.%2BA.%26atitle%3DCOPD%2520exacerbations%253A%2520defining%2520their%2520cause%2520and%2520prevention%26jtitle%3DLancet%26date%3D2007%26volume%3D370%26spage%3D786%26epage%3D796%26doi%3D10.1016%2FS0140-6736%2807%2961382-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirkham, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress in COPD</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>144</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1378/chest.12-2664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1378%2Fchest.12-2664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23880677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Chtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=144&publication_year=2013&pages=266-273&author=P.+A.+Kirkhamauthor=P.+J.+Barnes&title=Oxidative+stress+in+COPD&doi=10.1378%2Fchest.12-2664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress in COPD</span></div><div class="casAuthors">Kirkham, Paul A.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">144</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">266-273</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">A review.  Oxidative stress is now recognized as a major predisposing factor in the pathogenesis of COPD.  Existing therapies for COPD are ineffective at halting disease progression, with bronchodilators being the mainstay of pharmacotherapy, providing symptomatic relief only.  It is, therefore, important for a better understanding of the underlying mechanisms by which oxidative stress drives disease pathogenesis to develop novel and more effective therapies.  Antioxidant capacity in COPD is substantially reduced as a result of cigarette smoking and exacerbations, with oxidative stress persisting long after the cessation of cigarette smoking or exacerbation, due to the continued prodn. of reactive oxygen species from endogenous sources.  We discuss (1) how oxidative stress arises in the lung, (2) how it is neutralized, (3) what genetic factors may predispose to the development of COPD, and (4) how this impacts inflammation and autoimmunity in the development of emphysema and small airways disease.  Finally, various strategies have been considered to neutralize the increased oxidative burden present in COPD.  This review highlights why current antioxidant strategies have so far failed and what promising alternatives are on the horizon.  Moreover, a no. of studies have shown that there is no single "magic bullet" to combat oxidative stress, but instead a combination therapy, targeting oxidative stress in the various subcellular compartments, may prove to be more effective in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOpkJCKDjIPbVg90H21EOLACvtfcHk0lidP_u9Xymg7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Chtb3E&md5=895fa4278d4021be1292d6d1abcc892e</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1378%2Fchest.12-2664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.12-2664%26sid%3Dliteratum%253Aachs%26aulast%3DKirkham%26aufirst%3DP.%2BA.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DOxidative%2520stress%2520in%2520COPD%26jtitle%3DChest%26date%3D2013%26volume%3D144%26spage%3D266%26epage%3D273%26doi%3D10.1378%2Fchest.12-2664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chillappagari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preuss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahavadi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarode, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahrlich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, M. O.</span></span> <span> </span><span class="NLM_article-title">Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">85</span>, <span class="refDoi"> DOI: 10.1186/s12931-015-0247-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2Fs12931-015-0247-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26169056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FivVKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=85&author=S.+Chillappagariauthor=J.+Preussauthor=S.+Lichtauthor=C.+M%C3%BCllerauthor=P.+Mahavadiauthor=G.+Sarodeauthor=C.+Vogelmeierauthor=A.+Guentherauthor=L.+Nahrlichauthor=B.+K.+Rubinauthor=M.+O.+Henke&title=Altered+protease+and+antiprotease+balance+during+a+COPD+exacerbation+contributes+to+mucus+obstruction&doi=10.1186%2Fs12931-015-0247-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction</span></div><div class="casAuthors">Chillappagari Shashi; Nahrlich Lutz; Chillappagari Shashi; Mahavadi Poornima; Guenther Andreas; Chillappagari Shashi; Preuss Jenni; Licht Sebastian; Muller Christian; Vogelmeier Claus; Henke Markus O; Chillappagari Shashi; Mahavadi Poornima; Guenther Andreas; Nahrlich Lutz; Sarode Gaurav; Henke Markus O; Sarode Gaurav; Henke Markus O; Guenther Andreas; Guenther Andreas; Rubin Bruce K</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Proteases have been shown to degrade airway mucin proteins and to damage the epithelium impairing mucociliary clearance.  There are increased proteases in the COPD airway but changes in protease-antiprotease balance and mucin degradation have not been investigated during the course of a COPD exacerbation.  We hypothesized that increased protease levels would lead to mucin degradation in acute COPD exacerbations.  METHODS:  We measured neutrophil elastase (NE) and alpha 1 protease inhibitor (A1-PI) levels using immunoblotting, and conducted protease inhibitor studies, zymograms, elastin substrate assays and cigarette smoke condensate experiments to evaluate the stability of the gel-forming mucins, MUC5AC and MUC5B, before and 5-6 weeks after an acute pulmonary exacerbation of COPD (n = 9 subjects).  RESULTS:  Unexpectedly, mucin concentration and mucin stability were highest at the start of the exacerbation and restored to baseline after 6 weeks.  Consistent with these data, immunoblots and zymograms confirmed decreased NE concentration and activity and increased A1-PI at the start of the exacerbation.  After recovery there was an increase in NE activity and a decrease in A1-PI levels.  In vitro, protease inhibitor studies demonstrated that serine proteases played a key role in mucin degradation.  Mucin stability was further enhanced upon treating with cigarette smoke condensate (CSC).  CONCLUSION:  There appears to be rapid consumption of secreted proteases due to an increase in antiproteases, at the start of a COPD exacerbation.  This leads to increased mucin gel stability which may be important in trapping and clearing infectious and inflammatory mediators, but this may also contribute acutely to mucus retention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-fuLe5VCDtK-9TkgmBqTqfW6udTcc2eZLsoxlyJysibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FivVKrsA%253D%253D&md5=a285e6600fc7af294c94a7cf0478f678</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1186%2Fs12931-015-0247-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-015-0247-x%26sid%3Dliteratum%253Aachs%26aulast%3DChillappagari%26aufirst%3DS.%26aulast%3DPreuss%26aufirst%3DJ.%26aulast%3DLicht%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DMahavadi%26aufirst%3DP.%26aulast%3DSarode%26aufirst%3DG.%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DGuenther%26aufirst%3DA.%26aulast%3DNahrlich%26aufirst%3DL.%26aulast%3DRubin%26aufirst%3DB.%2BK.%26aulast%3DHenke%26aufirst%3DM.%2BO.%26atitle%3DAltered%2520protease%2520and%2520antiprotease%2520balance%2520during%2520a%2520COPD%2520exacerbation%2520contributes%2520to%2520mucus%2520obstruction%26jtitle%3DRespir.%2520Res.%26date%3D2015%26volume%3D16%26spage%3D85%26doi%3D10.1186%2Fs12931-015-0247-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Frontrunners in novel pharmacotherapy of COPD</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">300</span>– <span class="NLM_lpage">307</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2008.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.coph.2008.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18457992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVyls74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=300-307&author=P.+J.+Barnes&title=Frontrunners+in+novel+pharmacotherapy+of+COPD&doi=10.1016%2Fj.coph.2008.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Frontrunners in novel pharmacotherapy of COPD</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">300-307</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The mainstay of current drug therapy is long-acting bronchodilators; several longer acting inhaled β2-agonists and muscarinic antagonists (and combinations) are now in development.  No treatments reduce the progression or suppress the inflammation of COPD.  With better understanding of the inflammatory and destructive process, several new targets have been identified.  Several mediator antagonists tested in COPD have been disappointing, but of CXCR2 antagonists that block pulmonary neutrophil and monocyte recruitment may be more promising.  Broad spectrum anti-inflammatory drugs may be more effective, and include inhibitors of PDE4, p38 MAPK and NF-κB, but side effects will be a major limitation so that inhaled delivery will be necessary.  Perhaps the most promising approach is reversal corticosteroid resistance through increasing HDAC2 activity.  This may be achieved by theophylline-like drugs, more effective antioxidants and non-antibiotic macrolides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMyLX0gSpk6rVg90H21EOLACvtfcHk0lilI5549X8Aag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVyls74%253D&md5=b17303237111da63aba568a301b132fb</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2008.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2008.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DFrontrunners%2520in%2520novel%2520pharmacotherapy%2520of%2520COPD%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2008%26volume%3D8%26spage%3D300%26epage%3D307%26doi%3D10.1016%2Fj.coph.2008.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansel, T. T.</span></span> <span> </span><span class="NLM_article-title">Prospects for new drugs for chronic obstructive pulmonary disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">996</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(04)17025-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0140-6736%2804%2917025-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15364192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFSitLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2004&pages=985-996&author=P.+J.+Barnesauthor=T.+T.+Hansel&title=Prospects+for+new+drugs+for+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS0140-6736%2804%2917025-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Prospects for new drugs for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.; Hansel, Trevor T.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">9438</span>),
    <span class="NLM_cas:pages">985-996</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  No currently available treatments have been shown to slow the progression of chronic obstructive pulmonary disease (COPD) or suppress the inflammation in small airways and lung parenchyma.  However, several new treatments are in clin. development; some target the inflammatory process and others are directed against structural cells.  A group of specific therapies are directed against the influx of inflammatory cells into the airways and lung parenchyma that occurs in COPD; these include agents directed against adhesion mols. and chemokines, as well as therapies to oppose tumor necrosis factor α and increase interleukin 10.  Broad-range anti-inflammatory drugs are now in phase III development for COPD; they include inhibitors of phosphodiesterase 4.  Other drugs that inhibit cell signaling include inhibitors of p38 mitogen-activated protein kinase, nuclear factor κB, and phosphoinositide-3-kinase γ.  More specific approaches are to give antioxidants, inhibitors of inducible nitric oxide synthase, and antagonists of leukotriene B4 receptor.  Inhibitors of epidermal-growth-factor-receptor kinase and calcium-activated chloride channels have the potential to prevent overprodn. of mucus.  Therapy to inhibit fibrosis is being developed against transforming growth factor β1 and protease-activated receptor 2.  There is also a search for inhibitors of serine proteinases and matrix metalloproteinases to prevent lung destruction and the development of emphysema, as well as drugs such as retinoids that might even reverse this process.  Effective delivery of drugs to the sites of disease in the peripheral lung is an important consideration, and there is a need for validated biomarkers and monitoring techniques in early clin. studies with new therapies for COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGVjB6gIMp8rVg90H21EOLACvtfcHk0lilI5549X8Aag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFSitLg%253D&md5=cbfe89460d92c0cb47f9d10111f95585</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2804%2917025-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252804%252917025-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DHansel%26aufirst%3DT.%2BT.%26atitle%3DProspects%2520for%2520new%2520drugs%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%26date%3D2004%26volume%3D364%26spage%3D985%26epage%3D996%26doi%3D10.1016%2FS0140-6736%2804%2917025-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montuschi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciabattoni, G.</span></span> <span> </span><span class="NLM_article-title">Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4131</span>– <span class="NLM_lpage">4164</span>, <span class="refDoi"> DOI: 10.1021/jm5013227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5013227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXosVygtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4131-4164&author=P.+Montuschiauthor=G.+Ciabattoni&title=Bronchodilating+drugs+for+chronic+obstructive+pulmonary+disease%3A+current+status+and+future+trends&doi=10.1021%2Fjm5013227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends</span></div><div class="casAuthors">Montuschi, Paolo; Ciabattoni, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4131-4164</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacol. treatment of stable chronic obstructive pulmonary disease (COPD).  Among approved LAMA, tiotropium bromide, glycopyrronium bromide, and umeclidinium bromide are administered once daily, whereas aclidinium bromide is administered every 12 h.  New LAMA are under development for COPD.  Among the approved LABA, indacaterol has a 24 h duration of action, whereas salmeterol and formoterol require twice-daily administration.  New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abediterol, are in development.  LAMA/LABA fixed dose combinations (FDCs) provide the convenience of two bronchodilators with different mechanism of action in a single inhaler.  Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been approved or are under approval and are likely to become a std. pharmacol. strategy for COPD.  Inhaled dual-pharmacol. compds., combining muscarinic antagonism and β2-agonism (MABA) in a single mol., potentially provide additive or synergistic bronchodilation over either inhaled antimuscarinic or β2-agonist monotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLB6Vc0-8tzbVg90H21EOLACvtfcHk0lilI5549X8Aag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXosVygtA%253D%253D&md5=816e44be469a0396d859cd3576514085</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm5013227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5013227%26sid%3Dliteratum%253Aachs%26aulast%3DMontuschi%26aufirst%3DP.%26aulast%3DCiabattoni%26aufirst%3DG.%26atitle%3DBronchodilating%2520drugs%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520current%2520status%2520and%2520future%2520trends%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4131%26epage%3D4164%26doi%3D10.1021%2Fjm5013227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L.
E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">546</span>– <span class="NLM_lpage">553</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2006.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.tips.2006.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16911834" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Wgtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2006&pages=546-553&author=L.%0AE.+Donnellyauthor=P.+J.+Barnes&title=Chemokine+receptors+as+therapeutic+targets+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.tips.2006.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Donnelly, Louise E.; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">546-553</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is an increasing global health problem for which there are no effective disease-modifying therapies.  COPD involves chronic inflammation of small airways and lung parenchyma, with the recruitment of inflammatory cells.  This inflammatory-cell trafficking is orchestrated by multiple chemokines, so the blockade of chemokine receptors with selective antagonists might be an effective anti-inflammatory strategy in this disease.  Several studies support the implication of several chemokines and their receptors in COPD, including chemokine receptors CXCR2 and CXCR3, with small-mol. receptor antagonists that are in development being potential anti-inflammatory therapies.  Such a pharmacol. strategy would provide a mechanism with which to inhibit leukocyte recruitment and, hence, reduce the inflammatory profile in COPD, which is currently unaffected by pharmacotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXBb0OZsgMvbVg90H21EOLACvtfcHk0lilI5549X8Aag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Wgtr4%253D&md5=5c6ebf9f4cadfd30df7dbe3586fb624a</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2006.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2006.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DChemokine%2520receptors%2520as%2520therapeutic%2520targets%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2006%26volume%3D27%26spage%3D546%26epage%3D553%26doi%3D10.1016%2Fj.tips.2006.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Mediators of chronic obstructive pulmonary disease</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">515</span>– <span class="NLM_lpage">548</span>, <span class="refDoi"> DOI: 10.1124/pr.56.4.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fpr.56.4.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15602009" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2004&pages=515-548&author=P.+J.+Barnes&title=Mediators+of+chronic+obstructive+pulmonary+disease&doi=10.1124%2Fpr.56.4.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Mediators of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">515-548</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem that is now a leading cause of death.  COPD is assocd. with a chronic inflammatory response, predominantly in small airways and lung parenchyma, which is characterized by increased nos. of macrophages, neutrophils, and T lymphocytes.  The inflammatory mediators involved in COPD have not been clearly defined, in contrast to asthma, but it is now apparent that many lipid mediators, inflammatory peptides, reactive oxygen and nitrogen species, chemokines, cytokines, and growth factors are involved in orchestrating the complex inflammatory process that results in small airway fibrosis and alveolar destruction.  Many proteases are also involved in the inflammatory process and are responsible for the destruction of elastin fibers in the lung parenchyma, which is the hallmark of emphysema.  The identification of inflammatory mediators and understanding their interactions is important for the development of anti-inflammatory treatments for this important disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpISgwqcjIYtLVg90H21EOLACvtfcHk0ljnieICVFUomQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWlt7s%253D&md5=937a8351bde4c91872e956746a7d46e2</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fpr.56.4.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.56.4.2%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DMediators%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2004%26volume%3D56%26spage%3D515%26epage%3D548%26doi%3D10.1124%2Fpr.56.4.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stockley, R.
A.</span></span> <span> </span><span class="NLM_article-title">Neutrophils and protease/antiprotease imbalance</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>160</i></span>,  <span class="NLM_fpage">S49</span>– <span class="NLM_lpage">S52</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.160.supplement_1.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Fajrccm.160.supplement_1.13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10556170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FksFSiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=160&publication_year=1999&pages=S49-S52&author=R.%0AA.+Stockley&title=Neutrophils+and+protease%2Fantiprotease+imbalance&doi=10.1164%2Fajrccm.160.supplement_1.13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophils and protease/antiprotease imbalance</span></div><div class="casAuthors">Stockley R A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">160</span>
        (<span class="NLM_cas:issue">5 Pt 2</span>),
    <span class="NLM_cas:pages">S49-52</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">An imbalance between neutrophil proteases and the surrounding antiproteases is critical in the normal functioning of the neutrophil.  Enzyme activity is of importance in cell migration and may play a role in some beneficial aspects of host defense.  However, when persistent or excessive this imbalance can be detrimental and (even in the absence of antiprotease deficiency) central to most of the pathogenic processes in COPD.  Understanding of these complex relationships that alter a beneficial host defense response to a destructive one will be critical in the development of long-term therapeutic strategies.  Stockley RA.  Neutrophils and protease/antiprotease imbalance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTbByo80RnNtWxpATR2EQURfW6udTcc2ea7Xox-94Znubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FksFSiuw%253D%253D&md5=0ba262d3baca6bcfc298595e7bafddeb</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.160.supplement_1.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.160.supplement_1.13%26sid%3Dliteratum%253Aachs%26aulast%3DStockley%26aufirst%3DR.%2BA.%26atitle%3DNeutrophils%2520and%2520protease%252Fantiprotease%2520imbalance%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1999%26volume%3D160%26spage%3DS49%26epage%3DS52%26doi%3D10.1164%2Fajrccm.160.supplement_1.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belvisi, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, K. M.</span></span> <span> </span><span class="NLM_article-title">The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?</span>. <i>Inflammation Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1007/s000110300020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs000110300020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12755372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsFSru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2003&pages=95-100&author=M.+G.+Belvisiauthor=K.+M.+Bottomley&title=The+role+of+matrix+metalloproteinases+%28MMPs%29+in+the+pathophysiology+of+chronic+obstructive+pulmonary+disease+%28COPD%29%3A+a+therapeutic+role+for+inhibitors+of+MMPs%3F&doi=10.1007%2Fs000110300020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): A therapeutic role for inhibitors of MMPs?</span></div><div class="casAuthors">Belvisi, M. G.; Bottomley, K. M.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">95-100</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is the collective term describing two sep. chronic lung disease diseases: emphysema and chronic bronchitis (1).  Initial clin. symptoms are shortness of breath and occasional cough.  As the disease progresses difficulties in breathing becomes more pronounced, the cough more persistent and becomes assocd. with prodn. of a clear sputum.  In severe cases there are addnl. heart complications.  The major risk factor for COPD is cigarette smoking.  Between 1980 and 1990 there was a 22% increase in the occurrence of the disease with attributed 84,000 deaths in 1990 in the USA.  Current therapies address the symptoms and range from bronchodilators, corticosteroids to oxygen.  While there are no effective cures, although the disease can be prevented and progress slowed in many cases by removing the principal risk factor: cigarette smoking.  Progression of the disease is assocd. with degrdn. of elastin in the walls of the alveoli, resulting in the functional destruction of the these organs.  The net increase in proteolytic activity leading to this loss of alveoli function is a growing focus of pharmaceutical efforts for identification of a therapy for the amelioration of this disease.  Of specific interest for this review has been the potential roles of members of the MMP family in both the destruction of elastin and the aberrant remodeling of damaged alveoli.  An example of such a MMP is Metalloelastase.  Metalloelastase (MMP-12) is (as the name suggests) capable of degrading elastin, as well as other extra-cellular matrix components.  It is produced predominantly by infiltrating macrophages and appears essential for macrophage migration through extra-cellular matrix (2).  Mouse metalloelastase knock-out studies implicate this enzyme as a key mediator in the pathol. assocd. with cigarette smoke induced emphysema (3).  There is also associative evidence from human genetic and animal studies suggesting a pathol. link with other MMPs, such as MMPs 1,2,3,8&9.  The evidence for the role of these MMPs in the pathol. processes assocd. with COPD and prospects for MMP inhibitors as the basis for future therapies will be addressed in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRV6cfvmbSIrVg90H21EOLACvtfcHk0ljnieICVFUomQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsFSru7Y%253D&md5=3fb02f6b319c9c5f3707de0a1a7e7737</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1007%2Fs000110300020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs000110300020%26sid%3Dliteratum%253Aachs%26aulast%3DBelvisi%26aufirst%3DM.%2BG.%26aulast%3DBottomley%26aufirst%3DK.%2BM.%26atitle%3DThe%2520role%2520of%2520matrix%2520metalloproteinases%2520%2528MMPs%2529%2520in%2520the%2520pathophysiology%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%253A%2520a%2520therapeutic%2520role%2520for%2520inhibitors%2520of%2520MMPs%253F%26jtitle%3DInflammation%2520Res.%26date%3D2003%26volume%3D52%26spage%3D95%26epage%3D100%26doi%3D10.1007%2Fs000110300020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kodimuthali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabaris, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, M.</span></span> <span> </span><span class="NLM_article-title">Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5471</span>– <span class="NLM_lpage">5489</span>, <span class="refDoi"> DOI: 10.1021/jm800582j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800582j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1alsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5471-5489&author=A.+Kodimuthaliauthor=S.+S.+Jabarisauthor=M.+Pal&title=Recent+advances+on+phosphodiesterase+4+inhibitors+for+the+treatment+of+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1021%2Fjm800582j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances on Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Kodimuthali, Arumugam; Jabaris, S. Sugin Lal; Pal, Manojit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5471-5489</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDQPTfmPINKbVg90H21EOLACvtfcHk0ljRBqddp5Srlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1alsbg%253D&md5=d4502dc5ce4b8b17d5b1d4d853403768</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm800582j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800582j%26sid%3Dliteratum%253Aachs%26aulast%3DKodimuthali%26aufirst%3DA.%26aulast%3DJabaris%26aufirst%3DS.%2BS.%26aulast%3DPal%26aufirst%3DM.%26atitle%3DRecent%2520advances%2520on%2520phosphodiesterase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5471%26epage%3D5489%26doi%3D10.1021%2Fjm800582j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">New anti-inflammatory targets for chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">543</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1038/nrd4025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrd4025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23977698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3sbisVyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=543-559&author=P.+J.+Barnes&title=New+anti-inflammatory+targets+for+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fnrd4025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">New anti-inflammatory targets for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Drug discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">543-59</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is associated with chronic inflammation of the peripheral airways and lung parenchyma, which leads to progressive obstruction of the airways.  Current management with long-acting bronchodilators does not reduce disease progression, and there are no treatments that effectively suppress chronic inflammation in COPD.  An increased understanding of the inflammatory processes that are involved in the pathophysiology of COPD has identified several new therapeutic targets.  This Review discusses some of the most promising of these targets, including new antioxidants, kinase inhibitors and drugs that target cellular senescence, microbial colonization, epigenetic regulation of inflammatory gene expression and corticosteroid resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRombdIqyOV5mHOrQ6qeX-mfW6udTcc2eZNtbV56zWUb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbisVyiuw%253D%253D&md5=fa75de40a57b035f9b7351f4ad77beeb</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd4025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4025%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DNew%2520anti-inflammatory%2520targets%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D543%26epage%3D559%26doi%3D10.1038%2Fnrd4025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Polosa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, M. R.</span></span> <span> </span><span class="NLM_article-title">Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">535</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2009.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.tips.2009.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19762093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFyqtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2009&pages=528-535&author=R.+Polosaauthor=M.+R.+Blackburn&title=Adenosine+receptors+as+targets+for+therapeutic+intervention+in+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.tips.2009.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine receptors as targets for therapeutic intervention in asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Polosa, Riccardo; Blackburn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">528-535</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Asthma and chronic obstructive pulmonary disease (COPD) are pulmonary disorders characterized by various degrees of inflammation and tissue remodeling.  Adenosine is a signaling mol. that is elevated in the lungs of patients with asthma and COPD.  Adenosine elicits its actions by engaging cell surface adenosine receptors, and substantial preclin. evidence suggests that targeting these receptors will provide novel approaches for the treatment of asthma and COPD.  Studies in animal models of airway disease suggest that there may be clin. benefit to the use of A1, A3 and A2B adenosine receptor antagonists in the treatment of features of asthma and/or COPD, while A2A agonists may also prove effective.  Several adenosine receptor based pharmacol. agents have entered clin. development for the treatment of asthma and COPD; however, the studies have been limited and the efficacy of such approaches is not yet clear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLEk1XfcyAcrVg90H21EOLACvtfcHk0ljRBqddp5Srlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFyqtb3N&md5=d26adeb209992cfea4be52a789f4b2b3</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2009.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2009.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DPolosa%26aufirst%3DR.%26aulast%3DBlackburn%26aufirst%3DM.%2BR.%26atitle%3DAdenosine%2520receptors%2520as%2520targets%2520for%2520therapeutic%2520intervention%2520in%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2009%26volume%3D30%26spage%3D528%26epage%3D535%26doi%3D10.1016%2Fj.tips.2009.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khoury, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortega, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, S. V.</span></span> <span> </span><span class="NLM_article-title">Immunomodulatory cell therapy to target cystic fibrosis inflammation</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">12</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2017-0160TR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1165%2Frcmb.2017-0160TR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28707978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFKit7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2018&pages=12-20&author=O.+Khouryauthor=C.+Barriosauthor=V.+Ortegaauthor=A.+Atalaauthor=S.+V.+Murphy&title=Immunomodulatory+cell+therapy+to+target+cystic+fibrosis+inflammation&doi=10.1165%2Frcmb.2017-0160TR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Immunomodulatory cell therapy to target cystic fibrosis inflammation</span></div><div class="casAuthors">Khoury, Oula; Barrios, Christopher; Ortega, Victor; Atala, Anthony; Murphy, Sean V.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12-20</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Cystic fibrosis (CF) is assocd. with exaggerated and prolonged inflammation in the lungs, which contributes to lung injury, airway mucus obstruction, bronchiectasis, and loss of lung function.  This hyperinflammatory phenotype appears to be caused by an imbalance between the pro- and antiinflammatory regulatory pathways, with heightened proinflammatory stimuli, a decreased counter-regulatory response, and reduced effectiveness of immune cell function and inflammatory resoln.  Thus, therapies that can target this inflammatory environment would have a major impact on preventing the progression of lung disease.  Because of the complex phenotype of CF inflammation, current antiinflammatory regimens have proven to be inadequate for the targeting of these multiple dysregulated pathways and effects.  Several approaches using cell therapies have shown potential therapeutic benefit for the treatment of CF inflammation.  This review provides an overview of the immune dysfunctions in CF and current therapeutic regimens; explores the field of cell therapy as a treatment for CF inflammation; and focuses on the various cell types used, their immunomodulatory functions, and the current approaches to mitigate the inflammatory response and reduce the long-term damage for patients with CF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptSS-d0ulMO7Vg90H21EOLACvtfcHk0lhnTGslCL8yNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFKit7rN&md5=0f20254f728a37fba53027e8a51d80c9</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2017-0160TR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2017-0160TR%26sid%3Dliteratum%253Aachs%26aulast%3DKhoury%26aufirst%3DO.%26aulast%3DBarrios%26aufirst%3DC.%26aulast%3DOrtega%26aufirst%3DV.%26aulast%3DAtala%26aufirst%3DA.%26aulast%3DMurphy%26aufirst%3DS.%2BV.%26atitle%3DImmunomodulatory%2520cell%2520therapy%2520to%2520target%2520cystic%2520fibrosis%2520inflammation%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2018%26volume%3D58%26spage%3D12%26epage%3D20%26doi%3D10.1165%2Frcmb.2017-0160TR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ran, P.</span></span> <span> </span><span class="NLM_article-title">Tiotropium in early-stage chronic obstructive pulmonary disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">923</span>– <span class="NLM_lpage">935</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1700228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1056%2FNEJMoa1700228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28877027" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=2017&pages=923-935&author=Y.+Zhouauthor=N.+S.+Zhongauthor=X.+Liauthor=S.+Chenauthor=J.+Zhengauthor=D.+Zhaoauthor=W.+Yaoauthor=R.+Zhiauthor=L.+Weiauthor=B.+Heauthor=X.+Zhangauthor=C.+Yangauthor=Y.+Liauthor=F.+Liauthor=J.+Duauthor=J.+Guiauthor=B.+Huauthor=C.+Baiauthor=P.+Huangauthor=G.+Chenauthor=Y.+Xuauthor=C.+Wangauthor=B.+Liangauthor=Y.+Liauthor=G.+Huauthor=H.+Tanauthor=X.+Yeauthor=X.+Maauthor=Y.+Chenauthor=X.+Huauthor=J.+Tianauthor=X.+Zhuauthor=Z.+Shiauthor=X.+Duauthor=M.+Liauthor=S.+Liuauthor=R.+Yuauthor=J.+Zhaoauthor=Q.+Maauthor=C.+Xieauthor=X.+Liauthor=T.+Chenauthor=Y.+Linauthor=L.+Zengauthor=C.+Yeauthor=W.+Yeauthor=X.+Luoauthor=L.+Zengauthor=S.+Yuauthor=W.+J.+Guanauthor=P.+Ran&title=Tiotropium+in+early-stage+chronic+obstructive+pulmonary+disease&doi=10.1056%2FNEJMoa1700228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Tiotropium in early-stage chronic obstructive pulmonary disease</span></div><div class="casAuthors">Zhou, Y.; Zhong, N.; Li, Xiaochen; Chen, S.; Zheng, J.; Zhao, D.; Yao, W.; Zhi, R.; Wei, L.; He, B.; Zhang, X.; Yang, C.; Li, Ying; Li, F.; Du, J.; Gui, J.; Hu, B.; Bai, C.; Huang, P.; Chen, G.; Xu, Y.; Wang, C.; Liang, B.; Li, Yinhuan; Hu, G.; Tan, H.; Ye, X.; Ma, X.; Chen, Y.; Hu, X.; Tian, J.; Zhu, X.; Shi, Z.; Du, X.; Li, M.; Liu, S.; Yu, R.; Zhao, J.; Ma, Q.; Xie, C.; Li, Xiongbin; Chen, T.; Lin, Y.; Zeng, Lizhen; Ye, C.; Ye, W.; Luo, X.; Zeng, Lingshan; Yu, S.; Guan, W.; Ran, P.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">923-935</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Patients with mild or moderate chronic obstructive pulmonary disease (COPD) rarely receive medications, because they have few symptoms.  We hypothesized that long-term use of tiotropium would improve lung function and ameliorate the decline in lung function in patients with mild or moderate COPD.  METHODS In a multicenter, randomized, double-blind, placebo-controlled trial that was conducted in China, we randomly assigned 841 patients with COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 1 (mild) or 2 (moderate) severity to receive a once-daily inhaled dose (18 μg) of tiotropium (419 patients) or matching placebo (422) for 2 years.  The primary end point was the between-group difference in the change from baseline to 24 mo in the forced expiratory vol. in 1 s (FEV♂) before bronchodilator use.  Secondary end points included the between-group difference in the change from baseline to 24 mo in the FEV♂ after bronchodilator use and the between-group difference in the annual decline in the FEV♂ before and after bronchodilator use from day 30 to month 24.  RESULTS Of 841 patients who underwent randomization, 388 patients in the tiotropium group and 383 in the placebo group were included in the full anal. set.  The FEV♂ in patients who received tiotropium was higher than in those who received placebo throughout the trial (ranges of mean differences, 127 to 169 mL before bronchodilator use and 71 to 133 mL after bronchodilator use; P<0.001 for all comparisons).  There was no significant amelioration of the mean (±SE) annual decline in the FEV♂ before bronchodilator use: the decline was 38±6 mL per yr in the tiotropium group and 53±6 mL per yr in the placebo group (difference, 15 mL per yr; 95% confidence interval [CI], -1 to 31; P = 0.06).  In contrast, the annual decline in the FEV♂ after bronchodilator use was significantly less in the tiotropium group than in the placebo group (29±5 mL per yr vs. 51±6 mL per yr; difference, 22 mL per yr [95% CI, 6 to 37]; P = 0.006).  The incidence of adverse events was generally similar in the two groups.  CONCLUSIONS Tiotropium resulted in a higher FEV♂ than placebo at 24 mo and ameliorated the annual decline in the FEV♂ after bronchodilator use in patients with COPD of GOLD stage 1 or 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9MyyszWE8kLVg90H21EOLACvtfcHk0lhnTGslCL8yNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFSju7nN&md5=a402c9da20dddbe47b55f260417b62a0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1700228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1700228%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DN.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DD.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DZhi%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DGui%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DBai%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DLiang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DG.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DC.%26aulast%3DYe%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DGuan%26aufirst%3DW.%2BJ.%26aulast%3DRan%26aufirst%3DP.%26atitle%3DTiotropium%2520in%2520early-stage%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D377%26spage%3D923%26epage%3D935%26doi%3D10.1056%2FNEJMoa1700228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belmonte, K. E.</span></span> <span> </span><span class="NLM_article-title">Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease</span>. <i>Proc. Am. Thorac. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1513/pats.200504-043SR</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1513%2Fpats.200504-043SR" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16267352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlams7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=297-304&author=K.+E.+Belmonte&title=Cholinergic+pathways+in+the+lungs+and+anticholinergic+therapy+for+chronic+obstructive+pulmonary+disease&doi=10.1513%2Fpats.200504-043SR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Belmonte, Kristen E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-304</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Abundant data from animal models and humans support the hypothesis that changes at the level of parasympathetic neuronal control of airway smooth muscle result in increased bronchoconstriction in response to vagal stimulation, leading to airway hyper-responsiveness.  Neuronal inhibitory M2 muscarinic acetylcholine receptors on parasympathetic nerves are responsible for limiting acetylcholine release from these nerves.  In humans with asthma, and after pulmonary inflammatory events in exptl. animals, these receptors are dysfunctional, which results in airway hyper-responsiveness.  Although it is unknown what mechanisms underlie airway hyperresponsiveness in chronic obstructive pulmonary disease, loss of parasympathetic control of airway smooth muscle is thought to be a contributing mechanism.  As such, anticholinergic therapy is used extensively and with a high degree of success in the treatment of this condition.  The future for inhaled anticholinergic compds. for the treatment of chronic obstructive pulmonary disease appears to rest in their combination with other agents, such as β2 agonists and phosphodiesterase-4 inhibitors.  Nonselective anticholinergic agents might be the best choice, because M2 muscarinic receptors on airway smooth muscle inhibit the generation and accumulation of cyclic adenosine monophosphate.  Adequate concurrent blockade of M3 muscarinic receptors would be expected to counteract the enhanced acetylcholine release that would result from blockade of neuronal inhibitory M2 muscarinic receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf5AsHs2UOPLVg90H21EOLACvtfcHk0lhnTGslCL8yNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlams7vO&md5=98f86ecd7332496401526820d4efe9d7</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1513%2Fpats.200504-043SR&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.200504-043SR%26sid%3Dliteratum%253Aachs%26aulast%3DBelmonte%26aufirst%3DK.%2BE.%26atitle%3DCholinergic%2520pathways%2520in%2520the%2520lungs%2520and%2520anticholinergic%2520therapy%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2005%26volume%3D2%26spage%3D297%26epage%3D304%26doi%3D10.1513%2Fpats.200504-043SR" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M.</span></span> <span> </span><span class="NLM_article-title">The β-adrenoceptor</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">S146</span>– <span class="NLM_lpage">S153</span>, <span class="refDoi"> DOI: 10.1164/ajrccm.158.supplement_2.13tac110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Fajrccm.158.supplement_2.13tac110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=9817738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADyaK1M%252FlsFSksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=1998&pages=S146-S153&author=M.+Johnson&title=The+%CE%B2-adrenoceptor&doi=10.1164%2Fajrccm.158.supplement_2.13tac110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">The beta-adrenoceptor</span></div><div class="casAuthors">Johnson M</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue">5 Pt 3</span>),
    <span class="NLM_cas:pages">S146-53</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The human beta-adrenoceptor is a member of the seven-transmembrane family of receptors, encoded by a gene on chromosome 5. beta-Adrenoceptors have been classified into beta1, beta2, and beta3 subgroups, with beta2-receptors being widely distributed in the respiratory tract, particularly in airway smooth muscle.  Intracellular signaling following beta2-adrenoceptor activation is largely affected through a trimeric Gs protein coupled to adenylate cyclase.  Cyclic AMP (cAMP) induces airway relaxation through phosphorylation of muscle regulatory proteins and attenuation of cellular Ca2+ concentrations.  Alternative cAMP-independent pathways involving activation of membrane maxi-K+ channels and coupling through Gi to the MAP kinase system have also been described.  Site-directed mutagenesis has identified Asp 113 and Ser 204/207 within the third and fourth membrane domains as the active site of the beta2-receptor, critical for beta2-agonist binding and activity. beta2-Agonists have been characterized as those that directly activate the receptor (albuterol), those that are taken up into a membrane depot (formoterol), and those that interact with a receptor-specific auxiliary binding site (salmeterol).  These differences in mechanism of action are reflected in the kinetics of airway smooth muscle relaxation and bronchodilation in patients with asthma. beta-Adrenoceptor desensitization associated with beta2-agonist activation is a consequence of phosphorylation by beta-ARK and uncoupling of the receptor from Gs following beta-arrestin binding, of internalization and recycling of the receptor through processes of sequestration and resensitization and downregulation, modulated by an effect on receptor gene expression.  The degree of receptor desensitization appears to differ, depending on the cell or tissue type, and is reflected in the different profiles of clinical tolerance to chronic beta2-agonist therapy.  A number of polymorphisms of the beta2-receptor have been described that appear to alter the behavior of the receptor following agonist exposure.  These include Arg-Gly 16, Glu-Gln 27, and Thr-lle 164.  The Gly 16 receptor downregulates to a greater extent and is associated with increased airway hyperreactivity, nocturnal symptoms, and more severe asthma.  The Glu 27 form appears to protect against downregulation and is associated with less reactive airways.  An individual can be homozygous or heterozygous for given polymorphisms, and large populations will have to be studied to determine their importance to the asthma phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7eYHSZZemQ9yzdcP07UmufW6udTcc2eZCbK1cGtCo4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M%252FlsFSksg%253D%253D&md5=b35ba94acecce6e5da1f0373051d5c7f</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1164%2Fajrccm.158.supplement_2.13tac110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm.158.supplement_2.13tac110%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DM.%26atitle%3DThe%2520%25CE%25B2-adrenoceptor%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D1998%26volume%3D158%26spage%3DS146%26epage%3DS153%26doi%3D10.1164%2Fajrccm.158.supplement_2.13tac110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido-Rios, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasper, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammen, M.</span></span> <span> </span><span class="NLM_article-title">In vitro characterization of TD-4208, a lung-selective and long-acting muscarinic antagonist bronchodilator</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">A4553</span>, <span class="refDoi"> DOI: 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A4553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2009&pages=A4553&author=T.+Steinfeldauthor=M.+T.+Pulido-Riosauthor=K.+Chinauthor=K.+Kingauthor=J.+X.+Huangauthor=T.+W.+Leeauthor=J.+R.+Jasperauthor=Y.+Jiauthor=S.+Hegdeauthor=M.+Mammen&title=In+vitro+characterization+of+TD-4208%2C+a+lung-selective+and+long-acting+muscarinic+antagonist+bronchodilator&doi=10.1164%2Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1164%2Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553%26sid%3Dliteratum%253Aachs%26aulast%3DSteinfeld%26aufirst%3DT.%26aulast%3DPulido-Rios%26aufirst%3DM.%2BT.%26aulast%3DChin%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DJ.%2BX.%26aulast%3DLee%26aufirst%3DT.%2BW.%26aulast%3DJasper%26aufirst%3DJ.%2BR.%26aulast%3DJi%26aufirst%3DY.%26aulast%3DHegde%26aufirst%3DS.%26aulast%3DMammen%26aufirst%3DM.%26atitle%3DIn%2520vitro%2520characterization%2520of%2520TD-4208%252C%2520a%2520lung-selective%2520and%2520long-acting%2520muscarinic%2520antagonist%2520bronchodilator%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2009%26volume%3D179%26spage%3DA4553%26doi%3D10.1164%2Fajrccm-conference.2009.179.1_MeetingAbstracts.A4553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pudi, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haumann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerwin, E.</span></span> <span> </span><span class="NLM_article-title">A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">182</span>, <span class="refDoi"> DOI: 10.1186/s12931-017-0647-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2Fs12931-017-0647-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29096627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVyrsr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=182&author=K.+K.+Pudiauthor=C.+N.+Barnesauthor=E.+J.+Moranauthor=B.+Haumannauthor=E.+Kerwin&title=A+28-day%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel+group+study+of+nebulized+revefenacin+in+patients+with+chronic+obstructive+pulmonary+disease&doi=10.1186%2Fs12931-017-0647-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Pudi, Krishna K.; Barnes, Chris N.; Moran, Edmund J.; Haumann, Brett; Kerwin, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">182/1-182/11</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Revefenacin is a once-daily long-acting muscarinic antagonist (LAMA) in clin. development for the treatment of patients with chronic obstructive pulmonary disease (COPD).  In a dose-ranging study, nebulized oncedaily revefenacin had a long duration of action in patients after 7 days' administration of doses up to 700 μg.  In this multiple-dose study, the bronchodilation efficacy and adverse events profile were characterized in patients administered nebulized revefenacin once daily for 28 days.  Methods: A total of 355 COPD patients (mean age 62 years, mean forced expiratory vol. in 1 s [FEV1] 44% of predicted) were randomized in a double-blind, placebo-controlled parallel group study.  Inhaled corticosteroids as well as short-acting bronchodilators were permitted.  Once-daily treatments (44, 88, 175 or 350 μg revefenacin or matching placebo) were administered by a std. jet nebulizer, for 28 days.  The primary endpoint was change from baseline in D28 trough FEV1, and secondary endpoints included weighted mean FEV1 over 0 to 24 h and rescue medication (albuterol) use.  Safety evaluations included adverse events, lab. assessments, electrocardiograms and 24-h Holter profiles.  Results: Revefenacin (88, 175 and 350 μg) significantly improved D28 trough FEV1 over placebo (187.4, 166.6 and 170.6 mL, resp., all p < 0.001); 44 μg produced a sub-therapeutic response.  At doses ≥88 μg, more than 80% of patients achieved at least a 100-mL increase from baseline FEV1 in the first 4 h post dose compared with 33% of placebo patients.  For doses ≥88 μg, D28 24 h weighted mean differences from placebo for FEV1 were numerically similar to resp. trough FEV1 values, indicating bronchodilation was sustained for 24 h post dose.  Doses ≥88 μg reduced the av. no. of albuterol puffs/day by more than one puff/day.  The 350 μg dose did not demonstrate addnl. efficacy over that obsd. with 175 μg revefenacin.  Revefenacin was generally well tolerated, with minimal reports of systemic anti-cholinergic effects.  Conclusions: These data suggest that 88 and 175 μg revefenacin are appropriate doses for use in longer-term safety and efficacy trials.  Revefenacin offers the potential for the first once-daily LAMA for nebulization in patients with COPD who require or prefer a nebulized drug delivery option.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooD2n8krBRPLVg90H21EOLACvtfcHk0liUyGOQHAXsXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVyrsr%252FL&md5=3ebf961fdc817888271751b77f125755</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1186%2Fs12931-017-0647-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-017-0647-1%26sid%3Dliteratum%253Aachs%26aulast%3DPudi%26aufirst%3DK.%2BK.%26aulast%3DBarnes%26aufirst%3DC.%2BN.%26aulast%3DMoran%26aufirst%3DE.%2BJ.%26aulast%3DHaumann%26aufirst%3DB.%26aulast%3DKerwin%26aufirst%3DE.%26atitle%3DA%252028-day%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel%2520group%2520study%2520of%2520nebulized%2520revefenacin%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Res.%26date%3D2017%26volume%3D18%26spage%3D182%26doi%3D10.1186%2Fs12931-017-0647-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heo, Y. A.</span></span> <span> </span><span class="NLM_article-title">Revefenacin: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1036-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs40265-018-1036-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=30560478" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=85-91&author=Y.+A.+Heo&title=Revefenacin%3A+first+global+approval&doi=10.1007%2Fs40265-018-1036-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Revefenacin: First Global Approval</span></div><div class="casAuthors">Heo, Young-A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-91</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Revefenacin (YUPELRI) inhalation soln., a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD).  In Nov. 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD.  This article summarizes the milestones in the development of revefenacin leading to this first global approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreKt8JGiq2GLVg90H21EOLACvtfcHk0lhlnuWtQoMRjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFCitb7F&md5=09384e244c9d6b3f9b4d39dd87705057</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1036-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1036-x%26sid%3Dliteratum%253Aachs%26aulast%3DHeo%26aufirst%3DY.%2BA.%26atitle%3DRevefenacin%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2019%26volume%3D79%26spage%3D85%26epage%3D91%26doi%3D10.1007%2Fs40265-018-1036-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Q. M.</span></span> <span> </span><span class="NLM_article-title">Characterization of bencycloquidium bromide, a novel muscarinic M3 receptor antagonist in guinea pig airways</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>655</i></span>,  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2011.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.ejphar.2011.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21272572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFKisbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=655&publication_year=2011&pages=74-82&author=J.+X.+Jiangauthor=R.+Caoauthor=W.+D.+Dengauthor=F.+Jinauthor=X.+W.+Dongauthor=Y.+Zhuauthor=X.+P.+Chenauthor=Y.+C.+Xieauthor=M.+J.+Baoauthor=F.+F.+Liauthor=Q.+M.+Xie&title=Characterization+of+bencycloquidium+bromide%2C+a+novel+muscarinic+M3+receptor+antagonist+in+guinea+pig+airways&doi=10.1016%2Fj.ejphar.2011.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of bencycloquidium bromide, a novel muscarinic M3 receptor antagonist in guinea pig airways</span></div><div class="casAuthors">Jiang, Jun-Xia; Cao, Rui; Deng, Wan-Ding; Jin, Fang; Dong, Xin-Wei; Zhu, Yu; Chen, Xiao-Ping; Xie, Yi-Cheng; Bao, Meng-Jing; Li, Fen-Fen; Xie, Qiang-Min</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">655</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">74-82</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this study we have investigated the antagonist affinity, efficacy, and duration of action of bencycloquidium bromide (BCQB), a selective muscarinic M3 receptor antagonist, as a possible clin. bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.  In competition studies, BCQB showed high affinity toward the M3 receptor in Chinese hamster ovary (CHO) cells (M3 pKi = 8.21, M2 pKi = 7.21, and M1 pKi = 7.86); pA2 = 8.85, 8.71, and 8.57 in methacholine-induced contraction of trachea, ileum, and urinary bladder, 8.19 in methacholine-induced bradycardia of right atrium in vitro, resp.  In function studies, duration of inhibition of carbachol-induced tonic contraction, BCQB and ipratropium had a very similar onset and offset of action, but onset faster and offset slower than that of tiotropium.  After treatment with intratracheally instilled or the inhalation route, BCQB protects against methacholine or antigen-induced bronchoconstriction in a dose-dependent manner in the normal and sensitized guinea pigs in vivo.  BCQB and ipratropium-induced inhibitory activity was short lasting, as it declined quickly when compared to tiotropium.  These results suggest that BCQB bind muscarinic M3 receptors with high affinity.  On this basis we speculate that a putative BCQB-based therapy for COPD might require more than once-a-day administration to be as effective as the currently employed once-daily therapy with tiotropium.  Nevertheless, inhalable M3-selective compds. may spare M2-cardiac receptors and reduce the risks of cardiovascular events assocd. with the long-term treatment of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj0aNvoEtwBbVg90H21EOLACvtfcHk0lhlnuWtQoMRjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFKisbo%253D&md5=2a45a4d8cd0eddc8107ee6cd9eacaee3</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2011.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2011.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%2BX.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DDeng%26aufirst%3DW.%2BD.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DDong%26aufirst%3DX.%2BW.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%2BP.%26aulast%3DXie%26aufirst%3DY.%2BC.%26aulast%3DBao%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DF.%2BF.%26aulast%3DXie%26aufirst%3DQ.%2BM.%26atitle%3DCharacterization%2520of%2520bencycloquidium%2520bromide%252C%2520a%2520novel%2520muscarinic%2520M3%2520receptor%2520antagonist%2520in%2520guinea%2520pig%2520airways%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D655%26spage%3D74%26epage%3D82%26doi%3D10.1016%2Fj.ejphar.2011.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gan, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span> <span> </span><span class="NLM_article-title">Trachea relaxing effects and beta(2)-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits</span>. <i>Biol. Pharm. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">328</span>, <span class="refDoi"> DOI: 10.1248/bpb.26.323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1248%2Fbpb.26.323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12612441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3sXjsVajurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2003&pages=323-328&author=L.+L.+Ganauthor=M.+W.+Wangauthor=M.+Chengauthor=L.+Pan&title=Trachea+relaxing+effects+and+beta%282%29-selectivity+of+SPFF%2C+a+newly+developed+bronchodilating+agent%2C+in+guinea+pigs+and+rabbits&doi=10.1248%2Fbpb.26.323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Trachea relaxing effects and β2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits</span></div><div class="casAuthors">Gan, Le-Ling; Wang, Min-Wei; Cheng, Mao-Sheng; Pan, Li</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-328</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">In this paper we evaluated the bronchodilator effects of SPFF [2-(4-amino-3-chloro-5-trifluomethyl-phenyl)- 2-tert-butylamino-ethanol chloride], a newly synthesized β2 adrenergic agonist in guinea pigs and rabbits, in comparison with other β2 adrenergic agonists, isoprenaline or salbutamol.  We studied in vitro the bronchodilator effects of SPFF and isoprenaline on isolated guinea pig trachea strips with or without the precontraction of bronchocontractors (acetylcholine and histamine).  The pos. chronotropic effects of SPFF and isoprenaline on isolated guinea pig left atria were also tested in vitro.  Potency values (pD2, pA2 or ED50) were detd. from the cumulative concn.-response curves.  The results showed that SPFF and isoprenaline dose-dependently relaxed the isolated guinea pig trachea strips and the pD2 values of both drugs were 7.66±0.68 and 8.79±0.19, resp.  Moreover, we confirmed that the bronchodilator effect of SPFF was due to the activation of β2 adrenoceptor because this effect was easily antagonized by ICI-118551 (pA2 8.90±0.01), a specific β2 adrenoceptor antagonist.  SPFF also dose-dependently relaxed the isolated guinea pig trachea strip precontraction with acetylcholine or histamine with ED50 values of 10.2±0.7 μM and 550±38.2 nM, resp.  Furthermore, the pos. chronotropic effect of SPFF on isolated guinea pig left atria (pD2 5.41±0.38) was much weaker than that of isoprenaline (pD2 8.75±0.24), which implied that SPFF was more selective to airway β2 adrenoceptor than isoprenaline; the β1/β2 selectivity assay also showed that SPFF was about 162 times more selective to β2 adrenoceptor than isoprenaline.  A radioligand binding expt. using guinea pig lung and cardiac ventricle as β2 and β1 adrenoceptor sources, resp., also demonstrated that SPFF possesses high affinity (27.3 nM) and selectivity (4.6 fold) to β2 adrenoceptors.  The protective effects of SPFF and salbutamol on bronchospasm induced by bronchoconstrictor aerosol in guinea pigs in vivo were investigated, and the Konzett and Rossler expt. in rabbits in vivo was also carried out.  SPFF significantly prolonged the latency time of histamine and acetylcholine induced asphyxiation collapse in guinea pigs: the ED50 value of SPFF i.g. was 0.32±0.05 mg·kg-1 in this expt.  Meanwhile, the ED50 values of salbutamol was 2.37±0.22, which meant that the bronchorelaxation effect of salbutamol was about 6 times less potent than that of SPFF.  The Konzett and Rossler expt. performed in anesthetized rabbit showed that intraduodenal administration of SPFF exerted action of longer duration than salbutamol.  From the results above we suggested that SPFF was a potent, long-acting bronchodilator with relatively higher β2 adrenoceptor selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFgmv60MqHPLVg90H21EOLACvtfcHk0liW-gU-AhJwzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXjsVajurY%253D&md5=87227d7e445c13d7b74f1adf69cfaee9</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1248%2Fbpb.26.323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.26.323%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DL.%2BL.%26aulast%3DWang%26aufirst%3DM.%2BW.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DPan%26aufirst%3DL.%26atitle%3DTrachea%2520relaxing%2520effects%2520and%2520beta%25282%2529-selectivity%2520of%2520SPFF%252C%2520a%2520newly%2520developed%2520bronchodilating%2520agent%252C%2520in%2520guinea%2520pigs%2520and%2520rabbits%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2003%26volume%3D26%26spage%3D323%26epage%3D328%26doi%3D10.1248%2Fbpb.26.323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span> </span><span class="NLM_article-title">Pharmacokinetics
study of trantinterol hydrochloride tablets in the
elderly volunteers after a single dose administration</span>.  <i>Chinese Clinical Trials Registry</i>; <span class="NLM_publisher-name">Chictr.org</span>, <span class="NLM_year">2016</span>; <a href="http://www.chictr.org.cn/showprojen.aspx?proj=4773" class="extLink">http://www.chictr.org.cn/showprojen.aspx?proj=4773</a> (accessed Dec 9, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pharmacokinetics%0Astudy+of+trantinterol+hydrochloride+tablets+in+the%0Aelderly+volunteers+after+a+single+dose+administration.+Chinese+Clinical+Trials+Registry%3B+Chictr.org%2C+2016%3B+http%3A%2F%2Fwww.chictr.org.cn%2Fshowprojen.aspx%3Fproj%3D4773+%28accessed+Dec+9%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DPharmacokinetics%250Astudy%2520of%2520trantinterol%2520hydrochloride%2520tablets%2520in%2520the%250Aelderly%2520volunteers%2520after%2520a%2520single%2520dose%2520administration%26jtitle%3DChinese%2520Clinical%2520Trials%2520Registry%26pub%3DChictr.org%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, A.
D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jasper, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulido-Rios, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinfeld, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mammen, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1′-biphenyl]-2-ylcarbamate (TD-5959, GSK961081, batefenterol): first-in-class dual pharmacology multivalent muscarinic antagonist and β<sub>2</sub> agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2609</span>– <span class="NLM_lpage">2622</span>, <span class="refDoi"> DOI: 10.1021/jm501915g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501915g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs12lsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2609-2622&author=A.%0AD.+Hughesauthor=Y.+Chenauthor=S.+S.+Hegdeauthor=J.+R.+Jasperauthor=S.+Jaw-Tsaiauthor=T.+W.+Leeauthor=A.+McNamaraauthor=M.+T.+Pulido-Riosauthor=T.+Steinfeldauthor=M.+Mammen&title=Discovery+of+%28R%29-1-%283-%28%282-chloro-4-%28%28%282-hydroxy-2-%288-hydroxy-2-oxo-1%2C2-dihydroquinolin-5-yl%29ethyl%29amino%29methyl%29-5-methoxyphenyl%29amino%29-3-oxopropyl%29piperidin-4-yl+%5B1%2C1%E2%80%B2-biphenyl%5D-2-ylcarbamate+%28TD-5959%2C+GSK961081%2C+batefenterol%29%3A+first-in-class+dual+pharmacology+multivalent+muscarinic+antagonist+and+%CE%B22+agonist+%28MABA%29+for+the+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&doi=10.1021%2Fjm501915g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (R)-1-(3-((2-Chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl)piperidin-4-yl [1,1'-Biphenyl]-2-ylcarbamate (TD-5959, GSK961081, Batefenterol): First-in-Class Dual Pharmacology Multivalent Muscarinic Antagonist and β2 Agonist (MABA) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)</span></div><div class="casAuthors">Hughes, Adam D.; Chen, Yan; Hegde, Sharath S.; Jasper, Jeffrey R.; Jaw-Tsai, Sarah; Lee, Tae-Weon; McNamara, Alexander; Pulido-Rios, M. Teresa; Steinfeld, Tod; Mammen, Mathai</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2609-2622</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Through application of the multivalent approach to drug discovery the authors previously reported the first discovery of dual pharmacol. MABA bronchodilators.  Herein the authors describe the subsequent lead optimization of both muscarinic antagonist and β2 agonist activities, through modification of the linker motif, to achieve 24 h duration of action in a guinea pig bronchoprotection model.  Concomitantly the authors targeted high lung selectivities, low systemic exposures and identified cryst. forms suitable for inhalation devices.  This article culminates with the discovery of the first clin. candidate I (TD-5959, GSK961081, batefenterol).  In a phase 2b trial, batefenterol produced statistical and clin. significant differences compared to placebo and numerically greater improvements in the primary end point of trough FEV1 compared to salmeterol after 4 wk of dosing in patients with moderate to severe chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh-S4hJ7DcVbVg90H21EOLACvtfcHk0liW-gU-AhJwzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs12lsLg%253D&md5=f6f73dff89172f8b60890ba4c2b207fe</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm501915g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501915g%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DA.%2BD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHegde%26aufirst%3DS.%2BS.%26aulast%3DJasper%26aufirst%3DJ.%2BR.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DT.%2BW.%26aulast%3DMcNamara%26aufirst%3DA.%26aulast%3DPulido-Rios%26aufirst%3DM.%2BT.%26aulast%3DSteinfeld%26aufirst%3DT.%26aulast%3DMammen%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520%2528R%2529-1-%25283-%2528%25282-chloro-4-%2528%2528%25282-hydroxy-2-%25288-hydroxy-2-oxo-1%252C2-dihydroquinolin-5-yl%2529ethyl%2529amino%2529methyl%2529-5-methoxyphenyl%2529amino%2529-3-oxopropyl%2529piperidin-4-yl%2520%255B1%252C1%25E2%2580%25B2-biphenyl%255D-2-ylcarbamate%2520%2528TD-5959%252C%2520GSK961081%252C%2520batefenterol%2529%253A%2520first-in-class%2520dual%2520pharmacology%2520multivalent%2520muscarinic%2520antagonist%2520and%2520%25CE%25B22%2520agonist%2520%2528MABA%2529%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2609%26epage%3D2622%26doi%3D10.1021%2Fjm501915g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span> </span><span class="NLM_article-title">AZD8871 delivered
significant bronchodilation in two-week study</span>.  <i>Chest Physician</i>; <span class="NLM_publisher-name">Frontline Medical
Communications Inc</span>, <span class="NLM_year">2018</span>; <a href="https://www.mdedge.com/chestphysician/article/167156/copd/azd8871-delivered-significant-bronchodilation-two-week-study" class="extLink">https://www.mdedge.com/chestphysician/article/167156/copd/azd8871-delivered-significant-bronchodilation-two-week-study</a> (accessed Jun 3, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=AZD8871+delivered%0Asignificant+bronchodilation+in+two-week+study.+Chest+Physician%3B+Frontline+Medical%0ACommunications+Inc%2C+2018%3B+https%3A%2F%2Fwww.mdedge.com%2Fchestphysician%2Farticle%2F167156%2Fcopd%2Fazd8871-delivered-significant-bronchodilation-two-week-study+%28accessed+Jun+3%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAZD8871%2520delivered%250Asignificant%2520bronchodilation%2520in%2520two-week%2520study%26jtitle%3DChest%2520Physician%26pub%3DFrontline%2520Medical%250ACommunications%2520Inc%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aparici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortijo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puig, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist/β<sub>2</sub>-adrenoceptor agonist (MABA) molecule</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">10</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2017.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28729041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlOrsbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=1-10&author=M.+Apariciauthor=C.+Carcasonaauthor=I.+Ramosauthor=J.+L.+Monteroauthor=J.+L.+Ortizauthor=J.+Cortijoauthor=C.+Puigauthor=D.+Vilellaauthor=C.+Doeauthor=A.+Gavald%C3%A0author=M.+Miralpeix&title=Pharmacological+preclinical+characterization+of+LAS190792%2C+a+novel+inhaled+bifunctional+muscarinic+receptor+antagonist%2F%CE%B22-adrenoceptor+agonist+%28MABA%29+molecule&doi=10.1016%2Fj.pupt.2017.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β2-adrenoceptor agonist (MABA) molecule</span></div><div class="casAuthors">Aparici, Monica; Carcasona, Carla; Ramos, Israel; Montero, Jose Luis; Ortiz, Jose Luis; Cortijo, Julio; Puig, Carlos; Vilella, Dolors; Doe, Chris; Gavalda, Amadeu; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">LAS190792 is a novel muscarinic antagonist and β2-adrenoceptor agonist in development for chronic respiratory diseases.  This study investigated the pharmacol. profile of LAS190792 in comparison to batefenterol, tiotropium, indacaterol and olodaterol.  LAS190792 is potent at the human M3 receptor (pIC50: 8.8 in binding assays).  It is selective for the β2-adrenoceptor over the β1-and β3-adrenoceptor, and shows a functional potency in a similar range to batefenterol and LABA compds. (pEC50 in spontaneous tone isolated trachea: 9.6).  The relaxant potency of LAS190792 in elec. stimulated tissue is similar to batefenterol, with an antimuscarinic activity in presence of propranolol slightly higher than batefenterol (pIC50 of 8.3 vs. 7.9 in human tissue).  LAS190792 exhibits a sustained duration of action in isolated tissue longer than that of batefenterol.  Nebulized LAS190792 inhibits acetylcholine-induced bronchoconstriction in dog with minimal cardiac effects and sustained bronchodilation (t1/2: 13.3 h).  In conclusion, these studies suggest that LAS190792 is a dual-acting muscarinic antagonist β2-adrenoceptor agonist that has the potential to be a next generation bronchodilator with long-lasting effects and wide safety margin in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4xsgKu0EdJ7Vg90H21EOLACvtfcHk0liw8CM9bE_sUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlOrsbrJ&md5=c4199d8a8fccd880ff64bb6a07bd8a1d</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DAparici%26aufirst%3DM.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DRamos%26aufirst%3DI.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%26aulast%3DOrtiz%26aufirst%3DJ.%2BL.%26aulast%3DCortijo%26aufirst%3DJ.%26aulast%3DPuig%26aufirst%3DC.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DDoe%26aufirst%3DC.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DPharmacological%2520preclinical%2520characterization%2520of%2520LAS190792%252C%2520a%2520novel%2520inhaled%2520bifunctional%2520muscarinic%2520receptor%2520antagonist%252F%25CE%25B22-adrenoceptor%2520agonist%2520%2528MABA%2529%2520molecule%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.pupt.2017.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Annunziato, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romagnani, S.</span></span> <span> </span><span class="NLM_article-title">The 3 major types of innate and adaptive cell-mediated effector immunity</span>. <i>J. Allergy Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>135</i></span>,  <span class="NLM_fpage">626</span>– <span class="NLM_lpage">635</span>, <span class="refDoi"> DOI: 10.1016/j.jaci.2014.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.jaci.2014.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25528359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVSlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=135&publication_year=2015&pages=626-635&author=F.+Annunziatoauthor=C.+Romagnaniauthor=S.+Romagnani&title=The+3+major+types+of+innate+and+adaptive+cell-mediated+effector+immunity&doi=10.1016%2Fj.jaci.2014.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The 3 major types of innate and adaptive cell-mediated effector immunity</span></div><div class="casAuthors">Annunziato, Francesco; Romagnani, Chiara; Romagnani, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Allergy and Clinical Immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">135</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">626-635</span>CODEN:
                <span class="NLM_cas:coden">JACIBY</span>;
        ISSN:<span class="NLM_cas:issn">0091-6749</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  The immune system has tailored its effector functions to optimally respond to distinct species of microbes.  Based on emerging knowledge on the different effector T-cell and innate lymphoid cell (ILC) lineages, it is clear that the innate and adaptive immune systems converge into 3 major kinds of cell-mediated effector immunity, which we propose to categorize as type 1, type 2, and type 3.  Type 1 immunity consists of T-bet+ IFN-γ-producing group 1 ILCs (ILC1 and natural killer cells), CD8+ cytotoxic T cells (TC1), and CD4+ TH1 cells, which protect against intracellular microbes through activation of mononuclear phagocytes.  Type 2 immunity consists of GATA-3+ ILC2s, TC2 cells, and TH2 cells producing IL-4, IL-5, and IL-13, which induce mast cell, basophil, and eosinophil activation, as well as IgE antibody prodn., thus protecting against helminthes and venoms.  Type 3 immunity is mediated by retinoic acid-related orphan receptor γt+ ILC3s, TC17 cells, and TH17 cells producing IL-17, IL-22, or both, which activate mononuclear phagocytes but also recruit neutrophils and induce epithelial antimicrobial responses, thus protecting against extracellular bacteria and fungi.  On the other hand, type 1 and 3 immunity mediate autoimmune diseases, whereas type 2 responses can cause allergic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobOlI4X4Np67Vg90H21EOLACvtfcHk0liw8CM9bE_sUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVSlsr8%253D&md5=16371c1d39a427d5ea96f9237e7b4d5a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.jaci.2014.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jaci.2014.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DAnnunziato%26aufirst%3DF.%26aulast%3DRomagnani%26aufirst%3DC.%26aulast%3DRomagnani%26aufirst%3DS.%26atitle%3DThe%25203%2520major%2520types%2520of%2520innate%2520and%2520adaptive%2520cell-mediated%2520effector%2520immunity%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2015%26volume%3D135%26spage%3D626%26epage%3D635%26doi%3D10.1016%2Fj.jaci.2014.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Targeting cytokines to treat asthma and chronic obstructive pulmonary disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">454</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1038/s41577-018-0006-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fs41577-018-0006-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29626211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFWqs7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2018&pages=454-466&author=P.+J.+Barnes&title=Targeting+cytokines+to+treat+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1038%2Fs41577-018-0006-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cytokines to treat asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">454-466</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cytokines play a key role in orchestrating and perpetuating the chronic airway inflammation in asthma and chronic obstructive pulmonary disease (COPD), making them attractive targets for treating these disorders.  Asthma and some cases of COPD are mainly driven by type 2 immune responses, which comprise increased airway eosinophils, T helper 2 (TH2) cells and group 2 innate lymphoid cells (ILC2s) and the secretion of IL-4, IL-5 and IL-13.  Clin. trials of antibodies that block these interleukins have shown reduced acute exacerbations and oral corticosteroid use and improvements in lung function and symptoms in selected patients.  More recent approaches that block upstream cytokines, such as thymic stromal lymphopoietin (TSLP), show promise in improving patient outcome.  Importantly, the clin. trials in cytokine blockade have highlighted the crucial importance of patient selection for the successful use of these expensive therapies and the need for biomarkers to better predict drug responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCkQgpQoVN0LVg90H21EOLACvtfcHk0liyP3-SX7Bg0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFWqs7jO&md5=6110ff640aee238d10b3096957fbd866</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fs41577-018-0006-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41577-018-0006-6%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DTargeting%2520cytokines%2520to%2520treat%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2018%26volume%3D18%26spage%3D454%26epage%3D466%26doi%3D10.1038%2Fs41577-018-0006-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnussen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khanskaya, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stryszak, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sadeh, J.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">38S</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2010&pages=38S&author=H.+Magnussenauthor=O.+Holzauthor=H.+Watzauthor=M.+Sauerauthor=I.+Khanskayaauthor=L.+Gannauthor=P.+Stryszakauthor=J.+Sadeh&title=Safety+and+efficacy+of+SCH527123%2C+a+novel+CXCR2+antagonist%2C+in+patients+with+COPD"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMagnussen%26aufirst%3DH.%26aulast%3DHolz%26aufirst%3DO.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DSauer%26aufirst%3DM.%26aulast%3DKhanskaya%26aufirst%3DI.%26aulast%3DGann%26aufirst%3DL.%26aulast%3DStryszak%26aufirst%3DP.%26aulast%3DSadeh%26aufirst%3DJ.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520SCH527123%252C%2520a%2520novel%2520CXCR2%2520antagonist%252C%2520in%2520patients%2520with%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2010%26volume%3D36%26spage%3D38S" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A.
L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDonald, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexis, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span> <span> </span><span class="NLM_article-title">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">282</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2011.03968.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1365-2125.2011.03968.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21426372" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=282-293&author=A.%0AL.+Lazaarauthor=L.+E.+Sweeneyauthor=A.+J.+MacDonaldauthor=N.+E.+Alexisauthor=C.+Chenauthor=R.+Tal-Singer&title=SB-656933%2C+a+novel+CXCR2+selective+antagonist%2C+inhibits+ex+vivo+neutrophil+activation+and+ozone-induced+airway+inflammation+in+humans&doi=10.1111%2Fj.1365-2125.2011.03968.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans</span></div><div class="casAuthors">Lazaar, Aili L.; Sweeney, Lisa E.; MacDonald, Alexander J.; Alexis, Neil E.; Chen, Chao; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">282-293</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">AIMS To det. the safety and tolerability of a novel selective CXCR2 antagonist and assess its pharmacodynamic effects using measures of neutrophil activation and function, including CD11b expression in whole blood and ozone-induced airway inflammation in healthy subjects.  METHODS Flow cytometric detn. of ex vivo CXCL1-induced CD11b expression on peripheral blood neutrophils was performed following single dose oral administration of SB-656933 (dose range 2-1100 mg).  A subsequent randomized study (placebo, 50 mg and 150 mg) was performed to explore the dose-response for ozone-induced airway inflammation, as measured by sputum biomarkers.  RESULTS Oral administration of SB-656933 resulted in significant inhibition of CXCL1-induced CD11b expression on peripheral blood neutrophils at single doses greater than or equal to 50 mg.  Maximum inhibition (70%) relative to placebo was obsd. following administration of SB-656933 400 mg (95% CI 60%, 77%).  This was sustained up to a dose of 1100 mg.  Single doses of SB-656933 reduced ozone-induced airway inflammation in a dose-dependent manner.  Relative to placebo, there were 55% (95% CI 20%, 75%) and 74% (95% CI 55%, 85%) fewer neutrophils in the sputum of subjects after a single dose of 50 mg or 150 mg, resp.  There was a corresponding redn. in myeloperoxidase concns. in the sputum supernatant of 32.8% (95% CI 9.2, 50.3) and 50.5% (95% CI 33.3, 63.3).  SB-656933 was safe and well-tolerated at all doses.  CONCLUSIONS SB-656933 is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range.  These data suggest that SB-656933 may be an effective agent in neutrophil-predominant diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj4fRS8HijE7Vg90H21EOLACvtfcHk0liyP3-SX7Bg0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtrvO&md5=cd2f3253ca0b12435a59634ecb63ceea</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2011.03968.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2011.03968.x%26sid%3Dliteratum%253Aachs%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3DSweeney%26aufirst%3DL.%2BE.%26aulast%3DMacDonald%26aufirst%3DA.%2BJ.%26aulast%3DAlexis%26aufirst%3DN.%2BE.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DSB-656933%252C%2520a%2520novel%2520CXCR2%2520selective%2520antagonist%252C%2520inhibits%2520ex%2520vivo%2520neutrophil%2520activation%2520and%2520ozone-induced%2520airway%2520inflammation%2520in%2520humans%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D282%26epage%3D293%26doi%3D10.1111%2Fj.1365-2125.2011.03968.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Busch-Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunsberger, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilian, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonchuk, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tal-Singer, R.</span></span> <span> </span><span class="NLM_article-title">Danirixin: A reversible and selective antagonist of the CXC chemokine receptor 2</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">338</span>– <span class="NLM_lpage">346</span>, <span class="refDoi"> DOI: 10.1124/jpet.117.240705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.117.240705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28611093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1CmtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2017&pages=338-346&author=J.+Busch-Petersenauthor=D.+C.+Carpenterauthor=M.+Burmanauthor=J.+Foleyauthor=G.+E.+Hunsbergerauthor=D.+J.+Kilianauthor=M.+Salmonauthor=R.+J.+Mayerauthor=J.+G.+Yonchukauthor=R.+Tal-Singer&title=Danirixin%3A+A+reversible+and+selective+antagonist+of+the+CXC+chemokine+receptor+2&doi=10.1124%2Fjpet.117.240705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Danirixin: a reversible and selective antagonist of the CXC chemokine receptor 2</span></div><div class="casAuthors">Busch-Petersen, Jakob; Carpenter, Donald C.; Burman, Miriam; Foley, James; Hunsberger, Gerald E.; Kilian, David J.; Salmon, Michael; Mayer, Ruth J.; Yonchuk, John G.; Tal-Singer, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">338-346</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">CXC chemokine receptor 2 (CXCR2) is a key receptor in the chemotaxis of neutrophils to sites of inflammation.  The studies reported here describe the pharmacol. characterization of danirixin, a CXCR2 antagonist in the diaryl urea chem. class.  Danirixin has high affinity for CXCR2, with a neg. log of the 50% inhibitory concn. (pIC50) of 7.9 for binding to Chinese hamster ovary cell (CHO)-expressed human CXCR2, and 78-fold selectivity over binding to CHO-expressed CXCR1.  Danirixin is a competitive antagonist against CXCL8 in Ca2+-mobilization assays, with a KB (the concn. of antagonist that binds 50% of the receptor population) of 6.5 nM and antagonist potency (pA2) of 8.44, and is fully reversible in washout expts. over 180 min.  In rat and human whole-blood studies assessing neutrophil activation by surface CD11b expression following CXCL2 (rat) or CXCL1 (human) challenge, danirixin blocks the CD11b upregulation with pIC50s of 6.05 and 6.3, resp.  Danirixin dosed orally also blocked the influx of neutrophils into the lung in vivo in rats following aerosol lipopolysaccharide or ozone challenge, with median EDs (ED50s) of 1.4 and 16 mg/kg resp.  Thus, danirixin would be expected to block chemotaxis in disease states in which neutrophils are increased in response to inflammation, such as pulmonary diseases.  In comparison with navarixin, a CXCR2 antagonist from a different chem. class, the binding characterization of danirixin is distinct.  These observations may offer insight into the previously obsd. clin. differences in induction of neutropenia between these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVM2WbEvWO5LVg90H21EOLACvtfcHk0lgA4-XiAJcTZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1CmtbbK&md5=c4795989e2556f36d03aa9dd2f2307d2</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1124%2Fjpet.117.240705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.117.240705%26sid%3Dliteratum%253Aachs%26aulast%3DBusch-Petersen%26aufirst%3DJ.%26aulast%3DCarpenter%26aufirst%3DD.%2BC.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DJ.%26aulast%3DHunsberger%26aufirst%3DG.%2BE.%26aulast%3DKilian%26aufirst%3DD.%2BJ.%26aulast%3DSalmon%26aufirst%3DM.%26aulast%3DMayer%26aufirst%3DR.%2BJ.%26aulast%3DYonchuk%26aufirst%3DJ.%2BG.%26aulast%3DTal-Singer%26aufirst%3DR.%26atitle%3DDanirixin%253A%2520A%2520reversible%2520and%2520selective%2520antagonist%2520of%2520the%2520CXC%2520chemokine%2520receptor%25202%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D362%26spage%3D338%26epage%3D346%26doi%3D10.1124%2Fjpet.117.240705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leaker, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">137</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-14-137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2F1465-9921-14-137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24341382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmsVOks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=137&author=B.+R.+Leakerauthor=P.+J.+Barnesauthor=B.+O%E2%80%99Connor&title=Inhibition+of+LPS-induced+airway+neutrophilic+inflammation+in+healthy+volunteers+with+an+oral+CXCR2+antagonist&doi=10.1186%2F1465-9921-14-137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist</span></div><div class="casAuthors">Leaker, Brian R.; Barnes, Peter J.; O'Connor, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">137/1-137/9, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">RREEBZ</span>;
        ISSN:<span class="NLM_cas:issn">1465-993X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Inhaled lipopolysaccharide (LPS) induces a dose-dependent, acute neutrophilic response in the airways of healthy volunteers that can be quantified in induced sputum.  Chemokines, such as CXCL1 and CXCL8, play an important role in neutrophilic inflammation in the lung through the activation of CXCR2 and small mol. antagonists of these receptors have now been developed.  We investigated the effect of AZD8309, a CXCR2 antagonist, compared with placebo on LPS-induced inflammation measured in sputum of healthy volunteers.  Methods: Twenty healthy subjects were randomized in a double-blind placebo-controlled, cross-over study.  AZD8309 (300 mg) or placebo was dosed twice daily orally for 3 days prior to challenge with inhaled LPS and induced sputum was collected 6 h later.  Results: Treatment with AZD8309 showed a mean 77% redn. in total sputum cells (p<0.001) and 79% redn. in sputum neutrophils (p<0.05) compared with placebo after LPS challenge.  There was also a redn. in neutrophil elastase activity (p<0.05) and CXCL1 (p<0.05) and trends for redns. in sputum macrophages (47%), leukotriene B4 (39%) and CXCL8 (52%).  Conclusions: AZD8309 inhibited LPS-induced inflammation measured in induced sputum of normal volunteers, indicating that this treatment may be useful in the treatment of neutrophilic diseases of the airways, such as COPD, severe asthma and cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFlOITn_IsH7Vg90H21EOLACvtfcHk0lhol6kglNcAow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmsVOks78%253D&md5=d6e7617d2b9abb891b9c5b6e13a2d4c4</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-14-137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-14-137%26sid%3Dliteratum%253Aachs%26aulast%3DLeaker%26aufirst%3DB.%2BR.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520LPS-induced%2520airway%2520neutrophilic%2520inflammation%2520in%2520healthy%2520volunteers%2520with%2520an%2520oral%2520CXCR2%2520antagonist%26jtitle%3DRespir.%2520Res.%26date%3D2013%26volume%3D14%26spage%3D137%26doi%3D10.1186%2F1465-9921-14-137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dainty, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntosh, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardh, C. K.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>353</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">350</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.221358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.114.221358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25736418" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlvVWnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2015&pages=340-350&author=D.+J.+Nichollsauthor=K.+Wileyauthor=I.+Daintyauthor=F.+MacIntoshauthor=C.+Phillipsauthor=A.+Gawauthor=C.+K.+Mardh&title=Pharmacological+characterization+of+AZD5069%2C+a+slowly+reversible+CXC+chemokine+receptor+2+antagonist&doi=10.1124%2Fjpet.114.221358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist</span></div><div class="casAuthors">Nicholls, David J.; Wiley, Katherine; Dainty, Ian; MacIntosh, Fraser; Phillips, Caroline; Gaw, Alasdair; Mardh, Carina Karrman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">340-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">In normal physiol. responses to injury and infection, inflammatory cells enter tissue and sites of inflammation through a chemotactic process regulated by several families of proteins, including inflammatory chemokines, a family of small inducible cytokines.  In neutrophils, chemokines chemokine (CXC motif) ligand 1 (CXCL1) and CXCL8 are potent chemoattractants and activate G protein-coupled receptors CXC chemokine receptor 1 (CXCR1) and CXCR2.  Several small-mol. antagonists of CXCR2 have been developed to inhibit the inflammatory responses mediated by this receptor.  Here, we present the data describing the pharmacol. of AZD5069 [N-(2-(2,3-difluorobenzylthio)-6-((2R,3S)-3,4-dihydroxybutan-2-yloxy)[2,4,5,6-13C4, 1,3-15N-2]pyrimidin-4-yl)azetidine-1-sulfonamide,[15N2,13C4]N-(2-(2,3-difluoro-6-[3H]-benzylthio)-6-((2R,3S)-3,4-dihydroxybutan-2-yloxy)pyrimidin-4-yl)azetidine-1-sulfonamide], a novel antagonist of CXCR2.  AZD5069 was shown to inhibit binding of radio-labeled CXCL8 to human CXCR2 with a pIC50 value of 9.1.  Furthermore, AZD5069 inhibited neutrophil chemotaxis, with a pA2 of approx. 9.6, and adhesion mol. expression, with a pA2 of 6.9, in response to CXCL1.  AZD5069 was a slowly reversible antagonist of CXCR2 with effects of time and temp. evident on the pharmacol. and binding kinetics.  With short incubation times, AZD5069 appeared to have an antagonist profile with insurmountable antagonism of calcium response curves.  This behavior was also obsd. in vivo in an acute lipopolysaccharide-induced lung inflammation model.  Altogether, the data presented here show that AZD5069 represents a novel, potent, and selective CXCR2 antagonist with potential as a therapeutic agent in inflammatory conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj1gxnHr4vbbVg90H21EOLACvtfcHk0liMUDoOCyEdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlvVWnu7g%253D&md5=1ffebbdc9c02dbd015d985062ac820f2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.221358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.221358%26sid%3Dliteratum%253Aachs%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DWiley%26aufirst%3DK.%26aulast%3DDainty%26aufirst%3DI.%26aulast%3DMacIntosh%26aufirst%3DF.%26aulast%3DPhillips%26aufirst%3DC.%26aulast%3DGaw%26aufirst%3DA.%26aulast%3DMardh%26aufirst%3DC.%2BK.%26atitle%3DPharmacological%2520characterization%2520of%2520AZD5069%252C%2520a%2520slowly%2520reversible%2520CXC%2520chemokine%2520receptor%25202%2520antagonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D353%26spage%3D340%26epage%3D350%26doi%3D10.1124%2Fjpet.114.221358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, F.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel 1-cyclopentenyl-3-phenylureas as selective, brain penetrant, and orally bioavailable CXCR2 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2518</span>– <span class="NLM_lpage">2532</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01854</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01854" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2mtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2518-2532&author=H.+Luauthor=T.+Yangauthor=Z.+Xuauthor=X.+Linauthor=Q.+Dingauthor=Y.+Zhangauthor=X.+Caiauthor=K.+Dongauthor=S.+Gongauthor=W.+Zhangauthor=M.+Patelauthor=R.+C.+B.+Copleyauthor=J.+Xiangauthor=X.+Guanauthor=P.+Wrenauthor=F.+Ren&title=Discovery+of+novel+1-cyclopentenyl-3-phenylureas+as+selective%2C+brain+penetrant%2C+and+orally+bioavailable+CXCR2+antagonists&doi=10.1021%2Facs.jmedchem.7b01854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists</span></div><div class="casAuthors">Lu, Hongfu; Yang, Ting; Xu, Zhongmiao; Lin, Xichen; Ding, Qian; Zhang, Yueting; Cai, Xin; Dong, Kelly; Gong, Sophie; Zhang, Wei; Patel, Metul; Copley, Royston C. B.; Xiang, Jianing; Guan, Xiaoming; Wren, Paul; Ren, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2518-2532</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CXCR2 has emerged as a therapeutic target for not only peripheral inflammatory diseases but also neurol. abnormalities in the central nervous system (CNS).  Herein, we describe the discovery of a novel 1-cyclopentenyl-3-phenylurea series as potent and CNS penetrant CXCR2 antagonists.  Extensive SAR studies, wherein mols.' property forecast index (PFI) was carefully optimized for overall balanced developability profiles, led to the discovery of the advanced lead compd. I with a desirable PFI.  Compd. I demonstrated good in vitro pharmacol. with excellent selectivity over CXCR1 and other chemokine receptors.  Rat and dog pharmacokinetics (PK) revealed good oral bioavailability, high oral exposure, and desirable elimination half-life of the compd. in both species.  In addn., the compd. demonstrated dose-dependent efficacy in the in vivo pharmacol. neutrophil infiltration "air pouch" model in rodents after oral administration.  Further, compd. I is a CNS penetrant mol. with high unbound fraction in brain tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJoQpdzgs6WLVg90H21EOLACvtfcHk0liMUDoOCyEdjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2mtLY%253D&md5=883ab4646ae2318790c4b036b601930d</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01854%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DK.%26aulast%3DGong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DXiang%26aufirst%3DJ.%26aulast%3DGuan%26aufirst%3DX.%26aulast%3DWren%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DF.%26atitle%3DDiscovery%2520of%2520novel%25201-cyclopentenyl-3-phenylureas%2520as%2520selective%252C%2520brain%2520penetrant%252C%2520and%2520orally%2520bioavailable%2520CXCR2%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2518%26epage%3D2532%26doi%3D10.1021%2Facs.jmedchem.7b01854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peck, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirpotina, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicomb, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zebala, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-[5-(4-Fluorophenylcarbamoyl) pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517): noncompetitive boronic acid antagonist of CXCR1 and CXCR2</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8378</span>– <span class="NLM_lpage">8397</span>, <span class="refDoi"> DOI: 10.1021/jm500827t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500827t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wksr%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8378-8397&author=D.+Y.+Maedaauthor=A.+M.+Peckauthor=A.+D.+Schulerauthor=M.+T.+Quinnauthor=L.+N.+Kirpotinaauthor=W.+N.+Wicombauthor=G.+H.+Fanauthor=J.+A.+Zebala&title=Discovery+of+2-%5B5-%284-Fluorophenylcarbamoyl%29+pyridin-2-ylsulfanylmethyl%5Dphenylboronic+acid+%28SX-517%29%3A+noncompetitive+boronic+acid+antagonist+of+CXCR1+and+CXCR2&doi=10.1021%2Fjm500827t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2</span></div><div class="casAuthors">Maeda, Dean Y.; Peck, Angela M.; Schuler, Aaron D.; Quinn, Mark T.; Kirpotina, Liliya N.; Wicomb, Winston N.; Fan, Guo-Huang; Zebala, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8378-8397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The G protein-coupled chemokine receptors CXCR1 and CXCR2 play key roles in inflammatory diseases and carcinogenesis.  In inflammation, they activate and recruit polymorphonuclear cells (PMNs) through binding of the chemokines CXCL1 (CXCR1) and CXCL8 (CXCR1 and CXCR2).  Structure-activity studies that examd. the effect of a novel series of S-substituted 6-mercapto-N-phenyl-nicotinamides on CXCL1-stimulated Ca2+ flux in whole human PMNs led to the discovery of 2-[5-(4-fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517), a potent noncompetitive boronic acid CXCR1/2 antagonist.  SX-517 inhibited CXCL1-induced Ca2+ flux (IC50 = 38 nM) in human PMNs but had no effect on the Ca2+ flux induced by C5a, fMLF, or PAF.  In recombinant HEK293 cells that stably expressed CXCR2, SX-517 antagonized CXCL8-induced [35S]GTPγS binding (IC50 = 60 nM) and ERK1/2 phosphorylation.  Inhibition was noncompetitive, with SX-517 unable to compete the binding of [125I]-CXCL8 to CXCR2 membranes.  SX-517 (0.2 mg/kg iv) significantly inhibited inflammation in an in vivo murine model.  SX-517 is the first reported boronic acid chemokine antagonist and represents a novel pharmacophore for CXCR1/2 antagonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoojKLcTCrPlbVg90H21EOLACvtfcHk0ljYLnxyy23hBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wksr%252FE&md5=7808e8ab0cec509d7e6a6cabe1b52907</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fjm500827t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500827t%26sid%3Dliteratum%253Aachs%26aulast%3DMaeda%26aufirst%3DD.%2BY.%26aulast%3DPeck%26aufirst%3DA.%2BM.%26aulast%3DSchuler%26aufirst%3DA.%2BD.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26aulast%3DKirpotina%26aufirst%3DL.%2BN.%26aulast%3DWicomb%26aufirst%3DW.%2BN.%26aulast%3DFan%26aufirst%3DG.%2BH.%26aulast%3DZebala%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25202-%255B5-%25284-Fluorophenylcarbamoyl%2529%2520pyridin-2-ylsulfanylmethyl%255Dphenylboronic%2520acid%2520%2528SX-517%2529%253A%2520noncompetitive%2520boronic%2520acid%2520antagonist%2520of%2520CXCR1%2520and%2520CXCR2%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8378%26epage%3D8397%26doi%3D10.1021%2Fjm500827t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerstjens, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjermer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlström, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span> <span> </span><span class="NLM_article-title">Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">1297</span>– <span class="NLM_lpage">1303</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2010.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.rmed.2010.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20466530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3cjjtlygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2010&pages=1297-1303&author=H.+A.+Kerstjensauthor=L.+Bjermerauthor=L.+Erikssonauthor=K.+Dahlstr%C3%B6mauthor=J.+Vestbo&title=Tolerability+and+efficacy+of+inhaled+AZD4818%2C+a+CCR1+antagonist%2C+in+moderate+to+severe+COPD+patients&doi=10.1016%2Fj.rmed.2010.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients</span></div><div class="casAuthors">Kerstjens Huib A; Bjermer Leif; Eriksson Leif; Dahlstrom Kerstin; Vestbo Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1297-303</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  This study evaluated the tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in patients with COPD.  METHODS:  This double-blind, placebo-controlled study (NCT00629239) randomised patients with moderate to severe COPD to AZD4818 300mug or placebo twice daily via Turbuhaler((R)) for 4 weeks.  Safety, lung function, functional capacity and health status measures were measured.  Plasma concentrations of AZD4818 were measured after the first dose and after 2 and 4 weeks' treatment.  RESULTS:  Sixty-five patients (47 male; median age 65.6 years) received AZD4818 (n=33) or placebo (n=32).  There was no statistically significant difference between AZD4818 and placebo in change from baseline to endpoint for FEV(1) (AZD4818-placebo: 0.026L, p=0.69), morning PEF (-6L/min, p=0.23), or other lung function measures.  There was no difference between treatment groups in the 6-min walk test, MMRC dyspnoea index, BODE index and CCQ scores.  Plasma concentrations indicated that patients were exposed to AZD4818 as expected.  AZD4818 was well tolerated: 27 treatment-related adverse events (13 with AZD4818, 14 with placebo), 2 serious adverse events (both AZD4818: exacerbation [considered not treatment-related] and deep vein thrombosis [considered treatment-related]) and 11 discontinuations (7 with AZD4818).  CONCLUSIONS:  Inhaled AZD4818 was well tolerated at 300mug twice daily for 4 weeks in patients with COPD; however, there was no indication of a beneficial treatment effect despite exposure as expected.  These findings in COPD are in line with other studies reporting a lack of clinical efficacy with CCR1 antagonists in other therapy areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReNiH0l3TS4ZWtyewyzkyLfW6udTcc2eaQuZgSU84C8rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjjtlygsg%253D%253D&md5=157554642d8a8d754ca22d56328ce6f7</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2010.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2010.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DKerstjens%26aufirst%3DH.%2BA.%26aulast%3DBjermer%26aufirst%3DL.%26aulast%3DEriksson%26aufirst%3DL.%26aulast%3DDahlstr%25C3%25B6m%26aufirst%3DK.%26aulast%3DVestbo%26aufirst%3DJ.%26atitle%3DTolerability%2520and%2520efficacy%2520of%2520inhaled%2520AZD4818%252C%2520a%2520CCR1%2520antagonist%252C%2520in%2520moderate%2520to%2520severe%2520COPD%2520patients%26jtitle%3DRespir.%2520Med.%26date%3D2010%26volume%3D104%26spage%3D1297%26epage%3D1303%26doi%3D10.1016%2Fj.rmed.2010.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. J.</span></span> <span> </span><span class="NLM_article-title">Small molecule CXCR3 antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2894</span>– <span class="NLM_lpage">2917</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01337</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01337" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVCnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2894-2917&author=S.+P.+Andrewsauthor=R.+J.+Cox&title=Small+molecule+CXCR3+antagonists&doi=10.1021%2Facs.jmedchem.5b01337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule CXCR3 Antagonists</span></div><div class="casAuthors">Andrews, Stephen P.; Cox, Rhona J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2894-2917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chemokines and their receptors are known to play important roles in disease.  More than 40 chemokine ligands and 20 chemokine receptors have been identified, but, to date, only two small mol. chemokine receptor antagonists have been approved by the FDA.  The chemokine receptor CXCR3 was identified in 1996, and nearly 20 years later, new areas of CXCR3 disease biol. continue to emerge.  Several classes of small mol. CXCR3 antagonists have been developed, and two have shown efficacy in preclin. models of inflammatory disease.  However, only one CXCR3 antagonist has been evaluated in clin. trials, and there remain many opportunities to further investigate known classes of CXCR3 antagonists and to identify new chemotypes.  This Perspective reviews the known CXCR3 antagonists and considers future opportunities for the development of small mols. for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOCEhO7Ug3ULVg90H21EOLACvtfcHk0lgP4CPX0wrubQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVCnsrk%253D&md5=5e05dd6a3c7df567b579933f7d110f71</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01337%26sid%3Dliteratum%253Aachs%26aulast%3DAndrews%26aufirst%3DS.%2BP.%26aulast%3DCox%26aufirst%3DR.%2BJ.%26atitle%3DSmall%2520molecule%2520CXCR3%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2894%26epage%3D2917%26doi%3D10.1021%2Facs.jmedchem.5b01337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span> <span> </span><span class="NLM_article-title">Activation and regulation of the inflammasomes</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1038/nri3452</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnri3452" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23702978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFSgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=397-411&author=E.+Latzauthor=T.+S.+Xiaoauthor=A.+Stutz&title=Activation+and+regulation+of+the+inflammasomes&doi=10.1038%2Fnri3452"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and regulation of the inflammasomes</span></div><div class="casAuthors">Latz, Eicke; Xiao, T. Sam; Stutz, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">397-411</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Inflammasomes are key signalling platforms that detect pathogenic microorganisms and sterile stressors, and that activate the highly pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18.  In this Review, we discuss the complex regulatory mechanisms that facilitate a balanced but effective inflammasome-mediated immune response, and we highlight the similarities to another mol. signalling platform - the apoptosome - that monitors cellular health.  Extracellular regulatory mechanisms are discussed, as well as the intracellular control of inflammasome assembly, for example, via ion fluxes, free radicals and autophagy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGom16nKHEVN3bVg90H21EOLACvtfcHk0lgP4CPX0wrubQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFSgsLw%253D&md5=86c377fdd6dc6759679f4e410fad96af</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnri3452&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3452%26sid%3Dliteratum%253Aachs%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DXiao%26aufirst%3DT.%2BS.%26aulast%3DStutz%26aufirst%3DA.%26atitle%3DActivation%2520and%2520regulation%2520of%2520the%2520inflammasomes%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D397%26epage%3D411%26doi%3D10.1038%2Fnri3452" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelegrin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surprenant, A.</span></span> <span> </span><span class="NLM_article-title">Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2×7 receptor</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">5071</span>– <span class="NLM_lpage">5082</span>, <span class="refDoi"> DOI: 10.1038/sj.emboj.7601378</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fsj.emboj.7601378" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17036048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFChsrzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=5071-5082&author=P.+Pelegrinauthor=A.+Surprenant&title=Pannexin-1+mediates+large+pore+formation+and+interleukin-1%CE%B2+release+by+the+ATP-gated+P2%C3%977+receptor&doi=10.1038%2Fsj.emboj.7601378"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Pannexin-1 mediates large pore formation and interleukin-1β release by the ATP-gated P2X7 receptor</span></div><div class="casAuthors">Pelegrin, Pablo; Surprenant, Annmarie</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5071-5082</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">P2X7 receptors are ATP-gated cation channels; their activation in macrophage also leads to rapid opening of a membrane pore permeable to dyes such as ethidium, and to release of the pro-inflammatory cytokine, interleukin-1β (IL-1β).  It has not been known what this dye-uptake path is, or whether it is involved in downstream signaling to IL-1β release.  Here, we identify pannexin-1, a recently described mammalian protein that functions as a hemichannel when ectopically expressed, as this dye-uptake pathway and show that signaling through pannexin-1 is required for processing of caspase-1 and release of mature IL-1β induced by P2X7 receptor activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgKvoL27FfqbVg90H21EOLACvtfcHk0lgP4CPX0wrubQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFChsrzM&md5=9b4bb218bde9ee4145bd3f70d900012c</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601378&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601378%26sid%3Dliteratum%253Aachs%26aulast%3DPelegrin%26aufirst%3DP.%26aulast%3DSurprenant%26aufirst%3DA.%26atitle%3DPannexin-1%2520mediates%2520large%2520pore%2520formation%2520and%2520interleukin-1%25CE%25B2%2520release%2520by%2520the%2520ATP-gated%2520P2%25C3%25977%2520receptor%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D5071%26epage%3D5082%26doi%3D10.1038%2Fsj.emboj.7601378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hosseinian, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockey, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolliputi, N.</span></span> <span> </span><span class="NLM_article-title">The role of the NLRP3 inflammasome in pulmonary diseases</span>. <i>Ther. Adv. Respir. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1177/1753465815586335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1177%2F1753465815586335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26012351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xpsleqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=188-197&author=N.+Hosseinianauthor=Y.+Choauthor=R.+F.+Lockeyauthor=N.+Kolliputi&title=The+role+of+the+NLRP3+inflammasome+in+pulmonary+diseases&doi=10.1177%2F1753465815586335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The role of the NLRP3 inflammasome in pulmonary diseases</span></div><div class="casAuthors">Hosseinian, Nima; Cho, Young; Lockey, Richard F.; Kolliputi, Narasaiah</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Respiratory Disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">188-197</span>CODEN:
                <span class="NLM_cas:coden">TARDCZ</span>;
        ISSN:<span class="NLM_cas:issn">1753-4658</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Respiratory diseases and lung injuries are one of the leading causes of death in the world.  One crit. component of these diseases is exaggerated inflammatory response.  The recently discovered inflammasome is believed to play a key role in inflammation.  The inflammasome is an oligomer of intracellular proteins that, once activated by an insult or damage signal, produces mature cytokines from the interleukin-1 family that mediate an inflammatory response.  Previous research has provided evidence that suggests the role of the inflammasome in the pathogenesis of many chronic respiratory diseases and acute lung injuries, such as transfusion-related acute lung injury, ventilator-induced lung injury, asthma, chronic obstructive pulmonary disease and pulmonary fibrosis.  This article summarizes recent research on the inflammasome and reviews proposed mol. models of the role of the inflammasome in several prominent lung diseases and injuries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNTrnjBuYwzrVg90H21EOLACvtfcHk0lisk8tSSBxrQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xpsleqs7g%253D&md5=053acd2cf38af5f251818ce64f10f297</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1177%2F1753465815586335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1753465815586335%26sid%3Dliteratum%253Aachs%26aulast%3DHosseinian%26aufirst%3DN.%26aulast%3DCho%26aufirst%3DY.%26aulast%3DLockey%26aufirst%3DR.%2BF.%26aulast%3DKolliputi%26aufirst%3DN.%26atitle%3DThe%2520role%2520of%2520the%2520NLRP3%2520inflammasome%2520in%2520pulmonary%2520diseases%26jtitle%3DTher.%2520Adv.%2520Respir.%2520Dis.%26date%3D2015%26volume%3D9%26spage%3D188%26epage%3D197%26doi%3D10.1177%2F1753465815586335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rovina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dima, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerassimou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kollintza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gratziou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roussos, C.</span></span> <span> </span><span class="NLM_article-title">Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1056</span>– <span class="NLM_lpage">1062</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2009.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.rmed.2009.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19208460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1MvhsFGjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2009&pages=1056-1062&author=N.+Rovinaauthor=E.+Dimaauthor=C.+Gerassimouauthor=A.+Kollintzaauthor=C.+Gratziouauthor=C.+Roussos&title=Interleukin-18+in+induced+sputum%3A+association+with+lung+function+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.rmed.2009.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rovina Nikoletta; Dima Efrossini; Gerassimou Christina; Kollintza Androniki; Gratziou Christina; Roussos Charis</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1056-62</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  It has been shown that interleukin (IL)-18 levels in induced sputum are reduced in asthmatic and healthy smokers.  However, in chronic obstructive pulmonary disease (COPD) patients, recent data show an overproduction in the lungs and increased serum levels of IL-18, suggesting that IL-18 may be involved in the pathogenesis of COPD.  METHOD:  In order to assess the relation of IL-18 with pulmonary function and airway inflammation in COPD, IL-18, tumour necrosis factor-alpha, and IL-8 levels were measured by ELISA in sputum supernatants obtained from patients with bronchitis type COPD (n=28), and healthy subjects (18 smokers and 17 non-smokers).  Cellular localization of IL-18 was assessed by immunocytochemistry.  RESULTS:  The levels of IL-18 were significantly higher in sputum supernatants of COPD patients compared to healthy smokers and non-smokers (p<0.05).  IL-18 production was localized to sputum macrophages.  IL-18 levels were inversely correlated with FEV(1) (% predicted) (r=-0.572, p=0.002) and FEV(1)/FVC ratio in COPD smokers (r=-0.608, p=0.001).  No correlations were found between IL-18 levels and inflammatory markers studied in induced sputum obtained from COPD patients, healthy smokers and non-smokers.  CONCLUSION:  In patients with COPD, increased levels of IL-18 in induced sputum were associated with airflow limitation, suggesting that IL-18 may be implicated in the pathogenesis of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSTxbea41UcSDDnmmyUf5qOfW6udTcc2eZGNMRm8ceaN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvhsFGjtQ%253D%253D&md5=93e127d7873d267f22ac0ef2ce56a1f6</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2009.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2009.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DRovina%26aufirst%3DN.%26aulast%3DDima%26aufirst%3DE.%26aulast%3DGerassimou%26aufirst%3DC.%26aulast%3DKollintza%26aufirst%3DA.%26aulast%3DGratziou%26aufirst%3DC.%26aulast%3DRoussos%26aufirst%3DC.%26atitle%3DInterleukin-18%2520in%2520induced%2520sputum%253A%2520association%2520with%2520lung%2520function%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DRespir.%2520Med.%26date%3D2009%26volume%3D103%26spage%3D1056%26epage%3D1062%26doi%3D10.1016%2Fj.rmed.2009.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span> <span> </span><span class="NLM_article-title">Anti-IL-1β therapies</span>. <i>Recent Pat. DNA Gene Sequences</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.2174/187221511796392024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2174%2F187221511796392024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21762108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFelu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2011&pages=126-135&author=H.+Zhang&title=Anti-IL-1%CE%B2+therapies&doi=10.2174%2F187221511796392024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-IL-1 β therapies</span></div><div class="casAuthors">Zhang, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on DNA & Gene Sequences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">126-135</span>CODEN:
                <span class="NLM_cas:coden">RPDGBM</span>;
        ISSN:<span class="NLM_cas:issn">1872-2156</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  IL-1β is one of the major cytokines implicated in the pathogenesis of many inflammatory-assocd. diseases.  Recent studies demonstrate that IL-1β is activated through inflammasomes, which are formed upon recognition of danger signals by the immune system.  IL-1β is, therefore, becoming a focus for the development of new anti-inflammatory drug products.  Current issued patents mainly covered the methods and the use of four types of IL-1β blockade compds., namely anti-IL-1β antibody, IL-1 receptor antagonists such as sIL-1Ra and icIL-1Ra and IL1 trap.  Two agents, Rilonacept and canakinumab were approved by the US FDA and others are in trial, in which beneficial results have been reported.  One can expect that upcoming patents in the field of inflammasome research will facilitate the development of new therapeutic interventions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLkAs7WFiHQLVg90H21EOLACvtfcHk0lg2JEUdZhne3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFelu74%253D&md5=a22112be11c56a44e3faced8420b3f61</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.2174%2F187221511796392024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F187221511796392024%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DAnti-IL-1%25CE%25B2%2520therapies%26jtitle%3DRecent%2520Pat.%2520DNA%2520Gene%2520Sequences%26date%3D2011%26volume%3D5%26spage%3D126%26epage%3D135%26doi%3D10.2174%2F187221511796392024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brough, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S.</span></span> <span> </span><span class="NLM_article-title">Inhibiting the inflammasome: a chemical perspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1710</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01091</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01091" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1691-1710&author=A.+G.+Baldwinauthor=D.+Broughauthor=S.+Freeman&title=Inhibiting+the+inflammasome%3A+a+chemical+perspective&doi=10.1021%2Facs.jmedchem.5b01091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibiting the Inflammasome: A Chemical Perspective</span></div><div class="casAuthors">Baldwin, Alex G.; Brough, David; Freeman, Sally</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1691-1710</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inflammasomes are high mol. wt. complexes that sense and react to injury and infection.  Their activation induces caspase-1 activation and release of interleukin-1β, a pro-inflammatory cytokine involved in both acute and chronic inflammatory responses.  There is increasing evidence that inflammasomes, particularly the NLRP3 inflammasome, act as guardians against noninfectious material.  Inappropriate activation of the NLRP3 inflammasome contributes to the progression of many noncommunicable diseases such as gout, type II diabetes, and Alzheimer's disease.  Inhibiting the inflammasome may significantly reduce damaging inflammation and is therefore regarded as a therapeutic target.  Currently approved inhibitors of interleukin-1β are rilonacept, canakinumab, and anakinra.  However, these proteins do not possess ideal pharmacokinetic properties and are unlikely to easily cross the blood-brain barrier.  Because inflammation can contribute to neurol. disorders, this review focuses on the development of small-mol. inhibitors of the NLRP3 inflammasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjTr3TikmZprVg90H21EOLACvtfcHk0lg2JEUdZhne3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2lt7rE&md5=754a1ef05e17cd82a376bf5105a23990</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01091%26sid%3Dliteratum%253Aachs%26aulast%3DBaldwin%26aufirst%3DA.%2BG.%26aulast%3DBrough%26aufirst%3DD.%26aulast%3DFreeman%26aufirst%3DS.%26atitle%3DInhibiting%2520the%2520inflammasome%253A%2520a%2520chemical%2520perspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1691%26epage%3D1710%26doi%3D10.1021%2Facs.jmedchem.5b01091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangan, M. S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olhava, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roush, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glick, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Targeting the NLRP3 inflammasome in inflammatory diseases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">606</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.97</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrd.2018.97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=30026524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlGlt7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=588-606&author=M.+S.+J.+Manganauthor=E.+J.+Olhavaauthor=W.+R.+Roushauthor=H.+M.+Seidelauthor=G.+D.+Glickauthor=E.+Latz&title=Targeting+the+NLRP3+inflammasome+in+inflammatory+diseases&doi=10.1038%2Fnrd.2018.97"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the NLRP3 inflammasome in inflammatory diseases</span></div><div class="casAuthors">Mangan, Matthew S. J.; Olhava, Edward J.; Roush, William R.; Seidel, H. Martin; Glick, Gary D.; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">588-606</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Danger signals are a hallmark of many common inflammatory diseases, and these stimuli can function to activate the cytosolic innate immune signalling receptor NLRP3 (NOD-, LRR- and pyrin domain-contg. 3).  Once activated, NLRP3 nucleates the assembly of an inflammasome, leading to caspase 1-mediated proteolytic activation of the interleukin-1β (IL-1β) family of cytokines, and induces an inflammatory, pyroptotic cell death.  Pharmacol. inhibition of NLRP3 activation results in potent therapeutic effects in a wide variety of rodent models of inflammatory diseases, effects that are mirrored by genetic ablation of NLRP3.  Although these findings highlight the potential of NLRP3 as a drug target, an understanding of NLRP3 structure and activation mechanisms is incomplete, which has hampered the discovery and development of novel therapeutics against this target.  Here, we review recent advances in our understanding of NLRP3 activation and regulation, highlight the evolving landscape of NLRP3 modulators and discuss opportunities for pharmacol. targeting NLRP3 with novel small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw2JAJ8RPRXrVg90H21EOLACvtfcHk0lh4rpzjjzqfPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlGlt7bM&md5=57b064477ea056dc859f6c90c4d00c36</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.97%26sid%3Dliteratum%253Aachs%26aulast%3DMangan%26aufirst%3DM.%2BS.%2BJ.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26aulast%3DRoush%26aufirst%3DW.%2BR.%26aulast%3DSeidel%26aufirst%3DH.%2BM.%26aulast%3DGlick%26aufirst%3DG.%2BD.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DTargeting%2520the%2520NLRP3%2520inflammasome%2520in%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D588%26epage%3D606%26doi%3D10.1038%2Fnrd.2018.97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coll, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robertson, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chae, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Planillo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inserra, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vetter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dungan, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monks, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stutz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croker, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haneklaus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kastner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, L. A.</span></span> <span> </span><span class="NLM_article-title">A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">248</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1038/nm.3806</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnm.3806" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25686105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXivVSit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=248-255&author=R.+C.+Collauthor=A.+A.+Robertsonauthor=J.+J.+Chaeauthor=S.+C.+Higginsauthor=R.+Mu%C3%B1oz-Planilloauthor=M.+C.+Inserraauthor=I.+Vetterauthor=L.+S.+Dunganauthor=B.+G.+Monksauthor=A.+Stutzauthor=D.+E.+Crokerauthor=M.+S.+Butlerauthor=M.+Haneklausauthor=C.+E.+Suttonauthor=G.+N%C3%BA%C3%B1ezauthor=E.+Latzauthor=D.+L.+Kastnerauthor=K.+H.+Millsauthor=S.+L.+Mastersauthor=K.+Schroderauthor=M.+A.+Cooperauthor=L.+A.+O%E2%80%99Neill&title=A+small-molecule+inhibitor+of+the+NLRP3+inflammasome+for+the+treatment+of+inflammatory+diseases&doi=10.1038%2Fnm.3806"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases</span></div><div class="casAuthors">Coll, Rebecca C.; Robertson, Avril A. B.; Chae, Jae Jin; Higgins, Sarah C.; Munoz-Planillo, Raul; Inserra, Marco C.; Vetter, Irina; Dungan, Lara S.; Monks, Brian G.; Stutz, Andrea; Croker, Daniel E.; Butler, Mark S.; Haneklaus, Moritz; Sutton, Caroline E.; Nunez, Gabriel; Latz, Eicke; Kastner, Daniel L.; Mills, Kingston H. G.; Masters, Seth L.; Schroder, Kate; Cooper, Matthew A.; O'Neill, Luke A. J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">248-255</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The NOD-like receptor (NLR) family, pyrin domain-contg. protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activation is pathogenic in inherited disorders such as cryopyrin-assocd. periodic syndrome (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis.  We describe the development of MCC950, a potent, selective, small-mol. inhibitor of NLRP3.  MCC950 blocked canonical and noncanonical NLRP3 activation at nanomolar concns.  MCC950 specifically inhibited activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes.  MCC950 reduced interleukin-1β (IL-1β) prodn. in vivo and attenuated the severity of exptl. autoimmune encephalomyelitis (EAE), a disease model of multiple sclerosis.  Furthermore, MCC950 treatment rescued neonatal lethality in a mouse model of CAPS and was active in ex vivo samples from individuals with Muckle-Wells syndrome.  MCC950 is thus a potential therapeutic for NLRP3-assocd. syndromes, including autoinflammatory and autoimmune diseases, and a tool for further study of the NLRP3 inflammasome in human health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBPny7QJdNA7Vg90H21EOLACvtfcHk0lh4rpzjjzqfPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXivVSit7g%253D&md5=5ffe3683cc33ded3c3b18421e987cac5</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnm.3806&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3806%26sid%3Dliteratum%253Aachs%26aulast%3DColl%26aufirst%3DR.%2BC.%26aulast%3DRobertson%26aufirst%3DA.%2BA.%26aulast%3DChae%26aufirst%3DJ.%2BJ.%26aulast%3DHiggins%26aufirst%3DS.%2BC.%26aulast%3DMu%25C3%25B1oz-Planillo%26aufirst%3DR.%26aulast%3DInserra%26aufirst%3DM.%2BC.%26aulast%3DVetter%26aufirst%3DI.%26aulast%3DDungan%26aufirst%3DL.%2BS.%26aulast%3DMonks%26aufirst%3DB.%2BG.%26aulast%3DStutz%26aufirst%3DA.%26aulast%3DCroker%26aufirst%3DD.%2BE.%26aulast%3DButler%26aufirst%3DM.%2BS.%26aulast%3DHaneklaus%26aufirst%3DM.%26aulast%3DSutton%26aufirst%3DC.%2BE.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DG.%26aulast%3DLatz%26aufirst%3DE.%26aulast%3DKastner%26aufirst%3DD.%2BL.%26aulast%3DMills%26aufirst%3DK.%2BH.%26aulast%3DMasters%26aufirst%3DS.%2BL.%26aulast%3DSchroder%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DL.%2BA.%26atitle%3DA%2520small-molecule%2520inhibitor%2520of%2520the%2520NLRP3%2520inflammasome%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D248%26epage%3D255%26doi%3D10.1038%2Fnm.3806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinkerton, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horvat, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbro, P. M.</span></span> <span> </span><span class="NLM_article-title">Inflammasomes in COPD and neutrophilic asthma</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1201</span>, <span class="refDoi"> DOI: 10.1136/thoraxjnl-2014-206736</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1136%2Fthoraxjnl-2014-206736" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26493990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28zksFSltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2015&pages=1199-1201&author=R.+Y.+Kimauthor=J.+W.+Pinkertonauthor=P.+G.+Gibsonauthor=M.+A.+Cooperauthor=J.+C.+Horvatauthor=P.+M.+Hansbro&title=Inflammasomes+in+COPD+and+neutrophilic+asthma&doi=10.1136%2Fthoraxjnl-2014-206736"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammasomes in COPD and neutrophilic asthma</span></div><div class="casAuthors">Kim Richard Y; Pinkerton James W; Gibson Peter G; Horvat Jay C; Hansbro Philip M; Cooper Matthew A</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1199-201</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR84wrLFcBzAXELvajU9pjPfW6udTcc2ea3WQr6OM1uwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zksFSltA%253D%253D&md5=18de0090f99e02e25157853a9304c884</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1136%2Fthoraxjnl-2014-206736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthoraxjnl-2014-206736%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DR.%2BY.%26aulast%3DPinkerton%26aufirst%3DJ.%2BW.%26aulast%3DGibson%26aufirst%3DP.%2BG.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DHorvat%26aufirst%3DJ.%2BC.%26aulast%3DHansbro%26aufirst%3DP.%2BM.%26atitle%3DInflammasomes%2520in%2520COPD%2520and%2520neutrophilic%2520asthma%26jtitle%3DThorax%26date%3D2015%26volume%3D70%26spage%3D1199%26epage%3D1201%26doi%3D10.1136%2Fthoraxjnl-2014-206736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kean, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, W. W.</span></span> <span> </span><span class="NLM_article-title">Auranofin</span>. <i>Rheumatology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">572</span>, <span class="refDoi"> DOI: 10.1093/rheumatology/36.5.560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1093%2Frheumatology%2F36.5.560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1ert70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=560-572&author=W.+F.+Keanauthor=L.+Hartauthor=W.+W.+Buchanan&title=Auranofin&doi=10.1093%2Frheumatology%2F36.5.560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Auranofin</span></div><div class="casAuthors">Kean, W. F.; Hart, L.; Buchanan, W. W.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Rheumatology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">560-572</span>CODEN:
                <span class="NLM_cas:coden">BJRHDF</span>;
        ISSN:<span class="NLM_cas:issn">0263-7103</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review with 110 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDkbAGdbOko7Vg90H21EOLACvtfcHk0lgiSYziIs38GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1ert70%253D&md5=988732af6d9cd13a33abb16114550422</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1093%2Frheumatology%2F36.5.560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Frheumatology%252F36.5.560%26sid%3Dliteratum%253Aachs%26aulast%3DKean%26aufirst%3DW.%2BF.%26aulast%3DHart%26aufirst%3DL.%26aulast%3DBuchanan%26aufirst%3DW.%2BW.%26atitle%3DAuranofin%26jtitle%3DRheumatology%26date%3D1997%26volume%3D36%26spage%3D560%26epage%3D572%26doi%3D10.1093%2Frheumatology%2F36.5.560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span> <span> </span><span class="NLM_article-title">Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages</span>. <i>Arch. Pharmacal Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1007/s12272-008-1122-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs12272-008-1122-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18277610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlyitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=67-74&author=S.+Hanauthor=K.+Kimauthor=H.+Kimauthor=J.+Kwonauthor=Y.+H.+Leeauthor=C.+K.+Leeauthor=Y.+Songauthor=S.+J.+Leeauthor=N.+Haauthor=K.+Kim&title=Auranofin+inhibits+overproduction+of+pro-inflammatory+cytokines%2C+cyclooxygenase+expression+and+PGE2+production+in+macrophages&doi=10.1007%2Fs12272-008-1122-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages</span></div><div class="casAuthors">Han, Shinha; Kim, Kwanghee; Kim, Hyunyul; Kwon, Jeunghak; Lee, Young-Hee; Lee, Chong-Kil; Song, Youngcheon; Lee, Sang-Jin; Ha, Namjoo; Kim, Kyungjae</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-74</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">Auranofin (AF), a gold compd., is an orally active therapeutic agent used to treat rheumatoid arthritis (RA), a self-perpetuating inflammatory disease.  RA is characterized by autoimmune-mediated proliferation of synovial cells that leads to inflammation, pain, and swelling in most major joints.  However, the mechanism as to how AF relieves RA symptoms has not been fully elucidated.  The object of this study was to examine the ability of AF to immunomodulate macrophages as antigen presenting cells (APCs).  Macrophages are recognized as playing an important role in the pathogenesis of RA, in that there is a relative abundance of macrophage-derived cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6 (IL-6) in rheumatoid synovium.  In this work, we tested whether AF (2.5-20 mM) could inhibit inflammatory activity in the macrophage cell line RAW 264.7.  AF decreased prodn. of nitric oxide (NO) and the pro-inflammatory cytokines, TNF-α, IL-1β and IL-6 in macrophages.  Furthermore, AF inhibited cyclooxygenase-2 (COX-2)-dependent prostaglandin E2 (PGE2) prodn. in a concn.-dependent manner.  In conclusion, these findings may provide an explanation for the clin. effects of AF in patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOHN1I7ymmfbVg90H21EOLACvtfcHk0lj1p2srIwQHhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlyitLo%253D&md5=d050c6b43efddff06983e01e1652354a</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1007%2Fs12272-008-1122-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-008-1122-9%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DH.%26aulast%3DKwon%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%2BJ.%26aulast%3DHa%26aufirst%3DN.%26aulast%3DKim%26aufirst%3DK.%26atitle%3DAuranofin%2520inhibits%2520overproduction%2520of%2520pro-inflammatory%2520cytokines%252C%2520cyclooxygenase%2520expression%2520and%2520PGE2%2520production%2520in%2520macrophages%26jtitle%3DArch.%2520Pharmacal%2520Res.%26date%3D2008%26volume%3D31%26spage%3D67%26epage%3D74%26doi%3D10.1007%2Fs12272-008-1122-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1504</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2013.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bcp.2013.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23506741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1ejs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2013&pages=1504-1512&author=W.+Liuauthor=W.+Guoauthor=J.+Wuauthor=Q.+Luoauthor=F.+Taoauthor=Y.+Guauthor=Y.+Shenauthor=J.+Liauthor=R.+Tanauthor=Q.+Xuauthor=Y.+Sun&title=A+novel+benzo%5Bd%5Dimidazole+derivate+prevents+the+development+of+dextran+sulfate+sodium-induced+murine+experimental+colitis+via+inhibition+of+NLRP3+inflammasome&doi=10.1016%2Fj.bcp.2013.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome</span></div><div class="casAuthors">Liu, Wen; Guo, Wenjie; Wu, Jing; Luo, Qiong; Tao, Feifei; Gu, Yanhong; Shen, Yan; Li, Jianxin; Tan, Renxiang; Xu, Qiang; Sun, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1504-1512</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">NLRP3 inflammasome has been reported to be assocd. with various kinds of immunol. diseases including colitis.  However, there are few drug candidates targeting inflammasomes for the treatment of colitis.  In the present study, we aimed at examg. the effect of 1-ethyl-5-methyl-2-phenyl-1H-benzo[d]imidazole, a synthetic small mol. compd. also named Fc11a-2, for the treatment of dextran sulfate sodium (DSS)-induced exptl. colitis in mice via targeting NLRP3 inflammasome.  Treatment with Fc11a-2 dose-dependently attenuated the loss of body wt. and shortening of colon length induced by DSS.  In addn., the disease activity index, histopathol. scores and myeloperoxidase activity were also significantly reduced by Fc11a-2 treatment.  Moreover, protein and mRNA levels of DSS-induced proinflammatory cytokines in colon, including TNF-α, IL-1β, IL-18, IL-17A and IFN-γ, were markedly suppressed by Fc11a-2.  Furthermore, a decreased CD11c+ macrophage infiltration in colons and inactivation of caspase-1 in peritoneal macrophages were detected in Fc11a-2-treated mice.  The mechanism of action of Fc11a-2 was related to the inhibition of the cleavage of pro-caspase-1, pro-IL-1β and pro-IL-18 which in turn suppressed the activation of NLRP3 inflammasome.  Taken together, our results demonstrate the ability of Fc11a-2 to inhibit NLRP3 inflammasome activation and its potential use in the treatment of inflammatory bowel diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC4yBlq18j1bVg90H21EOLACvtfcHk0lj1p2srIwQHhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1ejs7s%253D&md5=28fe5ced430f1f103df5b34d7c5b0306</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2013.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2013.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DGuo%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DTao%26aufirst%3DF.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DA%2520novel%2520benzo%255Bd%255Dimidazole%2520derivate%2520prevents%2520the%2520development%2520of%2520dextran%2520sulfate%2520sodium-induced%2520murine%2520experimental%2520colitis%2520via%2520inhibition%2520of%2520NLRP3%2520inflammasome%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2013%26volume%3D85%26spage%3D1504%26epage%3D1512%26doi%3D10.1016%2Fj.bcp.2013.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsunaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchimori, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ii, M.</span></span> <span> </span><span class="NLM_article-title">TAK-242 (resatorvid), a small-molecule inhibitor of toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">41</span>, <span class="refDoi"> DOI: 10.1124/mol.110.068064</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fmol.110.068064" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20881006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1ehuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2011&pages=34-41&author=N.+Matsunagaauthor=N.+Tsuchimoriauthor=T.+Matsumotoauthor=M.+Ii&title=TAK-242+%28resatorvid%29%2C+a+small-molecule+inhibitor+of+toll-like+receptor+%28TLR%29+4+signaling%2C+binds+selectively+to+TLR4+and+interferes+with+interactions+between+TLR4+and+its+adaptor+molecules&doi=10.1124%2Fmol.110.068064"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules</span></div><div class="casAuthors">Matsunaga, Naoko; Tsuchimori, Noboru; Matsumoto, Tatsumi; Ii, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-41</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">TAK-242 (resatorvid), a small-mol.-specific inhibitor of Toll-like receptor (TLR) 4 signaling, inhibits the prodn. of lipopolysaccharide-induced inflammatory mediators by binding to the intracellular domain of TLR4.  Cys747 in TLR4 has been identified previously as the binding site of TAK-242.  However, the mechanism by which TAK-242 inhibits TLR4 signaling after binding to TLR4 remains unknown.  The present study demonstrated, using coimmunopptn., that TAK-242 interferes with protein-protein interactions between TLR4 and its adaptor mols.  Among 10 different human TLRs, TAK-242 selectively bound to TLR4.  The time course of the inhibitory effect of TAK-242 on inflammatory mediator prodn. corresponded to that of the binding of TAK-242 to TLR4.  TAK-242 inhibited the assocn. of TLR4 with Toll/interleukin-1 receptor domain-contg. adaptor protein (TIRAP) or Toll/interleukin-1 receptor domain-contg. adaptor protein inducing interferon-β-related adaptor mol. (TRAM) in human embryonic kidney (HEK) 293 cells overexpressing TLR4, MD-2, and TIRAP or TRAM, resp.  TAK-242 inhibited the TIRAP-mediated activation of nuclear factor βB (NF-κB) and the TRAM-mediated activation of NF-κB and interferon-sensitive response element in HEK293 cells stably expressing TLR4, MD-2, and CD14.  The activation of endogenous interleukin-1 receptor-assocd. kinase in RAW264.7 cells was also inhibited by TAK-242 treatment.  These findings suggest that TAK-242 binds selectively to TLR4 and subsequently disrupts the interaction of TLR4 with adaptor mols., thereby inhibiting TLR4 signal transduction and its downstream signaling events.  This work proposes a novel paradigm of a small mol. capable of disrupting protein-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEHy_7WltDNbVg90H21EOLACvtfcHk0ljT_Nm_lePciw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1ehuw%253D%253D&md5=c3ce97a9ab69101a59117c80c8f01044</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.068064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.068064%26sid%3Dliteratum%253Aachs%26aulast%3DMatsunaga%26aufirst%3DN.%26aulast%3DTsuchimori%26aufirst%3DN.%26aulast%3DMatsumoto%26aufirst%3DT.%26aulast%3DIi%26aufirst%3DM.%26atitle%3DTAK-242%2520%2528resatorvid%2529%252C%2520a%2520small-molecule%2520inhibitor%2520of%2520toll-like%2520receptor%2520%2528TLR%2529%25204%2520signaling%252C%2520binds%2520selectively%2520to%2520TLR4%2520and%2520interferes%2520with%2520interactions%2520between%2520TLR4%2520and%2520its%2520adaptor%2520molecules%26jtitle%3DMol.%2520Pharmacol.%26date%3D2011%26volume%3D79%26spage%3D34%26epage%3D41%26doi%3D10.1124%2Fmol.110.068064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, F.</span></span> <span> </span><span class="NLM_article-title">Chemical probing reveals insights into the signaling mechanism of inflammasome activation</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1289</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1038/cr.2010.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fcr.2010.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20856264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqu7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1289-1305&author=Y.+N.+Gongauthor=X.+Wangauthor=J.+Wangauthor=Z.+Yangauthor=S.+Liauthor=J.+Yangauthor=L.+Liuauthor=X.+Leiauthor=F.+Shao&title=Chemical+probing+reveals+insights+into+the+signaling+mechanism+of+inflammasome+activation&doi=10.1038%2Fcr.2010.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical probing reveals insights into the signaling mechanism of inflammasome activation</span></div><div class="casAuthors">Gong, Yi-Nan; Wang, Xiaoming; Wang, Jiayi; Yang, Zhenxiao; Li, Shan; Yang, Jieling; Liu, Liping; Lei, Xiaoguang; Shao, Feng</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1289-1305</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Caspase-1-mediated IL-1β prodn. is generally controlled by two pathways.  Toll-like receptors (TLRs) recognize pathogen-derived products and induce NF-κB-dependent pro-IL-1β transcription; NOD-like receptors (NLRs) assemble caspase-1-activating inflammasome complexes that sense bacterial products/danger signals.  Through a targeted chem. screen, we identify bromoxone, a marine natural product, as a specific and potent inhibitor of the caspase-1 pathway.  Bromoxone is effective over diverse inflammatory stimuli including TLR ligands plus ATP/nigericin, cytosolic DNA, flagellin and Bacillus anthracis lethal toxin.  Bromoxone also efficiently suppresses caspase-1 activation triggered by several types of bacterial infection.  Bromoxone acts upstream or at the level of the inflammasome in a transcription-independent manner.  Bromoxone also inhibits pro-IL-1β expression by targeting components upstream of IKK in the TLR-NF-κB pathway.  The unique dual activities of bromoxone are shared by the known TAK1 inhibitor that specifically blocks Nalp3 inflammasome activation.  Hinted from the mechanistic and pharmacol. properties of bromoxone, we further discover that several known NF-κB inhibitors that act upstream of IKK, but not those targeting IKK or IKK downstream, are potent blockers of different NLRs-mediated caspase-1 activation.  Our study uncovers a possible non-transcriptional mol. link between the NLR (Nalp3)-mediated inflammasome pathway and TLR-NF-κB signaling, and suggests a potential strategy to develop new anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppjC16zIWsMbVg90H21EOLACvtfcHk0ljT_Nm_lePciw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqu7nP&md5=efe3462264b2a58c9d54fd8fee8a06b1</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fcr.2010.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcr.2010.135%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DY.%2BN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLei%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DF.%26atitle%3DChemical%2520probing%2520reveals%2520insights%2520into%2520the%2520signaling%2520mechanism%2520of%2520inflammasome%2520activation%26jtitle%3DCell%2520Res.%26date%3D2010%26volume%3D20%26spage%3D1289%26epage%3D1305%26doi%3D10.1038%2Fcr.2010.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suissa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, M.</span></span> <span> </span><span class="NLM_article-title">TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">234</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2007.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2007.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17517530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlsVahtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=234-238&author=S.+Suissaauthor=P.+Ernstauthor=M.+Hudson&title=TNF-alpha+antagonists+and+the+prevention+of+hospitalisation+for+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.pupt.2007.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">TNF-α antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Suissa, Samy; Ernst, Pierre; Hudson, Marie</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">234-238</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: TNF-α may be important in the pathogenesis of COPD.  Consequently, the use of TNF-α antagonists has been advocated for its treatment.  Methods: We conducted an observational study to evaluate the effectiveness of TNF-α antagonists in preventing COPD hospitalizations in a cohort of patients diagnosed with both RA and COPD identified from a health claims database.  A nested case-control approach was used to match each case hospitalized to 10 controls on age and cohort entry date.  Data on prescribed medications during the year prior to the index date were obtained.  Rate ratios (RR) of COPD hospitalization were estd. by conditional logistic regression, after adjustment for COPD severity and concomitant RA medication use.  Results: The cohort included 15,771 subjects with both RA and COPD, of which 1205 were hospitalized for COPD during follow-up.  The adjusted RR of COPD hospitalization assocd. with the use of TNF-α antagonists was 0.62 (95% confidence interval (CI) 0.43-0.89).  This rate redn. was due to etanercept (RR 0.49, 95% CI 0.29-0.82) but not infliximab (RR 0.95, 95% CI 0.59-1.52).  Conclusion: Our finding of a halving in the rate of COPD hospitalization assocd. with the use of etanercept corroborates the potential importance of TNF-α in the pathogenesis of COPD.  This study supports the initiation of randomized controlled trials of this TNF-α antagonist among COPD patients at high risk of severe exacerbations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFXVPGvLzbkbVg90H21EOLACvtfcHk0lhNjvlzDcZGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlsVahtA%253D%253D&md5=68e5f1bf814578bf4248cf0bd2cec11a</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2007.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2007.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DSuissa%26aufirst%3DS.%26aulast%3DErnst%26aufirst%3DP.%26aulast%3DHudson%26aufirst%3DM.%26atitle%3DTNF-alpha%2520antagonists%2520and%2520the%2520prevention%2520of%2520hospitalisation%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2008%26volume%3D21%26spage%3D234%26epage%3D238%26doi%3D10.1016%2Fj.pupt.2007.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yokomizo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span> <span> </span><span class="NLM_article-title">Leukotriene B4: metabolism and signal transduction</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>385</i></span>,  <span class="NLM_fpage">231</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1006/abbi.2000.2168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1006%2Fabbi.2000.2168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11368003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitFyiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=385&publication_year=2001&pages=231-241&author=T.+Yokomizoauthor=T.+Izumiauthor=T.+Shimizu&title=Leukotriene+B4%3A+metabolism+and+signal+transduction&doi=10.1006%2Fabbi.2000.2168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene B4: Metabolism and Signal Transduction</span></div><div class="casAuthors">Yokomizo, Takehiko; Izumi, Takashi; Shimizu, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">385</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">231-241</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 107 refs.  Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases.  Enzymes involved in the biosynthesis and metab. of LTB4 have been cloned, and their properties are well understood.  Two G-protein-coupled receptors (BLT1 and BLT2) have been cloned and characterized.  BLT1 and BLT2 are high- and low-affinity LTB4 receptors, resp., and form a gene cluster in human and mouse.  In this article recent findings on the metab. of and the receptors for LTB4 are reviewed.  The authors also discuss briefly a coreceptor role of BLT in HIV infection, and ion channel modification by LTB4.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTGxA2t0BHibVg90H21EOLACvtfcHk0lhNjvlzDcZGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitFyiuw%253D%253D&md5=0bb5184aec44c54e40cacfbe907ca04a</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1006%2Fabbi.2000.2168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabbi.2000.2168%26sid%3Dliteratum%253Aachs%26aulast%3DYokomizo%26aufirst%3DT.%26aulast%3DIzumi%26aufirst%3DT.%26aulast%3DShimizu%26aufirst%3DT.%26atitle%3DLeukotriene%2520B4%253A%2520metabolism%2520and%2520signal%2520transduction%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2001%26volume%3D385%26spage%3D231%26epage%3D241%26doi%3D10.1006%2Fabbi.2000.2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lundeen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fourie, A. M.</span></span> <span> </span><span class="NLM_article-title">Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>177</i></span>,  <span class="NLM_fpage">3439</span>– <span class="NLM_lpage">3447</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.177.5.3439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4049%2Fjimmunol.177.5.3439" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16920986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1Cjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=177&publication_year=2006&pages=3439-3447&author=K.+A.+Lundeenauthor=B.+Sunauthor=L.+Karlssonauthor=A.+M.+Fourie&title=Leukotriene+B4+receptors+BLT1+and+BLT2%3A+expression+and+function+in+human+and+murine+mast+cells&doi=10.4049%2Fjimmunol.177.5.3439"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene B4 Receptors BLT1 and BLT2: Expression and Function in Human and Murine Mast Cells</span></div><div class="casAuthors">Lundeen, Katherine A.; Sun, Binggang; Karlsson, Lars; Fourie, Anne M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">177</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3439-3447</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Leukotriene B4 (LTB4) is a potent activator and chemoattractant for leukocytes and is implicated in several inflammatory diseases.  The actions of LTB4 are mediated by two cell surface receptors, BLT1, which is predominantly expressed in peripheral blood leukocytes, and BLT2, which is expressed more ubiquitously.  Recently, BLT1 expression and LTB4-dependent chemotaxis have been reported in immature mast cells (MCs).  We now show the first evidence for BLT2 mRNA expression, in addn. to BLT1, in murine bone marrow-derived MCs (mBMMCs) and in a human MC line (HMC-1).  Protein expression of BLT1 was confirmed by mAb staining in HMC-1 cells and shown to be predominantly intracellular.  Both HMC-1 cells and mBMMCs migrated to LTB4 in a dose-dependent manner in chemotaxis assays.  Migration to LTB4 could be inhibited by either a BLT1- or BLT2-selective antagonist.  Significant dose-dependent migration of mBMMCs also was obsd. to 12-(S)-hydroxyeicosatetraenoic acid, a BLT2-selective agonist, demonstrating functional BLT2 activity in these cells.  Stimulation of mBMMCs with LTB4 induced transient, dose-dependent, ERK phosphorylation and changes in Akt phosphorylation.  Dose-dependent ERK phosphorylation also was obsd. in response to 12-(S)-hydroxyeicosatetraenoic acid, indicating signaling downstream of BLT2.  Pretreatment of mBMMCs with stem cell factor significantly down-regulated expression of BLT1 and BLT2 mRNA and inhibited their migration to LTB4.  This study demonstrates expression of functional LTB4 receptors, both BLT1 and BLT2, in murine and human MCs and a regulatory role for stem cell factor in their expression.  These receptors may mediate recruitment and accumulation of MCs in response to LTB4 prodn. in areas of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDKctQ7LxVu7Vg90H21EOLACvtfcHk0lhNjvlzDcZGpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1Cjtbw%253D&md5=ae3816d3728de47d180dcc3b9afb73ee</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.177.5.3439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.177.5.3439%26sid%3Dliteratum%253Aachs%26aulast%3DLundeen%26aufirst%3DK.%2BA.%26aulast%3DSun%26aufirst%3DB.%26aulast%3DKarlsson%26aufirst%3DL.%26aulast%3DFourie%26aufirst%3DA.%2BM.%26atitle%3DLeukotriene%2520B4%2520receptors%2520BLT1%2520and%2520BLT2%253A%2520expression%2520and%2520function%2520in%2520human%2520and%2520murine%2520mast%2520cells%26jtitle%3DJ.%2520Immunol.%26date%3D2006%26volume%3D177%26spage%3D3439%26epage%3D3447%26doi%3D10.4049%2Fjimmunol.177.5.3439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monkarsh, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodnow, R.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1909</span>– <span class="NLM_lpage">1920</span>, <span class="refDoi"> DOI: 10.1517/13543784.16.12.1909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543784.16.12.1909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18042000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=1909-1920&author=A.+Hicksauthor=S.+P.+Monkarshauthor=A.+F.+Hoffmanauthor=R.+Goodnow&title=Leukotriene+B4+receptor+antagonists+as+therapeutics+for+inflammatory+disease%3A+preclinical+and+clinical+developments&doi=10.1517%2F13543784.16.12.1909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments</span></div><div class="casAuthors">Hicks, Alexandra; Monkarsh, Seth P.; Hoffman, Ann F.; Goodnow, Robert, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1909-1920</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Leukotriene B4 (LTB4) is a lipid inflammatory mediator derived from membrane phospholipids by the sequential actions of cytosolic phospholipase A2 (PLA2), 5-lipoxygenase (5-LO) and leukotriene A4 (LTA4) hydrolase.  Several inflammatory diseases, including asthma, chronic obstructive pulmonary disease, arthritis and inflammatory bowel disease, have been assocd. with elevated levels of LTB4.  As a result, pharmacol. strategies to modulate the synthesis of LTB4 (inhibition of PLA2, 5-LO or LTA4 hydrolase) or the effects of LTB4 itself (antagonism of LTB4 receptors) are being developed by several companies.  Two G-protein-coupled receptors mediate the effects of LTB4, namely BLT1 and BLT2.  The pharmacol., expression and function of these two receptors were last reviewed by Tager and Luster in 2004.  Since then, there has been an increased understanding of the function of these receptors, in particular for the lesser understood of the two receptors, BLT2.  Furthermore, since last reviewed in 1996, there have been several clin. developments in the use of BLT receptor antagonists for inflammatory diseases.  This review summarizes the latest preclin. and clin. developments in BLT antagonism for inflammatory diseases and discusses potential future developments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKU0SsXiyMCrVg90H21EOLACvtfcHk0lj-h6fxI9YOfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmu7%252FI&md5=7409513efd3c2dbdc101fb9565067896</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.12.1909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.12.1909%26sid%3Dliteratum%253Aachs%26aulast%3DHicks%26aufirst%3DA.%26aulast%3DMonkarsh%26aufirst%3DS.%2BP.%26aulast%3DHoffman%26aufirst%3DA.%2BF.%26aulast%3DGoodnow%26aufirst%3DR.%26atitle%3DLeukotriene%2520B4%2520receptor%2520antagonists%2520as%2520therapeutics%2520for%2520inflammatory%2520disease%253A%2520preclinical%2520and%2520clinical%2520developments%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D1909%26epage%3D1920%26doi%3D10.1517%2F13543784.16.12.1909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Profita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riccobono, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paternò, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siena, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirabella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonsignore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignola, A. M.</span></span> <span> </span><span class="NLM_article-title">15(S)-HETE modulates LTB(4) production and neutrophil chemotaxis in chronic bronchitis</span>. <i>Am. J. Physiol. Cell Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">C1249</span>– <span class="NLM_lpage">C1258</span>, <span class="refDoi"> DOI: 10.1152/ajpcell.2000.279.4.C1249</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1152%2Fajpcell.2000.279.4.C1249" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11003605" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2000&pages=C1249-C1258&author=M.+Profitaauthor=A.+Salaauthor=L.+Riccobonoauthor=E.+Paceauthor=A.+Patern%C3%B2author=S.+Zariniauthor=L.+Sienaauthor=A.+Mirabellaauthor=G.+Bonsignoreauthor=A.+M.+Vignola&title=15%28S%29-HETE+modulates+LTB%284%29+production+and+neutrophil+chemotaxis+in+chronic+bronchitis&doi=10.1152%2Fajpcell.2000.279.4.C1249"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1152%2Fajpcell.2000.279.4.C1249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajpcell.2000.279.4.C1249%26sid%3Dliteratum%253Aachs%26aulast%3DProfita%26aufirst%3DM.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DRiccobono%26aufirst%3DL.%26aulast%3DPace%26aufirst%3DE.%26aulast%3DPatern%25C3%25B2%26aufirst%3DA.%26aulast%3DZarini%26aufirst%3DS.%26aulast%3DSiena%26aufirst%3DL.%26aulast%3DMirabella%26aufirst%3DA.%26aulast%3DBonsignore%26aufirst%3DG.%26aulast%3DVignola%26aufirst%3DA.%2BM.%26atitle%3D15%2528S%2529-HETE%2520modulates%2520LTB%25284%2529%2520production%2520and%2520neutrophil%2520chemotaxis%2520in%2520chronic%2520bronchitis%26jtitle%3DAm.%2520J.%2520Physiol.%2520Cell%2520Physiol.%26date%3D2000%26volume%3D279%26spage%3DC1249%26epage%3DC1258%26doi%3D10.1152%2Fajpcell.2000.279.4.C1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Levy, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serhan, C. N.</span></span> <span> </span><span class="NLM_article-title">Resolution of acute inflammation in the lung</span>. <i>Annu. Rev. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">492</span>, <span class="refDoi"> DOI: 10.1146/annurev-physiol-021113-170408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1146%2Fannurev-physiol-021113-170408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24313723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVCmsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2014&pages=467-492&author=B.+D.+Levyauthor=C.+N.+Serhan&title=Resolution+of+acute+inflammation+in+the+lung&doi=10.1146%2Fannurev-physiol-021113-170408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Resolution of acute inflammation in the lung</span></div><div class="casAuthors">Levy, Bruce D.; Serhan, Charles N.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Physiology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">467-492</span>CODEN:
                <span class="NLM_cas:coden">ARPHAD</span>;
        ISSN:<span class="NLM_cas:issn">0066-4278</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">A review.  Acute inflammation in the lung is essential to health.  So too is its resoln.  In response to invading microbes, noxious stimuli, or tissue injury, an acute inflammatory response is mounted to protect the host.  To limit inflammation and prevent collateral injury of healthy, uninvolved tissue, the lung orchestrates the formation of specialized proresolving mediators, specifically lipoxins, resolvins, protectins, and maresins.  These immunoresolvents are agonists for resoln. that interact with specific receptors on leukocytes and structural cells to blunt further inflammation and promote catabasis.  This process appears to be defective in several common lung diseases that are characterized by excess or chronic inflammation.  Here, we review the mol. and cellular effectors of resoln. of acute inflammation in the lung.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNJh0sArfJMrVg90H21EOLACvtfcHk0liurtNu0Lml8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVCmsbc%253D&md5=b28ca357369a3387b978f18cf52bd331</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1146%2Fannurev-physiol-021113-170408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-physiol-021113-170408%26sid%3Dliteratum%253Aachs%26aulast%3DLevy%26aufirst%3DB.%2BD.%26aulast%3DSerhan%26aufirst%3DC.%2BN.%26atitle%3DResolution%2520of%2520acute%2520inflammation%2520in%2520the%2520lung%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2014%26volume%3D76%26spage%3D467%26epage%3D492%26doi%3D10.1146%2Fannurev-physiol-021113-170408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roinestad, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springman, E. B.</span></span> <span> </span><span class="NLM_article-title">Recent advances in clinical development of leukotriene B4 pathway drugs</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1016/j.smim.2017.08.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.smim.2017.08.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29042030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2017&pages=65-73&author=L.+Bhattauthor=K.+Roinestadauthor=T.+Vanauthor=E.+B.+Springman&title=Recent+advances+in+clinical+development+of+leukotriene+B4+pathway+drugs&doi=10.1016%2Fj.smim.2017.08.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in clinical development of leukotriene B4 pathway drugs</span></div><div class="casAuthors">Bhatt, L.; Roinestad, K.; Van, T.; Springman, E. B.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-73</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The LTB4 pathway is an attractive target for therapeutic drug development.  Two broad classes of drugs have been pursued: antagonists of the primary LTB4 receptors (BLT1 and BLT2) and inhibitors of LTA4 Hydrolase (LTA4H), the rate limiting enzyme in the prodn. of LTB4.  An initial wave of effort culminated in the 1990s.  Over the past 15 years, a second wave of more selective drug candidates, including at least 5 BLT antagonists and 6 LTA4H inhibitors, have reached Phase 2 clin. trials.  Despite the extensive efforts to discover and develop LTB4 pathway targeting drugs, only one has reached the market to date.  Recently discovered complexities in the pathway and challenges in matching pathway intervention with therapeutic effect could explain the limited clin. success of LTB4 pathway drugs, even though there is a large body of scientific evidence linking LTB4 to human diseases and demonstrating efficacy of these compds. in a wide array of preclin. models.  Herein, we describe the clin. programs for the most prominent recent examples from each broad class and discuss the clin. outcomes and their implications for future development of LTB4 pathway drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomAJhLJFJTE7Vg90H21EOLACvtfcHk0liurtNu0Lml8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1OiurfN&md5=a45e8c63d30430dbd71821c36b90c4ae</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.smim.2017.08.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.smim.2017.08.007%26sid%3Dliteratum%253Aachs%26aulast%3DBhatt%26aufirst%3DL.%26aulast%3DRoinestad%26aufirst%3DK.%26aulast%3DVan%26aufirst%3DT.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DRecent%2520advances%2520in%2520clinical%2520development%2520of%2520leukotriene%2520B4%2520pathway%2520drugs%26jtitle%3DSemin.%2520Immunol.%26date%3D2017%26volume%3D33%26spage%3D65%26epage%3D73%26doi%3D10.1016%2Fj.smim.2017.08.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chillappagari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preuss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahavadi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarode, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guenther, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahrlich, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henke, M. O.</span></span> <span> </span><span class="NLM_article-title">Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">85</span>, <span class="refDoi"> DOI: 10.1186/s12931-015-0247-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2Fs12931-015-0247-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26169056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28%252FivVKrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=85&author=S.+Chillappagariauthor=J.+Preussauthor=S.+Lichtauthor=C.+M%C3%BCllerauthor=P.+Mahavadiauthor=G.+Sarodeauthor=C.+Vogelmeierauthor=A.+Guentherauthor=L.+Nahrlichauthor=B.+K.+Rubinauthor=M.+O.+Henke&title=Altered+protease+and+antiprotease+balance+during+a+COPD+exacerbation+contributes+to+mucus+obstruction&doi=10.1186%2Fs12931-015-0247-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Altered protease and antiprotease balance during a COPD exacerbation contributes to mucus obstruction</span></div><div class="casAuthors">Chillappagari Shashi; Nahrlich Lutz; Chillappagari Shashi; Mahavadi Poornima; Guenther Andreas; Chillappagari Shashi; Preuss Jenni; Licht Sebastian; Muller Christian; Vogelmeier Claus; Henke Markus O; Chillappagari Shashi; Mahavadi Poornima; Guenther Andreas; Nahrlich Lutz; Sarode Gaurav; Henke Markus O; Sarode Gaurav; Henke Markus O; Guenther Andreas; Guenther Andreas; Rubin Bruce K</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Proteases have been shown to degrade airway mucin proteins and to damage the epithelium impairing mucociliary clearance.  There are increased proteases in the COPD airway but changes in protease-antiprotease balance and mucin degradation have not been investigated during the course of a COPD exacerbation.  We hypothesized that increased protease levels would lead to mucin degradation in acute COPD exacerbations.  METHODS:  We measured neutrophil elastase (NE) and alpha 1 protease inhibitor (A1-PI) levels using immunoblotting, and conducted protease inhibitor studies, zymograms, elastin substrate assays and cigarette smoke condensate experiments to evaluate the stability of the gel-forming mucins, MUC5AC and MUC5B, before and 5-6 weeks after an acute pulmonary exacerbation of COPD (n = 9 subjects).  RESULTS:  Unexpectedly, mucin concentration and mucin stability were highest at the start of the exacerbation and restored to baseline after 6 weeks.  Consistent with these data, immunoblots and zymograms confirmed decreased NE concentration and activity and increased A1-PI at the start of the exacerbation.  After recovery there was an increase in NE activity and a decrease in A1-PI levels.  In vitro, protease inhibitor studies demonstrated that serine proteases played a key role in mucin degradation.  Mucin stability was further enhanced upon treating with cigarette smoke condensate (CSC).  CONCLUSION:  There appears to be rapid consumption of secreted proteases due to an increase in antiproteases, at the start of a COPD exacerbation.  This leads to increased mucin gel stability which may be important in trapping and clearing infectious and inflammatory mediators, but this may also contribute acutely to mucus retention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT-fuLe5VCDtK-9TkgmBqTqfW6udTcc2eZn4t0cjeCqF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28%252FivVKrsA%253D%253D&md5=a285e6600fc7af294c94a7cf0478f678</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1186%2Fs12931-015-0247-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-015-0247-x%26sid%3Dliteratum%253Aachs%26aulast%3DChillappagari%26aufirst%3DS.%26aulast%3DPreuss%26aufirst%3DJ.%26aulast%3DLicht%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DMahavadi%26aufirst%3DP.%26aulast%3DSarode%26aufirst%3DG.%26aulast%3DVogelmeier%26aufirst%3DC.%26aulast%3DGuenther%26aufirst%3DA.%26aulast%3DNahrlich%26aufirst%3DL.%26aulast%3DRubin%26aufirst%3DB.%2BK.%26aulast%3DHenke%26aufirst%3DM.%2BO.%26atitle%3DAltered%2520protease%2520and%2520antiprotease%2520balance%2520during%2520a%2520COPD%2520exacerbation%2520contributes%2520to%2520mucus%2520obstruction%26jtitle%3DRespir.%2520Res.%26date%3D2015%26volume%3D16%26spage%3D85%26doi%3D10.1186%2Fs12931-015-0247-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gudmann, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manon-Jensen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sand, J. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diefenbach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danielsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsdal, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeming, D. J.</span></span> <span> </span><span class="NLM_article-title">Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>503</i></span>,  <span class="NLM_fpage">1284</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2018.07.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bbrc.2018.07.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=30017196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlart73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=503&publication_year=2018&pages=1284-1290&author=N.+S.+Gudmannauthor=T.+Manon-Jensenauthor=J.+M.+B.+Sandauthor=C.+Diefenbachauthor=S.+Sunauthor=A.+Danielsenauthor=M.+A.+Karsdalauthor=D.+J.+Leeming&title=Lung+tissue+destruction+by+proteinase+3+and+cathepsin+G+mediated+elastin+degradation+is+elevated+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2Fj.bbrc.2018.07.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Lung tissue destruction by proteinase 3 and cathepsin G mediated elastin degradation is elevated in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Gudmann, Natasja Staehr; Manon-Jensen, Tina; Sand, Jannie Marie Bulow; Diefenbach, Claudia; Sun, Shu; Danielsen, Annette; Karsdal, Morten Asser; Leeming, Diana Julie</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">503</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1284-1290</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is characterized by high levels of protease activity leading to degrdn. of elastin followed by loss of elasticity of the lung and the development of emphysema.  Elastin is an essential structural component of the lung parenchyma to support the expansion and recoil of the alveoli during breathing.  The lung extracellular matrix is vulnerable to pathol. structural changes upon upregulation of serine proteases, including cathepsin G (CG) and proteinase 3 (PR3).  In this study, we explored the diagnostic features of elastin neo-epitopes generated by CG and PR3.  Two novel competitive enzyme-linked immunosorbent assays (ELISA) measuring CG and PR3 generated elastin fragments (EL-CG and ELP-3 resp.) were developed for assessment in serum.  Both assays were tech. robust and biol. validated in serum from patients with COPD.  Serol. levels of both elastin fragments were significantly elevated in patients with COPD compared to healthy controls.  These data suggest that EL-CG and ELP-3 may serve as plausible biol. markers of destructive changes in COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps5lOyntqj07Vg90H21EOLACvtfcHk0li0-sgBVcLWvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlart73O&md5=a0cacd904df6c629630aab578cf6ad2c</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2018.07.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2018.07.038%26sid%3Dliteratum%253Aachs%26aulast%3DGudmann%26aufirst%3DN.%2BS.%26aulast%3DManon-Jensen%26aufirst%3DT.%26aulast%3DSand%26aufirst%3DJ.%2BM.%2BB.%26aulast%3DDiefenbach%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DDanielsen%26aufirst%3DA.%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26aulast%3DLeeming%26aufirst%3DD.%2BJ.%26atitle%3DLung%2520tissue%2520destruction%2520by%2520proteinase%25203%2520and%2520cathepsin%2520G%2520mediated%2520elastin%2520degradation%2520is%2520elevated%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2018%26volume%3D503%26spage%3D1284%26epage%3D1290%26doi%3D10.1016%2Fj.bbrc.2018.07.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sjö, P.</span></span> <span> </span><span class="NLM_article-title">Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">651</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.4155/fmc.12.17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4155%2Ffmc.12.17" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22458683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC38rgsF2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=651-660&author=P.+Sj%C3%B6&title=Neutrophil+elastase+inhibitors%3A+recent+advances+in+the+development+of+mechanism-based+and+nonelectrophilic+inhibitors&doi=10.4155%2Ffmc.12.17"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Neutrophil elastase inhibitors: recent advances in the development of mechanism-based and nonelectrophilic inhibitors</span></div><div class="casAuthors">Sjo Peter</div><div class="citationInfo"><span class="NLM_cas:title">Future medicinal chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">651-60</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Due to its implication in pathologies of prevalent diseases such as chronic obstructive pulmonary disease, fibrosis, bronchiectasis and ARDS, the serine protease, human neutrophil elastase, has been in focus for drug-development efforts over the last two decades.  In recent years, continued efforts to identify and optimize novel mechanism-based inhibitors have led to a number of new inhibitors being reported.  These compounds show promising potency and selectivity profiles, although their use is still limited by their inherent stability.  Recently, two novel classes of potent and selective, synthetic, nonelectrophilic human neutrophil elastase inhibitors that display improved stability and overall drug-like properties have been reported.  The most advanced compound from these classes, AZD9668, has been reported to show significant effects on relevant biomarkers in bronchiectasis and cystic fibrosis patient populations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnXplirlesAUmhnSqMnvzDfW6udTcc2earrvSgTsbv-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rgsF2gsg%253D%253D&md5=d3f350f9e0d9ebdcb7deb695f46fea48</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.17%26sid%3Dliteratum%253Aachs%26aulast%3DSj%25C3%25B6%26aufirst%3DP.%26atitle%3DNeutrophil%2520elastase%2520inhibitors%253A%2520recent%2520advances%2520in%2520the%2520development%2520of%2520mechanism-based%2520and%2520nonelectrophilic%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D651%26epage%3D660%26doi%3D10.4155%2Ffmc.12.17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohji, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Igarashi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gremillion, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimada, T.</span></span> <span> </span><span class="NLM_article-title">Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress (ARDS): a systematic review and meta-analysis</span>. <i>Intern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2423</span>– <span class="NLM_lpage">2432</span>, <span class="refDoi"> DOI: 10.2169/internalmedicine.49.4010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2169%2Finternalmedicine.49.4010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21088343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3cbotVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=2423-2432&author=K.+Iwataauthor=A.+Doiauthor=G.+Ohjiauthor=H.+Okaauthor=Y.+Obaauthor=K.+Takimotoauthor=W.+Igarashiauthor=D.+H.+Gremillionauthor=T.+Shimada&title=Effect+of+neutrophil+elastase+inhibitor+%28sivelestat+sodium%29+in+the+treatment+of+acute+lung+injury+%28ALI%29+and+acute+respiratory+distress+%28ARDS%29%3A+a+systematic+review+and+meta-analysis&doi=10.2169%2Finternalmedicine.49.4010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): a systematic review and meta-analysis</span></div><div class="casAuthors">Iwata Kentaro; Doi Asako; Ohji Goh; Oka Hideaki; Oba Yuichiro; Takimoto Kohei; Igarashi Wataru; Gremillion David H; Shimada Toshihiko</div><div class="citationInfo"><span class="NLM_cas:title">Internal medicine (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2423-32</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Sivelestat is neutrophil elastase inhibitor, which is widely used in Japan for the treatment of acute lung injury.  However, the clinical efficacy of the medication has not been convincingly demonstrated.  METHODS:  We conducted a systematic review and meta-analysis of randomized controlled trials on sivelestat for the treatment of acute lung injury and acute respiratory distress syndrome.  Studies were identified using MEDLINE, EMBASE, Cochrane library, conference proceedings, and references of included studies.  Authors were contacted if necessary.  ICHUSHI, the Japanese database for medical literature and conference proceedings was also used for the search, since many studies on sivelestat were published in Japanese language and not registered in major databases such as MEDLINE.  The primary outcome was mortality within 28-30 days after randomization.  Relative risks were pooled with the random effect model.  RESULTS:  8 trials were included in the analysis.  There was no difference in mortality within 28-30 days after randomization (relative risk 0.95, 95% confidence interval 0.72 to 1.26).  Subgroup analysis conducted only on studies conducted in Japan showed the same result (0.59, 0.28 to 1.28).  There was no difference in mechanical ventilation days (standardized mean difference -0.43, -1.12 to 0.27), but sivelestat was associated with a better short term PaO(2)/FiO(2) ratio (0.30, 0.05 to 0.56).  Heterogeneity was not significant for the main analysis and funnel plot did not suggest publication bias.  CONCLUSION:  Sivelestat was not associated with decreased mortality, even when including studies published in Japanese language.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRv_-Z2qP_xPh3YQQtAhNufW6udTcc2earrvSgTsbv-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbotVelsQ%253D%253D&md5=12473c878a1d894ff1847afb7a655f04</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.2169%2Finternalmedicine.49.4010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2169%252Finternalmedicine.49.4010%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DK.%26aulast%3DDoi%26aufirst%3DA.%26aulast%3DOhji%26aufirst%3DG.%26aulast%3DOka%26aufirst%3DH.%26aulast%3DOba%26aufirst%3DY.%26aulast%3DTakimoto%26aufirst%3DK.%26aulast%3DIgarashi%26aufirst%3DW.%26aulast%3DGremillion%26aufirst%3DD.%2BH.%26aulast%3DShimada%26aufirst%3DT.%26atitle%3DEffect%2520of%2520neutrophil%2520elastase%2520inhibitor%2520%2528sivelestat%2520sodium%2529%2520in%2520the%2520treatment%2520of%2520acute%2520lung%2520injury%2520%2528ALI%2529%2520and%2520acute%2520respiratory%2520distress%2520%2528ARDS%2529%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DIntern.%2520Med.%26date%3D2010%26volume%3D49%26spage%3D2423%26epage%3D2432%26doi%3D10.2169%2Finternalmedicine.49.4010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">von
Nussbaum, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerheiligen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anlauf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bärfacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bechem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delbeck, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gielen-Haertwig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haning, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karthaus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lustig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meibom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosentreter, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schamberger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Telan, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tersteegen, A.</span></span> <span> </span><span class="NLM_article-title">Freezing the bioactive conformation to boost potency: the identification of BAY 85–8501, a selective and potent inhibitor of human neutrophil elastase for pulmonary diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1173</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1002%2Fcmdc.201500131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26083237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1163-1173&author=F.+von%0ANussbaumauthor=V.+M.+Liauthor=S.+Allerheiligenauthor=S.+Anlaufauthor=L.+B%C3%A4rfackerauthor=M.+Bechemauthor=M.+Delbeckauthor=M.+F.+Fitzgeraldauthor=M.+Gerischauthor=H.+Gielen-Haertwigauthor=H.+Haningauthor=D.+Karthausauthor=D.+Langauthor=K.+Lustigauthor=D.+Meibomauthor=J.+Mittendorfauthor=U.+Rosentreterauthor=M.+Sch%C3%A4ferauthor=S.+Sch%C3%A4ferauthor=J.+Schambergerauthor=L.+A.+Telanauthor=A.+Tersteegen&title=Freezing+the+bioactive+conformation+to+boost+potency%3A+the+identification+of+BAY+85%E2%80%938501%2C+a+selective+and+potent+inhibitor+of+human+neutrophil+elastase+for+pulmonary+diseases&doi=10.1002%2Fcmdc.201500131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases</span></div><div class="casAuthors">von Nussbaum, Franz; Li, Volkhart M.-J.; Allerheiligen, Swen; Anlauf, Sonja; Baerfacker, Lars; Bechem, Martin; Delbeck, Martina; Fitzgerald, Mary F.; Gerisch, Michael; Gielen-Haertwig, Heike; Haning, Helmut; Karthaus, Dagmar; Lang, Dieter; Lustig, Klemens; Meibom, Daniel; Mittendorf, Joachim; Rosentreter, Ulrich; Schaefer, Martina; Schaefer, Stefan; Schamberger, Jens; Telan, Leila A.; Tersteegen, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1163-1173</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Human neutrophil elastase (HNE) is a key protease for matrix degrdn.  High HNE activity is obsd. in inflammatory diseases.  Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH).  HNE inhibitors should reestablish the protease-anti-protease balance.  By means of medicinal chem. a novel dihydropyrimidinone lead-structure class was identified.  Further chem. optimization yielded orally active compds. with favorable pharmacokinetics such as the chem. probe BAY-678.  While maintaining outstanding target selectivity, picomolar potency was achieved by locking the bioactive conformation of these inhibitors with a strategically positioned Me sulfone substituent.  An induced-fit binding mode allowed tight interactions with the S2 and S1 pockets of HNE.  BAY 85-8501 ((4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile) was shown to be efficacious in a rodent animal model related to ALI.  BAY 85-8501 is currently being tested in clin. studies for the treatment of pulmonary diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWfeHJY2lnE7Vg90H21EOLACvtfcHk0ljJiYToomrZ2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVSgtb3N&md5=bb2997077d114dde6769896f50574d3c</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500131%26sid%3Dliteratum%253Aachs%26aulast%3Dvon%2BNussbaum%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DV.%2BM.%26aulast%3DAllerheiligen%26aufirst%3DS.%26aulast%3DAnlauf%26aufirst%3DS.%26aulast%3DB%25C3%25A4rfacker%26aufirst%3DL.%26aulast%3DBechem%26aufirst%3DM.%26aulast%3DDelbeck%26aufirst%3DM.%26aulast%3DFitzgerald%26aufirst%3DM.%2BF.%26aulast%3DGerisch%26aufirst%3DM.%26aulast%3DGielen-Haertwig%26aufirst%3DH.%26aulast%3DHaning%26aufirst%3DH.%26aulast%3DKarthaus%26aufirst%3DD.%26aulast%3DLang%26aufirst%3DD.%26aulast%3DLustig%26aufirst%3DK.%26aulast%3DMeibom%26aufirst%3DD.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DRosentreter%26aufirst%3DU.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DM.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DS.%26aulast%3DSchamberger%26aufirst%3DJ.%26aulast%3DTelan%26aufirst%3DL.%2BA.%26aulast%3DTersteegen%26aufirst%3DA.%26atitle%3DFreezing%2520the%2520bioactive%2520conformation%2520to%2520boost%2520potency%253A%2520the%2520identification%2520of%2520BAY%252085%25E2%2580%25938501%252C%2520a%2520selective%2520and%2520potent%2520inhibitor%2520of%2520human%2520neutrophil%2520elastase%2520for%2520pulmonary%2520diseases%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D1163%26epage%3D1173%26doi%3D10.1002%2Fcmdc.201500131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crocetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepetkin, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cilibrizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graziano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giomi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khlebnikov, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giovannoni, M. P.</span></span> <span> </span><span class="NLM_article-title">Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">6259</span>– <span class="NLM_lpage">6272</span>, <span class="refDoi"> DOI: 10.1021/jm400742j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400742j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSis7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6259-6272&author=L.+Crocettiauthor=I.+A.+Schepetkinauthor=A.+Cilibrizziauthor=A.+Grazianoauthor=C.+Vergelliauthor=D.+Giomiauthor=A.+I.+Khlebnikovauthor=M.+T.+Quinnauthor=M.+P.+Giovannoni&title=Optimization+of+N-benzoylindazole+derivatives+as+inhibitors+of+human+neutrophil+elastase&doi=10.1021%2Fjm400742j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of N-Benzoylindazole Derivatives as Inhibitors of Human Neutrophil Elastase</span></div><div class="casAuthors">Crocetti, Letizia; Schepetkin, Igor A.; Cilibrizzi, Agostino; Graziano, Alessia; Vergelli, Claudia; Giomi, Donatella; Khlebnikov, Andrei I.; Quinn, Mark T.; Giovannoni, Maria Paola</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6259-6272</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases.  Previously, we identified novel N-benzoylindazole derivs. as potent, competitive, and pseudoirreversible HNE inhibitors.  Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads.  Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ∼10 nM) and modifications at position 3 resulted the most potent compd. in this series, the 3-CN deriv. 5b (IC50 = 7 nM); both derivs. demonstrated good stability and specificity for HNE vs. other serine proteases.  Mol. docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes.  Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTvXsdp5MK8bVg90H21EOLACvtfcHk0ljJiYToomrZ2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSis7bM&md5=edcc9aaa1c3589c5b044f12138c15986</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1021%2Fjm400742j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400742j%26sid%3Dliteratum%253Aachs%26aulast%3DCrocetti%26aufirst%3DL.%26aulast%3DSchepetkin%26aufirst%3DI.%2BA.%26aulast%3DCilibrizzi%26aufirst%3DA.%26aulast%3DGraziano%26aufirst%3DA.%26aulast%3DVergelli%26aufirst%3DC.%26aulast%3DGiomi%26aufirst%3DD.%26aulast%3DKhlebnikov%26aufirst%3DA.%2BI.%26aulast%3DQuinn%26aufirst%3DM.%2BT.%26aulast%3DGiovannoni%26aufirst%3DM.%2BP.%26atitle%3DOptimization%2520of%2520N-benzoylindazole%2520derivatives%2520as%2520inhibitors%2520of%2520human%2520neutrophil%2520elastase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6259%26epage%3D6272%26doi%3D10.1021%2Fjm400742j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enghild, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrydstrup, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">7900</span>– <span class="NLM_lpage">7908</span>, <span class="refDoi"> DOI: 10.1021/jm301000k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301000k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOru77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7900-7908&author=J.+L.+Madsenauthor=T.+L.+Andersenauthor=S.+Santamariaauthor=H.+Nagaseauthor=J.+J.+Enghildauthor=T.+Skrydstrup&title=Synthesis+and+evaluation+of+silanediols+as+highly+selective+uncompetitive+inhibitors+of+human+neutrophil+elastase&doi=10.1021%2Fjm301000k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase</span></div><div class="casAuthors">Madsen, Julie L. H.; Andersen, Thomas L.; Santamaria, Salvatore; Nagase, Hideaki; Enghild, Jan J.; Skrydstrup, Troels</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7900-7908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is an increasing health problem and is estd. to be the fifth leading cause of death in 2020 according to the World Health Organization.  Current treatments are only palliative, and therefore the development of new medicine for the treatment of COPD is urgent.  Human Neutrophil Elastase (HNE) is a serine protease that is heavily involved in the progression of COPD through inflammatory breakdown of lung tissue.  Consequently, inhibitors of HNE are of great interest as therapeutics.  In this article, the development of silanediol peptide isostere as inhibitors of HNE is presented.  Kinetic studies revealed that incorporation of a silanediol isostere in the inhibitor structure resulted in an uncompetitive mechanism of inhibition, which further resulted in excellent selectivity.  The peculiar mechanism of inhibition and the resulting selectivity makes the presented inhibitors promising leads for the development of new HNE-inhibitor-based therapeutics for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0hSNFQQrF0LVg90H21EOLACvtfcHk0lh0NeaXaU9D2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOru77F&md5=24f9ceffc1ab93a172f9fdb887120cac</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm301000k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301000k%26sid%3Dliteratum%253Aachs%26aulast%3DMadsen%26aufirst%3DJ.%2BL.%26aulast%3DAndersen%26aufirst%3DT.%2BL.%26aulast%3DSantamaria%26aufirst%3DS.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DEnghild%26aufirst%3DJ.%2BJ.%26aulast%3DSkrydstrup%26aufirst%3DT.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520silanediols%2520as%2520highly%2520selective%2520uncompetitive%2520inhibitors%2520of%2520human%2520neutrophil%2520elastase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7900%26epage%3D7908%26doi%3D10.1021%2Fjm301000k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correia, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Costa, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guedes, R. C.</span></span> <span> </span><span class="NLM_article-title">Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">9802</span>– <span class="NLM_lpage">9806</span>, <span class="refDoi"> DOI: 10.1021/jm4011725</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4011725" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOmsrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9802-9806&author=S.+D.+Lucasauthor=L.+M.+Gon%C3%A7alvesauthor=L.+A.+Carvalhoauthor=H.+F.+Correiaauthor=E.+M.+Da+Costaauthor=R.+A.+Guedesauthor=R.+Moreiraauthor=R.+C.+Guedes&title=Optimization+of+O3-acyl+kojic+acid+derivatives+as+potent+and+selective+human+neutrophil+elastase+inhibitors&doi=10.1021%2Fjm4011725"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of O3-Acyl Kojic Acid Derivatives as Potent and Selective Human Neutrophil Elastase Inhibitors</span></div><div class="casAuthors">Lucas, Susana D.; Goncalves, Lidia M.; Carvalho, Luis A. R.; Correia, Henrique F.; Da Costa, Eduardo M. R.; Guedes, Romina A.; Moreira, Rui; Guedes, Rita C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9802-9806</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human neutrophil elastase (HNE) is an attractive target for treating chronic and acute inflammatory lung diseases.  An optimization campaign of the kojic acid scaffold to develop new potent HNE inhibitors is reported.  O3-Pivaloyl derivs. I (X = O, R1 = Q, Q1; X = NPh, R1 = Q1) were shown to be the most potent inhibitors with IC5o values down to 80 nM.  These compds. presented excellent selectivity and cytotoxicity profiles with suitable ligand efficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa_3ZDmgEbCLVg90H21EOLACvtfcHk0lipVr3xeRVIvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOmsrvE&md5=ca456fa874a24666466f53f359aa8b4d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1021%2Fjm4011725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4011725%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DS.%2BD.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DL.%2BM.%26aulast%3DCarvalho%26aufirst%3DL.%2BA.%26aulast%3DCorreia%26aufirst%3DH.%2BF.%26aulast%3DDa%2BCosta%26aufirst%3DE.%2BM.%26aulast%3DGuedes%26aufirst%3DR.%2BA.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DGuedes%26aufirst%3DR.%2BC.%26atitle%3DOptimization%2520of%2520O3-acyl%2520kojic%2520acid%2520derivatives%2520as%2520potent%2520and%2520selective%2520human%2520neutrophil%2520elastase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9802%26epage%3D9806%26doi%3D10.1021%2Fjm4011725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gearing, A. J.</span></span> <span> </span><span class="NLM_article-title">Design and therapeutic application of matrix metalloproteinase inhibitors</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">2735</span>– <span class="NLM_lpage">2776</span>, <span class="refDoi"> DOI: 10.1021/cr9804543</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr9804543" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK1MXls1Kku7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=1999&pages=2735-2776&author=M.+Whittakerauthor=C.+D.+Floydauthor=P.+Brownauthor=A.+J.+Gearing&title=Design+and+therapeutic+application+of+matrix+metalloproteinase+inhibitors&doi=10.1021%2Fcr9804543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors</span></div><div class="casAuthors">Whittaker, Mark; Floyd, Christopher D.; Brown, Peter; Gearing, Andrew J. H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2735-2776</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with 389 refs.  MMP inhibitors may be an important new class of therapeutic agents for the treatment of diseases characterized by excessive extracellular matrix degrdn. and/or remodelling, such as cancer and chronic inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and MS.  This review describes progress in the design of MMP inhibitors and outlines the results of early clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGACjaK8AEZbVg90H21EOLACvtfcHk0lipVr3xeRVIvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXls1Kku7c%253D&md5=e226080188f791f5d1ce8c61b64ad33a</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fcr9804543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr9804543%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DC.%2BD.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DGearing%26aufirst%3DA.%2BJ.%26atitle%3DDesign%2520and%2520therapeutic%2520application%2520of%2520matrix%2520metalloproteinase%2520inhibitors%26jtitle%3DChem.%2520Rev.%26date%3D1999%26volume%3D99%26spage%3D2735%26epage%3D2776%26doi%3D10.1021%2Fcr9804543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. L.</span></span> <span> </span><span class="NLM_article-title">Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1083</span>– <span class="NLM_lpage">1089</span>, <span class="refDoi"> DOI: 10.1164/rccm.200212-1396OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200212-1396OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12522030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD3s7psF2htw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2003&pages=1083-1089&author=A.+Churgauthor=R.+D.+Wangauthor=H.+Taiauthor=X.+Wangauthor=C.+Xieauthor=J.+Daiauthor=S.+D.+Shapiroauthor=J.+L.+Wright&title=Macrophage+metalloelastase+mediates+acute+cigarette+smoke-induced+inflammation+via+tumor+necrosis+factor-alpha+release&doi=10.1164%2Frccm.200212-1396OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release</span></div><div class="casAuthors">Churg Andrew; Wang Rong D; Tai Hsin; Wang Xiaoshan; Xie Changshi; Dai Jin; Shapiro Steven D; Wright Joanne L</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1083-9</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">The cells and proteases that mediate cigarette smoke-induced emphysema are controversial, with evidence favoring either neutrophils and neutrophil-derived serine proteases or macrophages and macrophage-derived metalloproteases as the important effectors.  We recently reported that both macrophage metalloelastase (MMP-12) and neutrophils are required for acute cigarette smoke-induced connective tissue breakdown, the precursor of emphysema.  Here we show how these disparate observations can be linked.  Both wild-type (MMP-12 +/+) mice and mice lacking MMP-12 (MMP-12 -/-) demonstrated rapid increases in whole-lung nuclear factor-kappaB activation and gene expression of proinflammatory cytokines after cigarette smoke exposure, indicating that a lack of MMP-12 does not produce a global failure to upregulate inflammatory mediators.  However, only MMP-12 +/+ mice demonstrated increased whole-lung tumor necrosis factor-alpha (TNF-alpha) protein or release of TNF-alpha from cultured alveolar macrophages exposed to smoke in vitro.  Levels of whole-lung E-selectin, an endothelial activation marker, were increased in only MMP-12 +/+ mice.  These findings suggest that, acutely, MMP-12 mediates smoke-induced inflammation by releasing TNF-alpha from macrophages, with subsequent endothelial activation, neutrophil influx, and proteolytic matrix breakdown caused by neutrophil-derived proteases.  TNF-alpha release may be a general mechanism whereby metalloproteases drive cigarette smoke-induced inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSWRAWObDPcQNTiMd2aNQVUfW6udTcc2eYmCxL0cQPueLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s7psF2htw%253D%253D&md5=19f670fda0e1eb5db6980ce4418e11d9</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1164%2Frccm.200212-1396OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200212-1396OC%26sid%3Dliteratum%253Aachs%26aulast%3DChurg%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DR.%2BD.%26aulast%3DTai%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DShapiro%26aufirst%3DS.%2BD.%26aulast%3DWright%26aufirst%3DJ.%2BL.%26atitle%3DMacrophage%2520metalloelastase%2520mediates%2520acute%2520cigarette%2520smoke-induced%2520inflammation%2520via%2520tumor%2520necrosis%2520factor-alpha%2520release%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2003%26volume%3D167%26spage%3D1083%26epage%3D1089%26doi%3D10.1164%2Frccm.200212-1396OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hautamaki, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senior, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, S. D.</span></span> <span> </span><span class="NLM_article-title">Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">2002</span>– <span class="NLM_lpage">2004</span>, <span class="refDoi"> DOI: 10.1126/science.277.5334.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1126%2Fscience.277.5334.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=9302297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK2sXmt12qt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=2002-2004&author=R.+D.+Hautamakiauthor=D.+K.+Kobayashiauthor=R.+M.+Seniorauthor=S.+D.+Shapiro&title=Requirement+for+macrophage+elastase+for+cigarette+smoke-induced+emphysema+in+mice&doi=10.1126%2Fscience.277.5334.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice</span></div><div class="casAuthors">Hautamaki, R. Dean; Kobayashi, Dale K.; Senior, Robert M.; Shapiro, Steven D.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">5334</span>),
    <span class="NLM_cas:pages">2002-2004</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">To det. which proteinases are responsible for the lung destruction characteristic of pulmonary emphysema, macrophage elastase-deficient (MME-/-) mice were subjected to cigarette smoke.  In contrast to wild-type mice, MME-/- mice did not have increased nos. of macrophages in their lungs and did not develop emphysema in response to long-term exposure to cigarette smoke.  Smoke-exposed MME-/- mice that received monthly intratracheal instillations of monocyte chemoattractant protein-1 showed accumulation of alveolar macrophages but did not develop air space enlargement.  Thus, macrophage elastase is probably sufficient for the development of emphysema that result from chronic inhalation of cigarette smoke.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqojA6ekXaolLVg90H21EOLACvtfcHk0lg0_JrftXOoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmt12qt7Y%253D&md5=32540b3d50176e2276dc4493e1e7e50b</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1126%2Fscience.277.5334.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.277.5334.2002%26sid%3Dliteratum%253Aachs%26aulast%3DHautamaki%26aufirst%3DR.%2BD.%26aulast%3DKobayashi%26aufirst%3DD.%2BK.%26aulast%3DSenior%26aufirst%3DR.%2BM.%26aulast%3DShapiro%26aufirst%3DS.%2BD.%26atitle%3DRequirement%2520for%2520macrophage%2520elastase%2520for%2520cigarette%2520smoke-induced%2520emphysema%2520in%2520mice%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D2002%26epage%3D2004%26doi%3D10.1126%2Fscience.277.5334.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nénan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagente, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planquois, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boichot, E.</span></span> <span> </span><span class="NLM_article-title">Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2006.11.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.ejphar.2006.11.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17234180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2sXit1Kitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2007&pages=75-81&author=S.+N%C3%A9nanauthor=V.+Lagenteauthor=J.+M.+Planquoisauthor=S.+Hitierauthor=P.+Bernaauthor=C.+P.+Bertrandauthor=E.+Boichot&title=Metalloelastase+%28MMP-12%29+induced+inflammatory+response+in+mice+airways%3A+effects+of+dexamethasone%2C+rolipram+and+marimastat&doi=10.1016%2Fj.ejphar.2006.11.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Metalloelastase (MMP-12) induced inflammatory response in mice airways: Effects of dexamethasone, rolipram and marimastat</span></div><div class="casAuthors">Nenan, Soazig; Lagente, Vincent; Planquois, Jean-Michel; Hitier, Simon; Berna, Patrick; Bertrand, Claude P.; Boichot, Elisabeth</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-81</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Direct instillation of a recombinant human form of MMP-12 (rhMMP-12) in mice airways elicited an early inflammatory response characterized by neutrophil influx, cytokine release and gelatinase activation followed by a delayed response, mainly characterized by macrophage recruitment.  As this exptl. model of lung inflammation partially mimics some features of chronic obstructive pulmonary disease (COPD), we have investigated the effects of treatment by anti-inflammatory compds., dexamethasone and rolipram and a non-specific matrix metalloproteinase (MMP) inhibitor, marimastat.  The compds. were administered orally, 1 h before rhMMP-12 instillation (8×10- 3 U/mouse).  Total and differential cell counts were evaluated in the bronchoalveolar lavage fluids.  Cytokines and MMP-9 were quantified in bronchoalveolar lavage fluids and in lung homogenate supernatants.  Marimastat (100 mg/kg), dexamethasone (10 mg/kg) and rolipram (0.1 and 0.3 mg/kg) were able to decrease significantly neutrophil recruitment at 4 and 24 h after rhMMP-12 instillation, but only marimastat (30 and 100 mg/kg) was effective at decreasing the macrophage recruitment occurring at day 7.  Marimastat (100 mg/kg), dexamethasone (10 mg/kg) and rolipram (0.3 mg/kg) reduced significantly IL-6, KC/CXCL1, MIP-1α/CCL3 and MMP-9 levels in bronchoalveolar lavage fluid.  Similar results were obtained in lung homogenates except with rolipram.  Dexamethasone and rolipram were able to inhibit the early inflammatory response but were ineffective to limit the macrophage influx.  In contrast, marimastat was able to reduce early and late response.  These data indicate that MMP-12 instillation in mice could highlight some of the inflammatory response seen in COPD and could be used for the pharmacol. evaluation of new anti-inflammatory mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx-wOWDKdj5bVg90H21EOLACvtfcHk0lg0_JrftXOoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXit1Kitbs%253D&md5=0d6476f6791c47f68fc63beab8ee35bc</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2006.11.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2006.11.070%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25A9nan%26aufirst%3DS.%26aulast%3DLagente%26aufirst%3DV.%26aulast%3DPlanquois%26aufirst%3DJ.%2BM.%26aulast%3DHitier%26aufirst%3DS.%26aulast%3DBerna%26aufirst%3DP.%26aulast%3DBertrand%26aufirst%3DC.%2BP.%26aulast%3DBoichot%26aufirst%3DE.%26atitle%3DMetalloelastase%2520%2528MMP-12%2529%2520induced%2520inflammatory%2520response%2520in%2520mice%2520airways%253A%2520effects%2520of%2520dexamethasone%252C%2520rolipram%2520and%2520marimastat%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2007%26volume%3D559%26spage%3D75%26epage%3D81%26doi%3D10.1016%2Fj.ejphar.2006.11.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carmichael, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imrie, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neoptolemos, J. P.</span></span> <span> </span><span class="NLM_article-title">A phase II trial of marimastat in advanced pancreatic cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">1865</span>– <span class="NLM_lpage">1870</span>, <span class="refDoi"> DOI: 10.1054/bjoc.2001.2168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1054%2Fbjoc.2001.2168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11747327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38XhsVWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2001&pages=1865-1870&author=J.+D.+Evansauthor=A.+Starkauthor=C.+D.+Johnsonauthor=F.+Danielauthor=J.+Carmichaelauthor=J.+Buckelsauthor=C.+W.+Imrieauthor=P.+Brownauthor=J.+P.+Neoptolemos&title=A+phase+II+trial+of+marimastat+in+advanced+pancreatic+cancer&doi=10.1054%2Fbjoc.2001.2168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of marimastat in advanced pancreatic cancer</span></div><div class="casAuthors">Evans, J. D.; Stark, A.; Johnson, C. D.; Daniel, F.; Carmichael, J.; Buckels, J.; Imrie, C. W.; Brown, P.; Neoptolemos, J. P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1865-1870</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Harcourt Publishers Ltd.</span>)
        </div><div class="casAbstract">Pancreatic cancer has a poor response to conventional chemotherapy and radiotherapy.  Inhibition of matrix metalloproteinase activity involved in tumor invasion and metastases is a novel biol. approach for cancer treatment.  This multicenter phase II clin. trial assessed marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced pancreatic cancer.  A total of 113 patients received marimastat for 28 days at 100 mg b.d. (n = 9), 25 mg o.d. (n = 90) or 10 mg b.d. (n = 14).  Patients with a response to treatment could continue marimastat beyond 28 days.  Of 113 patients, 90 (80%) completed the 28-day study and 83 (73%) continued treatment.  The principal side effect was arthralgia in 14 (12%) patients at 28 days and 33 (29%) patients over the whole study.  There were 31 patients (27%) who required dose modification.  Of 76 patients with evaluable CA19-9 levels, 23 (30%) showed no increase or fall in CA19-9.  Of 83 patients with radiol. assessable disease, 41 (49%) had stable disease.  The median survival was 245 days for those with a stable or falling CA19-9 level 128 days in those with rising CA19-9.  The overall survival was 3.8 mo. 5.9 mo for stage II, 4.7 mo for stage III and 3 mo for stage IV disease.  Of 90 patients, 46 (51%) had stabilization or redn. in pain, mobility and analgesia scores.  Further development and clin. evaluation of matrix metalloproteinase inhibitors for the treatment of pancreatic cancer is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcKXN9MYpukLVg90H21EOLACvtfcHk0lg0_JrftXOoIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhsVWnuro%253D&md5=dacde8515ddb3ae90c2e6cd5b40cc7aa</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1054%2Fbjoc.2001.2168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1054%252Fbjoc.2001.2168%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DJ.%2BD.%26aulast%3DStark%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DC.%2BD.%26aulast%3DDaniel%26aufirst%3DF.%26aulast%3DCarmichael%26aufirst%3DJ.%26aulast%3DBuckels%26aufirst%3DJ.%26aulast%3DImrie%26aufirst%3DC.%2BW.%26aulast%3DBrown%26aufirst%3DP.%26aulast%3DNeoptolemos%26aufirst%3DJ.%2BP.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520marimastat%2520in%2520advanced%2520pancreatic%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2001%26volume%3D85%26spage%3D1865%26epage%3D1870%26doi%3D10.1054%2Fbjoc.2001.2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bramhall, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallissey, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiting, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholefield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tierney, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCulloch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maughan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielding, J. W.</span></span> <span> </span><span class="NLM_article-title">Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">1864</span>– <span class="NLM_lpage">1870</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6600310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fsj.bjc.6600310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12085177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVaiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2002&pages=1864-1870&author=S.+R.+Bramhallauthor=M.+T.+Hallisseyauthor=J.+Whitingauthor=J.+Scholefieldauthor=G.+Tierneyauthor=R.+C.+Stuartauthor=R.+E.+Hawkinsauthor=P.+McCullochauthor=T.+Maughanauthor=P.+D.+Brownauthor=M.+Bailletauthor=J.+W.+Fielding&title=Marimastat+as+maintenance+therapy+for+patients+with+advanced+gastric+cancer%3A+a+randomised+trial&doi=10.1038%2Fsj.bjc.6600310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial</span></div><div class="casAuthors">Bramhall, S. R.; Hallissey, M. T.; Whiting, J.; Scholefield, J.; Tierney, G.; Stuart, R. C.; Hawkins, R. E.; McCulloch, P.; Maughan, T.; Brown, P. D.; Baillet, M.; Fielding, J. W. L.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1864-1870</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This randomized, double-blind, placebo-controlled study was designed to evaluate the ability of the orally administered matrix metalloproteinase inhibitor, marimastat, to prolong survival in patients with non-resectable gastric and gastroesophageal adenocarcinoma.  Three hundred sixty-nine patients with histol. proof of adenocarcinoma, who had received no more than a single regimen of 5-fluorouracil-based chemotherapy, were randomized to receive either marimastat (10 mg b.d.) or placebo.  Patients were treated for as long as was tolerable.  The primary endpoint was overall survival with secondary endpoints of time to disease progression and quality of life.  At the point of protocol-defined study completion (85% mortality in the placebo arm) there was a modest difference in survival in the intention-to-treat population in favor of marimastat (P=0.07 log-rank test, hazard ratio=1.23 (95% confidence interval 0.98-1.55)).  This survival benefit was maintained over a further 2 yr of follow-up (P=0.024, hazard ratio=1.27 (1.03-1.57)).  The median survival was 138 days for placebo and 160 days for marimastat, with 2-yr survival of 3% and 9% resp.  A significant survival benefit was identified at study completion in the pre-defined sub-group of 123 patients who had received prior chemotherapy (P=0.045, hazard ratio=1.53 (1.00-2.34)).  This benefit increased with 2 yr addnl. follow-up (P=0.006, hazard ratio=1.68 (1.16-2.44)), with 2-yr survival of 5% and 18% resp.  Progression-free survival was also significantly longer for patients receiving marimastat compared to placebo (P=0.009, hazard ratio=1.32 (1.07-1.63)).  Marimastat treatment was assocd. with the development of musculoskeletal pain and inflammation.  Events of anemia, abdominal pain, jaundice and wt. loss were more common in the placebo arm.  This is one of the first demonstrations of a therapeutic benefit for a matrix metalloproteinase inhibitor in cancer patients.  The greatest benefit was obsd. in patients who had previously received chemotherapy.  A further randomised study of marimastat in these patients is warranted. doi:10.1038/sj.bjc.6600310 www.bjcancer.com.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsDzh16ALsKbVg90H21EOLACvtfcHk0lgfqyWiWbjK_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVaiurY%253D&md5=a9a36c873c4c5e73526dd47ffddf87cb</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600310%26sid%3Dliteratum%253Aachs%26aulast%3DBramhall%26aufirst%3DS.%2BR.%26aulast%3DHallissey%26aufirst%3DM.%2BT.%26aulast%3DWhiting%26aufirst%3DJ.%26aulast%3DScholefield%26aufirst%3DJ.%26aulast%3DTierney%26aufirst%3DG.%26aulast%3DStuart%26aufirst%3DR.%2BC.%26aulast%3DHawkins%26aufirst%3DR.%2BE.%26aulast%3DMcCulloch%26aufirst%3DP.%26aulast%3DMaughan%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DP.%2BD.%26aulast%3DBaillet%26aufirst%3DM.%26aulast%3DFielding%26aufirst%3DJ.%2BW.%26atitle%3DMarimastat%2520as%2520maintenance%2520therapy%2520for%2520patients%2520with%2520advanced%2520gastric%2520cancer%253A%2520a%2520randomised%2520trial%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D86%26spage%3D1864%26epage%3D1870%26doi%3D10.1038%2Fsj.bjc.6600310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Onnervik, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. L.</span></span> <span> </span><span class="NLM_article-title">Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">713</span>, <span class="refDoi"> DOI: 10.1136/thx.2006.068353</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1136%2Fthx.2006.068353" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17311841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD2svms1SktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2007&pages=706-713&author=A.+Churgauthor=R.+Wangauthor=X.+Wangauthor=P.+O.+Onnervikauthor=K.+Thimauthor=J.+L.+Wright&title=Effect+of+an+MMP-9%2FMMP-12+inhibitor+on+smoke-induced+emphysema+and+airway+remodelling+in+guinea+pigs&doi=10.1136%2Fthx.2006.068353"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs</span></div><div class="casAuthors">Churg Andrew; Wang Rona; Wang Xiaoshan; Onnervik Per-Ola; Thim Kerstin; Wright Joanne L</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">706-13</span>
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">BACKGROUND:  Matrix metalloproteases (MMPs) are believed to be important in the pathogenesis of cigarette smoke-induced emphysema, but this hypothesis has only been proved in the mouse and its applicability to other species, particularly humans, is uncertain.  The role of MMPs in smoke-induced small airway remodelling is unknown.  METHODS:  The effects of a dual MMP-9/MMP-12 inhibitor, AZ11557272, on the development of anatomical and functional changes of chronic obstructive pulmonary disease (COPD) in guinea pigs exposed daily to cigarette smoke for up to 6 months were examined.  RESULTS:  At all times, smoke-induced increases in lavage inflammatory cells, lavage desmosine (a marker of elastin breakdown) and serum tumour necrosis factor alpha (TNFalpha) were completely abolished by AZ11557272.  At 6 months there was an increase in lung volumes and airspace size.  AZ11557272 returned the pressure- volume curve to control levels, decreased smoke-induced increases in total lung capacity, residual volume and vital capacity by about 70%, and also reversed smoke-induced airspace enlargement by about 70%.  There was a very strong correlation between surface to volume ratio and both lavage desmosine and serum TNFalpha levels.  AZ11557272 protected against smoke-mediated increases in small airway wall thickness but did not prevent smoke-induced increases in mean pulmonary artery pressure.  CONCLUSIONS:  An MMP-9/MMP-12 inhibitor can substantially ameliorate morphological emphysema, small airway remodelling and the functional consequences of these lesions in a non-murine species.  These findings strengthen the idea that MMPs are important mediators of the anatomical changes behind COPD in humans, and suggest that MMP-9 and MMP-12 may be potential intervention targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfSjig6ZE6a6qcneEtCi92fW6udTcc2eYsigw9iWtBR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svms1SktA%253D%253D&md5=fe30cef0ff1e1dde6d64fa1f71acc747</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1136%2Fthx.2006.068353&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.2006.068353%26sid%3Dliteratum%253Aachs%26aulast%3DChurg%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DOnnervik%26aufirst%3DP.%2BO.%26aulast%3DThim%26aufirst%3DK.%26aulast%3DWright%26aufirst%3DJ.%2BL.%26atitle%3DEffect%2520of%2520an%2520MMP-9%252FMMP-12%2520inhibitor%2520on%2520smoke-induced%2520emphysema%2520and%2520airway%2520remodelling%2520in%2520guinea%2520pigs%26jtitle%3DThorax%26date%3D2007%26volume%3D62%26spage%3D706%26epage%3D713%26doi%3D10.1136%2Fthx.2006.068353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dahl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Titlestad, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wielders, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wray, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuelsson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span> <span> </span><span class="NLM_article-title">Effects of an oral MMP-9 and −12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2011.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2011.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22306193" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xis1yjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=169-177&author=R.+Dahlauthor=I.+Titlestadauthor=A.+Lindqvistauthor=P.+Wieldersauthor=H.+Wrayauthor=M.+Wangauthor=V.+Samuelssonauthor=J.+Moauthor=A.+Holt&title=Effects+of+an+oral+MMP-9+and+%E2%88%9212+inhibitor%2C+AZD1236%2C+on+biomarkers+in+moderate%2Fsevere+COPD%3A+a+randomised+controlled+trial&doi=10.1016%2Fj.pupt.2011.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomized controlled trial</span></div><div class="casAuthors">Dahl, Ronald; Titlestad, Ingrid; Lindqvist, Ari; Wielders, Pascal; Wray, Heather; Wang, Millie; Samuelsson, Viktoria; Mo, John; Holt, Alison</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: There is a pressing need for new forms of treatment for COPD.  Based on the known pathophysiol. of COPD, inhibition of matrix metalloproteinases is a theor. promising approach.  This Phase IIa study evaluated the effects of AZD1236, a selective MMP-9 and MMP-12 inhibitor, on the biomarkers of inflammation and emphysematous lung tissue degrdn. in patients with moderate-to-severe COPD.  Methods: This was a multinational, randomized, double-blind, placebo-controlled signal-searching study conducted in men and women aged ≥40 years with stable moderate-to-severe COPD.  After a 2-6-wk period to eliminate any remaining effects of previous medication, 55 patients received oral AZD1236 75 mg or matching placebo twice daily for 6 wk.  Differential cell count and TNF-α levels in induced sputum and 24-h urinary desmosine excretion were the main study variables, but a range of exploratory biomarkers was also assessed in induced sputum, blood and urine.  Secondary variables included lung function and patient-recorded Clin. COPD Questionnaire (CCQ) responses and diary records of symptoms, adverse events, use of rescue medication and AZD1236 plasma concns.  Results: The majority of variables showed little change compared to placebo although there was a possible, but not statistically significant redn. in urinary desmosine excretion and redns. in the no. and percentage of lymphocytes in sputum and blood with AZD1236.  No effect was seen on clin. parameters after 6 wk of treatment.  The proportion of patients experiencing adverse events was similar in both treatment groups.  Conclusions: AZD1236 dosed orally at 75 mg twice daily was generally well tolerated over 6 wk in patients with moderate-to-severe COPD.  No clin. efficacy of AZD1236 was demonstrated in this short-term signal-searching study, although possible evidence of an impact on desmosine may suggest the potential value of selective inhibitors of MMPs in the treatment of COPD in longer term trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQRT3GXQkab7Vg90H21EOLACvtfcHk0lgfqyWiWbjK_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xis1yjs7s%253D&md5=94d79657c3d6adde061b9e8016cf39dc</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2011.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2011.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DR.%26aulast%3DTitlestad%26aufirst%3DI.%26aulast%3DLindqvist%26aufirst%3DA.%26aulast%3DWielders%26aufirst%3DP.%26aulast%3DWray%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSamuelsson%26aufirst%3DV.%26aulast%3DMo%26aufirst%3DJ.%26aulast%3DHolt%26aufirst%3DA.%26atitle%3DEffects%2520of%2520an%2520oral%2520MMP-9%2520and%2520%25E2%2588%259212%2520inhibitor%252C%2520AZD1236%252C%2520on%2520biomarkers%2520in%2520moderate%252Fsevere%2520COPD%253A%2520a%2520randomised%2520controlled%2520trial%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D25%26spage%3D169%26epage%3D177%26doi%3D10.1016%2Fj.pupt.2011.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocourek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschesche, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bode, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maskos, K.</span></span> <span> </span><span class="NLM_article-title">Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">731</span>– <span class="NLM_lpage">742</span>, <span class="refDoi"> DOI: 10.1006/jmbi.2001.4954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1006%2Fjmbi.2001.4954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11575928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3MXntV2ms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2001&pages=731-742&author=R.+Langauthor=A.+Kocourekauthor=M.+Braunauthor=H.+Tschescheauthor=R.+Huberauthor=W.+Bodeauthor=K.+Maskos&title=Substrate+specificity+determinants+of+human+macrophage+elastase+%28MMP-12%29+based+on+the+1.1+A+crystal+structure&doi=10.1006%2Fjmbi.2001.4954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate Specificity Determinants of Human Macrophage Elastase (MMP-12) Based on the 1.1 Å Crystal Structure</span></div><div class="casAuthors">Lang, Rupert; Kocourek, Andreas; Braun, Marianne; Tschesche, Harald; Huber, Robert; Bode, Wolfram; Maskos, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">731-742</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The macrophage elastase enzyme (MMP-12) expressed mainly in alveolar macrophages has been identified in the mouse lung as the main destructive agent assocd. with cigarette smoking, which gives rise to emphysema, both directly via elastin degrdn. and indirectly by disturbing the proteinase/antiproteinase balance via inactivation of the α1-proteinase inhibitor (α1-PI), the antagonist of the leukocyte elastase.  The catalytic domain of human recombinant MMP-12 has been crystd. in complex with the broad-specificity inhibitor batimastat (BB-94).  The crystal structure anal. of this complex, detd. using X-ray data to 1.1 Å and refined to an R-value of 0.165, reveals an overall fold similar to that of other MMPs.  However, the S-shaped double loop connecting strands III and IV is fixed closer to the β-sheet and projects its His172 side-chain further into the rather hydrophobic active-site cleft, defining the S3 and the S1-pockets and sepg. them from each other to a larger extent than is obsd. in other MMPs.  The S2-site is planar, while the characteristic S1'-subsite is a continuous tube rather than a pocket, in which the MMP-12-specific Thr215 replaces a Val residue otherwise highly conserved in almost all other MMPs.  This alteration might allow MMP-12 to accept P1' Arg residues, making it unique among MMPs.  The active-site cleft of MMP-12 is well equipped to bind and efficiently cleave the AlaMetPhe-LeuGluAla sequence in the reactive-site loop of α1-PI, as occurs exptl.  Similarities in contouring and particularly a common surface hydrophobicity both inside and distant from the active-site cleft explain why MMP-12 shares many substrates with matrilysin (MMP-7).  The MMP-12 structure is an excellent template for the structure-based design of specific inhibitors for emphysema therapy and for the construction of mutants to clarify the role of this MMP.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1dZcnkP3FQbVg90H21EOLACvtfcHk0liRJCSKT1ZLpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXntV2ms7Y%253D&md5=ac2502bc9d98fa05d8d05f183878d8ef</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1006%2Fjmbi.2001.4954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fjmbi.2001.4954%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DR.%26aulast%3DKocourek%26aufirst%3DA.%26aulast%3DBraun%26aufirst%3DM.%26aulast%3DTschesche%26aufirst%3DH.%26aulast%3DHuber%26aufirst%3DR.%26aulast%3DBode%26aufirst%3DW.%26aulast%3DMaskos%26aufirst%3DK.%26atitle%3DSubstrate%2520specificity%2520determinants%2520of%2520human%2520macrophage%2520elastase%2520%2528MMP-12%2529%2520based%2520on%2520the%25201.1%2520A%2520crystal%2520structure%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2001%26volume%3D312%26spage%3D731%26epage%3D742%26doi%3D10.1006%2Fjmbi.2001.4954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le Quément, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guénon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillon, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valença, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cayron-Elizondo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagente, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boichot, E.</span></span> <span> </span><span class="NLM_article-title">The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>154</i></span>,  <span class="NLM_fpage">1206</span>– <span class="NLM_lpage">1215</span>, <span class="refDoi"> DOI: 10.1038/bjp.2008.180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fbjp.2008.180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18493250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosVCjtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=154&publication_year=2008&pages=1206-1215&author=C.+Le+Qu%C3%A9mentauthor=I.+Gu%C3%A9nonauthor=J.+Y.+Gillonauthor=S.+Valen%C3%A7aauthor=V.+Cayron-Elizondoauthor=V.+Lagenteauthor=E.+Boichot&title=The+selective+MMP-12+inhibitor%2C+AS111793+reduces+airway+inflammation+in+mice+exposed+to+cigarette+smoke&doi=10.1038%2Fbjp.2008.180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke</span></div><div class="casAuthors">Le Quement, C.; Guenon, I.; Gillon, J.-Y.; Valenca, S.; Cayron-Elizondo, V.; Lagente, V.; Boichot, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">154</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1206-1215</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Macrophage elastase (MMP-12) is involved in the inflammatory process of chronic obstructive pulmonary disease (COPD).  The aim of this study was to investigate in mice the effect of MMP-12 inhibition on the inflammatory process induced by cigarette smoke (CS) or by lipopolysaccharide (LPS) exposure of the airways.  Exptl. approach: C57BL/6 mice were given, orally, either the selective MMP-12 inhibitor AS111793 (3, 10, 30 and 100 mg kg-1), the PDE-4 inhibitor roflumilast (3 mg kg-1) or vehicle, then exposed to CS (for 3 days) or to LPS (100 μg mL-1, 30 min).  Subsequent to the last smoke or LPS exposure, bronchoalveolar lavages (BAL) were performed and lungs were removed and homogenized to analyze various markers of inflammation at appropriate times.  Key results: Inhibition of MMP-12 by AS111793 (10 and 30 mg kg-1) was assocd. with a redn. of the increase in neutrophil no. in BAL fluids after 4 days and of macrophages after 11 days.  On day 4, AS111793 also significantly reduced all the inflammation markers that had increased after CS exposure, including sol. TNF receptors I and II, MIP-1γ, IL-6 and pro-MMP-9 activity in BAL fluids, and KC/CXCL1, fractalkine/CX3CL1, TIMP-1 and I-TAC/CXCL11 in lung parenchyma.  In contrast, inhibition of MMP-12 did not reduce neutrophil influx, pro-MMP-9 activity or KC/CXCL1 release in BAL fluids of mice exposed to LPS.  Conclusion: Inhibition of MMP-12 with AS111793, reduced the inflammatory process assocd. with exposure of mice to CS, strongly suggesting a specific involvement of MMP-12 in lung inflammation following CS exposure.  British Journal of Pharmacol. (2008) 154, 1206-1215; doi:10.1038/bjp.2008.180; published online 19 May 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLwKquaUjjcbVg90H21EOLACvtfcHk0liRJCSKT1ZLpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosVCjtLY%253D&md5=c1daa3f322c9af9b0486a00e258161cd</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1038%2Fbjp.2008.180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjp.2008.180%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BQu%25C3%25A9ment%26aufirst%3DC.%26aulast%3DGu%25C3%25A9non%26aufirst%3DI.%26aulast%3DGillon%26aufirst%3DJ.%2BY.%26aulast%3DValen%25C3%25A7a%26aufirst%3DS.%26aulast%3DCayron-Elizondo%26aufirst%3DV.%26aulast%3DLagente%26aufirst%3DV.%26aulast%3DBoichot%26aufirst%3DE.%26atitle%3DThe%2520selective%2520MMP-12%2520inhibitor%252C%2520AS111793%2520reduces%2520airway%2520inflammation%2520in%2520mice%2520exposed%2520to%2520cigarette%2520smoke%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D154%26spage%3D1206%26epage%3D1215%26doi%3D10.1038%2Fbjp.2008.180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Q.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">456</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1021/jm051101g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051101g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlantL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=456-458&author=D.+Maauthor=Y.+Jiangauthor=F.+Chenauthor=L.+K.+Gongauthor=K.+Dingauthor=Y.+Xuauthor=R.+Wangauthor=A.+Geauthor=J.+Renauthor=J.+Liauthor=J.+Liauthor=Q.+Ye&title=Selective+inhibition+of+matrix+metalloproteinase+isozymes+and+in+vivo+protection+against+emphysema+by+substituted+gamma-keto+carboxylic+acids&doi=10.1021%2Fjm051101g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Matrix Metalloproteinase Isozymes and in Vivo Protection against Emphysema by Substituted γ-Keto Carboxylic Acids</span></div><div class="casAuthors">Ma, Dawei; Jiang, Yongwen; Chen, Fangping; Gong, Li-Kun; Ding, Ke; Xu, Yong; Wang, Renxiao; Ge, Aihua; Ren, Jin; Li, Jingya; Li, Jia; Ye, Qizhuang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">456-458</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The synthesis and matrix metalloproteinase (MMP) inhibitory activity of a series of γ-keto carboxylic acids are described.  Among nine MMP isoenzymes tested, compd. 1j displays selective inhibition of MMP-2, -9, and -12 with IC50 values between 0.20 and 1.51 μM, and in male golden Syrian hamsters, it shows protection against PPE-induced emphysema.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzNqGR3Guk6rVg90H21EOLACvtfcHk0liRJCSKT1ZLpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlantL7E&md5=d9d29336a364e9f95b8a6e90f209e394</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1021%2Fjm051101g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051101g%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DD.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DGong%26aufirst%3DL.%2BK.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DR.%26aulast%3DGe%26aufirst%3DA.%26aulast%3DRen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYe%26aufirst%3DQ.%26atitle%3DSelective%2520inhibition%2520of%2520matrix%2520metalloproteinase%2520isozymes%2520and%2520in%2520vivo%2520protection%2520against%2520emphysema%2520by%2520substituted%2520gamma-keto%2520carboxylic%2520acids%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D456%26epage%3D458%26doi%3D10.1021%2Fjm051101g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nuti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avramova, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cercignani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Amelio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uggeri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossello, A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6347</span>– <span class="NLM_lpage">6361</span>, <span class="refDoi"> DOI: 10.1021/jm900335a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900335a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFKkt7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6347-6361&author=E.+Nutiauthor=L.+Panelliauthor=F.+Casaliniauthor=S.+I.+Avramovaauthor=E.+Orlandiniauthor=S.+Santamariaauthor=S.+Nencettiauthor=T.+Tuccinardiauthor=A.+Martinelliauthor=G.+Cercignaniauthor=N.+D%E2%80%99Amelioauthor=A.+Maiocchiauthor=F.+Uggeriauthor=A.+Rossello&title=Design%2C+synthesis%2C+biological+evaluation%2C+and+NMR+studies+of+a+new+series+of+arylsulfones+as+selective+and+potent+matrix+metalloproteinase-12+inhibitors&doi=10.1021%2Fjm900335a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Biological Evaluation, and NMR Studies of a New Series of Arylsulfones As Selective and Potent Matrix Metalloproteinase-12 Inhibitors</span></div><div class="casAuthors">Nuti, Elisa; Panelli, Laura; Casalini, Francesca; Avramova, Stanislava I.; Orlandini, Elisabetta; Santamaria, Salvatore; Nencetti, Susanna; Tuccinardi, Tiziano; Martinelli, Adriano; Cercignani, Giovanni; D'Amelio, Nicola; Maiocchi, Alessandro; Uggeri, Fulvio; Rossello, Armando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6347-6361</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Overexpression of macrophage elastase (MMP-12), a member of the matrix metalloproteinases family, can be linked to tissue remodeling and degrdn. in some inflammatory processes, such as chronic obstructive pulmonary disease (COPD), emphysema, rheumatoid arthritis (RA), and atherosclerosis.  On this basis, MMP-12 can be considered an attractive target for studying selective inhibitors that are useful in the development of new therapies for COPD and other inflammatory diseases.  The design, synthesis, and in vitro evaluation of a new series of compds., possessing an arylsulfonyl scaffold, for their potential as selective inhibitors of MMP-12, are herein reported.  The best compd. I in the series showed an IC50 value of 0.2 nM, with good selectivity over MMP-1 and MMP-14.  A docking study was carried out on I in order to investigate its binding interactions with MMP-12, and NMR studies on the complex with the MMP-12 catalytic domain were able to validate the proposed binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofjDYuIX_eNLVg90H21EOLACvtfcHk0lj3SuI2GZEbHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFKkt7bN&md5=d71adf7f0859928c645d8822d7b12136</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1021%2Fjm900335a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900335a%26sid%3Dliteratum%253Aachs%26aulast%3DNuti%26aufirst%3DE.%26aulast%3DPanelli%26aufirst%3DL.%26aulast%3DCasalini%26aufirst%3DF.%26aulast%3DAvramova%26aufirst%3DS.%2BI.%26aulast%3DOrlandini%26aufirst%3DE.%26aulast%3DSantamaria%26aufirst%3DS.%26aulast%3DNencetti%26aufirst%3DS.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DMartinelli%26aufirst%3DA.%26aulast%3DCercignani%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Amelio%26aufirst%3DN.%26aulast%3DMaiocchi%26aufirst%3DA.%26aulast%3DUggeri%26aufirst%3DF.%26aulast%3DRossello%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520NMR%2520studies%2520of%2520a%2520new%2520series%2520of%2520arylsulfones%2520as%2520selective%2520and%2520potent%2520matrix%2520metalloproteinase-12%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6347%26epage%3D6361%26doi%3D10.1021%2Fjm900335a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchandani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFadyen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlerman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sypek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3 methylbutanoic acid (MMP408)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1799</span>– <span class="NLM_lpage">1802</span>, <span class="refDoi"> DOI: 10.1021/jm900093d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900093d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1799-1802&author=W.+Liauthor=J.+Liauthor=Y.+Wuauthor=J.+Wuauthor=R.+Hotchandaniauthor=K.+Cunninghamauthor=I.+McFadyenauthor=J.+Bardauthor=P.+Morganauthor=F.+Schlermanauthor=X.+Xuauthor=S.+Tamauthor=S.+J.+Goldmanauthor=C.+Williamsauthor=J.+Sypekauthor=T.+S.+Mansour&title=A+selective+matrix+metalloprotease+12+inhibitor+for+potential+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29%3A+discovery+of+%28S%29-2-%288-%28methoxycarbonylamino%29dibenzo%5Bb%2Cd%5Dfuran-3-sulfonamido%29-3+methylbutanoic+acid+%28MMP408%29&doi=10.1021%2Fjm900093d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">A Selective Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Chronic Obstructive Pulmonary Disease (COPD): Discovery of (S)-2-(8-(Methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)</span></div><div class="casAuthors">Li, Wei; Li, Jianchang; Wu, Yuchuan; Wu, Junjun; Hotchandani, Rajeev; Cunningham, Kristina; McFadyen, Iain; Bard, Joel; Morgan, Paul; Schlerman, Franklin; Xu, Xin; Tam, Steve; Goldman, Samuel J.; Williams, Cara; Sypek, Joseph; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1799-1802</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Matrix metalloprotease 12 plays a significant role in airway inflammation and remodeling.  Increased expression and prodn. of MMP-12 have been found in the lung of human COPD patients.  MMP408 (14), a potent and selective MMP-12 inhibitor, was derived from a potent matrix metalloprotease 2 and 13 inhibitor via lead optimization and has good phys. properties and bioavailability.  The compd. blocks rhMMP-12-induced lung inflammation in a mouse model and was advanced for further development for the treatment of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4TF1h22v7zbVg90H21EOLACvtfcHk0lj3SuI2GZEbHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSitr4%253D&md5=63c1b38560e93775a33adc50354c30e3</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm900093d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900093d%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DHotchandani%26aufirst%3DR.%26aulast%3DCunningham%26aufirst%3DK.%26aulast%3DMcFadyen%26aufirst%3DI.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSchlerman%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DS.%2BJ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DSypek%26aufirst%3DJ.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DA%2520selective%2520matrix%2520metalloprotease%252012%2520inhibitor%2520for%2520potential%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%253A%2520discovery%2520of%2520%2528S%2529-2-%25288-%2528methoxycarbonylamino%2529dibenzo%255Bb%252Cd%255Dfuran-3-sulfonamido%2529-3%2520methylbutanoic%2520acid%2520%2528MMP408%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1799%26epage%3D1802%26doi%3D10.1021%2Fjm900093d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rancati, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallese, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raveglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchandani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krykbaev, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saiah, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sypek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">143</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.11.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bmcl.2011.11.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22153340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVOrtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=138-143&author=Y.+Wuauthor=J.+Liauthor=J.+Wuauthor=P.+Morganauthor=X.+Xuauthor=F.+Rancatiauthor=S.+Valleseauthor=L.+Ravegliaauthor=R.+Hotchandaniauthor=N.+Fullerauthor=J.+Bardauthor=K.+Cunninghamauthor=S.+Fishauthor=R.+Krykbaevauthor=S.+Tamauthor=S.+J.+Goldmanauthor=C.+Williamsauthor=T.+S.+Mansourauthor=E.+Saiahauthor=J.+Sypekauthor=W.+Li&title=Discovery+of+potent+and+selective+matrix+metalloprotease+12+inhibitors+for+the+potential+treatment+of+chronic+obstructive+pulmonary+disease+%28COPD%29&doi=10.1016%2Fj.bmcl.2011.11.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)</span></div><div class="casAuthors">Wu, Yuchuan; Li, Jianchang; Wu, Junjun; Morgan, Paul; Xu, Xin; Rancati, Fabio; Vallese, Stefania; Raveglia, Luca; Hotchandani, Rajeev; Fuller, Nathan; Bard, Joel; Cunningham, Kristina; Fish, Susan; Krykbaev, Rustem; Tam, Steve; Goldman, Samuel J.; Williams, Cara; Mansour, Tarek S.; Saiah, Eddine; Sypek, Joseph; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">138-143</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease assocd. with irreversible progressive airflow limitation.  Matrix metalloproteinase-12 (MMP-12) has been characterized to be one of the major proteolytic enzymes to induce airway remodeling, destruction of elastin and the aberrant remodeling of damaged alveoli in COPD and asthma.  The goal of this project is to develop and identify an orally potent and selective small mol. inhibitor of MMP-12 for treatment of COPD and asthma.  Syntheses and structure-activity relationship (SAR) studies of a series of dibenzofuran (DBF) sulfonamides as MMP-12 inhibitors are described.  Potent inhibitors of MMP-12 with excellent selectivity against other MMPs were identified.  Compd. I (MMP118), which exhibits excellent oral efficacy in the MMP-12 induced ear-swelling inflammation and lung inflammation mouse models, had been successfully advanced into Development Track status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK4jcjsJ4QiLVg90H21EOLACvtfcHk0lipk6e1t-ciLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVOrtg%253D%253D&md5=8dd9fd541978708294aef0d526a8c17e</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.11.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.11.046%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DRancati%26aufirst%3DF.%26aulast%3DVallese%26aufirst%3DS.%26aulast%3DRaveglia%26aufirst%3DL.%26aulast%3DHotchandani%26aufirst%3DR.%26aulast%3DFuller%26aufirst%3DN.%26aulast%3DBard%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DK.%26aulast%3DFish%26aufirst%3DS.%26aulast%3DKrykbaev%26aufirst%3DR.%26aulast%3DTam%26aufirst%3DS.%26aulast%3DGoldman%26aufirst%3DS.%2BJ.%26aulast%3DWilliams%26aufirst%3DC.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26aulast%3DSaiah%26aufirst%3DE.%26aulast%3DSypek%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520matrix%2520metalloprotease%252012%2520inhibitors%2520for%2520the%2520potential%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528COPD%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D138%26epage%3D143%26doi%3D10.1016%2Fj.bmcl.2011.11.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butsch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwegmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schäfers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riemann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span> <span> </span><span class="NLM_article-title">Design, (radio)synthesis, and in vitro and in vivo evaluation of highly selective and potent matrix metalloproteinase 12 (MMP-12) inhibitors as radiotracers for positron emission tomography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4115</span>– <span class="NLM_lpage">4134</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXns1OjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4115-4134&author=V.+Butschauthor=F.+B%C3%B6rgelauthor=F.+Gallaauthor=K.+Schwegmannauthor=S.+Hermannauthor=M.+Sch%C3%A4fersauthor=B.+Riemannauthor=B.+W%C3%BCnschauthor=S.+Wagner&title=Design%2C+%28radio%29synthesis%2C+and+in+vitro+and+in+vivo+evaluation+of+highly+selective+and+potent+matrix+metalloproteinase+12+%28MMP-12%29+inhibitors+as+radiotracers+for+positron+emission+tomography&doi=10.1021%2Facs.jmedchem.8b00200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Design, (Radio)Synthesis, and in Vitro and in Vivo Evaluation of Highly Selective and Potent Matrix Metalloproteinase 12 (MMP-12) Inhibitors as Radiotracers for Positron Emission Tomography</span></div><div class="casAuthors">Butsch, Viktoria; Boergel, Frederik; Galla, Fabian; Schwegmann, Katrin; Hermann, Sven; Schaefers, Michael; Riemann, Burkhard; Wuensch, Bernhard; Wagner, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4115-4134</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulated levels of activated matrix metalloproteinases (MMPs) are linked to different pathologies, such as cancer, atherosclerosis, neuroinflammation, and arthritis.  Therefore, imaging of MMPs with positron-emission tomog. (PET) represents a powerful tool for the diagnosis of MMP-assocd. diseases.  Moreover, to distinguish between the distinct functions and roles of individual MMPs in particular pathophysiol. processes, their specific imaging must be realized with radiolabeled tracers, such as fluorine-18-labeled MMP inhibitors (MMPIs).  Therefore, fluorinated dibenzofuransulfonamide-based MMPIs showing excellent inhibition of MMP-12 and selectivity for MMP-12 over other MMPs were prepd.  MMP-12 is a key enzyme in diseases such as chronic obstructive pulmonary disease (COPD) and atherosclerosis.  Because of their promising in vitro properties, three candidates [{[8-(4-(3-Fluoropropyl)-1H-1,2,3-triazol-1-yl)dibenzo[b,d]furan-3-yl]sulfonyl}-(S)-valine (4), {[8-(1-(2-Fluoroethyl)-1,2,3-triazol-4-yl)dibenzo[b,d]furan-3-yl]sulfonyl}-(S)-valine (9), and ({8-[1-(2-Fluoroethyl)pyrazol-4-yl]dibenzo[b,d]furan-3-yl}sulfonyl)-(S)-valine (19)] were selected from this library, and radiofluorinated analogs ([18F]4, [18F]9, and [18F]19) were successfully synthesized.  Initial in vitro serum stability and in vivo biodistribution studies of the radiolabeled MMPIs with PET demonstrated their potential benefit for preferable MMP-12 imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqkbPFGaMBErVg90H21EOLACvtfcHk0lipk6e1t-ciLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXns1OjtLo%253D&md5=d49976fbe3046bf45321fcfaa8a20f77</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00200%26sid%3Dliteratum%253Aachs%26aulast%3DButsch%26aufirst%3DV.%26aulast%3DB%25C3%25B6rgel%26aufirst%3DF.%26aulast%3DGalla%26aufirst%3DF.%26aulast%3DSchwegmann%26aufirst%3DK.%26aulast%3DHermann%26aufirst%3DS.%26aulast%3DSch%25C3%25A4fers%26aufirst%3DM.%26aulast%3DRiemann%26aufirst%3DB.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26aulast%3DWagner%26aufirst%3DS.%26atitle%3DDesign%252C%2520%2528radio%2529synthesis%252C%2520and%2520in%2520vitro%2520and%2520in%2520vivo%2520evaluation%2520of%2520highly%2520selective%2520and%2520potent%2520matrix%2520metalloproteinase%252012%2520%2528MMP-12%2529%2520inhibitors%2520as%2520radiotracers%2520for%2520positron%2520emission%2520tomography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4115%26epage%3D4134%26doi%3D10.1021%2Facs.jmedchem.8b00200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nuti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuffaro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camodeca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciccone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tepshi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlandini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nencetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stura, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dive, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossello, A.</span></span> <span> </span><span class="NLM_article-title">Development of thioaryl-based matrix metalloproteinase-12 inhibitors with alternative zinc-binding groups: synthesis, potentiometric, NMR, and crystallographic studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4421</span>– <span class="NLM_lpage">4443</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00096</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00096" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptVWis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4421-4443&author=E.+Nutiauthor=D.+Cuffaroauthor=E.+Bernardiniauthor=C.+Camodecaauthor=L.+Panelliauthor=S.+Chavesauthor=L.+Cicconeauthor=L.+Tepshiauthor=L.+Veraauthor=E.+Orlandiniauthor=S.+Nencettiauthor=E.+A.+Sturaauthor=M.+A.+Santosauthor=V.+Diveauthor=A.+Rossello&title=Development+of+thioaryl-based+matrix+metalloproteinase-12+inhibitors+with+alternative+zinc-binding+groups%3A+synthesis%2C+potentiometric%2C+NMR%2C+and+crystallographic+studies&doi=10.1021%2Facs.jmedchem.8b00096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies</span></div><div class="casAuthors">Nuti, Elisa; Cuffaro, Doretta; Bernardini, Elisa; Camodeca, Caterina; Panelli, Laura; Chaves, Silvia; Ciccone, Lidia; Tepshi, Livia; Vera, Laura; Orlandini, Elisabetta; Nencetti, Susanna; Stura, Enrico A.; Santos, M. Amelia; Dive, Vincent; Rossello, Armando</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4421-4435</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Matrix metalloproteinase-12 (MMP-12) selective inhibitors could play a role in the treatment of lung inflammatory and cardiovascular diseases.  In the present study, the previously reported 4-methoxybiphenylsulfonyl hydroxamate and carboxylate based inhibitors (I and II) were modified to enhance their selectivity for MMP-12.  In the newly synthesized thioaryl derivs., the nature of the zinc binding group (ZBG) and the sulfur oxidn. state were changed.  Biol. assays carried out in vitro on human MMPs with the resulting compds. led to identification of a sulfide, III, bearing an N-1-hydroxypiperidine-2,6-dione (HPD) group as new ZBG.  Compd. III is a promising hit compd. since it displayed a nanomolar affinity for MMP-12 with a marked selectivity over MMP-9, MMP-1, and MMP-14.  Soln. complexation studies with Zn2+ were performed to characterize the chelating abilities of the new compds. and confirmed the bidentate binding mode of HPD derivs.  X-ray crystallog. studies using MMP-12 and MMP-9 catalytic domains were carried out to rationalize the biol. results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGompUvE-tYWNLVg90H21EOLACvtfcHk0lipk6e1t-ciLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptVWis7Y%253D&md5=2b8d3c42ee0eb148735605580ae9172d</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00096%26sid%3Dliteratum%253Aachs%26aulast%3DNuti%26aufirst%3DE.%26aulast%3DCuffaro%26aufirst%3DD.%26aulast%3DBernardini%26aufirst%3DE.%26aulast%3DCamodeca%26aufirst%3DC.%26aulast%3DPanelli%26aufirst%3DL.%26aulast%3DChaves%26aufirst%3DS.%26aulast%3DCiccone%26aufirst%3DL.%26aulast%3DTepshi%26aufirst%3DL.%26aulast%3DVera%26aufirst%3DL.%26aulast%3DOrlandini%26aufirst%3DE.%26aulast%3DNencetti%26aufirst%3DS.%26aulast%3DStura%26aufirst%3DE.%2BA.%26aulast%3DSantos%26aufirst%3DM.%2BA.%26aulast%3DDive%26aufirst%3DV.%26aulast%3DRossello%26aufirst%3DA.%26atitle%3DDevelopment%2520of%2520thioaryl-based%2520matrix%2520metalloproteinase-12%2520inhibitors%2520with%2520alternative%2520zinc-binding%2520groups%253A%2520synthesis%252C%2520potentiometric%252C%2520NMR%252C%2520and%2520crystallographic%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4421%26epage%3D4443%26doi%3D10.1021%2Facs.jmedchem.8b00096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dublanchet, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ducrot, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrianjara, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Gara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compère, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cluzeau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courté, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prunet, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tertre, A.</span></span> <span> </span><span class="NLM_article-title">Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">3787</span>– <span class="NLM_lpage">3790</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.05.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bmcl.2005.05.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16002291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlKiu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=3787-3790&author=A.+C.+Dublanchetauthor=P.+Ducrotauthor=C.+Andrianjaraauthor=M.+O%E2%80%99Garaauthor=R.+Moralesauthor=D.+Comp%C3%A8reauthor=A.+Denisauthor=S.+Blaisauthor=P.+Cluzeauauthor=K.+Court%C3%A9author=J.+Hamonauthor=F.+Moreauauthor=M.+L.+Prunetauthor=A.+Tertre&title=Structure-based+design+and+synthesis+of+novel+non-zinc+chelating+MMP-12+inhibitors&doi=10.1016%2Fj.bmcl.2005.05.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors</span></div><div class="casAuthors">Dublanchet, Anne-Claude; Ducrot, Pierre; Andrianjara, Charles; O'Gara, Margaret; Morales, Renaud; Compere, Delphine; Denis, Alexis; Blais, Stephane; Cluzeau, Philippe; Courte, Karine; Hamon, Jacques; Moreau, Francois; Prunet, Marie-Laure; Tertre, Anita</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3787-3790</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A class of MMP-12 inhibitors (arylthienylamides) was discovered and optimized using structure-based drug design methods.  Modeling studies using a known MMP-12 crystal structure identified an interaction mode for these arylthienylamide MMP-12 inhibitors.  Further optimization resulted in the discovery of a compd. displaying nanomolar activity against MMP-12 and which was co-crystd. with MMP-12.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-McBvzCs6T7Vg90H21EOLACvtfcHk0lggfjP2pMgJKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlKiu7o%253D&md5=06ba7fba14c771b2a9f0dd2457b21349</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.05.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.05.079%26sid%3Dliteratum%253Aachs%26aulast%3DDublanchet%26aufirst%3DA.%2BC.%26aulast%3DDucrot%26aufirst%3DP.%26aulast%3DAndrianjara%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Gara%26aufirst%3DM.%26aulast%3DMorales%26aufirst%3DR.%26aulast%3DComp%25C3%25A8re%26aufirst%3DD.%26aulast%3DDenis%26aufirst%3DA.%26aulast%3DBlais%26aufirst%3DS.%26aulast%3DCluzeau%26aufirst%3DP.%26aulast%3DCourt%25C3%25A9%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DMoreau%26aufirst%3DF.%26aulast%3DPrunet%26aufirst%3DM.%2BL.%26aulast%3DTertre%26aufirst%3DA.%26atitle%3DStructure-based%2520design%2520and%2520synthesis%2520of%2520novel%2520non-zinc%2520chelating%2520MMP-12%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D3787%26epage%3D3790%26doi%3D10.1016%2Fj.bmcl.2005.05.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajjar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broemstrup, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witko-Sarsat, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, N.</span></span> <span> </span><span class="NLM_article-title">Structures of human proteinase 3 and neutrophil elastase–so similar yet so different</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">2238</span>– <span class="NLM_lpage">2254</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2010.07659.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1742-4658.2010.07659.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20423453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtlakurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2010&pages=2238-2254&author=E.+Hajjarauthor=T.+Broemstrupauthor=C.+Kantariauthor=V.+Witko-Sarsatauthor=N.+Reuter&title=Structures+of+human+proteinase+3+and+neutrophil+elastase%E2%80%93so+similar+yet+so+different&doi=10.1111%2Fj.1742-4658.2010.07659.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human proteinase 3 and neutrophil elastase - so similar yet so different</span></div><div class="casAuthors">Hajjar, Eric; Broemstrup, Torben; Kantari, Chahrazade; Witko-Sarsat, Veronique; Reuter, Nathalie</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2238-2254</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Proteinase 3 and neutrophil elastase are serine proteinases of polymorphonuclear neutrophils, which are considered to have both similar localization and ligand specificity because of their high sequence similarity.  However, recent studies indicate that they might have different and yet complementary physiol. roles.  Specifically, proteinase 3 has intracellular specific protein substrates resulting in its involvement in the regulation of intracellular functions such as proliferation or apoptosis.  It behaves as a peripheral membrane protein and its membrane expression is a risk factor in chronic inflammatory diseases.  Moreover, in contrast to human neutrophil elastase, proteinase 3 is the preferred target antigen in Wegener's granulomatosis, a particular type of vasculitis.  Here, the authors review the structural basis for the different ligand specificities and membrane binding mechanisms of both enzymes, as well as the putative anti-neutrophil cytoplasm autoantibody epitopes on human neutrophil elastase 3.  The authors also address the differences existing between murine and human enzymes, and their consequences with respect to the development of animal models for the study of human proteinase 3-related pathologies.  By integrating the functional and the structural data, the authors assemble many pieces of a complicated puzzle to provide a new perspective on the structure-function relations of human proteinase 3 and its interaction with membrane, partner proteins or cleavable substrates.  Hence, precise and meticulous structural studies are essential tools for the rational design of specific proteinase 3 substrates or competitive ligands that modulate its activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK4_ZkL2JJXLVg90H21EOLACvtfcHk0lggfjP2pMgJKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtlakurY%253D&md5=c98feddf9fc134871fd8983e39375cf4</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2010.07659.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2010.07659.x%26sid%3Dliteratum%253Aachs%26aulast%3DHajjar%26aufirst%3DE.%26aulast%3DBroemstrup%26aufirst%3DT.%26aulast%3DKantari%26aufirst%3DC.%26aulast%3DWitko-Sarsat%26aufirst%3DV.%26aulast%3DReuter%26aufirst%3DN.%26atitle%3DStructures%2520of%2520human%2520proteinase%25203%2520and%2520neutrophil%2520elastase%25E2%2580%2593so%2520similar%2520yet%2520so%2520different%26jtitle%3DFEBS%2520J.%26date%3D2010%26volume%3D277%26spage%3D2238%26epage%3D2254%26doi%3D10.1111%2Fj.1742-4658.2010.07659.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Budnjo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narawane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grauffel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schillinger, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haug, B. E.</span></span> <span> </span><span class="NLM_article-title">Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9396</span>– <span class="NLM_lpage">9408</span>, <span class="refDoi"> DOI: 10.1021/jm500782s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500782s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9396-9408&author=A.+Budnjoauthor=S.+Narawaneauthor=C.+Grauffelauthor=A.+S.+Schillingerauthor=T.+Fossenauthor=N.+Reuterauthor=B.+E.+Haug&title=Reversible+ketomethylene-based+inhibitors+of+human+neutrophil+proteinase+3&doi=10.1021%2Fjm500782s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible Ketomethylene-Based Inhibitors of Human Neutrophil Proteinase 3</span></div><div class="casAuthors">Budnjo, Adnan; Narawane, Shailesh; Grauffel, Cedric; Schillinger, Anne-Sophie; Fossen, Torgils; Reuter, Nathalie; Haug, Bengt Erik</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9396-9408</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neutrophil serine proteases, proteinase 3 (PR3) and human neutrophil elastase (HNE), are considered as targets for chronic inflammatory diseases.  Despite sharing high sequence similarity, the two enzymes have different substrate specificities and functions.  While a plethora of HNE inhibitors exist, PR3 specific inhibitors are still in their infancy.  We have designed ketomethylene-based inhibitors for PR3 that show low micromolar IC50 values.  Their synthesis was made possible by amending a previously reported synthesis of ketomethylene dipeptide isosteres to allow for the prepn. of derivs. suitable for solid phase peptide synthesis.  The best inhibitor (Abz-VADnV[Ψ](COCH2)ADYQ-EDDnp) was found to be selective for PR3 over HNE and to display a competitive and reversible inhibition mechanism.  Mol. dynamics simulations show that the interactions between enzyme and ketomethylene-contg. inhibitors are similar to those with the corresponding substrates.  We also confirm that N- and C-terminal FRET groups are important for securing high inhibitory potency toward PR3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQQ0hqDoTShrVg90H21EOLACvtfcHk0lhh0vjjqc08Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGls7%252FL&md5=72379c3b173508e375d35baa86122639</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Fjm500782s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500782s%26sid%3Dliteratum%253Aachs%26aulast%3DBudnjo%26aufirst%3DA.%26aulast%3DNarawane%26aufirst%3DS.%26aulast%3DGrauffel%26aufirst%3DC.%26aulast%3DSchillinger%26aufirst%3DA.%2BS.%26aulast%3DFossen%26aufirst%3DT.%26aulast%3DReuter%26aufirst%3DN.%26aulast%3DHaug%26aufirst%3DB.%2BE.%26atitle%3DReversible%2520ketomethylene-based%2520inhibitors%2520of%2520human%2520neutrophil%2520proteinase%25203%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9396%26epage%3D9408%26doi%3D10.1021%2Fjm500782s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guarino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruba, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grzywa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyguda-Kazimierowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Łȩgowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoreński, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallet-Choisy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchand-Adam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kellenberger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenne, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sieńczyk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korkmaz, B.</span></span> <span> </span><span class="NLM_article-title">Exploiting the S4-S5 specificity of human neutrophil proteinase 3 to improve the potency of peptidyl di(chlorophenyl)-phosphonate ester inhibitors: a kinetic and molecular modeling analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1858</span>– <span class="NLM_lpage">1870</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01416</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01416" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCgsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1858-1870&author=C.+Guarinoauthor=N.+Grubaauthor=R.+Grzywaauthor=E.+Dyguda-Kazimierowiczauthor=Y.+Hamonauthor=M.+%C5%81%C8%A9gowskaauthor=M.+Skore%C5%84skiauthor=S.+Dallet-Choisyauthor=S.+Marchand-Adamauthor=C.+Kellenbergerauthor=D.+E.+Jenneauthor=M.+Sie%C5%84czykauthor=A.+Lesnerauthor=F.+Gauthierauthor=B.+Korkmaz&title=Exploiting+the+S4-S5+specificity+of+human+neutrophil+proteinase+3+to+improve+the+potency+of+peptidyl+di%28chlorophenyl%29-phosphonate+ester+inhibitors%3A+a+kinetic+and+molecular+modeling+analysis&doi=10.1021%2Facs.jmedchem.7b01416"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the S4-S5 Specificity of Human Neutrophil Proteinase 3 to Improve the Potency of Peptidyl Di(chlorophenyl)-phosphonate Ester Inhibitors: A Kinetic and Molecular Modeling Analysis</span></div><div class="casAuthors">Guarino, Carla; Gruba, Natalia; Grzywa, Renata; Dyguda-Kazimierowicz, Edyta; Hamon, Yveline; Legowska, Monika; Skorenski, Marcin; Dallet-Choisy, Sandrine; Marchand-Adam, Sylvain; Kellenberger, Christine; Jenne, Dieter E.; Sienczyk, Marcin; Lesner, Adam; Gauthier, Francis; Korkmaz, Brice</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1858-1870</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The neutrophilic serine protease proteinase 3 (PR3) is involved in inflammation and immune response and thus appears as a therapeutic target for a variety of infectious and inflammatory diseases.  Here we combined kinetic and mol. docking studies to increase the potency of peptidyl-diphenyl phosphonate PR3 inhibitors.  Occupancy of the S1 subsite of PR3 by a nVal residue and of the S4-S5 subsites by a biotinylated Val residue as obtained in biotin-VYDnVP(O-C6H4-4-Cl)2 enhanced the second-order inhibition const. k obs/[I] toward PR3 by more than 10 times (k obs/[I] = 73000 ± 5000 M-1 s-1) as compared to the best phosphonate PR3 inhibitor previously reported.  This inhibitor shows no significant inhibitory activity toward human neutrophil elastase and resists proteolytic degrdn. in sputa from cystic fibrosis patients.  It also inhibits macaque PR3 but not the PR3 from rodents and can thus be used for in vivo assays in a primate model of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriUBhR1OA7i7Vg90H21EOLACvtfcHk0lhh0vjjqc08Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCgsb0%253D&md5=1253f68919d227fb58edb495fa9c49c6</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01416%26sid%3Dliteratum%253Aachs%26aulast%3DGuarino%26aufirst%3DC.%26aulast%3DGruba%26aufirst%3DN.%26aulast%3DGrzywa%26aufirst%3DR.%26aulast%3DDyguda-Kazimierowicz%26aufirst%3DE.%26aulast%3DHamon%26aufirst%3DY.%26aulast%3D%25C5%2581%25C8%25A9gowska%26aufirst%3DM.%26aulast%3DSkore%25C5%2584ski%26aufirst%3DM.%26aulast%3DDallet-Choisy%26aufirst%3DS.%26aulast%3DMarchand-Adam%26aufirst%3DS.%26aulast%3DKellenberger%26aufirst%3DC.%26aulast%3DJenne%26aufirst%3DD.%2BE.%26aulast%3DSie%25C5%2584czyk%26aufirst%3DM.%26aulast%3DLesner%26aufirst%3DA.%26aulast%3DGauthier%26aufirst%3DF.%26aulast%3DKorkmaz%26aufirst%3DB.%26atitle%3DExploiting%2520the%2520S4-S5%2520specificity%2520of%2520human%2520neutrophil%2520proteinase%25203%2520to%2520improve%2520the%2520potency%2520of%2520peptidyl%2520di%2528chlorophenyl%2529-phosphonate%2520ester%2520inhibitors%253A%2520a%2520kinetic%2520and%2520molecular%2520modeling%2520analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1858%26epage%3D1870%26doi%3D10.1021%2Facs.jmedchem.7b01416" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alliston, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lushington, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span> <span> </span><span class="NLM_article-title">Utilization of the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold in the design of potential inhibitors of human neutrophil proteinase 3</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1102</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.12.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bmc.2009.12.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20061159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=1093-1102&author=D.+Douauthor=G.+Heauthor=Y.+Liauthor=Z.+Laiauthor=L.+Weiauthor=K.+R.+Allistonauthor=G.+H.+Lushingtonauthor=D.+M.+Eichhornauthor=W.+C.+Groutas&title=Utilization+of+the+1%2C2%2C3%2C5-thiatriazolidin-3-one+1%2C1-dioxide+scaffold+in+the+design+of+potential+inhibitors+of+human+neutrophil+proteinase+3&doi=10.1016%2Fj.bmc.2009.12.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Utilization of the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide scaffold in the design of potential inhibitors of human neutrophil proteinase 3</span></div><div class="casAuthors">Dou, Dengfeng; He, Guijia; Li, Yi; Lai, Zhong; Wei, Liuqing; Alliston, Kevin R.; Lushington, Gerald H.; Eichhorn, David M.; Groutas, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1093-1102</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The S' subsites of human neutrophil proteinase 3 (Pr 3) were probed by constructing diverse libraries of compds. based on the 1,2,3,5-thiatriazolidin-3-one 1,1-dioxide using combinational and click chem. methods.  The multiple points of diversity embodied in the heterocyclic scaffold render it well-suited to the exploration of the S' subsites of Pr 3.  Mol. modeling studies suggest that further exploration of the S' subsites of Pr 3 using the aforementioned heterocyclic scaffold may lead to the identification of highly selective, reversible competitive inhibitors of Pr 3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3ktbTJ8S5arVg90H21EOLACvtfcHk0lhh0vjjqc08Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGisrY%253D&md5=b951e7219c7308302c64e22e44ce4499</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.12.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.12.057%26sid%3Dliteratum%253Aachs%26aulast%3DDou%26aufirst%3DD.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DAlliston%26aufirst%3DK.%2BR.%26aulast%3DLushington%26aufirst%3DG.%2BH.%26aulast%3DEichhorn%26aufirst%3DD.%2BM.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26atitle%3DUtilization%2520of%2520the%25201%252C2%252C3%252C5-thiatriazolidin-3-one%25201%252C1-dioxide%2520scaffold%2520in%2520the%2520design%2520of%2520potential%2520inhibitors%2520of%2520human%2520neutrophil%2520proteinase%25203%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D1093%26epage%3D1102%26doi%3D10.1016%2Fj.bmc.2009.12.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bernardo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozinovski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlahos, R.</span></span> <span> </span><span class="NLM_article-title">Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">60</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2015.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pharmthera.2015.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26297673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlylsL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2015&pages=60-79&author=I.+Bernardoauthor=S.+Bozinovskiauthor=R.+Vlahos&title=Targeting+oxidant-dependent+mechanisms+for+the+treatment+of+COPD+and+its+comorbidities&doi=10.1016%2Fj.pharmthera.2015.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting oxidant-dependent mechanisms for the treatment of COPD and its comorbidities</span></div><div class="casAuthors">Bernardo, Ivan; Bozinovski, Steven; Vlahos, Ross</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">60-79</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is an incurable global health burden and is characterized by progressive airflow limitation and loss of lung function.  In addn. to the pulmonary impact of the disease, COPD patients often develop comorbid diseases such as cardiovascular disease, skeletal muscle wasting, lung cancer and osteoporosis.  One key feature of COPD, yet often underappreciated, is the contribution of oxidative stress in the onset and development of the disease.  Patients experience an increased burden of oxidative stress due to the combined effects of excess reactive oxygen species (ROS) and nitrogen species (RNS) generation, antioxidant depletion and reduced antioxidant enzyme activity.  Currently, there is a lack of effective treatments for COPD, and an even greater lack of research regarding interventions that treat both COPD and its comorbidities.  Due to the involvement of oxidative stress in the pathogenesis of COPD and many of its comorbidities, a unique therapeutic opportunity arises where the treatment of a multitude of diseases may be possible with only one therapeutic target.  In this review, oxidative stress and the roles of ROS/RNS in the context of COPD and comorbid cardiovascular disease, skeletal muscle wasting, lung cancer, and osteoporosis are discussed and the potential for therapeutic benefit of anti-oxidative treatment in these conditions is outlined.  Because of the unique interplay between oxidative stress and these diseases, oxidative stress represents a novel target for the treatment of COPD and its comorbidities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLiusRfdJwGLVg90H21EOLACvtfcHk0li5KeRBwLvERA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlylsL%252FN&md5=9cff79e8eb94f846d8ece7ff8e0c97af</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2015.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2015.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DBernardo%26aufirst%3DI.%26aulast%3DBozinovski%26aufirst%3DS.%26aulast%3DVlahos%26aufirst%3DR.%26atitle%3DTargeting%2520oxidant-dependent%2520mechanisms%2520for%2520the%2520treatment%2520of%2520COPD%2520and%2520its%2520comorbidities%26jtitle%3DPharmacol.%2520Ther.%26date%3D2015%26volume%3D155%26spage%3D60%26epage%3D79%26doi%3D10.1016%2Fj.pharmthera.2015.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sergakis, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koozehchian, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stimpfl, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Best, T. M.</span></span> <span> </span><span class="NLM_article-title">Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments</span>. <i>Am. J. Physiol. Lung Cell. Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">L205</span>– <span class="NLM_lpage">L218</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00330.2013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1152%2Fajplung.00330.2013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24879054" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2014&pages=L205-L218&author=L.+Zuoauthor=F.+Heauthor=G.+G.+Sergakisauthor=M.+S.+Koozehchianauthor=J.+N.+Stimpflauthor=Y.+Rongauthor=P.+T.+Diazauthor=T.+M.+Best&title=Interrelated+role+of+cigarette+smoking%2C+oxidative+stress%2C+and+immune+response+in+COPD+and+corresponding+treatments&doi=10.1152%2Fajplung.00330.2013"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00330.2013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00330.2013%26sid%3Dliteratum%253Aachs%26aulast%3DZuo%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DSergakis%26aufirst%3DG.%2BG.%26aulast%3DKoozehchian%26aufirst%3DM.%2BS.%26aulast%3DStimpfl%26aufirst%3DJ.%2BN.%26aulast%3DRong%26aufirst%3DY.%26aulast%3DDiaz%26aufirst%3DP.%2BT.%26aulast%3DBest%26aufirst%3DT.%2BM.%26atitle%3DInterrelated%2520role%2520of%2520cigarette%2520smoking%252C%2520oxidative%2520stress%252C%2520and%2520immune%2520response%2520in%2520COPD%2520and%2520corresponding%2520treatments%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell.%2520Mol.%2520Physiol.%26date%3D2014%26volume%3D307%26spage%3DL205%26epage%3DL218%26doi%3D10.1152%2Fajplung.00330.2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, F. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Q. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, N. S.</span></span> <span> </span><span class="NLM_article-title">PANTHEON study committee. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON study</span>. <i>COPD</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">164</span>– <span class="NLM_lpage">171</span>, <span class="refDoi"> DOI: 10.3109/15412555.2012.732628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.3109%2F15412555.2012.732628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23061828" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FkslyktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=164-171&author=J.+P.+Zhengauthor=F.+Q.+Wenauthor=C.+X.+Baiauthor=H.+Y.+Wanauthor=J.+Kangauthor=P.+Chenauthor=W.+Z.+Yaoauthor=L.+J.+Maauthor=Q.+K.+Xiaauthor=Y.+Gaoauthor=N.+S.+Zhong&title=PANTHEON+study+committee.+High-dose+N-acetylcysteine+in+the+prevention+of+COPD+exacerbations%3A+rationale+and+design+of+the+PANTHEON+study&doi=10.3109%2F15412555.2012.732628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study</span></div><div class="casAuthors">Zheng Jin-Ping; Wen Fu-Qiang; Bai Chun-Xue; Wan Huan-Ying; Kang Jian; Chen Ping; Yao Wan-Zhen; Ma Li-Jun; Xia Qi-Kui; Gao Yi; Zhong Nan-Shan</div><div class="citationInfo"><span class="NLM_cas:title">COPD</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">164-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation; from a pathophysiological point of view it involves many components, including mucus hypersecretion, oxidative stress and inflammation.  N-acetylcysteine (NAC) is a mucolytic agent with antioxidant and anti-inflammatory properties.  Long-term efficacy of NAC 600mg/d in COPD is controversial; a dose-effect relationship has been demonstrated, but at present it is not known whether a higher dose provides clinical benefits.  The PANTHEON Study is a prospective, ICS stratified, randomized, double-blind, placebo-controlled, parallel-group, multi-center trial designed to assess the efficacy and safety of high-dose (1200 mg/daily) NAC treatment for one year in moderate-to-severe COPD patients.  The primary endpoint is the annual exacerbation rate.  Secondary endpoints include recurrent exacerbations hazard ratio, time to first exacerbation, as well as quality of life and pulmonary function.  The hypothesis, design and methodology are described and baseline characteristics of recruited patients are presented. 1006 COPD patients (444 treated with maintenance ICS, 562 ICS naive, aged 66.27±8.76 yrs, average post-bronchodilator FEV1 48.95±11.80 of predicted) have been randomized at 34 hospitals in China.  Final results of this study will provide objective data on the effects of high-dose (1200 mg/daily) long-term NAC treatment in the prevention of COPD exacerbations and other outcome variables.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWKv4F72J5Deb6AVA-44PTfW6udTcc2eYZV9F6CMeil7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FkslyktA%253D%253D&md5=402e02791cdc668a779be893ba09eef1</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.3109%2F15412555.2012.732628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F15412555.2012.732628%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DJ.%2BP.%26aulast%3DWen%26aufirst%3DF.%2BQ.%26aulast%3DBai%26aufirst%3DC.%2BX.%26aulast%3DWan%26aufirst%3DH.%2BY.%26aulast%3DKang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DYao%26aufirst%3DW.%2BZ.%26aulast%3DMa%26aufirst%3DL.%2BJ.%26aulast%3DXia%26aufirst%3DQ.%2BK.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DN.%2BS.%26atitle%3DPANTHEON%2520study%2520committee.%2520High-dose%2520N-acetylcysteine%2520in%2520the%2520prevention%2520of%2520COPD%2520exacerbations%253A%2520rationale%2520and%2520design%2520of%2520the%2520PANTHEON%2520study%26jtitle%3DCOPD%26date%3D2013%26volume%3D10%26spage%3D164%26epage%3D171%26doi%3D10.3109%2F15412555.2012.732628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dal Negro, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedzicha, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iversen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontana, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicero, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calverley, P. M. A.</span></span>; <span class="NLM_contrib-group">RESTORE group; RESTORE study</span> <span> </span><span class="NLM_article-title">Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1700711</span>, <span class="refDoi"> DOI: 10.1183/13993003.00711-2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1183%2F13993003.00711-2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29025888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOqs77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2017&pages=1700711&author=R.+W.+Dal+Negroauthor=J.+A.+Wedzichaauthor=M.+Iversenauthor=G.+Fontanaauthor=C.+Pageauthor=A.+F.+Ciceroauthor=E.+Pozziauthor=P.+M.+A.+Calverleyauthor=RESTORE+group%3B+RESTORE+study&title=Effect+of+erdosteine+on+the+rate+and+duration+of+COPD+exacerbations%3A+the+RESTORE+study&doi=10.1183%2F13993003.00711-2017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study</span></div><div class="casAuthors">Dal Negro, Roberto W.; Wedzicha, Jadwiga A.; Iversen, Martin; Fontana, Giovanni; Page, Clive; Cicero, Arrigo F.; Pozzi, Edoardo; Calverley, Peter M. A.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1700711/1-1700711/10</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">1399-3003</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack data about the effect of such drugs on exacerbation duration.  The RESTORE (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD) study was a prospective randomised, double-blind, placebo-controlled study, enrolling patients aged 40̂aeuro"80 years with Global Initiative for Chronic Obstructive Lung Disease stage II/III.  Patients received erdosteine 300 mg twice daily or placebo added to usual COPD therapy for 12 mo.  The primary outcome was the no. of acute exacerbations during the study.  In the pre-specified intention-to-treat population of 445 patients (74% male; mean age 64.8 years, forced expiratory vol. in 1 s 51.8% predicted) erdosteine reduced the exacerbation rate by 19.4% (0.91 vs. 1.13 exacerbations·patient-1·year-11 for erdosteine and placebo, resp.; p=0.01), due to an effect on mild events; the redn. in the rate of mild exacerbations was 57.1% (0.23 vs. 0.54 exacerbations·patient-1·year-1 for erdosteine and placebo, resp.; p=0.002).  No significant difference was obsd. in the rate of moderate and severe exacerbations (0.68 vs. 0.59 exacerbations·patient-1·year-1 for erdosteine and placebo, resp.; p=0.054) despite a trend in favor of the comparison group.  Erdosteine decreased the exacerbation duration irresp. of event severity by 24.6% (9.55 vs. 12.63 days for erdosteine and placebo, resp.; p=0.023).  Erdosteine significantly improved subject and physician subjective severity scores ( p=0.022 and p=0.048, resp.), and reduced the use of reliever medication ( p>0.001), but did not affect the St George's Respiratory Questionnaire score or the time to first exacerbation.  In patients with COPD, erdosteine can reduce both the rate and duration of exacerbations.  The percentage of patients with adverse events was similar in both the placebo and erdosteine treatment groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMOfz4ayrHvbVg90H21EOLACvtfcHk0ljbwwdhzK6Ttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOqs77L&md5=4568dbddfeb048d7c33d4eb3d182d4ec</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1183%2F13993003.00711-2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F13993003.00711-2017%26sid%3Dliteratum%253Aachs%26aulast%3DDal%2BNegro%26aufirst%3DR.%2BW.%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26aulast%3DIversen%26aufirst%3DM.%26aulast%3DFontana%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DCicero%26aufirst%3DA.%2BF.%26aulast%3DPozzi%26aufirst%3DE.%26aulast%3DCalverley%26aufirst%3DP.%2BM.%2BA.%26aulast%3D%26atitle%3DEffect%2520of%2520erdosteine%2520on%2520the%2520rate%2520and%2520duration%2520of%2520COPD%2520exacerbations%253A%2520the%2520RESTORE%2520study%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2017%26volume%3D50%26spage%3D1700711%26doi%3D10.1183%2F13993003.00711-2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakabayashi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slocum, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoko, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span> <span> </span><span class="NLM_article-title">When NRF2 talks, who’s listening?</span>. <i>Antioxid. Redox Signaling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1649</span>– <span class="NLM_lpage">1663</span>, <span class="refDoi"> DOI: 10.1089/ars.2010.3216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1089%2Fars.2010.3216" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20367496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ltL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1649-1663&author=N.+Wakabayashiauthor=S.+L.+Slocumauthor=J.+J.+Skokoauthor=S.+Shinauthor=T.+W.+Kensler&title=When+NRF2+talks%2C+who%E2%80%99s+listening%3F&doi=10.1089%2Fars.2010.3216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">When NRF2 Talks, Who's Listening?</span></div><div class="casAuthors">Wakabayashi, Nobunao; Slocum, Stephen L.; Skoko, John J.; Shin, Soona; Kensler, Thomas W.</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1649-1663</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  Activation of the KEAP1-NRF2 signaling pathway is an adaptive response to environmental and endogenous stresses and serves to render animals resistant to chem. carcinogenesis and other forms of toxicity, whereas disruption of the pathway exacerbates these outcomes.  This pathway, which can be activated by sulfhydryl-reactive, small-mol. pharmacol. agents, regulates the inducible expression of an extended battery of cytoprotective genes, often by direct binding of the transcription factor to antioxidant response elements in the promoter regions of target genes.  However, it is becoming evident that some of the protective effects may be mediated indirectly through cross talk with addnl. pathways affecting cell survival and other aspects of cell fate.  These interactions provide a multi-tiered, integrated response to chem. stresses.  This review highlights recent observations on the mol. interactions and their functional consequences between NRF2 and the arylhydrocarbon receptor (AhR), NF-κB, p53, and Notch1 signaling pathways.  Antioxid. Redox Signal. 13, 1649-1663.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWKHQAx_wKmLVg90H21EOLACvtfcHk0ljbwwdhzK6Ttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ltL%252FJ&md5=86d2677f284fc1c881f6be885f1eac5c</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1089%2Fars.2010.3216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2010.3216%26sid%3Dliteratum%253Aachs%26aulast%3DWakabayashi%26aufirst%3DN.%26aulast%3DSlocum%26aufirst%3DS.%2BL.%26aulast%3DSkoko%26aufirst%3DJ.%2BJ.%26aulast%3DShin%26aufirst%3DS.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26atitle%3DWhen%2520NRF2%2520talks%252C%2520who%25E2%2580%2599s%2520listening%253F%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2010%26volume%3D13%26spage%3D1649%26epage%3D1663%26doi%3D10.1089%2Fars.2010.3216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mercado, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thimmulappa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chana, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2011.02.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bbrc.2011.02.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21320471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFKjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2011&pages=292-298&author=N.+Mercadoauthor=R.+Thimmulappaauthor=C.+M.+Thomasauthor=P.+S.+Fenwickauthor=K.+K.+Chanaauthor=L.+E.+Donnellyauthor=S.+Biswalauthor=K.+Itoauthor=P.+J.+Barnes&title=Decreased+histone+deacetylase+2+impairs+Nrf2+activation+by+oxidative+stress&doi=10.1016%2Fj.bbrc.2011.02.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress</span></div><div class="casAuthors">Mercado, Nicolas; Thimmulappa, Rajesh; Thomas, Catherine M. R.; Fenwick, Peter S.; Chana, Kirandeep K.; Donnelly, Louise E.; Biswal, Shyam; Ito, Kazuhiro; Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">292-298</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Nuclear factor erythroid 2-related factor 2 (Nrf2) plays a crucial role in cellular defense against oxidative stress by inducing the expression of multiple anti-oxidant genes.  However, where high levels of oxidative stress are obsd., such as chronic obstructive pulmonary disease (COPD), Nrf2 activity is reduced, although the mol. mechanism for this defect is uncertain.  Here, we show that down-regulation of histone deacetylase (HDAC) 2 causes Nrf2 instability, resulting in reduced antioxidant gene expression and increase sensitivity to oxidative stress.  Although Nrf2 protein was clearly stabilized after hydrogen peroxide (H2O2) stimulation in a bronchial epithelial cell line (BEAS2B), Nrf2 stability was decreased and Nrf2 acetylation increased in the presence of an HDAC inhibitor, trichostatin A (TSA).  TSA also reduced Nrf2-regulated heme-oxygenase-1 (HO-1) expression in these cells, and this was confirmed in acute cigarette-smoke exposed mice in vivo.  HDAC2 knock-down by RNA interference resulted in reduced H2O2-induced Nrf2 protein stability and activity in BEAS2B cells, whereas HDAC1 knockdown had no effect.  Furthermore, monocyte-derived macrophages obtained from healthy volunteers (non-smokers and smokers) and COPD patients showed a significant correlation between HDAC2 expression and Nrf2 expression (r = 0.92, p < 0.0001).  Thus, reduced HDAC2 activity in COPD may account for increased Nrf2 acetylation, reduced Nrf2 stability and impaired antioxidant defenses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhCb73e5Pa97Vg90H21EOLACvtfcHk0ljbwwdhzK6Ttg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFKjtL8%253D&md5=0b8be3847ba23c211040ba339e7b0f69</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2011.02.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2011.02.035%26sid%3Dliteratum%253Aachs%26aulast%3DMercado%26aufirst%3DN.%26aulast%3DThimmulappa%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DC.%2BM.%26aulast%3DFenwick%26aufirst%3DP.%2BS.%26aulast%3DChana%26aufirst%3DK.%2BK.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26aulast%3DBiswal%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DDecreased%2520histone%2520deacetylase%25202%2520impairs%2520Nrf2%2520activation%2520by%2520oxidative%2520stress%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2011%26volume%3D406%26spage%3D292%26epage%3D298%26doi%3D10.1016%2Fj.bbrc.2011.02.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wise, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holbrook, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sethi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayapudi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudini, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugar, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thimmulappa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talalay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahey, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenson, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span>; <span class="NLM_contrib-group">Broccoli Sprout Extract Trial Research Group</span> <span> </span><span class="NLM_article-title">Lack of effect of oral sulforaphane administration on Nrf2 expression in COPD: a randomized, double-blind, placebo controlled trial</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0163716</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0163716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1371%2Fjournal.pone.0163716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=27832073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitlWnur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0163716&author=R.+A.+Wiseauthor=J.+T.+Holbrookauthor=G.+Crinerauthor=S.+Sethiauthor=S.+Rayapudiauthor=K.+R.+Sudiniauthor=E.+A.+Sugarauthor=A.+Burkeauthor=R.+Thimmulappaauthor=A.+Singhauthor=P.+Talalayauthor=J.+W.+Faheyauthor=C.+S.+Berensonauthor=M.+R.+Jacobsauthor=S.+Biswalauthor=Broccoli+Sprout+Extract+Trial+Research+Group&title=Lack+of+effect+of+oral+sulforaphane+administration+on+Nrf2+expression+in+COPD%3A+a+randomized%2C+double-blind%2C+placebo+controlled+trial&doi=10.1371%2Fjournal.pone.0163716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Lack of effect of oral sulforaphane administration on Nrf2 expression in COPD: a randomized, double-blind, placebo controlled trial</span></div><div class="casAuthors">Wise, Robert A.; Holbrook, Janet T.; Criner, Gerard; Sethi, Sanjay; Rayapudi, Sobharani; Sudini, Kuladeep R.; Sugar, Elizabeth A.; Burke, Alyce; Thimmulappa, Rajesh; Singh, Anju; Talalay, Paul; Fahey, Jed W.; Berenson, Charles S.; Jacobs, Michael R.; Biswal, Shyam; Leatherman, Gwen; Daniel, Marie; Marchetti, Nathaniel; Kim, Victor; Shenoy, Kartik; Smith, Heidi; Rosario, Maria; Bolla, Sudheer; Mandapati, Chenna; Eberhardt, Ellana; Kruzel, Ragina; Kumar, Sarvesh; Noel, Sanjeev; Amend-Libercci, Debra; Ewing, Cathy; Hart, Adante; Lears, Andrea; Nowakowski, Deborah; Shade, David; Yasin, Razan; Brown, Ellen; Wang, Lucy; O'Connor, George; Strange, Charlie; Wendt, Christine; Punturieri, Anthony; Viviano, Lisa Weber</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e0163716/1-e0163716/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background COPD patients have high pulmonary and systemic oxidative stress that correlates with severity of disease.  Sulforaphane has been shown to induce expression of antioxidant genes via activation of a transcription factor, nuclear factor erythroid-2 related factor 2 (Nrf2).  Methods This parallel, placebo-controlled, phase 2, randomized trial was conducted at three US academic medical centers.  Patients who met GOLD criteria for COPD and were able to tolerate bronchoscopies were randomly assigned (1:1:1) to receive placebo, 25 μmoles, or 150 μmoles sulforaphane daily by mouth for four weeks.  The primary outcomes were changes in Nrf2 target gene expression (NQ01, HO1, AKR1C1 and AKR1C3) in alveolar macrophages and bronchial epithelial cells.  Secondary outcomes included measures of oxidative stress and airway inflammation, and pulmonary function tests.  Results Between July 2011 and May 2013, 89 patients were enrolled and randomized.  Sulforaphane was absorbed in the patients as evident from their plasma metabolite levels.  Changes in Nrf2 target gene expression relative to baseline ranged from 0.79 to 1.45 and there was no consistent pattern among the three groups; the changes were not statistically significantly different from baseline.  Changes in measures of inflammation and pulmonary function tests were not different among the groups.  Sulforaphane was well tolerated at both dose levels.  Conclusion Sulforaphane administered for four weeks at doses of 25 μmoles and 150 μmoles to patients with COPD did not stimulate the expression of Nrf2 target genes or have an effect on levels of other anti-oxidants or markers of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgs8FbgXmo9rVg90H21EOLACvtfcHk0liQ3UailomyiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitlWnur0%253D&md5=d40f0614bb7da8ec2cb1b3db5169ee37</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0163716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0163716%26sid%3Dliteratum%253Aachs%26aulast%3DWise%26aufirst%3DR.%2BA.%26aulast%3DHolbrook%26aufirst%3DJ.%2BT.%26aulast%3DCriner%26aufirst%3DG.%26aulast%3DSethi%26aufirst%3DS.%26aulast%3DRayapudi%26aufirst%3DS.%26aulast%3DSudini%26aufirst%3DK.%2BR.%26aulast%3DSugar%26aufirst%3DE.%2BA.%26aulast%3DBurke%26aufirst%3DA.%26aulast%3DThimmulappa%26aufirst%3DR.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DTalalay%26aufirst%3DP.%26aulast%3DFahey%26aufirst%3DJ.%2BW.%26aulast%3DBerenson%26aufirst%3DC.%2BS.%26aulast%3DJacobs%26aufirst%3DM.%2BR.%26aulast%3DBiswal%26aufirst%3DS.%26aulast%3D%26atitle%3DLack%2520of%2520effect%2520of%2520oral%2520sulforaphane%2520administration%2520on%2520Nrf2%2520expression%2520in%2520COPD%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo%2520controlled%2520trial%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0163716%26doi%3D10.1371%2Fjournal.pone.0163716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sussan, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rangasamy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blake, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Haddad, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedja, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kombairaju, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liby, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sporn, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabrielson, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Champion, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuder, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kensler, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1073/pnas.0804333106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1073%2Fpnas.0804333106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19104057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXltF2kuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=250-255&author=T.+E.+Sussanauthor=T.+Rangasamyauthor=D.+J.+Blakeauthor=D.+Malhotraauthor=H.+El-Haddadauthor=D.+Bedjaauthor=M.+S.+Yatesauthor=P.+Kombairajuauthor=M.+Yamamotoauthor=K.+T.+Libyauthor=M.+B.+Spornauthor=K.+L.+Gabrielsonauthor=H.+C.+Championauthor=R.+M.+Tuderauthor=T.+W.+Kenslerauthor=S.+Biswal&title=Targeting+Nrf2+with+the+triterpenoid+CDDO-imidazolide+attenuates+cigarette+smoke-induced+emphysema+and+cardiac+dysfunction+in+mice&doi=10.1073%2Fpnas.0804333106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice</span></div><div class="casAuthors">Sussan, Thomas E.; Rangasamy, Tirumalai; Blake, David J.; Malhotra, Deepti; El-Haddad, Hazim; Bedja, Djahida; Yates, Melinda S.; Kombairaju, Ponvijay; Yamamoto, Masayuki; Liby, Karen T.; Sporn, Michael B.; Gabrielson, Kathleen L.; Champion, Hunter C.; Tuder, Rubin M.; Kensler, Thomas W.; Biswal, Shyam</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250-255</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD), which comprises emphysema and chronic bronchitis resulting from prolonged exposure to cigarette smoke (CS), is a major public health burden with no effective treatment.  Emphysema is also assocd. with pulmonary hypertension, which can progress to right ventricular failure, an important cause of morbidity and mortality among patients with COPD.  Nuclear erythroid 2 p45 related factor-2 (Nrf2) is a redox-sensitive transcription factor that up-regulates a battery of antioxidative genes and cytoprotective enzymes that constitute the defense against oxidative stress.  Recently, it has been shown that patients with advanced COPD have a decline in expression of the Nrf2 pathway in lungs, suggesting that loss of this antioxidative protective response is a key factor in the pathophysiol. progression of emphysema.  Furthermore, genetic disruption of Nrf2 in mice causes early-onset and severe emphysema.  The present study evaluated whether the strategy of activation of Nrf2 and its downstream network of cytoprotective genes with a small mol. would attenuate CS-induced oxidative stress and emphysema.  Nrf2+/+ and Nrf2-/- mice were fed a diet contg. the potent Nrf2 activator, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im), while being exposed to CS for 6 mo.  CDDO-Im significantly reduced lung oxidative stress, alveolar cell apoptosis, alveolar destruction, and pulmonary hypertension in Nrf2+/+ mice caused by chronic exposure to CS.  This protection from CS-induced emphysema depended on Nrf2, as Nrf2-/- mice failed to show significant redn. in alveolar cell apoptosis and alveolar destruction after treatment with CDDO-lm.  These results suggest that targeting the Nrf2 pathway during the etiopathogenesis of emphysema may represent an important approach for prophylaxis against COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqH3swF6L7GbVg90H21EOLACvtfcHk0liQ3UailomyiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXltF2kuw%253D%253D&md5=0358617e58e2eb22a74dd008f0d3f116</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0804333106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0804333106%26sid%3Dliteratum%253Aachs%26aulast%3DSussan%26aufirst%3DT.%2BE.%26aulast%3DRangasamy%26aufirst%3DT.%26aulast%3DBlake%26aufirst%3DD.%2BJ.%26aulast%3DMalhotra%26aufirst%3DD.%26aulast%3DEl-Haddad%26aufirst%3DH.%26aulast%3DBedja%26aufirst%3DD.%26aulast%3DYates%26aufirst%3DM.%2BS.%26aulast%3DKombairaju%26aufirst%3DP.%26aulast%3DYamamoto%26aufirst%3DM.%26aulast%3DLiby%26aufirst%3DK.%2BT.%26aulast%3DSporn%26aufirst%3DM.%2BB.%26aulast%3DGabrielson%26aufirst%3DK.%2BL.%26aulast%3DChampion%26aufirst%3DH.%2BC.%26aulast%3DTuder%26aufirst%3DR.%2BM.%26aulast%3DKensler%26aufirst%3DT.%2BW.%26aulast%3DBiswal%26aufirst%3DS.%26atitle%3DTargeting%2520Nrf2%2520with%2520the%2520triterpenoid%2520CDDO-imidazolide%2520attenuates%2520cigarette%2520smoke-induced%2520emphysema%2520and%2520cardiac%2520dysfunction%2520in%2520mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2009%26volume%3D106%26spage%3D250%26epage%3D255%26doi%3D10.1073%2Fpnas.0804333106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thimmulappa, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parmar, V. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, S. V.</span></span> <span> </span><span class="NLM_article-title">Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4147</span>– <span class="NLM_lpage">4159</span>, <span class="refDoi"> DOI: 10.1021/jm2002348</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2002348" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlWrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4147-4159&author=V.+Kumarauthor=S.+Kumarauthor=M.+Hassanauthor=H.+Wuauthor=R.+K.+Thimmulappaauthor=A.+Kumarauthor=S.+K.+Sharmaauthor=V.+S.+Parmarauthor=S.+Biswalauthor=S.+V.+Malhotra&title=Novel+chalcone+derivatives+as+potent+Nrf2+activators+in+mice+and+human+lung+epithelial+cells&doi=10.1021%2Fjm2002348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Chalcone Derivatives as Potent Nrf2 Activators in Mice and Human Lung Epithelial Cells</span></div><div class="casAuthors">Kumar, Vineet; Kumar, Sarvesh; Hassan, Mohammad; Wu, Hailong; Thimmulappa, Rajesh K.; Kumar, Amit; Sharma, Sunil K.; Parmar, Virinder S.; Biswal, Shyam; Malhotra, Sanjay V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4147-4159</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Nrf2-mediated activation of antioxidant response element is a central part of mol. mechanisms governing the protective function of phase II detoxification and antioxidant enzymes against carcinogenesis, oxidative stress, and inflammation.  Nrf2 is sequestered in the cytoplasm by its repressor, Keap1.  We have designed and synthesized novel chalcone derivs. as Nrf2 activators.  The potency of these compds. was measured by the expression of Nrf2 dependent antioxidant genes GCLM, NQO1, and HO1 in human lung epithelial cells, while the cytotoxicity was analyzed using MTT assay.  In vivo potency of identified lead compds. to activate Nrf2 was evaluated using a mouse model.  Our studies showed 2-trifluoromethyl-2'-methoxychalone (2b) to be a potent activator of Nrf2, both in vitro and in mice.  Addnl. expts. showed that the activation of Nrf2 by this compd. is independent of reactive oxygen species or redox changes.  We have discussed a quant. structure-activity relationship and proposed a possible mechanism of Nrf2 activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouqD-6d2SPCLVg90H21EOLACvtfcHk0liQ3UailomyiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlWrsb0%253D&md5=8a6b7ab0af403bc3d0b2c52f7fcf84cd</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Fjm2002348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2002348%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DV.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DHassan%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DThimmulappa%26aufirst%3DR.%2BK.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BK.%26aulast%3DParmar%26aufirst%3DV.%2BS.%26aulast%3DBiswal%26aufirst%3DS.%26aulast%3DMalhotra%26aufirst%3DS.%2BV.%26atitle%3DNovel%2520chalcone%2520derivatives%2520as%2520potent%2520Nrf2%2520activators%2520in%2520mice%2520and%2520human%2520lung%2520epithelial%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4147%26epage%3D4159%26doi%3D10.1021%2Fjm2002348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q. D.</span></span> <span> </span><span class="NLM_article-title">Discovery and development of kelch-like ECH-associated protein 1. nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction inhibitors: achievements, challenges, and future directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10837</span>– <span class="NLM_lpage">10858</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00586</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00586" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1Smtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10837-10858&author=Z.+Y.+Jiangauthor=M.+C.+Luauthor=Q.+D.+You&title=Discovery+and+development+of+kelch-like+ECH-associated+protein+1.+nuclear+factor+erythroid+2-related+factor+2+%28KEAP1%3ANRF2%29+protein-protein+interaction+inhibitors%3A+achievements%2C+challenges%2C+and+future+directions&doi=10.1021%2Facs.jmedchem.6b00586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Development of Kelch-like ECH-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions</span></div><div class="casAuthors">Jiang, Zheng-Yu; Lu, Meng-Chen; You, Qi-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10837-10858</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The transcription factor Nrf2 is the primary regulator of the cellular defense system, and enhancing Nrf2 activity has potential usages in various diseases, esp. chronic age-related and inflammatory diseases.  Recently, directly targeting Keap1-Nrf2 protein-protein interaction (PPI) has been an emerging strategy to selectively and effectively activate Nrf2.  This Perspective summarizes the progress in the discovery and development of Keap1-Nrf2 PPI inhibitors, including the Keap1-Nrf2 regulatory mechanisms, biochem. techniques for inhibitor identification, and approaches for identifying peptide and small-mol. inhibitors, as well as discusses privileged structures and future directions for further development of Keap1-Nrf2 PPI inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCuMv4k9xi9LVg90H21EOLACvtfcHk0litvfyxyq6Wbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1Smtb%252FO&md5=487aa677ae8a86d71e2b15561656b0b7</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00586%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DLu%26aufirst%3DM.%2BC.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26atitle%3DDiscovery%2520and%2520development%2520of%2520kelch-like%2520ECH-associated%2520protein%25201.%2520nuclear%2520factor%2520erythroid%25202-related%2520factor%25202%2520%2528KEAP1%253ANRF2%2529%2520protein-protein%2520interaction%2520inhibitors%253A%2520achievements%252C%2520challenges%252C%2520and%2520future%2520directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10837%26epage%3D10858%26doi%3D10.1021%2Facs.jmedchem.6b00586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itoh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of the negative regulator of Nrf2, Keap1: a historical overview</span>. <i>Antioxid. Redox Signaling</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1665</span>– <span class="NLM_lpage">1678</span>, <span class="refDoi"> DOI: 10.1089/ars.2010.3222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1089%2Fars.2010.3222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20446768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2010&pages=1665-1678&author=K.+Itohauthor=J.+Mimuraauthor=M.+Yamamoto&title=Discovery+of+the+negative+regulator+of+Nrf2%2C+Keap1%3A+a+historical+overview&doi=10.1089%2Fars.2010.3222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the negative regulator of Nrf2, Keap1: A historical overview</span></div><div class="casAuthors">Itoh, Ken; Mimura, Junsei; Yamamoto, Masayuki</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1665-1678</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">A review.  An antioxidant response element (ARE) or an electrophile responsive element (EpRE) regulate the transcriptional induction of a battery of drug-detoxifying enzymes that are protective against electrophiles.  Based on the high similarity of the ARE consensus sequence to an erythroid gene regulatory element NF-E2 binding site, the authors have found that transcription factor Nrf2 is indispensable for the ARE-mediated induction of drug-metabolizing enzymes.  Recent genome-wide anal. demonstrated that Nrf2 regulates hundreds of genes that are involved in the cytoprotective response against oxidative stress.  In-depth anal. of Nrf2 regulatory mechanisms led the authors to the discovery of a novel protein, which they designated Keap1.  Keap1 suppresses Nrf2 activity by specifically binding to its evolutionarily conserved N-terminal Neh2 regulatory domain.  Here, the authors summarize findings and observations that have lead to the discovery of the Nrf2-Keap1 system.  Furthermore, the authors briefly discuss the function of the Nrf2-Keap1 system under the regulation of the endogenous electrophilic compd., 15-deoxy-Δ12,14-prostaglandin J2.  The authors propose that Nrf2-Keap1 plays a significant physiol. role in the response to endogenous, environmental, and pharmacol. electrophiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYEEgix9Qpi7Vg90H21EOLACvtfcHk0litvfyxyq6Wbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ltL%252FK&md5=2c3e700515df4eb5bb8414c8d69bfc9f</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1089%2Fars.2010.3222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2010.3222%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DK.%26aulast%3DMimura%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520the%2520negative%2520regulator%2520of%2520Nrf2%252C%2520Keap1%253A%2520a%2520historical%2520overview%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2010%26volume%3D13%26spage%3D1665%26epage%3D1678%26doi%3D10.1089%2Fars.2010.3222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wixted, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffiths-Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hearn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMenamin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rich, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saxty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willems, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolford, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottom, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonchuk, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldser, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognese, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podolin, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heightman, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, J. K.</span></span> <span> </span><span class="NLM_article-title">Monoacidic inhibitors of the kelch-like ECH-associated protein 1: nuclear factor eythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">4006</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00228</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00228" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlt1Gjtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3991-4006&author=T.+G.+Daviesauthor=W.+E.+Wixtedauthor=J.+E.+Coyleauthor=C.+Griffiths-Jonesauthor=K.+Hearnauthor=R.+McMenaminauthor=D.+Nortonauthor=S.+J.+Richauthor=C.+Richardsonauthor=G.+Saxtyauthor=H.+M.+Willemsauthor=A.+J.+Woolfordauthor=J.+E.+Cottomauthor=J.+P.+Kouauthor=J.+G.+Yonchukauthor=H.+G.+Feldserauthor=Y.+Sanchezauthor=J.+P.+Foleyauthor=B.+J.+Bologneseauthor=G.+Loganauthor=P.+L.+Podolinauthor=H.+Yanauthor=J.+F.+Callahanauthor=T.+D.+Heightmanauthor=J.+K.+Kerns&title=Monoacidic+inhibitors+of+the+kelch-like+ECH-associated+protein+1%3A+nuclear+factor+eythroid+2-related+factor+2+%28KEAP1%3ANRF2%29+protein-protein+interaction+with+high+cell+potency+identified+by+fragment-based+discovery&doi=10.1021%2Facs.jmedchem.6b00228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery</span></div><div class="casAuthors">Davies, Thomas G.; Wixted, William E.; Coyle, Joseph E.; Griffiths-Jones, Charlotte; Hearn, Keisha; McMenamin, Rachel; Norton, David; Rich, Sharna J.; Richardson, Caroline; Saxty, Gordon; Willems, Henriette M. G.; Woolford, Alison J.-A.; Cottom, Joshua E.; Kou, Jen-Pyng; Yonchuk, John G.; Feldser, Heidi G.; Sanchez, Yolanda; Foley, Joseph P.; Bolognese, Brian J.; Logan, Gregory; Podolin, Patricia L.; Yan, Hongxing; Callahan, James F.; Heightman, Tom D.; Kerns, Jeffrey K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3991-4006</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">KEAP1 is the key regulator of the NRF2-mediated cytoprotective response, and increasingly recognized as a target for diseases involving oxidative stress.  Pharmacol. intervention has focused on mols. that decrease NRF2-ubiquitination through covalent modification of KEAP1 cysteine residues, but such electrophilic compds. lack selectivity and may be assocd. with off-target toxicity.  We report here the first use of a fragment-based approach to directly target the KEAP1 Kelch-NRF2 interaction.  X-ray crystallog. screening identified three distinct "hot-spots" for fragment binding within the NRF2 binding pocket of KEAP1, allowing progression of a weak fragment hit to mols. with nanomolar affinity for KEAP1 while maintaining drug-like properties.  This work resulted in a promising lead compd. (I) which exhibits tight and selective binding to KEAP1, and activates the NRF2 antioxidant response in cellular and in vivo models, thereby providing a high quality chem. probe to explore the therapeutic potential of disrupting the KEAP1-NRF2 interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq-gfBTuYreLVg90H21EOLACvtfcHk0lit2B4rnp6p4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlt1Gjtr0%253D&md5=ae42cc9f06d14b340cb3a8f5d6c157a7</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00228%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DT.%2BG.%26aulast%3DWixted%26aufirst%3DW.%2BE.%26aulast%3DCoyle%26aufirst%3DJ.%2BE.%26aulast%3DGriffiths-Jones%26aufirst%3DC.%26aulast%3DHearn%26aufirst%3DK.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DNorton%26aufirst%3DD.%26aulast%3DRich%26aufirst%3DS.%2BJ.%26aulast%3DRichardson%26aufirst%3DC.%26aulast%3DSaxty%26aufirst%3DG.%26aulast%3DWillems%26aufirst%3DH.%2BM.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%26aulast%3DCottom%26aufirst%3DJ.%2BE.%26aulast%3DKou%26aufirst%3DJ.%2BP.%26aulast%3DYonchuk%26aufirst%3DJ.%2BG.%26aulast%3DFeldser%26aufirst%3DH.%2BG.%26aulast%3DSanchez%26aufirst%3DY.%26aulast%3DFoley%26aufirst%3DJ.%2BP.%26aulast%3DBolognese%26aufirst%3DB.%2BJ.%26aulast%3DLogan%26aufirst%3DG.%26aulast%3DPodolin%26aufirst%3DP.%2BL.%26aulast%3DYan%26aufirst%3DH.%26aulast%3DCallahan%26aufirst%3DJ.%2BF.%26aulast%3DHeightman%26aufirst%3DT.%2BD.%26aulast%3DKerns%26aufirst%3DJ.%2BK.%26atitle%3DMonoacidic%2520inhibitors%2520of%2520the%2520kelch-like%2520ECH-associated%2520protein%25201%253A%2520nuclear%2520factor%2520eythroid%25202-related%2520factor%25202%2520%2528KEAP1%253ANRF2%2529%2520protein-protein%2520interaction%2520with%2520high%2520cell%2520potency%2520identified%2520by%2520fragment-based%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3991%26epage%3D4006%26doi%3D10.1021%2Facs.jmedchem.6b00228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q. D.</span></span> <span> </span><span class="NLM_article-title">Structure-activity and structure-property relationship and exploratory in vivo evaluation of the nanomolar keap1-nrf2 protein-protein interaction inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6410</span>– <span class="NLM_lpage">6421</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht12ksb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6410-6421&author=Z.+Y.+Jiangauthor=L.+L.+Xuauthor=M.+C.+Luauthor=Z.+Y.+Chenauthor=Z.+W.+Yuanauthor=X.+L.+Xuauthor=X.+K.+Guoauthor=X.+J.+Zhangauthor=H.+P.+Sunauthor=Q.+D.+You&title=Structure-activity+and+structure-property+relationship+and+exploratory+in+vivo+evaluation+of+the+nanomolar+keap1-nrf2+protein-protein+interaction+inhibitor&doi=10.1021%2Facs.jmedchem.5b00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor</span></div><div class="casAuthors">Jiang, Zheng-Yu; Xu, Li-Li; Lu, Meng-Chen; Chen, Zhi-Yun; Yuan, Zhen-Wei; Xu, Xiao-Li; Guo, Xiao-Ke; Zhang, Xiao-Jin; Sun, Hao-Peng; You, Qi-Dong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6410-6421</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Directly disrupting the Keap1-Nrf2 protein-protein interaction (PPI) is an effective way to activate Nrf2.  Using the potent Keap1-Nrf2 PPI inhibitor that was reported by our group, we conducted a preliminary investigation of the structure-activity and structure-property relationships of the ring systems to improve the drug-like properties.  Compd. 18e (I), which bore p-acetamido substituents on the side chain Ph rings, was the best choice for balancing PPI inhibition activity, physicochem. properties, and cellular Nrf2 activity.  Cell-based expts. with 18e showed that the Keap1-Nrf2 PPI inhibitor can activate Nrf2 and induce the expression of Nrf2 downstream proteins in an Nrf2-dependent manner.  An exploratory in vivo expt. was carried out to further evaluate the anti-inflammatory effects of 18e in a LPS-challenged mouse model.  The primary results indicated that 18e could reduce the level of circulating pro-inflammatory cytokines induced by LPS and relieve the inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzcdu5HL_rp7Vg90H21EOLACvtfcHk0lit2B4rnp6p4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht12ksb7N&md5=458f0a612c34156a137759d99b741e3a</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00185%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DZ.%2BY.%26aulast%3DXu%26aufirst%3DL.%2BL.%26aulast%3DLu%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DZ.%2BY.%26aulast%3DYuan%26aufirst%3DZ.%2BW.%26aulast%3DXu%26aufirst%3DX.%2BL.%26aulast%3DGuo%26aufirst%3DX.%2BK.%26aulast%3DZhang%26aufirst%3DX.%2BJ.%26aulast%3DSun%26aufirst%3DH.%2BP.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26atitle%3DStructure-activity%2520and%2520structure-property%2520relationship%2520and%2520exploratory%2520in%2520vivo%2520evaluation%2520of%2520the%2520nanomolar%2520keap1-nrf2%2520protein-protein%2520interaction%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6410%26epage%3D6421%26doi%3D10.1021%2Facs.jmedchem.5b00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cifuentes-Pagano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Csanyi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagano, P. J.</span></span> <span> </span><span class="NLM_article-title">NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2315</span>– <span class="NLM_lpage">2325</span>, <span class="refDoi"> DOI: 10.1007/s00018-012-1009-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs00018-012-1009-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22585059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XptlWhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=2315-2325&author=E.+Cifuentes-Paganoauthor=G.+Csanyiauthor=P.+J.+Pagano&title=NADPH+oxidase+inhibitors%3A+a+decade+of+discovery+from+Nox2ds+to+HTS&doi=10.1007%2Fs00018-012-1009-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS</span></div><div class="casAuthors">Cifuentes-Pagano, Eugenia; Csanyi, Gabor; Pagano, Patrick J.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2315-2325</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  NADPH oxidases (Nox) are established as major sources of reactive oxygen species (ROS).  Over the past two decades, Nox-derived ROS have emerged as pivotal in the development of myriad diseases involving oxidative stress.  In contrast, Nox are also involved in signaling mechanisms necessary for normal cell function.  The study of these enzymes in physiol. and pathophysiol. conditions is made considerably more complex by the discovery of 7 isoforms: Nox1 through 5 as well as Duox1 and 2, each with its own specific cytosolic components, regulatory control mechanisms, subcellular localization and/or tissue distribution.  A clear understanding of the role individual isoforms play in a given system is hindered by the lack of isoform-specific inhibitors.  In animal models, knockdown or knockout methodologies are providing definitive answers to perplexing questions of the complex interplay of multiple Nox isoforms in cell and tissue signaling.  However, the complex structures and interactions of these heteromeric isoenzymes predict pleiotropic actions of the Nox subunits and thus suppression of these proteins is almost certain to have untoward effects.  Thus, as both therapies and pharmacol. tools, mol.-based inhibitors continue to prove extremely useful and rational in design.  Unfortunately, many of the available inhibitors have proven non-specific, falling into the category of scavengers or inhibitors of more than one source of ROS.  Here, we will review some of the efforts that have been undertaken to develop specific inhibitors of NADPH oxidase over the past decade, from the peptidic inhibitor Nox2ds-tat to more recent small mol. inhibitors that have emerged from high-throughput screening campaigns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplbm_6Ei6UqrVg90H21EOLACvtfcHk0lit2B4rnp6p4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptlWhtLw%253D&md5=3eea0331d80eec7d9aa53d93418dda70</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1007%2Fs00018-012-1009-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-012-1009-2%26sid%3Dliteratum%253Aachs%26aulast%3DCifuentes-Pagano%26aufirst%3DE.%26aulast%3DCsanyi%26aufirst%3DG.%26aulast%3DPagano%26aufirst%3DP.%2BJ.%26atitle%3DNADPH%2520oxidase%2520inhibitors%253A%2520a%2520decade%2520of%2520discovery%2520from%2520Nox2ds%2520to%2520HTS%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26spage%3D2315%26epage%3D2325%26doi%3D10.1007%2Fs00018-012-1009-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagirdar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luckhardt, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennathur, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thannickal, V. J.</span></span> <span> </span><span class="NLM_article-title">NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1077</span>– <span class="NLM_lpage">1081</span>, <span class="refDoi"> DOI: 10.1038/nm.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnm.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19701206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVersbjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=1077-1081&author=L.+Heckerauthor=R.+Vittalauthor=T.+Jonesauthor=R.+Jagirdarauthor=T.+R.+Luckhardtauthor=J.+C.+Horowitzauthor=S.+Pennathurauthor=F.+J.+Martinezauthor=V.+J.+Thannickal&title=NADPH+oxidase-4+mediates+myofibroblast+activation+and+fibrogenic+responses+to+lung+injury&doi=10.1038%2Fnm.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury</span></div><div class="casAuthors">Hecker, Louise; Vittal, Ragini; Jones, Tamara; Jagirdar, Rajesh; Luckhardt, Tracy R.; Horowitz, Jeffrey C.; Pennathur, Subramaniam; Martinez, Fernando J.; Thannickal, Victor J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1077-1081</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Members of the NADPH oxidase (NOX) family of enzymes, which catalyze the redn. of O2 to reactive oxygen species, have increased in no. during eukaryotic evolution.  Seven isoforms of the NOX gene family have been identified in mammals; however, specific roles of NOX enzymes in mammalian physiol. and pathophysiol. have not been fully elucidated.  The best established physiol. role of NOX enzymes is in host defense against pathogen invasion in diverse species, including plants.  The prototypical member of this family, NOX-2 (gp91phox), is expressed in phagocytic cells and mediates microbicidal activities.  Here we report a role for the NOX4 isoform in tissue repair functions of myofibroblasts and fibrogenesis.  Transforming growth factor-β1 (TGF-β1) induces NOX-4 expression in lung mesenchymal cells via SMAD-3, a receptor-regulated protein that modulates gene transcription.  NOX-4-dependent generation of hydrogen peroxide (H2O2) is required for TGF-β1-induced myofibroblast differentiation, extracellular matrix (ECM) prodn. and contractility.  NOX-4 is upregulated in lungs of mice subjected to noninfectious injury and in cases of human idiopathic pulmonary fibrosis (IPF).  Genetic or pharmacol. targeting of NOX-4 abrogates fibrogenesis in two murine models of lung injury.  These studies support a function for NOX4 in tissue fibrogenesis and provide proof of concept for therapeutic targeting of NOX-4 in recalcitrant fibrotic disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmporyhulB_bVg90H21EOLACvtfcHk0liXcsWwlnrJVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVersbjM&md5=7b7eaee1597ce9e91807879f5d0f7f1d</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1038%2Fnm.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2005%26sid%3Dliteratum%253Aachs%26aulast%3DHecker%26aufirst%3DL.%26aulast%3DVittal%26aufirst%3DR.%26aulast%3DJones%26aufirst%3DT.%26aulast%3DJagirdar%26aufirst%3DR.%26aulast%3DLuckhardt%26aufirst%3DT.%2BR.%26aulast%3DHorowitz%26aufirst%3DJ.%2BC.%26aulast%3DPennathur%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DThannickal%26aufirst%3DV.%2BJ.%26atitle%3DNADPH%2520oxidase-4%2520mediates%2520myofibroblast%2520activation%2520and%2520fibrogenic%2520responses%2520to%2520lung%2520injury%26jtitle%3DNat.%2520Med.%26date%3D2009%26volume%3D15%26spage%3D1077%26epage%3D1081%26doi%3D10.1038%2Fnm.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stielow, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catar, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wingler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheurer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morawietz, H.</span></span> <span> </span><span class="NLM_article-title">Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>344</i></span>,  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">205</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2006.03.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bbrc.2006.03.114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16603125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28XjvFWnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2006&pages=200-205&author=C.+Stielowauthor=R.+A.+Catarauthor=G.+Mullerauthor=K.+Winglerauthor=P.+Scheurerauthor=H.+H.+Schmidtauthor=H.+Morawietz&title=Novel+Nox+inhibitor+of+oxLDL-induced+reactive+oxygen+species+formation+in+human+endothelial+cells&doi=10.1016%2Fj.bbrc.2006.03.114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells</span></div><div class="casAuthors">Stielow, Claudia; Catar, Rusan A.; Muller, Gregor; Wingler, Kirstin; Scheurer, Peter; Schmidt, Harald H. H. W.; Morawietz, Henning</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">200-205</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">In this study, we investigated effects of a novel NAD(P)H oxidase (Nox)-inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine (VAS2870) on oxidized low-d. lipoprotein (oxLDL)-mediated reactive oxygen species (ROS) formation in human endothelial cells.  Primary cultures of human umbilical vein endothelial cells were cultured to confluence and ROS formation was induced with 50 μg/mL oxLDL for 2 h.  ROS formation was detected by chemiluminescence (CL) using the Diogenes reagent.  OxLDL induced ROS formation in human endothelial cells (171±12%; n = 10, P < 0.05 vs. control).  This augmented ROS formation in response to oxLDL was completely inhibited by the Nox inhibitor VAS2870 (101±9%; n = 7, P < 0.05 vs. oxLDL).  Similar results were obtained with superoxide dismutase (91±7%; n = 7, P < 0.05 vs. oxLDL).  However, the Nox4 mRNA expression level was neither changed by oxLDL nor VAS2870.  We conclude that VAS2870 could provide a novel strategy to inhibit the augmented endothelial superoxide anion formation in response to cardiovascular risk factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry4cCjOVh9GLVg90H21EOLACvtfcHk0liXcsWwlnrJVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjvFWnsLs%253D&md5=9c2b5961569232bd80072deb21409a33</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2006.03.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2006.03.114%26sid%3Dliteratum%253Aachs%26aulast%3DStielow%26aufirst%3DC.%26aulast%3DCatar%26aufirst%3DR.%2BA.%26aulast%3DMuller%26aufirst%3DG.%26aulast%3DWingler%26aufirst%3DK.%26aulast%3DScheurer%26aufirst%3DP.%26aulast%3DSchmidt%26aufirst%3DH.%2BH.%26aulast%3DMorawietz%26aufirst%3DH.%26atitle%3DNovel%2520Nox%2520inhibitor%2520of%2520oxLDL-induced%2520reactive%2520oxygen%2520species%2520formation%2520in%2520human%2520endothelial%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2006%26volume%3D344%26spage%3D200%26epage%3D205%26doi%3D10.1016%2Fj.bbrc.2006.03.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laleu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orchard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioraso-Cartier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cagnon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houngninou-Molango, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duboux, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitz, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szyndralewiez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, P.</span></span> <span> </span><span class="NLM_article-title">First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7715</span>– <span class="NLM_lpage">7730</span>, <span class="refDoi"> DOI: 10.1021/jm100773e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100773e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1OqtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7715-7730&author=B.+Laleuauthor=F.+Gagginiauthor=M.+Orchardauthor=L.+Fioraso-Cartierauthor=L.+Cagnonauthor=S.+Houngninou-Molangoauthor=A.+Gradiaauthor=G.+Dubouxauthor=C.+Merlotauthor=F.+Heitzauthor=C.+Szyndralewiezauthor=P.+Page&title=First+in+class%2C+potent%2C+and+orally+bioavailable+NADPH+oxidase+isoform+4+%28Nox4%29+inhibitors+for+the+treatment+of+idiopathic+pulmonary+fibrosis&doi=10.1021%2Fjm100773e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">First in Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis</span></div><div class="casAuthors">Laleu, Benoit; Gaggini, Francesca; Orchard, Mike; Fioraso-Cartier, Laetitia; Cagnon, Laurene; Houngninou-Molango, Sophie; Gradia, Angelo; Duboux, Guillaume; Merlot, Cedric; Heitz, Freddy; Szyndralewiez, Cedric; Page, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7715-7730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The design, synthesis, and optimization of first-in-class series of inhibitors I (R1 = H, MeCO, 4-FC6H4CH2, etc.; R2 = Ph, 2-ClC6H4, 2-benzothiazolyl, etc.; R3 = Me, 2-FC6H4, 1-pyrrolidinylmethyl, PhCH2NMeCH2, etc.; R4 = MeOCH2CH2, 3-pyridylmethyl, 4-morpholinyl, etc.) of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease, is described.  Initially, several moderately potent pyrazolopyridine dione derivs. were found during a high-throughput screening campaign.  SAR investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) prodn., showing high potency on Nox4 and Nox1.  The compds. have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms.  The specificity of these compds. was confirmed in an extensive in vitro pharmacol. profile, as well as in a counterscreening assay for potential ROS scavenging.  Concomitant benefits are good oral bioavailability and high plasma concns. in vivo, allowing further clin. trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSPjijoh4dLVg90H21EOLACvtfcHk0liXcsWwlnrJVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1OqtbzI&md5=39f3be6bed0d02fce6693e626788f125</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1021%2Fjm100773e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100773e%26sid%3Dliteratum%253Aachs%26aulast%3DLaleu%26aufirst%3DB.%26aulast%3DGaggini%26aufirst%3DF.%26aulast%3DOrchard%26aufirst%3DM.%26aulast%3DFioraso-Cartier%26aufirst%3DL.%26aulast%3DCagnon%26aufirst%3DL.%26aulast%3DHoungninou-Molango%26aufirst%3DS.%26aulast%3DGradia%26aufirst%3DA.%26aulast%3DDuboux%26aufirst%3DG.%26aulast%3DMerlot%26aufirst%3DC.%26aulast%3DHeitz%26aufirst%3DF.%26aulast%3DSzyndralewiez%26aufirst%3DC.%26aulast%3DPage%26aufirst%3DP.%26atitle%3DFirst%2520in%2520class%252C%2520potent%252C%2520and%2520orally%2520bioavailable%2520NADPH%2520oxidase%2520isoform%25204%2520%2528Nox4%2529%2520inhibitors%2520for%2520the%2520treatment%2520of%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7715%26epage%3D7730%26doi%3D10.1021%2Fjm100773e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hussein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Güner, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lassègue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griendling, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, J. P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.12.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.bmc.2017.12.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29426628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=989-998&author=Q.+Xuauthor=A.+A.+Kulkarniauthor=A.+M.+Sajithauthor=D.+Husseinauthor=D.+Brownauthor=O.+F.+G%C3%BCnerauthor=M.+D.+Reddyauthor=E.+B.+Watkinsauthor=B.+Lass%C3%A8gueauthor=K.+K.+Griendlingauthor=J.+P.+Bowen&title=Design%2C+synthesis%2C+and+biological+evaluation+of+inhibitors+of+the+NADPH+oxidase%2C+Nox4&doi=10.1016%2Fj.bmc.2017.12.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of inhibitors of the NADPH oxidase, Nox4</span></div><div class="casAuthors">Xu, Qian; Kulkarni, Amol A.; Sajith, Ayyiliath M.; Hussein, Dilbi; Brown, David; Guner, Osman F.; Reddy, M. Damoder; Watkins, E. Blake; Lassegue, Bernard; Griendling, Kathy K.; Bowen, J. Phillip</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">989-998</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">NADPH oxidases (Nox enzymes) are crit. mediators of both physiol. and pathophysiol. processes.  Nox enzymes catalyze NADPH-dependent generation of reactive oxygen species (ROS), including superoxide and hydrogen peroxide.  Until recently, Nox4 was proposed to be involved exclusively in normal physiol. functions.  Compelling evidence, however, suggests that Nox4 plays a crit. role in fibrosis, as well as a host of pathologies and diseases.  These considerations led to a search for novel, small mol. inhibitors of this important enzyme.  Ultimately, a series of novel tertiary sulfonylureas was designed using pharmacophore modeling, synthesized, and evaluated for inhibition of Nox4-dependent signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRNfIi9OVqT7Vg90H21EOLACvtfcHk0liSELeNCeAZ3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSqur8%253D&md5=3c63c9b9af0b92e36e1b84713518bbbd</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.12.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.12.023%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKulkarni%26aufirst%3DA.%2BA.%26aulast%3DSajith%26aufirst%3DA.%2BM.%26aulast%3DHussein%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DG%25C3%25BCner%26aufirst%3DO.%2BF.%26aulast%3DReddy%26aufirst%3DM.%2BD.%26aulast%3DWatkins%26aufirst%3DE.%2BB.%26aulast%3DLass%25C3%25A8gue%26aufirst%3DB.%26aulast%3DGriendling%26aufirst%3DK.%2BK.%26aulast%3DBowen%26aufirst%3DJ.%2BP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520inhibitors%2520of%2520the%2520NADPH%2520oxidase%252C%2520Nox4%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D989%26epage%3D998%26doi%3D10.1016%2Fj.bmc.2017.12.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tidén, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjögren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svensson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernlind, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senthilmohan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auchère, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markgren, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustavsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundquist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magon, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paton, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jameson, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, A. J.</span></span> <span> </span><span class="NLM_article-title">2-Thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">37578</span>– <span class="NLM_lpage">37589</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.266981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1074%2Fjbc.M111.266981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21880720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGnsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=37578-37589&author=A.+K.+Tid%C3%A9nauthor=T.+Sj%C3%B6grenauthor=M.+Svenssonauthor=A.+Bernlindauthor=R.+Senthilmohanauthor=F.+Auch%C3%A8reauthor=H.+Normanauthor=P.+O.+Markgrenauthor=S.+Gustavssonauthor=S.+Schmidtauthor=S.+Lundquistauthor=L.+V.+Forbesauthor=N.+J.+Magonauthor=L.+N.+Patonauthor=G.+N.+Jamesonauthor=H.+Erikssonauthor=A.+J.+Kettle&title=2-Thioxanthines+are+mechanism-based+inactivators+of+myeloperoxidase+that+block+oxidative+stress+during+inflammation&doi=10.1074%2Fjbc.M111.266981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">2-Thioxanthines Are Mechanism-based Inactivators of Myeloperoxidase That Block Oxidative Stress during Inflammation</span></div><div class="casAuthors">Tiden, Anna-Karin; Sjoegren, Tove; Svensson, Mats; Bernlind, Alexandra; Senthilmohan, Revathy; Auchere, Francoise; Norman, Henrietta; Markgren, Per-Olof; Gustavsson, Susanne; Schmidt, Staffan; Lundquist, Stefan; Forbes, Louisa V.; Magon, Nicholas J.; Paton, Louise N.; Jameson, Guy N. L.; Eriksson, Hakan; Kettle, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">37578-37589, S37578/1-S37578/13</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Myeloperoxidase (MPO) is a prime candidate for promoting oxidative stress during inflammation.  This abundant enzyme of neutrophils uses hydrogen peroxide to oxidize chloride to highly reactive and toxic chlorine bleach.  We have identified 2-thioxanthines as potent mechanism-based inactivators of MPO.  Mass spectrometry and x-ray crystal structures revealed that these inhibitors become covalently attached to the heme prosthetic groups of the enzyme.  We propose a mechanism whereby 2-thioxanthines are oxidized, and their incipient free radicals react with the heme groups of the enzyme before they can exit the active site. 2-Thioxanthines inhibited MPO in plasma and decreased protein chlorination in a mouse model of peritonitis.  They slowed but did not prevent neutrophils from killing bacteria and were poor inhibitors of thyroid peroxidase.  Our study shows that MPO is susceptible to the free radicals it generates, and this Achilles' heel of the enzyme can be exploited to block oxidative stress during inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm809SqpfydLVg90H21EOLACvtfcHk0liSELeNCeAZ3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGnsL3L&md5=66dcb9676c492df0a20df2523c879cb4</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.266981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.266981%26sid%3Dliteratum%253Aachs%26aulast%3DTid%25C3%25A9n%26aufirst%3DA.%2BK.%26aulast%3DSj%25C3%25B6gren%26aufirst%3DT.%26aulast%3DSvensson%26aufirst%3DM.%26aulast%3DBernlind%26aufirst%3DA.%26aulast%3DSenthilmohan%26aufirst%3DR.%26aulast%3DAuch%25C3%25A8re%26aufirst%3DF.%26aulast%3DNorman%26aufirst%3DH.%26aulast%3DMarkgren%26aufirst%3DP.%2BO.%26aulast%3DGustavsson%26aufirst%3DS.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DLundquist%26aufirst%3DS.%26aulast%3DForbes%26aufirst%3DL.%2BV.%26aulast%3DMagon%26aufirst%3DN.%2BJ.%26aulast%3DPaton%26aufirst%3DL.%2BN.%26aulast%3DJameson%26aufirst%3DG.%2BN.%26aulast%3DEriksson%26aufirst%3DH.%26aulast%3DKettle%26aufirst%3DA.%2BJ.%26atitle%3D2-Thioxanthines%2520are%2520mechanism-based%2520inactivators%2520of%2520myeloperoxidase%2520that%2520block%2520oxidative%2520stress%2520during%2520inflammation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D37578%26epage%3D37589%26doi%3D10.1074%2Fjbc.M111.266981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Churg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sin, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thain, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadogan, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maltby, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soars, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinder, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, J. L.</span></span> <span> </span><span class="NLM_article-title">Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>185</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1164/rccm.201103-0468OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.201103-0468OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21997333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XitF2rsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=185&publication_year=2012&pages=34-43&author=A.+Churgauthor=C.+V.+Marshallauthor=D.+D.+Sinauthor=S.+Boltonauthor=S.+Zhouauthor=K.+Thainauthor=E.+B.+Cadoganauthor=J.+Maltbyauthor=M.+G.+Soarsauthor=P.+R.+Mallinderauthor=J.+L.+Wright&title=Late+intervention+with+a+myeloperoxidase+inhibitor+stops+progression+of+experimental+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.201103-0468OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease</span></div><div class="casAuthors">Churg, Andrew; Marshall, Caroline V.; Sin, Don D.; Bolton, Sarah; Zhou, Steven; Thain, Katherine; Cadogan, Elaine B.; Maltby, Justine; Soars, Matthew G.; Mallinder, Philip R.; Wright, Joanne L.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">185</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-43</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Inflammation and oxidative stress are linked to the deleterious effects of cigarette smoke in producing chronic obstructive pulmonary disease (COPD).  Myeloperoxidase (MPO), a neutrophil and macrophage product, is important in bacterial killing, but also drives inflammatory reactions and tissue oxidn.  Objectives: To det. the role of MPO in COPD.  Methods: We treated guinea pigs with a 2-thioxanthine MPO inhibitor, AZ1, in a 6-mo cigarette smoke exposure model, with one group receiving compd. from Smoking Day 1 and another group treated after 3 mo of smoke exposure.  Results: At 6 mo both treatments abolished smoke-induced increases in lavage inflammatory cells, largely ameliorated physiol. changes, and prevented or stopped progression of morphol. emphysema and small airway remodeling.  Cigarette smoke caused a marked increase in immunohistochem. staining for the myeloperoxidase-generated protein oxidn. marker dityrosine, and this effect was considerably decreased with both treatment arms.  Serum 8-isoprostane, another marker of oxidative stress, showed similar trends.  Both treatments also prevented muscularization of the small intrapulmonary arteries, but only partially ameliorated smoke-induced pulmonary hypertension.  Acutely, AZ1 prevented smoke-induced increases in expression of cytokine mediators and nuclear factor-κB binding.  Conclusions: We conclude that an MPO inhibitor is able to stop progression of emphysema and small airway remodeling and to partially protect against pulmonary hypertension, even when treatment starts relatively late in the course of long-term smoke exposure, suggesting that inhibition of MPO may be a novel and useful therapeutic treatment for COPD.  Protection appears to relate to inhibition of oxidative damage and down-regulation of the smoke-induced inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm-d4sj2ZP6LVg90H21EOLACvtfcHk0liSELeNCeAZ3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitF2rsL4%253D&md5=2ed38089e836610c8e067acbac2015ad</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1164%2Frccm.201103-0468OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201103-0468OC%26sid%3Dliteratum%253Aachs%26aulast%3DChurg%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DC.%2BV.%26aulast%3DSin%26aufirst%3DD.%2BD.%26aulast%3DBolton%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DThain%26aufirst%3DK.%26aulast%3DCadogan%26aufirst%3DE.%2BB.%26aulast%3DMaltby%26aufirst%3DJ.%26aulast%3DSoars%26aufirst%3DM.%2BG.%26aulast%3DMallinder%26aufirst%3DP.%2BR.%26aulast%3DWright%26aufirst%3DJ.%2BL.%26atitle%3DLate%2520intervention%2520with%2520a%2520myeloperoxidase%2520inhibitor%2520stops%2520progression%2520of%2520experimental%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2012%26volume%3D185%26spage%3D34%26epage%3D43%26doi%3D10.1164%2Frccm.201103-0468OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruggeri, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckbinder, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagley, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpino, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conn, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowling, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocke, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warmus, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Widlicka, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryder, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolford, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okerberg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walters, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spath, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hepworth, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): a highly selective mechanism-based myeloperoxidase inhibitor for the treatment of cardiovascular diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8513</span>– <span class="NLM_lpage">8528</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00963</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00963" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslOrt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8513-8528&author=R.+B.+Ruggeriauthor=L.+Buckbinderauthor=S.+W.+Bagleyauthor=P.+A.+Carpinoauthor=E.+L.+Connauthor=M.+S.+Dowlingauthor=D.+P.+Fernandoauthor=W.+Jiaoauthor=D.+W.+Kungauthor=S.+T.+Orrauthor=Y.+Qiauthor=B.+N.+Rockeauthor=A.+Smithauthor=J.+S.+Warmusauthor=Y.+Zhangauthor=D.+Bowlesauthor=D.+W.+Widlickaauthor=H.+Engauthor=T.+Ryderauthor=R.+Sharmaauthor=A.+Wolfordauthor=C.+Okerbergauthor=K.+Waltersauthor=T.+S.+Maurerauthor=Y.+Zhangauthor=P.+D.+Boninauthor=S.+N.+Spathauthor=G.+Xingauthor=D.+Hepworthauthor=K.+Ahnauthor=A.+S.+Kalgutkar&title=Discovery+of+2-%286-%285-Chloro-2-methoxyphenyl%29-4-oxo-2-thioxo-3%2C4-dihydropyrimidin-1%282H%29-yl%29acetamide+%28PF-06282999%29%3A+a+highly+selective+mechanism-based+myeloperoxidase+inhibitor+for+the+treatment+of+cardiovascular+diseases&doi=10.1021%2Facs.jmedchem.5b00963"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases</span></div><div class="casAuthors">Ruggeri, Roger B.; Buckbinder, Leonard; Bagley, Scott W.; Carpino, Philip A.; Conn, Edward L.; Dowling, Matthew S.; Fernando, Dilinie P.; Jiao, Wenhua; Kung, Daniel W.; Orr, Suvi T. M.; Qi, Yingmei; Rocke, Benjamin N.; Smith, Aaron; Warmus, Joseph S.; Zhang, Yan; Bowles, Daniel; Widlicka, Daniel W.; Eng, Heather; Ryder, Tim; Sharma, Raman; Wolford, Angela; Okerberg, Carlin; Walters, Karen; Maurer, Tristan S.; Zhang, Yanwei; Bonin, Paul D.; Spath, Samantha N.; Xing, Gang; Hepworth, David; Ahn, Kay; Kalgutkar, Amit S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8513-8528</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the prodn. of hypochlorous acid.  Clin. evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying that MPO inhibitors may represent a therapeutic treatment option.  Herein, we present the design, synthesis, and preclin. evaluation of N1-substituted-6-arylthiouracils as potent and selective inhibitors of MPO.  Inhibition proceeded in a time-dependent manner by a covalent, irreversible mechanism, which was dependent upon MPO catalysis, consistent with mechanism-based inactivation.  N1-Substituted-6-arylthiouracils exhibited low partition ratios and high selectivity for MPO over thyroid peroxidase and cytochrome P 450 isoforms.  N1-Substituted-6-arylthiouracils also demonstrated inhibition of MPO activity in lipopolysaccharide-stimulated human whole blood.  Robust inhibition of plasma MPO activity was demonstrated with the lead compd. 2-(6-(5-chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999, I) upon oral administration to lipopolysaccharide-treated cynomolgus monkeys.  On the basis of its pharmacol. and pharmacokinetic profile, I has been advanced to first-in-human pharmacokinetic and safety studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgGF9fQeccCrVg90H21EOLACvtfcHk0lglWk80qnLBog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslOrt7%252FK&md5=3526e7d4753b59d99da66efdd3a628bb</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00963&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00963%26sid%3Dliteratum%253Aachs%26aulast%3DRuggeri%26aufirst%3DR.%2BB.%26aulast%3DBuckbinder%26aufirst%3DL.%26aulast%3DBagley%26aufirst%3DS.%2BW.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DConn%26aufirst%3DE.%2BL.%26aulast%3DDowling%26aufirst%3DM.%2BS.%26aulast%3DFernando%26aufirst%3DD.%2BP.%26aulast%3DJiao%26aufirst%3DW.%26aulast%3DKung%26aufirst%3DD.%2BW.%26aulast%3DOrr%26aufirst%3DS.%2BT.%26aulast%3DQi%26aufirst%3DY.%26aulast%3DRocke%26aufirst%3DB.%2BN.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DWarmus%26aufirst%3DJ.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBowles%26aufirst%3DD.%26aulast%3DWidlicka%26aufirst%3DD.%2BW.%26aulast%3DEng%26aufirst%3DH.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DWolford%26aufirst%3DA.%26aulast%3DOkerberg%26aufirst%3DC.%26aulast%3DWalters%26aufirst%3DK.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBonin%26aufirst%3DP.%2BD.%26aulast%3DSpath%26aufirst%3DS.%2BN.%26aulast%3DXing%26aufirst%3DG.%26aulast%3DHepworth%26aufirst%3DD.%26aulast%3DAhn%26aufirst%3DK.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26atitle%3DDiscovery%2520of%25202-%25286-%25285-Chloro-2-methoxyphenyl%2529-4-oxo-2-thioxo-3%252C4-dihydropyrimidin-1%25282H%2529-yl%2529acetamide%2520%2528PF-06282999%2529%253A%2520a%2520highly%2520selective%2520mechanism-based%2520myeloperoxidase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520cardiovascular%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8513%26epage%3D8528%26doi%3D10.1021%2Facs.jmedchem.5b00963" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjögren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auchère, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laughton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemsley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unitt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, A.</span></span> <span> </span><span class="NLM_article-title">Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">36636</span>– <span class="NLM_lpage">36647</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.507756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1074%2Fjbc.M113.507756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24194519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFyls7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=36636-36647&author=L.+Forbesauthor=T.+Sj%C3%B6grenauthor=F.+Auch%C3%A8reauthor=D.+Jenkinsauthor=B.+Thongauthor=D.+Laughtonauthor=P.+Hemsleyauthor=G.+Pairaudeauauthor=R.+Turnerauthor=H.+Erikssonauthor=J.+Unittauthor=A.+Kettle&title=Potent+reversible+inhibition+of+myeloperoxidase+by+aromatic+hydroxamates&doi=10.1074%2Fjbc.M113.507756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Potent reversible inhibition of myeloperoxidase by aromatic hydroxamates</span></div><div class="casAuthors">Forbes, Louisa V.; Sjogren, Tove; Auchere, Francoise; Jenkins, David W.; Thong, Bob; Laughton, David; Hemsley, Paul; Pairaudeau, Garry; Turner, Rufus; Eriksson, Hakan; Unitt, John F.; Kettle, Anthony J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">36636-36647</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Neutrophil myeloperoxidase (MPO) promotes oxidative stress in numerous inflammatory pathologies by producing hypohalous acids.  Its inadvertent activity is a prime target for pharmacol. control.  Previously, salicylhydroxamic acid was reported to be a weak reversible inhibitor of MPO.  Here, the authors aimed to identify related hydroxamates that are good inhibitors of the enzyme.  The authors report on 3 arom. hydroxamates as the 1st potent reversible inhibitors of MPO.  The chlorination activity of purified MPO was inhibited by 50% by a 5-nM concn. of a trifluoromethyl-substituted arom. hydroxamate, HX1.  The hydroxamates were specific for MPO in neutrophils and more potent toward MPO compared with a broad range of redox enzymes and alternative targets.  Surface plasmon resonance measurements showed that the strength of binding of hydroxamates to MPO correlated with the degree of enzyme inhibition.  The crystal structure of the MPO-HX1 complex revealed that the inhibitor was bound within the active site cavity above the heme and blocked the substrate channel.  HX1 was a mixed-type inhibitor of the halogenation activity of MPO with respect to both H2O2 and halide.  Spectral analyses demonstrated that hydroxamates could act variably as substrates for MPO and convert the enzyme to a nitrosyl ferrous intermediate.  This property was unrelated to their ability to inhibit MPO.  The authors proposed that arom. hydroxamates bind tightly to the active site of MPO and prevent it from producing hypohalous acids.  This mode of reversible inhibition has potential for blocking the activity of MPO and limiting oxidative stress during inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXRB0FCV7Qq7Vg90H21EOLACvtfcHk0lglWk80qnLBog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFyls7rM&md5=07dc6967210567a68683138ec3bd7978</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.507756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.507756%26sid%3Dliteratum%253Aachs%26aulast%3DForbes%26aufirst%3DL.%26aulast%3DSj%25C3%25B6gren%26aufirst%3DT.%26aulast%3DAuch%25C3%25A8re%26aufirst%3DF.%26aulast%3DJenkins%26aufirst%3DD.%26aulast%3DThong%26aufirst%3DB.%26aulast%3DLaughton%26aufirst%3DD.%26aulast%3DHemsley%26aufirst%3DP.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DTurner%26aufirst%3DR.%26aulast%3DEriksson%26aufirst%3DH.%26aulast%3DUnitt%26aufirst%3DJ.%26aulast%3DKettle%26aufirst%3DA.%26atitle%3DPotent%2520reversible%2520inhibition%2520of%2520myeloperoxidase%2520by%2520aromatic%2520hydroxamates%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D36636%26epage%3D36647%26doi%3D10.1074%2Fjbc.M113.507756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soubhye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elfving, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtmüller, P.
G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podrecca, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conotte, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colet, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarakbi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaeverbeek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nève, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prévost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zouaoui Boudjeltia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufrasne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Antwerpen, P.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of novel 3-alkylindole derivatives as selective and highly potent myeloperoxidase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3943</span>– <span class="NLM_lpage">3958</span>, <span class="refDoi"> DOI: 10.1021/jm4001538</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4001538" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVSrsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3943-3958&author=J.+Soubhyeauthor=I.+Aldibauthor=B.+Elfvingauthor=M.+Gelbckeauthor=P.%0AG.+Furtm%C3%BCllerauthor=M.+Podreccaauthor=R.+Conotteauthor=J.+M.+Coletauthor=A.+Rousseauauthor=F.+Reyeauthor=A.+Sarakbiauthor=M.+Vanhaeverbeekauthor=J.+M.+Kauffmannauthor=C.+Obingerauthor=J.+N%C3%A8veauthor=M.+Pr%C3%A9vostauthor=K.+Zouaoui+Boudjeltiaauthor=F.+Dufrasneauthor=P.+Van+Antwerpen&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+novel+3-alkylindole+derivatives+as+selective+and+highly+potent+myeloperoxidase+inhibitors&doi=10.1021%2Fjm4001538"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Structure-Activity Relationship Studies of Novel 3-Alkylindole Derivatives as Selective and Highly Potent Myeloperoxidase Inhibitors</span></div><div class="casAuthors">Soubhye, Jalal; Aldib, Iyas; Elfving, Betina; Gelbcke, Michel; Furtmuller, Paul G.; Podrecca, Manuel; Conotte, Raphael; Colet, Jean-Marie; Rousseau, Alexandre; Reye, Florence; Sarakbi, Ahmad; Vanhaeverbeek, Michel; Kauffmann, Jean-Michel; Obinger, Christian; Neve, Jean; Prevost, Martine; Zouaoui Boudjeltia, Karim; Dufrasne, Francois; Van Antwerpen, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3943-3958</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Due to its prodn. of potent antimicrobial oxidants including hypochlorous acid, human myeloperoxidase (MPO) plays a crit. role in innate immunity and inflammatory diseases.  Thus MPO is an attractive target in drug design.  (Aminoalkyl)fluoroindole derivs. were detected to be very potent MPO inhibitors; however, they also promote inhibition of the serotonin reuptake transporter (SERT) at the same concn. range.  Via structure-based drug design, a new series of MPO inhibitors derived from 3-alkylindole were synthesized and their effects were assessed on MPO-mediated taurine chlorination and low-d. lipoprotein oxidn. as well as on inhibition of SERT.  The fluoroindole compd. I with three carbons in the side chain and one amide group exhibited a selectivity index of 35 (Ki/IC50) with high inhibition of MPO activity (IC50 = 18 nM), whereas its effect on SERT was in the micromolar range.  Structure-function relationships, mechanism of action, and safety of the mol. are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRZx1jHWC8t7Vg90H21EOLACvtfcHk0lgK-ByhQtVhRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVSrsrc%253D&md5=63d0c4859e9b378933acbd6c7cdbb43c</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Fjm4001538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4001538%26sid%3Dliteratum%253Aachs%26aulast%3DSoubhye%26aufirst%3DJ.%26aulast%3DAldib%26aufirst%3DI.%26aulast%3DElfving%26aufirst%3DB.%26aulast%3DGelbcke%26aufirst%3DM.%26aulast%3DFurtm%25C3%25BCller%26aufirst%3DP.%2BG.%26aulast%3DPodrecca%26aufirst%3DM.%26aulast%3DConotte%26aufirst%3DR.%26aulast%3DColet%26aufirst%3DJ.%2BM.%26aulast%3DRousseau%26aufirst%3DA.%26aulast%3DReye%26aufirst%3DF.%26aulast%3DSarakbi%26aufirst%3DA.%26aulast%3DVanhaeverbeek%26aufirst%3DM.%26aulast%3DKauffmann%26aufirst%3DJ.%2BM.%26aulast%3DObinger%26aufirst%3DC.%26aulast%3DN%25C3%25A8ve%26aufirst%3DJ.%26aulast%3DPr%25C3%25A9vost%26aufirst%3DM.%26aulast%3DZouaoui%2BBoudjeltia%26aufirst%3DK.%26aulast%3DDufrasne%26aufirst%3DF.%26aulast%3DVan%2BAntwerpen%26aufirst%3DP.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520novel%25203-alkylindole%2520derivatives%2520as%2520selective%2520and%2520highly%2520potent%2520myeloperoxidase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3943%26epage%3D3958%26doi%3D10.1021%2Fjm4001538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soubhye, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chikh Alard, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aldib, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prévost, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelbcke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Carvalho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtmüller, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obinger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flemmig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tadrent, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousseau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nève, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zouaoui
Boudjeltia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufrasne, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Antwerpen, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel potent reversible and irreversible myeloperoxidase inhibitors using virtual screening procedure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">6563</span>– <span class="NLM_lpage">6586</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00285</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00285" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2ru7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=6563-6586&author=J.+Soubhyeauthor=I.+Chikh+Alardauthor=I.+Aldibauthor=M.+Pr%C3%A9vostauthor=M.+Gelbckeauthor=A.+De+Carvalhoauthor=P.+G.+Furtm%C3%BCllerauthor=C.+Obingerauthor=J.+Flemmigauthor=S.+Tadrentauthor=F.+Meyerauthor=A.+Rousseauauthor=J.+N%C3%A8veauthor=V.+Mathieuauthor=K.+Zouaoui%0ABoudjeltiaauthor=F.+Dufrasneauthor=P.+Van+Antwerpen&title=Discovery+of+novel+potent+reversible+and+irreversible+myeloperoxidase+inhibitors+using+virtual+screening+procedure&doi=10.1021%2Facs.jmedchem.7b00285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Potent Reversible and Irreversible Myeloperoxidase Inhibitors Using Virtual Screening Procedure</span></div><div class="casAuthors">Soubhye, Jalal; Chikh Alard, Ibaa; Aldib, Iyas; Prevost, Martine; Gelbcke, Michel; De Carvalho, Annelise; Furtmuller, Paul G.; Obinger, Christian; Flemmig, Jorg; Tadrent, Sara; Meyer, Franck; Rousseau, Alexandre; Neve, Jean; Mathieu, Veronique; Zouaoui Boudjeltia, Karim; Dufrasne, Francois; Van Antwerpen, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6563-6586</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The heme enzyme myeloperoxidase (MPO) participates in innate immune defense mechanism through formation of microbicidal reactive oxidants.  However, evidence has emerged that MPO-derived oxidants contribute to propagation of inflammatory diseases.  Because of the deleterious effects of circulating MPO, there is a great interest in the development of new efficient and specific inhibitors.  Here, we have performed a novel virtual screening procedure, depending on ligand-based pharmacophore modeling followed by structure-based virtual screening.  Starting from a set of 727842 compds., 28 mols. were selected by this virtual method and tested on MPO in vitro.  Twelve out of 28 compds. were found to have an IC50 less than 5 μM.  The best inhibitors were 2-(7-methoxy-4-methylquinazolin-2-yl)guanidine (28) and (R)-2-(1-((2,3-dihydro-1H-imidazol-2-yl)methyl)pyrrolidin-3-yl)-5-fluoro-1H-benzo[d]imidazole (42) with IC50 values of 44 and 50 nM, resp.  Studies on the mechanism of inhibition suggest that 28 is the first potent mechanism-based inhibitor and inhibits irreversibly MPO at nanomolar concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGQnLIYtnYX7Vg90H21EOLACvtfcHk0lgK-ByhQtVhRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2ru7fM&md5=fb3aed6a078040c2dfee51b74ee903c0</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00285%26sid%3Dliteratum%253Aachs%26aulast%3DSoubhye%26aufirst%3DJ.%26aulast%3DChikh%2BAlard%26aufirst%3DI.%26aulast%3DAldib%26aufirst%3DI.%26aulast%3DPr%25C3%25A9vost%26aufirst%3DM.%26aulast%3DGelbcke%26aufirst%3DM.%26aulast%3DDe%2BCarvalho%26aufirst%3DA.%26aulast%3DFurtm%25C3%25BCller%26aufirst%3DP.%2BG.%26aulast%3DObinger%26aufirst%3DC.%26aulast%3DFlemmig%26aufirst%3DJ.%26aulast%3DTadrent%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DF.%26aulast%3DRousseau%26aufirst%3DA.%26aulast%3DN%25C3%25A8ve%26aufirst%3DJ.%26aulast%3DMathieu%26aufirst%3DV.%26aulast%3DZouaoui%2BBoudjeltia%26aufirst%3DK.%26aulast%3DDufrasne%26aufirst%3DF.%26aulast%3DVan%2BAntwerpen%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520novel%2520potent%2520reversible%2520and%2520irreversible%2520myeloperoxidase%2520inhibitors%2520using%2520virtual%2520screening%2520procedure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D6563%26epage%3D6586%26doi%3D10.1021%2Facs.jmedchem.7b00285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domej, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oetll, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renner, W.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress and free radicals in COPD--implications and relevance for treatment</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1207</span>– <span class="NLM_lpage">1224</span>, <span class="refDoi"> DOI: 10.2147/COPD.S51226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2147%2FCOPD.S51226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25378921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFGgsLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1207-1224&author=W.+Domejauthor=K.+Oetllauthor=W.+Renner&title=Oxidative+stress+and+free+radicals+in+COPD%2D%2Dimplications+and+relevance+for+treatment&doi=10.2147%2FCOPD.S51226"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress and free radicals in COPD - implications and relevance for treatment</span></div><div class="casAuthors">Domej, Wolfgang; Oettl, Karl; Renner, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1207-1224, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Oxidative stress occurs when free radicals and other reactive species overwhelm the availability of antioxidants.  Reactive oxygen species (ROS), reactive nitrogen species, and their counterpart antioxidant agents are essential for physiol. signaling and host defense, as well as for the evolution and persistence of inflammation.  When their normal steady state is disturbed, imbalances between oxidants and antioxidants may provoke pathol. reactions causing a range of nonrespiratory and respiratory diseases, particularly chronic obstructive pulmonary disease (COPD).  In the respiratory system, ROS may be either exogenous from more or less inhalative gaseous or particulate agents such as air pollutants, cigarette smoke, ambient high-altitude hypoxia, and some occupational dusts, or endogenously generated in the context of defense mechanisms against such infectious pathogens as bacteria, viruses, or fungi.  ROS may also damage body tissues depending on the amt. and duration of exposure and may further act as triggers for enzymically generated ROS released from respiratory, immune, and inflammatory cells.  This paper focuses on the general relevance of free radicals for the development and progression of both COPD and pulmonary emphysema as well as novel perspectives on therapeutic options.  Unfortunately, current treatment options do not suffice to prevent chronic airway inflammation and are not yet able to substantially alter the course of COPD.  Effective therapeutic antioxidant measures are urgently needed to control and mitigate local as well as systemic oxygen bursts in COPD and other respiratory diseases.  In addn. to current therapeutic prospects and aspects of genomic medicine, trending research topics in COPD are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtbWBt_nTZEbVg90H21EOLACvtfcHk0lh8HeC52LI3vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFGgsLrO&md5=06bb8247587b67d7b281f54309049d50</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S51226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S51226%26sid%3Dliteratum%253Aachs%26aulast%3DDomej%26aufirst%3DW.%26aulast%3DOetll%26aufirst%3DK.%26aulast%3DRenner%26aufirst%3DW.%26atitle%3DOxidative%2520stress%2520and%2520free%2520radicals%2520in%2520COPD--implications%2520and%2520relevance%2520for%2520treatment%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2014%26volume%3D9%26spage%3D1207%26epage%3D1224%26doi%3D10.2147%2FCOPD.S51226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoder, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellison, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunday, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crapo, J. D.</span></span> <span> </span><span class="NLM_article-title">A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">57</span>– <span class="NLM_lpage">64</span>, <span class="refDoi"> DOI: 10.1164/rccm.200203-232OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200203-232OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12502477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252Fitlemuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2003&pages=57-64&author=L.+Y.+Changauthor=M.+Subramaniamauthor=B.+A.+Yoderauthor=B.+J.+Dayauthor=M.+C.+Ellisonauthor=M.+E.+Sundayauthor=J.+D.+Crapo&title=A+catalytic+antioxidant+attenuates+alveolar+structural+remodeling+in+bronchopulmonary+dysplasia&doi=10.1164%2Frccm.200203-232OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">A catalytic antioxidant attenuates alveolar structural remodeling in bronchopulmonary dysplasia</span></div><div class="casAuthors">Chang Ling-Yi L; Subramaniam Meera; Yoder Bradley A; Day Brian J; Ellison Misoo C; Sunday Mary E; Crapo James D</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57-64</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Superoxide anion and other oxygen-free radicals have been implicated in the pathogenesis of bronchopulmonary dysplasia.  We tested the hypothesis that a catalytic antioxidant metalloporphyrin AEOL 10113 can protect against hyperoxia-induced lung injury using a fetal baboon model of bronchopulmonary dysplasia.  Fetal baboons were delivered by hysterotomy at 140 days of gestation (term = 185 days) and given 100% oxygen for 10 days.  Morphometric analysis of alveolar structure showed that fetal baboons on 100% oxygen alone had increased parenchymal mast cells and eosinophils, increased alveolar tissue volume and septal thickness, and decreased alveolar surface area compared with animals given oxygen as needed.  Treatment with AEOL 10113 (continuous intravenous infusion) during 100% oxygen exposure partially reversed these oxygen-induced changes.  Hyperoxia increased the number of neuroendocrine cells in the peripheral lung, which was preceded by increased levels of urine bombesin-like peptide at 48 hours of age.  AEOL 10113 inhibited the hyperoxia-induced increases in urine bombesin-like peptide and numbers of neuroendocrine cells.  An increasing trend in oxygenation index over time was observed in the 100% oxygen group but not the mimetic-treated group.  These results suggest that AEOL 10113 might reduce the risk of pulmonary oxygen toxicity in prematurely born infants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTxiraH1KEj9tbHMBt0mMIXfW6udTcc2eb0OH_W63h65bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252Fitlemuw%253D%253D&md5=9f3a33636d2fdfef543f8ce5b7afaf54</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1164%2Frccm.200203-232OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200203-232OC%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DL.%2BY.%26aulast%3DSubramaniam%26aufirst%3DM.%26aulast%3DYoder%26aufirst%3DB.%2BA.%26aulast%3DDay%26aufirst%3DB.%2BJ.%26aulast%3DEllison%26aufirst%3DM.%2BC.%26aulast%3DSunday%26aufirst%3DM.%2BE.%26aulast%3DCrapo%26aufirst%3DJ.%2BD.%26atitle%3DA%2520catalytic%2520antioxidant%2520attenuates%2520alveolar%2520structural%2520remodeling%2520in%2520bronchopulmonary%2520dysplasia%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2003%26volume%3D167%26spage%3D57%26epage%3D64%26doi%3D10.1164%2Frccm.200203-232OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuzzocrea, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zacharowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mota-Filipe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiemermann, C.</span></span> <span> </span><span class="NLM_article-title">Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1046/j.1523-1755.2000.00212.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1046%2Fj.1523-1755.2000.00212.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10916089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlvFagsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2000&pages=658-673&author=P.+K.+Chatterjeeauthor=S.+Cuzzocreaauthor=P.+A.+Brownauthor=K.+Zacharowskiauthor=K.+N.+Stewartauthor=H.+Mota-Filipeauthor=C.+Thiemermann&title=Tempol%2C+a+membrane-permeable+radical+scavenger%2C+reduces+oxidant+stress-mediated+renal+dysfunction+and+injury+in+the+rat&doi=10.1046%2Fj.1523-1755.2000.00212.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat</span></div><div class="casAuthors">Chatterjee, Prabal K.; Cuzzocrea, Salvatore; Brown, Paul A. J.; Zacharowski, Kai; Stewart, Keith N.; Mota-Filipe, Helder; Thiemermann, Christoph</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">658-673</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">The generation of reactive oxygen species (ROS) contributes to the pathogenesis of renal ischemia-reperfusion injury.  The aim of this study was to investigate the effects of tempol in (1) an in vivo rat model of renal ischemia/reperfusion injury and on (2) cellular injury and death of rat renal proximal tubular (PT) cells exposed to oxidant stress in the form of H2O2.  Male Wistar rats underwent bilateral renal pedicle clamping for 45 min followed by reperfusion for 6 h.  Tempol (30 mg/kg/h), desferrioxamine (DEF; 40 mg/kg/h), or a combination of tempol (30 mg/kg/h) and DEF (40 mg/kg/h) were administered prior to and throughout reperfusion.  Blood plasma concns. of urea, creatinine, Na+, γ-glutamyl transferase (γGT), aspartate aminotransferase (AST), and urinary Na+ and N-acetyl-β-D-glucosaminidase (NAG) were measured for the assessment of renal function and reperfusion injury.  Kidney myeloperoxidase (MPO) activity and malondialdehyde (MDA) levels were measured for assessment of polymorphonuclear (PMN) cell infiltration and lipid peroxidn., resp.  Renal sections were used for histol. grading of renal injury and for immunohistochem. localization of nitrotyrosine and poly(ADP-ribose) synthetase (PARS).  Primary cultures of rat PT cells were incubated with H2O2 (1 mmol/L for 4 h) either in the absence or presence of increasing concns. of tempol (0.03 to 10 mmol/L), DEF (0.03 to 10 mmol/L), or a combination of tempol (3 mmol/L) or DEF (3 mmol/L).  PT cell injury and death were detd. by evaluating mitochondrial respiration and lactate dehydrogenase (LDH) release, resp.  In vivo, tempol reduced the increase in urea, creatinine, γGT, AST, NAG, and FENa produced by renal ischemia/reperfusion, suggesting an improvement in both renal function and injury.  Tempol also reduced kidney MPO activity and MDA levels, indicating a redn. in PMN infiltration and lipid peroxidn., resp.  Tempol reduced the histol. evidence of renal damage assocd. with ischemia/reperfusion and caused a substantial redn. in the staining for nitrotyrosine and PARS, suggesting reduced nitrosative and oxidative stress.  In vitro, tempol attenuated H2O2-mediated decrease in mitochondrial respiration and increase in LDH release from rat PT cells, indicating a redn. in cell injury and death.  Both in vivo and in vitro, the beneficial actions of tempol were similar to those obtained using the Fe2+ chelator DEF.  However, coadministration of DEF and tempol did not produce any addnl. beneficial actions against renal ischemia/reperfusion injury or against oxidative stress-mediated PT cell injury/death.  The authors' results suggest that the membrane-permeable radical scavenger, tempol, reduces the renal dysfunction and injury assocd. with ischemia/reperfusion of the kidney.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMfF0lpCUlprVg90H21EOLACvtfcHk0lh8HeC52LI3vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlvFagsrg%253D&md5=83c6f9013f0d0c95d835893a24ba7cfc</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1046%2Fj.1523-1755.2000.00212.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1523-1755.2000.00212.x%26sid%3Dliteratum%253Aachs%26aulast%3DChatterjee%26aufirst%3DP.%2BK.%26aulast%3DCuzzocrea%26aufirst%3DS.%26aulast%3DBrown%26aufirst%3DP.%2BA.%26aulast%3DZacharowski%26aufirst%3DK.%26aulast%3DStewart%26aufirst%3DK.%2BN.%26aulast%3DMota-Filipe%26aufirst%3DH.%26aulast%3DThiemermann%26aufirst%3DC.%26atitle%3DTempol%252C%2520a%2520membrane-permeable%2520radical%2520scavenger%252C%2520reduces%2520oxidant%2520stress-mediated%2520renal%2520dysfunction%2520and%2520injury%2520in%2520the%2520rat%26jtitle%3DKidney%2520Int.%26date%3D2000%26volume%3D58%26spage%3D658%26epage%3D673%26doi%3D10.1046%2Fj.1523-1755.2000.00212.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffin, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridley, R. M.</span></span> <span> </span><span class="NLM_article-title">NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">190</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1161/01.STR.32.1.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1161%2F01.STR.32.1.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11136936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtFKhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2001&pages=190-198&author=J.+W.+Marshallauthor=K.+J.+Duffinauthor=A.+R.+Greenauthor=R.+M.+Ridley&title=NXY-059%2C+a+free+radical%2D%2Dtrapping+agent%2C+substantially+lessens+the+functional+disability+resulting+from+cerebral+ischemia+in+a+primate+species&doi=10.1161%2F01.STR.32.1.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species</span></div><div class="casAuthors">Marshall, Jonathan W. B.; Duffin, Katharine J.; Green, A. Richard; Ridley, Rosalind M.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">190-198</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">NXY-059 is a novel nitrone with free radical-trapping properties that has a considerable neuroprotective effect in rats.  We have now examd. the efficacy of this drug at reducing long-term functional disability in a primate model of stroke.  Twelve monkeys were trained and tested on a variety of behavioral tasks used to dissoc. and quantify motor and spatial deficits.  Five minutes after permanent occlusion of the right middle cerebral artery, monkeys received a 1-mL i.v. infusion of either saline or NXY-059 (28 mg/kg), and osmotic minipumps, model 2001D, were implanted s.c. to provide continuous drug or saline infusion for 48 h.  Drug-filled pumps released NXY-059 at 16 mg/kg/h.  The monkeys were retested 3 and 10 wk after surgery to assess functional disability.  Surgery, behavioral testing, and histol. were all done blinded to treatment condition.  NXY-059-treated monkeys were significantly better at reaching with their hemiparetic arm than were saline-treated monkeys when retested 3 wk and 10 wk after surgery.  Drug treatment also significantly lessened the degree of spatial perceptual neglect, a debilitating though ameliorating consequence of this infarct.  NXY-059 treatment reduced the overall amt. of brain damage by >50% of saline-treatment values, with similar levels of protection afforded to both white and gray matter.  This novel drug has a substantial protective effect, lessening the disability caused by an exptl. induced stroke in a primate species.  These findings provide considerable encouragement for the clin. development of NXY-059.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-BC-S0fNDn7Vg90H21EOLACvtfcHk0lj2aBQCXScKzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtFKhs74%253D&md5=ad0cf46f1fb7916a110ee31dc9096dfd</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1161%2F01.STR.32.1.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252F01.STR.32.1.190%26sid%3Dliteratum%253Aachs%26aulast%3DMarshall%26aufirst%3DJ.%2BW.%26aulast%3DDuffin%26aufirst%3DK.%2BJ.%26aulast%3DGreen%26aufirst%3DA.%2BR.%26aulast%3DRidley%26aufirst%3DR.%2BM.%26atitle%3DNXY-059%252C%2520a%2520free%2520radical--trapping%2520agent%252C%2520substantially%2520lessens%2520the%2520functional%2520disability%2520resulting%2520from%2520cerebral%2520ischemia%2520in%2520a%2520primate%2520species%26jtitle%3DStroke%26date%3D2001%26volume%3D32%26spage%3D190%26epage%3D198%26doi%3D10.1161%2F01.STR.32.1.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seimetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parajuli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veit, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwapiszewska, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisel, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egemnazarov, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turowska, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sydykov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medebach, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klepetko, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaksch, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumitrascu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voswinckel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seeger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schermuly, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimminger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghofrani, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissmann, N.</span></span> <span> </span><span class="NLM_article-title">Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">293</span>– <span class="NLM_lpage">305</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2011.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.cell.2011.08.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22000010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlaksb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2011&pages=293-305&author=M.+Seimetzauthor=N.+Parajuliauthor=A.+Pichlauthor=F.+Veitauthor=G.+Kwapiszewskaauthor=F.+C.+Weiselauthor=K.+Milgerauthor=B.+Egemnazarovauthor=A.+Turowskaauthor=B.+Fuchsauthor=S.+Nikamauthor=M.+Rothauthor=A.+Sydykovauthor=T.+Medebachauthor=W.+Klepetkoauthor=P.+Jakschauthor=R.+Dumitrascuauthor=H.+Garnauthor=R.+Voswinckelauthor=S.+Kostinauthor=W.+Seegerauthor=R.+T.+Schermulyauthor=F.+Grimmingerauthor=H.+A.+Ghofraniauthor=N.+Weissmann&title=Inducible+NOS+inhibition+reverses+tobacco-smoke-induced+emphysema+and+pulmonary+hypertension+in+mice&doi=10.1016%2Fj.cell.2011.08.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice</span></div><div class="casAuthors">Seimetz, Michael; Parajuli, Nirmal; Pichl, Alexandra; Veit, Florian; Kwapiszewska, Grazyna; Weisel, Friederike C.; Milger, Katrin; Egemnazarov, Bakytbek; Turowska, Agnieszka; Fuchs, Beate; Nikam, Sandeep; Roth, Markus; Sydykov, Akylbek; Medebach, Thomas; Klepetko, Walter; Jaksch, Peter; Dumitrascu, Rio; Garn, Holger; Voswinckel, Robert; Kostin, Sawa; Seeger, Werner; Schermuly, Ralph T.; Grimminger, Friedrich; Ghofrani, Hossein A.; Weissmann, Norbert</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">293-305</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is one of the most common causes of death worldwide.  We report in an emphysema model of mice chronically exposed to tobacco smoke that pulmonary vascular dysfunction, vascular remodeling, and pulmonary hypertension (PH) precede development of alveolar destruction.  We provide evidence for a causative role of inducible nitric oxide synthase (iNOS) and peroxynitrite in this context.  Mice lacking iNOS were protected against emphysema and PH.  Treatment of wild-type mice with the iNOS inhibitor N6-(1-iminoethyl)-L-lysine (L-NIL) prevented structural and functional alterations of both the lung vasculature and alveoli and also reversed established disease.  In chimeric mice lacking iNOS in bone marrow (BM)-derived cells, PH was dependent on iNOS from BM-derived cells, whereas emphysema development was dependent on iNOS from non-BM-derived cells.  Similar regulatory and structural alterations as seen in mouse lungs were found in lung tissue from humans with end-stage COPD.  Smoking-related damage can be reversed by inhibition of iNOS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothjrcUQAAE7Vg90H21EOLACvtfcHk0lj2aBQCXScKzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlaksb3O&md5=ddebfbf25933ed6f6d1f590e6bde0269</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2011.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2011.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DSeimetz%26aufirst%3DM.%26aulast%3DParajuli%26aufirst%3DN.%26aulast%3DPichl%26aufirst%3DA.%26aulast%3DVeit%26aufirst%3DF.%26aulast%3DKwapiszewska%26aufirst%3DG.%26aulast%3DWeisel%26aufirst%3DF.%2BC.%26aulast%3DMilger%26aufirst%3DK.%26aulast%3DEgemnazarov%26aufirst%3DB.%26aulast%3DTurowska%26aufirst%3DA.%26aulast%3DFuchs%26aufirst%3DB.%26aulast%3DNikam%26aufirst%3DS.%26aulast%3DRoth%26aufirst%3DM.%26aulast%3DSydykov%26aufirst%3DA.%26aulast%3DMedebach%26aufirst%3DT.%26aulast%3DKlepetko%26aufirst%3DW.%26aulast%3DJaksch%26aufirst%3DP.%26aulast%3DDumitrascu%26aufirst%3DR.%26aulast%3DGarn%26aufirst%3DH.%26aulast%3DVoswinckel%26aufirst%3DR.%26aulast%3DKostin%26aufirst%3DS.%26aulast%3DSeeger%26aufirst%3DW.%26aulast%3DSchermuly%26aufirst%3DR.%2BT.%26aulast%3DGrimminger%26aufirst%3DF.%26aulast%3DGhofrani%26aufirst%3DH.%2BA.%26aulast%3DWeissmann%26aufirst%3DN.%26atitle%3DInducible%2520NOS%2520inhibition%2520reverses%2520tobacco-smoke-induced%2520emphysema%2520and%2520pulmonary%2520hypertension%2520in%2520mice%26jtitle%3DCell%26date%3D2011%26volume%3D147%26spage%3D293%26epage%3D305%26doi%3D10.1016%2Fj.cell.2011.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span> <span> </span><span class="NLM_article-title">Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7600</span>– <span class="NLM_lpage">7612</span>, <span class="refDoi"> DOI: 10.1021/jm5007534</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5007534" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7600-7612&author=W.+Tangauthor=J.+Xieauthor=S.+Xuauthor=H.+Lvauthor=M.+Linauthor=S.+Yuanauthor=J.+Baiauthor=Q.+Houauthor=S.+Yu&title=Novel+nitric+oxide-releasing+derivatives+of+brusatol+as+anti-inflammatory+agents%3A+design%2C+synthesis%2C+biological+evaluation%2C+and+nitric+oxide+release+studies&doi=10.1021%2Fjm5007534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Nitric Oxide-Releasing Derivatives of Brusatol as Anti-Inflammatory Agents: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies</span></div><div class="casAuthors">Tang, Weibin; Xie, Jianlin; Xu, Song; Lv, Haining; Lin, Mingbao; Yuan, Shaopeng; Bai, Jinye; Hou, Qi; Yu, Shishan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7600-7612</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Brusatol (I), a biol. active natural product, was modified in four distinct positions through the covalent attachment of a furoxan moiety, which acts as a nitric oxide (NO) donor.  Forty derivs. were synthesized and evaluated for their inhibitory effects on excess NO biosynthesis in activated macrophages.  Among them, compd. II demonstrated inhibition (IC50 = 0.067 μM) comparable to that of brusatol but was less cytotoxic.  More importantly, even at very low doses (2 μmol/kg/day), compd. II also showed substantial inhibitory efficacy against chronic obstructive pulmonary disease (COPD)-like inflammation in the mouse model induced by cigarette smoke (CS) and lipopolysaccharide (LPS).  Particularly, this compd. was over 100-fold less toxic (LD50 > 3852 μmol/kg) than brusatol and could be a promising lead for further studies.  Notably, the improved properties of this deriv. are assocd. with its NO-releasing capability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof9TEp1CBXfrVg90H21EOLACvtfcHk0lj2aBQCXScKzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGhtL%252FE&md5=d998e9259ca559dcf096c59173b75e80</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fjm5007534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5007534%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLv%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DJ.%26aulast%3DHou%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DS.%26atitle%3DNovel%2520nitric%2520oxide-releasing%2520derivatives%2520of%2520brusatol%2520as%2520anti-inflammatory%2520agents%253A%2520design%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520nitric%2520oxide%2520release%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7600%26epage%3D7612%26doi%3D10.1021%2Fjm5007534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Kinase inhibitors: the road ahead</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">353</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrd.2018.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29545548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=353-377&author=F.+M.+Fergusonauthor=N.+S.+Gray&title=Kinase+inhibitors%3A+the+road+ahead&doi=10.1038%2Fnrd.2018.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase inhibitors: the road ahead</span></div><div class="casAuthors">Ferguson, Fleur M.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">353-377</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinase signaling pathways have been successfully targeted to inhibit proliferation and angiogenesis for cancer therapy.  However, kinase deregulation has been firmly demonstrated to play an essential role in virtually all major disease areas.  Kinase inhibitor drug discovery programs have recently broadened their focus to include an expanded range of kinase targets and therapeutic areas.  In this Review, we provide an overview of the novel targets, biol. processes and disease areas that kinase-targeting small mols. are being developed against, highlight the assocd. challenges and assess the strategies and technologies that are enabling efficient generation of highly optimized kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZPospb1TP7Vg90H21EOLACvtfcHk0lhWxK62Lqg9GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks12ktbg%253D&md5=34e42911d8a70301905460c3507e737a</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.21%26sid%3Dliteratum%253Aachs%26aulast%3DFerguson%26aufirst%3DF.%2BM.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DKinase%2520inhibitors%253A%2520the%2520road%2520ahead%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D353%26epage%3D377%26doi%3D10.1038%2Fnrd.2018.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. S.</span></span> <span> </span><span class="NLM_article-title">Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1307</span>– <span class="NLM_lpage">1311</span>, <span class="refDoi"> DOI: 10.1111/cbdd.13032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fcbdd.13032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28557295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCrurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2017&pages=1307-1311&author=Y.+R.+Liauthor=C.+C.+Linauthor=C.+Y.+Huangauthor=Y.+H.+Wongauthor=C.+H.+Hsiehauthor=H.+W.+Wuauthor=J.+J.+W.+Chenauthor=Y.+S.+Wu&title=Study+of+the+inhibitory+effects+on+TNF-%CE%B1-induced+NF-%CE%BAB+activation+of+IMD0354+analogs&doi=10.1111%2Fcbdd.13032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Study of the inhibitory effects on TNF-α-induced NF-κB activation of IMD0354 analogs</span></div><div class="casAuthors">Li, Yi-Rong; Lin, Chi-Chen; Huang, Chih-Yuan; Wong, Yung-Hao; Hsieh, Cheng-Hung; Wu, Han-Wei; Chen, Jeremy J. W.; Wu, Yu-Shan</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1307-1311</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Nuclear factor-κB (NF-κB) is an important nuclear transcription factor which regulates pro-inflammatory cytokines such as TNF-α, IL-6.  Its role as immunoregulatory mediator makes it an attractive target in the development of treatments for inflammatory and autoimmune diseases.  In this study, we synthesized derivs. of IMD0354, a known inhibitor for NF-κB, in attempt to understand the effect of benzanilide substitutions on its activity.  The inhibition of these analogs on NF-κB activation was analyzed by luciferase assay.  The inhibition of IKKβ phosphorylation and pro-inflammatory cytokines was detd. by Western blot and real-time PCR.  The structure activity relationships showed that the hydroxyl group on IMD0354 is a crit. moiety that resulting in the inhibition of NF-κB.  Derivs. 1m, 2b, and 2c were shown to inhibit pro-inflammatory cytokine prodn. at low concn.  These newly synthesized compds. may be useful for the treatment of chronic inflammatory disorders or for cancer prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKT7Cu5CCzMrVg90H21EOLACvtfcHk0lhWxK62Lqg9GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCrurrF&md5=bb435591664cb6f04682dbc8cd88fa11</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.13032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.13032%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%2BR.%26aulast%3DLin%26aufirst%3DC.%2BC.%26aulast%3DHuang%26aufirst%3DC.%2BY.%26aulast%3DWong%26aufirst%3DY.%2BH.%26aulast%3DHsieh%26aufirst%3DC.%2BH.%26aulast%3DWu%26aufirst%3DH.%2BW.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%2BW.%26aulast%3DWu%26aufirst%3DY.%2BS.%26atitle%3DStudy%2520of%2520the%2520inhibitory%2520effects%2520on%2520TNF-%25CE%25B1-induced%2520NF-%25CE%25BAB%2520activation%2520of%2520IMD0354%2520analogs%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2017%26volume%3D90%26spage%3D1307%26epage%3D1311%26doi%3D10.1111%2Fcbdd.13032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sugita, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sone, S.</span></span> <span> </span><span class="NLM_article-title">Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>148</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1159/000161579</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1159%2F000161579" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18849610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjs1Kis74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=2009&pages=186-198&author=A.+Sugitaauthor=H.+Ogawaauthor=M.+Azumaauthor=S.+Mutoauthor=A.+Honjoauthor=H.+Yanagawaauthor=Y.+Nishiokaauthor=K.+Taniauthor=A.+Itaiauthor=S.+Sone&title=Antiallergic+and+anti-inflammatory+effects+of+a+novel+I+kappaB+kinase+beta+inhibitor%2C+IMD-0354%2C+in+a+mouse+model+of+allergic+inflammation&doi=10.1159%2F000161579"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Antiallergic and anti-inflammatory effects of a novel IκB Kinase β inhibitor, IMD-0354, in a mouse model of allergic inflammation</span></div><div class="casAuthors">Sugita, Akemi; Ogawa, Hirohisa; Azuma, Masahiko; Muto, Susumu; Honjo, Akifumi; Yanagawa, Hiroaki; Nishioka, Yasuhiko; Tani, Kenji; Itai, Akiko; Sone, Saburo</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">186-198</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Nuclear factor (NF)-κB is a transcription factor known to regulate allergy-assocd. cytokine and chemokine prodn. related to the induction of inflammation.  IκB kinase β (IKKβ), which is responsible for activation of the NF-κB pathway, may be an ideal mol. target to inhibit this process.  IMD-0354 [N-(3,5-bis-trifluoromethyl-phenyl)-5-chloro-2-hydroxy-benzamide] is an attractive novel IKKβ inhibitor that prevents the prodn. of inflammatory cytokines in various diseases, although it is not known if IMD-0354 is effective against allergic inflammation.  This study aimed to elucidate the antiallergic effects of a newly synthesized IKKβ inhibitor, IMD-0354, in a mouse model of allergic inflammation.  Methods: We generated ovalbumin (OVA)-sensitized mice which were then challenged with OVA.  IMD-0354 was administered i.p. to therapeutic groups.  Lung histopathol. and the concns. of cytokines and chemokines in bronchoalveolar lavage fluid (BALF) and supernatants of lung homogenates were detd.  Results: Administration of IMD-0354 ameliorated airway hyperresponsiveness and reduced the nos. of bronchial eosinophils and mucus-producing cells in OVA-sensitized mice.  The total nos. of cells and eosinophils in BALF were also reduced by treatment with IMD-0354.  Treatment with IMD-0354 inhibited the prodn. of Th2 cytokines such as interleukin (IL)-5 and IL-13 and eotaxin in the airways and/or lungs of OVA-sensitized mice, but it did not affect the restoration of Th1 cytokines such as IL-12 and interferon-γ under the same exptl. conditions.  IgE prodn. was also inhibited by IMD-0354.  Conclusion: A specific IKKβ inhibitor, IMD-0354, improved allergic airway inflammation and hyperresponsiveness in mice.  IMD-0354 may have therapeutic potential for bronchial asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyHAFj_1oj87Vg90H21EOLACvtfcHk0lhWxK62Lqg9GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjs1Kis74%253D&md5=bd9d5d904d37150cfa91b4a1f028b4dc</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1159%2F000161579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000161579%26sid%3Dliteratum%253Aachs%26aulast%3DSugita%26aufirst%3DA.%26aulast%3DOgawa%26aufirst%3DH.%26aulast%3DAzuma%26aufirst%3DM.%26aulast%3DMuto%26aufirst%3DS.%26aulast%3DHonjo%26aufirst%3DA.%26aulast%3DYanagawa%26aufirst%3DH.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DTani%26aufirst%3DK.%26aulast%3DItai%26aufirst%3DA.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DAntiallergic%2520and%2520anti-inflammatory%2520effects%2520of%2520a%2520novel%2520I%2520kappaB%2520kinase%2520beta%2520inhibitor%252C%2520IMD-0354%252C%2520in%2520a%2520mouse%2520model%2520of%2520allergic%2520inflammation%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2009%26volume%3D148%26spage%3D186%26epage%3D198%26doi%3D10.1159%2F000161579" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span> <span> </span><span class="NLM_article-title">Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">788</span>– <span class="NLM_lpage">815</span>, <span class="refDoi"> DOI: 10.1124/pr.116.012518</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fpr.116.012518" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=27363440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFCrs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2016&pages=788-815&author=P.+J.+Barnes&title=Kinases+as+novel+therapeutic+targets+in+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1124%2Fpr.116.012518"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Kinases as novel therapeutic targets in asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">788-815</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Multiple kinases play a crit. role in orchestrating the chronic inflammation and structural changes in the respiratory tract of patients with asthma and chronic obstructive pulmonary disease (COPD).  Kinases activate signaling pathways that lead to contraction of airway smooth muscle and release of inflammatory mediators (such as cytokines, chemokines, growth factors) as well as cell migration, activation, and proliferation.  For this reason there has been great interest in the development of kinase inhibitors as anti-inflammatory therapies, particular where corticosteroids are less effective, as in severe asthma and COPD.  However, it has proven difficult to develop selective kinase inhibitors that are both effective and safe after oral administration and this has led to a search for inhaled kinase inhibitors, which would reduce systemic exposure.  Although many kinases have been implicated in inflammation and remodeling of airway disease, very few classes of drug have reached the stage of clin. studies in these diseases.  The most promisingdrugs arep38MAPkinases, isoenzyme-selective PI3-kinases, Janus-activated kinases, and Syk-kinases, and inhaled formulations of these drugs are now in development.  There has also been interest in developing inhibitors that block more than one kinase, because these drugs may be more effective and with less risk of losing efficacy with time.  No kinase inhibitors are yet on the market for the treatment of airway diseases, but as kinase inhibitors are improved from other therapeutic areas there is hope that these drugs may eventually prove useful in treating refractory asthma and COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpeztyKAL-brVg90H21EOLACvtfcHk0lj1nXi6jtLsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFCrs7k%253D&md5=b1124d17b06af2c9577db2967d4914a9</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1124%2Fpr.116.012518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.116.012518%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DKinases%2520as%2520novel%2520therapeutic%2520targets%2520in%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DPharmacol.%2520Rev.%26date%3D2016%26volume%3D68%26spage%3D788%26epage%3D815%26doi%3D10.1124%2Fpr.116.012518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Renda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baraldo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazzan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turato, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maestrelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maselli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vatrella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsico, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saetta, M.</span></span> <span> </span><span class="NLM_article-title">Increased activation of p38 MAPK in COPD</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">62</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1183/09031936.00036707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1183%2F09031936.00036707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17959643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvVCgs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=62-69&author=T.+Rendaauthor=S.+Baraldoauthor=G.+Pelaiaauthor=E.+Bazzanauthor=G.+Turatoauthor=A.+Papiauthor=P.+Maestrelliauthor=R.+Maselliauthor=A.+Vatrellaauthor=L.+M.+Fabbriauthor=R.+Zuinauthor=S.+A.+Marsicoauthor=M.+Saetta&title=Increased+activation+of+p38+MAPK+in+COPD&doi=10.1183%2F09031936.00036707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Increased activation of p38 MAPK in COPD</span></div><div class="casAuthors">Renda, T.; Baraldo, S.; Pelaia, G.; Bazzan, E.; Turato, G.; Papi, A.; Maestrelli, P.; Maselli, R.; Vatrella, A.; Fabbri, L. M.; Zuin, R.; Marsico, S. A.; Saetta, M.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">62-69</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">Inflammation, oxidative stress and apoptosis, which are involved in chronic obstructive pulmonary disease (COPD) pathogenesis, may activate the p38 subgroup of mitogen-activated protein kinases (MAPKs).  Therefore, the aim of the present study was to evaluate the expression of the phosphorylated, active form of p38 MAPK (phospho-p38) in the lungs of COPD patients.  Surgical specimens were obtained from 18 smokers with COPD at different stages of disease severity, plus nine smoking and eight nonsmoking subjects with normal lung function.  Phospho-p38+ cells were quantified by immunohistochem. in both alveolar spaces and alveolar walls.  Moreover, a Western blot anal. of phospho-p38 and total p38α isoform expressed by alveolar macrophages was performed.  Phospho-p38+ alveolar macrophages and phospho-p38+ cells in alveolar walls were increased in patients with severe and mild/moderate COPD, compared with smoking and nonsmoking controls.  Moreover, they were inversely correlated to values of forced expiratory vol. in one second (FEV1) and FEV1/forced vital capacity.  Western blot anal. showed that phosphorylated p38, but not the total p38α isoform, was specifically increased in alveolar macrophages from COPD patients.  Activation of the p38 mitogen-activated protein kinase pathway appears to be involved in the pathogenesis of chronic obstructive pulmonary disease.  The present findings suggest that this protein may be a suitable pharmacol. target for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtAB3KTmtt7bVg90H21EOLACvtfcHk0lj1nXi6jtLsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvVCgs7g%253D&md5=39f304338b1fab6a54221a1ed305d220</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1183%2F09031936.00036707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00036707%26sid%3Dliteratum%253Aachs%26aulast%3DRenda%26aufirst%3DT.%26aulast%3DBaraldo%26aufirst%3DS.%26aulast%3DPelaia%26aufirst%3DG.%26aulast%3DBazzan%26aufirst%3DE.%26aulast%3DTurato%26aufirst%3DG.%26aulast%3DPapi%26aufirst%3DA.%26aulast%3DMaestrelli%26aufirst%3DP.%26aulast%3DMaselli%26aufirst%3DR.%26aulast%3DVatrella%26aufirst%3DA.%26aulast%3DFabbri%26aufirst%3DL.%2BM.%26aulast%3DZuin%26aufirst%3DR.%26aulast%3DMarsico%26aufirst%3DS.%2BA.%26aulast%3DSaetta%26aufirst%3DM.%26atitle%3DIncreased%2520activation%2520of%2520p38%2520MAPK%2520in%2520COPD%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2008%26volume%3D31%26spage%3D62%26epage%3D69%26doi%3D10.1183%2F09031936.00036707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Millan, D. S.</span></span> <span> </span><span class="NLM_article-title">What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1635</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.96</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4155%2Ffmc.11.96" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21942253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1635-1645&author=D.+S.+Millan&title=What+is+the+potential+for+inhaled+p38+inhibitors+in+the+treatment+of+chronic+obstructive+pulmonary+disease%3F&doi=10.4155%2Ffmc.11.96"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">What is the potential for inhaled p38 inhibitors in the treatment of chronic obstructive pulmonary disease?</span></div><div class="casAuthors">Millan, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1635-1645</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  P38 has been an intensely studied therapeutic target in the pharmaceutical industry.  With more than 20 compds. entering human trials, none have progressed beyond Phase II to the best of our knowledge.  The transient efficacy seen in many of the Phase II trials has raised some concerns for the future potential of this target, particularly in rheumatoid arthritis.  With this caveat, there is good evidence for p38 inhibition to be efficacious in chronic obstructive pulmonary disease and there are now several oral compds. currently in development for this disease, with encouraging data beginning to emerge.  With an inhaled agent likely to improve the therapeutic window between efficacy and some of the common adverse events obsd. with oral p38 inhibitors it would seem a sensible approach to take for a disease of the lung.  This review will highlight the potential for an inhaled p38 inhibitor in chronic obstructive pulmonary disease, as well as some of the design principles that are important to consider when developing an inhaled kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4waRvOu6S_LVg90H21EOLACvtfcHk0lj1nXi6jtLsWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WktrvK&md5=81104fda424ad56be567693b9207b4f3</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.96&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.96%26sid%3Dliteratum%253Aachs%26aulast%3DMillan%26aufirst%3DD.%2BS.%26atitle%3DWhat%2520is%2520the%2520potential%2520for%2520inhaled%2520p38%2520inhibitors%2520in%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253F%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D1635%26epage%3D1645%26doi%3D10.4155%2Ffmc.11.96" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1006358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543784.2015.1006358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25599809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVKrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=383-392&author=P.+Norman&title=Investigational+p38+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1517%2F13543784.2015.1006358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-392</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: The p38 protein kinases, in particular p38α and p38β, regulate the prodn. of multiple inflammatory mediators.  Consequentially, considerable effort has been focused on trying to develop p38 inhibitors for the treatment of inflammatory diseases.  Some 20 p38 inhibitors have progressed to clin. development, mostly for the treatment of rheumatoid arthritis, but with little success.  Increasingly, interest has turned to their use in other indications and notably chronic obstructive pulmonary disease (COPD).  Areas covered: In this review, the author discusses the eight p38 inhibitors that have been clin. evaluated.  Acumapimod is the only one of four orally delivered inhibitors that remains in active development while Phase II results of PH-797804 and losmapimod are compared.  The activity of two inhibitors designed for inhaled delivery, RV-568 and PF-03715455, is compared but little is known about AZD-7624 or the discontinued GSK-610677.  Expert opinion: Results from animal models provide a clear rationale for developing p38 inhibitors for COPD, and appear to be (partially) validated by the efficacy seen with PH-797804 and losmapimod.  Inhaled delivery provides the opportunity to enhance p38 inhibition in the lung while reducing unwanted systemic effects of p38 inhibition.  Validation of this hypothesis should come from the results of the recently completed Phase II study with RV-568.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKUbGhXQAMzrVg90H21EOLACvtfcHk0lggEWIVpV4kng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVKrtLk%253D&md5=97485678de1e2d15bf1ace5139cba51e</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1006358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1006358%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DInvestigational%2520p38%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D383%26epage%3D392%26doi%3D10.1517%2F13543784.2015.1006358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Medicherla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fitzgerald, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapoun, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Protter, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, L. S.</span></span> <span> </span><span class="NLM_article-title">p38α-Selective MAP kinase inhibitor, SD-282, reduces inflammation in a sub-chronic model of tobacco smoke-induced airway inflammation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.127092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.107.127092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18056868" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2007&pages=921-929&author=S.+Medicherlaauthor=M.+Fitzgeraldauthor=D.+Spicerauthor=P.+Woodmanauthor=J.+Y.+Maauthor=A.+M.+Kapounauthor=S.+Chakravartyauthor=S.+Dugarauthor=A.+A.+Protterauthor=L.+S.+Higgins&title=p38%CE%B1-Selective+MAP+kinase+inhibitor%2C+SD-282%2C+reduces+inflammation+in+a+sub-chronic+model+of+tobacco+smoke-induced+airway+inflammation&doi=10.1124%2Fjpet.107.127092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.127092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.127092%26sid%3Dliteratum%253Aachs%26aulast%3DMedicherla%26aufirst%3DS.%26aulast%3DFitzgerald%26aufirst%3DM.%26aulast%3DSpicer%26aufirst%3DD.%26aulast%3DWoodman%26aufirst%3DP.%26aulast%3DMa%26aufirst%3DJ.%2BY.%26aulast%3DKapoun%26aufirst%3DA.%2BM.%26aulast%3DChakravarty%26aufirst%3DS.%26aulast%3DDugar%26aufirst%3DS.%26aulast%3DProtter%26aufirst%3DA.%2BA.%26aulast%3DHiggins%26aufirst%3DL.%2BS.%26atitle%3Dp38%25CE%25B1-Selective%2520MAP%2520kinase%2520inhibitor%252C%2520SD-282%252C%2520reduces%2520inflammation%2520in%2520a%2520sub-chronic%2520model%2520of%2520tobacco%2520smoke-induced%2520airway%2520inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D324%26spage%3D921%26epage%3D929%26doi%3D10.1124%2Fjpet.107.127092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osborn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotzer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpenter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochnowicz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hay, D. W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griswold, D. E.</span></span> <span> </span><span class="NLM_article-title">SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">281</span>– <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10734180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvFGhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2000&pages=281-288&author=D.+C.+Underwoodauthor=R.+R.+Osbornauthor=C.+J.+Kotzerauthor=J.+L.+Adamsauthor=J.+C.+Leeauthor=E.+F.+Webbauthor=D.+C.+Carpenterauthor=S.+Bochnowiczauthor=H.+C.+Thomasauthor=D.+W.+P.+Hayauthor=D.+E.+Griswold&title=SB+239063%2C+a+potent+p38+MAP+kinase+inhibitor%2C+reduces+inflammatory+cytokine+production%2C+airways+eosinophil+infiltration%2C+and+persistence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence</span></div><div class="casAuthors">Underwood, David C.; Osborn, Ruth R.; Kotzer, Charles J.; Adams, Jerry L.; Lee, John C.; Webb, Edward F.; Carpenter, Donald C.; Bochnowicz, Steven; Thomas, Heath C.; Hay, Douglas W. P.; Griswold, Don E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">281-288</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The anti-inflammatory/antiallergic activity of a novel second-generation p38 mitogen-activated protein kinase inhibitor, SB 239063 [trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridim idin-4-yl)imidazole], was investigated in vivo and in vitro.  SB 239063 had an IC50 of 44 nM for inhibition of recombinant purified human p38α.  In lipopolysaccharide-stimulated human peripheral blood monocytes, SB 239063 inhibited interleukin-1 and tumor necrosis factor-α prodn. (IC50 values = 0.12 and 0.35 μM, resp.).  A role for p38 kinase in cytokine-assocd. inflammation in the mouse was shown by p38 activation in the lung and inhibition of lipopolysaccharide-induced tumor necrosis factor-α prodn. by SB 239063 (ED50 = 5.8 mg/kg p.o.).  Antiallergic activity was demonstrated by essential abolition (∼93% inhibition) of inhaled ovalbumin (OA)-induced airway eosinophilia by SB 239063 (12 mg/kg p.o.), measured by bronchoalveolar lavage (BAL) in OA-sensitized mice.  In addn., p38 kinase was found by Western anal. to be activated in guinea pig lung.  Administration of SB 239063 (10 or 30 mg/kg p.o.) in conscious guinea pigs markedly reduced (∼50% inhibition) OA-induced pulmonary eosinophil influx, measured by BAL 24 h after antigen.  SB 239063 (10 mg/kg b.i.d. p.o.) administered after leukotriene D4 inhalation, reduced by 60% the persistent airway eosinophilia seen at 4 days.  Apoptosis of cultured eosinophils isolated from guinea pig BAL was increased by SB 239063 (1-10 μM) in the presence of interleukin-5.  These results indicate that SB 239063 is a potent inhibitor of inflammatory cytokine prodn., inhibits eosinophil recruitment, in addn. to enhancing apoptosis of these cells.  Collectively, the results support the potential utility of p38 kinase inhibitors, such as SB 239063 for the treatment of asthma and other inflammatory disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLFMXLD74MwLVg90H21EOLACvtfcHk0lggEWIVpV4kng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvFGhuro%253D&md5=3a09fb3f2b3c67d8b359cea1d73ef27b</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DUnderwood%26aufirst%3DD.%2BC.%26aulast%3DOsborn%26aufirst%3DR.%2BR.%26aulast%3DKotzer%26aufirst%3DC.%2BJ.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DWebb%26aufirst%3DE.%2BF.%26aulast%3DCarpenter%26aufirst%3DD.%2BC.%26aulast%3DBochnowicz%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DH.%2BC.%26aulast%3DHay%26aufirst%3DD.%2BW.%2BP.%26aulast%3DGriswold%26aufirst%3DD.%2BE.%26atitle%3DSB%2520239063%252C%2520a%2520potent%2520p38%2520MAP%2520kinase%2520inhibitor%252C%2520reduces%2520inflammatory%2520cytokine%2520production%252C%2520airways%2520eosinophil%2520infiltration%252C%2520and%2520persistence%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2000%26volume%3D293%26spage%3D281%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onions, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charron, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colucci, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frickel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King-Underwood, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knowles, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapeport, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taddei, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of narrow spectrum kinase inhibitors: new therapeutic agents for the treatment of COPD and steroid-resistant asthma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1727</span>– <span class="NLM_lpage">1746</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01029</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1ahtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1727-1746&author=S.+T.+Onionsauthor=K.+Itoauthor=C.+E.+Charronauthor=R.+J.+Brownauthor=M.+Colucciauthor=F.+Frickelauthor=G.+Hardyauthor=K.+Jolyauthor=J.+King-Underwoodauthor=Y.+Kizawaauthor=I.+Knowlesauthor=P.+J.+Murrayauthor=A.+Novakauthor=A.+Raniauthor=G.+Rapeportauthor=A.+Smithauthor=P.+Strongauthor=D.+M.+Taddeiauthor=J.+G.+Williams&title=Discovery+of+narrow+spectrum+kinase+inhibitors%3A+new+therapeutic+agents+for+the+treatment+of+COPD+and+steroid-resistant+asthma&doi=10.1021%2Facs.jmedchem.5b01029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Narrow Spectrum Kinase Inhibitors: New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma</span></div><div class="casAuthors">Onions, Stuart T.; Ito, Kazuhiro; Charron, Catherine E.; Brown, Richard J.; Colucci, Marie; Frickel, Fritz; Hardy, George; Joly, Kevin; King-Underwood, John; Kizawa, Yasuo; Knowles, Ian; Murray, P. John; Novak, Andrew; Rani, Anjna; Rapeport, Garth; Smith, Alun; Strong, Peter; Taddei, David M.; Williams, Jonathan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1727-1746</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of a novel series of therapeutic agents that has been designed and optimized for treating chronic obstructive pulmonary disease is reported (I).  The pharmacol. strategy was based on the identification of compds. that inhibit a defined subset of kinase enzymes modulating inflammatory processes that would be effective against steroid refractory disease and exhibit a sustained duration of action after inhaled delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogkSJ05_wxaLVg90H21EOLACvtfcHk0lhpO5ql4_cSiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1ahtbk%253D&md5=1aa6f8356d2e2a18ce9ac8906c46a6d1</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01029%26sid%3Dliteratum%253Aachs%26aulast%3DOnions%26aufirst%3DS.%2BT.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DCharron%26aufirst%3DC.%2BE.%26aulast%3DBrown%26aufirst%3DR.%2BJ.%26aulast%3DColucci%26aufirst%3DM.%26aulast%3DFrickel%26aufirst%3DF.%26aulast%3DHardy%26aufirst%3DG.%26aulast%3DJoly%26aufirst%3DK.%26aulast%3DKing-Underwood%26aufirst%3DJ.%26aulast%3DKizawa%26aufirst%3DY.%26aulast%3DKnowles%26aufirst%3DI.%26aulast%3DMurray%26aufirst%3DP.%2BJ.%26aulast%3DNovak%26aufirst%3DA.%26aulast%3DRani%26aufirst%3DA.%26aulast%3DRapeport%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DStrong%26aufirst%3DP.%26aulast%3DTaddei%26aufirst%3DD.%2BM.%26aulast%3DWilliams%26aufirst%3DJ.%2BG.%26atitle%3DDiscovery%2520of%2520narrow%2520spectrum%2520kinase%2520inhibitors%253A%2520new%2520therapeutic%2520agents%2520for%2520the%2520treatment%2520of%2520COPD%2520and%2520steroid-resistant%2520asthma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1727%26epage%3D1746%26doi%3D10.1021%2Facs.jmedchem.5b01029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2979</span>– <span class="NLM_lpage">2994</span>, <span class="refDoi"> DOI: 10.2174/092986705774462914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2174%2F092986705774462914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16378500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Grt7jF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=2979-2994&author=M.+R.+Leeauthor=C.+Dominguez&title=MAP+kinase+p38+inhibitors%3A+clinical+results+and+an+intimate+look+at+their+interactions+with+p38alpha+protein&doi=10.2174%2F092986705774462914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38α protein</span></div><div class="casAuthors">Lee, Matthew R.; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2979-2994</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase p38 is a serine/threonine kinase originally isolated from lipopolysaccharide (LPS) stimulated monocytes.  There are four isoforms p38α, p38β, p38γ, and p38δ.  The most thoroughly studied isoform is p38α, whose activation has been obsd. in many hematopoietic and non-hematopoietic cell types upon appropriate stimuli.  Subsequently, p38α kinase has been shown to be involved in the biosynthesis of TNFα and IL-1β at the translational and transcriptional level.  MAP kinase p38α represents a point of convergence for multiple signaling processes that are activated in inflammation and thus a key potential target for the modulation of cytokine prodn.  The discovery and publication of p38α and the pyridinyl-imidazole inhibitor initiated a huge effort by many companies to develop p38α inhibitors as potential treatment for inflammatory diseases.  Herein we provide a brief overview of recent reported clin. results for AMG 548, BIRB 796, VX 702, SCIO 469, and SCIO 323.  However, our focus will be on the binding modes of these inhibitors and other p38 inhibitors in the recent literature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZSldsfUAO6bVg90H21EOLACvtfcHk0lhpO5ql4_cSiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Grt7jF&md5=eb21253fcc2df76280cd9a1812ed1015</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.2174%2F092986705774462914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986705774462914%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DM.%2BR.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DMAP%2520kinase%2520p38%2520inhibitors%253A%2520clinical%2520results%2520and%2520an%2520intimate%2520look%2520at%2520their%2520interactions%2520with%2520p38alpha%2520protein%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2005%26volume%3D12%26spage%3D2979%26epage%3D2994%26doi%3D10.2174%2F092986705774462914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span> <span> </span><span class="NLM_article-title">PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8559</span>– <span class="NLM_lpage">8581</span>, <span class="refDoi"> DOI: 10.1021/jm300847w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300847w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8559-8581&author=T.+D.+Cushingauthor=D.+P.+Metzauthor=D.+A.+Whittingtonauthor=L.+R.+McGee&title=PI3K%CE%B4+and+PI3K%CE%B3+as+targets+for+autoimmune+and+inflammatory+diseases&doi=10.1021%2Fjm300847w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">PI3Kδ and PI3Kγ as Targets for Autoimmune and Inflammatory Diseases</span></div><div class="casAuthors">Cushing, Timothy D.; Metz, Daniela P.; Whittington, Douglas A.; McGee, Lawrence R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8559-8581</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Targeting signaling mols. that are required for the activation of multiple immune cells may be a more likely route to success in combating chronic, immune cell-mediated diseases (such as rheumatoid arthritis, systemic lupus erythematosus, and asthma).  This review will highlight two such signaling mols., the related lipid kinases, class I PI3K (phosphoinositide 3-kinase) δ and γ, both of which are primarily expressed in leukocytes and seem to play important roles in their function and activation.  This review will compare and contrast these two kinases as targets for autoimmune and inflammatory diseases and summarize efforts toward the development of small mol. inhibitors of PI3Kδ and PI3Kγ.  Phosphoinositides (PIs) act as second messengers in a wide variety of cellular roles including signal transduction, control of membrane trafficking and transport, cytoskeleton organization, cell survival and death, among many other functions.  The target of PI3K kinase activity is the phosphoinositides within cell membranes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMqItqgMiGp7Vg90H21EOLACvtfcHk0lhpO5ql4_cSiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1KjsrjL&md5=76fc05c3bf303174add4aca98f526f8f</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm300847w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300847w%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26atitle%3DPI3K%25CE%25B4%2520and%2520PI3K%25CE%25B3%2520as%2520targets%2520for%2520autoimmune%2520and%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8559%26epage%3D8581%26doi%3D10.1021%2Fjm300847w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Down, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldwin, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deakin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felton, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guntrip, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, Z. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keeling, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunniss, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parr, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Washio, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span> <span> </span><span class="NLM_article-title">Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase δ for the treatment of respiratory disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">7381</span>– <span class="NLM_lpage">7399</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00767</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00767" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=7381-7399&author=K.+Downauthor=A.+Amourauthor=I.+R.+Baldwinauthor=A.+W.+Cooperauthor=A.+M.+Deakinauthor=L.+M.+Feltonauthor=S.+B.+Guntripauthor=C.+Hardyauthor=Z.+A.+Harrisonauthor=K.+L.+Jonesauthor=P.+Jonesauthor=S.+E.+Keelingauthor=J.+Leauthor=S.+Liviaauthor=F.+Lucasauthor=C.+J.+Lunnissauthor=N.+J.+Parrauthor=E.+Robinsonauthor=P.+Rowlandauthor=S.+Smithauthor=D.+A.+Thomasauthor=G.+Vitulliauthor=Y.+Washioauthor=J.+N.+Hamblin&title=Optimization+of+novel+indazoles+as+highly+potent+and+selective+inhibitors+of+phosphoinositide+3-kinase+%CE%B4+for+the+treatment+of+respiratory+disease&doi=10.1021%2Facs.jmedchem.5b00767"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Down, Kenneth; Amour, Augustin; Baldwin, Ian R.; Cooper, Anthony W. J.; Deakin, Angela M.; Felton, Leigh M.; Guntrip, Stephen B.; Hardy, Charlotte; Harrison, Zoe A.; Jones, Katherine L.; Jones, Paul; Keeling, Suzanne E.; Le, Joelle; Livia, Stefano; Lucas, Fiona; Lunniss, Christopher J.; Parr, Nigel J.; Robinson, Ed; Rowland, Paul; Smith, Sarah; Thomas, Daniel A.; Vitulli, Giovanni; Washio, Yoshiaki; Hamblin, J. Nicole</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7381-7399</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Optimization of lead compd., through extensive use of structure-based design and a focus on PI3Kδ potency, isoform selectivity, and inhaled PK properties, led to the discovery of clin. candidates I (GSK2269557) and II (GSK2292767) for the treatment of respiratory indications via inhalation.  Compds. I and II are both highly selective for PI3Kδ over the closely related isoforms and are active in a disease relevant brown Norway rat acute OVA model of Th2-driven lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUYzpPxn_ArbVg90H21EOLACvtfcHk0lhi-nqKaI0NCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyjsrvJ&md5=2fe8e51a64e6f7c798bdcb63781d02ad</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00767&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00767%26sid%3Dliteratum%253Aachs%26aulast%3DDown%26aufirst%3DK.%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBaldwin%26aufirst%3DI.%2BR.%26aulast%3DCooper%26aufirst%3DA.%2BW.%26aulast%3DDeakin%26aufirst%3DA.%2BM.%26aulast%3DFelton%26aufirst%3DL.%2BM.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DHardy%26aufirst%3DC.%26aulast%3DHarrison%26aufirst%3DZ.%2BA.%26aulast%3DJones%26aufirst%3DK.%2BL.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DKeeling%26aufirst%3DS.%2BE.%26aulast%3DLe%26aufirst%3DJ.%26aulast%3DLivia%26aufirst%3DS.%26aulast%3DLucas%26aufirst%3DF.%26aulast%3DLunniss%26aufirst%3DC.%2BJ.%26aulast%3DParr%26aufirst%3DN.%2BJ.%26aulast%3DRobinson%26aufirst%3DE.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26atitle%3DOptimization%2520of%2520novel%2520indazoles%2520as%2520highly%2520potent%2520and%2520selective%2520inhibitors%2520of%2520phosphoinositide%25203-kinase%2520%25CE%25B4%2520for%2520the%2520treatment%2520of%2520respiratory%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D7381%26epage%3D7399%26doi%3D10.1021%2Facs.jmedchem.5b00767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cahn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamblin, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunsire, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriskantharajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montembault, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leemereise, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galinanes-Garcia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirsten, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuhr, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span> <span> </span><span class="NLM_article-title">Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2017.08.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2017.08.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=28823947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVKnsb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=69-77&author=A.+Cahnauthor=J.+N.+Hamblinauthor=M.+Beggauthor=R.+Wilsonauthor=L.+Dunsireauthor=S.+Sriskantharajahauthor=M.+Montembaultauthor=C.+N.+Leemereiseauthor=L.+Galinanes-Garciaauthor=H.+Watzauthor=A.+M.+Kirstenauthor=R.+Fuhrauthor=E.+M.+Hessel&title=Safety%2C+pharmacokinetics+and+dose-response+characteristics+of+GSK2269557%2C+an+inhaled+PI3K%CE%B4+inhibitor+under+development+for+the+treatment+of+COPD&doi=10.1016%2Fj.pupt.2017.08.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD</span></div><div class="casAuthors">Cahn, A.; Hamblin, J. N.; Begg, M.; Wilson, R.; Dunsire, L.; Sriskantharajah, S.; Montembault, M.; Leemereise, C. N.; Galinanes-Garcia, L.; Watz, H.; Kirsten, A. M.; Fuhr, R.; Hessel, E. M.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-77</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">While current therapies reduce symptoms in chronic obstructive pulmonary disease (COPD) patients, substantial unmet need remains and novel treatments are highly desired.  Phosphoinositide 3-kinase δ (PI3Kδ) is a lipid kinase specifically expressed in leukocytes and involved in their recruitment and activation.  This study evaluated the safety, pharmacokinetics (PK) and dose-response characteristics of inhaled GSK2269557, a PI3Kδ inhibitor, in moderate-to-severe COPD patients with stable disease.  In this randomised, double-blind, placebo controlled, parallel group study, patients received once daily inhaled treatment with GSK2269557 1000 μg or placebo for 14 days (Part A, primary aim safety, N = 28 patients).  In part B of the study (primary aim pharmacodynamic dose-response, N = 36 patients), GSK2269557 100, 200, 500, 700, 1000, 2000 μg or placebo was given for 14 days.  In both Part A and B, GSK2269557 was added to the usual maintenance therapy.  Safety, PK assessments and induced sputum collection for cytokine anal. were conducted at baseline and after 7 and 14 days of treatment.  Adverse events (AEs) were monitored throughout.In Part A, mean age was 61.7 years (SD 6.7), 29% were females, and mean FEV1% predicted was 59.7% (SD 11.4)2.  In Part B, mean age was 63.3 years (SD 6.3), 44% were females, and mean FEV1% predicted was 56.5% (SD 11.5)2.  GSK2269557 was well tolerated in both parts of the study; the most commonly reported AEs were cough and headache, with cough being reported with a greater incidence in the GSK2269557 groups vs. placebo (Part A: 19% vs. 14% and Part B: range of 0-80% for different doses vs. 0% on placebo).  No drug-related serious AEs or clin. significant changes in any other safety parameters were reported.  GSK2269557 was rapidly absorbed into plasma following all doses with a max. peak at approx. 2 h.  Following repeat administration, accumulation in plasma was approx. 2-3 fold from Day 1 to Day 7.  At Day 14, relative to placebo, sputum interleukin (IL)-8 and IL-6 levels were reduced on av. by 32% and 29% resp. after inhalation of GSK2269557 1000 μg in Part A.  In Part B, although inhibition of both IL-8 and IL-6 levels was obsd., the levels were variable and there was insufficient evidence to support a monotonic dose-response.  In this study, inhaled GSK2269557 had an acceptable safety profile for progression into larger studies in COPD patients.  Moreover, inhalation of GSK2269557 resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known anti-inflammatory activity of a PI3Kδ inhibitor.  Inhibition of inflammatory cytokines in the airway compartment may contribute to the potential therapeutic benefit of a PI3Kδ inhibitor in chronically inflamed COPD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLev2M055yDLVg90H21EOLACvtfcHk0lhi-nqKaI0NCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVKnsb7M&md5=bf5733fdf1e02f3804724f1a523c758b</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2017.08.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2017.08.008%26sid%3Dliteratum%253Aachs%26aulast%3DCahn%26aufirst%3DA.%26aulast%3DHamblin%26aufirst%3DJ.%2BN.%26aulast%3DBegg%26aufirst%3DM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DDunsire%26aufirst%3DL.%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DMontembault%26aufirst%3DM.%26aulast%3DLeemereise%26aufirst%3DC.%2BN.%26aulast%3DGalinanes-Garcia%26aufirst%3DL.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DKirsten%26aufirst%3DA.%2BM.%26aulast%3DFuhr%26aufirst%3DR.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26atitle%3DSafety%252C%2520pharmacokinetics%2520and%2520dose-response%2520characteristics%2520of%2520GSK2269557%252C%2520an%2520inhaled%2520PI3K%25CE%25B4%2520inhibitor%2520under%2520development%2520for%2520the%2520treatment%2520of%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2017%26volume%3D46%26spage%3D69%26epage%3D77%26doi%3D10.1016%2Fj.pupt.2017.08.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Doukas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racanelli-Layton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dellamary, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dneprovskaia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noronha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrasidlo, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acevedo, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheresh, D. A.</span></span> <span> </span><span class="NLM_article-title">Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100–115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">758</span>– <span class="NLM_lpage">765</span>, <span class="refDoi"> DOI: 10.1124/jpet.108.144311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.108.144311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19056934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXislals78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2009&pages=758-765&author=J.+Doukasauthor=L.+Eideauthor=K.+Stebbinsauthor=A.+Racanelli-Laytonauthor=L.+Dellamaryauthor=M.+Martinauthor=E.+Dneprovskaiaauthor=G.+Noronhaauthor=R.+Sollauthor=W.+Wrasidloauthor=L.+M.+Acevedoauthor=D.+A.+Cheresh&title=Aerosolized+phosphoinositide+3-kinase+gamma%2Fdelta+inhibitor+TG100%E2%80%93115+%5B3-%5B2%2C4-diamino-6-%283-hydroxyphenyl%29pteridin-7-yl%5Dphenol%5D+as+a+therapeutic+candidate+for+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1124%2Fjpet.108.144311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Aerosolized phosphoinositide 3-kinase γ/δ inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Doukas, John; Eide, Lisa; Stebbins, Karin; Racanelli-Layton, Adrienne; Dellamary, Luis; Martin, Michael; Dneprovskaia, Elena; Noronha, Glenn; Soll, Richard; Wrasidlo, Wolfgang; Acevedo, Lisette M.; Cheresh, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">758-765</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Phosphatidylinositol 3-kinases (PI3Ks) are key elements in the signaling cascades that lie downstream of many cellular receptors.  In particular, PI3K δ and γ isoforms contribute to inflammatory cell recruitment and subsequent activation.  For this reason, in a series of preclin. studies, we tested the potential of a recently developed small-mol. inhibitor of these two isoforms, TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol], as a form of anti-inflammatory therapy for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).  To det. pharmacokinetic profiles, aerosolized formulations of the drug were delivered to mice by a nose-only inhalation route, yielding high pulmonary TG100-115 levels with minimal systemic exposure.  Safety assessments were favorable, with no clin. or histol. changes noted after 21 days of daily dosing.  In a murine asthma model, aerosolized TG100-115 markedly reduced the pulmonary eosinophilia and the concomitant interleukin-13 and mucin accumulation characteristic of this disease.  As a functional benefit, interventional dosing schedules of this inhibitor also reduced airway hyper-responsiveness.  To model the pulmonary neutrophilia characteristic of COPD, mice were exposed to either intranasal lipopolysaccharide or inhaled smoke.  Aerosolized TG100-115 again inhibited these inflammatory patterns, most notably in the smoke model, where interventional therapy overcame the steroid-resistant nature of the pulmonary inflammation.  In conclusion, aerosolized TG100-115 displays pharmacokinetic, safety, and biol. activity profiles favorable for further development as a therapy for both asthma and COPD.  Furthermore, these studies support the hypothesis that PI3K δ and γ are suitable mol. targets for these diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoidXci0t94JrVg90H21EOLACvtfcHk0lhnUcUPIfErHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXislals78%253D&md5=ec9227c014cdcdd0637e1bec10446255</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.144311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.144311%26sid%3Dliteratum%253Aachs%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DEide%26aufirst%3DL.%26aulast%3DStebbins%26aufirst%3DK.%26aulast%3DRacanelli-Layton%26aufirst%3DA.%26aulast%3DDellamary%26aufirst%3DL.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DDneprovskaia%26aufirst%3DE.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DSoll%26aufirst%3DR.%26aulast%3DWrasidlo%26aufirst%3DW.%26aulast%3DAcevedo%26aufirst%3DL.%2BM.%26aulast%3DCheresh%26aufirst%3DD.%2BA.%26atitle%3DAerosolized%2520phosphoinositide%25203-kinase%2520gamma%252Fdelta%2520inhibitor%2520TG100%25E2%2580%2593115%2520%255B3-%255B2%252C4-diamino-6-%25283-hydroxyphenyl%2529pteridin-7-yl%255Dphenol%255D%2520as%2520a%2520therapeutic%2520candidate%2520for%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2009%26volume%3D328%26spage%3D758%26epage%3D765%26doi%3D10.1124%2Fjpet.108.144311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amour, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luscombe, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peace, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tame, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uddin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitulli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellaway, N.</span></span> <span> </span><span class="NLM_article-title">Evolution of a novel, orally bioavailable series of PI3Kδ inhibitors from an inhaled lead for the treatment of respiratory disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7239</span>– <span class="NLM_lpage">7251</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00799</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00799" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFyitLnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7239-7251&author=A.+Amourauthor=N.+Bartonauthor=A.+W.+Cooperauthor=G.+Inglisauthor=C.+Jamiesonauthor=C.+N.+Luscombeauthor=J.+Morrellauthor=S.+Peaceauthor=D.+Perezauthor=P.+Rowlandauthor=C.+J.+Tameauthor=S.+Uddinauthor=G.+Vitulliauthor=N.+Wellaway&title=Evolution+of+a+novel%2C+orally+bioavailable+series+of+PI3K%CE%B4+inhibitors+from+an+inhaled+lead+for+the+treatment+of+respiratory+disease&doi=10.1021%2Facs.jmedchem.6b00799"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease</span></div><div class="casAuthors">Amour, Augustin; Barton, Nick; Cooper, Anthony W. J.; Inglis, Graham; Jamieson, Craig; Luscombe, Christopher N.; Morrell, Josie; Peace, Simon; Perez, David; Rowland, Paul; Tame, Christopher J.; Uddin, Sorif; Vitulli, Giovanni; Wellaway, Natalie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7239-7251</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A four-step process of high-quality modeling of existing data, deconstruction, identification of replacement cores, and an innovative synthetic regrowth strategy led to the rapid discovery of a novel oral series of PI3Kδ inhibitors with promising selectivity and excellent in vivo characteristics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKbdEJSHwYD7Vg90H21EOLACvtfcHk0lhnUcUPIfErHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFyitLnN&md5=ab4641778d1c80f0dd9551d6d75ff4ef</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00799%26sid%3Dliteratum%253Aachs%26aulast%3DAmour%26aufirst%3DA.%26aulast%3DBarton%26aufirst%3DN.%26aulast%3DCooper%26aufirst%3DA.%2BW.%26aulast%3DInglis%26aufirst%3DG.%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26aulast%3DMorrell%26aufirst%3DJ.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DPerez%26aufirst%3DD.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DTame%26aufirst%3DC.%2BJ.%26aulast%3DUddin%26aufirst%3DS.%26aulast%3DVitulli%26aufirst%3DG.%26aulast%3DWellaway%26aufirst%3DN.%26atitle%3DEvolution%2520of%2520a%2520novel%252C%2520orally%2520bioavailable%2520series%2520of%2520PI3K%25CE%25B4%2520inhibitors%2520from%2520an%2520inhaled%2520lead%2520for%2520the%2520treatment%2520of%2520respiratory%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7239%26epage%3D7251%26doi%3D10.1021%2Facs.jmedchem.6b00799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erra, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gréco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernal, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caturla, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gràcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domínguez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabaté, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armengol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent, selective, and orally available PI3Kδ inhibitor for the treatment of inflammatory diseases</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">123</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.6b00438</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.6b00438" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFyntrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=118-123&author=M.+Erraauthor=J.+Taltavullauthor=A.+Gr%C3%A9coauthor=F.+J.+Bernalauthor=J.+F.+Caturlaauthor=J.+Gr%C3%A0ciaauthor=M.+Dom%C3%ADnguezauthor=M.+Sabat%C3%A9author=S.+Parisauthor=S.+Soriaauthor=B.+Hern%C3%A1ndezauthor=C.+Armengolauthor=J.+Cabedoauthor=M.+Bravoauthor=E.+Calamaauthor=M.+Miralpeixauthor=M.+D.+Lehner&title=Discovery+of+a+potent%2C+selective%2C+and+orally+available+PI3K%CE%B4+inhibitor+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Facsmedchemlett.6b00438"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases</span></div><div class="casAuthors">Erra, Montse; Taltavull, Joan; Greco, Angelique; Bernal, Francisco Javier; Caturla, Juan Francisco; Gracia, Jordi; Dominguez, Maria; Sabate, Mar; Paris, Stephane; Soria, Salome; Hernandez, Begona; Armengol, Clara; Cabedo, Judit; Bravo, Monica; Calama, Elena; Miralpeix, Montserrat; Lehner, Martin D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">118-123</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The delta isoform of the phosphatidylinositol 3-kinase (PI3Kδ) has been shown to have an essential role in specific immune cell functions and thus represents a potential therapeutic target for autoimmune and inflammatory diseases.  Herein, the optimization of a series of pyrrolotriazinones as potent and selective PI3Kδ inhibitors is described.  The main challenge of the optimization process was to identify an orally available compd. with a good pharmacokinetic profile in preclin. species that predicted a suitable dosing regimen in humans.  Structure-activity relationships and structure-property relationships are discussed.  This medicinal chem. exercise led to the identification of LAS191954 as a candidate for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGKftcFDPpSLVg90H21EOLACvtfcHk0ljopPLXy-a0qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFyntrzN&md5=120b642b7adb9a5e2a1014abc93aaa98</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.6b00438&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.6b00438%26sid%3Dliteratum%253Aachs%26aulast%3DErra%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DGr%25C3%25A9co%26aufirst%3DA.%26aulast%3DBernal%26aufirst%3DF.%2BJ.%26aulast%3DCaturla%26aufirst%3DJ.%2BF.%26aulast%3DGr%25C3%25A0cia%26aufirst%3DJ.%26aulast%3DDom%25C3%25ADnguez%26aufirst%3DM.%26aulast%3DSabat%25C3%25A9%26aufirst%3DM.%26aulast%3DParis%26aufirst%3DS.%26aulast%3DSoria%26aufirst%3DS.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DArmengol%26aufirst%3DC.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DBravo%26aufirst%3DM.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DMiralpeix%26aufirst%3DM.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520PI3K%25CE%25B4%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D118%26epage%3D123%26doi%3D10.1021%2Facsmedchemlett.6b00438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fenwick, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kilty, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, L. E.</span></span> <span> </span><span class="NLM_article-title">Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e0128757</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0128757</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1371%2Fjournal.pone.0128757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26090665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Ort7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0128757&author=P.+S.+Fenwickauthor=P.+Macedoauthor=I.+C.+Kiltyauthor=P.+J.+Barnesauthor=L.+E.+Donnelly&title=Effect+of+JAK+inhibitors+on+release+of+CXCL9%2C+CXCL10+and+CXCL11+from+human+airway+epithelial+cells&doi=10.1371%2Fjournal.pone.0128757"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells</span></div><div class="casAuthors">Fenwick, Peter S.; Macedo, Patricia; Kilty, Iain C.; Barnes, Peter J.; Donnelly, Louise E.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e0128757/1-e0128757/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: CD8+ T-cells are located in the small airways of COPD patients and may contribute to pathophysiol.  CD8+ cells express the chemokine receptor, CXCR3 that binds CXCL9, CXCL10 and CXCL11, which are elevated in the airways of COPD patients.  These chemokines are released from airway epithelial cells via activation of receptor assocd. Janus kinases (JAK).  This study compared the efficacy of two structurally dissimilar pan-JAK inhibitors, PF956980 and PF1367550, and the glucocorticosteroid dexamethasone, in BEAS-2B and human primary airway epithelial cells from COPD patients and control subjects.  Methods: Cells were stimulated with either IFNγ alone or with TNFα, and release of CXCL9, CXCL10 and CXCL11 measured by ELISA and expression of CXCL9, CXCL10 and CXCL11 by qPCR.  Activation of JAK signalling was assessed by STAT1 phosphorylation and DNA binding.  Results: There were no differences in the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells from any of the subjects or following stimulation with either IFNγ alone or with TNFα.  Dexamethasone did not inhibit CXCR3 chemokine release from stimulated BEAS-2B or primary airway epithelial cells.  However, both JAK inhibitors suppressed this response with PF1367550 being ∼50-65-fold more potent than PF956980.  The response of cells from COPD patients did not differ from controls with similar responses regardless of whether inhibitors were added prophylactically or concomitant with stimuli.  These effects were mediated by JAK inhibition as both compds. suppressed STAT1 phosphorylation and DNA-binding of STAT1 and gene transcription.  Conclusions: These data suggest that the novel JAK inhibitor, PF1367550, is more potent than PF956980 and that JAK pathway inhibition in airway epithelium could provide an alternative anti-inflammatory approach for glucocorticosteroid-resistant diseases including COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8eUxA3RAYYbVg90H21EOLACvtfcHk0ljopPLXy-a0qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Ort7zK&md5=62be1664fe95083198f4c3f32b8c5e2c</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0128757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0128757%26sid%3Dliteratum%253Aachs%26aulast%3DFenwick%26aufirst%3DP.%2BS.%26aulast%3DMacedo%26aufirst%3DP.%26aulast%3DKilty%26aufirst%3DI.%2BC.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DDonnelly%26aufirst%3DL.%2BE.%26atitle%3DEffect%2520of%2520JAK%2520inhibitors%2520on%2520release%2520of%2520CXCL9%252C%2520CXCL10%2520and%2520CXCL11%2520from%2520human%2520airway%2520epithelial%2520cells%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0128757%26doi%3D10.1371%2Fjournal.pone.0128757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Takezawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, T.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor inhibitor AG1478 inhibits mucus hypersecretion in airway epithelium</span>. <i>Am. J. Rhinol. Allergy</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">e1</span>– <span class="NLM_lpage">e6</span>, <span class="refDoi"> DOI: 10.2500/ajra.2016.30.4263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2500%2Fajra.2016.30.4263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26867523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC28jgtV2qtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=e1-e6&author=K.+Takezawaauthor=T.+Ogawaauthor=S.+Shimizuauthor=T.+Shimizu&title=Epidermal+growth+factor+receptor+inhibitor+AG1478+inhibits+mucus+hypersecretion+in+airway+epithelium&doi=10.2500%2Fajra.2016.30.4263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor inhibitor AG1478 inhibits mucus hypersecretion in airway epithelium</span></div><div class="casAuthors">Takezawa Kumiko; Ogawa Takao; Shimizu Shino; Shimizu Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">American journal of rhinology & allergy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Mucus hypersecretion and neutrophil infiltration are important characteristics of airway inflammation.  Epidermal growth factor receptor (EGFR) transactivation induces mucus and inflammatory cytokine secretion from airway epithelial cells.  To elucidate the roles of EGFR in airway inflammation, the in vitro effects on mucin production and interleukin (IL) 8 secretion from cultured airway epithelial cells and the in vivo effects on mucus hypersecretion and neutrophil infiltration in rat nasal mucosa of the EGFR tyrosine kinase inhibitor AG1478 were examined.  METHODS:  The in vitro effects of AG1478 treatment of cultured NCI-H292 cells on lipopolysaccharide (LPS) induced or tumor necrosis factor (TNF) α induced MUC5AC mucin and IL-8 secretion were evaluated.  Hypertrophic and metaplastic changes of goblet cells, mucus production and neutrophil infiltration in rat nasal epithelium were induced by intranasal instillation of LPS in vivo, and the inhibitory effects of AG1478 by intraperitoneal injection or intranasal instillation were examined.  RESULTS:  AG1478 (1-1000 nM) significantly inhibited both LPS-induced and TNF-α-induced secretion of MUC5AC and IL-8 from cultured NCI-H292 cells in a dose-dependent manner.  The expression of MUC5AC and IL-8 messenger RNAs was also significantly inhibited.  Intranasal instillation of AG1478 one hour after intranasal LPS instillation significantly inhibited LPS-induced goblet cell metaplasia, mucus production, and neutrophil infiltration in rat nasal epithelium, as did intraperitoneal injection of AG1478 one hour before LPS instillation.  CONCLUSIONS:  These results indicated that EGFR transactivation plays an important role in mucin and IL-8 secretion from airway epithelial cells.  Intranasal instillation of an EGFR tyrosine kinase inhibitor may be a new therapeutic approach for the treatment of upper airway inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5p3FFJVZp31WTCLT8lX9SfW6udTcc2eZk8C-ROJDJZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jgtV2qtQ%253D%253D&md5=efbd7a5096d76f55f1d0634329043903</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.2500%2Fajra.2016.30.4263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2500%252Fajra.2016.30.4263%26sid%3Dliteratum%253Aachs%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DOgawa%26aufirst%3DT.%26aulast%3DShimizu%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DT.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520AG1478%2520inhibits%2520mucus%2520hypersecretion%2520in%2520airway%2520epithelium%26jtitle%3DAm.%2520J.%2520Rhinol.%2520Allergy%26date%3D2016%26volume%3D30%26spage%3De1%26epage%3De6%26doi%3D10.2500%2Fajra.2016.30.4263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hegab, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morishima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iizuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiwamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sekizawa, K.</span></span> <span> </span><span class="NLM_article-title">Niflumic acid and AG-1478 reduce cigarette smoke-induced mucin synthesis: the role of hCLCA1</span>. <i>Chest</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1156</span>, <span class="refDoi"> DOI: 10.1378/chest.06-2031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1378%2Fchest.06-2031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=17426222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltFOjtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1149-1156&author=A.+E.+Hegabauthor=T.+Sakamotoauthor=A.+Nomuraauthor=Y.+Ishiiauthor=Y.+Morishimaauthor=T.+Iizukaauthor=T.+Kiwamotoauthor=Y.+Matsunoauthor=S.+Hommaauthor=K.+Sekizawa&title=Niflumic+acid+and+AG-1478+reduce+cigarette+smoke-induced+mucin+synthesis%3A+the+role+of+hCLCA1&doi=10.1378%2Fchest.06-2031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Niflumic acid and AG-1478 reduce cigarette smoke-induced mucin synthesis. The Role of hCLCAI</span></div><div class="casAuthors">Hegab, Ahmed E.; Sakamoto, Tohru; Nomura, Akihiro; Ishii, Yukio; Morishima, Yuko; Iizuka, Takashi; Kiwamoto, Takumi; Matsuno, Yosuke; Homma, Shinsuke; Sekizawa, Kiyohisa</div><div class="citationInfo"><span class="NLM_cas:title">Chest</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1149-1156</span>CODEN:
                <span class="NLM_cas:coden">CHETBF</span>;
        ISSN:<span class="NLM_cas:issn">0012-3692</span>.
    
            (<span class="NLM_cas:orgname">American College of Chest Physicians</span>)
        </div><div class="casAbstract">Background: Cigarette smoke induces bronchial mucus secretion.  However, the mechanism of this induction is still unidentified.  In this study, we investigated the role of the putative calcium-activated chloride channel 1 (CLCA1) and its blocker, niflumic acid, in cigarette smoke-induced mucin synthesis both in vivo and in vitro.  Methods and results: Sprague-Dawley rats were exposed to cigarette smoke for 4 wk.  The CLCA1, epidermal growth factor receptor (EGFR), and MUC5AC expressions were increased in the trachea and lung tissues.  Goblet-cell hyperplasia with marked mucin staining was detected in the tracheal and bronchial epithelium.  In the human bronchial epithelial cell line NCI-H292, cigarette smoke soln. also induced mucin prodn. as well as the RNA and protein expressions of CLCA1, EGFR, and MUC5AC.  Both in vivo and in vitro, the induction of MUC5AC and mucin synthesis were inhibited by niflumic acid, and/or a selective EGFR tyrosine kinase inhibitor, AG-1478.  Niflumic acid also blocked the epidermal growth factor-induced MUC5AC and mucin staining in the NCI-H292 cell line.  Conclusion: Both EGFR and niflumic acid-sensitive chloride channels (probably CLCA1) are dependently affecting the mucin prodn. as a part of a single complex signaling pathway.  CLCA1 may be a key signaling member that can be targeted with pharmacol. interventions to treat mucus hypersecretion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7ZC4IKE2DTLVg90H21EOLACvtfcHk0liPpmWqGmsbfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltFOjtLg%253D&md5=dd253656133165eb89c71f76c332afcd</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1378%2Fchest.06-2031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1378%252Fchest.06-2031%26sid%3Dliteratum%253Aachs%26aulast%3DHegab%26aufirst%3DA.%2BE.%26aulast%3DSakamoto%26aufirst%3DT.%26aulast%3DNomura%26aufirst%3DA.%26aulast%3DIshii%26aufirst%3DY.%26aulast%3DMorishima%26aufirst%3DY.%26aulast%3DIizuka%26aufirst%3DT.%26aulast%3DKiwamoto%26aufirst%3DT.%26aulast%3DMatsuno%26aufirst%3DY.%26aulast%3DHomma%26aufirst%3DS.%26aulast%3DSekizawa%26aufirst%3DK.%26atitle%3DNiflumic%2520acid%2520and%2520AG-1478%2520reduce%2520cigarette%2520smoke-induced%2520mucin%2520synthesis%253A%2520the%2520role%2520of%2520hCLCA1%26jtitle%3DChest%26date%3D2007%26volume%3D131%26spage%3D1149%26epage%3D1156%26doi%3D10.1378%2Fchest.06-2031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woodruff, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohlfeld, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krug, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dransfield, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criner, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nivens, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tetzlaff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fahy, J. V.</span></span> <span> </span><span class="NLM_article-title">Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">445</span>, <span class="refDoi"> DOI: 10.1164/rccm.200909-1415OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200909-1415OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20007923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVSgsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2010&pages=438-445&author=P.+G.+Woodruffauthor=M.+Wolffauthor=J.+M.+Hohlfeldauthor=N.+Krugauthor=M.+T.+Dransfieldauthor=E.+R.+Sutherlandauthor=G.+J.+Crinerauthor=V.+Kimauthor=A.+Prasseauthor=M.+C.+Nivensauthor=K.+Tetzlaffauthor=R.+Heilkerauthor=J.+V.+Fahy&title=Safety+and+efficacy+of+an+inhaled+epidermal+growth+factor+receptor+inhibitor+%28BIBW+2948+BS%29+in+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.200909-1415OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Woodruff, Prescott G.; Wolff, Michael; Hohlfeld, Jens M.; Krug, Norbert; Dransfield, Mark T.; Sutherland, E. Rand; Criner, Gerard J.; Kim, Victor; Prasse, Antje; Nivens, Michael C.; Tetzlaff, Kay; Heilker, Ralf; Fahy, John V.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">438-445</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Epidermal growth factor receptor (EGFR) activation is implicated in mucin hypersecretion in chronic obstructive pulmonary disease (COPD).  Objectives: To investigate the safety and efficacy of an inhaled EGFR antagonist (BIBW 2948) in COPD.  Methods: Multicenter, double-blind, placebo-controlled trial of 4 wk of treatment with two doses of BIBW 2948 (15 and 30 mg twice a day) on safety and mucin-related outcomes in 48 patients with COPD.  The effect of BIBW 2948 on EGFR activation in airway epithelial cells was assessed using an ex vivo assay.  Efficacy measures included the vol. of mucin in the airway epithelium (Vs mu,bala) in bronchial biopsies and the expression of mucin genes in bronchial brushings.  Measurements and Main Results: Inhaled BIBW 2948 induced a dose-related inhibition of EGFR internalization (reflecting decreased EGFR activation) in epithelial cells from treated subjects.  However, BIBW 2948 was assocd. with a dose-related increase in adverse events, including reversible liver enzyme elevation (n = 2), and redn. in FEV1.  The changes in mucin stores and mucin gene expression were not significantly different in the pooled BIBW 2948 group vs. placebo (vol. of mucin per surface area of basal lamina = 0.22 ± 7.11 vs. 0.47 ± 8.06 μm3/μm2; P = 0.93).  However, in the 30 mg twice a day group, the redn. in epithelial mucin stores was greatest in subjects with the greatest degree of EGFR inhibition (Pearson r = 0.98; 95% confidence interval, 0.71-0.99).  Conclusions: Four-week treatment with BIBW 2948 did not significantly decrease epithelial mucin stores and was poorly tolerated in patients with COPD.  Ex vivo analyses suggest that higher doses may be more effective at both EGFR inhibition and decreases in mucin stores but that adverse events should be expected.  Clin. trial registered with www.clinicaltrials.gov (NCT00423137).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ1HZh3exTorVg90H21EOLACvtfcHk0liPpmWqGmsbfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVSgsbY%253D&md5=6691e62b4ebfa5ee86fef185a1c37138</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1164%2Frccm.200909-1415OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200909-1415OC%26sid%3Dliteratum%253Aachs%26aulast%3DWoodruff%26aufirst%3DP.%2BG.%26aulast%3DWolff%26aufirst%3DM.%26aulast%3DHohlfeld%26aufirst%3DJ.%2BM.%26aulast%3DKrug%26aufirst%3DN.%26aulast%3DDransfield%26aufirst%3DM.%2BT.%26aulast%3DSutherland%26aufirst%3DE.%2BR.%26aulast%3DCriner%26aufirst%3DG.%2BJ.%26aulast%3DKim%26aufirst%3DV.%26aulast%3DPrasse%26aufirst%3DA.%26aulast%3DNivens%26aufirst%3DM.%2BC.%26aulast%3DTetzlaff%26aufirst%3DK.%26aulast%3DHeilker%26aufirst%3DR.%26aulast%3DFahy%26aufirst%3DJ.%2BV.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520an%2520inhaled%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%2520%2528BIBW%25202948%2520BS%2529%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2010%26volume%3D181%26spage%3D438%26epage%3D445%26doi%3D10.1164%2Frccm.200909-1415OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmad, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganiello, V. C.</span></span> <span> </span><span class="NLM_article-title">Advances in targeting cyclic nucleotide phosphodiesterases</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1038/nrd4228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnrd4228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24687066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=290-314&author=D.+H.+Mauriceauthor=H.+Keauthor=F.+Ahmadauthor=Y.+Wangauthor=J.+Chungauthor=V.+C.+Manganiello&title=Advances+in+targeting+cyclic+nucleotide+phosphodiesterases&doi=10.1038%2Fnrd4228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeting cyclic nucleotide phosphodiesterases</span></div><div class="casAuthors">Maurice, Donald H.; Ke, Hengming; Ahmad, Faiyaz; Wang, Yousheng; Chung, Jay; Manganiello, Vincent C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cyclic GMP, thereby regulating the intracellular concns. of these cyclic nucleotides, their signalling pathways and, consequently, myriad biol. responses in health and disease.  Currently, a small no. of PDE inhibitors are used clin. for treating the pathophysiol. dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease.  However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMRfUs-zUmLVg90H21EOLACvtfcHk0liPpmWqGmsbfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D&md5=410c8d5bb5fbd7d2906e30dc1b5f2876</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1038%2Fnrd4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4228%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DD.%2BH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DManganiello%26aufirst%3DV.%2BC.%26atitle%3DAdvances%2520in%2520targeting%2520cyclic%2520nucleotide%2520phosphodiesterases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D290%26epage%3D314%26doi%3D10.1038%2Fnrd4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulhall, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Droege, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panos, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zafar, M. A.</span></span> <span> </span><span class="NLM_article-title">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1597</span>– <span class="NLM_lpage">1611</span>, <span class="refDoi"> DOI: 10.1517/13543784.2015.1094054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543784.2015.1094054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26419847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2015&pages=1597-1611&author=A.+M.+Mulhallauthor=C.+A.+Droegeauthor=N.+E.+Ernstauthor=R.+J.+Panosauthor=M.+A.+Zafar&title=Phosphodiesterase+4+inhibitors+for+the+treatment+of+chronic+obstructive+pulmonary+disease%3A+a+review+of+current+and+developing+drugs&doi=10.1517%2F13543784.2015.1094054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs</span></div><div class="casAuthors">Mulhall, Aaron M.; Droege, Christopher A.; Ernst, Neil E.; Panos, Ralph J.; Zafar, Muhammad A.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1597-1611</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Phosphodiesterase (PDE) inhibitors modulate lung inflammation and cause bronchodilation by increasing intracellular cyclic adenosine 3', 5'-monophosphate in airway smooth muscle and inflammatory cells.  Roflumilast is the only approved PDE-4 inhibitor (PDE4I) for use in chronic obstructive pulmonary disease (COPD).  Its beneficial clin. effects occur preferentially in patients with chronic bronchitis and frequent COPD exacerbations.  Use of roflumilast as adjunctive or alternate therapy to other COPD medications reduces exacerbations and modestly improves lung function.  This article reviews the current role of PDE4I in COPD treatment emphasizing roflumilast's clin. efficacy and adverse effects.  This article also reviews developing PDE4Is in early clin. trials and in preclin. studies.  After decades of research in drug development, PDE4Is are a welcomed addn. to the COPD therapeutic armamentarium.  In its current clin. role, the salubrious clin. effects of PDE4I in reducing exacerbations and stabilizing the frequent exacerbator phenotype have to be cautiously balanced with numerous adverse effects.  Developing drugs may provide similar or better clin. benefits while minimizing adverse effects by changing the mode of drug delivery to inhaled formulations, combining dual PDE isoenzyme inhibitors (PDE1/4I and PDE3/4I) and by forming hybrid mols. with other bronchodilators (muscarinic receptor antagonist/PDE4I and β2-agonist/PDE4I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFNEyjtRW-erVg90H21EOLACvtfcHk0lg9CgIckR9qLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKkur%252FJ&md5=8d5130af94558b2950f624ae1528c86f</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1517%2F13543784.2015.1094054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2015.1094054%26sid%3Dliteratum%253Aachs%26aulast%3DMulhall%26aufirst%3DA.%2BM.%26aulast%3DDroege%26aufirst%3DC.%2BA.%26aulast%3DErnst%26aufirst%3DN.%2BE.%26aulast%3DPanos%26aufirst%3DR.%2BJ.%26aulast%3DZafar%26aufirst%3DM.%2BA.%26atitle%3DPhosphodiesterase%25204%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520a%2520review%2520of%2520current%2520and%2520developing%2520drugs%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2015%26volume%3D24%26spage%3D1597%26epage%3D1611%26doi%3D10.1517%2F13543784.2015.1094054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fertig, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, G. S.</span></span> <span> </span><span class="NLM_article-title">PDE4-mediated cAMP signalling</span>. <i>J. Cardiovasc. Dev. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">8</span>, <span class="refDoi"> DOI: 10.3390/jcdd5010008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.3390%2Fjcdd5010008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjslyrurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2018&pages=8&author=B.+A.+Fertigauthor=G.+S.+Baillie&title=PDE4-mediated+cAMP+signalling&doi=10.3390%2Fjcdd5010008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4-mediated cAMP signalling</span></div><div class="casAuthors">Fertig, Bracy A.; Baillie, George S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Development and Disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8/1-8/14</span>CODEN:
                <span class="NLM_cas:coden">JCDDB4</span>;
        ISSN:<span class="NLM_cas:issn">2308-3425</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  CAMP is the archetypal and ubiquitous second messenger utilized for the fine control of many cardiovascular cell signalling systems.  The ability of cAMP to elicit cell surface receptor-specific responses relies on its compartmentalisation by cAMP hydrolyzing enzymes known as phosphodiesterases.  One family of these enzymes, PDE4, is particularly important in the cardiovascular system, where it has been extensively studied and shown to orchestrate complex, localised signalling that underpins many crucial functions of the heart.  In the cardiac myocyte, cAMP activates PKA, which phosphorylates a small subset of mostly sarcoplasmic substrate proteins that drive β-adrenergic enhancement of cardiac function.  The phosphorylation of these substrates, many of which are involved in cardiac excitation-contraction coupling, has been shown to be tightly regulated by highly localised pools of individual PDE4 isoforms.  The spatial and temporal regulation of cardiac signalling is made possible by the formation of macromol. "signalosomes", which often include a cAMP effector, such as PKA, its substrate, PDE4 and an anchoring protein such as an AKAP.  Studies described in the present review highlight the importance of this relationship for individual cardiac PKA substrates and we provide an overview of how this signalling paradigm is coordinated to promote efficient adrenergic enhancement of cardiac function.  The role of PDE4 also extends to the vascular endothelium, where it regulates vascular permeability and barrier function.  In this distinct location, PDE4 interacts with adherens junctions to regulate their stability.  These highly specific, non-redundant roles for PDE4 isoforms have far reaching therapeutic potential.  PDE inhibitors in the clinic have been plagued with problems due to the active site-directed nature of the compds. which concomitantly attenuate PDE activity in all highly localised "signalosomes".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG1GQOAKh0NLVg90H21EOLACvtfcHk0lg9CgIckR9qLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjslyrurs%253D&md5=55ab00b9daa0cd96454807732bd5f4bc</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.3390%2Fjcdd5010008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fjcdd5010008%26sid%3Dliteratum%253Aachs%26aulast%3DFertig%26aufirst%3DB.%2BA.%26aulast%3DBaillie%26aufirst%3DG.%2BS.%26atitle%3DPDE4-mediated%2520cAMP%2520signalling%26jtitle%3DJ.%2520Cardiovasc.%2520Dev.%2520Dis.%26date%3D2018%26volume%3D5%26spage%3D8%26doi%3D10.3390%2Fjcdd5010008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabe, K. F.</span></span> <span> </span><span class="NLM_article-title">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">67</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01218.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1476-5381.2011.01218.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21232047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=53-67&author=K.+F.+Rabe&title=Update+on+roflumilast%2C+a+phosphodiesterase+4+inhibitor+for+the+treatment+of+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1476-5381.2011.01218.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease</span></div><div class="casAuthors">Rabe, Klaus F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-67</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main PDE isoenzyme occurring in cells involved in inflammatory airway disease such as chronic obstructive pulmonary disease (COPD).  COPD is a preventable and treatable disease and is characterized by airflow obstruction that is not fully reversible.  Chronic progressive symptoms, particularly dyspnea, chronic bronchitis and impaired overall health are worse in those who have frequent, acute episodes of symptom exacerbation.  Although several exptl. PDE4 inhibitors are in clin. development, roflumilast, a highly selective PDE4 inhibitor, is the first in its class to be licensed, and has recently been approved in several countries for oral, once-daily treatment of severe COPD.  Clin. trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency in COPD.  Furthermore, its unique mode of action may offer the potential to target the inflammatory processes underlying COPD.  Roflumilast is effective when used concomitantly with all forms of bronchodilator and even in patients treated with inhaled corticosteroids.  Roflumilast thus represents an important addn. to current therapeutic options for COPD patients with chronic bronchitis, including those who remain symptomatic despite treatment.  This article reviews the current status of PDE4 inhibitors, focusing on the pharmacokinetics, efficacy and safety of roflumilast.  In particular, it provides an overview of the effects of roflumilast on lung function and exacerbations, glucose homoeostasis and wt. loss, and the concomitant use of long-acting beta2-adrenergic receptor agonists and short-acting muscarinic receptor antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryBUcu0ToPGrVg90H21EOLACvtfcHk0lg9CgIckR9qLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXls1GjtLw%253D&md5=c6ac3310e2d9ff1c7de86aecbd1356bb</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01218.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01218.x%26sid%3Dliteratum%253Aachs%26aulast%3DRabe%26aufirst%3DK.%2BF.%26atitle%3DUpdate%2520on%2520roflumilast%252C%2520a%2520phosphodiesterase%25204%2520inhibitor%2520for%2520the%2520treatment%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D53%26epage%3D67%26doi%3D10.1111%2Fj.1476-5381.2011.01218.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Facius, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marostica, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahu, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic and pharmacodynamic modelling to characterize the tolerability of alternative up-titration regimens of roflumilast in patients with chronic obstructive pulmonary disease</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1029</span>– <span class="NLM_lpage">1038</span>, <span class="refDoi"> DOI: 10.1007/s40262-018-0671-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1007%2Fs40262-018-0671-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29797235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOmu77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1029-1038&author=A.+Faciusauthor=E.+Marosticaauthor=P.+Gardinerauthor=H.+Watzauthor=G.+Lahu&title=Pharmacokinetic+and+pharmacodynamic+modelling+to+characterize+the+tolerability+of+alternative+up-titration+regimens+of+roflumilast+in+patients+with+chronic+obstructive+pulmonary+disease&doi=10.1007%2Fs40262-018-0671-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease</span></div><div class="casAuthors">Facius, Axel; Marostica, Eleonora; Gardiner, Philip; Watz, Henrik; Lahu, Gezim</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1029-1038</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Background: In the OPTIMIZE study, 4 wk of roflumilast 250 μg once daily before escalation to the approved 500 μg once daily maintenance dose reduced treatment discontinuations and improved tolerability to roflumilast among patients with chronic obstructive pulmonary disease (COPD).  In this study, we present the pharmacokinetic (PK) results and PK/pharmacodynamic (PD) modeling data from OPTIMIZE.  Methods: OPTIMIZE was a multicentre, double-blind, phase III study in which patients with severe COPD were randomized 1:1:1 to receive oral roflumilast 250 μg once daily, 500 μg every other day, or 500 μg once daily for 4 wk, followed by 500 μg once daily for 8 wk.  A population PK (popPK) model characterized roflumilast exposure levels (total phosphodiesterase-4 inhibition [tPDE4i]).  Furthermore, models characterized the percentage of patients with adverse events (AEs) of interest (PK/AE model), and time to discontinuation due to such AEs (PK/time-to-event model).  Results: The popPK model adequately described av. plasma concns. and variability from 1238 patients.  The percentage of patients with AEs of interest increased with predicted tPDE4i exposure (logit scale slope 0.484; confidence interval 0.262-0.706; p = 2 × 10-5).  PK/time-to-event model anal. predicted that patients receiving the 250 μg up-titrn. regimen had significantly lower discontinuation rates and longer time to discontinuation compared with roflumilast 500 μg every other day or 500 μg once daily (p = 0.0014).  Conclusions: In this PK/PD model, a 4-wk up-titrn. regimen with roflumilast 250 μg once daily was found to reduce discontinuations and improve tolerability, confirming the main clin. findings of the OPTIMIZE study.  However, use of this lower dose as long-term maintenance therapy may not induce sufficient phosphodiesterase-4 inhibition to exert clin. efficacy, supporting the approval of 500 μg as maintenance dose.  Trial Registration: OPTIMIZE: NCT02165826; REACT: NCT01329029.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIZaLOcoi8U7Vg90H21EOLACvtfcHk0lg9CgIckR9qLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOmu77N&md5=4efe7c4a9d05eff11ce32ffcf6478dfb</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1007%2Fs40262-018-0671-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-018-0671-4%26sid%3Dliteratum%253Aachs%26aulast%3DFacius%26aufirst%3DA.%26aulast%3DMarostica%26aufirst%3DE.%26aulast%3DGardiner%26aufirst%3DP.%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DLahu%26aufirst%3DG.%26atitle%3DPharmacokinetic%2520and%2520pharmacodynamic%2520modelling%2520to%2520characterize%2520the%2520tolerability%2520of%2520alternative%2520up-titration%2520regimens%2520of%2520roflumilast%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2018%26volume%3D57%26spage%3D1029%26epage%3D1038%26doi%3D10.1007%2Fs40262-018-0671-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">An update and appraisal of the cilomilast phase III clinical development programme for chronic obstructive pulmonary disease</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">152</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2006.02640.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fj.1365-2125.2006.02640.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16842388" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=138-152&author=M.+A.+Giembycz&title=An+update+and+appraisal+of+the+cilomilast+phase+III+clinical+development+programme+for+chronic+obstructive+pulmonary+disease&doi=10.1111%2Fj.1365-2125.2006.02640.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">138-152</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cilomilast (Ariflo, SB 207499) is an orally active, second-generation phosphodiesterase (PDE) 4 inhibitor that is being developed by GlaxoSmithkline for the treatment of chronic obstructive pulmonary disease (COPD).  The results of Phase I and Phase II studies have demonstrated that cilomilast significantly improves lung function and quality of life to a clin. meaningful extent, which has led to a comprehensive Phase III program of research evaluating efficacy, safety and mechanism of action.  However, the results of those Phase III studies are unremarkable and disappointing, raising doubt over the future of cilomilast as a novel therapy for COPD.  This review summarizes data obtained from the Phase III clin. development program, highlights some of the potential concerns both specific to cilomilast and to PDE4 inhibitors in general and assesses the likelihood that cilomilast will reach the market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqG3j4h3elSNrVg90H21EOLACvtfcHk0lgQG718PMD-Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersr8%253D&md5=0d8f4c3833a446ed6a43cc9b355a2c46</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2006.02640.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2006.02640.x%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3DAn%2520update%2520and%2520appraisal%2520of%2520the%2520cilomilast%2520phase%2520III%2520clinical%2520development%2520programme%2520for%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2006%26volume%3D62%26spage%3D138%26epage%3D152%26doi%3D10.1111%2Fj.1365-2125.2006.02640.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savoie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamatiou, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tattersall, F. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, C. C.</span></span> <span> </span><span class="NLM_article-title">PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">262</span>– <span class="NLM_lpage">269</span>, <span class="refDoi"> DOI: 10.1016/S0028-3908(00)00142-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0028-3908%2800%2900142-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11114405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3cXoslCksrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=262-269&author=A.+Robichaudauthor=C.+Savoieauthor=P.+B.+Stamatiouauthor=F.+D.+Tattersallauthor=C.+C.+Chan&title=PDE4+inhibitors+induce+emesis+in+ferrets+via+a+noradrenergic+pathway&doi=10.1016%2FS0028-3908%2800%2900142-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway</span></div><div class="casAuthors">Robichaud, A.; Savoie, C.; Stamatiou, P. B.; Tattersall, F. D.; Chan, C. C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">262-269</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The objective of this work was to assess the role of alpha2-adrenoceptors in emesis induced by inhibitors of type 4 phosphodiesterase (PDE4) in ferrets.  Pre-treatment with yohimbine, MK-912 or MK-467 (alpha2-adrenoceptor antagonists) caused sudden and unexpected vomiting.  In contrast, clonidine (alpha2-adrenoceptor agonist) did not induce emesis at doses ranging from 62.5-250 μg/kg s.c.  At the dose of 250 μg/kg, clonidine also provided protection against emesis induced by the PDE4 inhibitors, PMNPQ (i.e. 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline), CT-2450 and R-rolipram.  It was postulated that PDE4 inhibitors trigger emesis by mimicking the pharmacol. actions of alpha2-adrenoceptor antagonists.  This hypothesis was strengthened by the demonstration that PDE4 inhibitors can reverse the hypnotic effect of an alpha2-adrenoceptor mediated anesthetic regimen in rats and ferrets.  Similar to alpha2-adrenoceptor antagonists, PMNPQ, R-rolipram and S-rolipram dose-dependently decreased the duration of anesthesia in rats injected with the combination xylazine/ketamine.  While s.c. injections of CT-2450 (3-30 mg/kg) were without effect, a central infusion (6 μg i.c.v.) decreased the duration of anesthesia.  These studies suggest that the ferret is an appropriate model to study emesis induced by PDE4 inhibitors and that these compds. trigger the emetic reflex via a noradrenergic pathway, mimicking the pharmacol. actions of a pre-synaptic alpha2-adrenoceptor inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtP8JquEn-FbVg90H21EOLACvtfcHk0lgQG718PMD-Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXoslCksrc%253D&md5=ac72fb4c3a03d03424ed19d6d0550d51</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2800%2900142-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252800%252900142-8%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaud%26aufirst%3DA.%26aulast%3DSavoie%26aufirst%3DC.%26aulast%3DStamatiou%26aufirst%3DP.%2BB.%26aulast%3DTattersall%26aufirst%3DF.%2BD.%26aulast%3DChan%26aufirst%3DC.%2BC.%26atitle%3DPDE4%2520inhibitors%2520induce%2520emesis%2520in%2520ferrets%2520via%2520a%2520noradrenergic%2520pathway%26jtitle%3DNeuropharmacology%26date%3D2001%26volume%3D40%26spage%3D262%26epage%3D269%26doi%3D10.1016%2FS0028-3908%2800%2900142-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Livi, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torphy, T. J.</span></span> <span> </span><span class="NLM_article-title">Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">899</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=8863835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK28XmsFGgurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1996&pages=891-899&author=S.+Jacobitzauthor=M.+M.+McLaughlinauthor=G.+P.+Liviauthor=M.+Burmanauthor=T.+J.+Torphy&title=Mapping+the+functional+domains+of+human+recombinant+phosphodiesterase+4A%3A+structural+requirements+for+catalytic+activity+and+rolipram+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping the functional domains of human recombinant phosphodiesterase 4A: Structural requirements for catalytic activity and rolipram binding</span></div><div class="casAuthors">Jacobitz, Susanne; McLaughlin, Megan M.; Livi, George P.; Burman, Miriam; Torphy, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">891-899</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">To identify functional domains of the 886-amino acid human recombinant cAMP-specific phosphodiesterase (PDE) subtype A (rhPDE4A), we engineered the expression of seven mutant proteins contg. both NH2- and COOH-terminal truncations.  The level of rhPDE4A protein expression in yeast was monitored by immunoblotting using enzyme-specific antisera.  Biochem. profiles of the mutant proteins were compared with those of the full-length protein or a fully active truncated form of the enzyme (rhPDE4A Met265-886), lacking the first 264 amino acids.  The smallest catalytically active fragment generated was Met332-722, which at 45 kDa is less than half the mass of the full-length enzyme (∼110 kDa) but spans the most highly conserved region of the PDE superfamily.  Two prototypical PDE4 inhibitors, rolipram and RP 73401, inhibited cAMP-hydrolyzing activity of all truncated forms of the enzyme, with IC50 values of 70-2000 nM and 0.2-0.6 nM, resp.  [3H](R)-Rolipram bound to two sites on Met265-886, a high affinity site (Kd1 = 0.7 ± 0.3 nM) and a low affinity site (Kd2 = 34 ± 10 nM).  Interestingly, [3H](R)-rolipram failed to bind to Met332-886 with high affinity, indicating that high affinity binding is not required for inhibition of enzyme activity.  Low affinity rolipram-binding was still present in Met332-886 (Kd = 101 ± 7 nM).  In contrast to [3H](R)-rolipram, [3H]RP 73401 bound to a single class of high affinity sites on Met265-886 (Kd = 0.4 ± 0.1 nM).  Further truncation of the enzyme to Met332-886 had no effect on [3H]RP 73401 binding (Kd = 0.2 ± 0.03 nM).  We conclude that the catalytic center of rhPDE4A lies between amino acids 332 and 722.  Furthermore, amino acids 265-332 may form a high affinity binding site for rolipram that is outside the catalytic domain.  As a more likely alternative, these amino acids may not form a distinct binding site but instead may be required for the recombinant enzyme to assume a conformation that binds rolipram at the catalytic domain with a high affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQO9hB-XY4nrVg90H21EOLACvtfcHk0lgQG718PMD-Ug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmsFGgurs%253D&md5=17e514f10560b1472aedbac336b58882</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJacobitz%26aufirst%3DS.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DLivi%26aufirst%3DG.%2BP.%26aulast%3DBurman%26aufirst%3DM.%26aulast%3DTorphy%26aufirst%3DT.%2BJ.%26atitle%3DMapping%2520the%2520functional%2520domains%2520of%2520human%2520recombinant%2520phosphodiesterase%25204A%253A%2520structural%2520requirements%2520for%2520catalytic%2520activity%2520and%2520rolipram%2520binding%26jtitle%3DMol.%2520Pharmacol.%26date%3D1996%26volume%3D50%26spage%3D891%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conti, M.</span></span> <span> </span><span class="NLM_article-title">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNFα responses</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">7628</span>– <span class="NLM_lpage">7633</span>, <span class="refDoi"> DOI: 10.1073/pnas.122041599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1073%2Fpnas.122041599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12032334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=7628-7633&author=S.+L.+Jinauthor=M.+Conti&title=Induction+of+the+cyclic+nucleotide+phosphodiesterase+PDE4B+is+essential+for+LPS-activated+TNF%CE%B1+responses&doi=10.1073%2Fpnas.122041599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses</span></div><div class="casAuthors">Jin, S.-L. Catherine; Conti, Marco</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">7628-7633</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lipopolysaccharide (LPS) stimulation of the innate immune response requires the activation of signaling cascades that culminate in the synthesis and secretion of proinflammatory cytokines.  Given the inhibitory effects of phosphodiesterase (PDE) inhibitors on LPS-induced cytokine prodn., the authors have investigated LPS responses in mice deficient in PDE4 (type 4 cAMP-specific PDE)-B and PDE4D.  LPS stimulation of mouse peripheral leukocytes induced PDE4B mRNA accumulation and increased PDE4 activity.  This response was completely absent in mice deficient in PDE4B but not PDE4D.  LPS induction of tumor necrosis factor-α secretion by circulating leukocytes was decreased by approx. 90% in mice deficient in PDE4B but not in mice lacking PDE4D.  The impaired LPS response was evident regardless of the LPS dose used for stimulation and was assocd. with a more than 90% decrease in tumor necrosis factor-α mRNA accumulation.  A decreased responsiveness to LPS was also present in other inflammatory cells, including peritoneal and lung macrophages.  These findings demonstrate that PDE4B gene activation by LPS constitutes a feedback regulation essential for an efficient immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqczHCRpXjcOrVg90H21EOLACvtfcHk0lhBYMjhOAet8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlCrsrs%253D&md5=69e2c4452ce3aa7729376db46cba6a07</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1073%2Fpnas.122041599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.122041599%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DS.%2BL.%26aulast%3DConti%26aufirst%3DM.%26atitle%3DInduction%2520of%2520the%2520cyclic%2520nucleotide%2520phosphodiesterase%2520PDE4B%2520is%2520essential%2520for%2520LPS-activated%2520TNF%25CE%25B1%2520responses%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D7628%26epage%3D7633%26doi%3D10.1073%2Fpnas.122041599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giembycz, M. A.</span></span> <span> </span><span class="NLM_article-title">4D or not 4D-the emetogenic basis of PDE4 inhibitors uncovered?</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">548</span>, <span class="refDoi"> DOI: 10.1016/S0165-6147(02)02089-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS0165-6147%2802%2902089-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12457768" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFensr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2002&pages=548&author=M.+A.+Giembycz&title=4D+or+not+4D-the+emetogenic+basis+of+PDE4+inhibitors+uncovered%3F&doi=10.1016%2FS0165-6147%2802%2902089-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">4D or not 4D - the emetogenic basis of PDE4 inhibitors uncovered?</span></div><div class="casAuthors">Giembycz, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">548</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGossZAwrzef07Vg90H21EOLACvtfcHk0lhBYMjhOAet8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFensr4%253D&md5=45902ac9158ac09999bc5303d96e284a</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1016%2FS0165-6147%2802%2902089-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0165-6147%252802%252902089-8%26sid%3Dliteratum%253Aachs%26aulast%3DGiembycz%26aufirst%3DM.%2BA.%26atitle%3D4D%2520or%2520not%25204D-the%2520emetogenic%2520basis%2520of%2520PDE4%2520inhibitors%2520uncovered%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2002%26volume%3D23%26spage%3D548%26doi%3D10.1016%2FS0165-6147%2802%2902089-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastre-y-Hernandez, M.</span></span> <span> </span><span class="NLM_article-title">Clinical effects of neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports</span>. <i>Curr. Ther. Res.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">29</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1985&pages=23-29&author=R.+Horowskiauthor=M.+Sastre-y-Hernandez&title=Clinical+effects+of+neurotropic+selective+cAMP+phosphodiesterase+inhibitor+rolipram+in+depressed+patients%3A+Global+evaluation+of+the+preliminary+reports"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHorowski%26aufirst%3DR.%26aulast%3DSastre-y-Hernandez%26aufirst%3DM.%26atitle%3DClinical%2520effects%2520of%2520neurotropic%2520selective%2520cAMP%2520phosphodiesterase%2520inhibitor%2520rolipram%2520in%2520depressed%2520patients%253A%2520Global%2520evaluation%2520of%2520the%2520preliminary%2520reports%26jtitle%3DCurr.%2520Ther.%2520Res.%26date%3D1985%26volume%3D38%26spage%3D23%26epage%3D29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgin, A.
B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrafnsdottir, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiselyov, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurney, M. E.</span></span> <span> </span><span class="NLM_article-title">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">63</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nbt.1598</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnbt.1598" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20037581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=63-70&author=A.%0AB.+Burginauthor=O.+T.+Magnussonauthor=J.+Singhauthor=P.+Witteauthor=B.+L.+Stakerauthor=J.+M.+Bjornssonauthor=M.+Thorsteinsdottirauthor=S.+Hrafnsdottirauthor=T.+Hagenauthor=A.+S.+Kiselyovauthor=L.+J.+Stewartauthor=M.+E.+Gurney&title=Design+of+phosphodiesterase+4D+%28PDE4D%29+allosteric+modulators+for+enhancing+cognition+with+improved+safety&doi=10.1038%2Fnbt.1598"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety</span></div><div class="casAuthors">Burgin, Alex B.; Magnusson, Olafur T.; Singh, Jasbir; Witte, Pam; Staker, Bart L.; Bjornsson, Jon M.; Thorsteinsdottir, Margret; Hrafnsdottir, Sigrun; Hagen, Timothy; Kiselyov, Alex S.; Stewart, Lance J.; Gurney, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-70</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions.  Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation.  This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-mol. allosteric modulators of PDE4D that do not completely inhibit enzymic activity (Imax ∼ 80-90%).  These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biol. activity in cellular and in vivo models.  Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr18KdQE2oVsbVg90H21EOLACvtfcHk0lhBYMjhOAet8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbzJ&md5=1e8651a7116206eefddb9fa6b79d5112</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1598&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1598%26sid%3Dliteratum%253Aachs%26aulast%3DBurgin%26aufirst%3DA.%2BB.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWitte%26aufirst%3DP.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DBjornsson%26aufirst%3DJ.%2BM.%26aulast%3DThorsteinsdottir%26aufirst%3DM.%26aulast%3DHrafnsdottir%26aufirst%3DS.%26aulast%3DHagen%26aufirst%3DT.%26aulast%3DKiselyov%26aufirst%3DA.%2BS.%26aulast%3DStewart%26aufirst%3DL.%2BJ.%26aulast%3DGurney%26aufirst%3DM.%2BE.%26atitle%3DDesign%2520of%2520phosphodiesterase%25204D%2520%2528PDE4D%2529%2520allosteric%2520modulators%2520for%2520enhancing%2520cognition%2520with%2520improved%2520safety%26jtitle%3DNat.%2520Biotechnol.%26date%3D2010%26volume%3D28%26spage%3D63%26epage%3D70%26doi%3D10.1038%2Fnbt.1598" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weers, J. G.</span></span> <span> </span><span class="NLM_article-title">Enhanced design of inhaled therapeutics: what does the future hold?</span>. <i>Ther. Delivery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">148</span>, <span class="refDoi"> DOI: 10.4155/tde-2016-0004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4155%2Ftde-2016-0004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=26893244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XislSgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=145-148&author=J.+G.+Weers&title=Enhanced+design+of+inhaled+therapeutics%3A+what+does+the+future+hold%3F&doi=10.4155%2Ftde-2016-0004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Enhanced design of inhaled therapeutics: what does the future hold?</span></div><div class="casAuthors">Weers, Jeffry G.</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Delivery</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">145-148</span>CODEN:
                <span class="NLM_cas:coden">TDHEA7</span>;
        ISSN:<span class="NLM_cas:issn">2041-5990</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Overall, advances in the design of respiratory therapeutics and the aspiration to reduce or eliminate sources of error will necessitate novel particle engineering and advanced delivery systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqygT9Abzh797Vg90H21EOLACvtfcHk0liW1qqQ32TxWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XislSgt7w%253D&md5=be69799788093a0d41759fe9cd31568c</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.4155%2Ftde-2016-0004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ftde-2016-0004%26sid%3Dliteratum%253Aachs%26aulast%3DWeers%26aufirst%3DJ.%2BG.%26atitle%3DEnhanced%2520design%2520of%2520inhaled%2520therapeutics%253A%2520what%2520does%2520the%2520future%2520hold%253F%26jtitle%3DTher.%2520Delivery%26date%3D2016%26volume%3D7%26spage%3D145%26epage%3D148%26doi%3D10.4155%2Ftde-2016-0004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mistry, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazaar, A. L.</span></span>; <span class="NLM_contrib-group">IPC101939 investigators</span> <span> </span><span class="NLM_article-title">Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">588</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2013.05.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2013.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23701917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptFOmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=588-595&author=H.+Watzauthor=S.+J.+Mistryauthor=A.+L.+Lazaarauthor=IPC101939+investigators&title=Safety+and+tolerability+of+the+inhaled+phosphodiesterase+4+inhibitor+GSK256066+in+moderate+COPD&doi=10.1016%2Fj.pupt.2013.05.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD</span></div><div class="casAuthors">Watz, Henrik; Mistry, Sunil J.; Lazaar, Aili L.</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">588-595</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Inhibition of phosphodiesterase 4 (PDE4) represents an approach to anti-inflammatory therapy in chronic obstructive pulmonary disease (COPD).  GSK256066 is a potent and selective inhaled PDE4 inhibitor.  The aim of this study was to investigate the safety and tolerability of 28 days repeat inhaled dosing with GSK256066 in moderate COPD.  This was a Phase IIa, multicenter, parallel-group, double-blind, three-arm, placebo-controlled, four-week, randomized study with two doses of GSK256066 (25 μg, 87.5 μg).  The primary endpoint was safety and tolerability.  Secondary endpoints included changes in inflammatory markers in induced sputum and blood, lung function (spirometry, body plethysmog., impulse oscillometry), and pharmacokinetics.104 patients were randomized and 94 patients completed the study.  The incidence and intensity of treatment-related adverse events were similar between treatment groups.  The most frequent adverse event was nasopharyngitis and there were no serious adverse events in patients receiving GSK256066.  The overall incidence of gastrointestinal adverse events was low in all treatment groups.  There were no statistically significant changes in inflammatory markers in induced sputum and blood following treatment with GSK256066.  Anal. of sputum mRNA suggested engagement of pharmacol., based on increased expression of cAMP-dependent genes including amphiregulin and CREM in subjects receiving GSK256066.  There was a trend for an increase in post-bronchodilator FEV1 for both doses of GSK256066; in addn., for the 87.5 μg group, there was a mean redn. in residual vol. of 0.367 L (95% confidence interval: 0.112, 0.622 L) relative to placebo.Administration of inhaled GSK256066 was well-tolerated in patients with moderate COPD.  Further studies would be required to confirm the favorable safety profile and to demonstrate clin. efficacy of this compd.(ClinicalTrials.gov identifier: NCT00549679).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroY6YfcG-nOrVg90H21EOLACvtfcHk0liW1qqQ32TxWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptFOmur8%253D&md5=c0acb259a830da14112b673fa9623b7e</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2013.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2013.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DWatz%26aufirst%3DH.%26aulast%3DMistry%26aufirst%3DS.%2BJ.%26aulast%3DLazaar%26aufirst%3DA.%2BL.%26aulast%3D%26atitle%3DSafety%2520and%2520tolerability%2520of%2520the%2520inhaled%2520phosphodiesterase%25204%2520inhibitor%2520GSK256066%2520in%2520moderate%2520COPD%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D26%26spage%3D588%26epage%3D595%26doi%3D10.1016%2Fj.pupt.2013.05.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastore, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buccellati, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span> <span> </span><span class="NLM_article-title">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>352</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1124/jpet.114.220541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.114.220541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25576075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2015&pages=559-567&author=N.+Morettoauthor=P.+Carusoauthor=R.+Boscoauthor=G.+Marchiniauthor=F.+Pastoreauthor=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=E.+Ghidiniauthor=R.+De+Fantiauthor=C.+Capaldiauthor=L.+Carzanigaauthor=E.+Hirschauthor=C.+Buccellatiauthor=A.+Salaauthor=C.+Carniniauthor=R.+Patacchiniauthor=M.+Delcanaleauthor=M.+Civelliauthor=G.+Villettiauthor=F.+Facchinetti&title=CHF6001+I%3A+a+novel+highly+potent+and+selective+phosphodiesterase+4+inhibitor+with+robust+anti-inflammatory+activity+and+suitable+for+topical+pulmonary+administration&doi=10.1124%2Fjpet.114.220541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration</span></div><div class="casAuthors">Moretto, Nadia; Caruso, Paola; Bosco, Raffaella; Marchini, Gessica; Pastore, Fiorella; Armani, Elisabetta; Amari, Gabriele; Rizzi, Andrea; Ghidini, Eleonora; De Fanti, Renato; Capaldi, Carmelida; Carzaniga, Laura; Hirsch, Emilio; Buccellati, Carola; Sala, Angelo; Carnini, Chiara; Patacchini, Riccardo; Delcanale, Maurizio; Civelli, Maurizio; Villetti, Gino; Facchinetti, Fabrizio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">559-567, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">This study examd. the pharmacol. characterization of CHF6001 [(S)-3,5-dichloro-4-(2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3-(cyclopropylmethoxy)-4-(methylsulfonamido)benzoyloxy)ethyl)pyridine 1-oxide], a novel phosphodiesterase (PDE)4 inhibitor designed for treating pulmonary inflammatory diseases via inhaled administration.  CHF6001 was 7- and 923-fold more potent than roflumilast and cilomilast, resp., in inhibiting PDE4 enzymic activity (IC50 = 0.026 ± 0.006 nM).  CHF6001 inhibited PDE4 isoforms A-D with equal potency, showed an elevated ratio of high-affinity rolipram binding site vs. low-affinity rolipram binding site (i.e., >40) and displayed >20,000-fold selectivity vs. PDE4 compared with a panel of PDEs.  CHF6001 effectively inhibited (subnanomolar IC50 values) the release of tumor necrosis factor-α from human peripheral blood mononuclear cells, human acute monocytic leukemia cell line macrophages (THP-1), and rodent macrophages (RAW264.7 and NR8383).  Moreover, CHF6001 potently inhibited the activation of oxidative burst in neutrophils and eosinophils, neutrophil chemotaxis, and the release of interferon-γ from CD4+ T cells.  In all these functional assays, CHF6001 was more potent than previously described PDE4 inhibitors, including roflumilast, UK-500,001 [2-(3,4-difluorophenoxy)-5-fluoro-N-((1S,4S)-4-(2-hydroxy-5-methylbenzamido)cyclohexyl)nicotinamide], and cilomilast, and it was comparable to GSK256066 [6-((3-(dimethylcarbamoyl)phenyl)sulfonyl)-4-((3-methoxyphenyl)amino)-8-methylquinoline-3-carboxamide].  When administered intratracheally to rats as a micronized dry powder, CHF6001 inhibited liposaccharide-induced pulmonary neutrophilia (ED50 = 0.205 μmol/kg) and leukocyte infiltration (ED50 = 0.188 μmol/kg) with an efficacy comparable to a high dose of budesonide (1 μmol/kg i.p.).  In sum, CHF6001 has the potential to be an effective topical treatment of conditions assocd. with pulmonary inflammation, including asthma and chronic obstructive pulmonary disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYb2WLQC5SbVg90H21EOLACvtfcHk0liW1qqQ32TxWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Omurw%253D&md5=2be98d624fe49f7aba8673fa8aea8688</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1124%2Fjpet.114.220541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.114.220541%26sid%3Dliteratum%253Aachs%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DBosco%26aufirst%3DR.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DPastore%26aufirst%3DF.%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DBuccellati%26aufirst%3DC.%26aulast%3DSala%26aufirst%3DA.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DFacchinetti%26aufirst%3DF.%26atitle%3DCHF6001%2520I%253A%2520a%2520novel%2520highly%2520potent%2520and%2520selective%2520phosphodiesterase%25204%2520inhibitor%2520with%2520robust%2520anti-inflammatory%2520activity%2520and%2520suitable%2520for%2520topical%2520pulmonary%2520administration%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D352%26spage%3D559%26epage%3D567%26doi%3D10.1124%2Fjpet.114.220541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peretto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Porta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolzoni, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassani, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenacchi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catinella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span> <span> </span><span class="NLM_article-title">Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">793</span>– <span class="NLM_lpage">816</span>, <span class="refDoi"> DOI: 10.1021/jm401549m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401549m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvFGltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=793-816&author=E.+Armaniauthor=G.+Amariauthor=A.+Rizziauthor=R.+De+Fantiauthor=E.+Ghidiniauthor=C.+Capaldiauthor=L.+Carzanigaauthor=P.+Carusoauthor=M.+Gualaauthor=I.+Perettoauthor=E.+La+Portaauthor=P.+T.+Bolzoniauthor=F.+Facchinettiauthor=C.+Carniniauthor=N.+Morettoauthor=R.+Patacchiniauthor=F.+Bassaniauthor=V.+Cenacchiauthor=R.+Voltaauthor=F.+Amadeiauthor=S.+Capacchiauthor=M.+Delcanaleauthor=P.+Pucciniauthor=S.+Catinellaauthor=M.+Civelliauthor=G.+Villetti&title=Novel+class+of+benzoic+acid+ester+derivatives+as+potent+PDE4+inhibitors+for+inhaled+administration+in+the+treatment+of+respiratory+diseases&doi=10.1021%2Fjm401549m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases</span></div><div class="casAuthors">Armani, Elisabetta; Amari, Gabriele; Rizzi, Andrea; Fanti, Renato De; Ghidini, Eleonora; Capaldi, Carmelida; Carzaniga, Laura; Caruso, Paola; Guala, Matilde; Peretto, Ilaria; La Porta, Elena; Bolzoni, Pier T.; Facchinetti, Fabrizio; Carnini, Chiara; Moretto, Nadia; Patacchini, Riccardo; Bassani, Franco; Cenacchi, Valentina; Volta, Roberta; Amadei, Francesco; Capacchi, Silvia; Delcanale, Maurizio; Puccini, Paola; Catinella, Silvia; Civelli, Maurizio; Villetti, Gino</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">793-816</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The first steps in the selection process of a new anti-inflammatory drug for the inhaled treatment of asthma and chronic obstructive pulmonary disease are herein described.  A series of novel ester derivs. of 1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-dichloropyridin-4-yl) ethanol, e.g. I, have been synthesized and evaluated for inhibitory activity toward cAMP-specific phosphodiesterase-4 (PDE4).  In particular, esters of variously substituted benzoic acids were extensively explored, and structural modification of the alc. and benzoic moieties were performed to maximize the inhibitory potency.  Several compds. with high activity in cell-free and cell-based assays were obtained.  Through the evaluation of opportune in vitro ADME properties, a potential candidate suitable for inhaled administration in respiratory diseases was identified and tested in an in vivo model of pulmonary inflammation, proving its efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJlqwIuol5_rVg90H21EOLACvtfcHk0liT96FmKHFR0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvFGltA%253D%253D&md5=f272457442613574579ae4681b1261f0</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1021%2Fjm401549m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401549m%26sid%3Dliteratum%253Aachs%26aulast%3DArmani%26aufirst%3DE.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DGuala%26aufirst%3DM.%26aulast%3DPeretto%26aufirst%3DI.%26aulast%3DLa%2BPorta%26aufirst%3DE.%26aulast%3DBolzoni%26aufirst%3DP.%2BT.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DBassani%26aufirst%3DF.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DAmadei%26aufirst%3DF.%26aulast%3DCapacchi%26aufirst%3DS.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DPuccini%26aufirst%3DP.%26aulast%3DCatinella%26aufirst%3DS.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DVilletti%26aufirst%3DG.%26atitle%3DNovel%2520class%2520of%2520benzoic%2520acid%2520ester%2520derivatives%2520as%2520potent%2520PDE4%2520inhibitors%2520for%2520inhaled%2520administration%2520in%2520the%2520treatment%2520of%2520respiratory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D793%26epage%3D816%26doi%3D10.1021%2Fjm401549m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carzaniga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amari, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capaldi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Fanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carnini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facchinetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caruso, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battipaglia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patacchini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenacchi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadei, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bagnacani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delcanale, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puccini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catinella, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armani, E.</span></span> <span> </span><span class="NLM_article-title">Discovery and optimization of thiazolidinyl and pyrrolidinyl derivatives as inhaled PDE4 inhibitors for respiratory diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">10026</span>– <span class="NLM_lpage">10046</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01044</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01044" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhs7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=10026-10046&author=L.+Carzanigaauthor=G.+Amariauthor=A.+Rizziauthor=C.+Capaldiauthor=R.+De+Fantiauthor=E.+Ghidiniauthor=G.+Villettiauthor=C.+Carniniauthor=N.+Morettoauthor=F.+Facchinettiauthor=P.+Carusoauthor=G.+Marchiniauthor=L.+Battipagliaauthor=R.+Patacchiniauthor=V.+Cenacchiauthor=R.+Voltaauthor=F.+Amadeiauthor=A.+Pappaniauthor=S.+Capacchiauthor=V.+Bagnacaniauthor=M.+Delcanaleauthor=P.+Pucciniauthor=S.+Catinellaauthor=M.+Civelliauthor=E.+Armani&title=Discovery+and+optimization+of+thiazolidinyl+and+pyrrolidinyl+derivatives+as+inhaled+PDE4+inhibitors+for+respiratory+diseases&doi=10.1021%2Facs.jmedchem.7b01044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Optimization of Thiazolidinyl and Pyrrolidinyl Derivatives as Inhaled PDE4 Inhibitors for Respiratory Diseases</span></div><div class="casAuthors">Carzaniga, Laura; Amari, Gabriele; Rizzi, Andrea; Capaldi, Carmelida; De Fanti, Renato; Ghidini, Eleonora; Villetti, Gino; Carnini, Chiara; Moretto, Nadia; Facchinetti, Fabrizio; Caruso, Paola; Marchini, Gessica; Battipaglia, Loredana; Patacchini, Riccardo; Cenacchi, Valentina; Volta, Roberta; Amadei, Francesco; Pappani, Alice; Capacchi, Silvia; Bagnacani, Valentina; Delcanale, Maurizio; Puccini, Paola; Catinella, Silvia; Civelli, Maurizio; Armani, Elisabetta</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">10026-10046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphodiesterase 4 (PDE4) is a key cAMP-metabolizing enzyme involved in the pathogenesis of inflammatory disease, and its pharmacol. inhibition has been shown to exert therapeutic efficacy in chronic obstructive pulmonary disease (COPD).  Herein, the authors describe a drug discovery program aiming at the identification of novel classes of potent PDE4 inhibitors suitable for pulmonary administration.  Starting from a previous series of benzoic acid esters, the authors explored the chem. space in the solvent-exposed region of the enzyme catalytic binding pocket.  Extensive structural modifications led to the discovery of a no. of heterocycloalkyl esters as potent in vitro PDE4 inhibitors.  (S*,S**)-18e (3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(((S)-1-((3-(dimethylcarbamoyl)phenyl)sulfonyl)pyrrolidine-2-carbonyl)oxy)ethyl)pyridine 1-oxide) and (S*,S**)-22e (3,5-dichloro-4-((S)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-((S)-3-(3-(dimethylcarbamoyl)phenylsulfonyl)thiazolidine-2-carbonyloxy)ethyl)pyridine 1-oxide), in particular, exhibited optimal in vitro ADME and pharmacokinetics properties and dose-dependently counteracted acute lung eosinophilia in an exptl. animal model.  The optimal biol. profile as well as the excellent solid-state properties suggest that both compds. have the potential to be effective topical agents for treating respiratory inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgCLI9kb8q57Vg90H21EOLACvtfcHk0liT96FmKHFR0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhs7rI&md5=44f2dc4fbac0d34580ff06d6cbca352d</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01044%26sid%3Dliteratum%253Aachs%26aulast%3DCarzaniga%26aufirst%3DL.%26aulast%3DAmari%26aufirst%3DG.%26aulast%3DRizzi%26aufirst%3DA.%26aulast%3DCapaldi%26aufirst%3DC.%26aulast%3DDe%2BFanti%26aufirst%3DR.%26aulast%3DGhidini%26aufirst%3DE.%26aulast%3DVilletti%26aufirst%3DG.%26aulast%3DCarnini%26aufirst%3DC.%26aulast%3DMoretto%26aufirst%3DN.%26aulast%3DFacchinetti%26aufirst%3DF.%26aulast%3DCaruso%26aufirst%3DP.%26aulast%3DMarchini%26aufirst%3DG.%26aulast%3DBattipaglia%26aufirst%3DL.%26aulast%3DPatacchini%26aufirst%3DR.%26aulast%3DCenacchi%26aufirst%3DV.%26aulast%3DVolta%26aufirst%3DR.%26aulast%3DAmadei%26aufirst%3DF.%26aulast%3DPappani%26aufirst%3DA.%26aulast%3DCapacchi%26aufirst%3DS.%26aulast%3DBagnacani%26aufirst%3DV.%26aulast%3DDelcanale%26aufirst%3DM.%26aulast%3DPuccini%26aufirst%3DP.%26aulast%3DCatinella%26aufirst%3DS.%26aulast%3DCivelli%26aufirst%3DM.%26aulast%3DArmani%26aufirst%3DE.%26atitle%3DDiscovery%2520and%2520optimization%2520of%2520thiazolidinyl%2520and%2520pyrrolidinyl%2520derivatives%2520as%2520inhaled%2520PDE4%2520inhibitors%2520for%2520respiratory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D10026%26epage%3D10046%26doi%3D10.1021%2Facs.jmedchem.7b01044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gràcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buil, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagès, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrat, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">Biphenyl pyridazinone derivatives as inhaled PDE4 inhibitors: structural biology and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10479</span>– <span class="NLM_lpage">10497</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00829</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00829" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10479-10497&author=J.+Gr%C3%A0ciaauthor=M.+A.+Builauthor=J.+Castroauthor=P.+Eichhornauthor=M.+Ferrerauthor=A.+Gavald%C3%A0author=B.+Hern%C3%A1ndezauthor=V.+Segarraauthor=M.+D.+Lehnerauthor=I.+Morenoauthor=L.+Pag%C3%A8sauthor=R.+S.+Robertsauthor=J.+Serratauthor=S.+Sevillaauthor=J.+Taltavullauthor=M.+Andr%C3%A9sauthor=J.+Cabedoauthor=D.+Vilellaauthor=E.+Calamaauthor=C.+Carcasonaauthor=M.+Miralpeix&title=Biphenyl+pyridazinone+derivatives+as+inhaled+PDE4+inhibitors%3A+structural+biology+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.6b00829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships</span></div><div class="casAuthors">Gracia, Jordi; Buil, Maria Antonia; Castro, Jordi; Eichhorn, Peter; Ferrer, Manel; Gavalda, Amadeu; Hernandez, Begona; Segarra, Victor; Lehner, Martin D.; Moreno, Imma; Pages, Lluis; Roberts, Richard S.; Serrat, Jordi; Sevilla, Sara; Taltavull, Joan; Andres, Miriam; Cabedo, Judit; Vilella, Dolors; Calama, Elena; Carcasona, Carla; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10479-10497</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclic nucleotide cAMP is an ubiquitous second messenger involved in a plethora of cellular responses to biol. agents involving activation of adenylyl cyclase.  Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs.  In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD.  Here the authors describe efforts to discover novel, highly potent inhaled inhibitors of PDE4.  Through structure based design, with the intervention of a wide variety of functional groups and physichochem. profiles to occupy the solvent-filled pocket of the PDE4 enzyme, the authors modified the structure of the authors' oral PDE4 inhibitors to reach compds. up to picomolar enzymic potencies.  In vitro potencies were demonstrated in a rat lung neutrophilia model by suspension microspray administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCrwH5GRUxx7Vg90H21EOLACvtfcHk0lg8XZFytHDNAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVehs7vE&md5=13709b5d62c06b553655f88f65ff3bdf</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00829%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A0cia%26aufirst%3DJ.%26aulast%3DBuil%26aufirst%3DM.%2BA.%26aulast%3DCastro%26aufirst%3DJ.%26aulast%3DEichhorn%26aufirst%3DP.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DMoreno%26aufirst%3DI.%26aulast%3DPag%25C3%25A8s%26aufirst%3DL.%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSerrat%26aufirst%3DJ.%26aulast%3DSevilla%26aufirst%3DS.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DBiphenyl%2520pyridazinone%2520derivatives%2520as%2520inhaled%2520PDE4%2520inhibitors%253A%2520structural%2520biology%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10479%26epage%3D10497%26doi%3D10.1021%2Facs.jmedchem.6b00829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevilla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taltavull, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segarra, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gràcia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gavaldà, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrés, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabedo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilella, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calama, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcasona, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miralpeix, M.</span></span> <span> </span><span class="NLM_article-title">4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as inhaled phosphodiesterase type 4 (PDE4) inhibitors: structural biology and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2472</span>– <span class="NLM_lpage">2489</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01751</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01751" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjslKqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2472-2489&author=R.+S.+Robertsauthor=S.+Sevillaauthor=M.+Ferrerauthor=J.+Taltavullauthor=B.+Hern%C3%A1ndezauthor=V.+Segarraauthor=J.+Gr%C3%A0ciaauthor=M.+D.+Lehnerauthor=A.+Gavald%C3%A0author=M.+Andr%C3%A9sauthor=J.+Cabedoauthor=D.+Vilellaauthor=P.+Eichhornauthor=E.+Calamaauthor=C.+Carcasonaauthor=M.+Miralpeix&title=4-Amino-7%2C8-dihydro-1%2C6-naphthyridin-5%286+H%29-ones+as+inhaled+phosphodiesterase+type+4+%28PDE4%29+inhibitors%3A+structural+biology+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.7b01751"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">4-Amino-7,8-dihydro-1,6-naphthyridin-5(6H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships</span></div><div class="casAuthors">Roberts, Richard S.; Sevilla, Sara; Ferrer, Manel; Taltavull, Joan; Hernandez, Begona; Segarra, Victor; Gracia, Jordi; Lehner, Martin D.; Gavalda, Amadeu; Andres, Miriam; Cabedo, Judit; Vilella, Dolors; Eichhorn, Peter; Calama, Elena; Carcasona, Carla; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2472-2489</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Rational design of a novel template of naphthyridinones rapidly led to PDE4 inhibitors with subnanomolar enzymic potencies.  X-ray crystallog. confirmed the binding mode of this novel template.  We achieved compds. with double-digit picomolar enzymic potencies through further structure-based design by targeting both the PDE4 enzyme metal-binding pocket and occupying the solvent-filled pocket.  A strategy for lung retention and long duration of action based on low aq. soly. was followed.  In vivo efficacies were measured in a rat lung neutrophilia model by suspension microspray and dry powder administration.  Suspension microspray of potent compds. showed in vivo efficacy with a clear dose-response.  Despite sustained lung levels, dry powder administration performed much less well and without proper dose-response, highlighting clear differences between the two formulations.  This indicates a deficiency in the low aq. soly. strategy for long duration lung efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLargrI2V0NrVg90H21EOLACvtfcHk0lg8XZFytHDNAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjslKqs70%253D&md5=7b7b232d52ec716a6289f5aa9fdae41b</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01751&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01751%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DR.%2BS.%26aulast%3DSevilla%26aufirst%3DS.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DTaltavull%26aufirst%3DJ.%26aulast%3DHern%25C3%25A1ndez%26aufirst%3DB.%26aulast%3DSegarra%26aufirst%3DV.%26aulast%3DGr%25C3%25A0cia%26aufirst%3DJ.%26aulast%3DLehner%26aufirst%3DM.%2BD.%26aulast%3DGavald%25C3%25A0%26aufirst%3DA.%26aulast%3DAndr%25C3%25A9s%26aufirst%3DM.%26aulast%3DCabedo%26aufirst%3DJ.%26aulast%3DVilella%26aufirst%3DD.%26aulast%3DEichhorn%26aufirst%3DP.%26aulast%3DCalama%26aufirst%3DE.%26aulast%3DCarcasona%26aufirst%3DC.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3D4-Amino-7%252C8-dihydro-1%252C6-naphthyridin-5%25286%2520H%2529-ones%2520as%2520inhaled%2520phosphodiesterase%2520type%25204%2520%2528PDE4%2529%2520inhibitors%253A%2520structural%2520biology%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2472%26epage%3D2489%26doi%3D10.1021%2Facs.jmedchem.7b01751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abbott-Banner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases</span>. <i>Basic Clin. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">376</span>, <span class="refDoi"> DOI: 10.1111/bcpt.12209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1111%2Fbcpt.12209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24517491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlvVSitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=365-376&author=K.+H.+Abbott-Bannerauthor=C.+P.+Page&title=Dual+PDE3%2F4+and+PDE4+inhibitors%3A+novel+treatments+for+COPD+and+other+inflammatory+airway+diseases&doi=10.1111%2Fbcpt.12209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases</span></div><div class="casAuthors">Abbott-Banner, Katharine H.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">365-376</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Selective phosphodiesterase (PDE) 4 and dual PDE3/4 inhibitors have attracted considerable interest as potential therapeutic agents for the treatment of respiratory diseases, largely by virtue of their anti-inflammatory (PDE4) and bifunctional bronchodilator/anti-inflammatory (PDE3/4) effects.  Many of these agents have, however, failed in early development for various reasons, including dose-limiting side effects when administered orally and lack of sufficient activity when inhaled.  Indeed, only one selective PDE4 inhibitor, the orally active roflumilast-n-oxide, has to date received marketing authorization.  The majority of the compds. that have failed were, however, orally administered and non-selective for either PDE3 (A,B) or PDE4 (A,B,C,D) subtypes.  Developing an inhaled dual PDE3/4 inhibitor that is rapidly cleared from the systemic circulation, potentially with subtype specificity, may represent one strategy to improve the therapeutic index and also exhibit enhanced efficacy vs. inhibition of either PDE3 or PDE4 alone, given the potential pos. interactions with regard to anti-inflammatory and bronchodilator effects that have been obsd. pre-clin. with dual inhibition of PDE3 and PDE4 compared with inhibition of either isoenzyme alone.  This MiniReview will summarize recent clin. data obtained with PDE inhibitors and the potential for these drugs to treat COPD and other inflammatory airways diseases such as asthma and cystic fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj1ILnRPA11rVg90H21EOLACvtfcHk0lh6X6-ZrXtDJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlvVSitL4%253D&md5=d29edfe27d2514633d532bdd47d938d4</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12209%26sid%3Dliteratum%253Aachs%26aulast%3DAbbott-Banner%26aufirst%3DK.%2BH.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DDual%2520PDE3%252F4%2520and%2520PDE4%2520inhibitors%253A%2520novel%2520treatments%2520for%2520COPD%2520and%2520other%2520inflammatory%2520airway%2520diseases%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26spage%3D365%26epage%3D376%26doi%3D10.1111%2Fbcpt.12209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franciosi, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diamant, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuiker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morelli, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamerling, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Kam, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burggraaf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calzetta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C. P.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">714</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(13)70187-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS2213-2600%2813%2970187-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24429275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCmsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=714-727&author=L.+G.+Franciosiauthor=Z.+Diamantauthor=K.+H.+Bannerauthor=R.+Zuikerauthor=N.+Morelliauthor=I.+M.+Kamerlingauthor=M.+L.+de+Kamauthor=J.+Burggraafauthor=A.+F.+Cohenauthor=M.+Cazzolaauthor=L.+Calzettaauthor=D.+Singhauthor=D.+Spinaauthor=M.+J.+Walkerauthor=C.+P.+Page&title=Efficacy+and+safety+of+RPL554%2C+a+dual+PDE3+and+PDE4+inhibitor%2C+in+healthy+volunteers+and+in+patients+with+asthma+or+chronic+obstructive+pulmonary+disease%3A+findings+from+four+clinical+trials&doi=10.1016%2FS2213-2600%2813%2970187-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials</span></div><div class="casAuthors">Franciosi, Lui G.; Diamant, Zuzana; Banner, Katharine H.; Zuiker, Rob; Morelli, Nicoletta; Kamerling, Ingrid M. C.; de Kam, Marieke L.; Burggraaf, Jacobus; Cohen, Adam F.; Cazzola, Mario; Calzetta, Luigino; Singh, Dave; Spina, Domenico; Walker, Michael J. A.; Page, Clive P.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">714-727</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug.  We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.  Between Feb., 2009, and Jan., 2013, we undertook four proof-of-concept clin. trials in the Netherlands, Italy, and the UK.  Nebulised RPL554 was examd. in study 1 for safety in 18 healthy men who were randomly assigned (1:1:1) to receive an inhaled dose of RPL554 (0·003 mg/kg or 0·009 mg/kg) or placebo by a computer-generated randomisation table.  Subsequently, six non-smoking men with mild allergic asthma received single doses of RPL554 (three received 0·009 mg/kg and three received 0·018 mg/kg) in an open-label, adaptive study, and then ten men with mild allergic asthma were randomly assigned to receive placebo or RPL554 (0·018 mg/kg) by a computer-generated randomisation table for an assessment of safety, bronchodilation, and bronchoprotection.  Study 2 examd. the reproducibility of the bronchodilator response to a daily dose of nebulised RPL554 (0·018 mg/kg) for 6 consecutive days in a single-blind (patients masked), placebo-controlled study in 12 men with clin. stable asthma.  The safety and bronchodilator effect of RPL554 (0·018 mg/kg) was assessed in study 3, an open-label, placebo-controlled crossover trial, in 12 men with mild-to-moderate COPD.  In study 4, a placebo-controlled crossover trial, the effect of RPL554 (0·018 mg/kg) on lipopolysaccharide-induced inflammatory cell infiltration in induced sputum was investigated in 21 healthy men.  In studies 3 and 4, randomisation was done by computer-generated permutation with a block size of two for study 3 and four for study 4.  Unless otherwise stated, participants and clinicians were masked to treatment assignment.  Analyses were by intention to treat.  All trials were registered with EudraCT, nos. 2008-005048-17, 2011-001698-22, 2010-023573-18, and 2012-000742-34.  Safety was a primary endpoint of studies 1 and 3 and a secondary endpoint of studies 2 and 4.  Overall, RPL554 was well tolerated, and adverse events were generally mild and of equal frequency between placebo and active treatment groups.  Efficacy was a primary endpoint of study 2 and a secondary endpoint of studies 1 and 3.  Study 1 measured change in forced expiratory vol. in 1 s (FEV1) and provocative concn. of methacholine causing a 20% fall in FEV1 (PC20MCh) in participants with asthma.  RPL554 produced rapid bronchodilation in patients with asthma with an FEV1 increase at 1 h of 520 mL (95% CI 320-720; p<0·0001), which was a 14% increase from placebo, and increased the PC20MCh by 1·5 doubling doses (95% CI 0·63-2·28; p=0·004) compared with placebo.  The primary endpoint of study 2 was max. FEV1 reached during 6 h after dosing with RPL554 in patients with asthma.  RPL554 produced a similar max. mean increase in FEV1 from placebo on day 1 (555 mL, 95% CI 442-668), day 3 (505 mL, 392-618), and day 6 (485 mL, 371-598; overall p<0·0001).  A secondary endpoint of study 3 (patients with COPD) was the increase from baseline in FEV1.  RPL554 produced bronchodilation with a mean max. FEV1 increase of 17·2% (SE 5·2).  In healthy individuals (study 4), the primary endpoint was percentage change in neutrophil counts in induced sputum 6 h after lipopolysaccharide challenge.  RPL554 (0·018 mg/kg) did not significantly reduce the percentage of neutrophils in sputum (80·3% in the RPL554 group vs 84·2% in the placebo group; difference -3·9%, 95% CI -9·4 to 1·6, p=0·15), since RPL554 significantly reduced neutrophils (p=0·002) and total cells (p=0·002) to a similar degree.  In four exploratory studies, inhaled RPL554 is an effective and well tolerated bronchodilator, bronchoprotector, and anti-inflammatory drug and further studies will establish the full potential of this new drug for the treatment of patients with COPD or asthma.Verona Pharma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrFl2Dd6i-MbVg90H21EOLACvtfcHk0lh6X6-ZrXtDJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCmsro%253D&md5=6dda9a9076d111b844540ea8add319fa</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2813%2970187-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252813%252970187-5%26sid%3Dliteratum%253Aachs%26aulast%3DFranciosi%26aufirst%3DL.%2BG.%26aulast%3DDiamant%26aufirst%3DZ.%26aulast%3DBanner%26aufirst%3DK.%2BH.%26aulast%3DZuiker%26aufirst%3DR.%26aulast%3DMorelli%26aufirst%3DN.%26aulast%3DKamerling%26aufirst%3DI.%2BM.%26aulast%3Dde%2BKam%26aufirst%3DM.%2BL.%26aulast%3DBurggraaf%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DA.%2BF.%26aulast%3DCazzola%26aufirst%3DM.%26aulast%3DCalzetta%26aufirst%3DL.%26aulast%3DSingh%26aufirst%3DD.%26aulast%3DSpina%26aufirst%3DD.%26aulast%3DWalker%26aufirst%3DM.%2BJ.%26aulast%3DPage%26aufirst%3DC.%2BP.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520RPL554%252C%2520a%2520dual%2520PDE3%2520and%2520PDE4%2520inhibitor%252C%2520in%2520healthy%2520volunteers%2520and%2520in%2520patients%2520with%2520asthma%2520or%2520chronic%2520obstructive%2520pulmonary%2520disease%253A%2520findings%2520from%2520four%2520clinical%2520trials%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2013%26volume%3D1%26spage%3D714%26epage%3D727%26doi%3D10.1016%2FS2213-2600%2813%2970187-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, V. K.</span></span> <span> </span><span class="NLM_article-title">Lipopolysaccharide binds to and activates A(1) adenosine receptors on human pulmonary artery endothelial cells</span>. <i>J. Endotoxin Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">271</span>, <span class="refDoi"> DOI: 10.1179/096805102125000470</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1179%2F096805102125000470" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=12230916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD38Xot1ajtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=263-271&author=C.+N.+Wilsonauthor=V.+K.+Batra&title=Lipopolysaccharide+binds+to+and+activates+A%281%29+adenosine+receptors+on+human+pulmonary+artery+endothelial+cells&doi=10.1179%2F096805102125000470"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Lipopolysaccharide binds to and activates A1 adenosine receptors on human pulmonary artery endothelial cells</span></div><div class="casAuthors">Wilson, Constance Neely; Batra, Vinod K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endotoxin Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">263-271</span>CODEN:
                <span class="NLM_cas:coden">JENREB</span>;
        ISSN:<span class="NLM_cas:issn">0968-0519</span>.
    
            (<span class="NLM_cas:orgname">Maney Publishing</span>)
        </div><div class="casAbstract">Previously, it was reported that A1 adenosine receptor antagonists prevent endotoxin-induced acute lung injury and pulmonary arterial endothelial cell damage.  In competition radioligand binding expts. in membranes prepd. from human pulmonary artery endothelial cells (PAECs), lipopolysaccharides (LPSs) of Escherichia coli, Salmonella typhimurium, Klebsiella pneumoniae, and Pseudomonas aeruginosa displaced the binding of a selective A1 adenosine receptor antagonist [125I]-BWA844U (IC50 values: 195 ng/mL, 290 ng/mL, 602 ng/mL, and 693 ng/mL, resp.) in a dose-dependent, competitive manner.  There was no displacement of this radioligand by enterotoxin (≤ 10 μg/mL), diphosphoryl lipid A (≤ 10 μg/mL), and glycolipids, monosialoganglioside (≤ 1 μg/mL), lactocerebroside (≤ 100 μg/mL), or NBD galactocerebroside (≤ 100 μg/mL).  Based on calcd. IC50 values, LPS (E. coli, IC50 111 ng/mL) displaced the selective A1 adenosine receptor agonist, [3H]-2-chloro, N6-cyclopentyladenosine (CCPA) in human PAECs with a potency profile, CCPA > LPS > 2-phenylaminoadenosine (CV 1808), a selective A2 adenosine receptor agonist.  The potency profile for displacement of the selective A2a adenosine receptor agonist [3H]-CGS 21680 was CV 1808 > CCPA.  LPS (E. coli 0.1 pg/mL-10 μg/mL) did not displace [3H]-CGS 21680 binding.  In human PAECs, IL-6 and TXA2 release induced by LPS (0-1 μg/mL) or CCPA (0-1 μM) at high doses was significantly reduced by the selective A1 adenosine receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 1 μM).  These data suggest that LPS binds to and activates A1 adenosine receptors on human PAECs to induce the release of IL-6 and TXA2.  Activation of A1 adenosine receptors on human PAECs by LPS may contribute to the pathophysiol. of acute lung injury assocd. with Gram-neg. septicemia and endotoxemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpilSpTohXHwrVg90H21EOLACvtfcHk0lh6X6-ZrXtDJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xot1ajtrg%253D&md5=eb4d2173d4f468af1863346cb8c95a52</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1179%2F096805102125000470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1179%252F096805102125000470%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DC.%2BN.%26aulast%3DBatra%26aufirst%3DV.%2BK.%26atitle%3DLipopolysaccharide%2520binds%2520to%2520and%2520activates%2520A%25281%2529%2520adenosine%2520receptors%2520on%2520human%2520pulmonary%2520artery%2520endothelial%2520cells%26jtitle%3DJ.%2520Endotoxin%2520Res.%26date%3D2002%26volume%3D8%26spage%3D263%26epage%3D271%26doi%3D10.1179%2F096805102125000470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lappas, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linden, J.</span></span> <span> </span><span class="NLM_article-title">Adenosine A<sub>2A</sub> agonists in development for the treatment of inflammation</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">797</span>– <span class="NLM_lpage">806</span>, <span class="refDoi"> DOI: 10.1517/13543784.14.7.797</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543784.14.7.797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16022569" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmvFelsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2005&pages=797-806&author=C.+M.+Lappasauthor=G.+W.+Sullivanauthor=J.+Linden&title=Adenosine+A2A+agonists+in+development+for+the+treatment+of+inflammation&doi=10.1517%2F13543784.14.7.797"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine A2A agonists in development for the treatment of inflammation</span></div><div class="casAuthors">Lappas, Courtney M.; Sullivan, Gail W.; Linden, Joel</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">797-806</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Extracellular adenosine binds specifically to a family of four G protein-coupled cell-surface adenosine receptors (ARs).  As the activation of the A2AAR modulates the activity of multiple inflammatory cells including neutrophils, macrophages and T lymphocytes, the receptor is considered to be a promising pharmacol. target for the treatment of inflammatory disorders.  Although adenosine binds nonselectively to all four AR subtypes, A2AAR selective agonists have been developed and shown to inhibit multiple manifestations of inflammatory cell activation including superoxide anion generation, cytokine prodn. and adhesion mol. expression.  A2AAR agonists are also vasodilators, but the inhibition of inflammation occurs at low doses that produce few or no cardiovascular side effects.  Therefore, the selective activation of the A2AAR by these compds. holds significant potential in the treatment of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX_jD7VYc8h7Vg90H21EOLACvtfcHk0ljD2OyKD_omRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmvFelsb0%253D&md5=4e6dd54f575fad5993e4b294ef83b94f</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1517%2F13543784.14.7.797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.14.7.797%26sid%3Dliteratum%253Aachs%26aulast%3DLappas%26aufirst%3DC.%2BM.%26aulast%3DSullivan%26aufirst%3DG.%2BW.%26aulast%3DLinden%26aufirst%3DJ.%26atitle%3DAdenosine%2520A2A%2520agonists%2520in%2520development%2520for%2520the%2520treatment%2520of%2520inflammation%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2005%26volume%3D14%26spage%3D797%26epage%3D806%26doi%3D10.1517%2F13543784.14.7.797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Varani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caramori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincenzi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adcock, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casolari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maclennan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morello, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallesco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzena, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span> <span> </span><span class="NLM_article-title">Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">398</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1164/rccm.200506-869OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200506-869OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16322645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD28XmslSlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2006&pages=398-406&author=K.+Varaniauthor=G.+Caramoriauthor=F.+Vincenziauthor=I.+Adcockauthor=P.+Casolariauthor=E.+Leungauthor=S.+Maclennanauthor=S.+Gessiauthor=S.+Morelloauthor=P.+J.+Barnesauthor=K.+Itoauthor=K.+F.+Chungauthor=G.+Cavallescoauthor=G.+Azzenaauthor=A.+Papiauthor=P.+A.+Borea&title=Alteration+of+adenosine+receptors+in+patients+with+chronic+obstructive+pulmonary+disease&doi=10.1164%2Frccm.200506-869OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease</span></div><div class="casAuthors">Varani, Katia; Caramori, Gaetano; Vincenzi, Fabrizio; Adcock, Ian; Casolari, Paolo; Leung, Edward; MacLennan, Stephen; Gessi, Stefania; Morello, Silvania; Barnes, Peter J.; Ito, Kazuhiro; Chung, Kian Fan; Cavallesco, Giorgio; Azzena, Gianfranco; Papi, Alberto; Borea, Pier Andrea</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">398-406</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Rationale: Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of mortality worldwide.  Adenosine is an inflammatory regulator that acts through four distinct receptors to mediate pro- and antiinflammatory effects.  Objectives: The primary aim of this study was to investigate the expression, affinity, and d. of adenosine receptors in peripheral lung parenchyma from age-matched smokers with COPD (n = 14) and smokers with normal lung function (control group; n = 20).  Methods: Adenosine receptors were analyzed by immunohistochem. and satn. binding assays using typical antagonist radioligands.  Results: A1, A2A, A2B, and A3 receptors were expressed in different cells in peripheral lung parenchyma.  The affinity of A1, A2A, and A3 receptors was significantly decreased in patients with COPD compared with the control group (KD[A1] = 3.15 ± 0.19 vs. 1.70 ± 0.14 nM; KD[A2A] = 7.88 ± 0.68 vs. 1.87 ± 0.09 nM; KD[A3] = 9.34 ± 0.27 vs. 4.41 ± 0.25 nM; p < 0.01), whereas their d. was increased (Bmax[A1] = 53 ± 4 vs. 32 ± 3 fmol/mg protein; Bmax[A2A] = 852 ± 50 vs. 302 ± 12 fmol/mg protein; Bmax[A3] = 2,078 ± 108 vs. 770 ± 34 fmol/mg protein; p < 0.01).  The affinity of A2B receptors was not altered, but the d. was significantly decreased in patients with COPD compared with the control group (Bmax = 66 ± 5 vs. 189 ± 16 fmol/mg protein; p < 0.01).  A significant correlation was found between the affinity and d. of the adenosine receptors and the FEV1/FVC ratio.  Conclusions: This is the first report showing the presence of adenosine receptors in lung parenchyma in subjects with COPD compared with control smokers.  These novel findings strengthen the hypothesis of a potential role played by adenosine receptors in the pathogenesis of COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBVPEVprddDbVg90H21EOLACvtfcHk0ljD2OyKD_omRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmslSlu78%253D&md5=0c6087812da1f8adad7ac5e9ac9defee</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1164%2Frccm.200506-869OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200506-869OC%26sid%3Dliteratum%253Aachs%26aulast%3DVarani%26aufirst%3DK.%26aulast%3DCaramori%26aufirst%3DG.%26aulast%3DVincenzi%26aufirst%3DF.%26aulast%3DAdcock%26aufirst%3DI.%26aulast%3DCasolari%26aufirst%3DP.%26aulast%3DLeung%26aufirst%3DE.%26aulast%3DMaclennan%26aufirst%3DS.%26aulast%3DGessi%26aufirst%3DS.%26aulast%3DMorello%26aufirst%3DS.%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DChung%26aufirst%3DK.%2BF.%26aulast%3DCavallesco%26aufirst%3DG.%26aulast%3DAzzena%26aufirst%3DG.%26aulast%3DPapi%26aufirst%3DA.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26atitle%3DAlteration%2520of%2520adenosine%2520receptors%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2006%26volume%3D173%26spage%3D398%26epage%3D406%26doi%3D10.1164%2Frccm.200506-869OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blackburn, M. R.</span></span> <span> </span><span class="NLM_article-title">A<sub>3</sub> adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">1380</span>– <span class="NLM_lpage">1389</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.173.2.1380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4049%2Fjimmunol.173.2.1380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15240734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsVGiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2004&pages=1380-1389&author=H.+W.+Youngauthor=J.+G.+Molinaauthor=D.+Diminaauthor=H.+Zhongauthor=M.+Jacobsonauthor=L.+N.+Chanauthor=T.+S.+Chanauthor=J.+J.+Leeauthor=M.+R.+Blackburn&title=A3+adenosine+receptor+signaling+contributes+to+airway+inflammation+and+mucus+production+in+adenosine+deaminase-deficient+mice&doi=10.4049%2Fjimmunol.173.2.1380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">A3 Adenosine Receptor Signaling Contributes to Airway Inflammation and Mucus Production in Adenosine Deaminase-Deficient Mice</span></div><div class="casAuthors">Young, Hays W. J.; Molina, Jose G.; Dimina, Dawn; Zhong, Hongyan; Jacobson, Marlene; Chan, Lee-Nien L.; Chan, Teh-Sheng; Lee, James J.; Blackburn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1380-1389</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Adenosine signaling has been implicated in chronic lung diseases such as asthma and chronic obstructive pulmonary disease; however, the specific roles of the various adenosine receptors in processes central to these disorders are not well understood.  In this study, the authors have investigated the role(s) of the A3 adenosine receptor in adenosine-dependent pulmonary inflammation obsd. in adenosine deaminase (ADA)-deficient mice.  The A3 receptor (A3R) was expressed in eosinophils and mucus-producing cells in the airways of ADA-deficient mice.  Treatment of ADA-deficient mice with MRS 1523, a selective A3R antagonist, prevented airway eosinophilia and mucus prodn.  Similar findings were seen in the lungs of ADA/A3 double knockout mice.  Although eosinophils were decreased in the airways of ADA-deficient mice following antagonism or removal of the A3R, elevations in circulating and lung interstitial eosinophils persisted, suggesting signaling through the A3R is needed for the migration of eosinophils into the airways.  These findings identify an important role for the A3R in regulating lung eosinophilia and mucus prodn. in an environment of elevated adenosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUukkD1DW_rLVg90H21EOLACvtfcHk0ljD2OyKD_omRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsVGiu7Y%253D&md5=ea93b9057fda0a0070db5e3d14e98708</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.173.2.1380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.173.2.1380%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DH.%2BW.%26aulast%3DMolina%26aufirst%3DJ.%2BG.%26aulast%3DDimina%26aufirst%3DD.%26aulast%3DZhong%26aufirst%3DH.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DChan%26aufirst%3DL.%2BN.%26aulast%3DChan%26aufirst%3DT.%2BS.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DBlackburn%26aufirst%3DM.%2BR.%26atitle%3DA3%2520adenosine%2520receptor%2520signaling%2520contributes%2520to%2520airway%2520inflammation%2520and%2520mucus%2520production%2520in%2520adenosine%2520deaminase-deficient%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2004%26volume%3D173%26spage%3D1380%26epage%3D1389%26doi%3D10.4049%2Fjimmunol.173.2.1380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obiefuna, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadeem, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, S. J.</span></span> <span> </span><span class="NLM_article-title">A novel A1 adenosine receptor antagonist, L-97–1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3,7 dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.088179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.105.088179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=16020631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2005&pages=329-336&author=P.+C.+Obiefunaauthor=V.+K.+Batraauthor=A.+Nadeemauthor=P.+Borronauthor=C.+N.+Wilsonauthor=S.+J.+Mustafa&title=A+novel+A1+adenosine+receptor+antagonist%2C+L-97%E2%80%931+%5B3-%5B2-%284-aminophenyl%29-ethyl%5D-8-benzyl-7-%7B2-ethyl-%282-hydroxy-ethyl%29-amino%5D-ethyl%7D-1-propyl-3%2C7+dihydro-purine-2%2C6-dione%5D%2C+reduces+allergic+responses+to+house+dust+mite+in+an+allergic+rabbit+model+of+asthma&doi=10.1124%2Fjpet.105.088179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino] -ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma</span></div><div class="casAuthors">Obiefuna, P. C. M.; Batra, V. K.; Nadeem, A.; Borron, P.; Wilson, C. N.; Mustafa, S. Jamal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Adenosine, an important signaling mol. in asthma, produces bronchoconstriction in asthmatics.  Adenosine produces bronchoconstriction in allergic rabbits, primates, and humans by activating A1 adenosine receptors (ARs).  Effects of L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino-ethyl}-1-propyl-3,7-dihydro-purine-2,6-dione] a water-sol., small mol. A1 AR antagonist were investigated on early and late phase allergic responses (EAR and LAR) in a hyper-responsive rabbit model of asthma.  Rabbits were made allergic by i.p. injections of house dust mite [HDM; 312 allergen units (AU)] ext. within 24 h of their birth.  Booster HDM injections were given weekly for 1 mo, bi-weekly for 4 mo, and continued monthly thereafter.  Hyper-responsiveness was monitored by measuring lung dynamic compliance (Cdyn), after histamine or adenosine aerosol challenge in allergic rabbits.  Hyper-responsive rabbits were subjected to aerosol of HDM (2500 AU), 1 h after intragastric administration of L-97-1 (10 mg/kg) soln. or an equiv. vol. of saline.  Cdyn was significantly higher after treatment with L-97-1 compared with untreated controls (p < 0.05 n = 5).  Histamine PC30 was significantly higher (p < 0.05; n = 5) after L-97-1 at 24 h compared with histamine PC30 at 24 h after HDM.  Adenosine PC30 was significantly higher at 15 min and 6 h after L-97-1 compared with control (p < 0.05; n = 5).  L-97-1 showed strong affinity for human A1 ARs in radioligand binding studies and no inhibition toward human phosphodiesterase II, III, IV, and V enzymes.  These data suggest that L-97-1 produces a significant redn. of histamine or adenosine-induced hyper-responsiveness and HDM-induced EAR and LAR in allergic rabbits by blocking A1 ARs and may be beneficial as an oral therapy for human asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrANyGMjnvs_bVg90H21EOLACvtfcHk0ljBE-RXs2xSoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVOks7vL&md5=097275b3ea3879fe8e5c582a73a00051</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.088179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.088179%26sid%3Dliteratum%253Aachs%26aulast%3DObiefuna%26aufirst%3DP.%2BC.%26aulast%3DBatra%26aufirst%3DV.%2BK.%26aulast%3DNadeem%26aufirst%3DA.%26aulast%3DBorron%26aufirst%3DP.%26aulast%3DWilson%26aufirst%3DC.%2BN.%26aulast%3DMustafa%26aufirst%3DS.%2BJ.%26atitle%3DA%2520novel%2520A1%2520adenosine%2520receptor%2520antagonist%252C%2520L-97%25E2%2580%25931%2520%255B3-%255B2-%25284-aminophenyl%2529-ethyl%255D-8-benzyl-7-%257B2-ethyl-%25282-hydroxy-ethyl%2529-amino%255D-ethyl%257D-1-propyl-3%252C7%2520dihydro-purine-2%252C6-dione%255D%252C%2520reduces%2520allergic%2520responses%2520to%2520house%2520dust%2520mite%2520in%2520an%2520allergic%2520rabbit%2520model%2520of%2520asthma%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D315%26spage%3D329%26epage%3D336%26doi%3D10.1124%2Fjpet.105.088179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Maatougui, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuaje, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Gómez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carbajales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escalante, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Mera, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutiérrez-de-Terán, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotelo, E.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and highly selective A<sub>2B</sub> adenosine receptor antagonist chemotypes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1967</span>– <span class="NLM_lpage">1983</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01586</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01586" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1967-1983&author=A.+El+Maatouguiauthor=J.+Azuajeauthor=M.+Gonz%C3%A1lez-G%C3%B3mezauthor=G.+Miguezauthor=A.+Crespoauthor=C.+Carbajalesauthor=L.+Escalanteauthor=X.+Garc%C3%ADa-Meraauthor=H.+Guti%C3%A9rrez-de-Ter%C3%A1nauthor=E.+Sotelo&title=Discovery+of+potent+and+highly+selective+A2B+adenosine+receptor+antagonist+chemotypes&doi=10.1021%2Facs.jmedchem.5b01586"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes</span></div><div class="casAuthors">El Maatougui, Abdelaziz; Azuaje, Jhonny; Gonzalez-Gomez, Manuel; Miguez, Gabriel; Crespo, Abel; Carbajales, Carlos; Escalante, Luz; Garcia-Mera, Xerardo; Gutierrez-de-Teran, Hugo; Sotelo, Eddy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1967-1983</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three novel families of A2B adenosine receptor antagonists were identified in the context of the structural exploration of the 3,4-dihydropyrimidin-2(1H)-one chemotype.  The most appealing series contain imidazole, 1,2,4-triazole, or benzimidazole rings fused to the 2,3-positions of the parent diazinone core.  The optimization process enabled identification of a highly potent (3.49 nM) A2B ligand that exhibits complete selectivity toward A1, A2A, and A3 receptors.  The results of functional cAMP expts. confirmed the antagonistic behavior of representative ligands.  The main SAR trends identified within the series were substantiated by a mol. modeling study based on a receptor-driven docking model constructed on the basis of the crystal structure of the human A2A receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRWpBQuLXYG7Vg90H21EOLACvtfcHk0ljBE-RXs2xSoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKnu7g%253D&md5=4df99ab9a9e7dea11b5592ba9d64b334</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01586&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01586%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BMaatougui%26aufirst%3DA.%26aulast%3DAzuaje%26aufirst%3DJ.%26aulast%3DGonz%25C3%25A1lez-G%25C3%25B3mez%26aufirst%3DM.%26aulast%3DMiguez%26aufirst%3DG.%26aulast%3DCrespo%26aufirst%3DA.%26aulast%3DCarbajales%26aufirst%3DC.%26aulast%3DEscalante%26aufirst%3DL.%26aulast%3DGarc%25C3%25ADa-Mera%26aufirst%3DX.%26aulast%3DGuti%25C3%25A9rrez-de-Ter%25C3%25A1n%26aufirst%3DH.%26aulast%3DSotelo%26aufirst%3DE.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520highly%2520selective%2520A2B%2520adenosine%2520receptor%2520antagonist%2520chemotypes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1967%26epage%3D1983%26doi%3D10.1021%2Facs.jmedchem.5b01586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baraldi, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Preti, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borea, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varani, K.</span></span> <span> </span><span class="NLM_article-title">Medicinal chemistry of A<sub>3</sub> adenosine receptor modulators: pharmacological activities and therapeutic implications</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5676</span>– <span class="NLM_lpage">5703</span>, <span class="refDoi"> DOI: 10.1021/jm300087j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300087j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOnsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5676-5703&author=P.+G.+Baraldiauthor=D.+Pretiauthor=P.+A.+Boreaauthor=K.+Varani&title=Medicinal+chemistry+of+A3+adenosine+receptor+modulators%3A+pharmacological+activities+and+therapeutic+implications&doi=10.1021%2Fjm300087j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal Chemistry of A3 Adenosine Receptor Modulators: Pharmacological Activities and Therapeutic Implications</span></div><div class="casAuthors">Baraldi, Pier Giovanni; Preti, Delia; Borea, Pier Andrea; Varani, Katia</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5676-5703</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_0_ZpkzjfnbVg90H21EOLACvtfcHk0ljBE-RXs2xSoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOnsrk%253D&md5=6b85d21f7be2a968d291ce6f73c54d46</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1021%2Fjm300087j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300087j%26sid%3Dliteratum%253Aachs%26aulast%3DBaraldi%26aufirst%3DP.%2BG.%26aulast%3DPreti%26aufirst%3DD.%26aulast%3DBorea%26aufirst%3DP.%2BA.%26aulast%3DVarani%26aufirst%3DK.%26atitle%3DMedicinal%2520chemistry%2520of%2520A3%2520adenosine%2520receptor%2520modulators%253A%2520pharmacological%2520activities%2520and%2520therapeutic%2520implications%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5676%26epage%3D5703%26doi%3D10.1021%2Fjm300087j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, P.
J.</span></span> <span> </span><span class="NLM_article-title">Theophylline</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">901</span>– <span class="NLM_lpage">906</span>, <span class="refDoi"> DOI: 10.1164/rccm.201302-0388PP</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.201302-0388PP" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23672674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslymsLfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2013&pages=901-906&author=P.%0AJ.+Barnes&title=Theophylline&doi=10.1164%2Frccm.201302-0388PP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Theophylline</span></div><div class="casAuthors">Barnes, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">901-906</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Theophylline (dimethylxanthine) has been used to treat airway diseases for more than 80 years.  It was originally used as a bronchodilator, but the relatively high doses required are assocd. with frequent side effects, so its use declined as inhaled β2-agonists became more widely used.  More recently it has been shown to have antiinflammatory effects in asthma and chronic obstructive pulmonary disease (COPD) at lower concns.  The mol. mechanism of bronchodilation is inhibition of phosphodiesterase (PDE)3, but the antiinflammatory effect may be due to inhibition of PDE4 and histone deacetylase-2 activation, resulting in switching off of activated inflammatory genes.  Through this mechanism, theophylline also reverses corticosteroid resistance, and this may be of particular value in severe asthma and COPD, wherein histone deacetylase-2 activity is reduced.  Theophylline is given systemically (orally as slow-release prepns. for chronic treatment and i.v. for acute exacerbations of asthma).  Efficacy is related to blood concns., which are detd. mainly by hepatic metab., which may be increased or decreased in several diseases and by concomitant drug therapy.  Theophylline is now usually used as an add-on therapy in patients with asthma not well controlled on inhaled corticosteroids with or without long-acting β2-agonists and in patients with COPD with severe disease not controlled by bronchodilator therapy.  Side effects are related to plasma concns. and include nausea, vomiting, and headaches due to PDE inhibition and at higher concns. to cardiac arrhythmias and seizures due to adenosine A1-receptor antagonism.  In the future, low-dose theophylline may be useful in reversing corticosteroid resistance in COPD and severe asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqniUExR5YzkrVg90H21EOLACvtfcHk0lgCCMK-FG8RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslymsLfI&md5=5ad4233b2b1860d403de0d0fd1d6e85f</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1164%2Frccm.201302-0388PP&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.201302-0388PP%26sid%3Dliteratum%253Aachs%26aulast%3DBarnes%26aufirst%3DP.%2BJ.%26atitle%3DTheophylline%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2013%26volume%3D188%26spage%3D901%26epage%3D906%26doi%3D10.1164%2Frccm.201302-0388PP" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manocha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vijayan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease</span>. <i>J. Basic Clin. Physiol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">451</span>, <span class="refDoi"> DOI: 10.1515/jbcpp-2015-0006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1515%2Fjbcpp-2015-0006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25894641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OnsL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=443-451&author=D.+Lalauthor=S.+Manochaauthor=A.+Rayauthor=V.+K.+Vijayanauthor=R.+Kumar&title=Comparative+study+of+the+efficacy+and+safety+of+theophylline+and+doxofylline+in+patients+with+bronchial+asthma+and+chronic+obstructive+pulmonary+disease&doi=10.1515%2Fjbcpp-2015-0006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease</span></div><div class="casAuthors">Lal, Dushyant; Manocha, Sachin; Ray, Arunabha; Vijayan, V. K.; Kumar, Raj</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Basic and Clinical Physiology and Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">443-451</span>CODEN:
                <span class="NLM_cas:coden">JBPPES</span>;
        ISSN:<span class="NLM_cas:issn">0792-6855</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">Background: Bronchial asthma and chronic obstructive pulmonary disease (COPD) are the major obstructive disorders that may contribute to the severity in individual patients.  The present study was designed to compare the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and COPD.  Methods: A total of 60 patients, 30 each with bronchial asthma and COPD, were enrolled for the study.  Each group of 30 patients received std. treatment for asthma and COPD.  Each group was again subdivided into two with 15 patients each, who received theophylline or doxofylline in addn. to std. therapy, for a period of 2 mo.  Each patient was followed up fortnightly for the assessment of efficacy parameters using a pulmonary function test (PFT), clin. symptoms and emergency drug use, and safety was assessed by recording adverse drug reactions.  Results: Both theophylline and doxofylline produced enhancements in PFT at different time intervals in both asthma and COPD patients.  The max. beneficial effects were seen at 6 wk for asthma patients and at 8 wk for COPD patients for both theophylline and doxofylline.  Conclusions: The comparative study showed that doxofylline was more effective as evidenced by improvement in PFT as well as clin. symptoms, and reduced incidence of adverse effects and emergency bronchodilator use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY4bwKNqTCILVg90H21EOLACvtfcHk0lgCCMK-FG8RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OnsL%252FO&md5=58eaa00ab6e4a4ba98cc3662af7cc7de</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1515%2Fjbcpp-2015-0006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fjbcpp-2015-0006%26sid%3Dliteratum%253Aachs%26aulast%3DLal%26aufirst%3DD.%26aulast%3DManocha%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DVijayan%26aufirst%3DV.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DComparative%2520study%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520theophylline%2520and%2520doxofylline%2520in%2520patients%2520with%2520bronchial%2520asthma%2520and%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DJ.%2520Basic%2520Clin.%2520Physiol.%2520Pharmacol.%26date%3D2015%26volume%3D26%26spage%3D443%26epage%3D451%26doi%3D10.1515%2Fjbcpp-2015-0006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matera, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Page, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazzola, M.</span></span> <span> </span><span class="NLM_article-title">Doxofylline is not just another theophylline!</span>. <i>Int. J. Chronic Obstruct. Pulm. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3487</span>– <span class="NLM_lpage">3493</span>, <span class="refDoi"> DOI: 10.2147/COPD.S150887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.2147%2FCOPD.S150887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=29255355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntVKnsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=3487-3493&author=M.+G.+Materaauthor=C.+Pageauthor=M.+Cazzola&title=Doxofylline+is+not+just+another+theophylline%21&doi=10.2147%2FCOPD.S150887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Doxofylline is not just another theophylline!</span></div><div class="casAuthors">Matera, Maria Gabriella; Page, Clive; Cazzola, Mario</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Chronic Obstructive Pulmonary Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3487-3493</span>CODEN:
                <span class="NLM_cas:coden">IJCOC3</span>;
        ISSN:<span class="NLM_cas:issn">1178-2005</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Doxofylline, which differs from theophylline in contg. the dioxalane group at position 7, has comparable efficacy to theophylline in the treatment of respiratory diseases, but with an improved tolerability profile and a favorable risk-to-benefit ratio.  Furthermore, it does not have significant drug-drug interactions as exhibited with theophylline, which make using theophylline more challenging, esp. in elderly patients with co-morbidities receiving multiple classes of drug.  It is now clear that doxofylline also possesses a distinct pharmacol. profile from theophylline (no significant effect on any of the known phosphodiesterase isoforms, no significant adenosine receptor antagonism, no direct effect on histone deacetylases, interaction with β2-adrenoceptors) and therefore, should not be considered as just a modified theophylline.  Randomized clin. trials of doxofylline to investigate the use of this drug to reduce exacerbations and hospitalizations due to asthma or COPD as an alternative to expensive biologics, and certainly as an alternative to theophylline are to be encouraged.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW97uF_60k7bVg90H21EOLACvtfcHk0lgCCMK-FG8RIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntVKnsb4%253D&md5=5d94dfedf43b6ebab35b7858f12984e8</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.2147%2FCOPD.S150887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FCOPD.S150887%26sid%3Dliteratum%253Aachs%26aulast%3DMatera%26aufirst%3DM.%2BG.%26aulast%3DPage%26aufirst%3DC.%26aulast%3DCazzola%26aufirst%3DM.%26atitle%3DDoxofylline%2520is%2520not%2520just%2520another%2520theophylline%2521%26jtitle%3DInt.%2520J.%2520Chronic%2520Obstruct.%2520Pulm.%2520Dis.%26date%3D2017%26volume%3D12%26spage%3D3487%26epage%3D3493%26doi%3D10.2147%2FCOPD.S150887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshie, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenmotsu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichimasa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugamura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, K.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>193</i></span>,  <span class="NLM_fpage">255</span>– <span class="NLM_lpage">261</span>, <span class="refDoi"> DOI: 10.1084/jem.193.2.255</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1084%2Fjem.193.2.255" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=11208866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksl2msg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=2001&pages=255-261&author=H.+Hiraiauthor=K.+Tanakaauthor=O.+Yoshieauthor=K.+Ogawaauthor=K.+Kenmotsuauthor=Y.+Takamoriauthor=M.+Ichimasaauthor=K.+Sugamuraauthor=M.+Nakamuraauthor=S.+Takanoauthor=K.+Nagata&title=Prostaglandin+D2+selectively+induces+chemotaxis+in+T+helper+type+2+cells%2C+eosinophils%2C+and+basophils+via+seven-transmembrane+receptor+CRTH2&doi=10.1084%2Fjem.193.2.255"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2</span></div><div class="casAuthors">Hirai, Hiroyuki; Tanaka, Kazuya; Yoshie, Osamu; Ogawa, Kazuyuki; Kenmotsu, Kazumi; Takamori, Yasushi; Ichimasa, Michiko; Sugamura, Kazuo; Nakamura, Masataka; Takano, Shoichi; Nagata, Kinya</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">255-261</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">0022-1007</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">Prostaglandin (PG)D2, which has long been implicated in allergic diseases, is currently considered to elicit its biol. actions through the DP receptor (DP).  Involvement of DP in the formation of allergic asthma was recently demonstrated with DP-deficient mice.  However, proinflammatory functions of PGD2 cannot be explained by DP alone.  The authors show here that a 7-transmembrane receptor, CRTH2, which is preferentially expressed in T helper type 2 (Th2) cells, eosinophils, and basophils in humans, serves as the novel receptor for PGD2.  In response to PGD2, CRTH2 induces intracellular Ca2+ mobilization and chemotaxis in Th2 cells in a Gαi-dependent manner.  In addn., CRTH2, but not DP, mediates PGD2-dependent cell migration of blood eosinophils and basophils.  Thus, PGD2 is likely involved in multiple aspects of allergic inflammation through its dual receptor systems, DP and CRTH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzrVzvfWtBArVg90H21EOLACvtfcHk0ljkCVLoicraVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksl2msg%253D%253D&md5=be2c6671805c587029df75738463ccd3</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1084%2Fjem.193.2.255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.193.2.255%26sid%3Dliteratum%253Aachs%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DYoshie%26aufirst%3DO.%26aulast%3DOgawa%26aufirst%3DK.%26aulast%3DKenmotsu%26aufirst%3DK.%26aulast%3DTakamori%26aufirst%3DY.%26aulast%3DIchimasa%26aufirst%3DM.%26aulast%3DSugamura%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DM.%26aulast%3DTakano%26aufirst%3DS.%26aulast%3DNagata%26aufirst%3DK.%26atitle%3DProstaglandin%2520D2%2520selectively%2520induces%2520chemotaxis%2520in%2520T%2520helper%2520type%25202%2520cells%252C%2520eosinophils%252C%2520and%2520basophils%2520via%2520seven-transmembrane%2520receptor%2520CRTH2%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2001%26volume%3D193%26spage%3D255%26epage%3D261%26doi%3D10.1084%2Fjem.193.2.255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiraishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakajima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oguma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagyo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizaka, A.</span></span> <span> </span><span class="NLM_article-title">Prostaglandin D2-induced eosinophilic airways inflammation is mediated by CRTH2 receptor</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>312</i></span>,  <span class="NLM_fpage">954</span>– <span class="NLM_lpage">960</span>, <span class="refDoi"> DOI: 10.1124/jpet.104.078212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.104.078212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=15528449" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2004&pages=954-960&author=Y.+Shiraishiauthor=K.+Asanoauthor=T.+Nakajimaauthor=T.+Ogumaauthor=Y.+Suzukiauthor=T.+Shiomiauthor=K.+Sayamaauthor=K.+Niimiauthor=M.+Wakakiauthor=J.+Kagyoauthor=E.+Ikedaauthor=H.+Hiraiauthor=K.+Yamaguchiauthor=A.+Ishizaka&title=Prostaglandin+D2-induced+eosinophilic+airways+inflammation+is+mediated+by+CRTH2+receptor&doi=10.1124%2Fjpet.104.078212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1124%2Fjpet.104.078212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.104.078212%26sid%3Dliteratum%253Aachs%26aulast%3DShiraishi%26aufirst%3DY.%26aulast%3DAsano%26aufirst%3DK.%26aulast%3DNakajima%26aufirst%3DT.%26aulast%3DOguma%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DShiomi%26aufirst%3DT.%26aulast%3DSayama%26aufirst%3DK.%26aulast%3DNiimi%26aufirst%3DK.%26aulast%3DWakaki%26aufirst%3DM.%26aulast%3DKagyo%26aufirst%3DJ.%26aulast%3DIkeda%26aufirst%3DE.%26aulast%3DHirai%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DIshizaka%26aufirst%3DA.%26atitle%3DProstaglandin%2520D2-induced%2520eosinophilic%2520airways%2520inflammation%2520is%2520mediated%2520by%2520CRTH2%2520receptor%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2004%26volume%3D312%26spage%3D954%26epage%3D960%26doi%3D10.1124%2Fjpet.104.078212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steinke, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payne, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borish, L.</span></span> <span> </span><span class="NLM_article-title">Eosinophils and mast cells in aspirin-exacerbated respiratory disease</span>. <i>Immunol. Allergy Clin. North Am.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">719</span>– <span class="NLM_lpage">734</span>, <span class="refDoi"> DOI: 10.1016/j.iac.2016.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.iac.2016.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=27712766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2svnvFWntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=719-734&author=J.+W.+Steinkeauthor=S.+C.+Payneauthor=L.+Borish&title=Eosinophils+and+mast+cells+in+aspirin-exacerbated+respiratory+disease&doi=10.1016%2Fj.iac.2016.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease</span></div><div class="casAuthors">Steinke John W; Payne Spencer C; Borish Larry</div><div class="citationInfo"><span class="NLM_cas:title">Immunology and allergy clinics of North America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">719-734</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aspirin-exacerbated respiratory disease (AERD) involves overexpression of proinflammatory mediators, including 5-lipoxygenase and leukotriene C4 synthase (LTC4S), resulting in constitutive overproduction of cysteinyl leukotrienes.  Mast cells and eosinophils have roles in mediating many of the observed effects.  Increased levels of both interleukin-4 (IL-4) and interferon (IFN)-γ are present in the tissue of patients with AERD.  Previous studies showed that IL-4 is primarily responsible for the upregulation of LTC4S by mast cells.  Our studies show that IFN-γ, but not IL-4, drives this process in eosinophils.  This article examines the overall role that eosinophils and mast cells contribute to the pathophysiology of AERD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQKUjf8dgw-aXELvajU9pjPfW6udTcc2eZnCt6pf9_zcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svnvFWntA%253D%253D&md5=6c71572c54fe92bf92b3d44ea87fefee</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1016%2Fj.iac.2016.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.iac.2016.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DSteinke%26aufirst%3DJ.%2BW.%26aulast%3DPayne%26aufirst%3DS.%2BC.%26aulast%3DBorish%26aufirst%3DL.%26atitle%3DEosinophils%2520and%2520mast%2520cells%2520in%2520aspirin-exacerbated%2520respiratory%2520disease%26jtitle%3DImmunol.%2520Allergy%2520Clin.%2520North%2520Am.%26date%3D2016%26volume%3D36%26spage%3D719%26epage%3D734%26doi%3D10.1016%2Fj.iac.2016.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D. S.</span></span> <span> </span><span class="NLM_article-title">DP2 receptor antagonists: novel therapeutic target for COPD</span>. <i>Mol. Cell. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.4255/mcpharmacol.10.12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4255%2Fmcpharmacol.10.12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXovFGltbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=89-96&author=K.+J.+Stebbinsauthor=J.+F.+Evansauthor=D.+S.+Lorrain&title=DP2+receptor+antagonists%3A+novel+therapeutic+target+for+COPD&doi=10.4255%2Fmcpharmacol.10.12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit209R"><div class="casContent"><span class="casTitleNuber">209</span><div class="casTitle"><span class="NLM_cas:atitle">DP2 receptor antagonists: novel therapeutic target for COPD</span></div><div class="casAuthors">Stebbins, Karin J.; Evans, Jilly F.; Lorrain, Daniel S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">89-96</span>CODEN:
                <span class="NLM_cas:coden">MCPOCT</span>;
        ISSN:<span class="NLM_cas:issn">1938-1247</span>.
    
            (<span class="NLM_cas:orgname">LumiText Publishing</span>)
        </div><div class="casAbstract">A review.  Chronic obstructive pulmonary disease (COPD) is a chronic and progressive disease of the small airways and lung parenchyma that is characterized by chronic airway inflammation, airway remodeling and parenchymal destruction.  Current treatment options for patients with COPD consist primarily of long acting bronchodilators.  Inhaled corticosteroids provide benefit for exacerbations but have little impact on the persistent inflammation.  At present, there are no approved drugs that are disease modifying to treat the underlying causes of COPD.  One pharmacol. mechanism we and others are exploring as a therapeutic target for COPD is antagonism of the DP2 receptor (also known as chemoattractant receptor-homologous mol. expressed on Th2 cells, CRTh2).  Since cigarette smoking is a risk factor for COPD, we used mouse models of acute and subchronic cigarette smoke exposure to explore the role of DP2 in COPD.  We obsd. an increase in prostaglandin D2 (PGD2), the natural ligand for DP2, in the mouse lungs following subchronic smoke exposure.  We demonstrated that DP2 antagonism alleviated much of the cigarette smoke-induced lung phenotype, including cellular inflammation, mucus cell metaplasia and epithelial hyperplasia.  Although the role of PGD2 and DP2 in COPD is yet to be fully elucidated, our results support the development of DP2 antagonists clin. as a novel pharmacol. mechanism to treat COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAgc2PbdqO7rVg90H21EOLACvtfcHk0lhI0I0ZLEoixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXovFGltbY%253D&md5=a155d881b3fec80fcb4ad0a6fad6c1a0</span></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.4255%2Fmcpharmacol.10.12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4255%252Fmcpharmacol.10.12%26sid%3Dliteratum%253Aachs%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26atitle%3DDP2%2520receptor%2520antagonists%253A%2520novel%2520therapeutic%2520target%2520for%2520COPD%26jtitle%3DMol.%2520Cell.%2520Pharmacol.%26date%3D2010%26volume%3D2%26spage%3D89%26epage%3D96%26doi%3D10.4255%2Fmcpharmacol.10.12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD</span>. <i>Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">1722</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1016/j.rmed.2013.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.rmed.2013.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23827726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC3sjotFKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2013&pages=1722-1730&author=N.+Snellauthor=M.+Fosterauthor=J.+Vestbo&title=Efficacy+and+safety+of+AZD1981%2C+a+CRTH2+receptor+antagonist%2C+in+patients+with+moderate+to+severe+COPD&doi=10.1016%2Fj.rmed.2013.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of AZD1981, a CRTH2 receptor antagonist, in patients with moderate to severe COPD</span></div><div class="casAuthors">Snell Noel; Foster Martyn; Vestbo Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1722-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To evaluate the efficacy and tolerability of the selective CRTh2 (DP2) receptor antagonist AZD1981 compared with placebo in patients with moderate to severe COPD.  METHODS:  In this multicentre, randomised, double-blind, parallel-group, phase IIa study (ClinicalTrials.gov identifier: NCT00690482) patients with moderate to severe COPD received either AZD1981 1000 mg twice daily or matching placebo for 4 weeks.  Inhaled terbutaline was used as-needed as reliever medication throughout.  The co-primary endpoints were change from baseline to end of treatment in pre-bronchodilator forced expiratory volume in 1 s [FEV1] and the Clinical COPD Questionnaire (CCQ).  Additional endpoints included other lung function measures, 6-min walk test (6-MWT), COPD symptom score, reliever medication use and tolerability.  RESULTS:  118 patients were randomised to treatment (AZD1981 n = 61; placebo n = 57); 83% of patients were male and the mean age was 63 years (range 43-83).  There were no significant differences in the mean difference in change from baseline to end of treatment between AZD1981 and placebo for the co-primary endpoints of pre-bronchodilator FEV1 (AZD1981-placebo: -0.015, 95% CI: -0.10 to 0.070; p = 0.72) and CCQ total score (difference: 0.042, 95% CI: -0.21 to 0.30; p = 0.75).  Similarly, no differences were observed between treatments for the other outcomes of lung function, COPD symptom score, 6-MWT, BODE index, and use of reliever medication.  AZD1981 was well tolerated.  CONCLUSION:  There was no beneficial clinical effect of AZD1981, at a dose of 1000 mg twice daily for 4 weeks, in patients with moderate to severe COPD.  AZD1981 was well tolerated and no safety concerns were identified.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTPSqgbSDH0Dhcr74wzj5o5fW6udTcc2eaNXyGgLbuXLbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sjotFKktg%253D%253D&md5=1cb066d5739b23480039c884b1950ccd</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1016%2Fj.rmed.2013.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.rmed.2013.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DSnell%26aufirst%3DN.%26aulast%3DFoster%26aufirst%3DM.%26aulast%3DVestbo%26aufirst%3DJ.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520AZD1981%252C%2520a%2520CRTH2%2520receptor%2520antagonist%252C%2520in%2520patients%2520with%2520moderate%2520to%2520severe%2520COPD%26jtitle%3DRespir.%2520Med.%26date%3D2013%26volume%3D107%26spage%3D1722%26epage%3D1730%26doi%3D10.1016%2Fj.rmed.2013.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorrain, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stebbins, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhead, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baccei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troung, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span> <span> </span><span class="NLM_article-title">Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">290</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.180430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.111.180430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=21487069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFChsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=290-301&author=G.+Bainauthor=D.+S.+Lorrainauthor=K.+J.+Stebbinsauthor=A.+R.+Broadheadauthor=A.+M.+Santiniauthor=P.+Prodanovichauthor=J.+Darlingtonauthor=C.+D.+Kingauthor=C.+Leeauthor=C.+Bacceiauthor=B.+Stearnsauthor=Y.+Troungauthor=J.+H.+Hutchinsonauthor=P.+Prasitauthor=J.+F.+Evans&title=Pharmacology+of+AM211%2C+a+potent+and+selective+prostaglandin+D2+receptor+type+2+antagonist+that+is+active+in+animal+models+of+allergic+inflammation&doi=10.1124%2Fjpet.111.180430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation</span></div><div class="casAuthors">Bain, Gretchen; Lorrain, Daniel S.; Stebbins, Karin J.; Broadhead, Alex R.; Santini, Angelina M.; Prodanovich, Pat; Darlington, Janice; King, Christopher D.; Lee, Catherine; Baccei, Christopher; Stearns, Brian; Troung, Yen; Hutchinson, John H.; Prasit, Peppi; Evans, Jilly F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">290-301</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The prostaglandin D2 (PGD2) receptor type 2 (DP2) is a G protein-coupled receptor that has been shown to be involved in a variety of allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis.  In this study, we describe the preclin. pharmacol. and pharmacokinetic properties of the small-mol. DP2 antagonist [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid (AM211).  We det. that AM211 has high affinity for human, mouse, rat, and guinea pig DP2 and it shows selectivity over other prostanoid receptors and enzymes.  Antagonist activity of AM211 at the DP2 receptor was confirmed by inhibition of PGD2-stimulated guanosine 5'-O-[γ-thio]triphosphate binding to membranes expressing human DP2.  A basophil activation assay and a whole-blood assay of eosinophil shape change were used to demonstrate the ability of AM211 to potently antagonize PGD2-stimulated functional responses in relevant human cells and in the context of a physiol. relevant environment.  AM211 exhibits good oral bioavailability in rats and dogs and dose-dependently inhibits 13,14-dihydro-15-keto-PGD2-induced leukocytosis in a guinea pig pharmacodynamic assay.  AM211 demonstrates efficacy in two animal models of allergic inflammation, including an ovalbumin-induced lung inflammation model in guinea pigs and an ovalbumin-induced mouse model of allergic rhinitis.  AM211 represents a potent and selective antagonist of DP2 that may be used clin. to evaluate the role of DP2 in T helper 2-driven allergic inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0R5IR6qyfzLVg90H21EOLACvtfcHk0lhI0I0ZLEoixQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFChsrY%253D&md5=85947de08474cbc68015b481097e2bd2</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.180430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.180430%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DG.%26aulast%3DLorrain%26aufirst%3DD.%2BS.%26aulast%3DStebbins%26aufirst%3DK.%2BJ.%26aulast%3DBroadhead%26aufirst%3DA.%2BR.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBaccei%26aufirst%3DC.%26aulast%3DStearns%26aufirst%3DB.%26aulast%3DTroung%26aufirst%3DY.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DPrasit%26aufirst%3DP.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26atitle%3DPharmacology%2520of%2520AM211%252C%2520a%2520potent%2520and%2520selective%2520prostaglandin%2520D2%2520receptor%2520type%25202%2520antagonist%2520that%2520is%2520active%2520in%2520animal%2520models%2520of%2520allergic%2520inflammation%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D290%26epage%3D301%26doi%3D10.1124%2Fjpet.111.180430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brittain, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearmond, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stearns, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truong, Y. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holme, K.</span></span> <span> </span><span class="NLM_article-title">Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">1482</span>– <span class="NLM_lpage">1493</span>, <span class="refDoi"> DOI: 10.1177/0091270011421912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1177%2F0091270011421912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22110163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyqsLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=1482-1493&author=G.+Bainauthor=C.+D.+Kingauthor=J.+Brittainauthor=J.+P.+Hartungauthor=I.+Dearmondauthor=B.+Stearnsauthor=Y.+P.+Truongauthor=J.+H.+Hutchinsonauthor=J.+F.+Evansauthor=K.+Holme&title=Pharmacodynamics%2C+pharmacokinetics%2C+and+safety+of+AM211%3A+a+novel+and+potent+antagonist+of+the+prostaglandin+D2+receptor+type+2&doi=10.1177%2F0091270011421912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2</span></div><div class="casAuthors">Bain, G.; King, C. D.; Brittain, J.; Hartung, J. P.; De Armond, I.; Stearns, B.; Truong, Y. P.; Hutchinson, J. H.; Evans, J. F.; Holme, K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1482-1493</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The prostaglandin D2 receptor type 2 (DP2) and its ligand, PGD2, have been implicated in the development of asthma and other inflammatory diseases.  The authors evaluated the pharmacodynamics, pharmacokinetics and safety of [2'-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid sodium salt (AM211), a novel and potent DP2 antagonist, in healthy participants.  Single and multiple doses of AM211 demonstrated dose-dependent inhibition of eosinophil shape change in blood with near-complete inhibition obsd. at trough after dosing 200 mg once daily for 7 days.  Maximum plasma concns. and exposures of AM211 increased in a greater-than-dose-proportional manner after single and multiple dosing.  After multiple dosing, the exposures on day 7 were higher than on day 1 with accumulation ratio values ranging from 1.4 to 1.5.  Mean terminal half-life values ranged from 14 to 25 h across the dose range of 100 to 600 mg.  AM211 was well tolerated at all doses in both the single- and multiple-dose cohorts.  These data support addnl. clin. studies to evaluate AM211 in asthma and other inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgTV_Wdw_bxLVg90H21EOLACvtfcHk0lg062_ErhbZ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyqsLfP&md5=bb5cf8f73626f6181d435b37265d10ce</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1177%2F0091270011421912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270011421912%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DG.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DBrittain%26aufirst%3DJ.%26aulast%3DHartung%26aufirst%3DJ.%2BP.%26aulast%3DDearmond%26aufirst%3DI.%26aulast%3DStearns%26aufirst%3DB.%26aulast%3DTruong%26aufirst%3DY.%2BP.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DHolme%26aufirst%3DK.%26atitle%3DPharmacodynamics%252C%2520pharmacokinetics%252C%2520and%2520safety%2520of%2520AM211%253A%2520a%2520novel%2520and%2520potent%2520antagonist%2520of%2520the%2520prostaglandin%2520D2%2520receptor%2520type%25202%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2012%26volume%3D52%26spage%3D1482%26epage%3D1493%26doi%3D10.1177%2F0091270011421912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norman, P.</span></span> <span> </span><span class="NLM_article-title">A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1931</span>– <span class="NLM_lpage">1936</span>, <span class="refDoi"> DOI: 10.1517/13543776.2011.636738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543776.2011.636738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22082220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVyksrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1931-1936&author=P.+Norman&title=A+novel+DP2+receptor+antagonist+%28AM-461%29%3A+a+patent+evaluation+of+WO2011085033&doi=10.1517%2F13543776.2011.636738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033</span></div><div class="casAuthors">Norman, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1931-1936</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  This application claims salts and cryst. forms of a previously disclosed DP2 receptor antagonist (2-[3-[2-(tert-butylsulfanylmethyl)-4-(2,2-dimethylpropanoylamino)phenoxy]-4-methoxy-phenyl]acetic acid (1)).  It also claims compns. contg. the free acid and its salts, esp. the sodium salt and their use in the treatment of inflammatory and respiratory diseases, esp. asthma.  Notably, the application presents Phase I clin. data on compd. (1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgHu0_v41IFrVg90H21EOLACvtfcHk0lg062_ErhbZ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVyksrvL&md5=5899d49348c46eedb55efc71bf699910</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1517%2F13543776.2011.636738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2011.636738%26sid%3Dliteratum%253Aachs%26aulast%3DNorman%26aufirst%3DP.%26atitle%3DA%2520novel%2520DP2%2520receptor%2520antagonist%2520%2528AM-461%2529%253A%2520a%2520patent%2520evaluation%2520of%2520WO2011085033%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2011%26volume%3D21%26spage%3D1931%26epage%3D1936%26doi%3D10.1517%2F13543776.2011.636738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulven, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kostenis, E.</span></span> <span> </span><span class="NLM_article-title">Novel CRTH2 antagonists: a review of patents from 2006 to 2009</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1505</span>– <span class="NLM_lpage">1530</span>, <span class="refDoi"> DOI: 10.1517/13543776.2010.525506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1517%2F13543776.2010.525506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=20946089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1505-1530&author=T.+Ulvenauthor=E.+Kostenis&title=Novel+CRTH2+antagonists%3A+a+review+of+patents+from+2006+to+2009&doi=10.1517%2F13543776.2010.525506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">Novel CRTH2 antagonists: a review of patents from 2006 to 2009</span></div><div class="casAuthors">Ulven, Trond; Kostenis, Evi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1505-1530</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: The receptor CRTH2 (also known as DP2) is an important mediator of the inflammatory effects of prostaglandin D2 and has attracted much attention as a therapeutic target for the treatment of conditions such as asthma, COPD, allergic rhinitis and atopic dermatitis.  Areas covered in this review: The validation of CRTH2 as a therapeutic target and the early antagonists are summarized, CRTH2 antagonists published in the patent literature from 2006 to 2009 are comprehensively covered and a general update on the recent progress in the development of CRTH2 antagonists for the treatment of inflammatory diseases is provided.  What the reader will gain: Insight into the validation of CRTH2 as a therapeutic target, a comprehensive overview of the development of new CRTH2 ligands between 2006 and 2009, and a general overview of the state of the art.  Take home message: Many diverse potent CRTH2 antagonists are now available, and several are in or on the way into the clinic.  It is still early to draw final conclusions, but preliminary results give reason for optimism, and the prospect that we will see new CRTH2 antagonists reaching the market for the treatment of asthma, rhinitis, atopic dermatitis and/or COPD seems good.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0vwLWB8G_DbVg90H21EOLACvtfcHk0lg062_ErhbZ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWmtL%252FE&md5=0600e42595e4de51ab405331687630ca</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1517%2F13543776.2010.525506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2010.525506%26sid%3Dliteratum%253Aachs%26aulast%3DUlven%26aufirst%3DT.%26aulast%3DKostenis%26aufirst%3DE.%26atitle%3DNovel%2520CRTH2%2520antagonists%253A%2520a%2520review%2520of%2520patents%2520from%25202006%2520to%25202009%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26spage%3D1505%26epage%3D1530%26doi%3D10.1517%2F13543776.2010.525506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kogan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dupré, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAbee, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassir, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, I. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanderslice, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, R. A.</span></span> <span> </span><span class="NLM_article-title">Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1099</span>– <span class="NLM_lpage">1111</span>, <span class="refDoi"> DOI: 10.1021/jm9704917</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9704917" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADyaK1cXhs12ks70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=1099-1111&author=T.+P.+Koganauthor=B.+Dupr%C3%A9author=H.+Buiauthor=K.+L.+McAbeeauthor=J.+M.+Kassirauthor=I.+L.+Scottauthor=X.+Huauthor=P.+Vandersliceauthor=P.+J.+Beckauthor=R.+A.+Dixon&title=Novel+synthetic+inhibitors+of+selectin-mediated+cell+adhesion%3A+synthesis+of+1%2C6-bis%5B3-%283-carboxymethylphenyl%29-4-%282-alpha-D-+mannopyranosyloxy%29phenyl%5Dhexane+%28TBC1269%29&doi=10.1021%2Fjm9704917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Synthetic Inhibitors of Selectin-Mediated Cell Adhesion: Synthesis of 1,6-Bis[3-(3-carboxymethylphenyl)-4-(2-α-D-mannopyranosyloxy)phenyl]hexane (TBC1269)</span></div><div class="casAuthors">Kogan, Timothy P.; Dupre, Brian; Bui, Huong; McAbee, Kathy L.; Kassir, Jamal M.; Scott, Ian L.; Hu, Xin; Vanderslice, Peter; Beck, Pamela J.; Dixon, Richard A. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1099-1111</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reports of a high-affinity ligand for E-selectin, sialyl di-Lewisx motivated the authors to incorporate modifications to previously reported biphenyl-based inhibitors that would provide addnl. interactions with the protein.  These compds. were assayed for the ability to inhibit the binding of sialyl Lewisx (sLex) bearing HL-60 cells to E-, P-, and L-selectin fusion proteins.  The authors report that dimeric or trimeric compds. contg. multiple components of simple nonoligosaccharide selectin antagonists inhibit sLex-dependent binding with significantly enhanced potency over the monomeric compd.  The enhanced potency is consistent with addnl. binding interactions within a single selectin lectin domain; however, multivalent interaction with multiple lectin domains as a possible alternative cannot be ruled out.  Compd. I (TBC 1269) showed optimal in vitro activity from this class of antagonists and is currently under development for use in the treatment of asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUeXjoakahVLVg90H21EOLACvtfcHk0lg062_ErhbZ0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhs12ks70%253D&md5=da0974c175dcb37e2aad448636be74f9</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1021%2Fjm9704917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9704917%26sid%3Dliteratum%253Aachs%26aulast%3DKogan%26aufirst%3DT.%2BP.%26aulast%3DDupr%25C3%25A9%26aufirst%3DB.%26aulast%3DBui%26aufirst%3DH.%26aulast%3DMcAbee%26aufirst%3DK.%2BL.%26aulast%3DKassir%26aufirst%3DJ.%2BM.%26aulast%3DScott%26aufirst%3DI.%2BL.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DVanderslice%26aufirst%3DP.%26aulast%3DBeck%26aufirst%3DP.%2BJ.%26aulast%3DDixon%26aufirst%3DR.%2BA.%26atitle%3DNovel%2520synthetic%2520inhibitors%2520of%2520selectin-mediated%2520cell%2520adhesion%253A%2520synthesis%2520of%25201%252C6-bis%255B3-%25283-carboxymethylphenyl%2529-4-%25282-alpha-D-%2520mannopyranosyloxy%2529phenyl%255Dhexane%2520%2528TBC1269%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D1099%26epage%3D1111%26doi%3D10.1021%2Fjm9704917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finney, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singanayagam, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallia, P.</span></span> <span> </span><span class="NLM_article-title">Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">932</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(14)70169-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS2213-2600%2814%2970169-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25240963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsF2mu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2014&pages=919-932&author=L.+Finneyauthor=M.+Berryauthor=A.+Singanayagamauthor=S.+L.+Elkinauthor=S.+L.+Johnstonauthor=P.+Mallia&title=Inhaled+corticosteroids+and+pneumonia+in+chronic+obstructive+pulmonary+disease&doi=10.1016%2FS2213-2600%2814%2970169-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease</span></div><div class="casAuthors">Finney, Lydia; Berry, Matthew; Singanayagam, Aran; Elkin, Sarah L.; Johnston, Sebastian L.; Mallia, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">919-932</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhaled corticosteroids are widely used in chronic obstructive pulmonary disease (COPD) and, in combination with long-acting β2 agonists, reduce exacerbations and improve lung function and quality of life.  However, inhaled corticosteroids have been linked with an increased risk of pneumonia in individuals with COPD, but the magnitude of this risk, the effects of different prepns. and doses, and the mechanisms of this effect remain unclear.  Therefore, making informed clin. decisions-balancing the beneficial and adverse effects of inhaled corticosteroids in individuals with COPD-is difficult.  Understanding of the mechanisms of increased pneumonia risk with inhaled corticosteroids is urgently needed to clarify their role in the management of COPD and to aid the development of new, safer therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6TwIovcm_c7Vg90H21EOLACvtfcHk0liQ6swZVeENJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsF2mu7nL&md5=93731fb68654146c29e6bb8426df568c</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2814%2970169-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252814%252970169-9%26sid%3Dliteratum%253Aachs%26aulast%3DFinney%26aufirst%3DL.%26aulast%3DBerry%26aufirst%3DM.%26aulast%3DSinganayagam%26aufirst%3DA.%26aulast%3DElkin%26aufirst%3DS.%2BL.%26aulast%3DJohnston%26aufirst%3DS.%2BL.%26aulast%3DMallia%26aufirst%3DP.%26atitle%3DInhaled%2520corticosteroids%2520and%2520pneumonia%2520in%2520chronic%2520obstructive%2520pulmonary%2520disease%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2014%26volume%3D2%26spage%3D919%26epage%3D932%26doi%3D10.1016%2FS2213-2600%2814%2970169-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vogelmeier, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alagappan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Andrea, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, D.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">60</span>, <span class="refDoi"> DOI: 10.1016/S2213-2600(12)70052-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2FS2213-2600%2812%2970052-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24321804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFCmtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2013&pages=51-60&author=C.+F.+Vogelmeierauthor=E.+D.+Batemanauthor=J.+Pallanteauthor=V.+K.+Alagappanauthor=P.+D%E2%80%99Andreaauthor=H.+Chenauthor=D.+Banerji&title=Efficacy+and+safety+of+once-daily+QVA149+compared+with+twice-daily+salmeterol-fluticasone+in+patients+with+chronic+obstructive+pulmonary+disease+%28ILLUMINATE%29%3A+a+randomised%2C+double-blind%2C+parallel+group+study&doi=10.1016%2FS2213-2600%2812%2970052-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study</span></div><div class="casAuthors">Vogelmeier, Claus F.; Bateman, Eric D.; Pallante, John; Alagappan, Vijay K. T.; D'Andrea, Peter; Chen, Hungta; Banerji, Donald</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-60</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">QVA149 is an inhaled fixed-dose combination therapy under development for the treatment of chronic obstructive pulmonary disease (COPD).  It combines indacaterol (a longacting β2-agonist) with glycopyrronium (a longacting muscarinic antagonist) as a dual bronchodilator.  We aimed to compare the efficacy, safety, and tolerability of QVA149 vs. salmeterol-fluticasone (SFC) over 26 wk in patients with moderate-to-severe COPD.  In this multicentre double-blind, double-dummy, parallel-group study, 523 patients (age 40 years or older, Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages II-III, without exacerbations in the previous year) were randomly assigned (1:1; via automated, interactive response technol. and stratified for smoking status) to once-daily QVA149 110/50 μg or twice-daily SFC 50/500 μg for 26 wk.  Efficacy was assessed in the full anal. set (randomised patients who received at least one dose of study drug); safety was assessed in all patients who received at least one dose of study drug.  The primary endpoint was to demonstrate the superiority of QVA149 compared with SFC for the standardized area under the curve from 0 to 12 h post dose for forced expiratory vol. in 1 s (FEV1 AUC0-12h) after 26 wk of treatment.  This trial was registered at ClinicalTrial.gov, NCT01315249.  Between March 25, 2011, and March 12, 2012, 259 patients were randomly assigned to receive QVA149 and 264 to receive SFC.  At week 26, FEV1 AUC0-12h was significantly higher with QVA149 than with SFC (treatment difference 0·138 L; 95% CI 0·100-0·176; p<0·0001).  Overall incidence of adverse events (including COPD exacerbations) was 55·4% (143 of 258) for the QVA149 group and 60·2% (159 of 264) for the SFC group.  Incidence of serious adverse events was similar between treatment groups (QVA149, 13 of 258 [5·0%]; SFC 14 of 264 [5·3%]); COPD worsening was the most frequent serious adverse event (one of 13 [0·4%] and three of 14 [1·1%], resp.).  Once-daily QVA149 provides significant, sustained, and clin. meaningful improvements in lung function vs. twice-daily SFC, with significant symptomatic benefit.  These results indicate the potential of dual bronchodilation as a treatment option for non-exacerbating symptomatic COPD patients.Novartis Pharma AG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOxmQ6p9ONmbVg90H21EOLACvtfcHk0liQ6swZVeENJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFCmtr4%253D&md5=c39b6cf8dd09f1165ee0373328493090</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2FS2213-2600%2812%2970052-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2213-2600%252812%252970052-8%26sid%3Dliteratum%253Aachs%26aulast%3DVogelmeier%26aufirst%3DC.%2BF.%26aulast%3DBateman%26aufirst%3DE.%2BD.%26aulast%3DPallante%26aufirst%3DJ.%26aulast%3DAlagappan%26aufirst%3DV.%2BK.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DBanerji%26aufirst%3DD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520once-daily%2520QVA149%2520compared%2520with%2520twice-daily%2520salmeterol-fluticasone%2520in%2520patients%2520with%2520chronic%2520obstructive%2520pulmonary%2520disease%2520%2528ILLUMINATE%2529%253A%2520a%2520randomised%252C%2520double-blind%252C%2520parallel%2520group%2520study%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2013%26volume%3D1%26spage%3D51%26epage%3D60%26doi%3D10.1016%2FS2213-2600%2812%2970052-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span>Global Strategy
for
Diagnosis, Management and Prevention of COPD, GOLD, 2019.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Global+Strategy%0Afor%0ADiagnosis%2C+Management+and+Prevention+of+COPD%2C+GOLD%2C+2019."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tannheimer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span> <span> </span><span class="NLM_article-title">Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2012.01.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1016%2Fj.pupt.2012.01.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22306235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref219/cit219&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XivFyhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2012&pages=178-184&author=S.+L.+Tannheimerauthor=E.+A.+Sorensenauthor=A.+C.+Haranauthor=C.+N.+Mansfieldauthor=C.+D.+Wrightauthor=M.+Salmon&title=Additive+anti-inflammatory+effects+of+beta+2+adrenoceptor+agonists+or+glucocorticosteroid+with+roflumilast+in+human+peripheral+blood+mononuclear+cells&doi=10.1016%2Fj.pupt.2012.01.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit219R"><div class="casContent"><span class="casTitleNuber">219</span><div class="casTitle"><span class="NLM_cas:atitle">Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells</span></div><div class="casAuthors">Tannheimer, Stacey L.; Sorensen, Eric A.; Haran, Aaron C.; Mansfield, Christopher N.; Wright, Clifford D.; Salmon, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-184</span>CODEN:
                <span class="NLM_cas:coden">PPTHFJ</span>;
        ISSN:<span class="NLM_cas:issn">1094-5539</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phosphodiesterase 4 inhibitor (PDE4i) roflumilast has been approved in the US and EU for treatment of GOLD stage 3 and 4 chronic obstructive pulmonary disease (COPD).  Inhaled β2 adrenoceptor agonist bronchodilators and anti-inflammatory glucocorticosteroids are also used as std. of care in COPD.  We investigated the anti-inflammatory interaction of roflumilast in combination with long-acting β2 agonists (LABA), salmeterol or formoterol, or a glucocorticosteroid, dexamethasone, on cytokine prodn. from LPS-stimulated human primary peripheral blood mononuclear cells (PBMC).  Salmeterol or formoterol caused a concn.-dependent inhibition of tumor necrosis factor-α (TNFα) secretion with an IC50 of 0.33 pM (C.I. 0.006-19) and 34 pM (C.I. 13-87), resp.  When roflumilast was evaluated, the addn. of salmeterol (1 nM) to roflumilast caused the IC50 for roflumilast to shift from 1.8 nM (C.I. 0.8-4) to 4.1 pM (C.I.0.3-69) (p < 0.01), and maximal inhibition increased from 72.5 ± 3.2% to 90.9 ± 3.1%.  Addn. of formoterol to roflumilast also produced an increased TNFα inhibition more than either drug alone (p < 0.05).  The inhibition of TNFα prodn. with salmeterol was both β2 adrenoceptor- and protein kinase A-dependent.  Addn. of roflumilast (10 nM) in the presence of dexamethasone increased the inhibition of LPS-induced TNFα and CCL3.  Roflumilast in combination with salmeterol, formoterol, or dexamethasone increased the inhibition of LPS-induced TNFα from human PBMC, in an additive manner.  Addn. of roflumilast to either a β2 adrenoceptor agonist or a glucocorticosteroid may provide superior anti-inflammatory activity and greater efficacy in COPD patients and be dose sparing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozTD47FfS8ibVg90H21EOLACvtfcHk0ljgc285eQ076w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivFyhu7k%253D&md5=3b0486800c03c9a934909e9ee9a7fa8b</span></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2012.01.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2012.01.003%26sid%3Dliteratum%253Aachs%26aulast%3DTannheimer%26aufirst%3DS.%2BL.%26aulast%3DSorensen%26aufirst%3DE.%2BA.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DMansfield%26aufirst%3DC.%2BN.%26aulast%3DWright%26aufirst%3DC.%2BD.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DAdditive%2520anti-inflammatory%2520effects%2520of%2520beta%25202%2520adrenoceptor%2520agonists%2520or%2520glucocorticosteroid%2520with%2520roflumilast%2520in%2520human%2520peripheral%2520blood%2520mononuclear%2520cells%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D25%26spage%3D178%26epage%3D184%26doi%3D10.1016%2Fj.pupt.2012.01.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fortin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Anjou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgins, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gougeon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubé, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moktefi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouissi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Séguin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Séguin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renzi, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paquet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, N.</span></span> <span> </span><span class="NLM_article-title">A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">39</span>, <span class="refDoi"> DOI: 10.1186/1465-9921-10-39</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2F1465-9921-10-39" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=19457265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BD1MvitVWnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2009&pages=39&author=M.+Fortinauthor=H.+D%E2%80%99Anjouauthor=M.+E.+Higginsauthor=J.+Gougeonauthor=P.+Aub%C3%A9author=K.+Moktefiauthor=S.+Mouissiauthor=S.+S%C3%A9guinauthor=R.+S%C3%A9guinauthor=P.+M.+Renziauthor=L.+Paquetauthor=N.+Ferrari&title=A+multi-target+antisense+approach+against+PDE4+and+PDE7+reduces+smoke-induced+lung+inflammation+in+mice&doi=10.1186%2F1465-9921-10-39"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice</span></div><div class="casAuthors">Fortin Marylene; D'Anjou Helene; Higgins Marie-Eve; Gougeon Jasmine; Aube Pamela; Moktefi Kamel; Mouissi Sonia; Seguin Serge; Seguin Rosanne; Renzi Paolo M; Paquet Luc; Ferrari Nicolay</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">39</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Recent development in the field of COPD has focused on strategies aimed at reducing the underlying inflammation through selective inhibition of the phosphodiesterase type IV (PDE4) isoform.  Although the anti-inflammatory and bronchodilator activity of selective PDE4 inhibitors has been well documented, their low therapeutic ratio and dose-dependent systemic side effects have limited their clinical utility.  This study examined the effect of 2'-deoxy-2'-Fluoro-beta-D-Arabinonucleic Acid (FANA)-containing antisense oligonucleotides (AON) targeting the mRNA for the PDE4B/4D and 7A subtypes on lung inflammatory markers, both in vitro and in vivo.  METHODS:  Normal human bronchial epithelial (NHBE) cells were transfected with FANA AON against PDE4B/4D and 7A alone or in combination. mRNA levels for target PDE subtypes, as well as secretion of pro-inflammatory chemokines were then measured following cell stimulation.  Mice were treated with combined PDE4B/4D and 7A AON via endo-tracheal delivery, or with roflumilast via oral delivery, and exposed to cigarette smoke for one week.  Target mRNA inhibition, as well as influx of inflammatory cells and mediators were measured in lung lavages.  A two-week smoke exposure protocol was also used to test the longer term potency of PDE4B/4D and 7A AONs.  RESULTS:  In NHBE cells, PDE4B/4D and 7A AONs dose-dependently and specifically inhibited expression of their respective target mRNA.  When used in combination, PDE4B/4D and 7A AONs significantly abrogated the cytokine-induced secretion of IL-8 and MCP-1 to near baseline levels.  In mice treated with combined PDE4B/4D and 7A AONs and exposed to cigarette smoke, significant protection against the smoke-induced recruitment of neutrophils and production of KC and pro-MMP-9 was obtained, which was correlated with inhibition of target mRNA in cells from lung lavages.  In this model, PDE AONs exerted more potent and broader anti-inflammatory effects against smoke-induced lung inflammation than roflumilast.  Moreover, the protective effect of PDE4B/4D and 7A AON was maintained when a once-weekly treatment schedule was used.  CONCLUSION:  These results indicate that inhaled AON against PDE4B/4D and 7A have unique effects on biomarkers that are believed to be important in the pathophysiology of COPD, which supports further development as a potential therapy in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRSgo7GQRV05jToTC3aBaesfW6udTcc2eZwVSJw6XZVibntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MvitVWnsg%253D%253D&md5=27d1b8e274312718032163bb017e2717</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.1186%2F1465-9921-10-39&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1465-9921-10-39%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DM.%26aulast%3DD%25E2%2580%2599Anjou%26aufirst%3DH.%26aulast%3DHiggins%26aufirst%3DM.%2BE.%26aulast%3DGougeon%26aufirst%3DJ.%26aulast%3DAub%25C3%25A9%26aufirst%3DP.%26aulast%3DMoktefi%26aufirst%3DK.%26aulast%3DMouissi%26aufirst%3DS.%26aulast%3DS%25C3%25A9guin%26aufirst%3DS.%26aulast%3DS%25C3%25A9guin%26aufirst%3DR.%26aulast%3DRenzi%26aufirst%3DP.%2BM.%26aulast%3DPaquet%26aufirst%3DL.%26aulast%3DFerrari%26aufirst%3DN.%26atitle%3DA%2520multi-target%2520antisense%2520approach%2520against%2520PDE4%2520and%2520PDE7%2520reduces%2520smoke-induced%2520lung%2520inflammation%2520in%2520mice%26jtitle%3DRespir.%2520Res.%26date%3D2009%26volume%3D10%26spage%3D39%26doi%3D10.1186%2F1465-9921-10-39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tannheimer, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, Z. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmon, M.</span></span> <span> </span><span class="NLM_article-title">The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>349</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.210997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1124%2Fjpet.113.210997" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=24513870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkvVOiu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=85-93&author=S.+L.+Tannheimerauthor=E.+A.+Sorensenauthor=Z.+H.+Cuiauthor=M.+Kimauthor=L.+Patelauthor=W.+R.+Bakerauthor=G.+B.+Phillipsauthor=C.+D.+Wrightauthor=M.+Salmon&title=The+in+vitro+pharmacology+of+GS-5759%2C+a+novel+bifunctional+phosphodiesterase+4+inhibitor+and+long+acting+%CE%B22-adrenoceptor+agonist&doi=10.1124%2Fjpet.113.210997"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">The in vitro pharmacology of GS-5759, a novel bifunctional phosphodiesterase 4 inhibitor and long acting β2-adrenoceptor agonist</span></div><div class="casAuthors">Tannheimer, Stacey L.; Sorensen, Eric A.; Cui, Zhi-Hua; Kim, Musong; Patel, Leena; Baker, William R.; Phillips, Gary B.; Wright, Clifford D.; Salmon, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-93, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Inhaled long-acting β2-adrenoceptor agonists (LABA) that act as bronchodilators and the oral anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor roflumilast are both approved therapies for chronic obstructive pulmonary disease (COPD).  Here we describe the activity of a novel, inhaled, bifunctional, small mol. (R)-6-[(3-{[4-(5-{[2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}pent-1-yn-1-yl)phenyl]carbamoyl}phenyl)sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methylquinoline-3-carboxamide (GS-5759), which has specific β2 agonist and PDE4 inhibitory activity.  GS-5759 demonstrated potent and full agonist activity at β2 adrenoceptors (EC50 = 8 ± 4 nM) and is a potent inhibitor of the PDE4 enzyme (IC50 = 5 ± 3 nM).  In cell assays, GS-5759 inhibited lipopolysaccharide (LPS)-induced tumor necrosis factor α (TNFα) prodn. in human peripheral mononuclear cells (PBMC) with an IC50 = 0.3 nM [confidence interval (CI) 0.1-0.6] and in human neutrophils formyl-methionyl-leucyl-phenylalanine (fMLP)-induced super oxide anion prodn. with an IC50 = 3 nM (CI 0.8-8).  The addn. of the β2 antagonist ICI 118551 shifted the IC50 in these cell assays to 4 and 38 nM, resp., demonstrating the contribution of both β2 agonist and PDE4 inhibitory activity to GS-5759.  GS-5759 was also a potent inhibitor of profibrotic and proinflammatory mediator release from human lung fibroblasts.  GS-5759 relaxed guinea pig airway smooth muscle strips precontracted with carbachol in a concn.-dependent manner with an EC50 = 0.5 μM (CI 0.2-2) and had slow dissocn. kinetics with an Off T1/2 > 720 min at an EC80 concn. of 3 μM.  GS-5759 is a novel bifunctional mol. with both potent β2 agonist and PDE4 inhibitor activity that could provide inhaled bronchodilator and anti-inflammatory therapy for COPD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj_BKbLa3cVLVg90H21EOLACvtfcHk0ljgc285eQ076w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkvVOiu7Y%253D&md5=b0017107ab4935141406708f98a8eec3</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.210997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.210997%26sid%3Dliteratum%253Aachs%26aulast%3DTannheimer%26aufirst%3DS.%2BL.%26aulast%3DSorensen%26aufirst%3DE.%2BA.%26aulast%3DCui%26aufirst%3DZ.%2BH.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DBaker%26aufirst%3DW.%2BR.%26aulast%3DPhillips%26aufirst%3DG.%2BB.%26aulast%3DWright%26aufirst%3DC.%2BD.%26aulast%3DSalmon%26aufirst%3DM.%26atitle%3DThe%2520in%2520vitro%2520pharmacology%2520of%2520GS-5759%252C%2520a%2520novel%2520bifunctional%2520phosphodiesterase%25204%2520inhibitor%2520and%2520long%2520acting%2520%25CE%25B22-adrenoceptor%2520agonist%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D85%26epage%3D93%26doi%3D10.1124%2Fjpet.113.210997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-{4-[5-(4-fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a dual p38α MAPK/PDE-4 inhibitor with activity against TNFα-related diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5290</span>– <span class="NLM_lpage">5305</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01647</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVSjtrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5290-5305&author=W.+Albrechtauthor=A.+Ungerauthor=S.+M.+Bauerauthor=S.+A.+Laufer&title=Discovery+of+N-%7B4-%5B5-%284-fluorophenyl%29-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl%5D-pyridin-2-yl%7D-acetamide+%28CBS-3595%29%2C+a+dual+p38%CE%B1+MAPK%2FPDE-4+inhibitor+with+activity+against+TNF%CE%B1-related+diseases&doi=10.1021%2Facs.jmedchem.6b01647"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases</span></div><div class="casAuthors">Albrecht, Wolfgang; Unger, Anke; Bauer, Silke M.; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5290-5305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The anti-inflammatory potential of p38 mitogen-activated protein kinase (MAPK) inhibitors was coincidentally expanded to a dual inhibition of p38α MAPK and phosphodiesterase 4 (PDE4), and the potential benefits arising from the blockage of both inflammation-related enzymes were thoroughly investigated.  The most promising compd., CBS-3595 (1), was successively evaluated in in vitro expts. as well as in ex vivo and in vivo preclin. studies after administration of 1 to rodents, dogs, and monkeys.  The resulting data clearly indicated a potent suppression of tumor necrosis factor alpha release.  For reconfirming the findings of the animal studies when administering 1 to healthy human volunteers, a phase I clin. trial was conducted.  Apart from further information regarding the pharmacokinetic and pharmacodynamic characteristics of 1, it was demonstrated that dual inhibition of p38α MAPK and PDE4 is able to synergistically attenuate the excessive anti-inflammatory response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn0tCfKq3bG7Vg90H21EOLACvtfcHk0liaF2K8APtPVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVSjtrvL&md5=fb0a040161db70ade8a3032b0c978537</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01647%26sid%3Dliteratum%253Aachs%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDiscovery%2520of%2520N-%257B4-%255B5-%25284-fluorophenyl%2529-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl%255D-pyridin-2-yl%257D-acetamide%2520%2528CBS-3595%2529%252C%2520a%2520dual%2520p38%25CE%25B1%2520MAPK%252FPDE-4%2520inhibitor%2520with%2520activity%2520against%2520TNF%25CE%25B1-related%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5290%26epage%3D5305%26doi%3D10.1021%2Facs.jmedchem.6b01647" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seemungal, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sapsford, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wedzicha, J. A.</span></span> <span> </span><span class="NLM_article-title">Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">1139</span>– <span class="NLM_lpage">1147</span>, <span class="refDoi"> DOI: 10.1164/rccm.200801-145OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1164%2Frccm.200801-145OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=18723437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref223/cit223&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlvVenuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2008&pages=1139-1147&author=T.+A.+Seemungalauthor=T.+M.+Wilkinsonauthor=J.+R.+Hurstauthor=W.+R.+Pereraauthor=R.+J.+Sapsfordauthor=J.+A.+Wedzicha&title=Long-term+erythromycin+therapy+is+associated+with+decreased+chronic+obstructive+pulmonary+disease+exacerbations&doi=10.1164%2Frccm.200801-145OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit223R"><div class="casContent"><span class="casTitleNuber">223</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations</span></div><div class="casAuthors">Seemungal, Terence A. R.; Wilkinson, Tom M. A.; Hurst, John R.; Perera, Wayomi R.; Sapsford, Ray J.; Wedzicha, Jadwiga A.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1139-1147</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Frequent chronic obstructive pulmonary disease (COPD) exacerbations are a major cause of hospital admission and mortality and are assocd. with increased airway inflammation.  Macrolides have airway antiinflammatory actions and may reduce the incidence of COPD exacerbations.  To det. whether regular therapy with macrolides reduces exacerbation frequency.  We performed a randomized, double-blind, placebo-controlled study of erythromycin administered at 250 mg twice daily to patients with COPD over 12 mo, with primary outcome variable being the no. of moderate and/or severe exacerbations (treated with systemic steroids, treated with antibiotics, or hospitalized).  We randomized 109 outpatients: 69 (63%) males, 52 (48%) current smokers, mean (SD) age 67.2 (8.6) years, FEV1 1.32 (0.53) L, FEV1% predicted 50 (18)%.  Thirty-eight (35%) of the patients had three or more exacerbations in the year before recruitment, with no differences between treatment groups.  There were a total of 206 moderate to severe exacerbations: 125 occurred in the placebo arm.  Ten in the placebo group and nine in the macrolide group withdrew.  Generalized linear modeling showed that the rate ratio for exacerbations for the macrolide-treated patients compared with placebo-treated patients was 0.648 (95% confidence interval: 0.489, 0.859; P = 0.003) and that these patients had shorter duration exacerbations compared with placebo.  There were no differences between the macrolide and placebo arms in terms of stable FEV1, sputum IL-6, IL-8, myeloperoxidase, bacterial flora, serum C-reactive protein, or serum IL-6 or in changes in these parameters from baseline to first exacerbation over the 1-yr study period.  Macrolide therapy was assocd. with a significant redn. in exacerbations compared with placebo and may be useful in decreasing the excessive disease burden in this important patient population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqrSa10DhQS7Vg90H21EOLACvtfcHk0liaF2K8APtPVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlvVenuw%253D%253D&md5=d31d00823f09f2c0039625cf014c84d4</span></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=10.1164%2Frccm.200801-145OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200801-145OC%26sid%3Dliteratum%253Aachs%26aulast%3DSeemungal%26aufirst%3DT.%2BA.%26aulast%3DWilkinson%26aufirst%3DT.%2BM.%26aulast%3DHurst%26aufirst%3DJ.%2BR.%26aulast%3DPerera%26aufirst%3DW.%2BR.%26aulast%3DSapsford%26aufirst%3DR.%2BJ.%26aulast%3DWedzicha%26aufirst%3DJ.%2BA.%26atitle%3DLong-term%2520erythromycin%2520therapy%2520is%2520associated%2520with%2520decreased%2520chronic%2520obstructive%2520pulmonary%2520disease%2520exacerbations%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2008%26volume%3D178%26spage%3D1139%26epage%3D1147%26doi%3D10.1164%2Frccm.200801-145OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Belkina, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolajczyk, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, G. V.</span></span> <span> </span><span class="NLM_article-title">BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">3670</span>– <span class="NLM_lpage">3678</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1202838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.4049%2Fjimmunol.1202838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=23420887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref224/cit224&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVynsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2013&pages=3670-3678&author=A.+C.+Belkinaauthor=B.+S.+Nikolajczykauthor=G.+V.+Denis&title=BET+protein+function+is+required+for+inflammation%3A+Brd2+genetic+disruption+and+BET+inhibitor+JQ1+impair+mouse+macrophage+inflammatory+responses&doi=10.4049%2Fjimmunol.1202838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit224R"><div class="casContent"><span class="casTitleNuber">224</span><div class="casTitle"><span class="NLM_cas:atitle">BET Protein Function Is Required for Inflammation: Brd2 Genetic Disruption and BET Inhibitor JQ1 Impair Mouse Macrophage Inflammatory Responses</span></div><div class="casAuthors">Belkina, Anna C.; Nikolajczyk, Barbara S.; Denis, Gerald V.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3670-3678</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Histone acetylation regulates activation and repression of multiple inflammatory genes known to play crit. roles in chronic inflammatory diseases.  However, proteins responsible for translating the histone acetylation code into an orchestrated proinflammatory cytokine response remain poorly characterized.  Bromodomain and extraterminal (BET) proteins are "readers" of histone acetylation marks, with demonstrated roles in gene transcription, but the ability of BET proteins to coordinate the response of inflammatory cytokine genes through translation of histone marks is unknown.  We hypothesize that members of the BET family of dual bromodomain-contg. transcriptional regulators directly control inflammatory genes.  We examd. the genetic model of brd2 lo mice, a BET protein hypomorph, to show that Brd2 is essential for proinflammatory cytokine prodn. in macrophages.  Studies that use small interfering RNA knockdown and a small-mol. inhibitor of BET protein binding, JQ1, independently demonstrate BET proteins are crit. for macrophage inflammatory responses.  Furthermore, we show that Brd2 and Brd4 phys. assoc. with the promoters of inflammatory cytokine genes in macrophages.  This assocn. is absent in the presence of BET inhibition by JQ1.  Finally, we demonstrate that JQ1 ablates cytokine prodn. in vitro and blunts the "cytokine storm" in endotoxemic mice by reducing levels of IL-6 and TNF-α while rescuing mice from LPS-induced death.  We propose that targeting BET proteins with small-mol. inhibitors will benefit hyperinflammatory conditions assocd. with high levels of cytokine prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrbebEe0G277Vg90H21EOLACvtfcHk0liaF2K8APtPVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVynsbk%253D&md5=8c4f69177b9ed814a7db339a8e2ab7ed</span></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1202838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1202838%26sid%3Dliteratum%253Aachs%26aulast%3DBelkina%26aufirst%3DA.%2BC.%26aulast%3DNikolajczyk%26aufirst%3DB.%2BS.%26aulast%3DDenis%26aufirst%3DG.%2BV.%26atitle%3DBET%2520protein%2520function%2520is%2520required%2520for%2520inflammation%253A%2520Brd2%2520genetic%2520disruption%2520and%2520BET%2520inhibitor%2520JQ1%2520impair%2520mouse%2520macrophage%2520inflammatory%2520responses%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D190%26spage%3D3670%26epage%3D3678%26doi%3D10.4049%2Fjimmunol.1202838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Che, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joberty, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantscheff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bountra, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diallo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberhard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveridge, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez-Molina, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppermann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, D. M.</span></span> <span> </span><span class="NLM_article-title">A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">408</span>, <span class="refDoi"> DOI: 10.1038/nature11262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1038%2Fnature11262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=22842901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFWjtbfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=404-408&author=L.+Kruidenierauthor=C.+W.+Chungauthor=Z.+Chengauthor=J.+Liddleauthor=K.+Cheauthor=G.+Jobertyauthor=M.+Bantscheffauthor=C.+Bountraauthor=A.+Bridgesauthor=H.+Dialloauthor=D.+Eberhardauthor=S.+Hutchinsonauthor=E.+Jonesauthor=R.+Katsoauthor=M.+Leveridgeauthor=P.+K.+Manderauthor=J.+Mosleyauthor=C.+Ramirez-Molinaauthor=P.+Rowlandauthor=C.+J.+Schofieldauthor=R.+J.+Sheppardauthor=J.+E.+Smithauthor=C.+Swalesauthor=R.+Tannerauthor=P.+Thomasauthor=A.+Tumberauthor=G.+Drewesauthor=U.+Oppermannauthor=D.+J.+Patelauthor=K.+Leeauthor=D.+M.+Wilson&title=A+selective+jumonji+H3K27+demethylase+inhibitor+modulates+the+proinflammatory+macrophage+response&doi=10.1038%2Fnature11262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit225R"><div class="casContent"><span class="casTitleNuber">225</span><div class="casTitle"><span class="NLM_cas:atitle">A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response</span></div><div class="casAuthors">Kruidenier, Laurens; Chung, Chun-wa; Cheng, Zhongjun; Liddle, John; Che, Ka Hing; Joberty, Gerard; Bantscheff, Marcus; Bountra, Chas; Bridges, Angela; Diallo, Hawa; Eberhard, Dirk; Hutchinson, Sue; Jones, Emma; Katso, Roy; Leveridge, Melanie; Mander, Palwinder K.; Mosley, Julie; Ramirez-Molina, Cesar; Rowland, Paul; Schofield, Christopher J.; Sheppard, Robert J.; Smith, Julia E.; Swales, Catherine; Tanner, Robert; Thomas, Pamela; Tumber, Anthony; Drewes, Gerard; Oppermann, Udo; Patel, Dinshaw J.; Lee, Kevin; Wilson, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">488</span>
        (<span class="NLM_cas:issue">7411</span>),
    <span class="NLM_cas:pages">404-408</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The jumonji (JMJ) family of histone demethylases are Fe2+- and α-ketoglutarate-dependent oxygenases that are essential components of regulatory transcriptional chromatin complexes.  These enzymes demethylate lysine residues in histones in a methylation-state and sequence-specific context.  Considerable effort has been devoted to gaining a mechanistic understanding of the roles of histone lysine demethylases in eukaryotic transcription, genome integrity and epigenetic inheritance, as well as in development, physiol. and disease.  However, because of the absence of any selective inhibitors, the relevance of the demethylase activity of JMJ enzymes in regulating cellular responses remains poorly understood.  Here we present a structure-guided small-mol. and chemoproteomics approach to elucidating the functional role of the H3K27me3-specific demethylase subfamily (KDM6 subfamily members JMJD3 and UTX).  The liganded structures of human and mouse JMJD3 provide novel insight into the specificity determinants for cofactor, substrate and inhibitor recognition by the KDM6 subfamily of demethylases.  We exploited these structural features to generate the first small-mol. catalytic site inhibitor that is selective for the H3K27me3-specific JMJ subfamily.  We demonstrate that this inhibitor binds in a novel manner and reduces lipopolysaccharide-induced proinflammatory cytokine prodn. by human primary macrophages, a process that depends on both JMJD3 and UTX.  Our results resolve the ambiguity assocd. with the catalytic function of H3K27-specific JMJs in regulating disease-relevant inflammatory responses and provide encouragement for designing small-mol. inhibitors to allow selective pharmacol. intervention across the JMJ family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-lxSNmxjfsbVg90H21EOLACvtfcHk0lgnZKGYkdx7ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFWjtbfI&md5=a4fa470a86070b4777e16a71e51763c8</span></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1038%2Fnature11262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11262%26sid%3Dliteratum%253Aachs%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DChung%26aufirst%3DC.%2BW.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DLiddle%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DK.%26aulast%3DJoberty%26aufirst%3DG.%26aulast%3DBantscheff%26aufirst%3DM.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DBridges%26aufirst%3DA.%26aulast%3DDiallo%26aufirst%3DH.%26aulast%3DEberhard%26aufirst%3DD.%26aulast%3DHutchinson%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DE.%26aulast%3DKatso%26aufirst%3DR.%26aulast%3DLeveridge%26aufirst%3DM.%26aulast%3DMander%26aufirst%3DP.%2BK.%26aulast%3DMosley%26aufirst%3DJ.%26aulast%3DRamirez-Molina%26aufirst%3DC.%26aulast%3DRowland%26aufirst%3DP.%26aulast%3DSchofield%26aufirst%3DC.%2BJ.%26aulast%3DSheppard%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DJ.%2BE.%26aulast%3DSwales%26aufirst%3DC.%26aulast%3DTanner%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DP.%26aulast%3DTumber%26aufirst%3DA.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DOppermann%26aufirst%3DU.%26aulast%3DPatel%26aufirst%3DD.%2BJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DA%2520selective%2520jumonji%2520H3K27%2520demethylase%2520inhibitor%2520modulates%2520the%2520proinflammatory%2520macrophage%2520response%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D404%26epage%3D408%26doi%3D10.1038%2Fnature11262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lock-Johansson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vestbo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorensen, G. L.</span></span> <span> </span><span class="NLM_article-title">Surfactant protein D, club cell protein 16, pulmonary and activation-regulated chemokine, C-reactive protein, and fibrinogen biomarker variation in chronic obstructive lung disease</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">147</span>, <span class="refDoi"> DOI: 10.1186/s12931-014-0147-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=10.1186%2Fs12931-014-0147-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=25425298" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;key=1%3ACAS%3A280%3ADC%252BC2MzgvVShtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=147&author=S.+Lock-Johanssonauthor=J.+Vestboauthor=G.+L.+Sorensen&title=Surfactant+protein+D%2C+club+cell+protein+16%2C+pulmonary+and+activation-regulated+chemokine%2C+C-reactive+protein%2C+and+fibrinogen+biomarker+variation+in+chronic+obstructive+lung+disease&doi=10.1186%2Fs12931-014-0147-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease</span></div><div class="casAuthors">Lock-Johansson Sofie; Sorensen Grith Lykke; Vestbo Jorgen; Vestbo Jorgen</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">147</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic obstructive pulmonary disease (COPD) is a multifaceted condition that cannot be fully described by the severity of airway obstruction.  The limitations of spirometry and clinical history have prompted researchers to investigate a multitude of surrogate biomarkers of disease for the assessment of patients, prediction of risk, and guidance of treatment.  The aim of this review is to provide a comprehensive summary of observations for a selection of recently investigated pulmonary inflammatory biomarkers (Surfactant protein D (SP-D), Club cell protein 16 (CC-16), and Pulmonary and activation-regulated chemokine (PARC/CCL-18)) and systemic inflammatory biomarkers (C-reactive protein (CRP) and fibrinogen) with COPD.  The relevance of these biomarkers for COPD is discussed in terms of their biological plausibility, their independent association to disease and hard clinical outcomes, their modification by interventions, and whether changes in clinical outcomes are reflected by changes in the biomarker.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRakau9BP_N15NiNltV31zlfW6udTcc2eb1AAqeCamUbrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MzgvVShtA%253D%253D&md5=e3fa237cd9d20cea61ef2b04cc6c7e5a</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1186%2Fs12931-014-0147-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-014-0147-5%26sid%3Dliteratum%253Aachs%26aulast%3DLock-Johansson%26aufirst%3DS.%26aulast%3DVestbo%26aufirst%3DJ.%26aulast%3DSorensen%26aufirst%3DG.%2BL.%26atitle%3DSurfactant%2520protein%2520D%252C%2520club%2520cell%2520protein%252016%252C%2520pulmonary%2520and%2520activation-regulated%2520chemokine%252C%2520C-reactive%2520protein%252C%2520and%2520fibrinogen%2520biomarker%2520variation%2520in%2520chronic%2520obstructive%2520lung%2520disease%26jtitle%3DRespir.%2520Res.%26date%3D2014%26volume%3D15%26spage%3D147%26doi%3D10.1186%2Fs12931-014-0147-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JK3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1JK3','PDB','1JK3'); return false;">PDB: 1JK3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1A9U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1A9U','PDB','1A9U'); return false;">PDB: 1A9U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2','PDB','1KV2'); return false;">PDB: 1KV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XMU','PDB','1XMU'); return false;">PDB: 1XMU</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i82"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01520">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_32362"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01520">10.1021/acs.jmedchem.8b01520</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Supplementary figures, charts and references (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01520/suppl_file/jm8b01520_si_001.pdf">jm8b01520_si_001.pdf (1.12 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01520&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01520%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01520" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67c752b808bdd1d7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
